{"docstore/data": {"a4454e1f-4542-4e09-a1ce-f78891dd1e8c": {"__data__": {"id_": "a4454e1f-4542-4e09-a1ce-f78891dd1e8c", "embedding": null, "metadata": {"window": "Cencora R epor ts Fiscal 2023 Four th Quar ter and Y ear End R esults\n11/2/2023\nRevenue of $68.9 Billion for the Fourth Quarter, a 12.7 Percent Year-Over-Year Increase\nFourth Quarter GAAP Diluted EPS of $1.72 and Adjusted Diluted EPS of $2.86\nRevenue of $262.2 Billion for Fiscal Year 2023, a 9.9 Percent Year-Over-Year Increase\nFiscal Year 2023 GAAP Diluted EPS of $8.53 and Adjusted Diluted EPS of $11.99\nCONSHOHOCKEN, P a.--(BUSINESS WIRE)-- Cencora, Inc.  (NYSE: C OR), formerly AmerisourceBergen Corporation, today reported that\nin its fiscal year 2023 fourth quarter ended September 30, 2023, revenue increased 12.7 percent to $68.9 billion.  R evenue increased\n9.9 percent to $262.2 billion for the fiscal year.  On the basis of U.S. ", "original_text": "Cencora R epor ts Fiscal 2023 Four th Quar ter and Y ear End R esults\n11/2/2023\nRevenue of $68.9 Billion for the Fourth Quarter, a 12.7 Percent Year-Over-Year Increase\nFourth Quarter GAAP Diluted EPS of $1.72 and Adjusted Diluted EPS of $2.86\nRevenue of $262.2 Billion for Fiscal Year 2023, a 9.9 Percent Year-Over-Year Increase\nFiscal Year 2023 GAAP Diluted EPS of $8.53 and Adjusted Diluted EPS of $11.99\nCONSHOHOCKEN, P a.--(BUSINESS WIRE)-- Cencora, Inc. ", "page_label": "1", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "751beaeb-087d-4f58-8f44-70cbbdf28794", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5488add78a40417902779b76b00e7895fc7e708f8d0a1a78c0ed1f8110f22ecd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ac252ed7-1453-48e0-b1be-22da698c291f", "node_type": "1", "metadata": {"window": "Cencora R epor ts Fiscal 2023 Four th Quar ter and Y ear End R esults\n11/2/2023\nRevenue of $68.9 Billion for the Fourth Quarter, a 12.7 Percent Year-Over-Year Increase\nFourth Quarter GAAP Diluted EPS of $1.72 and Adjusted Diluted EPS of $2.86\nRevenue of $262.2 Billion for Fiscal Year 2023, a 9.9 Percent Year-Over-Year Increase\nFiscal Year 2023 GAAP Diluted EPS of $8.53 and Adjusted Diluted EPS of $11.99\nCONSHOHOCKEN, P a.--(BUSINESS WIRE)-- Cencora, Inc.  (NYSE: C OR), formerly AmerisourceBergen Corporation, today reported that\nin its fiscal year 2023 fourth quarter ended September 30, 2023, revenue increased 12.7 percent to $68.9 billion.  R evenue increased\n9.9 percent to $262.2 billion for the fiscal year.  On the basis of U.S.  generally accepted accounting principles (GAAP), diluted\nearnings per share (EPS) was $1.72 for the September quarter of fiscal 2023, compared to $1.40 in the prior year quarter. ", "original_text": "(NYSE: C OR), formerly AmerisourceBergen Corporation, today reported that\nin its fiscal year 2023 fourth quarter ended September 30, 2023, revenue increased 12.7 percent to $68.9 billion. "}, "hash": "301c1e2e9c41e41b6f0503d99f24967268e3ddf56ea544aa5960bcf6d003f853", "class_name": "RelatedNodeInfo"}}, "text": "Cencora R epor ts Fiscal 2023 Four th Quar ter and Y ear End R esults\n11/2/2023\nRevenue of $68.9 Billion for the Fourth Quarter, a 12.7 Percent Year-Over-Year Increase\nFourth Quarter GAAP Diluted EPS of $1.72 and Adjusted Diluted EPS of $2.86\nRevenue of $262.2 Billion for Fiscal Year 2023, a 9.9 Percent Year-Over-Year Increase\nFiscal Year 2023 GAAP Diluted EPS of $8.53 and Adjusted Diluted EPS of $11.99\nCONSHOHOCKEN, P a.--(BUSINESS WIRE)-- Cencora, Inc. ", "start_char_idx": 0, "end_char_idx": 459, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ac252ed7-1453-48e0-b1be-22da698c291f": {"__data__": {"id_": "ac252ed7-1453-48e0-b1be-22da698c291f", "embedding": null, "metadata": {"window": "Cencora R epor ts Fiscal 2023 Four th Quar ter and Y ear End R esults\n11/2/2023\nRevenue of $68.9 Billion for the Fourth Quarter, a 12.7 Percent Year-Over-Year Increase\nFourth Quarter GAAP Diluted EPS of $1.72 and Adjusted Diluted EPS of $2.86\nRevenue of $262.2 Billion for Fiscal Year 2023, a 9.9 Percent Year-Over-Year Increase\nFiscal Year 2023 GAAP Diluted EPS of $8.53 and Adjusted Diluted EPS of $11.99\nCONSHOHOCKEN, P a.--(BUSINESS WIRE)-- Cencora, Inc.  (NYSE: C OR), formerly AmerisourceBergen Corporation, today reported that\nin its fiscal year 2023 fourth quarter ended September 30, 2023, revenue increased 12.7 percent to $68.9 billion.  R evenue increased\n9.9 percent to $262.2 billion for the fiscal year.  On the basis of U.S.  generally accepted accounting principles (GAAP), diluted\nearnings per share (EPS) was $1.72 for the September quarter of fiscal 2023, compared to $1.40 in the prior year quarter. ", "original_text": "(NYSE: C OR), formerly AmerisourceBergen Corporation, today reported that\nin its fiscal year 2023 fourth quarter ended September 30, 2023, revenue increased 12.7 percent to $68.9 billion. ", "page_label": "1", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "751beaeb-087d-4f58-8f44-70cbbdf28794", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5488add78a40417902779b76b00e7895fc7e708f8d0a1a78c0ed1f8110f22ecd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a4454e1f-4542-4e09-a1ce-f78891dd1e8c", "node_type": "1", "metadata": {"window": "Cencora R epor ts Fiscal 2023 Four th Quar ter and Y ear End R esults\n11/2/2023\nRevenue of $68.9 Billion for the Fourth Quarter, a 12.7 Percent Year-Over-Year Increase\nFourth Quarter GAAP Diluted EPS of $1.72 and Adjusted Diluted EPS of $2.86\nRevenue of $262.2 Billion for Fiscal Year 2023, a 9.9 Percent Year-Over-Year Increase\nFiscal Year 2023 GAAP Diluted EPS of $8.53 and Adjusted Diluted EPS of $11.99\nCONSHOHOCKEN, P a.--(BUSINESS WIRE)-- Cencora, Inc.  (NYSE: C OR), formerly AmerisourceBergen Corporation, today reported that\nin its fiscal year 2023 fourth quarter ended September 30, 2023, revenue increased 12.7 percent to $68.9 billion.  R evenue increased\n9.9 percent to $262.2 billion for the fiscal year.  On the basis of U.S. ", "original_text": "Cencora R epor ts Fiscal 2023 Four th Quar ter and Y ear End R esults\n11/2/2023\nRevenue of $68.9 Billion for the Fourth Quarter, a 12.7 Percent Year-Over-Year Increase\nFourth Quarter GAAP Diluted EPS of $1.72 and Adjusted Diluted EPS of $2.86\nRevenue of $262.2 Billion for Fiscal Year 2023, a 9.9 Percent Year-Over-Year Increase\nFiscal Year 2023 GAAP Diluted EPS of $8.53 and Adjusted Diluted EPS of $11.99\nCONSHOHOCKEN, P a.--(BUSINESS WIRE)-- Cencora, Inc. ", "page_label": "1", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f999ac33cc16f5686d5dddafe4bbc4db20a9e326098d5ac9de1382a57c763869", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c466d288-3978-47d6-99b3-d5491119dbca", "node_type": "1", "metadata": {"window": "Cencora R epor ts Fiscal 2023 Four th Quar ter and Y ear End R esults\n11/2/2023\nRevenue of $68.9 Billion for the Fourth Quarter, a 12.7 Percent Year-Over-Year Increase\nFourth Quarter GAAP Diluted EPS of $1.72 and Adjusted Diluted EPS of $2.86\nRevenue of $262.2 Billion for Fiscal Year 2023, a 9.9 Percent Year-Over-Year Increase\nFiscal Year 2023 GAAP Diluted EPS of $8.53 and Adjusted Diluted EPS of $11.99\nCONSHOHOCKEN, P a.--(BUSINESS WIRE)-- Cencora, Inc.  (NYSE: C OR), formerly AmerisourceBergen Corporation, today reported that\nin its fiscal year 2023 fourth quarter ended September 30, 2023, revenue increased 12.7 percent to $68.9 billion.  R evenue increased\n9.9 percent to $262.2 billion for the fiscal year.  On the basis of U.S.  generally accepted accounting principles (GAAP), diluted\nearnings per share (EPS) was $1.72 for the September quarter of fiscal 2023, compared to $1.40 in the prior year quarter.  Adjusted\ndiluted EPS, which is a non-GAAP measure that excludes items described below, increased 10.0 percent to $2.86 in the fiscal fourth\nquarter. ", "original_text": "R evenue increased\n9.9 percent to $262.2 billion for the fiscal year. "}, "hash": "a3b648a9bb589e335bd8f5b13fd54b54a0623c0511fa7029232a7464df352a8f", "class_name": "RelatedNodeInfo"}}, "text": "(NYSE: C OR), formerly AmerisourceBergen Corporation, today reported that\nin its fiscal year 2023 fourth quarter ended September 30, 2023, revenue increased 12.7 percent to $68.9 billion. ", "start_char_idx": 459, "end_char_idx": 647, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c466d288-3978-47d6-99b3-d5491119dbca": {"__data__": {"id_": "c466d288-3978-47d6-99b3-d5491119dbca", "embedding": null, "metadata": {"window": "Cencora R epor ts Fiscal 2023 Four th Quar ter and Y ear End R esults\n11/2/2023\nRevenue of $68.9 Billion for the Fourth Quarter, a 12.7 Percent Year-Over-Year Increase\nFourth Quarter GAAP Diluted EPS of $1.72 and Adjusted Diluted EPS of $2.86\nRevenue of $262.2 Billion for Fiscal Year 2023, a 9.9 Percent Year-Over-Year Increase\nFiscal Year 2023 GAAP Diluted EPS of $8.53 and Adjusted Diluted EPS of $11.99\nCONSHOHOCKEN, P a.--(BUSINESS WIRE)-- Cencora, Inc.  (NYSE: C OR), formerly AmerisourceBergen Corporation, today reported that\nin its fiscal year 2023 fourth quarter ended September 30, 2023, revenue increased 12.7 percent to $68.9 billion.  R evenue increased\n9.9 percent to $262.2 billion for the fiscal year.  On the basis of U.S.  generally accepted accounting principles (GAAP), diluted\nearnings per share (EPS) was $1.72 for the September quarter of fiscal 2023, compared to $1.40 in the prior year quarter.  Adjusted\ndiluted EPS, which is a non-GAAP measure that excludes items described below, increased 10.0 percent to $2.86 in the fiscal fourth\nquarter. ", "original_text": "R evenue increased\n9.9 percent to $262.2 billion for the fiscal year. ", "page_label": "1", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "751beaeb-087d-4f58-8f44-70cbbdf28794", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5488add78a40417902779b76b00e7895fc7e708f8d0a1a78c0ed1f8110f22ecd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ac252ed7-1453-48e0-b1be-22da698c291f", "node_type": "1", "metadata": {"window": "Cencora R epor ts Fiscal 2023 Four th Quar ter and Y ear End R esults\n11/2/2023\nRevenue of $68.9 Billion for the Fourth Quarter, a 12.7 Percent Year-Over-Year Increase\nFourth Quarter GAAP Diluted EPS of $1.72 and Adjusted Diluted EPS of $2.86\nRevenue of $262.2 Billion for Fiscal Year 2023, a 9.9 Percent Year-Over-Year Increase\nFiscal Year 2023 GAAP Diluted EPS of $8.53 and Adjusted Diluted EPS of $11.99\nCONSHOHOCKEN, P a.--(BUSINESS WIRE)-- Cencora, Inc.  (NYSE: C OR), formerly AmerisourceBergen Corporation, today reported that\nin its fiscal year 2023 fourth quarter ended September 30, 2023, revenue increased 12.7 percent to $68.9 billion.  R evenue increased\n9.9 percent to $262.2 billion for the fiscal year.  On the basis of U.S.  generally accepted accounting principles (GAAP), diluted\nearnings per share (EPS) was $1.72 for the September quarter of fiscal 2023, compared to $1.40 in the prior year quarter. ", "original_text": "(NYSE: C OR), formerly AmerisourceBergen Corporation, today reported that\nin its fiscal year 2023 fourth quarter ended September 30, 2023, revenue increased 12.7 percent to $68.9 billion. ", "page_label": "1", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cb71718c6865a7087ccc65aa153ffd6b7b43b3faa3f47fc17ce8b7c3436cac4c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3ae576b1-521b-4910-b1dd-ac8e054cafc6", "node_type": "1", "metadata": {"window": "Cencora R epor ts Fiscal 2023 Four th Quar ter and Y ear End R esults\n11/2/2023\nRevenue of $68.9 Billion for the Fourth Quarter, a 12.7 Percent Year-Over-Year Increase\nFourth Quarter GAAP Diluted EPS of $1.72 and Adjusted Diluted EPS of $2.86\nRevenue of $262.2 Billion for Fiscal Year 2023, a 9.9 Percent Year-Over-Year Increase\nFiscal Year 2023 GAAP Diluted EPS of $8.53 and Adjusted Diluted EPS of $11.99\nCONSHOHOCKEN, P a.--(BUSINESS WIRE)-- Cencora, Inc.  (NYSE: C OR), formerly AmerisourceBergen Corporation, today reported that\nin its fiscal year 2023 fourth quarter ended September 30, 2023, revenue increased 12.7 percent to $68.9 billion.  R evenue increased\n9.9 percent to $262.2 billion for the fiscal year.  On the basis of U.S.  generally accepted accounting principles (GAAP), diluted\nearnings per share (EPS) was $1.72 for the September quarter of fiscal 2023, compared to $1.40 in the prior year quarter.  Adjusted\ndiluted EPS, which is a non-GAAP measure that excludes items described below, increased 10.0 percent to $2.86 in the fiscal fourth\nquarter.  For fiscal year 2023, diluted EPS increased 6.1 percent to $8.53 . ", "original_text": "On the basis of U.S. "}, "hash": "4521a80b9c59508f6b28dc3fc49989c36f1fc959b19b166b62af05a6ac7ae80a", "class_name": "RelatedNodeInfo"}}, "text": "R evenue increased\n9.9 percent to $262.2 billion for the fiscal year. ", "start_char_idx": 647, "end_char_idx": 717, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3ae576b1-521b-4910-b1dd-ac8e054cafc6": {"__data__": {"id_": "3ae576b1-521b-4910-b1dd-ac8e054cafc6", "embedding": null, "metadata": {"window": "Cencora R epor ts Fiscal 2023 Four th Quar ter and Y ear End R esults\n11/2/2023\nRevenue of $68.9 Billion for the Fourth Quarter, a 12.7 Percent Year-Over-Year Increase\nFourth Quarter GAAP Diluted EPS of $1.72 and Adjusted Diluted EPS of $2.86\nRevenue of $262.2 Billion for Fiscal Year 2023, a 9.9 Percent Year-Over-Year Increase\nFiscal Year 2023 GAAP Diluted EPS of $8.53 and Adjusted Diluted EPS of $11.99\nCONSHOHOCKEN, P a.--(BUSINESS WIRE)-- Cencora, Inc.  (NYSE: C OR), formerly AmerisourceBergen Corporation, today reported that\nin its fiscal year 2023 fourth quarter ended September 30, 2023, revenue increased 12.7 percent to $68.9 billion.  R evenue increased\n9.9 percent to $262.2 billion for the fiscal year.  On the basis of U.S.  generally accepted accounting principles (GAAP), diluted\nearnings per share (EPS) was $1.72 for the September quarter of fiscal 2023, compared to $1.40 in the prior year quarter.  Adjusted\ndiluted EPS, which is a non-GAAP measure that excludes items described below, increased 10.0 percent to $2.86 in the fiscal fourth\nquarter.  For fiscal year 2023, diluted EPS increased 6.1 percent to $8.53 . ", "original_text": "On the basis of U.S. ", "page_label": "1", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "751beaeb-087d-4f58-8f44-70cbbdf28794", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5488add78a40417902779b76b00e7895fc7e708f8d0a1a78c0ed1f8110f22ecd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c466d288-3978-47d6-99b3-d5491119dbca", "node_type": "1", "metadata": {"window": "Cencora R epor ts Fiscal 2023 Four th Quar ter and Y ear End R esults\n11/2/2023\nRevenue of $68.9 Billion for the Fourth Quarter, a 12.7 Percent Year-Over-Year Increase\nFourth Quarter GAAP Diluted EPS of $1.72 and Adjusted Diluted EPS of $2.86\nRevenue of $262.2 Billion for Fiscal Year 2023, a 9.9 Percent Year-Over-Year Increase\nFiscal Year 2023 GAAP Diluted EPS of $8.53 and Adjusted Diluted EPS of $11.99\nCONSHOHOCKEN, P a.--(BUSINESS WIRE)-- Cencora, Inc.  (NYSE: C OR), formerly AmerisourceBergen Corporation, today reported that\nin its fiscal year 2023 fourth quarter ended September 30, 2023, revenue increased 12.7 percent to $68.9 billion.  R evenue increased\n9.9 percent to $262.2 billion for the fiscal year.  On the basis of U.S.  generally accepted accounting principles (GAAP), diluted\nearnings per share (EPS) was $1.72 for the September quarter of fiscal 2023, compared to $1.40 in the prior year quarter.  Adjusted\ndiluted EPS, which is a non-GAAP measure that excludes items described below, increased 10.0 percent to $2.86 in the fiscal fourth\nquarter. ", "original_text": "R evenue increased\n9.9 percent to $262.2 billion for the fiscal year. ", "page_label": "1", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0176acdd22267b9f2ef333c7e59ecf477e5bbb53f1a775c0c8d2454cd4358821", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cc798f13-adad-45d5-a189-950b8a842339", "node_type": "1", "metadata": {"window": "(NYSE: C OR), formerly AmerisourceBergen Corporation, today reported that\nin its fiscal year 2023 fourth quarter ended September 30, 2023, revenue increased 12.7 percent to $68.9 billion.  R evenue increased\n9.9 percent to $262.2 billion for the fiscal year.  On the basis of U.S.  generally accepted accounting principles (GAAP), diluted\nearnings per share (EPS) was $1.72 for the September quarter of fiscal 2023, compared to $1.40 in the prior year quarter.  Adjusted\ndiluted EPS, which is a non-GAAP measure that excludes items described below, increased 10.0 percent to $2.86 in the fiscal fourth\nquarter.  For fiscal year 2023, diluted EPS increased 6.1 percent to $8.53 .  For fiscal year 2023, adjusted diluted EPS increased 8.7\npercent to $11.99.\n", "original_text": "generally accepted accounting principles (GAAP), diluted\nearnings per share (EPS) was $1.72 for the September quarter of fiscal 2023, compared to $1.40 in the prior year quarter. "}, "hash": "2091380b2640239eb2a40f1a9ef629d6795d1a593866756c4cb6efc314a6cc6b", "class_name": "RelatedNodeInfo"}}, "text": "On the basis of U.S. ", "start_char_idx": 717, "end_char_idx": 738, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cc798f13-adad-45d5-a189-950b8a842339": {"__data__": {"id_": "cc798f13-adad-45d5-a189-950b8a842339", "embedding": null, "metadata": {"window": "(NYSE: C OR), formerly AmerisourceBergen Corporation, today reported that\nin its fiscal year 2023 fourth quarter ended September 30, 2023, revenue increased 12.7 percent to $68.9 billion.  R evenue increased\n9.9 percent to $262.2 billion for the fiscal year.  On the basis of U.S.  generally accepted accounting principles (GAAP), diluted\nearnings per share (EPS) was $1.72 for the September quarter of fiscal 2023, compared to $1.40 in the prior year quarter.  Adjusted\ndiluted EPS, which is a non-GAAP measure that excludes items described below, increased 10.0 percent to $2.86 in the fiscal fourth\nquarter.  For fiscal year 2023, diluted EPS increased 6.1 percent to $8.53 .  For fiscal year 2023, adjusted diluted EPS increased 8.7\npercent to $11.99.\n", "original_text": "generally accepted accounting principles (GAAP), diluted\nearnings per share (EPS) was $1.72 for the September quarter of fiscal 2023, compared to $1.40 in the prior year quarter. ", "page_label": "1", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "751beaeb-087d-4f58-8f44-70cbbdf28794", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5488add78a40417902779b76b00e7895fc7e708f8d0a1a78c0ed1f8110f22ecd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3ae576b1-521b-4910-b1dd-ac8e054cafc6", "node_type": "1", "metadata": {"window": "Cencora R epor ts Fiscal 2023 Four th Quar ter and Y ear End R esults\n11/2/2023\nRevenue of $68.9 Billion for the Fourth Quarter, a 12.7 Percent Year-Over-Year Increase\nFourth Quarter GAAP Diluted EPS of $1.72 and Adjusted Diluted EPS of $2.86\nRevenue of $262.2 Billion for Fiscal Year 2023, a 9.9 Percent Year-Over-Year Increase\nFiscal Year 2023 GAAP Diluted EPS of $8.53 and Adjusted Diluted EPS of $11.99\nCONSHOHOCKEN, P a.--(BUSINESS WIRE)-- Cencora, Inc.  (NYSE: C OR), formerly AmerisourceBergen Corporation, today reported that\nin its fiscal year 2023 fourth quarter ended September 30, 2023, revenue increased 12.7 percent to $68.9 billion.  R evenue increased\n9.9 percent to $262.2 billion for the fiscal year.  On the basis of U.S.  generally accepted accounting principles (GAAP), diluted\nearnings per share (EPS) was $1.72 for the September quarter of fiscal 2023, compared to $1.40 in the prior year quarter.  Adjusted\ndiluted EPS, which is a non-GAAP measure that excludes items described below, increased 10.0 percent to $2.86 in the fiscal fourth\nquarter.  For fiscal year 2023, diluted EPS increased 6.1 percent to $8.53 . ", "original_text": "On the basis of U.S. ", "page_label": "1", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "96a189e985d5b7b45dc922a044be4e75711d0c92cfb7803f7b79b11399fc3d6f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4942cea5-8069-40be-bad5-0d2307d62baa", "node_type": "1", "metadata": {"window": "R evenue increased\n9.9 percent to $262.2 billion for the fiscal year.  On the basis of U.S.  generally accepted accounting principles (GAAP), diluted\nearnings per share (EPS) was $1.72 for the September quarter of fiscal 2023, compared to $1.40 in the prior year quarter.  Adjusted\ndiluted EPS, which is a non-GAAP measure that excludes items described below, increased 10.0 percent to $2.86 in the fiscal fourth\nquarter.  For fiscal year 2023, diluted EPS increased 6.1 percent to $8.53 .  For fiscal year 2023, adjusted diluted EPS increased 8.7\npercent to $11.99.\n \u201cCencora delivered strong performance in fiscal 2023, which was a seminal year for our company as our purpose-driven teams took\nkey steps to execute on our strategic imperatives and advance our position at the center of healthcare,\u201d said S teven H. Collis,\nChairman, President and Chief Executive Officer of Cencora.\n", "original_text": "Adjusted\ndiluted EPS, which is a non-GAAP measure that excludes items described below, increased 10.0 percent to $2.86 in the fiscal fourth\nquarter. "}, "hash": "07ff150636dd9382c9c7d590307b8fecbdcd07d73b4666b22e79152cc9eba258", "class_name": "RelatedNodeInfo"}}, "text": "generally accepted accounting principles (GAAP), diluted\nearnings per share (EPS) was $1.72 for the September quarter of fiscal 2023, compared to $1.40 in the prior year quarter. ", "start_char_idx": 738, "end_char_idx": 917, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4942cea5-8069-40be-bad5-0d2307d62baa": {"__data__": {"id_": "4942cea5-8069-40be-bad5-0d2307d62baa", "embedding": null, "metadata": {"window": "R evenue increased\n9.9 percent to $262.2 billion for the fiscal year.  On the basis of U.S.  generally accepted accounting principles (GAAP), diluted\nearnings per share (EPS) was $1.72 for the September quarter of fiscal 2023, compared to $1.40 in the prior year quarter.  Adjusted\ndiluted EPS, which is a non-GAAP measure that excludes items described below, increased 10.0 percent to $2.86 in the fiscal fourth\nquarter.  For fiscal year 2023, diluted EPS increased 6.1 percent to $8.53 .  For fiscal year 2023, adjusted diluted EPS increased 8.7\npercent to $11.99.\n \u201cCencora delivered strong performance in fiscal 2023, which was a seminal year for our company as our purpose-driven teams took\nkey steps to execute on our strategic imperatives and advance our position at the center of healthcare,\u201d said S teven H. Collis,\nChairman, President and Chief Executive Officer of Cencora.\n", "original_text": "Adjusted\ndiluted EPS, which is a non-GAAP measure that excludes items described below, increased 10.0 percent to $2.86 in the fiscal fourth\nquarter. ", "page_label": "1", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "751beaeb-087d-4f58-8f44-70cbbdf28794", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5488add78a40417902779b76b00e7895fc7e708f8d0a1a78c0ed1f8110f22ecd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cc798f13-adad-45d5-a189-950b8a842339", "node_type": "1", "metadata": {"window": "(NYSE: C OR), formerly AmerisourceBergen Corporation, today reported that\nin its fiscal year 2023 fourth quarter ended September 30, 2023, revenue increased 12.7 percent to $68.9 billion.  R evenue increased\n9.9 percent to $262.2 billion for the fiscal year.  On the basis of U.S.  generally accepted accounting principles (GAAP), diluted\nearnings per share (EPS) was $1.72 for the September quarter of fiscal 2023, compared to $1.40 in the prior year quarter.  Adjusted\ndiluted EPS, which is a non-GAAP measure that excludes items described below, increased 10.0 percent to $2.86 in the fiscal fourth\nquarter.  For fiscal year 2023, diluted EPS increased 6.1 percent to $8.53 .  For fiscal year 2023, adjusted diluted EPS increased 8.7\npercent to $11.99.\n", "original_text": "generally accepted accounting principles (GAAP), diluted\nearnings per share (EPS) was $1.72 for the September quarter of fiscal 2023, compared to $1.40 in the prior year quarter. ", "page_label": "1", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b97817eb572170ab385a5d37b63f65088e431cb28de6fe0fc439d81c341dc589", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6b4ecd28-20b9-4081-ad83-8812f65cfd81", "node_type": "1", "metadata": {"window": "On the basis of U.S.  generally accepted accounting principles (GAAP), diluted\nearnings per share (EPS) was $1.72 for the September quarter of fiscal 2023, compared to $1.40 in the prior year quarter.  Adjusted\ndiluted EPS, which is a non-GAAP measure that excludes items described below, increased 10.0 percent to $2.86 in the fiscal fourth\nquarter.  For fiscal year 2023, diluted EPS increased 6.1 percent to $8.53 .  For fiscal year 2023, adjusted diluted EPS increased 8.7\npercent to $11.99.\n \u201cCencora delivered strong performance in fiscal 2023, which was a seminal year for our company as our purpose-driven teams took\nkey steps to execute on our strategic imperatives and advance our position at the center of healthcare,\u201d said S teven H. Collis,\nChairman, President and Chief Executive Officer of Cencora.\n \u201cComing together as a unified team under our new identity as Cencora, we are showcasing our impact across pharmaceutical care\nand our global footprint,\" Mr. ", "original_text": "For fiscal year 2023, diluted EPS increased 6.1 percent to $8.53 . "}, "hash": "f04981e92f35ef75c1ffa9f43ffa34162988e51b15729e1f2a72ccdb4b8c2eca", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted\ndiluted EPS, which is a non-GAAP measure that excludes items described below, increased 10.0 percent to $2.86 in the fiscal fourth\nquarter. ", "start_char_idx": 917, "end_char_idx": 1066, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6b4ecd28-20b9-4081-ad83-8812f65cfd81": {"__data__": {"id_": "6b4ecd28-20b9-4081-ad83-8812f65cfd81", "embedding": null, "metadata": {"window": "On the basis of U.S.  generally accepted accounting principles (GAAP), diluted\nearnings per share (EPS) was $1.72 for the September quarter of fiscal 2023, compared to $1.40 in the prior year quarter.  Adjusted\ndiluted EPS, which is a non-GAAP measure that excludes items described below, increased 10.0 percent to $2.86 in the fiscal fourth\nquarter.  For fiscal year 2023, diluted EPS increased 6.1 percent to $8.53 .  For fiscal year 2023, adjusted diluted EPS increased 8.7\npercent to $11.99.\n \u201cCencora delivered strong performance in fiscal 2023, which was a seminal year for our company as our purpose-driven teams took\nkey steps to execute on our strategic imperatives and advance our position at the center of healthcare,\u201d said S teven H. Collis,\nChairman, President and Chief Executive Officer of Cencora.\n \u201cComing together as a unified team under our new identity as Cencora, we are showcasing our impact across pharmaceutical care\nand our global footprint,\" Mr. ", "original_text": "For fiscal year 2023, diluted EPS increased 6.1 percent to $8.53 . ", "page_label": "1", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "751beaeb-087d-4f58-8f44-70cbbdf28794", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5488add78a40417902779b76b00e7895fc7e708f8d0a1a78c0ed1f8110f22ecd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4942cea5-8069-40be-bad5-0d2307d62baa", "node_type": "1", "metadata": {"window": "R evenue increased\n9.9 percent to $262.2 billion for the fiscal year.  On the basis of U.S.  generally accepted accounting principles (GAAP), diluted\nearnings per share (EPS) was $1.72 for the September quarter of fiscal 2023, compared to $1.40 in the prior year quarter.  Adjusted\ndiluted EPS, which is a non-GAAP measure that excludes items described below, increased 10.0 percent to $2.86 in the fiscal fourth\nquarter.  For fiscal year 2023, diluted EPS increased 6.1 percent to $8.53 .  For fiscal year 2023, adjusted diluted EPS increased 8.7\npercent to $11.99.\n \u201cCencora delivered strong performance in fiscal 2023, which was a seminal year for our company as our purpose-driven teams took\nkey steps to execute on our strategic imperatives and advance our position at the center of healthcare,\u201d said S teven H. Collis,\nChairman, President and Chief Executive Officer of Cencora.\n", "original_text": "Adjusted\ndiluted EPS, which is a non-GAAP measure that excludes items described below, increased 10.0 percent to $2.86 in the fiscal fourth\nquarter. ", "page_label": "1", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "642f2a962f17fa927f90e194ddb9e637e329e42df66a82db9a28895082577a46", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "45925fee-f88d-4ba3-98ea-f67646da83db", "node_type": "1", "metadata": {"window": "generally accepted accounting principles (GAAP), diluted\nearnings per share (EPS) was $1.72 for the September quarter of fiscal 2023, compared to $1.40 in the prior year quarter.  Adjusted\ndiluted EPS, which is a non-GAAP measure that excludes items described below, increased 10.0 percent to $2.86 in the fiscal fourth\nquarter.  For fiscal year 2023, diluted EPS increased 6.1 percent to $8.53 .  For fiscal year 2023, adjusted diluted EPS increased 8.7\npercent to $11.99.\n \u201cCencora delivered strong performance in fiscal 2023, which was a seminal year for our company as our purpose-driven teams took\nkey steps to execute on our strategic imperatives and advance our position at the center of healthcare,\u201d said S teven H. Collis,\nChairman, President and Chief Executive Officer of Cencora.\n \u201cComing together as a unified team under our new identity as Cencora, we are showcasing our impact across pharmaceutical care\nand our global footprint,\" Mr.  Collis continued. ", "original_text": "For fiscal year 2023, adjusted diluted EPS increased 8.7\npercent to $11.99.\n"}, "hash": "9a51bc504179d305f14a2b7c6746e8477ce98a565e058e1ec4b052428ad90833", "class_name": "RelatedNodeInfo"}}, "text": "For fiscal year 2023, diluted EPS increased 6.1 percent to $8.53 . ", "start_char_idx": 1066, "end_char_idx": 1133, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "45925fee-f88d-4ba3-98ea-f67646da83db": {"__data__": {"id_": "45925fee-f88d-4ba3-98ea-f67646da83db", "embedding": null, "metadata": {"window": "generally accepted accounting principles (GAAP), diluted\nearnings per share (EPS) was $1.72 for the September quarter of fiscal 2023, compared to $1.40 in the prior year quarter.  Adjusted\ndiluted EPS, which is a non-GAAP measure that excludes items described below, increased 10.0 percent to $2.86 in the fiscal fourth\nquarter.  For fiscal year 2023, diluted EPS increased 6.1 percent to $8.53 .  For fiscal year 2023, adjusted diluted EPS increased 8.7\npercent to $11.99.\n \u201cCencora delivered strong performance in fiscal 2023, which was a seminal year for our company as our purpose-driven teams took\nkey steps to execute on our strategic imperatives and advance our position at the center of healthcare,\u201d said S teven H. Collis,\nChairman, President and Chief Executive Officer of Cencora.\n \u201cComing together as a unified team under our new identity as Cencora, we are showcasing our impact across pharmaceutical care\nand our global footprint,\" Mr.  Collis continued. ", "original_text": "For fiscal year 2023, adjusted diluted EPS increased 8.7\npercent to $11.99.\n", "page_label": "1", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "751beaeb-087d-4f58-8f44-70cbbdf28794", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5488add78a40417902779b76b00e7895fc7e708f8d0a1a78c0ed1f8110f22ecd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6b4ecd28-20b9-4081-ad83-8812f65cfd81", "node_type": "1", "metadata": {"window": "On the basis of U.S.  generally accepted accounting principles (GAAP), diluted\nearnings per share (EPS) was $1.72 for the September quarter of fiscal 2023, compared to $1.40 in the prior year quarter.  Adjusted\ndiluted EPS, which is a non-GAAP measure that excludes items described below, increased 10.0 percent to $2.86 in the fiscal fourth\nquarter.  For fiscal year 2023, diluted EPS increased 6.1 percent to $8.53 .  For fiscal year 2023, adjusted diluted EPS increased 8.7\npercent to $11.99.\n \u201cCencora delivered strong performance in fiscal 2023, which was a seminal year for our company as our purpose-driven teams took\nkey steps to execute on our strategic imperatives and advance our position at the center of healthcare,\u201d said S teven H. Collis,\nChairman, President and Chief Executive Officer of Cencora.\n \u201cComing together as a unified team under our new identity as Cencora, we are showcasing our impact across pharmaceutical care\nand our global footprint,\" Mr. ", "original_text": "For fiscal year 2023, diluted EPS increased 6.1 percent to $8.53 . ", "page_label": "1", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "989012318bf0bf6c6ffdbc01fdc29a289e07d141184afb94bf48cf09776b9157", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7bc3b277-cc63-4abd-a97b-23ce6f9c2744", "node_type": "1", "metadata": {"window": "Adjusted\ndiluted EPS, which is a non-GAAP measure that excludes items described below, increased 10.0 percent to $2.86 in the fiscal fourth\nquarter.  For fiscal year 2023, diluted EPS increased 6.1 percent to $8.53 .  For fiscal year 2023, adjusted diluted EPS increased 8.7\npercent to $11.99.\n \u201cCencora delivered strong performance in fiscal 2023, which was a seminal year for our company as our purpose-driven teams took\nkey steps to execute on our strategic imperatives and advance our position at the center of healthcare,\u201d said S teven H. Collis,\nChairman, President and Chief Executive Officer of Cencora.\n \u201cComing together as a unified team under our new identity as Cencora, we are showcasing our impact across pharmaceutical care\nand our global footprint,\" Mr.  Collis continued.  \"W e move into fiscal 2024 with strong momentum and remain focused on\ncontinuing to enhance our position as a partner of choice for our customers and pharmaceutical manufacturers as we drive\ndifferentiated value-creation for all of our stakeholders.\"\n", "original_text": "\u201cCencora delivered strong performance in fiscal 2023, which was a seminal year for our company as our purpose-driven teams took\nkey steps to execute on our strategic imperatives and advance our position at the center of healthcare,\u201d said S teven H. Collis,\nChairman, President and Chief Executive Officer of Cencora.\n"}, "hash": "0c643673cc2608631314cef3d8024b8f2a161c5808017e7b7fc548a1fe113187", "class_name": "RelatedNodeInfo"}}, "text": "For fiscal year 2023, adjusted diluted EPS increased 8.7\npercent to $11.99.\n", "start_char_idx": 1133, "end_char_idx": 1209, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7bc3b277-cc63-4abd-a97b-23ce6f9c2744": {"__data__": {"id_": "7bc3b277-cc63-4abd-a97b-23ce6f9c2744", "embedding": null, "metadata": {"window": "Adjusted\ndiluted EPS, which is a non-GAAP measure that excludes items described below, increased 10.0 percent to $2.86 in the fiscal fourth\nquarter.  For fiscal year 2023, diluted EPS increased 6.1 percent to $8.53 .  For fiscal year 2023, adjusted diluted EPS increased 8.7\npercent to $11.99.\n \u201cCencora delivered strong performance in fiscal 2023, which was a seminal year for our company as our purpose-driven teams took\nkey steps to execute on our strategic imperatives and advance our position at the center of healthcare,\u201d said S teven H. Collis,\nChairman, President and Chief Executive Officer of Cencora.\n \u201cComing together as a unified team under our new identity as Cencora, we are showcasing our impact across pharmaceutical care\nand our global footprint,\" Mr.  Collis continued.  \"W e move into fiscal 2024 with strong momentum and remain focused on\ncontinuing to enhance our position as a partner of choice for our customers and pharmaceutical manufacturers as we drive\ndifferentiated value-creation for all of our stakeholders.\"\n", "original_text": "\u201cCencora delivered strong performance in fiscal 2023, which was a seminal year for our company as our purpose-driven teams took\nkey steps to execute on our strategic imperatives and advance our position at the center of healthcare,\u201d said S teven H. Collis,\nChairman, President and Chief Executive Officer of Cencora.\n", "page_label": "1", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "751beaeb-087d-4f58-8f44-70cbbdf28794", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5488add78a40417902779b76b00e7895fc7e708f8d0a1a78c0ed1f8110f22ecd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "45925fee-f88d-4ba3-98ea-f67646da83db", "node_type": "1", "metadata": {"window": "generally accepted accounting principles (GAAP), diluted\nearnings per share (EPS) was $1.72 for the September quarter of fiscal 2023, compared to $1.40 in the prior year quarter.  Adjusted\ndiluted EPS, which is a non-GAAP measure that excludes items described below, increased 10.0 percent to $2.86 in the fiscal fourth\nquarter.  For fiscal year 2023, diluted EPS increased 6.1 percent to $8.53 .  For fiscal year 2023, adjusted diluted EPS increased 8.7\npercent to $11.99.\n \u201cCencora delivered strong performance in fiscal 2023, which was a seminal year for our company as our purpose-driven teams took\nkey steps to execute on our strategic imperatives and advance our position at the center of healthcare,\u201d said S teven H. Collis,\nChairman, President and Chief Executive Officer of Cencora.\n \u201cComing together as a unified team under our new identity as Cencora, we are showcasing our impact across pharmaceutical care\nand our global footprint,\" Mr.  Collis continued. ", "original_text": "For fiscal year 2023, adjusted diluted EPS increased 8.7\npercent to $11.99.\n", "page_label": "1", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d930f1810813afda82d66a59b5b5138f1c8f0e803367e2008bfa0cbbfebddfa4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4c2cde99-63ae-4a6a-9e5b-235f1a62beff", "node_type": "1", "metadata": {"window": "For fiscal year 2023, diluted EPS increased 6.1 percent to $8.53 .  For fiscal year 2023, adjusted diluted EPS increased 8.7\npercent to $11.99.\n \u201cCencora delivered strong performance in fiscal 2023, which was a seminal year for our company as our purpose-driven teams took\nkey steps to execute on our strategic imperatives and advance our position at the center of healthcare,\u201d said S teven H. Collis,\nChairman, President and Chief Executive Officer of Cencora.\n \u201cComing together as a unified team under our new identity as Cencora, we are showcasing our impact across pharmaceutical care\nand our global footprint,\" Mr.  Collis continued.  \"W e move into fiscal 2024 with strong momentum and remain focused on\ncontinuing to enhance our position as a partner of choice for our customers and pharmaceutical manufacturers as we drive\ndifferentiated value-creation for all of our stakeholders.\"\n Four th Quar ter Fiscal Y ear 2023 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $68.9B $68.9B\nGross Pr ofit $2.3B $2.3B\nOperating Expenses $1.8B $1.5B\nOperating Income $477M $801M\nInterest Expense, Net $61M $61M\nEffectiv e Tax Rat e 21.8% 21.6%\n1", "original_text": "\u201cComing together as a unified team under our new identity as Cencora, we are showcasing our impact across pharmaceutical care\nand our global footprint,\" Mr. "}, "hash": "1770acb34c972562b43c22c814da32890c7a522dc15eaf4a38ba81aadbe37dca", "class_name": "RelatedNodeInfo"}}, "text": "\u201cCencora delivered strong performance in fiscal 2023, which was a seminal year for our company as our purpose-driven teams took\nkey steps to execute on our strategic imperatives and advance our position at the center of healthcare,\u201d said S teven H. Collis,\nChairman, President and Chief Executive Officer of Cencora.\n", "start_char_idx": 1209, "end_char_idx": 1526, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4c2cde99-63ae-4a6a-9e5b-235f1a62beff": {"__data__": {"id_": "4c2cde99-63ae-4a6a-9e5b-235f1a62beff", "embedding": null, "metadata": {"window": "For fiscal year 2023, diluted EPS increased 6.1 percent to $8.53 .  For fiscal year 2023, adjusted diluted EPS increased 8.7\npercent to $11.99.\n \u201cCencora delivered strong performance in fiscal 2023, which was a seminal year for our company as our purpose-driven teams took\nkey steps to execute on our strategic imperatives and advance our position at the center of healthcare,\u201d said S teven H. Collis,\nChairman, President and Chief Executive Officer of Cencora.\n \u201cComing together as a unified team under our new identity as Cencora, we are showcasing our impact across pharmaceutical care\nand our global footprint,\" Mr.  Collis continued.  \"W e move into fiscal 2024 with strong momentum and remain focused on\ncontinuing to enhance our position as a partner of choice for our customers and pharmaceutical manufacturers as we drive\ndifferentiated value-creation for all of our stakeholders.\"\n Four th Quar ter Fiscal Y ear 2023 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $68.9B $68.9B\nGross Pr ofit $2.3B $2.3B\nOperating Expenses $1.8B $1.5B\nOperating Income $477M $801M\nInterest Expense, Net $61M $61M\nEffectiv e Tax Rat e 21.8% 21.6%\n1", "original_text": "\u201cComing together as a unified team under our new identity as Cencora, we are showcasing our impact across pharmaceutical care\nand our global footprint,\" Mr. ", "page_label": "1", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "751beaeb-087d-4f58-8f44-70cbbdf28794", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5488add78a40417902779b76b00e7895fc7e708f8d0a1a78c0ed1f8110f22ecd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7bc3b277-cc63-4abd-a97b-23ce6f9c2744", "node_type": "1", "metadata": {"window": "Adjusted\ndiluted EPS, which is a non-GAAP measure that excludes items described below, increased 10.0 percent to $2.86 in the fiscal fourth\nquarter.  For fiscal year 2023, diluted EPS increased 6.1 percent to $8.53 .  For fiscal year 2023, adjusted diluted EPS increased 8.7\npercent to $11.99.\n \u201cCencora delivered strong performance in fiscal 2023, which was a seminal year for our company as our purpose-driven teams took\nkey steps to execute on our strategic imperatives and advance our position at the center of healthcare,\u201d said S teven H. Collis,\nChairman, President and Chief Executive Officer of Cencora.\n \u201cComing together as a unified team under our new identity as Cencora, we are showcasing our impact across pharmaceutical care\nand our global footprint,\" Mr.  Collis continued.  \"W e move into fiscal 2024 with strong momentum and remain focused on\ncontinuing to enhance our position as a partner of choice for our customers and pharmaceutical manufacturers as we drive\ndifferentiated value-creation for all of our stakeholders.\"\n", "original_text": "\u201cCencora delivered strong performance in fiscal 2023, which was a seminal year for our company as our purpose-driven teams took\nkey steps to execute on our strategic imperatives and advance our position at the center of healthcare,\u201d said S teven H. Collis,\nChairman, President and Chief Executive Officer of Cencora.\n", "page_label": "1", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7609a87072b9e05ebd32114fd73c8c4dd8921076d5a03a1f46c9b02439023499", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4f8703b0-ed0a-477e-b757-2d56115db514", "node_type": "1", "metadata": {"window": "For fiscal year 2023, adjusted diluted EPS increased 8.7\npercent to $11.99.\n \u201cCencora delivered strong performance in fiscal 2023, which was a seminal year for our company as our purpose-driven teams took\nkey steps to execute on our strategic imperatives and advance our position at the center of healthcare,\u201d said S teven H. Collis,\nChairman, President and Chief Executive Officer of Cencora.\n \u201cComing together as a unified team under our new identity as Cencora, we are showcasing our impact across pharmaceutical care\nand our global footprint,\" Mr.  Collis continued.  \"W e move into fiscal 2024 with strong momentum and remain focused on\ncontinuing to enhance our position as a partner of choice for our customers and pharmaceutical manufacturers as we drive\ndifferentiated value-creation for all of our stakeholders.\"\n Four th Quar ter Fiscal Y ear 2023 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $68.9B $68.9B\nGross Pr ofit $2.3B $2.3B\nOperating Expenses $1.8B $1.5B\nOperating Income $477M $801M\nInterest Expense, Net $61M $61M\nEffectiv e Tax Rat e 21.8% 21.6%\n1", "original_text": "Collis continued. "}, "hash": "5777b4b17e18f02d01ce68a44a1dd7c9bc6e9563f6456b363838cc8a340aad4f", "class_name": "RelatedNodeInfo"}}, "text": "\u201cComing together as a unified team under our new identity as Cencora, we are showcasing our impact across pharmaceutical care\nand our global footprint,\" Mr. ", "start_char_idx": 1526, "end_char_idx": 1683, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4f8703b0-ed0a-477e-b757-2d56115db514": {"__data__": {"id_": "4f8703b0-ed0a-477e-b757-2d56115db514", "embedding": null, "metadata": {"window": "For fiscal year 2023, adjusted diluted EPS increased 8.7\npercent to $11.99.\n \u201cCencora delivered strong performance in fiscal 2023, which was a seminal year for our company as our purpose-driven teams took\nkey steps to execute on our strategic imperatives and advance our position at the center of healthcare,\u201d said S teven H. Collis,\nChairman, President and Chief Executive Officer of Cencora.\n \u201cComing together as a unified team under our new identity as Cencora, we are showcasing our impact across pharmaceutical care\nand our global footprint,\" Mr.  Collis continued.  \"W e move into fiscal 2024 with strong momentum and remain focused on\ncontinuing to enhance our position as a partner of choice for our customers and pharmaceutical manufacturers as we drive\ndifferentiated value-creation for all of our stakeholders.\"\n Four th Quar ter Fiscal Y ear 2023 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $68.9B $68.9B\nGross Pr ofit $2.3B $2.3B\nOperating Expenses $1.8B $1.5B\nOperating Income $477M $801M\nInterest Expense, Net $61M $61M\nEffectiv e Tax Rat e 21.8% 21.6%\n1", "original_text": "Collis continued. ", "page_label": "1", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "751beaeb-087d-4f58-8f44-70cbbdf28794", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5488add78a40417902779b76b00e7895fc7e708f8d0a1a78c0ed1f8110f22ecd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4c2cde99-63ae-4a6a-9e5b-235f1a62beff", "node_type": "1", "metadata": {"window": "For fiscal year 2023, diluted EPS increased 6.1 percent to $8.53 .  For fiscal year 2023, adjusted diluted EPS increased 8.7\npercent to $11.99.\n \u201cCencora delivered strong performance in fiscal 2023, which was a seminal year for our company as our purpose-driven teams took\nkey steps to execute on our strategic imperatives and advance our position at the center of healthcare,\u201d said S teven H. Collis,\nChairman, President and Chief Executive Officer of Cencora.\n \u201cComing together as a unified team under our new identity as Cencora, we are showcasing our impact across pharmaceutical care\nand our global footprint,\" Mr.  Collis continued.  \"W e move into fiscal 2024 with strong momentum and remain focused on\ncontinuing to enhance our position as a partner of choice for our customers and pharmaceutical manufacturers as we drive\ndifferentiated value-creation for all of our stakeholders.\"\n Four th Quar ter Fiscal Y ear 2023 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $68.9B $68.9B\nGross Pr ofit $2.3B $2.3B\nOperating Expenses $1.8B $1.5B\nOperating Income $477M $801M\nInterest Expense, Net $61M $61M\nEffectiv e Tax Rat e 21.8% 21.6%\n1", "original_text": "\u201cComing together as a unified team under our new identity as Cencora, we are showcasing our impact across pharmaceutical care\nand our global footprint,\" Mr. ", "page_label": "1", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "85ea7d8647109c01f0970a08c902d0480f04406140226889691ad07da788d3cb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b501d36d-525b-4697-ba72-5e3ea3095340", "node_type": "1", "metadata": {"window": "\u201cCencora delivered strong performance in fiscal 2023, which was a seminal year for our company as our purpose-driven teams took\nkey steps to execute on our strategic imperatives and advance our position at the center of healthcare,\u201d said S teven H. Collis,\nChairman, President and Chief Executive Officer of Cencora.\n \u201cComing together as a unified team under our new identity as Cencora, we are showcasing our impact across pharmaceutical care\nand our global footprint,\" Mr.  Collis continued.  \"W e move into fiscal 2024 with strong momentum and remain focused on\ncontinuing to enhance our position as a partner of choice for our customers and pharmaceutical manufacturers as we drive\ndifferentiated value-creation for all of our stakeholders.\"\n Four th Quar ter Fiscal Y ear 2023 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $68.9B $68.9B\nGross Pr ofit $2.3B $2.3B\nOperating Expenses $1.8B $1.5B\nOperating Income $477M $801M\nInterest Expense, Net $61M $61M\nEffectiv e Tax Rat e 21.8% 21.6%\n1", "original_text": "\"W e move into fiscal 2024 with strong momentum and remain focused on\ncontinuing to enhance our position as a partner of choice for our customers and pharmaceutical manufacturers as we drive\ndifferentiated value-creation for all of our stakeholders.\"\n"}, "hash": "8ba0e962c091a9d58409a6fa1f6508145321177e24c26e12327f4b05daea70f0", "class_name": "RelatedNodeInfo"}}, "text": "Collis continued. ", "start_char_idx": 1683, "end_char_idx": 1701, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b501d36d-525b-4697-ba72-5e3ea3095340": {"__data__": {"id_": "b501d36d-525b-4697-ba72-5e3ea3095340", "embedding": null, "metadata": {"window": "\u201cCencora delivered strong performance in fiscal 2023, which was a seminal year for our company as our purpose-driven teams took\nkey steps to execute on our strategic imperatives and advance our position at the center of healthcare,\u201d said S teven H. Collis,\nChairman, President and Chief Executive Officer of Cencora.\n \u201cComing together as a unified team under our new identity as Cencora, we are showcasing our impact across pharmaceutical care\nand our global footprint,\" Mr.  Collis continued.  \"W e move into fiscal 2024 with strong momentum and remain focused on\ncontinuing to enhance our position as a partner of choice for our customers and pharmaceutical manufacturers as we drive\ndifferentiated value-creation for all of our stakeholders.\"\n Four th Quar ter Fiscal Y ear 2023 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $68.9B $68.9B\nGross Pr ofit $2.3B $2.3B\nOperating Expenses $1.8B $1.5B\nOperating Income $477M $801M\nInterest Expense, Net $61M $61M\nEffectiv e Tax Rat e 21.8% 21.6%\n1", "original_text": "\"W e move into fiscal 2024 with strong momentum and remain focused on\ncontinuing to enhance our position as a partner of choice for our customers and pharmaceutical manufacturers as we drive\ndifferentiated value-creation for all of our stakeholders.\"\n", "page_label": "1", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "751beaeb-087d-4f58-8f44-70cbbdf28794", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5488add78a40417902779b76b00e7895fc7e708f8d0a1a78c0ed1f8110f22ecd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4f8703b0-ed0a-477e-b757-2d56115db514", "node_type": "1", "metadata": {"window": "For fiscal year 2023, adjusted diluted EPS increased 8.7\npercent to $11.99.\n \u201cCencora delivered strong performance in fiscal 2023, which was a seminal year for our company as our purpose-driven teams took\nkey steps to execute on our strategic imperatives and advance our position at the center of healthcare,\u201d said S teven H. Collis,\nChairman, President and Chief Executive Officer of Cencora.\n \u201cComing together as a unified team under our new identity as Cencora, we are showcasing our impact across pharmaceutical care\nand our global footprint,\" Mr.  Collis continued.  \"W e move into fiscal 2024 with strong momentum and remain focused on\ncontinuing to enhance our position as a partner of choice for our customers and pharmaceutical manufacturers as we drive\ndifferentiated value-creation for all of our stakeholders.\"\n Four th Quar ter Fiscal Y ear 2023 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $68.9B $68.9B\nGross Pr ofit $2.3B $2.3B\nOperating Expenses $1.8B $1.5B\nOperating Income $477M $801M\nInterest Expense, Net $61M $61M\nEffectiv e Tax Rat e 21.8% 21.6%\n1", "original_text": "Collis continued. ", "page_label": "1", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "41f5c4a76d7846b929f90c0e3488b5d18e415dea3be624f9ac658e7c53315e64", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0bd4223d-52e3-4c0d-9c81-c8d017fc56a6", "node_type": "1", "metadata": {"window": "\u201cComing together as a unified team under our new identity as Cencora, we are showcasing our impact across pharmaceutical care\nand our global footprint,\" Mr.  Collis continued.  \"W e move into fiscal 2024 with strong momentum and remain focused on\ncontinuing to enhance our position as a partner of choice for our customers and pharmaceutical manufacturers as we drive\ndifferentiated value-creation for all of our stakeholders.\"\n Four th Quar ter Fiscal Y ear 2023 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $68.9B $68.9B\nGross Pr ofit $2.3B $2.3B\nOperating Expenses $1.8B $1.5B\nOperating Income $477M $801M\nInterest Expense, Net $61M $61M\nEffectiv e Tax Rat e 21.8% 21.6%\n1", "original_text": "Four th Quar ter Fiscal Y ear 2023 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $68.9B $68.9B\nGross Pr ofit $2.3B $2.3B\nOperating Expenses $1.8B $1.5B\nOperating Income $477M $801M\nInterest Expense, Net $61M $61M\nEffectiv e Tax Rat e 21.8% 21.6%\n1"}, "hash": "9f76fd2edbd0a9fd41407783d24b434d8845235a96b778ef5b3ddc7209ec4fe8", "class_name": "RelatedNodeInfo"}}, "text": "\"W e move into fiscal 2024 with strong momentum and remain focused on\ncontinuing to enhance our position as a partner of choice for our customers and pharmaceutical manufacturers as we drive\ndifferentiated value-creation for all of our stakeholders.\"\n", "start_char_idx": 1701, "end_char_idx": 1952, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0bd4223d-52e3-4c0d-9c81-c8d017fc56a6": {"__data__": {"id_": "0bd4223d-52e3-4c0d-9c81-c8d017fc56a6", "embedding": null, "metadata": {"window": "\u201cComing together as a unified team under our new identity as Cencora, we are showcasing our impact across pharmaceutical care\nand our global footprint,\" Mr.  Collis continued.  \"W e move into fiscal 2024 with strong momentum and remain focused on\ncontinuing to enhance our position as a partner of choice for our customers and pharmaceutical manufacturers as we drive\ndifferentiated value-creation for all of our stakeholders.\"\n Four th Quar ter Fiscal Y ear 2023 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $68.9B $68.9B\nGross Pr ofit $2.3B $2.3B\nOperating Expenses $1.8B $1.5B\nOperating Income $477M $801M\nInterest Expense, Net $61M $61M\nEffectiv e Tax Rat e 21.8% 21.6%\n1", "original_text": "Four th Quar ter Fiscal Y ear 2023 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $68.9B $68.9B\nGross Pr ofit $2.3B $2.3B\nOperating Expenses $1.8B $1.5B\nOperating Income $477M $801M\nInterest Expense, Net $61M $61M\nEffectiv e Tax Rat e 21.8% 21.6%\n1", "page_label": "1", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "751beaeb-087d-4f58-8f44-70cbbdf28794", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5488add78a40417902779b76b00e7895fc7e708f8d0a1a78c0ed1f8110f22ecd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b501d36d-525b-4697-ba72-5e3ea3095340", "node_type": "1", "metadata": {"window": "\u201cCencora delivered strong performance in fiscal 2023, which was a seminal year for our company as our purpose-driven teams took\nkey steps to execute on our strategic imperatives and advance our position at the center of healthcare,\u201d said S teven H. Collis,\nChairman, President and Chief Executive Officer of Cencora.\n \u201cComing together as a unified team under our new identity as Cencora, we are showcasing our impact across pharmaceutical care\nand our global footprint,\" Mr.  Collis continued.  \"W e move into fiscal 2024 with strong momentum and remain focused on\ncontinuing to enhance our position as a partner of choice for our customers and pharmaceutical manufacturers as we drive\ndifferentiated value-creation for all of our stakeholders.\"\n Four th Quar ter Fiscal Y ear 2023 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $68.9B $68.9B\nGross Pr ofit $2.3B $2.3B\nOperating Expenses $1.8B $1.5B\nOperating Income $477M $801M\nInterest Expense, Net $61M $61M\nEffectiv e Tax Rat e 21.8% 21.6%\n1", "original_text": "\"W e move into fiscal 2024 with strong momentum and remain focused on\ncontinuing to enhance our position as a partner of choice for our customers and pharmaceutical manufacturers as we drive\ndifferentiated value-creation for all of our stakeholders.\"\n", "page_label": "1", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f8c341eb5968ab0a26f27460b0013154e31fbfb8a892d356cd52dc44bf7b32c2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1480aff5-c5c0-4511-8879-fd795907f0a9", "node_type": "1", "metadata": {"window": "Net Income A ttributable t o Cencora $351M $581M\nDilut ed Earnings P er Shar e $1.72 $2.86\nDilut ed Shar es Outstanding 203.4M 203.4M\nBelow, Cencora presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly and fiscal year results.\n In the tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental Information\nRegarding Non-GAAP Financial Measures following the tables.\n Four th Quar ter GAAP R esults\nRevenue:  In the fourth quarter of fiscal 2023, revenue was $68.9 billion, up 12.7 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 13.0 percent increase in revenue within U.S. ", "original_text": "Net Income A ttributable t o Cencora $351M $581M\nDilut ed Earnings P er Shar e $1.72 $2.86\nDilut ed Shar es Outstanding 203.4M 203.4M\nBelow, Cencora presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly and fiscal year results.\n"}, "hash": "e4aa5e43d15af3eb86f683984cb46cbe4e6ace0e2085a502628541ca6de2b404", "class_name": "RelatedNodeInfo"}}, "text": "Four th Quar ter Fiscal Y ear 2023 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $68.9B $68.9B\nGross Pr ofit $2.3B $2.3B\nOperating Expenses $1.8B $1.5B\nOperating Income $477M $801M\nInterest Expense, Net $61M $61M\nEffectiv e Tax Rat e 21.8% 21.6%\n1", "start_char_idx": 1952, "end_char_idx": 2206, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1480aff5-c5c0-4511-8879-fd795907f0a9": {"__data__": {"id_": "1480aff5-c5c0-4511-8879-fd795907f0a9", "embedding": null, "metadata": {"window": "Net Income A ttributable t o Cencora $351M $581M\nDilut ed Earnings P er Shar e $1.72 $2.86\nDilut ed Shar es Outstanding 203.4M 203.4M\nBelow, Cencora presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly and fiscal year results.\n In the tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental Information\nRegarding Non-GAAP Financial Measures following the tables.\n Four th Quar ter GAAP R esults\nRevenue:  In the fourth quarter of fiscal 2023, revenue was $68.9 billion, up 12.7 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 13.0 percent increase in revenue within U.S. ", "original_text": "Net Income A ttributable t o Cencora $351M $581M\nDilut ed Earnings P er Shar e $1.72 $2.86\nDilut ed Shar es Outstanding 203.4M 203.4M\nBelow, Cencora presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly and fiscal year results.\n", "page_label": "2", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8d68cffe-a6e2-4827-9f5b-bc33a23ae109", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5a32713f40aba7e7a72c91cdb5ee51314462c4550a91df39ba31447fae2944c8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0bd4223d-52e3-4c0d-9c81-c8d017fc56a6", "node_type": "1", "metadata": {"window": "\u201cComing together as a unified team under our new identity as Cencora, we are showcasing our impact across pharmaceutical care\nand our global footprint,\" Mr.  Collis continued.  \"W e move into fiscal 2024 with strong momentum and remain focused on\ncontinuing to enhance our position as a partner of choice for our customers and pharmaceutical manufacturers as we drive\ndifferentiated value-creation for all of our stakeholders.\"\n Four th Quar ter Fiscal Y ear 2023 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $68.9B $68.9B\nGross Pr ofit $2.3B $2.3B\nOperating Expenses $1.8B $1.5B\nOperating Income $477M $801M\nInterest Expense, Net $61M $61M\nEffectiv e Tax Rat e 21.8% 21.6%\n1", "original_text": "Four th Quar ter Fiscal Y ear 2023 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $68.9B $68.9B\nGross Pr ofit $2.3B $2.3B\nOperating Expenses $1.8B $1.5B\nOperating Income $477M $801M\nInterest Expense, Net $61M $61M\nEffectiv e Tax Rat e 21.8% 21.6%\n1", "page_label": "1", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f60caa8ec5b656ba1955d030ab6d4c7ddb3f0346b7c467fb436ab726bea8b010", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dc4ef9c5-d141-4ae0-b5cf-a94ee37d76c0", "node_type": "1", "metadata": {"window": "Net Income A ttributable t o Cencora $351M $581M\nDilut ed Earnings P er Shar e $1.72 $2.86\nDilut ed Shar es Outstanding 203.4M 203.4M\nBelow, Cencora presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly and fiscal year results.\n In the tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental Information\nRegarding Non-GAAP Financial Measures following the tables.\n Four th Quar ter GAAP R esults\nRevenue:  In the fourth quarter of fiscal 2023, revenue was $68.9 billion, up 12.7 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 13.0 percent increase in revenue within U.S.  Healthcare Solutions and a 9.5 percent increase in\nrevenue within International Healthcare Solutions.\n", "original_text": "In the tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented. "}, "hash": "3fb4f555b6adcb8bea0a64934f79e0fcf49515074b4e85079f3eb5e3379fbfe0", "class_name": "RelatedNodeInfo"}}, "text": "Net Income A ttributable t o Cencora $351M $581M\nDilut ed Earnings P er Shar e $1.72 $2.86\nDilut ed Shar es Outstanding 203.4M 203.4M\nBelow, Cencora presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly and fiscal year results.\n", "start_char_idx": 0, "end_char_idx": 261, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dc4ef9c5-d141-4ae0-b5cf-a94ee37d76c0": {"__data__": {"id_": "dc4ef9c5-d141-4ae0-b5cf-a94ee37d76c0", "embedding": null, "metadata": {"window": "Net Income A ttributable t o Cencora $351M $581M\nDilut ed Earnings P er Shar e $1.72 $2.86\nDilut ed Shar es Outstanding 203.4M 203.4M\nBelow, Cencora presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly and fiscal year results.\n In the tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental Information\nRegarding Non-GAAP Financial Measures following the tables.\n Four th Quar ter GAAP R esults\nRevenue:  In the fourth quarter of fiscal 2023, revenue was $68.9 billion, up 12.7 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 13.0 percent increase in revenue within U.S.  Healthcare Solutions and a 9.5 percent increase in\nrevenue within International Healthcare Solutions.\n", "original_text": "In the tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented. ", "page_label": "2", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8d68cffe-a6e2-4827-9f5b-bc33a23ae109", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5a32713f40aba7e7a72c91cdb5ee51314462c4550a91df39ba31447fae2944c8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1480aff5-c5c0-4511-8879-fd795907f0a9", "node_type": "1", "metadata": {"window": "Net Income A ttributable t o Cencora $351M $581M\nDilut ed Earnings P er Shar e $1.72 $2.86\nDilut ed Shar es Outstanding 203.4M 203.4M\nBelow, Cencora presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly and fiscal year results.\n In the tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental Information\nRegarding Non-GAAP Financial Measures following the tables.\n Four th Quar ter GAAP R esults\nRevenue:  In the fourth quarter of fiscal 2023, revenue was $68.9 billion, up 12.7 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 13.0 percent increase in revenue within U.S. ", "original_text": "Net Income A ttributable t o Cencora $351M $581M\nDilut ed Earnings P er Shar e $1.72 $2.86\nDilut ed Shar es Outstanding 203.4M 203.4M\nBelow, Cencora presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly and fiscal year results.\n", "page_label": "2", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ee4a99d988c3442bd05fe19d6294f1a47e850433003024de8573fa42d595d8a0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9d821aef-9c5c-4c75-ab18-5054e605106d", "node_type": "1", "metadata": {"window": "Net Income A ttributable t o Cencora $351M $581M\nDilut ed Earnings P er Shar e $1.72 $2.86\nDilut ed Shar es Outstanding 203.4M 203.4M\nBelow, Cencora presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly and fiscal year results.\n In the tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental Information\nRegarding Non-GAAP Financial Measures following the tables.\n Four th Quar ter GAAP R esults\nRevenue:  In the fourth quarter of fiscal 2023, revenue was $68.9 billion, up 12.7 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 13.0 percent increase in revenue within U.S.  Healthcare Solutions and a 9.5 percent increase in\nrevenue within International Healthcare Solutions.\n Gross Profit:  Gross profit in the fiscal 2023 fourth quarter was $2.3 billion, a 13.5 percent increase compared to the same\nperiod in the previous fiscal year primarily due to increases in gross profit in both reportable segments and gains from\nantitrust litigation settlements in the current year quarter. ", "original_text": "For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental Information\nRegarding Non-GAAP Financial Measures following the tables.\n"}, "hash": "5152e9bf12981799d15d90f7242883b7ecb973524382ffe59aa03a24df1be945", "class_name": "RelatedNodeInfo"}}, "text": "In the tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented. ", "start_char_idx": 261, "end_char_idx": 353, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9d821aef-9c5c-4c75-ab18-5054e605106d": {"__data__": {"id_": "9d821aef-9c5c-4c75-ab18-5054e605106d", "embedding": null, "metadata": {"window": "Net Income A ttributable t o Cencora $351M $581M\nDilut ed Earnings P er Shar e $1.72 $2.86\nDilut ed Shar es Outstanding 203.4M 203.4M\nBelow, Cencora presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly and fiscal year results.\n In the tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental Information\nRegarding Non-GAAP Financial Measures following the tables.\n Four th Quar ter GAAP R esults\nRevenue:  In the fourth quarter of fiscal 2023, revenue was $68.9 billion, up 12.7 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 13.0 percent increase in revenue within U.S.  Healthcare Solutions and a 9.5 percent increase in\nrevenue within International Healthcare Solutions.\n Gross Profit:  Gross profit in the fiscal 2023 fourth quarter was $2.3 billion, a 13.5 percent increase compared to the same\nperiod in the previous fiscal year primarily due to increases in gross profit in both reportable segments and gains from\nantitrust litigation settlements in the current year quarter. ", "original_text": "For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental Information\nRegarding Non-GAAP Financial Measures following the tables.\n", "page_label": "2", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8d68cffe-a6e2-4827-9f5b-bc33a23ae109", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5a32713f40aba7e7a72c91cdb5ee51314462c4550a91df39ba31447fae2944c8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dc4ef9c5-d141-4ae0-b5cf-a94ee37d76c0", "node_type": "1", "metadata": {"window": "Net Income A ttributable t o Cencora $351M $581M\nDilut ed Earnings P er Shar e $1.72 $2.86\nDilut ed Shar es Outstanding 203.4M 203.4M\nBelow, Cencora presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly and fiscal year results.\n In the tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental Information\nRegarding Non-GAAP Financial Measures following the tables.\n Four th Quar ter GAAP R esults\nRevenue:  In the fourth quarter of fiscal 2023, revenue was $68.9 billion, up 12.7 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 13.0 percent increase in revenue within U.S.  Healthcare Solutions and a 9.5 percent increase in\nrevenue within International Healthcare Solutions.\n", "original_text": "In the tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented. ", "page_label": "2", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e1eae4f3c79fde468d519315aa8d5a00d151fc2078641a41d1c054475d199bc8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8c44791a-2860-406f-a04c-bee689fc5f90", "node_type": "1", "metadata": {"window": "Net Income A ttributable t o Cencora $351M $581M\nDilut ed Earnings P er Shar e $1.72 $2.86\nDilut ed Shar es Outstanding 203.4M 203.4M\nBelow, Cencora presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly and fiscal year results.\n In the tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental Information\nRegarding Non-GAAP Financial Measures following the tables.\n Four th Quar ter GAAP R esults\nRevenue:  In the fourth quarter of fiscal 2023, revenue was $68.9 billion, up 12.7 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 13.0 percent increase in revenue within U.S.  Healthcare Solutions and a 9.5 percent increase in\nrevenue within International Healthcare Solutions.\n Gross Profit:  Gross profit in the fiscal 2023 fourth quarter was $2.3 billion, a 13.5 percent increase compared to the same\nperiod in the previous fiscal year primarily due to increases in gross profit in both reportable segments and gains from\nantitrust litigation settlements in the current year quarter.  Gross profit as a percentage of revenue was 3.27 percent, an\nincrease of 2 basis points from the prior year quarter.\n", "original_text": "Four th Quar ter GAAP R esults\nRevenue:  In the fourth quarter of fiscal 2023, revenue was $68.9 billion, up 12.7 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 13.0 percent increase in revenue within U.S. "}, "hash": "10935b999cf1c0be081e2f3802efc83ec57ca10be875c60f7a3b54757cd991bd", "class_name": "RelatedNodeInfo"}}, "text": "For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental Information\nRegarding Non-GAAP Financial Measures following the tables.\n", "start_char_idx": 353, "end_char_idx": 573, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8c44791a-2860-406f-a04c-bee689fc5f90": {"__data__": {"id_": "8c44791a-2860-406f-a04c-bee689fc5f90", "embedding": null, "metadata": {"window": "Net Income A ttributable t o Cencora $351M $581M\nDilut ed Earnings P er Shar e $1.72 $2.86\nDilut ed Shar es Outstanding 203.4M 203.4M\nBelow, Cencora presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly and fiscal year results.\n In the tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental Information\nRegarding Non-GAAP Financial Measures following the tables.\n Four th Quar ter GAAP R esults\nRevenue:  In the fourth quarter of fiscal 2023, revenue was $68.9 billion, up 12.7 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 13.0 percent increase in revenue within U.S.  Healthcare Solutions and a 9.5 percent increase in\nrevenue within International Healthcare Solutions.\n Gross Profit:  Gross profit in the fiscal 2023 fourth quarter was $2.3 billion, a 13.5 percent increase compared to the same\nperiod in the previous fiscal year primarily due to increases in gross profit in both reportable segments and gains from\nantitrust litigation settlements in the current year quarter.  Gross profit as a percentage of revenue was 3.27 percent, an\nincrease of 2 basis points from the prior year quarter.\n", "original_text": "Four th Quar ter GAAP R esults\nRevenue:  In the fourth quarter of fiscal 2023, revenue was $68.9 billion, up 12.7 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 13.0 percent increase in revenue within U.S. ", "page_label": "2", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8d68cffe-a6e2-4827-9f5b-bc33a23ae109", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5a32713f40aba7e7a72c91cdb5ee51314462c4550a91df39ba31447fae2944c8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9d821aef-9c5c-4c75-ab18-5054e605106d", "node_type": "1", "metadata": {"window": "Net Income A ttributable t o Cencora $351M $581M\nDilut ed Earnings P er Shar e $1.72 $2.86\nDilut ed Shar es Outstanding 203.4M 203.4M\nBelow, Cencora presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly and fiscal year results.\n In the tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental Information\nRegarding Non-GAAP Financial Measures following the tables.\n Four th Quar ter GAAP R esults\nRevenue:  In the fourth quarter of fiscal 2023, revenue was $68.9 billion, up 12.7 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 13.0 percent increase in revenue within U.S.  Healthcare Solutions and a 9.5 percent increase in\nrevenue within International Healthcare Solutions.\n Gross Profit:  Gross profit in the fiscal 2023 fourth quarter was $2.3 billion, a 13.5 percent increase compared to the same\nperiod in the previous fiscal year primarily due to increases in gross profit in both reportable segments and gains from\nantitrust litigation settlements in the current year quarter. ", "original_text": "For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental Information\nRegarding Non-GAAP Financial Measures following the tables.\n", "page_label": "2", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "71fc6e4717b6932dac63607f79f5ee91a2c9e6ac5f179af1559dc856e1465add", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "013a3f5e-7c5a-41ae-ade5-09699ec5f0db", "node_type": "1", "metadata": {"window": "In the tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental Information\nRegarding Non-GAAP Financial Measures following the tables.\n Four th Quar ter GAAP R esults\nRevenue:  In the fourth quarter of fiscal 2023, revenue was $68.9 billion, up 12.7 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 13.0 percent increase in revenue within U.S.  Healthcare Solutions and a 9.5 percent increase in\nrevenue within International Healthcare Solutions.\n Gross Profit:  Gross profit in the fiscal 2023 fourth quarter was $2.3 billion, a 13.5 percent increase compared to the same\nperiod in the previous fiscal year primarily due to increases in gross profit in both reportable segments and gains from\nantitrust litigation settlements in the current year quarter.  Gross profit as a percentage of revenue was 3.27 percent, an\nincrease of 2 basis points from the prior year quarter.\n Operating Expenses:  In the fourth quarter of fiscal 2023, operating expenses were $1.8 billion, up 16.0 percent from the same\nperiod last fiscal year, primarily driven by increases in distribution, selling, and administrative expenses, and amortization\nexpense compared to the prior year quarter. ", "original_text": "Healthcare Solutions and a 9.5 percent increase in\nrevenue within International Healthcare Solutions.\n"}, "hash": "2dfda57bacf83dcbbc6906a80282e97b20f6fad3a7a2eefe3273b66abc29ef7d", "class_name": "RelatedNodeInfo"}}, "text": "Four th Quar ter GAAP R esults\nRevenue:  In the fourth quarter of fiscal 2023, revenue was $68.9 billion, up 12.7 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 13.0 percent increase in revenue within U.S. ", "start_char_idx": 573, "end_char_idx": 811, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "013a3f5e-7c5a-41ae-ade5-09699ec5f0db": {"__data__": {"id_": "013a3f5e-7c5a-41ae-ade5-09699ec5f0db", "embedding": null, "metadata": {"window": "In the tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental Information\nRegarding Non-GAAP Financial Measures following the tables.\n Four th Quar ter GAAP R esults\nRevenue:  In the fourth quarter of fiscal 2023, revenue was $68.9 billion, up 12.7 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 13.0 percent increase in revenue within U.S.  Healthcare Solutions and a 9.5 percent increase in\nrevenue within International Healthcare Solutions.\n Gross Profit:  Gross profit in the fiscal 2023 fourth quarter was $2.3 billion, a 13.5 percent increase compared to the same\nperiod in the previous fiscal year primarily due to increases in gross profit in both reportable segments and gains from\nantitrust litigation settlements in the current year quarter.  Gross profit as a percentage of revenue was 3.27 percent, an\nincrease of 2 basis points from the prior year quarter.\n Operating Expenses:  In the fourth quarter of fiscal 2023, operating expenses were $1.8 billion, up 16.0 percent from the same\nperiod last fiscal year, primarily driven by increases in distribution, selling, and administrative expenses, and amortization\nexpense compared to the prior year quarter. ", "original_text": "Healthcare Solutions and a 9.5 percent increase in\nrevenue within International Healthcare Solutions.\n", "page_label": "2", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8d68cffe-a6e2-4827-9f5b-bc33a23ae109", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5a32713f40aba7e7a72c91cdb5ee51314462c4550a91df39ba31447fae2944c8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8c44791a-2860-406f-a04c-bee689fc5f90", "node_type": "1", "metadata": {"window": "Net Income A ttributable t o Cencora $351M $581M\nDilut ed Earnings P er Shar e $1.72 $2.86\nDilut ed Shar es Outstanding 203.4M 203.4M\nBelow, Cencora presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly and fiscal year results.\n In the tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental Information\nRegarding Non-GAAP Financial Measures following the tables.\n Four th Quar ter GAAP R esults\nRevenue:  In the fourth quarter of fiscal 2023, revenue was $68.9 billion, up 12.7 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 13.0 percent increase in revenue within U.S.  Healthcare Solutions and a 9.5 percent increase in\nrevenue within International Healthcare Solutions.\n Gross Profit:  Gross profit in the fiscal 2023 fourth quarter was $2.3 billion, a 13.5 percent increase compared to the same\nperiod in the previous fiscal year primarily due to increases in gross profit in both reportable segments and gains from\nantitrust litigation settlements in the current year quarter.  Gross profit as a percentage of revenue was 3.27 percent, an\nincrease of 2 basis points from the prior year quarter.\n", "original_text": "Four th Quar ter GAAP R esults\nRevenue:  In the fourth quarter of fiscal 2023, revenue was $68.9 billion, up 12.7 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 13.0 percent increase in revenue within U.S. ", "page_label": "2", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "00d1cba302e3f1ef1ff64a5118aa00643db852fb66884c095d9479b0298d9571", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1705c2b2-fc15-4cc9-8eac-79d82cab8bbb", "node_type": "1", "metadata": {"window": "For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental Information\nRegarding Non-GAAP Financial Measures following the tables.\n Four th Quar ter GAAP R esults\nRevenue:  In the fourth quarter of fiscal 2023, revenue was $68.9 billion, up 12.7 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 13.0 percent increase in revenue within U.S.  Healthcare Solutions and a 9.5 percent increase in\nrevenue within International Healthcare Solutions.\n Gross Profit:  Gross profit in the fiscal 2023 fourth quarter was $2.3 billion, a 13.5 percent increase compared to the same\nperiod in the previous fiscal year primarily due to increases in gross profit in both reportable segments and gains from\nantitrust litigation settlements in the current year quarter.  Gross profit as a percentage of revenue was 3.27 percent, an\nincrease of 2 basis points from the prior year quarter.\n Operating Expenses:  In the fourth quarter of fiscal 2023, operating expenses were $1.8 billion, up 16.0 percent from the same\nperiod last fiscal year, primarily driven by increases in distribution, selling, and administrative expenses, and amortization\nexpense compared to the prior year quarter.  Operating expenses as a percentage of revenue in the fiscal 2023 fourth quarter\nwere 2.58 percent compared to 2.50 percent for the same period in the previous fiscal year.\n", "original_text": "Gross Profit:  Gross profit in the fiscal 2023 fourth quarter was $2.3 billion, a 13.5 percent increase compared to the same\nperiod in the previous fiscal year primarily due to increases in gross profit in both reportable segments and gains from\nantitrust litigation settlements in the current year quarter. "}, "hash": "41c9a8e764282938f703474271501e933c6f04869346e093ae16998d2429204b", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions and a 9.5 percent increase in\nrevenue within International Healthcare Solutions.\n", "start_char_idx": 811, "end_char_idx": 913, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1705c2b2-fc15-4cc9-8eac-79d82cab8bbb": {"__data__": {"id_": "1705c2b2-fc15-4cc9-8eac-79d82cab8bbb", "embedding": null, "metadata": {"window": "For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental Information\nRegarding Non-GAAP Financial Measures following the tables.\n Four th Quar ter GAAP R esults\nRevenue:  In the fourth quarter of fiscal 2023, revenue was $68.9 billion, up 12.7 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 13.0 percent increase in revenue within U.S.  Healthcare Solutions and a 9.5 percent increase in\nrevenue within International Healthcare Solutions.\n Gross Profit:  Gross profit in the fiscal 2023 fourth quarter was $2.3 billion, a 13.5 percent increase compared to the same\nperiod in the previous fiscal year primarily due to increases in gross profit in both reportable segments and gains from\nantitrust litigation settlements in the current year quarter.  Gross profit as a percentage of revenue was 3.27 percent, an\nincrease of 2 basis points from the prior year quarter.\n Operating Expenses:  In the fourth quarter of fiscal 2023, operating expenses were $1.8 billion, up 16.0 percent from the same\nperiod last fiscal year, primarily driven by increases in distribution, selling, and administrative expenses, and amortization\nexpense compared to the prior year quarter.  Operating expenses as a percentage of revenue in the fiscal 2023 fourth quarter\nwere 2.58 percent compared to 2.50 percent for the same period in the previous fiscal year.\n", "original_text": "Gross Profit:  Gross profit in the fiscal 2023 fourth quarter was $2.3 billion, a 13.5 percent increase compared to the same\nperiod in the previous fiscal year primarily due to increases in gross profit in both reportable segments and gains from\nantitrust litigation settlements in the current year quarter. ", "page_label": "2", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8d68cffe-a6e2-4827-9f5b-bc33a23ae109", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5a32713f40aba7e7a72c91cdb5ee51314462c4550a91df39ba31447fae2944c8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "013a3f5e-7c5a-41ae-ade5-09699ec5f0db", "node_type": "1", "metadata": {"window": "In the tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental Information\nRegarding Non-GAAP Financial Measures following the tables.\n Four th Quar ter GAAP R esults\nRevenue:  In the fourth quarter of fiscal 2023, revenue was $68.9 billion, up 12.7 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 13.0 percent increase in revenue within U.S.  Healthcare Solutions and a 9.5 percent increase in\nrevenue within International Healthcare Solutions.\n Gross Profit:  Gross profit in the fiscal 2023 fourth quarter was $2.3 billion, a 13.5 percent increase compared to the same\nperiod in the previous fiscal year primarily due to increases in gross profit in both reportable segments and gains from\nantitrust litigation settlements in the current year quarter.  Gross profit as a percentage of revenue was 3.27 percent, an\nincrease of 2 basis points from the prior year quarter.\n Operating Expenses:  In the fourth quarter of fiscal 2023, operating expenses were $1.8 billion, up 16.0 percent from the same\nperiod last fiscal year, primarily driven by increases in distribution, selling, and administrative expenses, and amortization\nexpense compared to the prior year quarter. ", "original_text": "Healthcare Solutions and a 9.5 percent increase in\nrevenue within International Healthcare Solutions.\n", "page_label": "2", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eb1d83c483abb38381eea1b79292f8d482b1352346cf407caa122353ed326373", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1aa202f4-72d5-4766-8e30-cd400fd352b2", "node_type": "1", "metadata": {"window": "Four th Quar ter GAAP R esults\nRevenue:  In the fourth quarter of fiscal 2023, revenue was $68.9 billion, up 12.7 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 13.0 percent increase in revenue within U.S.  Healthcare Solutions and a 9.5 percent increase in\nrevenue within International Healthcare Solutions.\n Gross Profit:  Gross profit in the fiscal 2023 fourth quarter was $2.3 billion, a 13.5 percent increase compared to the same\nperiod in the previous fiscal year primarily due to increases in gross profit in both reportable segments and gains from\nantitrust litigation settlements in the current year quarter.  Gross profit as a percentage of revenue was 3.27 percent, an\nincrease of 2 basis points from the prior year quarter.\n Operating Expenses:  In the fourth quarter of fiscal 2023, operating expenses were $1.8 billion, up 16.0 percent from the same\nperiod last fiscal year, primarily driven by increases in distribution, selling, and administrative expenses, and amortization\nexpense compared to the prior year quarter.  Operating expenses as a percentage of revenue in the fiscal 2023 fourth quarter\nwere 2.58 percent compared to 2.50 percent for the same period in the previous fiscal year.\n Operating Income:  In the fiscal 2023 fourth quarter, operating income was $476.9 million, up 4.9 percent compared to the\nsame period in the previous fiscal year due to the increase in gross profit, offset in part by the increase in operating expenses.\n", "original_text": "Gross profit as a percentage of revenue was 3.27 percent, an\nincrease of 2 basis points from the prior year quarter.\n"}, "hash": "1f3bc614a131b940ebcea792fe3ec19d807d45df6ce54eb678fb4643e504341a", "class_name": "RelatedNodeInfo"}}, "text": "Gross Profit:  Gross profit in the fiscal 2023 fourth quarter was $2.3 billion, a 13.5 percent increase compared to the same\nperiod in the previous fiscal year primarily due to increases in gross profit in both reportable segments and gains from\nantitrust litigation settlements in the current year quarter. ", "start_char_idx": 913, "end_char_idx": 1221, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1aa202f4-72d5-4766-8e30-cd400fd352b2": {"__data__": {"id_": "1aa202f4-72d5-4766-8e30-cd400fd352b2", "embedding": null, "metadata": {"window": "Four th Quar ter GAAP R esults\nRevenue:  In the fourth quarter of fiscal 2023, revenue was $68.9 billion, up 12.7 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 13.0 percent increase in revenue within U.S.  Healthcare Solutions and a 9.5 percent increase in\nrevenue within International Healthcare Solutions.\n Gross Profit:  Gross profit in the fiscal 2023 fourth quarter was $2.3 billion, a 13.5 percent increase compared to the same\nperiod in the previous fiscal year primarily due to increases in gross profit in both reportable segments and gains from\nantitrust litigation settlements in the current year quarter.  Gross profit as a percentage of revenue was 3.27 percent, an\nincrease of 2 basis points from the prior year quarter.\n Operating Expenses:  In the fourth quarter of fiscal 2023, operating expenses were $1.8 billion, up 16.0 percent from the same\nperiod last fiscal year, primarily driven by increases in distribution, selling, and administrative expenses, and amortization\nexpense compared to the prior year quarter.  Operating expenses as a percentage of revenue in the fiscal 2023 fourth quarter\nwere 2.58 percent compared to 2.50 percent for the same period in the previous fiscal year.\n Operating Income:  In the fiscal 2023 fourth quarter, operating income was $476.9 million, up 4.9 percent compared to the\nsame period in the previous fiscal year due to the increase in gross profit, offset in part by the increase in operating expenses.\n", "original_text": "Gross profit as a percentage of revenue was 3.27 percent, an\nincrease of 2 basis points from the prior year quarter.\n", "page_label": "2", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8d68cffe-a6e2-4827-9f5b-bc33a23ae109", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5a32713f40aba7e7a72c91cdb5ee51314462c4550a91df39ba31447fae2944c8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1705c2b2-fc15-4cc9-8eac-79d82cab8bbb", "node_type": "1", "metadata": {"window": "For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental Information\nRegarding Non-GAAP Financial Measures following the tables.\n Four th Quar ter GAAP R esults\nRevenue:  In the fourth quarter of fiscal 2023, revenue was $68.9 billion, up 12.7 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 13.0 percent increase in revenue within U.S.  Healthcare Solutions and a 9.5 percent increase in\nrevenue within International Healthcare Solutions.\n Gross Profit:  Gross profit in the fiscal 2023 fourth quarter was $2.3 billion, a 13.5 percent increase compared to the same\nperiod in the previous fiscal year primarily due to increases in gross profit in both reportable segments and gains from\nantitrust litigation settlements in the current year quarter.  Gross profit as a percentage of revenue was 3.27 percent, an\nincrease of 2 basis points from the prior year quarter.\n Operating Expenses:  In the fourth quarter of fiscal 2023, operating expenses were $1.8 billion, up 16.0 percent from the same\nperiod last fiscal year, primarily driven by increases in distribution, selling, and administrative expenses, and amortization\nexpense compared to the prior year quarter.  Operating expenses as a percentage of revenue in the fiscal 2023 fourth quarter\nwere 2.58 percent compared to 2.50 percent for the same period in the previous fiscal year.\n", "original_text": "Gross Profit:  Gross profit in the fiscal 2023 fourth quarter was $2.3 billion, a 13.5 percent increase compared to the same\nperiod in the previous fiscal year primarily due to increases in gross profit in both reportable segments and gains from\nantitrust litigation settlements in the current year quarter. ", "page_label": "2", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4c06a2ddcf10d19f07ceae670b9b991ea2bb927a17cd3d22811663c6ce9c7b7a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "64e46371-4dc8-47ff-984e-f495fb7b5161", "node_type": "1", "metadata": {"window": "Healthcare Solutions and a 9.5 percent increase in\nrevenue within International Healthcare Solutions.\n Gross Profit:  Gross profit in the fiscal 2023 fourth quarter was $2.3 billion, a 13.5 percent increase compared to the same\nperiod in the previous fiscal year primarily due to increases in gross profit in both reportable segments and gains from\nantitrust litigation settlements in the current year quarter.  Gross profit as a percentage of revenue was 3.27 percent, an\nincrease of 2 basis points from the prior year quarter.\n Operating Expenses:  In the fourth quarter of fiscal 2023, operating expenses were $1.8 billion, up 16.0 percent from the same\nperiod last fiscal year, primarily driven by increases in distribution, selling, and administrative expenses, and amortization\nexpense compared to the prior year quarter.  Operating expenses as a percentage of revenue in the fiscal 2023 fourth quarter\nwere 2.58 percent compared to 2.50 percent for the same period in the previous fiscal year.\n Operating Income:  In the fiscal 2023 fourth quarter, operating income was $476.9 million, up 4.9 percent compared to the\nsame period in the previous fiscal year due to the increase in gross profit, offset in part by the increase in operating expenses.\n Operating income as a percentage of revenue was 0.69 percent in the fourth quarter of fiscal 2023 compared to 0.74 percent\nfor the same period in the previous fiscal year.\n", "original_text": "Operating Expenses:  In the fourth quarter of fiscal 2023, operating expenses were $1.8 billion, up 16.0 percent from the same\nperiod last fiscal year, primarily driven by increases in distribution, selling, and administrative expenses, and amortization\nexpense compared to the prior year quarter. "}, "hash": "f1ed785c8eab3734532c26e9f3f89703de06d5076b48f2555e02f5fe57412fe9", "class_name": "RelatedNodeInfo"}}, "text": "Gross profit as a percentage of revenue was 3.27 percent, an\nincrease of 2 basis points from the prior year quarter.\n", "start_char_idx": 1221, "end_char_idx": 1338, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "64e46371-4dc8-47ff-984e-f495fb7b5161": {"__data__": {"id_": "64e46371-4dc8-47ff-984e-f495fb7b5161", "embedding": null, "metadata": {"window": "Healthcare Solutions and a 9.5 percent increase in\nrevenue within International Healthcare Solutions.\n Gross Profit:  Gross profit in the fiscal 2023 fourth quarter was $2.3 billion, a 13.5 percent increase compared to the same\nperiod in the previous fiscal year primarily due to increases in gross profit in both reportable segments and gains from\nantitrust litigation settlements in the current year quarter.  Gross profit as a percentage of revenue was 3.27 percent, an\nincrease of 2 basis points from the prior year quarter.\n Operating Expenses:  In the fourth quarter of fiscal 2023, operating expenses were $1.8 billion, up 16.0 percent from the same\nperiod last fiscal year, primarily driven by increases in distribution, selling, and administrative expenses, and amortization\nexpense compared to the prior year quarter.  Operating expenses as a percentage of revenue in the fiscal 2023 fourth quarter\nwere 2.58 percent compared to 2.50 percent for the same period in the previous fiscal year.\n Operating Income:  In the fiscal 2023 fourth quarter, operating income was $476.9 million, up 4.9 percent compared to the\nsame period in the previous fiscal year due to the increase in gross profit, offset in part by the increase in operating expenses.\n Operating income as a percentage of revenue was 0.69 percent in the fourth quarter of fiscal 2023 compared to 0.74 percent\nfor the same period in the previous fiscal year.\n", "original_text": "Operating Expenses:  In the fourth quarter of fiscal 2023, operating expenses were $1.8 billion, up 16.0 percent from the same\nperiod last fiscal year, primarily driven by increases in distribution, selling, and administrative expenses, and amortization\nexpense compared to the prior year quarter. ", "page_label": "2", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8d68cffe-a6e2-4827-9f5b-bc33a23ae109", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5a32713f40aba7e7a72c91cdb5ee51314462c4550a91df39ba31447fae2944c8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1aa202f4-72d5-4766-8e30-cd400fd352b2", "node_type": "1", "metadata": {"window": "Four th Quar ter GAAP R esults\nRevenue:  In the fourth quarter of fiscal 2023, revenue was $68.9 billion, up 12.7 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 13.0 percent increase in revenue within U.S.  Healthcare Solutions and a 9.5 percent increase in\nrevenue within International Healthcare Solutions.\n Gross Profit:  Gross profit in the fiscal 2023 fourth quarter was $2.3 billion, a 13.5 percent increase compared to the same\nperiod in the previous fiscal year primarily due to increases in gross profit in both reportable segments and gains from\nantitrust litigation settlements in the current year quarter.  Gross profit as a percentage of revenue was 3.27 percent, an\nincrease of 2 basis points from the prior year quarter.\n Operating Expenses:  In the fourth quarter of fiscal 2023, operating expenses were $1.8 billion, up 16.0 percent from the same\nperiod last fiscal year, primarily driven by increases in distribution, selling, and administrative expenses, and amortization\nexpense compared to the prior year quarter.  Operating expenses as a percentage of revenue in the fiscal 2023 fourth quarter\nwere 2.58 percent compared to 2.50 percent for the same period in the previous fiscal year.\n Operating Income:  In the fiscal 2023 fourth quarter, operating income was $476.9 million, up 4.9 percent compared to the\nsame period in the previous fiscal year due to the increase in gross profit, offset in part by the increase in operating expenses.\n", "original_text": "Gross profit as a percentage of revenue was 3.27 percent, an\nincrease of 2 basis points from the prior year quarter.\n", "page_label": "2", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bb08dc894eb28b84b0aa611142a2b7cd2a67fa62316f7f08c7608aae2c07ceca", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "37dceed8-1267-4e8d-ba64-c0a9415b0905", "node_type": "1", "metadata": {"window": "Gross Profit:  Gross profit in the fiscal 2023 fourth quarter was $2.3 billion, a 13.5 percent increase compared to the same\nperiod in the previous fiscal year primarily due to increases in gross profit in both reportable segments and gains from\nantitrust litigation settlements in the current year quarter.  Gross profit as a percentage of revenue was 3.27 percent, an\nincrease of 2 basis points from the prior year quarter.\n Operating Expenses:  In the fourth quarter of fiscal 2023, operating expenses were $1.8 billion, up 16.0 percent from the same\nperiod last fiscal year, primarily driven by increases in distribution, selling, and administrative expenses, and amortization\nexpense compared to the prior year quarter.  Operating expenses as a percentage of revenue in the fiscal 2023 fourth quarter\nwere 2.58 percent compared to 2.50 percent for the same period in the previous fiscal year.\n Operating Income:  In the fiscal 2023 fourth quarter, operating income was $476.9 million, up 4.9 percent compared to the\nsame period in the previous fiscal year due to the increase in gross profit, offset in part by the increase in operating expenses.\n Operating income as a percentage of revenue was 0.69 percent in the fourth quarter of fiscal 2023 compared to 0.74 percent\nfor the same period in the previous fiscal year.\n Interest Expense, Net:  In the fiscal 2023 fourth quarter, net interest expense of $60.9 million increased 18.3 percent versus the\nprior year quarter primarily due to increases in intra-period variable-rate borrowings and associated interest rates, offset in\npart by an increase in interest income as a result of higher investment interest rates.\n", "original_text": "Operating expenses as a percentage of revenue in the fiscal 2023 fourth quarter\nwere 2.58 percent compared to 2.50 percent for the same period in the previous fiscal year.\n"}, "hash": "e9b74899728338050051263500ed4ceb6860a10b220a1ada4e3be4f79ebb9b4f", "class_name": "RelatedNodeInfo"}}, "text": "Operating Expenses:  In the fourth quarter of fiscal 2023, operating expenses were $1.8 billion, up 16.0 percent from the same\nperiod last fiscal year, primarily driven by increases in distribution, selling, and administrative expenses, and amortization\nexpense compared to the prior year quarter. ", "start_char_idx": 1338, "end_char_idx": 1636, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "37dceed8-1267-4e8d-ba64-c0a9415b0905": {"__data__": {"id_": "37dceed8-1267-4e8d-ba64-c0a9415b0905", "embedding": null, "metadata": {"window": "Gross Profit:  Gross profit in the fiscal 2023 fourth quarter was $2.3 billion, a 13.5 percent increase compared to the same\nperiod in the previous fiscal year primarily due to increases in gross profit in both reportable segments and gains from\nantitrust litigation settlements in the current year quarter.  Gross profit as a percentage of revenue was 3.27 percent, an\nincrease of 2 basis points from the prior year quarter.\n Operating Expenses:  In the fourth quarter of fiscal 2023, operating expenses were $1.8 billion, up 16.0 percent from the same\nperiod last fiscal year, primarily driven by increases in distribution, selling, and administrative expenses, and amortization\nexpense compared to the prior year quarter.  Operating expenses as a percentage of revenue in the fiscal 2023 fourth quarter\nwere 2.58 percent compared to 2.50 percent for the same period in the previous fiscal year.\n Operating Income:  In the fiscal 2023 fourth quarter, operating income was $476.9 million, up 4.9 percent compared to the\nsame period in the previous fiscal year due to the increase in gross profit, offset in part by the increase in operating expenses.\n Operating income as a percentage of revenue was 0.69 percent in the fourth quarter of fiscal 2023 compared to 0.74 percent\nfor the same period in the previous fiscal year.\n Interest Expense, Net:  In the fiscal 2023 fourth quarter, net interest expense of $60.9 million increased 18.3 percent versus the\nprior year quarter primarily due to increases in intra-period variable-rate borrowings and associated interest rates, offset in\npart by an increase in interest income as a result of higher investment interest rates.\n", "original_text": "Operating expenses as a percentage of revenue in the fiscal 2023 fourth quarter\nwere 2.58 percent compared to 2.50 percent for the same period in the previous fiscal year.\n", "page_label": "2", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8d68cffe-a6e2-4827-9f5b-bc33a23ae109", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5a32713f40aba7e7a72c91cdb5ee51314462c4550a91df39ba31447fae2944c8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "64e46371-4dc8-47ff-984e-f495fb7b5161", "node_type": "1", "metadata": {"window": "Healthcare Solutions and a 9.5 percent increase in\nrevenue within International Healthcare Solutions.\n Gross Profit:  Gross profit in the fiscal 2023 fourth quarter was $2.3 billion, a 13.5 percent increase compared to the same\nperiod in the previous fiscal year primarily due to increases in gross profit in both reportable segments and gains from\nantitrust litigation settlements in the current year quarter.  Gross profit as a percentage of revenue was 3.27 percent, an\nincrease of 2 basis points from the prior year quarter.\n Operating Expenses:  In the fourth quarter of fiscal 2023, operating expenses were $1.8 billion, up 16.0 percent from the same\nperiod last fiscal year, primarily driven by increases in distribution, selling, and administrative expenses, and amortization\nexpense compared to the prior year quarter.  Operating expenses as a percentage of revenue in the fiscal 2023 fourth quarter\nwere 2.58 percent compared to 2.50 percent for the same period in the previous fiscal year.\n Operating Income:  In the fiscal 2023 fourth quarter, operating income was $476.9 million, up 4.9 percent compared to the\nsame period in the previous fiscal year due to the increase in gross profit, offset in part by the increase in operating expenses.\n Operating income as a percentage of revenue was 0.69 percent in the fourth quarter of fiscal 2023 compared to 0.74 percent\nfor the same period in the previous fiscal year.\n", "original_text": "Operating Expenses:  In the fourth quarter of fiscal 2023, operating expenses were $1.8 billion, up 16.0 percent from the same\nperiod last fiscal year, primarily driven by increases in distribution, selling, and administrative expenses, and amortization\nexpense compared to the prior year quarter. ", "page_label": "2", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b0318efcbc008ef81d9eb6bf042cb5afc14341402a7a5adc9651a9cb339a3aa0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "54fbee63-c89e-4186-b826-7da5fa8bb4cb", "node_type": "1", "metadata": {"window": "Gross profit as a percentage of revenue was 3.27 percent, an\nincrease of 2 basis points from the prior year quarter.\n Operating Expenses:  In the fourth quarter of fiscal 2023, operating expenses were $1.8 billion, up 16.0 percent from the same\nperiod last fiscal year, primarily driven by increases in distribution, selling, and administrative expenses, and amortization\nexpense compared to the prior year quarter.  Operating expenses as a percentage of revenue in the fiscal 2023 fourth quarter\nwere 2.58 percent compared to 2.50 percent for the same period in the previous fiscal year.\n Operating Income:  In the fiscal 2023 fourth quarter, operating income was $476.9 million, up 4.9 percent compared to the\nsame period in the previous fiscal year due to the increase in gross profit, offset in part by the increase in operating expenses.\n Operating income as a percentage of revenue was 0.69 percent in the fourth quarter of fiscal 2023 compared to 0.74 percent\nfor the same period in the previous fiscal year.\n Interest Expense, Net:  In the fiscal 2023 fourth quarter, net interest expense of $60.9 million increased 18.3 percent versus the\nprior year quarter primarily due to increases in intra-period variable-rate borrowings and associated interest rates, offset in\npart by an increase in interest income as a result of higher investment interest rates.\n Effective T ax Rate:  The effective tax rate was 21.8 percent for the fourth quarter of fiscal 2023. ", "original_text": "Operating Income:  In the fiscal 2023 fourth quarter, operating income was $476.9 million, up 4.9 percent compared to the\nsame period in the previous fiscal year due to the increase in gross profit, offset in part by the increase in operating expenses.\n"}, "hash": "746c0786c6eb913e04983d026069e5ea5314cdb89256ca8915b8455aa45dddb7", "class_name": "RelatedNodeInfo"}}, "text": "Operating expenses as a percentage of revenue in the fiscal 2023 fourth quarter\nwere 2.58 percent compared to 2.50 percent for the same period in the previous fiscal year.\n", "start_char_idx": 1636, "end_char_idx": 1808, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "54fbee63-c89e-4186-b826-7da5fa8bb4cb": {"__data__": {"id_": "54fbee63-c89e-4186-b826-7da5fa8bb4cb", "embedding": null, "metadata": {"window": "Gross profit as a percentage of revenue was 3.27 percent, an\nincrease of 2 basis points from the prior year quarter.\n Operating Expenses:  In the fourth quarter of fiscal 2023, operating expenses were $1.8 billion, up 16.0 percent from the same\nperiod last fiscal year, primarily driven by increases in distribution, selling, and administrative expenses, and amortization\nexpense compared to the prior year quarter.  Operating expenses as a percentage of revenue in the fiscal 2023 fourth quarter\nwere 2.58 percent compared to 2.50 percent for the same period in the previous fiscal year.\n Operating Income:  In the fiscal 2023 fourth quarter, operating income was $476.9 million, up 4.9 percent compared to the\nsame period in the previous fiscal year due to the increase in gross profit, offset in part by the increase in operating expenses.\n Operating income as a percentage of revenue was 0.69 percent in the fourth quarter of fiscal 2023 compared to 0.74 percent\nfor the same period in the previous fiscal year.\n Interest Expense, Net:  In the fiscal 2023 fourth quarter, net interest expense of $60.9 million increased 18.3 percent versus the\nprior year quarter primarily due to increases in intra-period variable-rate borrowings and associated interest rates, offset in\npart by an increase in interest income as a result of higher investment interest rates.\n Effective T ax Rate:  The effective tax rate was 21.8 percent for the fourth quarter of fiscal 2023. ", "original_text": "Operating Income:  In the fiscal 2023 fourth quarter, operating income was $476.9 million, up 4.9 percent compared to the\nsame period in the previous fiscal year due to the increase in gross profit, offset in part by the increase in operating expenses.\n", "page_label": "2", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8d68cffe-a6e2-4827-9f5b-bc33a23ae109", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5a32713f40aba7e7a72c91cdb5ee51314462c4550a91df39ba31447fae2944c8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "37dceed8-1267-4e8d-ba64-c0a9415b0905", "node_type": "1", "metadata": {"window": "Gross Profit:  Gross profit in the fiscal 2023 fourth quarter was $2.3 billion, a 13.5 percent increase compared to the same\nperiod in the previous fiscal year primarily due to increases in gross profit in both reportable segments and gains from\nantitrust litigation settlements in the current year quarter.  Gross profit as a percentage of revenue was 3.27 percent, an\nincrease of 2 basis points from the prior year quarter.\n Operating Expenses:  In the fourth quarter of fiscal 2023, operating expenses were $1.8 billion, up 16.0 percent from the same\nperiod last fiscal year, primarily driven by increases in distribution, selling, and administrative expenses, and amortization\nexpense compared to the prior year quarter.  Operating expenses as a percentage of revenue in the fiscal 2023 fourth quarter\nwere 2.58 percent compared to 2.50 percent for the same period in the previous fiscal year.\n Operating Income:  In the fiscal 2023 fourth quarter, operating income was $476.9 million, up 4.9 percent compared to the\nsame period in the previous fiscal year due to the increase in gross profit, offset in part by the increase in operating expenses.\n Operating income as a percentage of revenue was 0.69 percent in the fourth quarter of fiscal 2023 compared to 0.74 percent\nfor the same period in the previous fiscal year.\n Interest Expense, Net:  In the fiscal 2023 fourth quarter, net interest expense of $60.9 million increased 18.3 percent versus the\nprior year quarter primarily due to increases in intra-period variable-rate borrowings and associated interest rates, offset in\npart by an increase in interest income as a result of higher investment interest rates.\n", "original_text": "Operating expenses as a percentage of revenue in the fiscal 2023 fourth quarter\nwere 2.58 percent compared to 2.50 percent for the same period in the previous fiscal year.\n", "page_label": "2", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0bf0601a8572f9a1ef89ec40e6ef2732be07489625c26c41fe7f5ead31dc79c2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ded1d99d-2cac-4640-b5e1-2b69c9734f9e", "node_type": "1", "metadata": {"window": "Operating Expenses:  In the fourth quarter of fiscal 2023, operating expenses were $1.8 billion, up 16.0 percent from the same\nperiod last fiscal year, primarily driven by increases in distribution, selling, and administrative expenses, and amortization\nexpense compared to the prior year quarter.  Operating expenses as a percentage of revenue in the fiscal 2023 fourth quarter\nwere 2.58 percent compared to 2.50 percent for the same period in the previous fiscal year.\n Operating Income:  In the fiscal 2023 fourth quarter, operating income was $476.9 million, up 4.9 percent compared to the\nsame period in the previous fiscal year due to the increase in gross profit, offset in part by the increase in operating expenses.\n Operating income as a percentage of revenue was 0.69 percent in the fourth quarter of fiscal 2023 compared to 0.74 percent\nfor the same period in the previous fiscal year.\n Interest Expense, Net:  In the fiscal 2023 fourth quarter, net interest expense of $60.9 million increased 18.3 percent versus the\nprior year quarter primarily due to increases in intra-period variable-rate borrowings and associated interest rates, offset in\npart by an increase in interest income as a result of higher investment interest rates.\n Effective T ax Rate:  The effective tax rate was 21.8 percent for the fourth quarter of fiscal 2023.  This compares to 21.9 percent\nin the prior year quarter.\n", "original_text": "Operating income as a percentage of revenue was 0.69 percent in the fourth quarter of fiscal 2023 compared to 0.74 percent\nfor the same period in the previous fiscal year.\n"}, "hash": "a24e7ab6f3e4ab770f0b68d1529896be0c6fc28024397c8276561bf6ab4c132e", "class_name": "RelatedNodeInfo"}}, "text": "Operating Income:  In the fiscal 2023 fourth quarter, operating income was $476.9 million, up 4.9 percent compared to the\nsame period in the previous fiscal year due to the increase in gross profit, offset in part by the increase in operating expenses.\n", "start_char_idx": 1808, "end_char_idx": 2061, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ded1d99d-2cac-4640-b5e1-2b69c9734f9e": {"__data__": {"id_": "ded1d99d-2cac-4640-b5e1-2b69c9734f9e", "embedding": null, "metadata": {"window": "Operating Expenses:  In the fourth quarter of fiscal 2023, operating expenses were $1.8 billion, up 16.0 percent from the same\nperiod last fiscal year, primarily driven by increases in distribution, selling, and administrative expenses, and amortization\nexpense compared to the prior year quarter.  Operating expenses as a percentage of revenue in the fiscal 2023 fourth quarter\nwere 2.58 percent compared to 2.50 percent for the same period in the previous fiscal year.\n Operating Income:  In the fiscal 2023 fourth quarter, operating income was $476.9 million, up 4.9 percent compared to the\nsame period in the previous fiscal year due to the increase in gross profit, offset in part by the increase in operating expenses.\n Operating income as a percentage of revenue was 0.69 percent in the fourth quarter of fiscal 2023 compared to 0.74 percent\nfor the same period in the previous fiscal year.\n Interest Expense, Net:  In the fiscal 2023 fourth quarter, net interest expense of $60.9 million increased 18.3 percent versus the\nprior year quarter primarily due to increases in intra-period variable-rate borrowings and associated interest rates, offset in\npart by an increase in interest income as a result of higher investment interest rates.\n Effective T ax Rate:  The effective tax rate was 21.8 percent for the fourth quarter of fiscal 2023.  This compares to 21.9 percent\nin the prior year quarter.\n", "original_text": "Operating income as a percentage of revenue was 0.69 percent in the fourth quarter of fiscal 2023 compared to 0.74 percent\nfor the same period in the previous fiscal year.\n", "page_label": "2", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8d68cffe-a6e2-4827-9f5b-bc33a23ae109", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5a32713f40aba7e7a72c91cdb5ee51314462c4550a91df39ba31447fae2944c8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "54fbee63-c89e-4186-b826-7da5fa8bb4cb", "node_type": "1", "metadata": {"window": "Gross profit as a percentage of revenue was 3.27 percent, an\nincrease of 2 basis points from the prior year quarter.\n Operating Expenses:  In the fourth quarter of fiscal 2023, operating expenses were $1.8 billion, up 16.0 percent from the same\nperiod last fiscal year, primarily driven by increases in distribution, selling, and administrative expenses, and amortization\nexpense compared to the prior year quarter.  Operating expenses as a percentage of revenue in the fiscal 2023 fourth quarter\nwere 2.58 percent compared to 2.50 percent for the same period in the previous fiscal year.\n Operating Income:  In the fiscal 2023 fourth quarter, operating income was $476.9 million, up 4.9 percent compared to the\nsame period in the previous fiscal year due to the increase in gross profit, offset in part by the increase in operating expenses.\n Operating income as a percentage of revenue was 0.69 percent in the fourth quarter of fiscal 2023 compared to 0.74 percent\nfor the same period in the previous fiscal year.\n Interest Expense, Net:  In the fiscal 2023 fourth quarter, net interest expense of $60.9 million increased 18.3 percent versus the\nprior year quarter primarily due to increases in intra-period variable-rate borrowings and associated interest rates, offset in\npart by an increase in interest income as a result of higher investment interest rates.\n Effective T ax Rate:  The effective tax rate was 21.8 percent for the fourth quarter of fiscal 2023. ", "original_text": "Operating Income:  In the fiscal 2023 fourth quarter, operating income was $476.9 million, up 4.9 percent compared to the\nsame period in the previous fiscal year due to the increase in gross profit, offset in part by the increase in operating expenses.\n", "page_label": "2", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "93b93980c0b65a8a84723255b222c32bc41fcd6544ad6b9cea1ec1e4efb44cf9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "800b856d-6f65-4af6-9281-83c63781d15d", "node_type": "1", "metadata": {"window": "Operating expenses as a percentage of revenue in the fiscal 2023 fourth quarter\nwere 2.58 percent compared to 2.50 percent for the same period in the previous fiscal year.\n Operating Income:  In the fiscal 2023 fourth quarter, operating income was $476.9 million, up 4.9 percent compared to the\nsame period in the previous fiscal year due to the increase in gross profit, offset in part by the increase in operating expenses.\n Operating income as a percentage of revenue was 0.69 percent in the fourth quarter of fiscal 2023 compared to 0.74 percent\nfor the same period in the previous fiscal year.\n Interest Expense, Net:  In the fiscal 2023 fourth quarter, net interest expense of $60.9 million increased 18.3 percent versus the\nprior year quarter primarily due to increases in intra-period variable-rate borrowings and associated interest rates, offset in\npart by an increase in interest income as a result of higher investment interest rates.\n Effective T ax Rate:  The effective tax rate was 21.8 percent for the fourth quarter of fiscal 2023.  This compares to 21.9 percent\nin the prior year quarter.\n Diluted Earnings P er Share:  Diluted earnings per share was $1.72 in the fourth quarter of fiscal 2023, up 22.9 percent\ncompared to the previous fiscal year fourth quarter.\n", "original_text": "Interest Expense, Net:  In the fiscal 2023 fourth quarter, net interest expense of $60.9 million increased 18.3 percent versus the\nprior year quarter primarily due to increases in intra-period variable-rate borrowings and associated interest rates, offset in\npart by an increase in interest income as a result of higher investment interest rates.\n"}, "hash": "bf69336f3b47d3c4c73d88daad9293ac5cbd99aca345d9c57601f77e2a0ab829", "class_name": "RelatedNodeInfo"}}, "text": "Operating income as a percentage of revenue was 0.69 percent in the fourth quarter of fiscal 2023 compared to 0.74 percent\nfor the same period in the previous fiscal year.\n", "start_char_idx": 2061, "end_char_idx": 2233, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "800b856d-6f65-4af6-9281-83c63781d15d": {"__data__": {"id_": "800b856d-6f65-4af6-9281-83c63781d15d", "embedding": null, "metadata": {"window": "Operating expenses as a percentage of revenue in the fiscal 2023 fourth quarter\nwere 2.58 percent compared to 2.50 percent for the same period in the previous fiscal year.\n Operating Income:  In the fiscal 2023 fourth quarter, operating income was $476.9 million, up 4.9 percent compared to the\nsame period in the previous fiscal year due to the increase in gross profit, offset in part by the increase in operating expenses.\n Operating income as a percentage of revenue was 0.69 percent in the fourth quarter of fiscal 2023 compared to 0.74 percent\nfor the same period in the previous fiscal year.\n Interest Expense, Net:  In the fiscal 2023 fourth quarter, net interest expense of $60.9 million increased 18.3 percent versus the\nprior year quarter primarily due to increases in intra-period variable-rate borrowings and associated interest rates, offset in\npart by an increase in interest income as a result of higher investment interest rates.\n Effective T ax Rate:  The effective tax rate was 21.8 percent for the fourth quarter of fiscal 2023.  This compares to 21.9 percent\nin the prior year quarter.\n Diluted Earnings P er Share:  Diluted earnings per share was $1.72 in the fourth quarter of fiscal 2023, up 22.9 percent\ncompared to the previous fiscal year fourth quarter.\n", "original_text": "Interest Expense, Net:  In the fiscal 2023 fourth quarter, net interest expense of $60.9 million increased 18.3 percent versus the\nprior year quarter primarily due to increases in intra-period variable-rate borrowings and associated interest rates, offset in\npart by an increase in interest income as a result of higher investment interest rates.\n", "page_label": "2", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8d68cffe-a6e2-4827-9f5b-bc33a23ae109", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5a32713f40aba7e7a72c91cdb5ee51314462c4550a91df39ba31447fae2944c8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ded1d99d-2cac-4640-b5e1-2b69c9734f9e", "node_type": "1", "metadata": {"window": "Operating Expenses:  In the fourth quarter of fiscal 2023, operating expenses were $1.8 billion, up 16.0 percent from the same\nperiod last fiscal year, primarily driven by increases in distribution, selling, and administrative expenses, and amortization\nexpense compared to the prior year quarter.  Operating expenses as a percentage of revenue in the fiscal 2023 fourth quarter\nwere 2.58 percent compared to 2.50 percent for the same period in the previous fiscal year.\n Operating Income:  In the fiscal 2023 fourth quarter, operating income was $476.9 million, up 4.9 percent compared to the\nsame period in the previous fiscal year due to the increase in gross profit, offset in part by the increase in operating expenses.\n Operating income as a percentage of revenue was 0.69 percent in the fourth quarter of fiscal 2023 compared to 0.74 percent\nfor the same period in the previous fiscal year.\n Interest Expense, Net:  In the fiscal 2023 fourth quarter, net interest expense of $60.9 million increased 18.3 percent versus the\nprior year quarter primarily due to increases in intra-period variable-rate borrowings and associated interest rates, offset in\npart by an increase in interest income as a result of higher investment interest rates.\n Effective T ax Rate:  The effective tax rate was 21.8 percent for the fourth quarter of fiscal 2023.  This compares to 21.9 percent\nin the prior year quarter.\n", "original_text": "Operating income as a percentage of revenue was 0.69 percent in the fourth quarter of fiscal 2023 compared to 0.74 percent\nfor the same period in the previous fiscal year.\n", "page_label": "2", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "035b90da2d8fd9c5aca0caa5c95ffd813e41cf9808756d541d6331817da4d53b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d4ebb983-95d2-4cc3-8eeb-d81ec217e66d", "node_type": "1", "metadata": {"window": "Operating Income:  In the fiscal 2023 fourth quarter, operating income was $476.9 million, up 4.9 percent compared to the\nsame period in the previous fiscal year due to the increase in gross profit, offset in part by the increase in operating expenses.\n Operating income as a percentage of revenue was 0.69 percent in the fourth quarter of fiscal 2023 compared to 0.74 percent\nfor the same period in the previous fiscal year.\n Interest Expense, Net:  In the fiscal 2023 fourth quarter, net interest expense of $60.9 million increased 18.3 percent versus the\nprior year quarter primarily due to increases in intra-period variable-rate borrowings and associated interest rates, offset in\npart by an increase in interest income as a result of higher investment interest rates.\n Effective T ax Rate:  The effective tax rate was 21.8 percent for the fourth quarter of fiscal 2023.  This compares to 21.9 percent\nin the prior year quarter.\n Diluted Earnings P er Share:  Diluted earnings per share was $1.72 in the fourth quarter of fiscal 2023, up 22.9 percent\ncompared to the previous fiscal year fourth quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the fourth quarter of fiscal 2023 were 203.4\nmillion, a decrease of 3.1 percent versus the prior fiscal year fourth quarter primarily as a result of share repurchases.\n", "original_text": "Effective T ax Rate:  The effective tax rate was 21.8 percent for the fourth quarter of fiscal 2023. "}, "hash": "330bee2facbb79ff6ec625b800ce826fbe1ac1da8496d9e7fca7a89af640341c", "class_name": "RelatedNodeInfo"}}, "text": "Interest Expense, Net:  In the fiscal 2023 fourth quarter, net interest expense of $60.9 million increased 18.3 percent versus the\nprior year quarter primarily due to increases in intra-period variable-rate borrowings and associated interest rates, offset in\npart by an increase in interest income as a result of higher investment interest rates.\n", "start_char_idx": 2233, "end_char_idx": 2580, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d4ebb983-95d2-4cc3-8eeb-d81ec217e66d": {"__data__": {"id_": "d4ebb983-95d2-4cc3-8eeb-d81ec217e66d", "embedding": null, "metadata": {"window": "Operating Income:  In the fiscal 2023 fourth quarter, operating income was $476.9 million, up 4.9 percent compared to the\nsame period in the previous fiscal year due to the increase in gross profit, offset in part by the increase in operating expenses.\n Operating income as a percentage of revenue was 0.69 percent in the fourth quarter of fiscal 2023 compared to 0.74 percent\nfor the same period in the previous fiscal year.\n Interest Expense, Net:  In the fiscal 2023 fourth quarter, net interest expense of $60.9 million increased 18.3 percent versus the\nprior year quarter primarily due to increases in intra-period variable-rate borrowings and associated interest rates, offset in\npart by an increase in interest income as a result of higher investment interest rates.\n Effective T ax Rate:  The effective tax rate was 21.8 percent for the fourth quarter of fiscal 2023.  This compares to 21.9 percent\nin the prior year quarter.\n Diluted Earnings P er Share:  Diluted earnings per share was $1.72 in the fourth quarter of fiscal 2023, up 22.9 percent\ncompared to the previous fiscal year fourth quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the fourth quarter of fiscal 2023 were 203.4\nmillion, a decrease of 3.1 percent versus the prior fiscal year fourth quarter primarily as a result of share repurchases.\n", "original_text": "Effective T ax Rate:  The effective tax rate was 21.8 percent for the fourth quarter of fiscal 2023. ", "page_label": "2", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8d68cffe-a6e2-4827-9f5b-bc33a23ae109", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5a32713f40aba7e7a72c91cdb5ee51314462c4550a91df39ba31447fae2944c8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "800b856d-6f65-4af6-9281-83c63781d15d", "node_type": "1", "metadata": {"window": "Operating expenses as a percentage of revenue in the fiscal 2023 fourth quarter\nwere 2.58 percent compared to 2.50 percent for the same period in the previous fiscal year.\n Operating Income:  In the fiscal 2023 fourth quarter, operating income was $476.9 million, up 4.9 percent compared to the\nsame period in the previous fiscal year due to the increase in gross profit, offset in part by the increase in operating expenses.\n Operating income as a percentage of revenue was 0.69 percent in the fourth quarter of fiscal 2023 compared to 0.74 percent\nfor the same period in the previous fiscal year.\n Interest Expense, Net:  In the fiscal 2023 fourth quarter, net interest expense of $60.9 million increased 18.3 percent versus the\nprior year quarter primarily due to increases in intra-period variable-rate borrowings and associated interest rates, offset in\npart by an increase in interest income as a result of higher investment interest rates.\n Effective T ax Rate:  The effective tax rate was 21.8 percent for the fourth quarter of fiscal 2023.  This compares to 21.9 percent\nin the prior year quarter.\n Diluted Earnings P er Share:  Diluted earnings per share was $1.72 in the fourth quarter of fiscal 2023, up 22.9 percent\ncompared to the previous fiscal year fourth quarter.\n", "original_text": "Interest Expense, Net:  In the fiscal 2023 fourth quarter, net interest expense of $60.9 million increased 18.3 percent versus the\nprior year quarter primarily due to increases in intra-period variable-rate borrowings and associated interest rates, offset in\npart by an increase in interest income as a result of higher investment interest rates.\n", "page_label": "2", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3f53fe68f9d8427c6ead3fc2b389eca2cbe49b8891eb61792fc97bdaff445f9f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "459a00ea-eb96-45ab-85e4-7dd1bd7523f0", "node_type": "1", "metadata": {"window": "Operating income as a percentage of revenue was 0.69 percent in the fourth quarter of fiscal 2023 compared to 0.74 percent\nfor the same period in the previous fiscal year.\n Interest Expense, Net:  In the fiscal 2023 fourth quarter, net interest expense of $60.9 million increased 18.3 percent versus the\nprior year quarter primarily due to increases in intra-period variable-rate borrowings and associated interest rates, offset in\npart by an increase in interest income as a result of higher investment interest rates.\n Effective T ax Rate:  The effective tax rate was 21.8 percent for the fourth quarter of fiscal 2023.  This compares to 21.9 percent\nin the prior year quarter.\n Diluted Earnings P er Share:  Diluted earnings per share was $1.72 in the fourth quarter of fiscal 2023, up 22.9 percent\ncompared to the previous fiscal year fourth quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the fourth quarter of fiscal 2023 were 203.4\nmillion, a decrease of 3.1 percent versus the prior fiscal year fourth quarter primarily as a result of share repurchases.\n Four th Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue. ", "original_text": "This compares to 21.9 percent\nin the prior year quarter.\n"}, "hash": "1bcbf9c624c04a9d348461ba84e0f278ebbd8619a55cea005d83a853d0036c0f", "class_name": "RelatedNodeInfo"}}, "text": "Effective T ax Rate:  The effective tax rate was 21.8 percent for the fourth quarter of fiscal 2023. ", "start_char_idx": 2580, "end_char_idx": 2681, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "459a00ea-eb96-45ab-85e4-7dd1bd7523f0": {"__data__": {"id_": "459a00ea-eb96-45ab-85e4-7dd1bd7523f0", "embedding": null, "metadata": {"window": "Operating income as a percentage of revenue was 0.69 percent in the fourth quarter of fiscal 2023 compared to 0.74 percent\nfor the same period in the previous fiscal year.\n Interest Expense, Net:  In the fiscal 2023 fourth quarter, net interest expense of $60.9 million increased 18.3 percent versus the\nprior year quarter primarily due to increases in intra-period variable-rate borrowings and associated interest rates, offset in\npart by an increase in interest income as a result of higher investment interest rates.\n Effective T ax Rate:  The effective tax rate was 21.8 percent for the fourth quarter of fiscal 2023.  This compares to 21.9 percent\nin the prior year quarter.\n Diluted Earnings P er Share:  Diluted earnings per share was $1.72 in the fourth quarter of fiscal 2023, up 22.9 percent\ncompared to the previous fiscal year fourth quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the fourth quarter of fiscal 2023 were 203.4\nmillion, a decrease of 3.1 percent versus the prior fiscal year fourth quarter primarily as a result of share repurchases.\n Four th Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue. ", "original_text": "This compares to 21.9 percent\nin the prior year quarter.\n", "page_label": "2", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8d68cffe-a6e2-4827-9f5b-bc33a23ae109", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5a32713f40aba7e7a72c91cdb5ee51314462c4550a91df39ba31447fae2944c8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d4ebb983-95d2-4cc3-8eeb-d81ec217e66d", "node_type": "1", "metadata": {"window": "Operating Income:  In the fiscal 2023 fourth quarter, operating income was $476.9 million, up 4.9 percent compared to the\nsame period in the previous fiscal year due to the increase in gross profit, offset in part by the increase in operating expenses.\n Operating income as a percentage of revenue was 0.69 percent in the fourth quarter of fiscal 2023 compared to 0.74 percent\nfor the same period in the previous fiscal year.\n Interest Expense, Net:  In the fiscal 2023 fourth quarter, net interest expense of $60.9 million increased 18.3 percent versus the\nprior year quarter primarily due to increases in intra-period variable-rate borrowings and associated interest rates, offset in\npart by an increase in interest income as a result of higher investment interest rates.\n Effective T ax Rate:  The effective tax rate was 21.8 percent for the fourth quarter of fiscal 2023.  This compares to 21.9 percent\nin the prior year quarter.\n Diluted Earnings P er Share:  Diluted earnings per share was $1.72 in the fourth quarter of fiscal 2023, up 22.9 percent\ncompared to the previous fiscal year fourth quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the fourth quarter of fiscal 2023 were 203.4\nmillion, a decrease of 3.1 percent versus the prior fiscal year fourth quarter primarily as a result of share repurchases.\n", "original_text": "Effective T ax Rate:  The effective tax rate was 21.8 percent for the fourth quarter of fiscal 2023. ", "page_label": "2", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4cabe9f654695b3b7520a206dbeaa557ea91f0a95f45e8ab5935405c1494172a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "38d550a3-b8d2-4444-9dba-e56a1c8fbcec", "node_type": "1", "metadata": {"window": "Interest Expense, Net:  In the fiscal 2023 fourth quarter, net interest expense of $60.9 million increased 18.3 percent versus the\nprior year quarter primarily due to increases in intra-period variable-rate borrowings and associated interest rates, offset in\npart by an increase in interest income as a result of higher investment interest rates.\n Effective T ax Rate:  The effective tax rate was 21.8 percent for the fourth quarter of fiscal 2023.  This compares to 21.9 percent\nin the prior year quarter.\n Diluted Earnings P er Share:  Diluted earnings per share was $1.72 in the fourth quarter of fiscal 2023, up 22.9 percent\ncompared to the previous fiscal year fourth quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the fourth quarter of fiscal 2023 were 203.4\nmillion, a decrease of 3.1 percent versus the prior fiscal year fourth quarter primarily as a result of share repurchases.\n Four th Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the fourth quarter of fiscal 2023, revenue was\n$68.9 billion, up 12.7 percent compared to the same quarter in the previous fiscal year, reflecting a 13.0 percent increase in\nrevenue within U.S. ", "original_text": "Diluted Earnings P er Share:  Diluted earnings per share was $1.72 in the fourth quarter of fiscal 2023, up 22.9 percent\ncompared to the previous fiscal year fourth quarter.\n"}, "hash": "bb436b1868bd10362a3d4cb65c95979d7bcec4ede33f475497460dfe2725c296", "class_name": "RelatedNodeInfo"}}, "text": "This compares to 21.9 percent\nin the prior year quarter.\n", "start_char_idx": 2681, "end_char_idx": 2738, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "38d550a3-b8d2-4444-9dba-e56a1c8fbcec": {"__data__": {"id_": "38d550a3-b8d2-4444-9dba-e56a1c8fbcec", "embedding": null, "metadata": {"window": "Interest Expense, Net:  In the fiscal 2023 fourth quarter, net interest expense of $60.9 million increased 18.3 percent versus the\nprior year quarter primarily due to increases in intra-period variable-rate borrowings and associated interest rates, offset in\npart by an increase in interest income as a result of higher investment interest rates.\n Effective T ax Rate:  The effective tax rate was 21.8 percent for the fourth quarter of fiscal 2023.  This compares to 21.9 percent\nin the prior year quarter.\n Diluted Earnings P er Share:  Diluted earnings per share was $1.72 in the fourth quarter of fiscal 2023, up 22.9 percent\ncompared to the previous fiscal year fourth quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the fourth quarter of fiscal 2023 were 203.4\nmillion, a decrease of 3.1 percent versus the prior fiscal year fourth quarter primarily as a result of share repurchases.\n Four th Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the fourth quarter of fiscal 2023, revenue was\n$68.9 billion, up 12.7 percent compared to the same quarter in the previous fiscal year, reflecting a 13.0 percent increase in\nrevenue within U.S. ", "original_text": "Diluted Earnings P er Share:  Diluted earnings per share was $1.72 in the fourth quarter of fiscal 2023, up 22.9 percent\ncompared to the previous fiscal year fourth quarter.\n", "page_label": "2", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8d68cffe-a6e2-4827-9f5b-bc33a23ae109", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5a32713f40aba7e7a72c91cdb5ee51314462c4550a91df39ba31447fae2944c8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "459a00ea-eb96-45ab-85e4-7dd1bd7523f0", "node_type": "1", "metadata": {"window": "Operating income as a percentage of revenue was 0.69 percent in the fourth quarter of fiscal 2023 compared to 0.74 percent\nfor the same period in the previous fiscal year.\n Interest Expense, Net:  In the fiscal 2023 fourth quarter, net interest expense of $60.9 million increased 18.3 percent versus the\nprior year quarter primarily due to increases in intra-period variable-rate borrowings and associated interest rates, offset in\npart by an increase in interest income as a result of higher investment interest rates.\n Effective T ax Rate:  The effective tax rate was 21.8 percent for the fourth quarter of fiscal 2023.  This compares to 21.9 percent\nin the prior year quarter.\n Diluted Earnings P er Share:  Diluted earnings per share was $1.72 in the fourth quarter of fiscal 2023, up 22.9 percent\ncompared to the previous fiscal year fourth quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the fourth quarter of fiscal 2023 were 203.4\nmillion, a decrease of 3.1 percent versus the prior fiscal year fourth quarter primarily as a result of share repurchases.\n Four th Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue. ", "original_text": "This compares to 21.9 percent\nin the prior year quarter.\n", "page_label": "2", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8ce2749b6d2699c4ce6a70c7f247c956315748cdfae79f3df35610256257f282", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d455cd11-d663-48ae-b44d-19048a5ebb5f", "node_type": "1", "metadata": {"window": "Effective T ax Rate:  The effective tax rate was 21.8 percent for the fourth quarter of fiscal 2023.  This compares to 21.9 percent\nin the prior year quarter.\n Diluted Earnings P er Share:  Diluted earnings per share was $1.72 in the fourth quarter of fiscal 2023, up 22.9 percent\ncompared to the previous fiscal year fourth quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the fourth quarter of fiscal 2023 were 203.4\nmillion, a decrease of 3.1 percent versus the prior fiscal year fourth quarter primarily as a result of share repurchases.\n Four th Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the fourth quarter of fiscal 2023, revenue was\n$68.9 billion, up 12.7 percent compared to the same quarter in the previous fiscal year, reflecting a 13.0 percent increase in\nrevenue within U.S.  Healthcare Solutions and a 9.5 percent increase in revenue within International Healthcare Solutions. ", "original_text": "Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the fourth quarter of fiscal 2023 were 203.4\nmillion, a decrease of 3.1 percent versus the prior fiscal year fourth quarter primarily as a result of share repurchases.\n"}, "hash": "635a8b51696a2b686e23c6b62ec783d006ddaa9892bfe6e3ff2ace3ed0cc1d0d", "class_name": "RelatedNodeInfo"}}, "text": "Diluted Earnings P er Share:  Diluted earnings per share was $1.72 in the fourth quarter of fiscal 2023, up 22.9 percent\ncompared to the previous fiscal year fourth quarter.\n", "start_char_idx": 2738, "end_char_idx": 2912, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d455cd11-d663-48ae-b44d-19048a5ebb5f": {"__data__": {"id_": "d455cd11-d663-48ae-b44d-19048a5ebb5f", "embedding": null, "metadata": {"window": "Effective T ax Rate:  The effective tax rate was 21.8 percent for the fourth quarter of fiscal 2023.  This compares to 21.9 percent\nin the prior year quarter.\n Diluted Earnings P er Share:  Diluted earnings per share was $1.72 in the fourth quarter of fiscal 2023, up 22.9 percent\ncompared to the previous fiscal year fourth quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the fourth quarter of fiscal 2023 were 203.4\nmillion, a decrease of 3.1 percent versus the prior fiscal year fourth quarter primarily as a result of share repurchases.\n Four th Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the fourth quarter of fiscal 2023, revenue was\n$68.9 billion, up 12.7 percent compared to the same quarter in the previous fiscal year, reflecting a 13.0 percent increase in\nrevenue within U.S.  Healthcare Solutions and a 9.5 percent increase in revenue within International Healthcare Solutions. ", "original_text": "Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the fourth quarter of fiscal 2023 were 203.4\nmillion, a decrease of 3.1 percent versus the prior fiscal year fourth quarter primarily as a result of share repurchases.\n", "page_label": "2", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8d68cffe-a6e2-4827-9f5b-bc33a23ae109", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5a32713f40aba7e7a72c91cdb5ee51314462c4550a91df39ba31447fae2944c8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "38d550a3-b8d2-4444-9dba-e56a1c8fbcec", "node_type": "1", "metadata": {"window": "Interest Expense, Net:  In the fiscal 2023 fourth quarter, net interest expense of $60.9 million increased 18.3 percent versus the\nprior year quarter primarily due to increases in intra-period variable-rate borrowings and associated interest rates, offset in\npart by an increase in interest income as a result of higher investment interest rates.\n Effective T ax Rate:  The effective tax rate was 21.8 percent for the fourth quarter of fiscal 2023.  This compares to 21.9 percent\nin the prior year quarter.\n Diluted Earnings P er Share:  Diluted earnings per share was $1.72 in the fourth quarter of fiscal 2023, up 22.9 percent\ncompared to the previous fiscal year fourth quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the fourth quarter of fiscal 2023 were 203.4\nmillion, a decrease of 3.1 percent versus the prior fiscal year fourth quarter primarily as a result of share repurchases.\n Four th Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the fourth quarter of fiscal 2023, revenue was\n$68.9 billion, up 12.7 percent compared to the same quarter in the previous fiscal year, reflecting a 13.0 percent increase in\nrevenue within U.S. ", "original_text": "Diluted Earnings P er Share:  Diluted earnings per share was $1.72 in the fourth quarter of fiscal 2023, up 22.9 percent\ncompared to the previous fiscal year fourth quarter.\n", "page_label": "2", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9699b108ae0e57e17d1e43be22f33874ff73f9d697271a25b71ad256883be754", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "62610197-df01-41b8-9ab8-44594b47421c", "node_type": "1", "metadata": {"window": "This compares to 21.9 percent\nin the prior year quarter.\n Diluted Earnings P er Share:  Diluted earnings per share was $1.72 in the fourth quarter of fiscal 2023, up 22.9 percent\ncompared to the previous fiscal year fourth quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the fourth quarter of fiscal 2023 were 203.4\nmillion, a decrease of 3.1 percent versus the prior fiscal year fourth quarter primarily as a result of share repurchases.\n Four th Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the fourth quarter of fiscal 2023, revenue was\n$68.9 billion, up 12.7 percent compared to the same quarter in the previous fiscal year, reflecting a 13.0 percent increase in\nrevenue within U.S.  Healthcare Solutions and a 9.5 percent increase in revenue within International Healthcare Solutions.  On a\nconstant currency basis, International Healthcare Solutions' revenue was up 10.1 percent.\n", "original_text": "Four th Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue. "}, "hash": "1d1a4bee1642fce197e4c3355f8903ab003aa0d42bf79d018ea81079ad3f0a85", "class_name": "RelatedNodeInfo"}}, "text": "Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the fourth quarter of fiscal 2023 were 203.4\nmillion, a decrease of 3.1 percent versus the prior fiscal year fourth quarter primarily as a result of share repurchases.\n", "start_char_idx": 2912, "end_char_idx": 3157, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "62610197-df01-41b8-9ab8-44594b47421c": {"__data__": {"id_": "62610197-df01-41b8-9ab8-44594b47421c", "embedding": null, "metadata": {"window": "This compares to 21.9 percent\nin the prior year quarter.\n Diluted Earnings P er Share:  Diluted earnings per share was $1.72 in the fourth quarter of fiscal 2023, up 22.9 percent\ncompared to the previous fiscal year fourth quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the fourth quarter of fiscal 2023 were 203.4\nmillion, a decrease of 3.1 percent versus the prior fiscal year fourth quarter primarily as a result of share repurchases.\n Four th Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the fourth quarter of fiscal 2023, revenue was\n$68.9 billion, up 12.7 percent compared to the same quarter in the previous fiscal year, reflecting a 13.0 percent increase in\nrevenue within U.S.  Healthcare Solutions and a 9.5 percent increase in revenue within International Healthcare Solutions.  On a\nconstant currency basis, International Healthcare Solutions' revenue was up 10.1 percent.\n", "original_text": "Four th Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue. ", "page_label": "2", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8d68cffe-a6e2-4827-9f5b-bc33a23ae109", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5a32713f40aba7e7a72c91cdb5ee51314462c4550a91df39ba31447fae2944c8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d455cd11-d663-48ae-b44d-19048a5ebb5f", "node_type": "1", "metadata": {"window": "Effective T ax Rate:  The effective tax rate was 21.8 percent for the fourth quarter of fiscal 2023.  This compares to 21.9 percent\nin the prior year quarter.\n Diluted Earnings P er Share:  Diluted earnings per share was $1.72 in the fourth quarter of fiscal 2023, up 22.9 percent\ncompared to the previous fiscal year fourth quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the fourth quarter of fiscal 2023 were 203.4\nmillion, a decrease of 3.1 percent versus the prior fiscal year fourth quarter primarily as a result of share repurchases.\n Four th Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the fourth quarter of fiscal 2023, revenue was\n$68.9 billion, up 12.7 percent compared to the same quarter in the previous fiscal year, reflecting a 13.0 percent increase in\nrevenue within U.S.  Healthcare Solutions and a 9.5 percent increase in revenue within International Healthcare Solutions. ", "original_text": "Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the fourth quarter of fiscal 2023 were 203.4\nmillion, a decrease of 3.1 percent versus the prior fiscal year fourth quarter primarily as a result of share repurchases.\n", "page_label": "2", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "110515dd66bd1506d35da052b26e6d49eb1035abc1466e2a2878e90ada860075", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "efb3776d-dbfa-4152-b65b-f04e1e560f83", "node_type": "1", "metadata": {"window": "Diluted Earnings P er Share:  Diluted earnings per share was $1.72 in the fourth quarter of fiscal 2023, up 22.9 percent\ncompared to the previous fiscal year fourth quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the fourth quarter of fiscal 2023 were 203.4\nmillion, a decrease of 3.1 percent versus the prior fiscal year fourth quarter primarily as a result of share repurchases.\n Four th Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the fourth quarter of fiscal 2023, revenue was\n$68.9 billion, up 12.7 percent compared to the same quarter in the previous fiscal year, reflecting a 13.0 percent increase in\nrevenue within U.S.  Healthcare Solutions and a 9.5 percent increase in revenue within International Healthcare Solutions.  On a\nconstant currency basis, International Healthcare Solutions' revenue was up 10.1 percent.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2023 fourth quarter was $2.3 billion, a 9.4 percent increase compared\nto the same period in the previous fiscal year due to an increase in gross profit in both reportable segments. ", "original_text": "In the fourth quarter of fiscal 2023, revenue was\n$68.9 billion, up 12.7 percent compared to the same quarter in the previous fiscal year, reflecting a 13.0 percent increase in\nrevenue within U.S. "}, "hash": "d29dce31e3698e9884f5bdff3e3eb2d6d10f95fa488d3df3acd075c204e7d5e7", "class_name": "RelatedNodeInfo"}}, "text": "Four th Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue. ", "start_char_idx": 3157, "end_char_idx": 3276, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "efb3776d-dbfa-4152-b65b-f04e1e560f83": {"__data__": {"id_": "efb3776d-dbfa-4152-b65b-f04e1e560f83", "embedding": null, "metadata": {"window": "Diluted Earnings P er Share:  Diluted earnings per share was $1.72 in the fourth quarter of fiscal 2023, up 22.9 percent\ncompared to the previous fiscal year fourth quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the fourth quarter of fiscal 2023 were 203.4\nmillion, a decrease of 3.1 percent versus the prior fiscal year fourth quarter primarily as a result of share repurchases.\n Four th Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the fourth quarter of fiscal 2023, revenue was\n$68.9 billion, up 12.7 percent compared to the same quarter in the previous fiscal year, reflecting a 13.0 percent increase in\nrevenue within U.S.  Healthcare Solutions and a 9.5 percent increase in revenue within International Healthcare Solutions.  On a\nconstant currency basis, International Healthcare Solutions' revenue was up 10.1 percent.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2023 fourth quarter was $2.3 billion, a 9.4 percent increase compared\nto the same period in the previous fiscal year due to an increase in gross profit in both reportable segments. ", "original_text": "In the fourth quarter of fiscal 2023, revenue was\n$68.9 billion, up 12.7 percent compared to the same quarter in the previous fiscal year, reflecting a 13.0 percent increase in\nrevenue within U.S. ", "page_label": "2", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8d68cffe-a6e2-4827-9f5b-bc33a23ae109", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5a32713f40aba7e7a72c91cdb5ee51314462c4550a91df39ba31447fae2944c8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "62610197-df01-41b8-9ab8-44594b47421c", "node_type": "1", "metadata": {"window": "This compares to 21.9 percent\nin the prior year quarter.\n Diluted Earnings P er Share:  Diluted earnings per share was $1.72 in the fourth quarter of fiscal 2023, up 22.9 percent\ncompared to the previous fiscal year fourth quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the fourth quarter of fiscal 2023 were 203.4\nmillion, a decrease of 3.1 percent versus the prior fiscal year fourth quarter primarily as a result of share repurchases.\n Four th Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the fourth quarter of fiscal 2023, revenue was\n$68.9 billion, up 12.7 percent compared to the same quarter in the previous fiscal year, reflecting a 13.0 percent increase in\nrevenue within U.S.  Healthcare Solutions and a 9.5 percent increase in revenue within International Healthcare Solutions.  On a\nconstant currency basis, International Healthcare Solutions' revenue was up 10.1 percent.\n", "original_text": "Four th Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue. ", "page_label": "2", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7237b1f8e02e7c47deb16e4f0386357a953d01b3c6a88202cd13281a63d7e687", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d4eb03b6-ef81-4590-bacc-943307f4aab0", "node_type": "1", "metadata": {"window": "Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the fourth quarter of fiscal 2023 were 203.4\nmillion, a decrease of 3.1 percent versus the prior fiscal year fourth quarter primarily as a result of share repurchases.\n Four th Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the fourth quarter of fiscal 2023, revenue was\n$68.9 billion, up 12.7 percent compared to the same quarter in the previous fiscal year, reflecting a 13.0 percent increase in\nrevenue within U.S.  Healthcare Solutions and a 9.5 percent increase in revenue within International Healthcare Solutions.  On a\nconstant currency basis, International Healthcare Solutions' revenue was up 10.1 percent.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2023 fourth quarter was $2.3 billion, a 9.4 percent increase compared\nto the same period in the previous fiscal year due to an increase in gross profit in both reportable segments.  Adjusted gross\nprofit as a percentage of revenue was 3.34 percent in the fiscal 2023 fourth quarter, a decrease of 10 basis points when\n2", "original_text": "Healthcare Solutions and a 9.5 percent increase in revenue within International Healthcare Solutions. "}, "hash": "5aaa1c77038123762750da377f5c082590d505f65b1bef0335ac0ddb0676188e", "class_name": "RelatedNodeInfo"}}, "text": "In the fourth quarter of fiscal 2023, revenue was\n$68.9 billion, up 12.7 percent compared to the same quarter in the previous fiscal year, reflecting a 13.0 percent increase in\nrevenue within U.S. ", "start_char_idx": 3276, "end_char_idx": 3473, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d4eb03b6-ef81-4590-bacc-943307f4aab0": {"__data__": {"id_": "d4eb03b6-ef81-4590-bacc-943307f4aab0", "embedding": null, "metadata": {"window": "Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the fourth quarter of fiscal 2023 were 203.4\nmillion, a decrease of 3.1 percent versus the prior fiscal year fourth quarter primarily as a result of share repurchases.\n Four th Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the fourth quarter of fiscal 2023, revenue was\n$68.9 billion, up 12.7 percent compared to the same quarter in the previous fiscal year, reflecting a 13.0 percent increase in\nrevenue within U.S.  Healthcare Solutions and a 9.5 percent increase in revenue within International Healthcare Solutions.  On a\nconstant currency basis, International Healthcare Solutions' revenue was up 10.1 percent.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2023 fourth quarter was $2.3 billion, a 9.4 percent increase compared\nto the same period in the previous fiscal year due to an increase in gross profit in both reportable segments.  Adjusted gross\nprofit as a percentage of revenue was 3.34 percent in the fiscal 2023 fourth quarter, a decrease of 10 basis points when\n2", "original_text": "Healthcare Solutions and a 9.5 percent increase in revenue within International Healthcare Solutions. ", "page_label": "2", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8d68cffe-a6e2-4827-9f5b-bc33a23ae109", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5a32713f40aba7e7a72c91cdb5ee51314462c4550a91df39ba31447fae2944c8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "efb3776d-dbfa-4152-b65b-f04e1e560f83", "node_type": "1", "metadata": {"window": "Diluted Earnings P er Share:  Diluted earnings per share was $1.72 in the fourth quarter of fiscal 2023, up 22.9 percent\ncompared to the previous fiscal year fourth quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the fourth quarter of fiscal 2023 were 203.4\nmillion, a decrease of 3.1 percent versus the prior fiscal year fourth quarter primarily as a result of share repurchases.\n Four th Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the fourth quarter of fiscal 2023, revenue was\n$68.9 billion, up 12.7 percent compared to the same quarter in the previous fiscal year, reflecting a 13.0 percent increase in\nrevenue within U.S.  Healthcare Solutions and a 9.5 percent increase in revenue within International Healthcare Solutions.  On a\nconstant currency basis, International Healthcare Solutions' revenue was up 10.1 percent.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2023 fourth quarter was $2.3 billion, a 9.4 percent increase compared\nto the same period in the previous fiscal year due to an increase in gross profit in both reportable segments. ", "original_text": "In the fourth quarter of fiscal 2023, revenue was\n$68.9 billion, up 12.7 percent compared to the same quarter in the previous fiscal year, reflecting a 13.0 percent increase in\nrevenue within U.S. ", "page_label": "2", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "09f3356d9acc00c9c1126e8711fa4a41d85e588fab9f9f357fd455f7bc8d19de", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d258aaca-bc2d-42f2-a50d-8034aac78a11", "node_type": "1", "metadata": {"window": "Four th Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the fourth quarter of fiscal 2023, revenue was\n$68.9 billion, up 12.7 percent compared to the same quarter in the previous fiscal year, reflecting a 13.0 percent increase in\nrevenue within U.S.  Healthcare Solutions and a 9.5 percent increase in revenue within International Healthcare Solutions.  On a\nconstant currency basis, International Healthcare Solutions' revenue was up 10.1 percent.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2023 fourth quarter was $2.3 billion, a 9.4 percent increase compared\nto the same period in the previous fiscal year due to an increase in gross profit in both reportable segments.  Adjusted gross\nprofit as a percentage of revenue was 3.34 percent in the fiscal 2023 fourth quarter, a decrease of 10 basis points when\n2", "original_text": "On a\nconstant currency basis, International Healthcare Solutions' revenue was up 10.1 percent.\n"}, "hash": "cb1cd08d18fc129f1fd14bea36b12c0184e268f54e32e61a956962e7114e2a92", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions and a 9.5 percent increase in revenue within International Healthcare Solutions. ", "start_char_idx": 3473, "end_char_idx": 3575, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d258aaca-bc2d-42f2-a50d-8034aac78a11": {"__data__": {"id_": "d258aaca-bc2d-42f2-a50d-8034aac78a11", "embedding": null, "metadata": {"window": "Four th Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the fourth quarter of fiscal 2023, revenue was\n$68.9 billion, up 12.7 percent compared to the same quarter in the previous fiscal year, reflecting a 13.0 percent increase in\nrevenue within U.S.  Healthcare Solutions and a 9.5 percent increase in revenue within International Healthcare Solutions.  On a\nconstant currency basis, International Healthcare Solutions' revenue was up 10.1 percent.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2023 fourth quarter was $2.3 billion, a 9.4 percent increase compared\nto the same period in the previous fiscal year due to an increase in gross profit in both reportable segments.  Adjusted gross\nprofit as a percentage of revenue was 3.34 percent in the fiscal 2023 fourth quarter, a decrease of 10 basis points when\n2", "original_text": "On a\nconstant currency basis, International Healthcare Solutions' revenue was up 10.1 percent.\n", "page_label": "2", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8d68cffe-a6e2-4827-9f5b-bc33a23ae109", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5a32713f40aba7e7a72c91cdb5ee51314462c4550a91df39ba31447fae2944c8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d4eb03b6-ef81-4590-bacc-943307f4aab0", "node_type": "1", "metadata": {"window": "Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the fourth quarter of fiscal 2023 were 203.4\nmillion, a decrease of 3.1 percent versus the prior fiscal year fourth quarter primarily as a result of share repurchases.\n Four th Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the fourth quarter of fiscal 2023, revenue was\n$68.9 billion, up 12.7 percent compared to the same quarter in the previous fiscal year, reflecting a 13.0 percent increase in\nrevenue within U.S.  Healthcare Solutions and a 9.5 percent increase in revenue within International Healthcare Solutions.  On a\nconstant currency basis, International Healthcare Solutions' revenue was up 10.1 percent.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2023 fourth quarter was $2.3 billion, a 9.4 percent increase compared\nto the same period in the previous fiscal year due to an increase in gross profit in both reportable segments.  Adjusted gross\nprofit as a percentage of revenue was 3.34 percent in the fiscal 2023 fourth quarter, a decrease of 10 basis points when\n2", "original_text": "Healthcare Solutions and a 9.5 percent increase in revenue within International Healthcare Solutions. ", "page_label": "2", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1f0a95b7bb4112ec745a0fa7021d372a886dea7c78d917ba4562f5acf7afed95", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3e043939-87a8-458f-bedb-7bab7562332c", "node_type": "1", "metadata": {"window": "In the fourth quarter of fiscal 2023, revenue was\n$68.9 billion, up 12.7 percent compared to the same quarter in the previous fiscal year, reflecting a 13.0 percent increase in\nrevenue within U.S.  Healthcare Solutions and a 9.5 percent increase in revenue within International Healthcare Solutions.  On a\nconstant currency basis, International Healthcare Solutions' revenue was up 10.1 percent.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2023 fourth quarter was $2.3 billion, a 9.4 percent increase compared\nto the same period in the previous fiscal year due to an increase in gross profit in both reportable segments.  Adjusted gross\nprofit as a percentage of revenue was 3.34 percent in the fiscal 2023 fourth quarter, a decrease of 10 basis points when\n2", "original_text": "Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2023 fourth quarter was $2.3 billion, a 9.4 percent increase compared\nto the same period in the previous fiscal year due to an increase in gross profit in both reportable segments. "}, "hash": "6fd2a5c826bddafb1d585253f1849f2f8a2c11bc7d27e76f3e656ba31a0fccd2", "class_name": "RelatedNodeInfo"}}, "text": "On a\nconstant currency basis, International Healthcare Solutions' revenue was up 10.1 percent.\n", "start_char_idx": 3575, "end_char_idx": 3670, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3e043939-87a8-458f-bedb-7bab7562332c": {"__data__": {"id_": "3e043939-87a8-458f-bedb-7bab7562332c", "embedding": null, "metadata": {"window": "In the fourth quarter of fiscal 2023, revenue was\n$68.9 billion, up 12.7 percent compared to the same quarter in the previous fiscal year, reflecting a 13.0 percent increase in\nrevenue within U.S.  Healthcare Solutions and a 9.5 percent increase in revenue within International Healthcare Solutions.  On a\nconstant currency basis, International Healthcare Solutions' revenue was up 10.1 percent.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2023 fourth quarter was $2.3 billion, a 9.4 percent increase compared\nto the same period in the previous fiscal year due to an increase in gross profit in both reportable segments.  Adjusted gross\nprofit as a percentage of revenue was 3.34 percent in the fiscal 2023 fourth quarter, a decrease of 10 basis points when\n2", "original_text": "Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2023 fourth quarter was $2.3 billion, a 9.4 percent increase compared\nto the same period in the previous fiscal year due to an increase in gross profit in both reportable segments. ", "page_label": "2", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8d68cffe-a6e2-4827-9f5b-bc33a23ae109", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5a32713f40aba7e7a72c91cdb5ee51314462c4550a91df39ba31447fae2944c8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d258aaca-bc2d-42f2-a50d-8034aac78a11", "node_type": "1", "metadata": {"window": "Four th Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the fourth quarter of fiscal 2023, revenue was\n$68.9 billion, up 12.7 percent compared to the same quarter in the previous fiscal year, reflecting a 13.0 percent increase in\nrevenue within U.S.  Healthcare Solutions and a 9.5 percent increase in revenue within International Healthcare Solutions.  On a\nconstant currency basis, International Healthcare Solutions' revenue was up 10.1 percent.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2023 fourth quarter was $2.3 billion, a 9.4 percent increase compared\nto the same period in the previous fiscal year due to an increase in gross profit in both reportable segments.  Adjusted gross\nprofit as a percentage of revenue was 3.34 percent in the fiscal 2023 fourth quarter, a decrease of 10 basis points when\n2", "original_text": "On a\nconstant currency basis, International Healthcare Solutions' revenue was up 10.1 percent.\n", "page_label": "2", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5fc935d683bb66f2c64c91f9f82ef58ea3ad7cc7e6bde44d74fd69c8592a41c6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f2941e01-d3e5-440e-a914-8562aa337169", "node_type": "1", "metadata": {"window": "Healthcare Solutions and a 9.5 percent increase in revenue within International Healthcare Solutions.  On a\nconstant currency basis, International Healthcare Solutions' revenue was up 10.1 percent.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2023 fourth quarter was $2.3 billion, a 9.4 percent increase compared\nto the same period in the previous fiscal year due to an increase in gross profit in both reportable segments.  Adjusted gross\nprofit as a percentage of revenue was 3.34 percent in the fiscal 2023 fourth quarter, a decrease of 10 basis points when\n2", "original_text": "Adjusted gross\nprofit as a percentage of revenue was 3.34 percent in the fiscal 2023 fourth quarter, a decrease of 10 basis points when\n2"}, "hash": "bdef4a60df8c4a1c4d0f732b99a7d3f62559c3cbb484b907b66a44fa76aed98a", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2023 fourth quarter was $2.3 billion, a 9.4 percent increase compared\nto the same period in the previous fiscal year due to an increase in gross profit in both reportable segments. ", "start_char_idx": 3670, "end_char_idx": 3911, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f2941e01-d3e5-440e-a914-8562aa337169": {"__data__": {"id_": "f2941e01-d3e5-440e-a914-8562aa337169", "embedding": null, "metadata": {"window": "Healthcare Solutions and a 9.5 percent increase in revenue within International Healthcare Solutions.  On a\nconstant currency basis, International Healthcare Solutions' revenue was up 10.1 percent.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2023 fourth quarter was $2.3 billion, a 9.4 percent increase compared\nto the same period in the previous fiscal year due to an increase in gross profit in both reportable segments.  Adjusted gross\nprofit as a percentage of revenue was 3.34 percent in the fiscal 2023 fourth quarter, a decrease of 10 basis points when\n2", "original_text": "Adjusted gross\nprofit as a percentage of revenue was 3.34 percent in the fiscal 2023 fourth quarter, a decrease of 10 basis points when\n2", "page_label": "2", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8d68cffe-a6e2-4827-9f5b-bc33a23ae109", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5a32713f40aba7e7a72c91cdb5ee51314462c4550a91df39ba31447fae2944c8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3e043939-87a8-458f-bedb-7bab7562332c", "node_type": "1", "metadata": {"window": "In the fourth quarter of fiscal 2023, revenue was\n$68.9 billion, up 12.7 percent compared to the same quarter in the previous fiscal year, reflecting a 13.0 percent increase in\nrevenue within U.S.  Healthcare Solutions and a 9.5 percent increase in revenue within International Healthcare Solutions.  On a\nconstant currency basis, International Healthcare Solutions' revenue was up 10.1 percent.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2023 fourth quarter was $2.3 billion, a 9.4 percent increase compared\nto the same period in the previous fiscal year due to an increase in gross profit in both reportable segments.  Adjusted gross\nprofit as a percentage of revenue was 3.34 percent in the fiscal 2023 fourth quarter, a decrease of 10 basis points when\n2", "original_text": "Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2023 fourth quarter was $2.3 billion, a 9.4 percent increase compared\nto the same period in the previous fiscal year due to an increase in gross profit in both reportable segments. ", "page_label": "2", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9631761adf08fbb91c2eb6ccbcfab4921df949a07e8a0434fc618b70097e962f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "01e1be5f-63be-45b5-9902-2e599ac705d9", "node_type": "1", "metadata": {"window": "compared to the prior year quarter.  The decrease was due to the decline of U.S.  Healthcare Solutions' gross profit margin as a\nresult of increased sales of products labeled for diabetes and/or weight loss in the GLP-1 class, which have lower gross profit\nmargins, and lower sales of government-owned C OVID-19 treatments, which have higher gross profit margins.\n Adjusted Operating Expenses:  In the fourth quarter of fiscal 2023, adjusted operating expenses were $1.5 billion, an increase\nof 10.2 percent compared to the same period in the previous fiscal year primarily due to an increase in distribution, selling,\nand administrative expenses compared to the prior year quarter. ", "original_text": "compared to the prior year quarter. "}, "hash": "ba96cc6b9f05c300e2994735f84289ae692870345b59e6c1cf832417cb043936", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted gross\nprofit as a percentage of revenue was 3.34 percent in the fiscal 2023 fourth quarter, a decrease of 10 basis points when\n2", "start_char_idx": 3911, "end_char_idx": 4048, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "01e1be5f-63be-45b5-9902-2e599ac705d9": {"__data__": {"id_": "01e1be5f-63be-45b5-9902-2e599ac705d9", "embedding": null, "metadata": {"window": "compared to the prior year quarter.  The decrease was due to the decline of U.S.  Healthcare Solutions' gross profit margin as a\nresult of increased sales of products labeled for diabetes and/or weight loss in the GLP-1 class, which have lower gross profit\nmargins, and lower sales of government-owned C OVID-19 treatments, which have higher gross profit margins.\n Adjusted Operating Expenses:  In the fourth quarter of fiscal 2023, adjusted operating expenses were $1.5 billion, an increase\nof 10.2 percent compared to the same period in the previous fiscal year primarily due to an increase in distribution, selling,\nand administrative expenses compared to the prior year quarter. ", "original_text": "compared to the prior year quarter. ", "page_label": "3", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "20e3d800-bd50-438f-b446-f823062e13e0", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2b8ab5cb1f2f22e45b46c0907985e10171e973b7b7e4d6e0e2df6b38fdf7db3c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f2941e01-d3e5-440e-a914-8562aa337169", "node_type": "1", "metadata": {"window": "Healthcare Solutions and a 9.5 percent increase in revenue within International Healthcare Solutions.  On a\nconstant currency basis, International Healthcare Solutions' revenue was up 10.1 percent.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2023 fourth quarter was $2.3 billion, a 9.4 percent increase compared\nto the same period in the previous fiscal year due to an increase in gross profit in both reportable segments.  Adjusted gross\nprofit as a percentage of revenue was 3.34 percent in the fiscal 2023 fourth quarter, a decrease of 10 basis points when\n2", "original_text": "Adjusted gross\nprofit as a percentage of revenue was 3.34 percent in the fiscal 2023 fourth quarter, a decrease of 10 basis points when\n2", "page_label": "2", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2cc5a355a9c667e5b3ccf50f387907e25db3f8975aaf3b9b2e76d5c25720f8e4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "89c6a0e3-e830-40a4-b525-e51d25eb8e15", "node_type": "1", "metadata": {"window": "compared to the prior year quarter.  The decrease was due to the decline of U.S.  Healthcare Solutions' gross profit margin as a\nresult of increased sales of products labeled for diabetes and/or weight loss in the GLP-1 class, which have lower gross profit\nmargins, and lower sales of government-owned C OVID-19 treatments, which have higher gross profit margins.\n Adjusted Operating Expenses:  In the fourth quarter of fiscal 2023, adjusted operating expenses were $1.5 billion, an increase\nof 10.2 percent compared to the same period in the previous fiscal year primarily due to an increase in distribution, selling,\nand administrative expenses compared to the prior year quarter.  Adjusted operating expenses as a percentage of revenue in\nthe fiscal 2023 fourth quarter was 2.18 percent, a decrease of 5 basis points when compared to the prior year quarter.\n", "original_text": "The decrease was due to the decline of U.S. "}, "hash": "7dea89d7f400b4c1e27d41bed5d2017bd4e391ec34af224084d785376ed61094", "class_name": "RelatedNodeInfo"}}, "text": "compared to the prior year quarter. ", "start_char_idx": 0, "end_char_idx": 36, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "89c6a0e3-e830-40a4-b525-e51d25eb8e15": {"__data__": {"id_": "89c6a0e3-e830-40a4-b525-e51d25eb8e15", "embedding": null, "metadata": {"window": "compared to the prior year quarter.  The decrease was due to the decline of U.S.  Healthcare Solutions' gross profit margin as a\nresult of increased sales of products labeled for diabetes and/or weight loss in the GLP-1 class, which have lower gross profit\nmargins, and lower sales of government-owned C OVID-19 treatments, which have higher gross profit margins.\n Adjusted Operating Expenses:  In the fourth quarter of fiscal 2023, adjusted operating expenses were $1.5 billion, an increase\nof 10.2 percent compared to the same period in the previous fiscal year primarily due to an increase in distribution, selling,\nand administrative expenses compared to the prior year quarter.  Adjusted operating expenses as a percentage of revenue in\nthe fiscal 2023 fourth quarter was 2.18 percent, a decrease of 5 basis points when compared to the prior year quarter.\n", "original_text": "The decrease was due to the decline of U.S. ", "page_label": "3", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "20e3d800-bd50-438f-b446-f823062e13e0", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2b8ab5cb1f2f22e45b46c0907985e10171e973b7b7e4d6e0e2df6b38fdf7db3c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "01e1be5f-63be-45b5-9902-2e599ac705d9", "node_type": "1", "metadata": {"window": "compared to the prior year quarter.  The decrease was due to the decline of U.S.  Healthcare Solutions' gross profit margin as a\nresult of increased sales of products labeled for diabetes and/or weight loss in the GLP-1 class, which have lower gross profit\nmargins, and lower sales of government-owned C OVID-19 treatments, which have higher gross profit margins.\n Adjusted Operating Expenses:  In the fourth quarter of fiscal 2023, adjusted operating expenses were $1.5 billion, an increase\nof 10.2 percent compared to the same period in the previous fiscal year primarily due to an increase in distribution, selling,\nand administrative expenses compared to the prior year quarter. ", "original_text": "compared to the prior year quarter. ", "page_label": "3", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "084047671842dab92bddc4edba838854728984a27e0e8791f50aa6c32cf39049", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9e89b35a-0ed1-4f98-b157-5747a429d6cb", "node_type": "1", "metadata": {"window": "compared to the prior year quarter.  The decrease was due to the decline of U.S.  Healthcare Solutions' gross profit margin as a\nresult of increased sales of products labeled for diabetes and/or weight loss in the GLP-1 class, which have lower gross profit\nmargins, and lower sales of government-owned C OVID-19 treatments, which have higher gross profit margins.\n Adjusted Operating Expenses:  In the fourth quarter of fiscal 2023, adjusted operating expenses were $1.5 billion, an increase\nof 10.2 percent compared to the same period in the previous fiscal year primarily due to an increase in distribution, selling,\nand administrative expenses compared to the prior year quarter.  Adjusted operating expenses as a percentage of revenue in\nthe fiscal 2023 fourth quarter was 2.18 percent, a decrease of 5 basis points when compared to the prior year quarter.\n Adjusted Operating Income:  In the fiscal 2023 fourth quarter, adjusted operating income of $801.0 million increased 8.0\npercent from the prior year quarter due to a 9.4 percent increase in U.S. ", "original_text": "Healthcare Solutions' gross profit margin as a\nresult of increased sales of products labeled for diabetes and/or weight loss in the GLP-1 class, which have lower gross profit\nmargins, and lower sales of government-owned C OVID-19 treatments, which have higher gross profit margins.\n"}, "hash": "6efdd47875412311cab045eb26a44d85421898d492fdfd7a70b583a1f9ae8d82", "class_name": "RelatedNodeInfo"}}, "text": "The decrease was due to the decline of U.S. ", "start_char_idx": 36, "end_char_idx": 80, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9e89b35a-0ed1-4f98-b157-5747a429d6cb": {"__data__": {"id_": "9e89b35a-0ed1-4f98-b157-5747a429d6cb", "embedding": null, "metadata": {"window": "compared to the prior year quarter.  The decrease was due to the decline of U.S.  Healthcare Solutions' gross profit margin as a\nresult of increased sales of products labeled for diabetes and/or weight loss in the GLP-1 class, which have lower gross profit\nmargins, and lower sales of government-owned C OVID-19 treatments, which have higher gross profit margins.\n Adjusted Operating Expenses:  In the fourth quarter of fiscal 2023, adjusted operating expenses were $1.5 billion, an increase\nof 10.2 percent compared to the same period in the previous fiscal year primarily due to an increase in distribution, selling,\nand administrative expenses compared to the prior year quarter.  Adjusted operating expenses as a percentage of revenue in\nthe fiscal 2023 fourth quarter was 2.18 percent, a decrease of 5 basis points when compared to the prior year quarter.\n Adjusted Operating Income:  In the fiscal 2023 fourth quarter, adjusted operating income of $801.0 million increased 8.0\npercent from the prior year quarter due to a 9.4 percent increase in U.S. ", "original_text": "Healthcare Solutions' gross profit margin as a\nresult of increased sales of products labeled for diabetes and/or weight loss in the GLP-1 class, which have lower gross profit\nmargins, and lower sales of government-owned C OVID-19 treatments, which have higher gross profit margins.\n", "page_label": "3", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "20e3d800-bd50-438f-b446-f823062e13e0", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2b8ab5cb1f2f22e45b46c0907985e10171e973b7b7e4d6e0e2df6b38fdf7db3c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "89c6a0e3-e830-40a4-b525-e51d25eb8e15", "node_type": "1", "metadata": {"window": "compared to the prior year quarter.  The decrease was due to the decline of U.S.  Healthcare Solutions' gross profit margin as a\nresult of increased sales of products labeled for diabetes and/or weight loss in the GLP-1 class, which have lower gross profit\nmargins, and lower sales of government-owned C OVID-19 treatments, which have higher gross profit margins.\n Adjusted Operating Expenses:  In the fourth quarter of fiscal 2023, adjusted operating expenses were $1.5 billion, an increase\nof 10.2 percent compared to the same period in the previous fiscal year primarily due to an increase in distribution, selling,\nand administrative expenses compared to the prior year quarter.  Adjusted operating expenses as a percentage of revenue in\nthe fiscal 2023 fourth quarter was 2.18 percent, a decrease of 5 basis points when compared to the prior year quarter.\n", "original_text": "The decrease was due to the decline of U.S. ", "page_label": "3", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2f6602a51ab52bbafbb969395de10c7485384428e0ff58f7e5ebde2039ad0982", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9aaf4b69-e82f-4639-afe5-0601a348e3a7", "node_type": "1", "metadata": {"window": "compared to the prior year quarter.  The decrease was due to the decline of U.S.  Healthcare Solutions' gross profit margin as a\nresult of increased sales of products labeled for diabetes and/or weight loss in the GLP-1 class, which have lower gross profit\nmargins, and lower sales of government-owned C OVID-19 treatments, which have higher gross profit margins.\n Adjusted Operating Expenses:  In the fourth quarter of fiscal 2023, adjusted operating expenses were $1.5 billion, an increase\nof 10.2 percent compared to the same period in the previous fiscal year primarily due to an increase in distribution, selling,\nand administrative expenses compared to the prior year quarter.  Adjusted operating expenses as a percentage of revenue in\nthe fiscal 2023 fourth quarter was 2.18 percent, a decrease of 5 basis points when compared to the prior year quarter.\n Adjusted Operating Income:  In the fiscal 2023 fourth quarter, adjusted operating income of $801.0 million increased 8.0\npercent from the prior year quarter due to a 9.4 percent increase in U.S.  Healthcare Solutions' operating income and a 3.1\npercent increase in operating income within International Healthcare Solutions. ", "original_text": "Adjusted Operating Expenses:  In the fourth quarter of fiscal 2023, adjusted operating expenses were $1.5 billion, an increase\nof 10.2 percent compared to the same period in the previous fiscal year primarily due to an increase in distribution, selling,\nand administrative expenses compared to the prior year quarter. "}, "hash": "826b465e0482315e8875b3678aa4a0d9f732bdfcbf20a445041c2972e655ee50", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions' gross profit margin as a\nresult of increased sales of products labeled for diabetes and/or weight loss in the GLP-1 class, which have lower gross profit\nmargins, and lower sales of government-owned C OVID-19 treatments, which have higher gross profit margins.\n", "start_char_idx": 80, "end_char_idx": 362, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9aaf4b69-e82f-4639-afe5-0601a348e3a7": {"__data__": {"id_": "9aaf4b69-e82f-4639-afe5-0601a348e3a7", "embedding": null, "metadata": {"window": "compared to the prior year quarter.  The decrease was due to the decline of U.S.  Healthcare Solutions' gross profit margin as a\nresult of increased sales of products labeled for diabetes and/or weight loss in the GLP-1 class, which have lower gross profit\nmargins, and lower sales of government-owned C OVID-19 treatments, which have higher gross profit margins.\n Adjusted Operating Expenses:  In the fourth quarter of fiscal 2023, adjusted operating expenses were $1.5 billion, an increase\nof 10.2 percent compared to the same period in the previous fiscal year primarily due to an increase in distribution, selling,\nand administrative expenses compared to the prior year quarter.  Adjusted operating expenses as a percentage of revenue in\nthe fiscal 2023 fourth quarter was 2.18 percent, a decrease of 5 basis points when compared to the prior year quarter.\n Adjusted Operating Income:  In the fiscal 2023 fourth quarter, adjusted operating income of $801.0 million increased 8.0\npercent from the prior year quarter due to a 9.4 percent increase in U.S.  Healthcare Solutions' operating income and a 3.1\npercent increase in operating income within International Healthcare Solutions. ", "original_text": "Adjusted Operating Expenses:  In the fourth quarter of fiscal 2023, adjusted operating expenses were $1.5 billion, an increase\nof 10.2 percent compared to the same period in the previous fiscal year primarily due to an increase in distribution, selling,\nand administrative expenses compared to the prior year quarter. ", "page_label": "3", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "20e3d800-bd50-438f-b446-f823062e13e0", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2b8ab5cb1f2f22e45b46c0907985e10171e973b7b7e4d6e0e2df6b38fdf7db3c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9e89b35a-0ed1-4f98-b157-5747a429d6cb", "node_type": "1", "metadata": {"window": "compared to the prior year quarter.  The decrease was due to the decline of U.S.  Healthcare Solutions' gross profit margin as a\nresult of increased sales of products labeled for diabetes and/or weight loss in the GLP-1 class, which have lower gross profit\nmargins, and lower sales of government-owned C OVID-19 treatments, which have higher gross profit margins.\n Adjusted Operating Expenses:  In the fourth quarter of fiscal 2023, adjusted operating expenses were $1.5 billion, an increase\nof 10.2 percent compared to the same period in the previous fiscal year primarily due to an increase in distribution, selling,\nand administrative expenses compared to the prior year quarter.  Adjusted operating expenses as a percentage of revenue in\nthe fiscal 2023 fourth quarter was 2.18 percent, a decrease of 5 basis points when compared to the prior year quarter.\n Adjusted Operating Income:  In the fiscal 2023 fourth quarter, adjusted operating income of $801.0 million increased 8.0\npercent from the prior year quarter due to a 9.4 percent increase in U.S. ", "original_text": "Healthcare Solutions' gross profit margin as a\nresult of increased sales of products labeled for diabetes and/or weight loss in the GLP-1 class, which have lower gross profit\nmargins, and lower sales of government-owned C OVID-19 treatments, which have higher gross profit margins.\n", "page_label": "3", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6f4ba362ad02624a475d7d513e8ffe732f72e70ed14021937b40588fb4f713c3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4b7ddded-d19c-4b76-9683-80a2e92db665", "node_type": "1", "metadata": {"window": "The decrease was due to the decline of U.S.  Healthcare Solutions' gross profit margin as a\nresult of increased sales of products labeled for diabetes and/or weight loss in the GLP-1 class, which have lower gross profit\nmargins, and lower sales of government-owned C OVID-19 treatments, which have higher gross profit margins.\n Adjusted Operating Expenses:  In the fourth quarter of fiscal 2023, adjusted operating expenses were $1.5 billion, an increase\nof 10.2 percent compared to the same period in the previous fiscal year primarily due to an increase in distribution, selling,\nand administrative expenses compared to the prior year quarter.  Adjusted operating expenses as a percentage of revenue in\nthe fiscal 2023 fourth quarter was 2.18 percent, a decrease of 5 basis points when compared to the prior year quarter.\n Adjusted Operating Income:  In the fiscal 2023 fourth quarter, adjusted operating income of $801.0 million increased 8.0\npercent from the prior year quarter due to a 9.4 percent increase in U.S.  Healthcare Solutions' operating income and a 3.1\npercent increase in operating income within International Healthcare Solutions.  On a constant currency basis, the Company\u2019s\nadjusted operating income increased 8.2 percent compared to the prior year quarter. ", "original_text": "Adjusted operating expenses as a percentage of revenue in\nthe fiscal 2023 fourth quarter was 2.18 percent, a decrease of 5 basis points when compared to the prior year quarter.\n"}, "hash": "d81e06b998fe2c1a88a973d54d7390c575379cceed6a24f886b7854daa6fb55a", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted Operating Expenses:  In the fourth quarter of fiscal 2023, adjusted operating expenses were $1.5 billion, an increase\nof 10.2 percent compared to the same period in the previous fiscal year primarily due to an increase in distribution, selling,\nand administrative expenses compared to the prior year quarter. ", "start_char_idx": 362, "end_char_idx": 680, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4b7ddded-d19c-4b76-9683-80a2e92db665": {"__data__": {"id_": "4b7ddded-d19c-4b76-9683-80a2e92db665", "embedding": null, "metadata": {"window": "The decrease was due to the decline of U.S.  Healthcare Solutions' gross profit margin as a\nresult of increased sales of products labeled for diabetes and/or weight loss in the GLP-1 class, which have lower gross profit\nmargins, and lower sales of government-owned C OVID-19 treatments, which have higher gross profit margins.\n Adjusted Operating Expenses:  In the fourth quarter of fiscal 2023, adjusted operating expenses were $1.5 billion, an increase\nof 10.2 percent compared to the same period in the previous fiscal year primarily due to an increase in distribution, selling,\nand administrative expenses compared to the prior year quarter.  Adjusted operating expenses as a percentage of revenue in\nthe fiscal 2023 fourth quarter was 2.18 percent, a decrease of 5 basis points when compared to the prior year quarter.\n Adjusted Operating Income:  In the fiscal 2023 fourth quarter, adjusted operating income of $801.0 million increased 8.0\npercent from the prior year quarter due to a 9.4 percent increase in U.S.  Healthcare Solutions' operating income and a 3.1\npercent increase in operating income within International Healthcare Solutions.  On a constant currency basis, the Company\u2019s\nadjusted operating income increased 8.2 percent compared to the prior year quarter. ", "original_text": "Adjusted operating expenses as a percentage of revenue in\nthe fiscal 2023 fourth quarter was 2.18 percent, a decrease of 5 basis points when compared to the prior year quarter.\n", "page_label": "3", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "20e3d800-bd50-438f-b446-f823062e13e0", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2b8ab5cb1f2f22e45b46c0907985e10171e973b7b7e4d6e0e2df6b38fdf7db3c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9aaf4b69-e82f-4639-afe5-0601a348e3a7", "node_type": "1", "metadata": {"window": "compared to the prior year quarter.  The decrease was due to the decline of U.S.  Healthcare Solutions' gross profit margin as a\nresult of increased sales of products labeled for diabetes and/or weight loss in the GLP-1 class, which have lower gross profit\nmargins, and lower sales of government-owned C OVID-19 treatments, which have higher gross profit margins.\n Adjusted Operating Expenses:  In the fourth quarter of fiscal 2023, adjusted operating expenses were $1.5 billion, an increase\nof 10.2 percent compared to the same period in the previous fiscal year primarily due to an increase in distribution, selling,\nand administrative expenses compared to the prior year quarter.  Adjusted operating expenses as a percentage of revenue in\nthe fiscal 2023 fourth quarter was 2.18 percent, a decrease of 5 basis points when compared to the prior year quarter.\n Adjusted Operating Income:  In the fiscal 2023 fourth quarter, adjusted operating income of $801.0 million increased 8.0\npercent from the prior year quarter due to a 9.4 percent increase in U.S.  Healthcare Solutions' operating income and a 3.1\npercent increase in operating income within International Healthcare Solutions. ", "original_text": "Adjusted Operating Expenses:  In the fourth quarter of fiscal 2023, adjusted operating expenses were $1.5 billion, an increase\nof 10.2 percent compared to the same period in the previous fiscal year primarily due to an increase in distribution, selling,\nand administrative expenses compared to the prior year quarter. ", "page_label": "3", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d2e53a851b9020518ee48191dc8e7a64ad7087f72b3cf7939b09fb0b9704a69d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "13057d64-5674-4122-adc4-48eae99844d7", "node_type": "1", "metadata": {"window": "Healthcare Solutions' gross profit margin as a\nresult of increased sales of products labeled for diabetes and/or weight loss in the GLP-1 class, which have lower gross profit\nmargins, and lower sales of government-owned C OVID-19 treatments, which have higher gross profit margins.\n Adjusted Operating Expenses:  In the fourth quarter of fiscal 2023, adjusted operating expenses were $1.5 billion, an increase\nof 10.2 percent compared to the same period in the previous fiscal year primarily due to an increase in distribution, selling,\nand administrative expenses compared to the prior year quarter.  Adjusted operating expenses as a percentage of revenue in\nthe fiscal 2023 fourth quarter was 2.18 percent, a decrease of 5 basis points when compared to the prior year quarter.\n Adjusted Operating Income:  In the fiscal 2023 fourth quarter, adjusted operating income of $801.0 million increased 8.0\npercent from the prior year quarter due to a 9.4 percent increase in U.S.  Healthcare Solutions' operating income and a 3.1\npercent increase in operating income within International Healthcare Solutions.  On a constant currency basis, the Company\u2019s\nadjusted operating income increased 8.2 percent compared to the prior year quarter.  On a constant currency basis,\nInternational Healthcare Solutions segment operating income increased 4.0 percent. ", "original_text": "Adjusted Operating Income:  In the fiscal 2023 fourth quarter, adjusted operating income of $801.0 million increased 8.0\npercent from the prior year quarter due to a 9.4 percent increase in U.S. "}, "hash": "8dcb75887b1c0218edd7db6ed6276241d618e9ac142e4cc4076ff835135c6fd8", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operating expenses as a percentage of revenue in\nthe fiscal 2023 fourth quarter was 2.18 percent, a decrease of 5 basis points when compared to the prior year quarter.\n", "start_char_idx": 680, "end_char_idx": 857, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "13057d64-5674-4122-adc4-48eae99844d7": {"__data__": {"id_": "13057d64-5674-4122-adc4-48eae99844d7", "embedding": null, "metadata": {"window": "Healthcare Solutions' gross profit margin as a\nresult of increased sales of products labeled for diabetes and/or weight loss in the GLP-1 class, which have lower gross profit\nmargins, and lower sales of government-owned C OVID-19 treatments, which have higher gross profit margins.\n Adjusted Operating Expenses:  In the fourth quarter of fiscal 2023, adjusted operating expenses were $1.5 billion, an increase\nof 10.2 percent compared to the same period in the previous fiscal year primarily due to an increase in distribution, selling,\nand administrative expenses compared to the prior year quarter.  Adjusted operating expenses as a percentage of revenue in\nthe fiscal 2023 fourth quarter was 2.18 percent, a decrease of 5 basis points when compared to the prior year quarter.\n Adjusted Operating Income:  In the fiscal 2023 fourth quarter, adjusted operating income of $801.0 million increased 8.0\npercent from the prior year quarter due to a 9.4 percent increase in U.S.  Healthcare Solutions' operating income and a 3.1\npercent increase in operating income within International Healthcare Solutions.  On a constant currency basis, the Company\u2019s\nadjusted operating income increased 8.2 percent compared to the prior year quarter.  On a constant currency basis,\nInternational Healthcare Solutions segment operating income increased 4.0 percent. ", "original_text": "Adjusted Operating Income:  In the fiscal 2023 fourth quarter, adjusted operating income of $801.0 million increased 8.0\npercent from the prior year quarter due to a 9.4 percent increase in U.S. ", "page_label": "3", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "20e3d800-bd50-438f-b446-f823062e13e0", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2b8ab5cb1f2f22e45b46c0907985e10171e973b7b7e4d6e0e2df6b38fdf7db3c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4b7ddded-d19c-4b76-9683-80a2e92db665", "node_type": "1", "metadata": {"window": "The decrease was due to the decline of U.S.  Healthcare Solutions' gross profit margin as a\nresult of increased sales of products labeled for diabetes and/or weight loss in the GLP-1 class, which have lower gross profit\nmargins, and lower sales of government-owned C OVID-19 treatments, which have higher gross profit margins.\n Adjusted Operating Expenses:  In the fourth quarter of fiscal 2023, adjusted operating expenses were $1.5 billion, an increase\nof 10.2 percent compared to the same period in the previous fiscal year primarily due to an increase in distribution, selling,\nand administrative expenses compared to the prior year quarter.  Adjusted operating expenses as a percentage of revenue in\nthe fiscal 2023 fourth quarter was 2.18 percent, a decrease of 5 basis points when compared to the prior year quarter.\n Adjusted Operating Income:  In the fiscal 2023 fourth quarter, adjusted operating income of $801.0 million increased 8.0\npercent from the prior year quarter due to a 9.4 percent increase in U.S.  Healthcare Solutions' operating income and a 3.1\npercent increase in operating income within International Healthcare Solutions.  On a constant currency basis, the Company\u2019s\nadjusted operating income increased 8.2 percent compared to the prior year quarter. ", "original_text": "Adjusted operating expenses as a percentage of revenue in\nthe fiscal 2023 fourth quarter was 2.18 percent, a decrease of 5 basis points when compared to the prior year quarter.\n", "page_label": "3", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c42eb677141efe432d0417c1824eea413bd88a6d7a72abe1c97c002fa269d667", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "38ddf0b6-f99d-4c83-afa0-1e4a43cc51e8", "node_type": "1", "metadata": {"window": "Adjusted Operating Expenses:  In the fourth quarter of fiscal 2023, adjusted operating expenses were $1.5 billion, an increase\nof 10.2 percent compared to the same period in the previous fiscal year primarily due to an increase in distribution, selling,\nand administrative expenses compared to the prior year quarter.  Adjusted operating expenses as a percentage of revenue in\nthe fiscal 2023 fourth quarter was 2.18 percent, a decrease of 5 basis points when compared to the prior year quarter.\n Adjusted Operating Income:  In the fiscal 2023 fourth quarter, adjusted operating income of $801.0 million increased 8.0\npercent from the prior year quarter due to a 9.4 percent increase in U.S.  Healthcare Solutions' operating income and a 3.1\npercent increase in operating income within International Healthcare Solutions.  On a constant currency basis, the Company\u2019s\nadjusted operating income increased 8.2 percent compared to the prior year quarter.  On a constant currency basis,\nInternational Healthcare Solutions segment operating income increased 4.0 percent.  Adjusted operating income as a\npercentage of revenue was 1.16 percent in the fiscal 2023 fourth quarter, a decrease of 5 basis points when compared to the\nprior year quarter.\n", "original_text": "Healthcare Solutions' operating income and a 3.1\npercent increase in operating income within International Healthcare Solutions. "}, "hash": "0db4c8242d0517dfd75fa4c63bfbd4e8b9a127694ea1eaf0a24a83c5c7773cd3", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted Operating Income:  In the fiscal 2023 fourth quarter, adjusted operating income of $801.0 million increased 8.0\npercent from the prior year quarter due to a 9.4 percent increase in U.S. ", "start_char_idx": 857, "end_char_idx": 1052, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "38ddf0b6-f99d-4c83-afa0-1e4a43cc51e8": {"__data__": {"id_": "38ddf0b6-f99d-4c83-afa0-1e4a43cc51e8", "embedding": null, "metadata": {"window": "Adjusted Operating Expenses:  In the fourth quarter of fiscal 2023, adjusted operating expenses were $1.5 billion, an increase\nof 10.2 percent compared to the same period in the previous fiscal year primarily due to an increase in distribution, selling,\nand administrative expenses compared to the prior year quarter.  Adjusted operating expenses as a percentage of revenue in\nthe fiscal 2023 fourth quarter was 2.18 percent, a decrease of 5 basis points when compared to the prior year quarter.\n Adjusted Operating Income:  In the fiscal 2023 fourth quarter, adjusted operating income of $801.0 million increased 8.0\npercent from the prior year quarter due to a 9.4 percent increase in U.S.  Healthcare Solutions' operating income and a 3.1\npercent increase in operating income within International Healthcare Solutions.  On a constant currency basis, the Company\u2019s\nadjusted operating income increased 8.2 percent compared to the prior year quarter.  On a constant currency basis,\nInternational Healthcare Solutions segment operating income increased 4.0 percent.  Adjusted operating income as a\npercentage of revenue was 1.16 percent in the fiscal 2023 fourth quarter, a decrease of 5 basis points when compared to the\nprior year quarter.\n", "original_text": "Healthcare Solutions' operating income and a 3.1\npercent increase in operating income within International Healthcare Solutions. ", "page_label": "3", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "20e3d800-bd50-438f-b446-f823062e13e0", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2b8ab5cb1f2f22e45b46c0907985e10171e973b7b7e4d6e0e2df6b38fdf7db3c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "13057d64-5674-4122-adc4-48eae99844d7", "node_type": "1", "metadata": {"window": "Healthcare Solutions' gross profit margin as a\nresult of increased sales of products labeled for diabetes and/or weight loss in the GLP-1 class, which have lower gross profit\nmargins, and lower sales of government-owned C OVID-19 treatments, which have higher gross profit margins.\n Adjusted Operating Expenses:  In the fourth quarter of fiscal 2023, adjusted operating expenses were $1.5 billion, an increase\nof 10.2 percent compared to the same period in the previous fiscal year primarily due to an increase in distribution, selling,\nand administrative expenses compared to the prior year quarter.  Adjusted operating expenses as a percentage of revenue in\nthe fiscal 2023 fourth quarter was 2.18 percent, a decrease of 5 basis points when compared to the prior year quarter.\n Adjusted Operating Income:  In the fiscal 2023 fourth quarter, adjusted operating income of $801.0 million increased 8.0\npercent from the prior year quarter due to a 9.4 percent increase in U.S.  Healthcare Solutions' operating income and a 3.1\npercent increase in operating income within International Healthcare Solutions.  On a constant currency basis, the Company\u2019s\nadjusted operating income increased 8.2 percent compared to the prior year quarter.  On a constant currency basis,\nInternational Healthcare Solutions segment operating income increased 4.0 percent. ", "original_text": "Adjusted Operating Income:  In the fiscal 2023 fourth quarter, adjusted operating income of $801.0 million increased 8.0\npercent from the prior year quarter due to a 9.4 percent increase in U.S. ", "page_label": "3", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "283ee95222e88ee1d1c19da7f3923879701cc2020563594d12a4447634610be5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "efe0d55c-07c7-4acc-916d-68a3889bc549", "node_type": "1", "metadata": {"window": "Adjusted operating expenses as a percentage of revenue in\nthe fiscal 2023 fourth quarter was 2.18 percent, a decrease of 5 basis points when compared to the prior year quarter.\n Adjusted Operating Income:  In the fiscal 2023 fourth quarter, adjusted operating income of $801.0 million increased 8.0\npercent from the prior year quarter due to a 9.4 percent increase in U.S.  Healthcare Solutions' operating income and a 3.1\npercent increase in operating income within International Healthcare Solutions.  On a constant currency basis, the Company\u2019s\nadjusted operating income increased 8.2 percent compared to the prior year quarter.  On a constant currency basis,\nInternational Healthcare Solutions segment operating income increased 4.0 percent.  Adjusted operating income as a\npercentage of revenue was 1.16 percent in the fiscal 2023 fourth quarter, a decrease of 5 basis points when compared to the\nprior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense. ", "original_text": "On a constant currency basis, the Company\u2019s\nadjusted operating income increased 8.2 percent compared to the prior year quarter. "}, "hash": "27d02351a6df44f83262592aed3e8c964f280d2a92de379cb97ae27fae4d955b", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions' operating income and a 3.1\npercent increase in operating income within International Healthcare Solutions. ", "start_char_idx": 1052, "end_char_idx": 1181, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "efe0d55c-07c7-4acc-916d-68a3889bc549": {"__data__": {"id_": "efe0d55c-07c7-4acc-916d-68a3889bc549", "embedding": null, "metadata": {"window": "Adjusted operating expenses as a percentage of revenue in\nthe fiscal 2023 fourth quarter was 2.18 percent, a decrease of 5 basis points when compared to the prior year quarter.\n Adjusted Operating Income:  In the fiscal 2023 fourth quarter, adjusted operating income of $801.0 million increased 8.0\npercent from the prior year quarter due to a 9.4 percent increase in U.S.  Healthcare Solutions' operating income and a 3.1\npercent increase in operating income within International Healthcare Solutions.  On a constant currency basis, the Company\u2019s\nadjusted operating income increased 8.2 percent compared to the prior year quarter.  On a constant currency basis,\nInternational Healthcare Solutions segment operating income increased 4.0 percent.  Adjusted operating income as a\npercentage of revenue was 1.16 percent in the fiscal 2023 fourth quarter, a decrease of 5 basis points when compared to the\nprior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense. ", "original_text": "On a constant currency basis, the Company\u2019s\nadjusted operating income increased 8.2 percent compared to the prior year quarter. ", "page_label": "3", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "20e3d800-bd50-438f-b446-f823062e13e0", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2b8ab5cb1f2f22e45b46c0907985e10171e973b7b7e4d6e0e2df6b38fdf7db3c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "38ddf0b6-f99d-4c83-afa0-1e4a43cc51e8", "node_type": "1", "metadata": {"window": "Adjusted Operating Expenses:  In the fourth quarter of fiscal 2023, adjusted operating expenses were $1.5 billion, an increase\nof 10.2 percent compared to the same period in the previous fiscal year primarily due to an increase in distribution, selling,\nand administrative expenses compared to the prior year quarter.  Adjusted operating expenses as a percentage of revenue in\nthe fiscal 2023 fourth quarter was 2.18 percent, a decrease of 5 basis points when compared to the prior year quarter.\n Adjusted Operating Income:  In the fiscal 2023 fourth quarter, adjusted operating income of $801.0 million increased 8.0\npercent from the prior year quarter due to a 9.4 percent increase in U.S.  Healthcare Solutions' operating income and a 3.1\npercent increase in operating income within International Healthcare Solutions.  On a constant currency basis, the Company\u2019s\nadjusted operating income increased 8.2 percent compared to the prior year quarter.  On a constant currency basis,\nInternational Healthcare Solutions segment operating income increased 4.0 percent.  Adjusted operating income as a\npercentage of revenue was 1.16 percent in the fiscal 2023 fourth quarter, a decrease of 5 basis points when compared to the\nprior year quarter.\n", "original_text": "Healthcare Solutions' operating income and a 3.1\npercent increase in operating income within International Healthcare Solutions. ", "page_label": "3", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "763aed3bfd0cdab7dda239a21b3267f977350775c5a6a31016c801899ef26d50", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1a04af32-691a-44cd-b80e-78fb931ce9d6", "node_type": "1", "metadata": {"window": "Adjusted Operating Income:  In the fiscal 2023 fourth quarter, adjusted operating income of $801.0 million increased 8.0\npercent from the prior year quarter due to a 9.4 percent increase in U.S.  Healthcare Solutions' operating income and a 3.1\npercent increase in operating income within International Healthcare Solutions.  On a constant currency basis, the Company\u2019s\nadjusted operating income increased 8.2 percent compared to the prior year quarter.  On a constant currency basis,\nInternational Healthcare Solutions segment operating income increased 4.0 percent.  Adjusted operating income as a\npercentage of revenue was 1.16 percent in the fiscal 2023 fourth quarter, a decrease of 5 basis points when compared to the\nprior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2023 fourth\nquarter, net interest expense of $60.9 million increased 18.3 percent versus the prior year quarter primarily due to increases in\nintra-period variable-rate borrowings and associated interest rates, offset in part by an increase in interest income as a result\nof higher investment interest rates.\n", "original_text": "On a constant currency basis,\nInternational Healthcare Solutions segment operating income increased 4.0 percent. "}, "hash": "8c5550e97cfd6bd1f4fb343e1b8e8aef44f937202eb24ca91c9f96d684b6a4c6", "class_name": "RelatedNodeInfo"}}, "text": "On a constant currency basis, the Company\u2019s\nadjusted operating income increased 8.2 percent compared to the prior year quarter. ", "start_char_idx": 1181, "end_char_idx": 1309, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1a04af32-691a-44cd-b80e-78fb931ce9d6": {"__data__": {"id_": "1a04af32-691a-44cd-b80e-78fb931ce9d6", "embedding": null, "metadata": {"window": "Adjusted Operating Income:  In the fiscal 2023 fourth quarter, adjusted operating income of $801.0 million increased 8.0\npercent from the prior year quarter due to a 9.4 percent increase in U.S.  Healthcare Solutions' operating income and a 3.1\npercent increase in operating income within International Healthcare Solutions.  On a constant currency basis, the Company\u2019s\nadjusted operating income increased 8.2 percent compared to the prior year quarter.  On a constant currency basis,\nInternational Healthcare Solutions segment operating income increased 4.0 percent.  Adjusted operating income as a\npercentage of revenue was 1.16 percent in the fiscal 2023 fourth quarter, a decrease of 5 basis points when compared to the\nprior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2023 fourth\nquarter, net interest expense of $60.9 million increased 18.3 percent versus the prior year quarter primarily due to increases in\nintra-period variable-rate borrowings and associated interest rates, offset in part by an increase in interest income as a result\nof higher investment interest rates.\n", "original_text": "On a constant currency basis,\nInternational Healthcare Solutions segment operating income increased 4.0 percent. ", "page_label": "3", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "20e3d800-bd50-438f-b446-f823062e13e0", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2b8ab5cb1f2f22e45b46c0907985e10171e973b7b7e4d6e0e2df6b38fdf7db3c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "efe0d55c-07c7-4acc-916d-68a3889bc549", "node_type": "1", "metadata": {"window": "Adjusted operating expenses as a percentage of revenue in\nthe fiscal 2023 fourth quarter was 2.18 percent, a decrease of 5 basis points when compared to the prior year quarter.\n Adjusted Operating Income:  In the fiscal 2023 fourth quarter, adjusted operating income of $801.0 million increased 8.0\npercent from the prior year quarter due to a 9.4 percent increase in U.S.  Healthcare Solutions' operating income and a 3.1\npercent increase in operating income within International Healthcare Solutions.  On a constant currency basis, the Company\u2019s\nadjusted operating income increased 8.2 percent compared to the prior year quarter.  On a constant currency basis,\nInternational Healthcare Solutions segment operating income increased 4.0 percent.  Adjusted operating income as a\npercentage of revenue was 1.16 percent in the fiscal 2023 fourth quarter, a decrease of 5 basis points when compared to the\nprior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense. ", "original_text": "On a constant currency basis, the Company\u2019s\nadjusted operating income increased 8.2 percent compared to the prior year quarter. ", "page_label": "3", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "93249e9ba7cd50c6f5061eb4fb5e012e91976d914b9328372c222bfa26469def", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b9c901e0-fe44-4f9a-9c86-4e9995246faf", "node_type": "1", "metadata": {"window": "Healthcare Solutions' operating income and a 3.1\npercent increase in operating income within International Healthcare Solutions.  On a constant currency basis, the Company\u2019s\nadjusted operating income increased 8.2 percent compared to the prior year quarter.  On a constant currency basis,\nInternational Healthcare Solutions segment operating income increased 4.0 percent.  Adjusted operating income as a\npercentage of revenue was 1.16 percent in the fiscal 2023 fourth quarter, a decrease of 5 basis points when compared to the\nprior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2023 fourth\nquarter, net interest expense of $60.9 million increased 18.3 percent versus the prior year quarter primarily due to increases in\nintra-period variable-rate borrowings and associated interest rates, offset in part by an increase in interest income as a result\nof higher investment interest rates.\n Adjusted Effective T ax Rate:  The adjusted effective tax rate was 21.6 percent for the fourth quarter of fiscal 2023 compared to\n19.8 percent in the prior year quarter.\n", "original_text": "Adjusted operating income as a\npercentage of revenue was 1.16 percent in the fiscal 2023 fourth quarter, a decrease of 5 basis points when compared to the\nprior year quarter.\n"}, "hash": "eefc9a717b2fdc5b26ce8ce99865e32f3fa4451aa979feb913ad24936add52f4", "class_name": "RelatedNodeInfo"}}, "text": "On a constant currency basis,\nInternational Healthcare Solutions segment operating income increased 4.0 percent. ", "start_char_idx": 1309, "end_char_idx": 1422, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b9c901e0-fe44-4f9a-9c86-4e9995246faf": {"__data__": {"id_": "b9c901e0-fe44-4f9a-9c86-4e9995246faf", "embedding": null, "metadata": {"window": "Healthcare Solutions' operating income and a 3.1\npercent increase in operating income within International Healthcare Solutions.  On a constant currency basis, the Company\u2019s\nadjusted operating income increased 8.2 percent compared to the prior year quarter.  On a constant currency basis,\nInternational Healthcare Solutions segment operating income increased 4.0 percent.  Adjusted operating income as a\npercentage of revenue was 1.16 percent in the fiscal 2023 fourth quarter, a decrease of 5 basis points when compared to the\nprior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2023 fourth\nquarter, net interest expense of $60.9 million increased 18.3 percent versus the prior year quarter primarily due to increases in\nintra-period variable-rate borrowings and associated interest rates, offset in part by an increase in interest income as a result\nof higher investment interest rates.\n Adjusted Effective T ax Rate:  The adjusted effective tax rate was 21.6 percent for the fourth quarter of fiscal 2023 compared to\n19.8 percent in the prior year quarter.\n", "original_text": "Adjusted operating income as a\npercentage of revenue was 1.16 percent in the fiscal 2023 fourth quarter, a decrease of 5 basis points when compared to the\nprior year quarter.\n", "page_label": "3", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "20e3d800-bd50-438f-b446-f823062e13e0", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2b8ab5cb1f2f22e45b46c0907985e10171e973b7b7e4d6e0e2df6b38fdf7db3c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1a04af32-691a-44cd-b80e-78fb931ce9d6", "node_type": "1", "metadata": {"window": "Adjusted Operating Income:  In the fiscal 2023 fourth quarter, adjusted operating income of $801.0 million increased 8.0\npercent from the prior year quarter due to a 9.4 percent increase in U.S.  Healthcare Solutions' operating income and a 3.1\npercent increase in operating income within International Healthcare Solutions.  On a constant currency basis, the Company\u2019s\nadjusted operating income increased 8.2 percent compared to the prior year quarter.  On a constant currency basis,\nInternational Healthcare Solutions segment operating income increased 4.0 percent.  Adjusted operating income as a\npercentage of revenue was 1.16 percent in the fiscal 2023 fourth quarter, a decrease of 5 basis points when compared to the\nprior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2023 fourth\nquarter, net interest expense of $60.9 million increased 18.3 percent versus the prior year quarter primarily due to increases in\nintra-period variable-rate borrowings and associated interest rates, offset in part by an increase in interest income as a result\nof higher investment interest rates.\n", "original_text": "On a constant currency basis,\nInternational Healthcare Solutions segment operating income increased 4.0 percent. ", "page_label": "3", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d26c366bc55f1fe9da780321e0fab67dcaaf4dbd080ddeb29ed9d906bcc1c22c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cf3e3334-ba76-4b6e-9276-ae04cb3b75b3", "node_type": "1", "metadata": {"window": "On a constant currency basis, the Company\u2019s\nadjusted operating income increased 8.2 percent compared to the prior year quarter.  On a constant currency basis,\nInternational Healthcare Solutions segment operating income increased 4.0 percent.  Adjusted operating income as a\npercentage of revenue was 1.16 percent in the fiscal 2023 fourth quarter, a decrease of 5 basis points when compared to the\nprior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2023 fourth\nquarter, net interest expense of $60.9 million increased 18.3 percent versus the prior year quarter primarily due to increases in\nintra-period variable-rate borrowings and associated interest rates, offset in part by an increase in interest income as a result\nof higher investment interest rates.\n Adjusted Effective T ax Rate:  The adjusted effective tax rate was 21.6 percent for the fourth quarter of fiscal 2023 compared to\n19.8 percent in the prior year quarter.\n Adjusted Diluted Earnings P er Share:  Adjusted diluted earnings per share was up 10.0 percent to $2.86 in the fourth quarter of\nfiscal 2023 compared to $2.60 in the previous fiscal year fourth quarter.\n", "original_text": "Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense. "}, "hash": "506c21df616875965022edb78ed296736cd52fa5f3809fa9d02f2ebdb0936c87", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operating income as a\npercentage of revenue was 1.16 percent in the fiscal 2023 fourth quarter, a decrease of 5 basis points when compared to the\nprior year quarter.\n", "start_char_idx": 1422, "end_char_idx": 1597, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cf3e3334-ba76-4b6e-9276-ae04cb3b75b3": {"__data__": {"id_": "cf3e3334-ba76-4b6e-9276-ae04cb3b75b3", "embedding": null, "metadata": {"window": "On a constant currency basis, the Company\u2019s\nadjusted operating income increased 8.2 percent compared to the prior year quarter.  On a constant currency basis,\nInternational Healthcare Solutions segment operating income increased 4.0 percent.  Adjusted operating income as a\npercentage of revenue was 1.16 percent in the fiscal 2023 fourth quarter, a decrease of 5 basis points when compared to the\nprior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2023 fourth\nquarter, net interest expense of $60.9 million increased 18.3 percent versus the prior year quarter primarily due to increases in\nintra-period variable-rate borrowings and associated interest rates, offset in part by an increase in interest income as a result\nof higher investment interest rates.\n Adjusted Effective T ax Rate:  The adjusted effective tax rate was 21.6 percent for the fourth quarter of fiscal 2023 compared to\n19.8 percent in the prior year quarter.\n Adjusted Diluted Earnings P er Share:  Adjusted diluted earnings per share was up 10.0 percent to $2.86 in the fourth quarter of\nfiscal 2023 compared to $2.60 in the previous fiscal year fourth quarter.\n", "original_text": "Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense. ", "page_label": "3", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "20e3d800-bd50-438f-b446-f823062e13e0", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2b8ab5cb1f2f22e45b46c0907985e10171e973b7b7e4d6e0e2df6b38fdf7db3c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b9c901e0-fe44-4f9a-9c86-4e9995246faf", "node_type": "1", "metadata": {"window": "Healthcare Solutions' operating income and a 3.1\npercent increase in operating income within International Healthcare Solutions.  On a constant currency basis, the Company\u2019s\nadjusted operating income increased 8.2 percent compared to the prior year quarter.  On a constant currency basis,\nInternational Healthcare Solutions segment operating income increased 4.0 percent.  Adjusted operating income as a\npercentage of revenue was 1.16 percent in the fiscal 2023 fourth quarter, a decrease of 5 basis points when compared to the\nprior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2023 fourth\nquarter, net interest expense of $60.9 million increased 18.3 percent versus the prior year quarter primarily due to increases in\nintra-period variable-rate borrowings and associated interest rates, offset in part by an increase in interest income as a result\nof higher investment interest rates.\n Adjusted Effective T ax Rate:  The adjusted effective tax rate was 21.6 percent for the fourth quarter of fiscal 2023 compared to\n19.8 percent in the prior year quarter.\n", "original_text": "Adjusted operating income as a\npercentage of revenue was 1.16 percent in the fiscal 2023 fourth quarter, a decrease of 5 basis points when compared to the\nprior year quarter.\n", "page_label": "3", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "16c77f74b2e6c3a501e804cb91e73c6ea9bcb9bdf1ff812f8be47b35e5ad405a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aee4e122-d26c-4c09-963a-583e370ec4b8", "node_type": "1", "metadata": {"window": "On a constant currency basis,\nInternational Healthcare Solutions segment operating income increased 4.0 percent.  Adjusted operating income as a\npercentage of revenue was 1.16 percent in the fiscal 2023 fourth quarter, a decrease of 5 basis points when compared to the\nprior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2023 fourth\nquarter, net interest expense of $60.9 million increased 18.3 percent versus the prior year quarter primarily due to increases in\nintra-period variable-rate borrowings and associated interest rates, offset in part by an increase in interest income as a result\nof higher investment interest rates.\n Adjusted Effective T ax Rate:  The adjusted effective tax rate was 21.6 percent for the fourth quarter of fiscal 2023 compared to\n19.8 percent in the prior year quarter.\n Adjusted Diluted Earnings P er Share:  Adjusted diluted earnings per share was up 10.0 percent to $2.86 in the fourth quarter of\nfiscal 2023 compared to $2.60 in the previous fiscal year fourth quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding. ", "original_text": "In the fiscal 2023 fourth\nquarter, net interest expense of $60.9 million increased 18.3 percent versus the prior year quarter primarily due to increases in\nintra-period variable-rate borrowings and associated interest rates, offset in part by an increase in interest income as a result\nof higher investment interest rates.\n"}, "hash": "498086cce3e4bbe6164d4ba9bdace4bfaaa7ef2e3d2e155bcc864b784fa7c239", "class_name": "RelatedNodeInfo"}}, "text": "Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense. ", "start_char_idx": 1597, "end_char_idx": 1696, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aee4e122-d26c-4c09-963a-583e370ec4b8": {"__data__": {"id_": "aee4e122-d26c-4c09-963a-583e370ec4b8", "embedding": null, "metadata": {"window": "On a constant currency basis,\nInternational Healthcare Solutions segment operating income increased 4.0 percent.  Adjusted operating income as a\npercentage of revenue was 1.16 percent in the fiscal 2023 fourth quarter, a decrease of 5 basis points when compared to the\nprior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2023 fourth\nquarter, net interest expense of $60.9 million increased 18.3 percent versus the prior year quarter primarily due to increases in\nintra-period variable-rate borrowings and associated interest rates, offset in part by an increase in interest income as a result\nof higher investment interest rates.\n Adjusted Effective T ax Rate:  The adjusted effective tax rate was 21.6 percent for the fourth quarter of fiscal 2023 compared to\n19.8 percent in the prior year quarter.\n Adjusted Diluted Earnings P er Share:  Adjusted diluted earnings per share was up 10.0 percent to $2.86 in the fourth quarter of\nfiscal 2023 compared to $2.60 in the previous fiscal year fourth quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding. ", "original_text": "In the fiscal 2023 fourth\nquarter, net interest expense of $60.9 million increased 18.3 percent versus the prior year quarter primarily due to increases in\nintra-period variable-rate borrowings and associated interest rates, offset in part by an increase in interest income as a result\nof higher investment interest rates.\n", "page_label": "3", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "20e3d800-bd50-438f-b446-f823062e13e0", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2b8ab5cb1f2f22e45b46c0907985e10171e973b7b7e4d6e0e2df6b38fdf7db3c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cf3e3334-ba76-4b6e-9276-ae04cb3b75b3", "node_type": "1", "metadata": {"window": "On a constant currency basis, the Company\u2019s\nadjusted operating income increased 8.2 percent compared to the prior year quarter.  On a constant currency basis,\nInternational Healthcare Solutions segment operating income increased 4.0 percent.  Adjusted operating income as a\npercentage of revenue was 1.16 percent in the fiscal 2023 fourth quarter, a decrease of 5 basis points when compared to the\nprior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2023 fourth\nquarter, net interest expense of $60.9 million increased 18.3 percent versus the prior year quarter primarily due to increases in\nintra-period variable-rate borrowings and associated interest rates, offset in part by an increase in interest income as a result\nof higher investment interest rates.\n Adjusted Effective T ax Rate:  The adjusted effective tax rate was 21.6 percent for the fourth quarter of fiscal 2023 compared to\n19.8 percent in the prior year quarter.\n Adjusted Diluted Earnings P er Share:  Adjusted diluted earnings per share was up 10.0 percent to $2.86 in the fourth quarter of\nfiscal 2023 compared to $2.60 in the previous fiscal year fourth quarter.\n", "original_text": "Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense. ", "page_label": "3", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "85dd08710a7889e985cc5284300bb63b52139b03c4526c59686c7560722e00f4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "81b20521-ac95-4d2a-a3e4-d3a983427b1a", "node_type": "1", "metadata": {"window": "Adjusted operating income as a\npercentage of revenue was 1.16 percent in the fiscal 2023 fourth quarter, a decrease of 5 basis points when compared to the\nprior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2023 fourth\nquarter, net interest expense of $60.9 million increased 18.3 percent versus the prior year quarter primarily due to increases in\nintra-period variable-rate borrowings and associated interest rates, offset in part by an increase in interest income as a result\nof higher investment interest rates.\n Adjusted Effective T ax Rate:  The adjusted effective tax rate was 21.6 percent for the fourth quarter of fiscal 2023 compared to\n19.8 percent in the prior year quarter.\n Adjusted Diluted Earnings P er Share:  Adjusted diluted earnings per share was up 10.0 percent to $2.86 in the fourth quarter of\nfiscal 2023 compared to $2.60 in the previous fiscal year fourth quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the fourth quarter of fiscal 2023 were 203.4 million, a decrease of 3.1 percent versus\nthe prior fiscal year fourth quarter primarily as a result of share repurchases.\n", "original_text": "Adjusted Effective T ax Rate:  The adjusted effective tax rate was 21.6 percent for the fourth quarter of fiscal 2023 compared to\n19.8 percent in the prior year quarter.\n"}, "hash": "1c5aef5fd4bf61ba974c87517ebc786498e2de33eda5168e46b695f4cb75c08f", "class_name": "RelatedNodeInfo"}}, "text": "In the fiscal 2023 fourth\nquarter, net interest expense of $60.9 million increased 18.3 percent versus the prior year quarter primarily due to increases in\nintra-period variable-rate borrowings and associated interest rates, offset in part by an increase in interest income as a result\nof higher investment interest rates.\n", "start_char_idx": 1696, "end_char_idx": 2019, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "81b20521-ac95-4d2a-a3e4-d3a983427b1a": {"__data__": {"id_": "81b20521-ac95-4d2a-a3e4-d3a983427b1a", "embedding": null, "metadata": {"window": "Adjusted operating income as a\npercentage of revenue was 1.16 percent in the fiscal 2023 fourth quarter, a decrease of 5 basis points when compared to the\nprior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2023 fourth\nquarter, net interest expense of $60.9 million increased 18.3 percent versus the prior year quarter primarily due to increases in\nintra-period variable-rate borrowings and associated interest rates, offset in part by an increase in interest income as a result\nof higher investment interest rates.\n Adjusted Effective T ax Rate:  The adjusted effective tax rate was 21.6 percent for the fourth quarter of fiscal 2023 compared to\n19.8 percent in the prior year quarter.\n Adjusted Diluted Earnings P er Share:  Adjusted diluted earnings per share was up 10.0 percent to $2.86 in the fourth quarter of\nfiscal 2023 compared to $2.60 in the previous fiscal year fourth quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the fourth quarter of fiscal 2023 were 203.4 million, a decrease of 3.1 percent versus\nthe prior fiscal year fourth quarter primarily as a result of share repurchases.\n", "original_text": "Adjusted Effective T ax Rate:  The adjusted effective tax rate was 21.6 percent for the fourth quarter of fiscal 2023 compared to\n19.8 percent in the prior year quarter.\n", "page_label": "3", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "20e3d800-bd50-438f-b446-f823062e13e0", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2b8ab5cb1f2f22e45b46c0907985e10171e973b7b7e4d6e0e2df6b38fdf7db3c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aee4e122-d26c-4c09-963a-583e370ec4b8", "node_type": "1", "metadata": {"window": "On a constant currency basis,\nInternational Healthcare Solutions segment operating income increased 4.0 percent.  Adjusted operating income as a\npercentage of revenue was 1.16 percent in the fiscal 2023 fourth quarter, a decrease of 5 basis points when compared to the\nprior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2023 fourth\nquarter, net interest expense of $60.9 million increased 18.3 percent versus the prior year quarter primarily due to increases in\nintra-period variable-rate borrowings and associated interest rates, offset in part by an increase in interest income as a result\nof higher investment interest rates.\n Adjusted Effective T ax Rate:  The adjusted effective tax rate was 21.6 percent for the fourth quarter of fiscal 2023 compared to\n19.8 percent in the prior year quarter.\n Adjusted Diluted Earnings P er Share:  Adjusted diluted earnings per share was up 10.0 percent to $2.86 in the fourth quarter of\nfiscal 2023 compared to $2.60 in the previous fiscal year fourth quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding. ", "original_text": "In the fiscal 2023 fourth\nquarter, net interest expense of $60.9 million increased 18.3 percent versus the prior year quarter primarily due to increases in\nintra-period variable-rate borrowings and associated interest rates, offset in part by an increase in interest income as a result\nof higher investment interest rates.\n", "page_label": "3", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0e29a492747f394e42992ff384cfa26ee359bd5800875ea0ade8cee337ffa5aa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e1d6b9ca-e518-4470-961c-d0fc19bf6cfe", "node_type": "1", "metadata": {"window": "Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2023 fourth\nquarter, net interest expense of $60.9 million increased 18.3 percent versus the prior year quarter primarily due to increases in\nintra-period variable-rate borrowings and associated interest rates, offset in part by an increase in interest income as a result\nof higher investment interest rates.\n Adjusted Effective T ax Rate:  The adjusted effective tax rate was 21.6 percent for the fourth quarter of fiscal 2023 compared to\n19.8 percent in the prior year quarter.\n Adjusted Diluted Earnings P er Share:  Adjusted diluted earnings per share was up 10.0 percent to $2.86 in the fourth quarter of\nfiscal 2023 compared to $2.60 in the previous fiscal year fourth quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the fourth quarter of fiscal 2023 were 203.4 million, a decrease of 3.1 percent versus\nthe prior fiscal year fourth quarter primarily as a result of share repurchases.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S. ", "original_text": "Adjusted Diluted Earnings P er Share:  Adjusted diluted earnings per share was up 10.0 percent to $2.86 in the fourth quarter of\nfiscal 2023 compared to $2.60 in the previous fiscal year fourth quarter.\n"}, "hash": "afdc7dc0d0890a4eafa6eea3928a227d9d5c4933e0d0f06dde7c9f7cc783d637", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted Effective T ax Rate:  The adjusted effective tax rate was 21.6 percent for the fourth quarter of fiscal 2023 compared to\n19.8 percent in the prior year quarter.\n", "start_char_idx": 2019, "end_char_idx": 2189, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e1d6b9ca-e518-4470-961c-d0fc19bf6cfe": {"__data__": {"id_": "e1d6b9ca-e518-4470-961c-d0fc19bf6cfe", "embedding": null, "metadata": {"window": "Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2023 fourth\nquarter, net interest expense of $60.9 million increased 18.3 percent versus the prior year quarter primarily due to increases in\nintra-period variable-rate borrowings and associated interest rates, offset in part by an increase in interest income as a result\nof higher investment interest rates.\n Adjusted Effective T ax Rate:  The adjusted effective tax rate was 21.6 percent for the fourth quarter of fiscal 2023 compared to\n19.8 percent in the prior year quarter.\n Adjusted Diluted Earnings P er Share:  Adjusted diluted earnings per share was up 10.0 percent to $2.86 in the fourth quarter of\nfiscal 2023 compared to $2.60 in the previous fiscal year fourth quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the fourth quarter of fiscal 2023 were 203.4 million, a decrease of 3.1 percent versus\nthe prior fiscal year fourth quarter primarily as a result of share repurchases.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S. ", "original_text": "Adjusted Diluted Earnings P er Share:  Adjusted diluted earnings per share was up 10.0 percent to $2.86 in the fourth quarter of\nfiscal 2023 compared to $2.60 in the previous fiscal year fourth quarter.\n", "page_label": "3", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "20e3d800-bd50-438f-b446-f823062e13e0", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2b8ab5cb1f2f22e45b46c0907985e10171e973b7b7e4d6e0e2df6b38fdf7db3c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "81b20521-ac95-4d2a-a3e4-d3a983427b1a", "node_type": "1", "metadata": {"window": "Adjusted operating income as a\npercentage of revenue was 1.16 percent in the fiscal 2023 fourth quarter, a decrease of 5 basis points when compared to the\nprior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2023 fourth\nquarter, net interest expense of $60.9 million increased 18.3 percent versus the prior year quarter primarily due to increases in\nintra-period variable-rate borrowings and associated interest rates, offset in part by an increase in interest income as a result\nof higher investment interest rates.\n Adjusted Effective T ax Rate:  The adjusted effective tax rate was 21.6 percent for the fourth quarter of fiscal 2023 compared to\n19.8 percent in the prior year quarter.\n Adjusted Diluted Earnings P er Share:  Adjusted diluted earnings per share was up 10.0 percent to $2.86 in the fourth quarter of\nfiscal 2023 compared to $2.60 in the previous fiscal year fourth quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the fourth quarter of fiscal 2023 were 203.4 million, a decrease of 3.1 percent versus\nthe prior fiscal year fourth quarter primarily as a result of share repurchases.\n", "original_text": "Adjusted Effective T ax Rate:  The adjusted effective tax rate was 21.6 percent for the fourth quarter of fiscal 2023 compared to\n19.8 percent in the prior year quarter.\n", "page_label": "3", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "96f2ccf63bbb6564a198ae13a027df50ba59c3f6301f008f3fcb5b879a14b9f0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "49787032-84c4-413a-abb6-69ee678443c5", "node_type": "1", "metadata": {"window": "In the fiscal 2023 fourth\nquarter, net interest expense of $60.9 million increased 18.3 percent versus the prior year quarter primarily due to increases in\nintra-period variable-rate borrowings and associated interest rates, offset in part by an increase in interest income as a result\nof higher investment interest rates.\n Adjusted Effective T ax Rate:  The adjusted effective tax rate was 21.6 percent for the fourth quarter of fiscal 2023 compared to\n19.8 percent in the prior year quarter.\n Adjusted Diluted Earnings P er Share:  Adjusted diluted earnings per share was up 10.0 percent to $2.86 in the fourth quarter of\nfiscal 2023 compared to $2.60 in the previous fiscal year fourth quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the fourth quarter of fiscal 2023 were 203.4 million, a decrease of 3.1 percent versus\nthe prior fiscal year fourth quarter primarily as a result of share repurchases.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S.  Healthcare Solutions and International Healthcare Solutions.\n", "original_text": "Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding. "}, "hash": "63719f5dc20bea12cd83537f24c56c75a5cfeb8a06c3cafe16ba1d475b32afaf", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted Diluted Earnings P er Share:  Adjusted diluted earnings per share was up 10.0 percent to $2.86 in the fourth quarter of\nfiscal 2023 compared to $2.60 in the previous fiscal year fourth quarter.\n", "start_char_idx": 2189, "end_char_idx": 2392, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "49787032-84c4-413a-abb6-69ee678443c5": {"__data__": {"id_": "49787032-84c4-413a-abb6-69ee678443c5", "embedding": null, "metadata": {"window": "In the fiscal 2023 fourth\nquarter, net interest expense of $60.9 million increased 18.3 percent versus the prior year quarter primarily due to increases in\nintra-period variable-rate borrowings and associated interest rates, offset in part by an increase in interest income as a result\nof higher investment interest rates.\n Adjusted Effective T ax Rate:  The adjusted effective tax rate was 21.6 percent for the fourth quarter of fiscal 2023 compared to\n19.8 percent in the prior year quarter.\n Adjusted Diluted Earnings P er Share:  Adjusted diluted earnings per share was up 10.0 percent to $2.86 in the fourth quarter of\nfiscal 2023 compared to $2.60 in the previous fiscal year fourth quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the fourth quarter of fiscal 2023 were 203.4 million, a decrease of 3.1 percent versus\nthe prior fiscal year fourth quarter primarily as a result of share repurchases.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S.  Healthcare Solutions and International Healthcare Solutions.\n", "original_text": "Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding. ", "page_label": "3", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "20e3d800-bd50-438f-b446-f823062e13e0", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2b8ab5cb1f2f22e45b46c0907985e10171e973b7b7e4d6e0e2df6b38fdf7db3c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e1d6b9ca-e518-4470-961c-d0fc19bf6cfe", "node_type": "1", "metadata": {"window": "Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2023 fourth\nquarter, net interest expense of $60.9 million increased 18.3 percent versus the prior year quarter primarily due to increases in\nintra-period variable-rate borrowings and associated interest rates, offset in part by an increase in interest income as a result\nof higher investment interest rates.\n Adjusted Effective T ax Rate:  The adjusted effective tax rate was 21.6 percent for the fourth quarter of fiscal 2023 compared to\n19.8 percent in the prior year quarter.\n Adjusted Diluted Earnings P er Share:  Adjusted diluted earnings per share was up 10.0 percent to $2.86 in the fourth quarter of\nfiscal 2023 compared to $2.60 in the previous fiscal year fourth quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the fourth quarter of fiscal 2023 were 203.4 million, a decrease of 3.1 percent versus\nthe prior fiscal year fourth quarter primarily as a result of share repurchases.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S. ", "original_text": "Adjusted Diluted Earnings P er Share:  Adjusted diluted earnings per share was up 10.0 percent to $2.86 in the fourth quarter of\nfiscal 2023 compared to $2.60 in the previous fiscal year fourth quarter.\n", "page_label": "3", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f0fe55175688714aafa64e39da2eb8f5e5beb3c676353ca504d9bc7b281c15ce", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c9ee42c3-8b51-4d74-9ee6-1a59965a71b1", "node_type": "1", "metadata": {"window": "Adjusted Effective T ax Rate:  The adjusted effective tax rate was 21.6 percent for the fourth quarter of fiscal 2023 compared to\n19.8 percent in the prior year quarter.\n Adjusted Diluted Earnings P er Share:  Adjusted diluted earnings per share was up 10.0 percent to $2.86 in the fourth quarter of\nfiscal 2023 compared to $2.60 in the previous fiscal year fourth quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the fourth quarter of fiscal 2023 were 203.4 million, a decrease of 3.1 percent versus\nthe prior fiscal year fourth quarter primarily as a result of share repurchases.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S.  Healthcare Solutions and International Healthcare Solutions.\n U.S. ", "original_text": "Diluted\nweighted average shares outstanding for the fourth quarter of fiscal 2023 were 203.4 million, a decrease of 3.1 percent versus\nthe prior fiscal year fourth quarter primarily as a result of share repurchases.\n"}, "hash": "bcf067d445918594d0713a54ec58dbcca044272c306c59ac779badfa4c74a9e0", "class_name": "RelatedNodeInfo"}}, "text": "Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding. ", "start_char_idx": 2392, "end_char_idx": 2502, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c9ee42c3-8b51-4d74-9ee6-1a59965a71b1": {"__data__": {"id_": "c9ee42c3-8b51-4d74-9ee6-1a59965a71b1", "embedding": null, "metadata": {"window": "Adjusted Effective T ax Rate:  The adjusted effective tax rate was 21.6 percent for the fourth quarter of fiscal 2023 compared to\n19.8 percent in the prior year quarter.\n Adjusted Diluted Earnings P er Share:  Adjusted diluted earnings per share was up 10.0 percent to $2.86 in the fourth quarter of\nfiscal 2023 compared to $2.60 in the previous fiscal year fourth quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the fourth quarter of fiscal 2023 were 203.4 million, a decrease of 3.1 percent versus\nthe prior fiscal year fourth quarter primarily as a result of share repurchases.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S.  Healthcare Solutions and International Healthcare Solutions.\n U.S. ", "original_text": "Diluted\nweighted average shares outstanding for the fourth quarter of fiscal 2023 were 203.4 million, a decrease of 3.1 percent versus\nthe prior fiscal year fourth quarter primarily as a result of share repurchases.\n", "page_label": "3", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "20e3d800-bd50-438f-b446-f823062e13e0", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2b8ab5cb1f2f22e45b46c0907985e10171e973b7b7e4d6e0e2df6b38fdf7db3c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "49787032-84c4-413a-abb6-69ee678443c5", "node_type": "1", "metadata": {"window": "In the fiscal 2023 fourth\nquarter, net interest expense of $60.9 million increased 18.3 percent versus the prior year quarter primarily due to increases in\nintra-period variable-rate borrowings and associated interest rates, offset in part by an increase in interest income as a result\nof higher investment interest rates.\n Adjusted Effective T ax Rate:  The adjusted effective tax rate was 21.6 percent for the fourth quarter of fiscal 2023 compared to\n19.8 percent in the prior year quarter.\n Adjusted Diluted Earnings P er Share:  Adjusted diluted earnings per share was up 10.0 percent to $2.86 in the fourth quarter of\nfiscal 2023 compared to $2.60 in the previous fiscal year fourth quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the fourth quarter of fiscal 2023 were 203.4 million, a decrease of 3.1 percent versus\nthe prior fiscal year fourth quarter primarily as a result of share repurchases.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S.  Healthcare Solutions and International Healthcare Solutions.\n", "original_text": "Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding. ", "page_label": "3", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4c862c8910b66a5d2961e4ebec7c97be3a60373d36956a463f3225c4083a5efe", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4eff1dfd-092c-4f1f-bb66-2378a922e541", "node_type": "1", "metadata": {"window": "Adjusted Diluted Earnings P er Share:  Adjusted diluted earnings per share was up 10.0 percent to $2.86 in the fourth quarter of\nfiscal 2023 compared to $2.60 in the previous fiscal year fourth quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the fourth quarter of fiscal 2023 were 203.4 million, a decrease of 3.1 percent versus\nthe prior fiscal year fourth quarter primarily as a result of share repurchases.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S.  Healthcare Solutions and International Healthcare Solutions.\n U.S.  Healthcare Solutions Segment\nU.S. ", "original_text": "Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S. "}, "hash": "96016f7a12db6e5d7fadc94b26b3c4b1a28be08b1b0f082fddb7730ac5a58062", "class_name": "RelatedNodeInfo"}}, "text": "Diluted\nweighted average shares outstanding for the fourth quarter of fiscal 2023 were 203.4 million, a decrease of 3.1 percent versus\nthe prior fiscal year fourth quarter primarily as a result of share repurchases.\n", "start_char_idx": 2502, "end_char_idx": 2718, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4eff1dfd-092c-4f1f-bb66-2378a922e541": {"__data__": {"id_": "4eff1dfd-092c-4f1f-bb66-2378a922e541", "embedding": null, "metadata": {"window": "Adjusted Diluted Earnings P er Share:  Adjusted diluted earnings per share was up 10.0 percent to $2.86 in the fourth quarter of\nfiscal 2023 compared to $2.60 in the previous fiscal year fourth quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the fourth quarter of fiscal 2023 were 203.4 million, a decrease of 3.1 percent versus\nthe prior fiscal year fourth quarter primarily as a result of share repurchases.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S.  Healthcare Solutions and International Healthcare Solutions.\n U.S.  Healthcare Solutions Segment\nU.S. ", "original_text": "Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S. ", "page_label": "3", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "20e3d800-bd50-438f-b446-f823062e13e0", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2b8ab5cb1f2f22e45b46c0907985e10171e973b7b7e4d6e0e2df6b38fdf7db3c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c9ee42c3-8b51-4d74-9ee6-1a59965a71b1", "node_type": "1", "metadata": {"window": "Adjusted Effective T ax Rate:  The adjusted effective tax rate was 21.6 percent for the fourth quarter of fiscal 2023 compared to\n19.8 percent in the prior year quarter.\n Adjusted Diluted Earnings P er Share:  Adjusted diluted earnings per share was up 10.0 percent to $2.86 in the fourth quarter of\nfiscal 2023 compared to $2.60 in the previous fiscal year fourth quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the fourth quarter of fiscal 2023 were 203.4 million, a decrease of 3.1 percent versus\nthe prior fiscal year fourth quarter primarily as a result of share repurchases.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S.  Healthcare Solutions and International Healthcare Solutions.\n U.S. ", "original_text": "Diluted\nweighted average shares outstanding for the fourth quarter of fiscal 2023 were 203.4 million, a decrease of 3.1 percent versus\nthe prior fiscal year fourth quarter primarily as a result of share repurchases.\n", "page_label": "3", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2697fec7b4cb9cdfc8ba83a0a47db25f1a9a8d2f95f55f2ef7ae366e0a565463", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "18a39604-f37f-4f9e-a250-97c6fd2c2b1e", "node_type": "1", "metadata": {"window": "Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the fourth quarter of fiscal 2023 were 203.4 million, a decrease of 3.1 percent versus\nthe prior fiscal year fourth quarter primarily as a result of share repurchases.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S.  Healthcare Solutions and International Healthcare Solutions.\n U.S.  Healthcare Solutions Segment\nU.S.  Healthcare Solutions revenue was $61.9 billion, an increase of 13.0 percent compared to the same quarter in the prior fiscal year\nprimarily due to overall market growth primarily driven by unit volume growth, including increased sales of products labeled for\ndiabetes and/or weight loss in the GLP-1 class and increased sales of specialty products to physician practices and health systems.\n", "original_text": "Healthcare Solutions and International Healthcare Solutions.\n"}, "hash": "15c7d8af04f4c17dbf31c9be3f92e3c1d89c4d9a59c3e641a863ac6b41565000", "class_name": "RelatedNodeInfo"}}, "text": "Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S. ", "start_char_idx": 2718, "end_char_idx": 2879, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "18a39604-f37f-4f9e-a250-97c6fd2c2b1e": {"__data__": {"id_": "18a39604-f37f-4f9e-a250-97c6fd2c2b1e", "embedding": null, "metadata": {"window": "Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the fourth quarter of fiscal 2023 were 203.4 million, a decrease of 3.1 percent versus\nthe prior fiscal year fourth quarter primarily as a result of share repurchases.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S.  Healthcare Solutions and International Healthcare Solutions.\n U.S.  Healthcare Solutions Segment\nU.S.  Healthcare Solutions revenue was $61.9 billion, an increase of 13.0 percent compared to the same quarter in the prior fiscal year\nprimarily due to overall market growth primarily driven by unit volume growth, including increased sales of products labeled for\ndiabetes and/or weight loss in the GLP-1 class and increased sales of specialty products to physician practices and health systems.\n", "original_text": "Healthcare Solutions and International Healthcare Solutions.\n", "page_label": "3", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "20e3d800-bd50-438f-b446-f823062e13e0", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2b8ab5cb1f2f22e45b46c0907985e10171e973b7b7e4d6e0e2df6b38fdf7db3c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4eff1dfd-092c-4f1f-bb66-2378a922e541", "node_type": "1", "metadata": {"window": "Adjusted Diluted Earnings P er Share:  Adjusted diluted earnings per share was up 10.0 percent to $2.86 in the fourth quarter of\nfiscal 2023 compared to $2.60 in the previous fiscal year fourth quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the fourth quarter of fiscal 2023 were 203.4 million, a decrease of 3.1 percent versus\nthe prior fiscal year fourth quarter primarily as a result of share repurchases.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S.  Healthcare Solutions and International Healthcare Solutions.\n U.S.  Healthcare Solutions Segment\nU.S. ", "original_text": "Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S. ", "page_label": "3", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8b1eb5464afcbc5e9107fb30140c6090a0a301c6508e196b61e6444ab4c54efa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f9f2b925-03ec-48ad-a9f3-c0636dbd699f", "node_type": "1", "metadata": {"window": "Diluted\nweighted average shares outstanding for the fourth quarter of fiscal 2023 were 203.4 million, a decrease of 3.1 percent versus\nthe prior fiscal year fourth quarter primarily as a result of share repurchases.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S.  Healthcare Solutions and International Healthcare Solutions.\n U.S.  Healthcare Solutions Segment\nU.S.  Healthcare Solutions revenue was $61.9 billion, an increase of 13.0 percent compared to the same quarter in the prior fiscal year\nprimarily due to overall market growth primarily driven by unit volume growth, including increased sales of products labeled for\ndiabetes and/or weight loss in the GLP-1 class and increased sales of specialty products to physician practices and health systems.\n Segment operating income of $632.8 million in the fourth quarter of fiscal 2023 was up 9.4 percent compared to the same period in\nthe previous fiscal year as a result of an increase in gross profit of 6.3%, offset in part by an increase in operating expenses of 4.1%.\n", "original_text": "U.S. "}, "hash": "b772fc6b456584cee0f8182b88575fab0ca2417bad90bfd5e12b25e07faadd13", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions and International Healthcare Solutions.\n", "start_char_idx": 2879, "end_char_idx": 2940, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f9f2b925-03ec-48ad-a9f3-c0636dbd699f": {"__data__": {"id_": "f9f2b925-03ec-48ad-a9f3-c0636dbd699f", "embedding": null, "metadata": {"window": "Diluted\nweighted average shares outstanding for the fourth quarter of fiscal 2023 were 203.4 million, a decrease of 3.1 percent versus\nthe prior fiscal year fourth quarter primarily as a result of share repurchases.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S.  Healthcare Solutions and International Healthcare Solutions.\n U.S.  Healthcare Solutions Segment\nU.S.  Healthcare Solutions revenue was $61.9 billion, an increase of 13.0 percent compared to the same quarter in the prior fiscal year\nprimarily due to overall market growth primarily driven by unit volume growth, including increased sales of products labeled for\ndiabetes and/or weight loss in the GLP-1 class and increased sales of specialty products to physician practices and health systems.\n Segment operating income of $632.8 million in the fourth quarter of fiscal 2023 was up 9.4 percent compared to the same period in\nthe previous fiscal year as a result of an increase in gross profit of 6.3%, offset in part by an increase in operating expenses of 4.1%.\n", "original_text": "U.S. ", "page_label": "3", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "20e3d800-bd50-438f-b446-f823062e13e0", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2b8ab5cb1f2f22e45b46c0907985e10171e973b7b7e4d6e0e2df6b38fdf7db3c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "18a39604-f37f-4f9e-a250-97c6fd2c2b1e", "node_type": "1", "metadata": {"window": "Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the fourth quarter of fiscal 2023 were 203.4 million, a decrease of 3.1 percent versus\nthe prior fiscal year fourth quarter primarily as a result of share repurchases.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S.  Healthcare Solutions and International Healthcare Solutions.\n U.S.  Healthcare Solutions Segment\nU.S.  Healthcare Solutions revenue was $61.9 billion, an increase of 13.0 percent compared to the same quarter in the prior fiscal year\nprimarily due to overall market growth primarily driven by unit volume growth, including increased sales of products labeled for\ndiabetes and/or weight loss in the GLP-1 class and increased sales of specialty products to physician practices and health systems.\n", "original_text": "Healthcare Solutions and International Healthcare Solutions.\n", "page_label": "3", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fe5d5af3c8eb2b5612901ca58e15829fbf7625f3e47a6c364cb37a3b6ec3126b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ace5e9f1-6b37-4720-8ea0-dc8440664239", "node_type": "1", "metadata": {"window": "Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S.  Healthcare Solutions and International Healthcare Solutions.\n U.S.  Healthcare Solutions Segment\nU.S.  Healthcare Solutions revenue was $61.9 billion, an increase of 13.0 percent compared to the same quarter in the prior fiscal year\nprimarily due to overall market growth primarily driven by unit volume growth, including increased sales of products labeled for\ndiabetes and/or weight loss in the GLP-1 class and increased sales of specialty products to physician practices and health systems.\n Segment operating income of $632.8 million in the fourth quarter of fiscal 2023 was up 9.4 percent compared to the same period in\nthe previous fiscal year as a result of an increase in gross profit of 6.3%, offset in part by an increase in operating expenses of 4.1%.\n International Healthcare Solutions\nRevenue in International Healthcare Solutions was $7.0 billion in the fourth quarter of fiscal 2023, an increase of 9.5 percent\ncompared to the same period in the prior fiscal year due to increased revenue across its businesses. ", "original_text": "Healthcare Solutions Segment\nU.S. "}, "hash": "a7446475a543995fae07b5435a7a96bc087da20a4dcbd1194577047ac27a717b", "class_name": "RelatedNodeInfo"}}, "text": "U.S. ", "start_char_idx": 75, "end_char_idx": 80, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ace5e9f1-6b37-4720-8ea0-dc8440664239": {"__data__": {"id_": "ace5e9f1-6b37-4720-8ea0-dc8440664239", "embedding": null, "metadata": {"window": "Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S.  Healthcare Solutions and International Healthcare Solutions.\n U.S.  Healthcare Solutions Segment\nU.S.  Healthcare Solutions revenue was $61.9 billion, an increase of 13.0 percent compared to the same quarter in the prior fiscal year\nprimarily due to overall market growth primarily driven by unit volume growth, including increased sales of products labeled for\ndiabetes and/or weight loss in the GLP-1 class and increased sales of specialty products to physician practices and health systems.\n Segment operating income of $632.8 million in the fourth quarter of fiscal 2023 was up 9.4 percent compared to the same period in\nthe previous fiscal year as a result of an increase in gross profit of 6.3%, offset in part by an increase in operating expenses of 4.1%.\n International Healthcare Solutions\nRevenue in International Healthcare Solutions was $7.0 billion in the fourth quarter of fiscal 2023, an increase of 9.5 percent\ncompared to the same period in the prior fiscal year due to increased revenue across its businesses. ", "original_text": "Healthcare Solutions Segment\nU.S. ", "page_label": "3", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "20e3d800-bd50-438f-b446-f823062e13e0", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2b8ab5cb1f2f22e45b46c0907985e10171e973b7b7e4d6e0e2df6b38fdf7db3c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f9f2b925-03ec-48ad-a9f3-c0636dbd699f", "node_type": "1", "metadata": {"window": "Diluted\nweighted average shares outstanding for the fourth quarter of fiscal 2023 were 203.4 million, a decrease of 3.1 percent versus\nthe prior fiscal year fourth quarter primarily as a result of share repurchases.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S.  Healthcare Solutions and International Healthcare Solutions.\n U.S.  Healthcare Solutions Segment\nU.S.  Healthcare Solutions revenue was $61.9 billion, an increase of 13.0 percent compared to the same quarter in the prior fiscal year\nprimarily due to overall market growth primarily driven by unit volume growth, including increased sales of products labeled for\ndiabetes and/or weight loss in the GLP-1 class and increased sales of specialty products to physician practices and health systems.\n Segment operating income of $632.8 million in the fourth quarter of fiscal 2023 was up 9.4 percent compared to the same period in\nthe previous fiscal year as a result of an increase in gross profit of 6.3%, offset in part by an increase in operating expenses of 4.1%.\n", "original_text": "U.S. ", "page_label": "3", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e84a7203e0b58afc8cd5b8bfea7f955912f260e40164b170150709538116c242", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b7c25434-60bc-4fd0-aaaf-72ff812ececf", "node_type": "1", "metadata": {"window": "Healthcare Solutions and International Healthcare Solutions.\n U.S.  Healthcare Solutions Segment\nU.S.  Healthcare Solutions revenue was $61.9 billion, an increase of 13.0 percent compared to the same quarter in the prior fiscal year\nprimarily due to overall market growth primarily driven by unit volume growth, including increased sales of products labeled for\ndiabetes and/or weight loss in the GLP-1 class and increased sales of specialty products to physician practices and health systems.\n Segment operating income of $632.8 million in the fourth quarter of fiscal 2023 was up 9.4 percent compared to the same period in\nthe previous fiscal year as a result of an increase in gross profit of 6.3%, offset in part by an increase in operating expenses of 4.1%.\n International Healthcare Solutions\nRevenue in International Healthcare Solutions was $7.0 billion in the fourth quarter of fiscal 2023, an increase of 9.5 percent\ncompared to the same period in the prior fiscal year due to increased revenue across its businesses.  Operating income within\nInternational Healthcare Solutions increased 3.1 percent to $168.2 million in the fourth quarter of fiscal 2023 due to growth at its\nglobal specialty logistics business and the January 2023 acquisition of PharmaLex, offset in part by a significant decline at its less-\nthan-wholly-owned Alliance Healthcare subsidiary in Egypt. ", "original_text": "Healthcare Solutions revenue was $61.9 billion, an increase of 13.0 percent compared to the same quarter in the prior fiscal year\nprimarily due to overall market growth primarily driven by unit volume growth, including increased sales of products labeled for\ndiabetes and/or weight loss in the GLP-1 class and increased sales of specialty products to physician practices and health systems.\n"}, "hash": "906a735b7f0d74f08552390c7eabd625e42654eabbb5cc6e0e0587294b5a00f8", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions Segment\nU.S. ", "start_char_idx": 2945, "end_char_idx": 2979, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b7c25434-60bc-4fd0-aaaf-72ff812ececf": {"__data__": {"id_": "b7c25434-60bc-4fd0-aaaf-72ff812ececf", "embedding": null, "metadata": {"window": "Healthcare Solutions and International Healthcare Solutions.\n U.S.  Healthcare Solutions Segment\nU.S.  Healthcare Solutions revenue was $61.9 billion, an increase of 13.0 percent compared to the same quarter in the prior fiscal year\nprimarily due to overall market growth primarily driven by unit volume growth, including increased sales of products labeled for\ndiabetes and/or weight loss in the GLP-1 class and increased sales of specialty products to physician practices and health systems.\n Segment operating income of $632.8 million in the fourth quarter of fiscal 2023 was up 9.4 percent compared to the same period in\nthe previous fiscal year as a result of an increase in gross profit of 6.3%, offset in part by an increase in operating expenses of 4.1%.\n International Healthcare Solutions\nRevenue in International Healthcare Solutions was $7.0 billion in the fourth quarter of fiscal 2023, an increase of 9.5 percent\ncompared to the same period in the prior fiscal year due to increased revenue across its businesses.  Operating income within\nInternational Healthcare Solutions increased 3.1 percent to $168.2 million in the fourth quarter of fiscal 2023 due to growth at its\nglobal specialty logistics business and the January 2023 acquisition of PharmaLex, offset in part by a significant decline at its less-\nthan-wholly-owned Alliance Healthcare subsidiary in Egypt. ", "original_text": "Healthcare Solutions revenue was $61.9 billion, an increase of 13.0 percent compared to the same quarter in the prior fiscal year\nprimarily due to overall market growth primarily driven by unit volume growth, including increased sales of products labeled for\ndiabetes and/or weight loss in the GLP-1 class and increased sales of specialty products to physician practices and health systems.\n", "page_label": "3", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "20e3d800-bd50-438f-b446-f823062e13e0", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2b8ab5cb1f2f22e45b46c0907985e10171e973b7b7e4d6e0e2df6b38fdf7db3c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ace5e9f1-6b37-4720-8ea0-dc8440664239", "node_type": "1", "metadata": {"window": "Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S.  Healthcare Solutions and International Healthcare Solutions.\n U.S.  Healthcare Solutions Segment\nU.S.  Healthcare Solutions revenue was $61.9 billion, an increase of 13.0 percent compared to the same quarter in the prior fiscal year\nprimarily due to overall market growth primarily driven by unit volume growth, including increased sales of products labeled for\ndiabetes and/or weight loss in the GLP-1 class and increased sales of specialty products to physician practices and health systems.\n Segment operating income of $632.8 million in the fourth quarter of fiscal 2023 was up 9.4 percent compared to the same period in\nthe previous fiscal year as a result of an increase in gross profit of 6.3%, offset in part by an increase in operating expenses of 4.1%.\n International Healthcare Solutions\nRevenue in International Healthcare Solutions was $7.0 billion in the fourth quarter of fiscal 2023, an increase of 9.5 percent\ncompared to the same period in the prior fiscal year due to increased revenue across its businesses. ", "original_text": "Healthcare Solutions Segment\nU.S. ", "page_label": "3", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d80e7c0041b43c057bcfa5bce32b2cc3e73e67700e3c410537210b613f584454", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "99ceaa20-7247-4386-8dd0-105da8c3ad3f", "node_type": "1", "metadata": {"window": "U.S.  Healthcare Solutions Segment\nU.S.  Healthcare Solutions revenue was $61.9 billion, an increase of 13.0 percent compared to the same quarter in the prior fiscal year\nprimarily due to overall market growth primarily driven by unit volume growth, including increased sales of products labeled for\ndiabetes and/or weight loss in the GLP-1 class and increased sales of specialty products to physician practices and health systems.\n Segment operating income of $632.8 million in the fourth quarter of fiscal 2023 was up 9.4 percent compared to the same period in\nthe previous fiscal year as a result of an increase in gross profit of 6.3%, offset in part by an increase in operating expenses of 4.1%.\n International Healthcare Solutions\nRevenue in International Healthcare Solutions was $7.0 billion in the fourth quarter of fiscal 2023, an increase of 9.5 percent\ncompared to the same period in the prior fiscal year due to increased revenue across its businesses.  Operating income within\nInternational Healthcare Solutions increased 3.1 percent to $168.2 million in the fourth quarter of fiscal 2023 due to growth at its\nglobal specialty logistics business and the January 2023 acquisition of PharmaLex, offset in part by a significant decline at its less-\nthan-wholly-owned Alliance Healthcare subsidiary in Egypt.  Cencora recently completed the divestiture of its stake in its subsidiary\nin Egypt and the results of the business will no longer be consolidated beginning in fiscal 2024. ", "original_text": "Segment operating income of $632.8 million in the fourth quarter of fiscal 2023 was up 9.4 percent compared to the same period in\nthe previous fiscal year as a result of an increase in gross profit of 6.3%, offset in part by an increase in operating expenses of 4.1%.\n"}, "hash": "180ba6ec59580bbac307ef87e080da2353797225cf29fd8df770c294556a937f", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions revenue was $61.9 billion, an increase of 13.0 percent compared to the same quarter in the prior fiscal year\nprimarily due to overall market growth primarily driven by unit volume growth, including increased sales of products labeled for\ndiabetes and/or weight loss in the GLP-1 class and increased sales of specialty products to physician practices and health systems.\n", "start_char_idx": 2979, "end_char_idx": 3370, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "99ceaa20-7247-4386-8dd0-105da8c3ad3f": {"__data__": {"id_": "99ceaa20-7247-4386-8dd0-105da8c3ad3f", "embedding": null, "metadata": {"window": "U.S.  Healthcare Solutions Segment\nU.S.  Healthcare Solutions revenue was $61.9 billion, an increase of 13.0 percent compared to the same quarter in the prior fiscal year\nprimarily due to overall market growth primarily driven by unit volume growth, including increased sales of products labeled for\ndiabetes and/or weight loss in the GLP-1 class and increased sales of specialty products to physician practices and health systems.\n Segment operating income of $632.8 million in the fourth quarter of fiscal 2023 was up 9.4 percent compared to the same period in\nthe previous fiscal year as a result of an increase in gross profit of 6.3%, offset in part by an increase in operating expenses of 4.1%.\n International Healthcare Solutions\nRevenue in International Healthcare Solutions was $7.0 billion in the fourth quarter of fiscal 2023, an increase of 9.5 percent\ncompared to the same period in the prior fiscal year due to increased revenue across its businesses.  Operating income within\nInternational Healthcare Solutions increased 3.1 percent to $168.2 million in the fourth quarter of fiscal 2023 due to growth at its\nglobal specialty logistics business and the January 2023 acquisition of PharmaLex, offset in part by a significant decline at its less-\nthan-wholly-owned Alliance Healthcare subsidiary in Egypt.  Cencora recently completed the divestiture of its stake in its subsidiary\nin Egypt and the results of the business will no longer be consolidated beginning in fiscal 2024. ", "original_text": "Segment operating income of $632.8 million in the fourth quarter of fiscal 2023 was up 9.4 percent compared to the same period in\nthe previous fiscal year as a result of an increase in gross profit of 6.3%, offset in part by an increase in operating expenses of 4.1%.\n", "page_label": "3", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "20e3d800-bd50-438f-b446-f823062e13e0", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2b8ab5cb1f2f22e45b46c0907985e10171e973b7b7e4d6e0e2df6b38fdf7db3c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b7c25434-60bc-4fd0-aaaf-72ff812ececf", "node_type": "1", "metadata": {"window": "Healthcare Solutions and International Healthcare Solutions.\n U.S.  Healthcare Solutions Segment\nU.S.  Healthcare Solutions revenue was $61.9 billion, an increase of 13.0 percent compared to the same quarter in the prior fiscal year\nprimarily due to overall market growth primarily driven by unit volume growth, including increased sales of products labeled for\ndiabetes and/or weight loss in the GLP-1 class and increased sales of specialty products to physician practices and health systems.\n Segment operating income of $632.8 million in the fourth quarter of fiscal 2023 was up 9.4 percent compared to the same period in\nthe previous fiscal year as a result of an increase in gross profit of 6.3%, offset in part by an increase in operating expenses of 4.1%.\n International Healthcare Solutions\nRevenue in International Healthcare Solutions was $7.0 billion in the fourth quarter of fiscal 2023, an increase of 9.5 percent\ncompared to the same period in the prior fiscal year due to increased revenue across its businesses.  Operating income within\nInternational Healthcare Solutions increased 3.1 percent to $168.2 million in the fourth quarter of fiscal 2023 due to growth at its\nglobal specialty logistics business and the January 2023 acquisition of PharmaLex, offset in part by a significant decline at its less-\nthan-wholly-owned Alliance Healthcare subsidiary in Egypt. ", "original_text": "Healthcare Solutions revenue was $61.9 billion, an increase of 13.0 percent compared to the same quarter in the prior fiscal year\nprimarily due to overall market growth primarily driven by unit volume growth, including increased sales of products labeled for\ndiabetes and/or weight loss in the GLP-1 class and increased sales of specialty products to physician practices and health systems.\n", "page_label": "3", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "965c684dd0dcd454a1e42a193ce4f7c4fe5bf7619e6384013a97f1d0ec547dd9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7c9c234f-7b20-4bb2-ade4-469fdf5114c2", "node_type": "1", "metadata": {"window": "Healthcare Solutions Segment\nU.S.  Healthcare Solutions revenue was $61.9 billion, an increase of 13.0 percent compared to the same quarter in the prior fiscal year\nprimarily due to overall market growth primarily driven by unit volume growth, including increased sales of products labeled for\ndiabetes and/or weight loss in the GLP-1 class and increased sales of specialty products to physician practices and health systems.\n Segment operating income of $632.8 million in the fourth quarter of fiscal 2023 was up 9.4 percent compared to the same period in\nthe previous fiscal year as a result of an increase in gross profit of 6.3%, offset in part by an increase in operating expenses of 4.1%.\n International Healthcare Solutions\nRevenue in International Healthcare Solutions was $7.0 billion in the fourth quarter of fiscal 2023, an increase of 9.5 percent\ncompared to the same period in the prior fiscal year due to increased revenue across its businesses.  Operating income within\nInternational Healthcare Solutions increased 3.1 percent to $168.2 million in the fourth quarter of fiscal 2023 due to growth at its\nglobal specialty logistics business and the January 2023 acquisition of PharmaLex, offset in part by a significant decline at its less-\nthan-wholly-owned Alliance Healthcare subsidiary in Egypt.  Cencora recently completed the divestiture of its stake in its subsidiary\nin Egypt and the results of the business will no longer be consolidated beginning in fiscal 2024.  On a constant currency basis,\nInternational Healthcare Solutions revenue and operating income increased by 10.1 percent and 4.0 percent, respectively.\n", "original_text": "International Healthcare Solutions\nRevenue in International Healthcare Solutions was $7.0 billion in the fourth quarter of fiscal 2023, an increase of 9.5 percent\ncompared to the same period in the prior fiscal year due to increased revenue across its businesses. "}, "hash": "bf30becaf86050117fe3a49a677589d698b16de49bcf413c3c94fbe6baaa22db", "class_name": "RelatedNodeInfo"}}, "text": "Segment operating income of $632.8 million in the fourth quarter of fiscal 2023 was up 9.4 percent compared to the same period in\nthe previous fiscal year as a result of an increase in gross profit of 6.3%, offset in part by an increase in operating expenses of 4.1%.\n", "start_char_idx": 3370, "end_char_idx": 3638, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7c9c234f-7b20-4bb2-ade4-469fdf5114c2": {"__data__": {"id_": "7c9c234f-7b20-4bb2-ade4-469fdf5114c2", "embedding": null, "metadata": {"window": "Healthcare Solutions Segment\nU.S.  Healthcare Solutions revenue was $61.9 billion, an increase of 13.0 percent compared to the same quarter in the prior fiscal year\nprimarily due to overall market growth primarily driven by unit volume growth, including increased sales of products labeled for\ndiabetes and/or weight loss in the GLP-1 class and increased sales of specialty products to physician practices and health systems.\n Segment operating income of $632.8 million in the fourth quarter of fiscal 2023 was up 9.4 percent compared to the same period in\nthe previous fiscal year as a result of an increase in gross profit of 6.3%, offset in part by an increase in operating expenses of 4.1%.\n International Healthcare Solutions\nRevenue in International Healthcare Solutions was $7.0 billion in the fourth quarter of fiscal 2023, an increase of 9.5 percent\ncompared to the same period in the prior fiscal year due to increased revenue across its businesses.  Operating income within\nInternational Healthcare Solutions increased 3.1 percent to $168.2 million in the fourth quarter of fiscal 2023 due to growth at its\nglobal specialty logistics business and the January 2023 acquisition of PharmaLex, offset in part by a significant decline at its less-\nthan-wholly-owned Alliance Healthcare subsidiary in Egypt.  Cencora recently completed the divestiture of its stake in its subsidiary\nin Egypt and the results of the business will no longer be consolidated beginning in fiscal 2024.  On a constant currency basis,\nInternational Healthcare Solutions revenue and operating income increased by 10.1 percent and 4.0 percent, respectively.\n", "original_text": "International Healthcare Solutions\nRevenue in International Healthcare Solutions was $7.0 billion in the fourth quarter of fiscal 2023, an increase of 9.5 percent\ncompared to the same period in the prior fiscal year due to increased revenue across its businesses. ", "page_label": "3", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "20e3d800-bd50-438f-b446-f823062e13e0", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2b8ab5cb1f2f22e45b46c0907985e10171e973b7b7e4d6e0e2df6b38fdf7db3c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "99ceaa20-7247-4386-8dd0-105da8c3ad3f", "node_type": "1", "metadata": {"window": "U.S.  Healthcare Solutions Segment\nU.S.  Healthcare Solutions revenue was $61.9 billion, an increase of 13.0 percent compared to the same quarter in the prior fiscal year\nprimarily due to overall market growth primarily driven by unit volume growth, including increased sales of products labeled for\ndiabetes and/or weight loss in the GLP-1 class and increased sales of specialty products to physician practices and health systems.\n Segment operating income of $632.8 million in the fourth quarter of fiscal 2023 was up 9.4 percent compared to the same period in\nthe previous fiscal year as a result of an increase in gross profit of 6.3%, offset in part by an increase in operating expenses of 4.1%.\n International Healthcare Solutions\nRevenue in International Healthcare Solutions was $7.0 billion in the fourth quarter of fiscal 2023, an increase of 9.5 percent\ncompared to the same period in the prior fiscal year due to increased revenue across its businesses.  Operating income within\nInternational Healthcare Solutions increased 3.1 percent to $168.2 million in the fourth quarter of fiscal 2023 due to growth at its\nglobal specialty logistics business and the January 2023 acquisition of PharmaLex, offset in part by a significant decline at its less-\nthan-wholly-owned Alliance Healthcare subsidiary in Egypt.  Cencora recently completed the divestiture of its stake in its subsidiary\nin Egypt and the results of the business will no longer be consolidated beginning in fiscal 2024. ", "original_text": "Segment operating income of $632.8 million in the fourth quarter of fiscal 2023 was up 9.4 percent compared to the same period in\nthe previous fiscal year as a result of an increase in gross profit of 6.3%, offset in part by an increase in operating expenses of 4.1%.\n", "page_label": "3", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1c66dce1c6b152175d69c0775c93b1b64c909244bf4c8bd7e4b8926eb453cb77", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0f14efc8-b446-44ee-ac88-8f94fa11ff8f", "node_type": "1", "metadata": {"window": "Healthcare Solutions revenue was $61.9 billion, an increase of 13.0 percent compared to the same quarter in the prior fiscal year\nprimarily due to overall market growth primarily driven by unit volume growth, including increased sales of products labeled for\ndiabetes and/or weight loss in the GLP-1 class and increased sales of specialty products to physician practices and health systems.\n Segment operating income of $632.8 million in the fourth quarter of fiscal 2023 was up 9.4 percent compared to the same period in\nthe previous fiscal year as a result of an increase in gross profit of 6.3%, offset in part by an increase in operating expenses of 4.1%.\n International Healthcare Solutions\nRevenue in International Healthcare Solutions was $7.0 billion in the fourth quarter of fiscal 2023, an increase of 9.5 percent\ncompared to the same period in the prior fiscal year due to increased revenue across its businesses.  Operating income within\nInternational Healthcare Solutions increased 3.1 percent to $168.2 million in the fourth quarter of fiscal 2023 due to growth at its\nglobal specialty logistics business and the January 2023 acquisition of PharmaLex, offset in part by a significant decline at its less-\nthan-wholly-owned Alliance Healthcare subsidiary in Egypt.  Cencora recently completed the divestiture of its stake in its subsidiary\nin Egypt and the results of the business will no longer be consolidated beginning in fiscal 2024.  On a constant currency basis,\nInternational Healthcare Solutions revenue and operating income increased by 10.1 percent and 4.0 percent, respectively.\n 3", "original_text": "Operating income within\nInternational Healthcare Solutions increased 3.1 percent to $168.2 million in the fourth quarter of fiscal 2023 due to growth at its\nglobal specialty logistics business and the January 2023 acquisition of PharmaLex, offset in part by a significant decline at its less-\nthan-wholly-owned Alliance Healthcare subsidiary in Egypt. "}, "hash": "49a3ca87f3e80d0245a9c1c5770ba16c7a8e48f87c9e004693e617aa78bbb445", "class_name": "RelatedNodeInfo"}}, "text": "International Healthcare Solutions\nRevenue in International Healthcare Solutions was $7.0 billion in the fourth quarter of fiscal 2023, an increase of 9.5 percent\ncompared to the same period in the prior fiscal year due to increased revenue across its businesses. ", "start_char_idx": 3638, "end_char_idx": 3902, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0f14efc8-b446-44ee-ac88-8f94fa11ff8f": {"__data__": {"id_": "0f14efc8-b446-44ee-ac88-8f94fa11ff8f", "embedding": null, "metadata": {"window": "Healthcare Solutions revenue was $61.9 billion, an increase of 13.0 percent compared to the same quarter in the prior fiscal year\nprimarily due to overall market growth primarily driven by unit volume growth, including increased sales of products labeled for\ndiabetes and/or weight loss in the GLP-1 class and increased sales of specialty products to physician practices and health systems.\n Segment operating income of $632.8 million in the fourth quarter of fiscal 2023 was up 9.4 percent compared to the same period in\nthe previous fiscal year as a result of an increase in gross profit of 6.3%, offset in part by an increase in operating expenses of 4.1%.\n International Healthcare Solutions\nRevenue in International Healthcare Solutions was $7.0 billion in the fourth quarter of fiscal 2023, an increase of 9.5 percent\ncompared to the same period in the prior fiscal year due to increased revenue across its businesses.  Operating income within\nInternational Healthcare Solutions increased 3.1 percent to $168.2 million in the fourth quarter of fiscal 2023 due to growth at its\nglobal specialty logistics business and the January 2023 acquisition of PharmaLex, offset in part by a significant decline at its less-\nthan-wholly-owned Alliance Healthcare subsidiary in Egypt.  Cencora recently completed the divestiture of its stake in its subsidiary\nin Egypt and the results of the business will no longer be consolidated beginning in fiscal 2024.  On a constant currency basis,\nInternational Healthcare Solutions revenue and operating income increased by 10.1 percent and 4.0 percent, respectively.\n 3", "original_text": "Operating income within\nInternational Healthcare Solutions increased 3.1 percent to $168.2 million in the fourth quarter of fiscal 2023 due to growth at its\nglobal specialty logistics business and the January 2023 acquisition of PharmaLex, offset in part by a significant decline at its less-\nthan-wholly-owned Alliance Healthcare subsidiary in Egypt. ", "page_label": "3", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "20e3d800-bd50-438f-b446-f823062e13e0", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2b8ab5cb1f2f22e45b46c0907985e10171e973b7b7e4d6e0e2df6b38fdf7db3c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7c9c234f-7b20-4bb2-ade4-469fdf5114c2", "node_type": "1", "metadata": {"window": "Healthcare Solutions Segment\nU.S.  Healthcare Solutions revenue was $61.9 billion, an increase of 13.0 percent compared to the same quarter in the prior fiscal year\nprimarily due to overall market growth primarily driven by unit volume growth, including increased sales of products labeled for\ndiabetes and/or weight loss in the GLP-1 class and increased sales of specialty products to physician practices and health systems.\n Segment operating income of $632.8 million in the fourth quarter of fiscal 2023 was up 9.4 percent compared to the same period in\nthe previous fiscal year as a result of an increase in gross profit of 6.3%, offset in part by an increase in operating expenses of 4.1%.\n International Healthcare Solutions\nRevenue in International Healthcare Solutions was $7.0 billion in the fourth quarter of fiscal 2023, an increase of 9.5 percent\ncompared to the same period in the prior fiscal year due to increased revenue across its businesses.  Operating income within\nInternational Healthcare Solutions increased 3.1 percent to $168.2 million in the fourth quarter of fiscal 2023 due to growth at its\nglobal specialty logistics business and the January 2023 acquisition of PharmaLex, offset in part by a significant decline at its less-\nthan-wholly-owned Alliance Healthcare subsidiary in Egypt.  Cencora recently completed the divestiture of its stake in its subsidiary\nin Egypt and the results of the business will no longer be consolidated beginning in fiscal 2024.  On a constant currency basis,\nInternational Healthcare Solutions revenue and operating income increased by 10.1 percent and 4.0 percent, respectively.\n", "original_text": "International Healthcare Solutions\nRevenue in International Healthcare Solutions was $7.0 billion in the fourth quarter of fiscal 2023, an increase of 9.5 percent\ncompared to the same period in the prior fiscal year due to increased revenue across its businesses. ", "page_label": "3", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e774c2150afbe94826ddd0eff3fa2f2db79da78219d51d4d550611c5d3b6da6b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6686a994-3d07-4d5c-b05f-b9e13d4caca0", "node_type": "1", "metadata": {"window": "Segment operating income of $632.8 million in the fourth quarter of fiscal 2023 was up 9.4 percent compared to the same period in\nthe previous fiscal year as a result of an increase in gross profit of 6.3%, offset in part by an increase in operating expenses of 4.1%.\n International Healthcare Solutions\nRevenue in International Healthcare Solutions was $7.0 billion in the fourth quarter of fiscal 2023, an increase of 9.5 percent\ncompared to the same period in the prior fiscal year due to increased revenue across its businesses.  Operating income within\nInternational Healthcare Solutions increased 3.1 percent to $168.2 million in the fourth quarter of fiscal 2023 due to growth at its\nglobal specialty logistics business and the January 2023 acquisition of PharmaLex, offset in part by a significant decline at its less-\nthan-wholly-owned Alliance Healthcare subsidiary in Egypt.  Cencora recently completed the divestiture of its stake in its subsidiary\nin Egypt and the results of the business will no longer be consolidated beginning in fiscal 2024.  On a constant currency basis,\nInternational Healthcare Solutions revenue and operating income increased by 10.1 percent and 4.0 percent, respectively.\n 3", "original_text": "Cencora recently completed the divestiture of its stake in its subsidiary\nin Egypt and the results of the business will no longer be consolidated beginning in fiscal 2024. "}, "hash": "8e9033b26588624f44ac1795d36fbfa4a81bc4a1f5633fa318bc4a2d1e89dcdd", "class_name": "RelatedNodeInfo"}}, "text": "Operating income within\nInternational Healthcare Solutions increased 3.1 percent to $168.2 million in the fourth quarter of fiscal 2023 due to growth at its\nglobal specialty logistics business and the January 2023 acquisition of PharmaLex, offset in part by a significant decline at its less-\nthan-wholly-owned Alliance Healthcare subsidiary in Egypt. ", "start_char_idx": 3902, "end_char_idx": 4254, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6686a994-3d07-4d5c-b05f-b9e13d4caca0": {"__data__": {"id_": "6686a994-3d07-4d5c-b05f-b9e13d4caca0", "embedding": null, "metadata": {"window": "Segment operating income of $632.8 million in the fourth quarter of fiscal 2023 was up 9.4 percent compared to the same period in\nthe previous fiscal year as a result of an increase in gross profit of 6.3%, offset in part by an increase in operating expenses of 4.1%.\n International Healthcare Solutions\nRevenue in International Healthcare Solutions was $7.0 billion in the fourth quarter of fiscal 2023, an increase of 9.5 percent\ncompared to the same period in the prior fiscal year due to increased revenue across its businesses.  Operating income within\nInternational Healthcare Solutions increased 3.1 percent to $168.2 million in the fourth quarter of fiscal 2023 due to growth at its\nglobal specialty logistics business and the January 2023 acquisition of PharmaLex, offset in part by a significant decline at its less-\nthan-wholly-owned Alliance Healthcare subsidiary in Egypt.  Cencora recently completed the divestiture of its stake in its subsidiary\nin Egypt and the results of the business will no longer be consolidated beginning in fiscal 2024.  On a constant currency basis,\nInternational Healthcare Solutions revenue and operating income increased by 10.1 percent and 4.0 percent, respectively.\n 3", "original_text": "Cencora recently completed the divestiture of its stake in its subsidiary\nin Egypt and the results of the business will no longer be consolidated beginning in fiscal 2024. ", "page_label": "3", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "20e3d800-bd50-438f-b446-f823062e13e0", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2b8ab5cb1f2f22e45b46c0907985e10171e973b7b7e4d6e0e2df6b38fdf7db3c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0f14efc8-b446-44ee-ac88-8f94fa11ff8f", "node_type": "1", "metadata": {"window": "Healthcare Solutions revenue was $61.9 billion, an increase of 13.0 percent compared to the same quarter in the prior fiscal year\nprimarily due to overall market growth primarily driven by unit volume growth, including increased sales of products labeled for\ndiabetes and/or weight loss in the GLP-1 class and increased sales of specialty products to physician practices and health systems.\n Segment operating income of $632.8 million in the fourth quarter of fiscal 2023 was up 9.4 percent compared to the same period in\nthe previous fiscal year as a result of an increase in gross profit of 6.3%, offset in part by an increase in operating expenses of 4.1%.\n International Healthcare Solutions\nRevenue in International Healthcare Solutions was $7.0 billion in the fourth quarter of fiscal 2023, an increase of 9.5 percent\ncompared to the same period in the prior fiscal year due to increased revenue across its businesses.  Operating income within\nInternational Healthcare Solutions increased 3.1 percent to $168.2 million in the fourth quarter of fiscal 2023 due to growth at its\nglobal specialty logistics business and the January 2023 acquisition of PharmaLex, offset in part by a significant decline at its less-\nthan-wholly-owned Alliance Healthcare subsidiary in Egypt.  Cencora recently completed the divestiture of its stake in its subsidiary\nin Egypt and the results of the business will no longer be consolidated beginning in fiscal 2024.  On a constant currency basis,\nInternational Healthcare Solutions revenue and operating income increased by 10.1 percent and 4.0 percent, respectively.\n 3", "original_text": "Operating income within\nInternational Healthcare Solutions increased 3.1 percent to $168.2 million in the fourth quarter of fiscal 2023 due to growth at its\nglobal specialty logistics business and the January 2023 acquisition of PharmaLex, offset in part by a significant decline at its less-\nthan-wholly-owned Alliance Healthcare subsidiary in Egypt. ", "page_label": "3", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0bca0fdfab27a6729d63928118ada3619bee3a83d728b793d6812c69c19cd67c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "41ee8191-516e-4405-ab00-ac4684af0e4a", "node_type": "1", "metadata": {"window": "International Healthcare Solutions\nRevenue in International Healthcare Solutions was $7.0 billion in the fourth quarter of fiscal 2023, an increase of 9.5 percent\ncompared to the same period in the prior fiscal year due to increased revenue across its businesses.  Operating income within\nInternational Healthcare Solutions increased 3.1 percent to $168.2 million in the fourth quarter of fiscal 2023 due to growth at its\nglobal specialty logistics business and the January 2023 acquisition of PharmaLex, offset in part by a significant decline at its less-\nthan-wholly-owned Alliance Healthcare subsidiary in Egypt.  Cencora recently completed the divestiture of its stake in its subsidiary\nin Egypt and the results of the business will no longer be consolidated beginning in fiscal 2024.  On a constant currency basis,\nInternational Healthcare Solutions revenue and operating income increased by 10.1 percent and 4.0 percent, respectively.\n 3", "original_text": "On a constant currency basis,\nInternational Healthcare Solutions revenue and operating income increased by 10.1 percent and 4.0 percent, respectively.\n"}, "hash": "5194f1d530d2241196abf39cd7970150910ad666f2ac3567960cc330c24cce90", "class_name": "RelatedNodeInfo"}}, "text": "Cencora recently completed the divestiture of its stake in its subsidiary\nin Egypt and the results of the business will no longer be consolidated beginning in fiscal 2024. ", "start_char_idx": 4254, "end_char_idx": 4426, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "41ee8191-516e-4405-ab00-ac4684af0e4a": {"__data__": {"id_": "41ee8191-516e-4405-ab00-ac4684af0e4a", "embedding": null, "metadata": {"window": "International Healthcare Solutions\nRevenue in International Healthcare Solutions was $7.0 billion in the fourth quarter of fiscal 2023, an increase of 9.5 percent\ncompared to the same period in the prior fiscal year due to increased revenue across its businesses.  Operating income within\nInternational Healthcare Solutions increased 3.1 percent to $168.2 million in the fourth quarter of fiscal 2023 due to growth at its\nglobal specialty logistics business and the January 2023 acquisition of PharmaLex, offset in part by a significant decline at its less-\nthan-wholly-owned Alliance Healthcare subsidiary in Egypt.  Cencora recently completed the divestiture of its stake in its subsidiary\nin Egypt and the results of the business will no longer be consolidated beginning in fiscal 2024.  On a constant currency basis,\nInternational Healthcare Solutions revenue and operating income increased by 10.1 percent and 4.0 percent, respectively.\n 3", "original_text": "On a constant currency basis,\nInternational Healthcare Solutions revenue and operating income increased by 10.1 percent and 4.0 percent, respectively.\n", "page_label": "3", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "20e3d800-bd50-438f-b446-f823062e13e0", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2b8ab5cb1f2f22e45b46c0907985e10171e973b7b7e4d6e0e2df6b38fdf7db3c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6686a994-3d07-4d5c-b05f-b9e13d4caca0", "node_type": "1", "metadata": {"window": "Segment operating income of $632.8 million in the fourth quarter of fiscal 2023 was up 9.4 percent compared to the same period in\nthe previous fiscal year as a result of an increase in gross profit of 6.3%, offset in part by an increase in operating expenses of 4.1%.\n International Healthcare Solutions\nRevenue in International Healthcare Solutions was $7.0 billion in the fourth quarter of fiscal 2023, an increase of 9.5 percent\ncompared to the same period in the prior fiscal year due to increased revenue across its businesses.  Operating income within\nInternational Healthcare Solutions increased 3.1 percent to $168.2 million in the fourth quarter of fiscal 2023 due to growth at its\nglobal specialty logistics business and the January 2023 acquisition of PharmaLex, offset in part by a significant decline at its less-\nthan-wholly-owned Alliance Healthcare subsidiary in Egypt.  Cencora recently completed the divestiture of its stake in its subsidiary\nin Egypt and the results of the business will no longer be consolidated beginning in fiscal 2024.  On a constant currency basis,\nInternational Healthcare Solutions revenue and operating income increased by 10.1 percent and 4.0 percent, respectively.\n 3", "original_text": "Cencora recently completed the divestiture of its stake in its subsidiary\nin Egypt and the results of the business will no longer be consolidated beginning in fiscal 2024. ", "page_label": "3", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "926db6ab8bb91f0093fd3c4281143a1c88b84067285cda60171cd511702559e9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2075c00a-57ee-4c6f-ab83-227868e02c10", "node_type": "1", "metadata": {"window": "Operating income within\nInternational Healthcare Solutions increased 3.1 percent to $168.2 million in the fourth quarter of fiscal 2023 due to growth at its\nglobal specialty logistics business and the January 2023 acquisition of PharmaLex, offset in part by a significant decline at its less-\nthan-wholly-owned Alliance Healthcare subsidiary in Egypt.  Cencora recently completed the divestiture of its stake in its subsidiary\nin Egypt and the results of the business will no longer be consolidated beginning in fiscal 2024.  On a constant currency basis,\nInternational Healthcare Solutions revenue and operating income increased by 10.1 percent and 4.0 percent, respectively.\n 3", "original_text": "3"}, "hash": "c43a7110a712c31ac17120499dd49a70d856dc4d3c3f2fd9bb7a45de16ae2ab6", "class_name": "RelatedNodeInfo"}}, "text": "On a constant currency basis,\nInternational Healthcare Solutions revenue and operating income increased by 10.1 percent and 4.0 percent, respectively.\n", "start_char_idx": 4426, "end_char_idx": 4577, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2075c00a-57ee-4c6f-ab83-227868e02c10": {"__data__": {"id_": "2075c00a-57ee-4c6f-ab83-227868e02c10", "embedding": null, "metadata": {"window": "Operating income within\nInternational Healthcare Solutions increased 3.1 percent to $168.2 million in the fourth quarter of fiscal 2023 due to growth at its\nglobal specialty logistics business and the January 2023 acquisition of PharmaLex, offset in part by a significant decline at its less-\nthan-wholly-owned Alliance Healthcare subsidiary in Egypt.  Cencora recently completed the divestiture of its stake in its subsidiary\nin Egypt and the results of the business will no longer be consolidated beginning in fiscal 2024.  On a constant currency basis,\nInternational Healthcare Solutions revenue and operating income increased by 10.1 percent and 4.0 percent, respectively.\n 3", "original_text": "3", "page_label": "3", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "20e3d800-bd50-438f-b446-f823062e13e0", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2b8ab5cb1f2f22e45b46c0907985e10171e973b7b7e4d6e0e2df6b38fdf7db3c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "41ee8191-516e-4405-ab00-ac4684af0e4a", "node_type": "1", "metadata": {"window": "International Healthcare Solutions\nRevenue in International Healthcare Solutions was $7.0 billion in the fourth quarter of fiscal 2023, an increase of 9.5 percent\ncompared to the same period in the prior fiscal year due to increased revenue across its businesses.  Operating income within\nInternational Healthcare Solutions increased 3.1 percent to $168.2 million in the fourth quarter of fiscal 2023 due to growth at its\nglobal specialty logistics business and the January 2023 acquisition of PharmaLex, offset in part by a significant decline at its less-\nthan-wholly-owned Alliance Healthcare subsidiary in Egypt.  Cencora recently completed the divestiture of its stake in its subsidiary\nin Egypt and the results of the business will no longer be consolidated beginning in fiscal 2024.  On a constant currency basis,\nInternational Healthcare Solutions revenue and operating income increased by 10.1 percent and 4.0 percent, respectively.\n 3", "original_text": "On a constant currency basis,\nInternational Healthcare Solutions revenue and operating income increased by 10.1 percent and 4.0 percent, respectively.\n", "page_label": "3", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3c0f4446bda2955170768d59f7e0813416849f39146e0a070ba52b5fd2d340d6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dc7e8a9d-e742-4625-9453-8624a32c1c4c", "node_type": "1", "metadata": {"window": "Fiscal Y ear 2023 Summar y Results\n\u00a0 GAAP Adjust ed (non-GAAP)\nRevenue $262.2B $262.2B\nGross Pr ofit $9.0B $9.0B\nOperating Expenses $6.6B $5.7B\nOperating Income $2.3B $3.3B\nInterest Expense, Net $229M $229M\nEffectiv e Tax Rat e 19.8% 20.3%\nNet Income A ttributable t o Cencora $1.7B $2.5B\nDilut ed Earnings P er Shar e $8.53 $11.99\nDilut ed Shar es Outstanding 204.6M 204.6M\nSummary Fiscal Y ear GAAP R esults\nIn fiscal year 2023, GAAP diluted EPS was $8.53 compared to $8.04 in the prior fiscal year.  R evenue increased 9.9 percent from last\nfiscal year to $262.2 billion.  Gross profit increased 8.0 percent to $9.0 billion due to increases in gross profit in both reportable\nsegments, and an increase in gains from antitrust litigation settlements, partially offset by an increase in LIFO expense in the current\nfiscal year.  Operating expenses increased 11.6 percent primarily due to an increase in distribution, selling, and administrative\nexpenses, amortization expense and restructuring and other expenses, offset in part by a litigation and opioid-related credit in the\ncurrent fiscal year in comparison to an expense in the prior fiscal year and the prior fiscal year included a goodwill impairment.\n", "original_text": "Fiscal Y ear 2023 Summar y Results\n\u00a0 GAAP Adjust ed (non-GAAP)\nRevenue $262.2B $262.2B\nGross Pr ofit $9.0B $9.0B\nOperating Expenses $6.6B $5.7B\nOperating Income $2.3B $3.3B\nInterest Expense, Net $229M $229M\nEffectiv e Tax Rat e 19.8% 20.3%\nNet Income A ttributable t o Cencora $1.7B $2.5B\nDilut ed Earnings P er Shar e $8.53 $11.99\nDilut ed Shar es Outstanding 204.6M 204.6M\nSummary Fiscal Y ear GAAP R esults\nIn fiscal year 2023, GAAP diluted EPS was $8.53 compared to $8.04 in the prior fiscal year. "}, "hash": "3280748f2aa1e536d9dedb28f2776f29bcac5dcb09a4a518da006538b741afab", "class_name": "RelatedNodeInfo"}}, "text": "3", "start_char_idx": 427, "end_char_idx": 428, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dc7e8a9d-e742-4625-9453-8624a32c1c4c": {"__data__": {"id_": "dc7e8a9d-e742-4625-9453-8624a32c1c4c", "embedding": null, "metadata": {"window": "Fiscal Y ear 2023 Summar y Results\n\u00a0 GAAP Adjust ed (non-GAAP)\nRevenue $262.2B $262.2B\nGross Pr ofit $9.0B $9.0B\nOperating Expenses $6.6B $5.7B\nOperating Income $2.3B $3.3B\nInterest Expense, Net $229M $229M\nEffectiv e Tax Rat e 19.8% 20.3%\nNet Income A ttributable t o Cencora $1.7B $2.5B\nDilut ed Earnings P er Shar e $8.53 $11.99\nDilut ed Shar es Outstanding 204.6M 204.6M\nSummary Fiscal Y ear GAAP R esults\nIn fiscal year 2023, GAAP diluted EPS was $8.53 compared to $8.04 in the prior fiscal year.  R evenue increased 9.9 percent from last\nfiscal year to $262.2 billion.  Gross profit increased 8.0 percent to $9.0 billion due to increases in gross profit in both reportable\nsegments, and an increase in gains from antitrust litigation settlements, partially offset by an increase in LIFO expense in the current\nfiscal year.  Operating expenses increased 11.6 percent primarily due to an increase in distribution, selling, and administrative\nexpenses, amortization expense and restructuring and other expenses, offset in part by a litigation and opioid-related credit in the\ncurrent fiscal year in comparison to an expense in the prior fiscal year and the prior fiscal year included a goodwill impairment.\n", "original_text": "Fiscal Y ear 2023 Summar y Results\n\u00a0 GAAP Adjust ed (non-GAAP)\nRevenue $262.2B $262.2B\nGross Pr ofit $9.0B $9.0B\nOperating Expenses $6.6B $5.7B\nOperating Income $2.3B $3.3B\nInterest Expense, Net $229M $229M\nEffectiv e Tax Rat e 19.8% 20.3%\nNet Income A ttributable t o Cencora $1.7B $2.5B\nDilut ed Earnings P er Shar e $8.53 $11.99\nDilut ed Shar es Outstanding 204.6M 204.6M\nSummary Fiscal Y ear GAAP R esults\nIn fiscal year 2023, GAAP diluted EPS was $8.53 compared to $8.04 in the prior fiscal year. ", "page_label": "4", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8e5f2760-457b-40e5-a61e-1e4e45be6670", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d18904d15a84570bc399063d573c66e340fe992cd76a358f1983a6e01aaa7815", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2075c00a-57ee-4c6f-ab83-227868e02c10", "node_type": "1", "metadata": {"window": "Operating income within\nInternational Healthcare Solutions increased 3.1 percent to $168.2 million in the fourth quarter of fiscal 2023 due to growth at its\nglobal specialty logistics business and the January 2023 acquisition of PharmaLex, offset in part by a significant decline at its less-\nthan-wholly-owned Alliance Healthcare subsidiary in Egypt.  Cencora recently completed the divestiture of its stake in its subsidiary\nin Egypt and the results of the business will no longer be consolidated beginning in fiscal 2024.  On a constant currency basis,\nInternational Healthcare Solutions revenue and operating income increased by 10.1 percent and 4.0 percent, respectively.\n 3", "original_text": "3", "page_label": "3", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "be272be903a073a9345ccaf4bad5648b6a4812f0edbcca66879ba55f82f49d6d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f6acad40-6d7e-400a-9e06-a4f37be68469", "node_type": "1", "metadata": {"window": "Fiscal Y ear 2023 Summar y Results\n\u00a0 GAAP Adjust ed (non-GAAP)\nRevenue $262.2B $262.2B\nGross Pr ofit $9.0B $9.0B\nOperating Expenses $6.6B $5.7B\nOperating Income $2.3B $3.3B\nInterest Expense, Net $229M $229M\nEffectiv e Tax Rat e 19.8% 20.3%\nNet Income A ttributable t o Cencora $1.7B $2.5B\nDilut ed Earnings P er Shar e $8.53 $11.99\nDilut ed Shar es Outstanding 204.6M 204.6M\nSummary Fiscal Y ear GAAP R esults\nIn fiscal year 2023, GAAP diluted EPS was $8.53 compared to $8.04 in the prior fiscal year.  R evenue increased 9.9 percent from last\nfiscal year to $262.2 billion.  Gross profit increased 8.0 percent to $9.0 billion due to increases in gross profit in both reportable\nsegments, and an increase in gains from antitrust litigation settlements, partially offset by an increase in LIFO expense in the current\nfiscal year.  Operating expenses increased 11.6 percent primarily due to an increase in distribution, selling, and administrative\nexpenses, amortization expense and restructuring and other expenses, offset in part by a litigation and opioid-related credit in the\ncurrent fiscal year in comparison to an expense in the prior fiscal year and the prior fiscal year included a goodwill impairment.\n Operating income decreased 1.1 percent due to higher operating expenses, largely offset by higher gross profit. ", "original_text": "R evenue increased 9.9 percent from last\nfiscal year to $262.2 billion. "}, "hash": "a83ddf7e7dcf77f2408a9868a9e243662ac55dba72085dcbca799d634b60446c", "class_name": "RelatedNodeInfo"}}, "text": "Fiscal Y ear 2023 Summar y Results\n\u00a0 GAAP Adjust ed (non-GAAP)\nRevenue $262.2B $262.2B\nGross Pr ofit $9.0B $9.0B\nOperating Expenses $6.6B $5.7B\nOperating Income $2.3B $3.3B\nInterest Expense, Net $229M $229M\nEffectiv e Tax Rat e 19.8% 20.3%\nNet Income A ttributable t o Cencora $1.7B $2.5B\nDilut ed Earnings P er Shar e $8.53 $11.99\nDilut ed Shar es Outstanding 204.6M 204.6M\nSummary Fiscal Y ear GAAP R esults\nIn fiscal year 2023, GAAP diluted EPS was $8.53 compared to $8.04 in the prior fiscal year. ", "start_char_idx": 0, "end_char_idx": 502, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f6acad40-6d7e-400a-9e06-a4f37be68469": {"__data__": {"id_": "f6acad40-6d7e-400a-9e06-a4f37be68469", "embedding": null, "metadata": {"window": "Fiscal Y ear 2023 Summar y Results\n\u00a0 GAAP Adjust ed (non-GAAP)\nRevenue $262.2B $262.2B\nGross Pr ofit $9.0B $9.0B\nOperating Expenses $6.6B $5.7B\nOperating Income $2.3B $3.3B\nInterest Expense, Net $229M $229M\nEffectiv e Tax Rat e 19.8% 20.3%\nNet Income A ttributable t o Cencora $1.7B $2.5B\nDilut ed Earnings P er Shar e $8.53 $11.99\nDilut ed Shar es Outstanding 204.6M 204.6M\nSummary Fiscal Y ear GAAP R esults\nIn fiscal year 2023, GAAP diluted EPS was $8.53 compared to $8.04 in the prior fiscal year.  R evenue increased 9.9 percent from last\nfiscal year to $262.2 billion.  Gross profit increased 8.0 percent to $9.0 billion due to increases in gross profit in both reportable\nsegments, and an increase in gains from antitrust litigation settlements, partially offset by an increase in LIFO expense in the current\nfiscal year.  Operating expenses increased 11.6 percent primarily due to an increase in distribution, selling, and administrative\nexpenses, amortization expense and restructuring and other expenses, offset in part by a litigation and opioid-related credit in the\ncurrent fiscal year in comparison to an expense in the prior fiscal year and the prior fiscal year included a goodwill impairment.\n Operating income decreased 1.1 percent due to higher operating expenses, largely offset by higher gross profit. ", "original_text": "R evenue increased 9.9 percent from last\nfiscal year to $262.2 billion. ", "page_label": "4", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8e5f2760-457b-40e5-a61e-1e4e45be6670", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d18904d15a84570bc399063d573c66e340fe992cd76a358f1983a6e01aaa7815", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dc7e8a9d-e742-4625-9453-8624a32c1c4c", "node_type": "1", "metadata": {"window": "Fiscal Y ear 2023 Summar y Results\n\u00a0 GAAP Adjust ed (non-GAAP)\nRevenue $262.2B $262.2B\nGross Pr ofit $9.0B $9.0B\nOperating Expenses $6.6B $5.7B\nOperating Income $2.3B $3.3B\nInterest Expense, Net $229M $229M\nEffectiv e Tax Rat e 19.8% 20.3%\nNet Income A ttributable t o Cencora $1.7B $2.5B\nDilut ed Earnings P er Shar e $8.53 $11.99\nDilut ed Shar es Outstanding 204.6M 204.6M\nSummary Fiscal Y ear GAAP R esults\nIn fiscal year 2023, GAAP diluted EPS was $8.53 compared to $8.04 in the prior fiscal year.  R evenue increased 9.9 percent from last\nfiscal year to $262.2 billion.  Gross profit increased 8.0 percent to $9.0 billion due to increases in gross profit in both reportable\nsegments, and an increase in gains from antitrust litigation settlements, partially offset by an increase in LIFO expense in the current\nfiscal year.  Operating expenses increased 11.6 percent primarily due to an increase in distribution, selling, and administrative\nexpenses, amortization expense and restructuring and other expenses, offset in part by a litigation and opioid-related credit in the\ncurrent fiscal year in comparison to an expense in the prior fiscal year and the prior fiscal year included a goodwill impairment.\n", "original_text": "Fiscal Y ear 2023 Summar y Results\n\u00a0 GAAP Adjust ed (non-GAAP)\nRevenue $262.2B $262.2B\nGross Pr ofit $9.0B $9.0B\nOperating Expenses $6.6B $5.7B\nOperating Income $2.3B $3.3B\nInterest Expense, Net $229M $229M\nEffectiv e Tax Rat e 19.8% 20.3%\nNet Income A ttributable t o Cencora $1.7B $2.5B\nDilut ed Earnings P er Shar e $8.53 $11.99\nDilut ed Shar es Outstanding 204.6M 204.6M\nSummary Fiscal Y ear GAAP R esults\nIn fiscal year 2023, GAAP diluted EPS was $8.53 compared to $8.04 in the prior fiscal year. ", "page_label": "4", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bd5fcfe01cffb69207ebe16b2b4d911da8b2ba57d78e53b9d51469069851593e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9e30dfe7-40bf-4712-a46c-914d67d7c02f", "node_type": "1", "metadata": {"window": "Fiscal Y ear 2023 Summar y Results\n\u00a0 GAAP Adjust ed (non-GAAP)\nRevenue $262.2B $262.2B\nGross Pr ofit $9.0B $9.0B\nOperating Expenses $6.6B $5.7B\nOperating Income $2.3B $3.3B\nInterest Expense, Net $229M $229M\nEffectiv e Tax Rat e 19.8% 20.3%\nNet Income A ttributable t o Cencora $1.7B $2.5B\nDilut ed Earnings P er Shar e $8.53 $11.99\nDilut ed Shar es Outstanding 204.6M 204.6M\nSummary Fiscal Y ear GAAP R esults\nIn fiscal year 2023, GAAP diluted EPS was $8.53 compared to $8.04 in the prior fiscal year.  R evenue increased 9.9 percent from last\nfiscal year to $262.2 billion.  Gross profit increased 8.0 percent to $9.0 billion due to increases in gross profit in both reportable\nsegments, and an increase in gains from antitrust litigation settlements, partially offset by an increase in LIFO expense in the current\nfiscal year.  Operating expenses increased 11.6 percent primarily due to an increase in distribution, selling, and administrative\nexpenses, amortization expense and restructuring and other expenses, offset in part by a litigation and opioid-related credit in the\ncurrent fiscal year in comparison to an expense in the prior fiscal year and the prior fiscal year included a goodwill impairment.\n Operating income decreased 1.1 percent due to higher operating expenses, largely offset by higher gross profit.  Diluted weighted\naverage shares outstanding in fiscal 2023 were 204.6 million, down 3.1 percent from the prior fiscal year primarily due to share\nrepurchases.\n", "original_text": "Gross profit increased 8.0 percent to $9.0 billion due to increases in gross profit in both reportable\nsegments, and an increase in gains from antitrust litigation settlements, partially offset by an increase in LIFO expense in the current\nfiscal year. "}, "hash": "5c91762da2ad5bb793a9504521f85e48975da562de00cd78b2f811ff94ddaaf7", "class_name": "RelatedNodeInfo"}}, "text": "R evenue increased 9.9 percent from last\nfiscal year to $262.2 billion. ", "start_char_idx": 502, "end_char_idx": 574, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9e30dfe7-40bf-4712-a46c-914d67d7c02f": {"__data__": {"id_": "9e30dfe7-40bf-4712-a46c-914d67d7c02f", "embedding": null, "metadata": {"window": "Fiscal Y ear 2023 Summar y Results\n\u00a0 GAAP Adjust ed (non-GAAP)\nRevenue $262.2B $262.2B\nGross Pr ofit $9.0B $9.0B\nOperating Expenses $6.6B $5.7B\nOperating Income $2.3B $3.3B\nInterest Expense, Net $229M $229M\nEffectiv e Tax Rat e 19.8% 20.3%\nNet Income A ttributable t o Cencora $1.7B $2.5B\nDilut ed Earnings P er Shar e $8.53 $11.99\nDilut ed Shar es Outstanding 204.6M 204.6M\nSummary Fiscal Y ear GAAP R esults\nIn fiscal year 2023, GAAP diluted EPS was $8.53 compared to $8.04 in the prior fiscal year.  R evenue increased 9.9 percent from last\nfiscal year to $262.2 billion.  Gross profit increased 8.0 percent to $9.0 billion due to increases in gross profit in both reportable\nsegments, and an increase in gains from antitrust litigation settlements, partially offset by an increase in LIFO expense in the current\nfiscal year.  Operating expenses increased 11.6 percent primarily due to an increase in distribution, selling, and administrative\nexpenses, amortization expense and restructuring and other expenses, offset in part by a litigation and opioid-related credit in the\ncurrent fiscal year in comparison to an expense in the prior fiscal year and the prior fiscal year included a goodwill impairment.\n Operating income decreased 1.1 percent due to higher operating expenses, largely offset by higher gross profit.  Diluted weighted\naverage shares outstanding in fiscal 2023 were 204.6 million, down 3.1 percent from the prior fiscal year primarily due to share\nrepurchases.\n", "original_text": "Gross profit increased 8.0 percent to $9.0 billion due to increases in gross profit in both reportable\nsegments, and an increase in gains from antitrust litigation settlements, partially offset by an increase in LIFO expense in the current\nfiscal year. ", "page_label": "4", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8e5f2760-457b-40e5-a61e-1e4e45be6670", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d18904d15a84570bc399063d573c66e340fe992cd76a358f1983a6e01aaa7815", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f6acad40-6d7e-400a-9e06-a4f37be68469", "node_type": "1", "metadata": {"window": "Fiscal Y ear 2023 Summar y Results\n\u00a0 GAAP Adjust ed (non-GAAP)\nRevenue $262.2B $262.2B\nGross Pr ofit $9.0B $9.0B\nOperating Expenses $6.6B $5.7B\nOperating Income $2.3B $3.3B\nInterest Expense, Net $229M $229M\nEffectiv e Tax Rat e 19.8% 20.3%\nNet Income A ttributable t o Cencora $1.7B $2.5B\nDilut ed Earnings P er Shar e $8.53 $11.99\nDilut ed Shar es Outstanding 204.6M 204.6M\nSummary Fiscal Y ear GAAP R esults\nIn fiscal year 2023, GAAP diluted EPS was $8.53 compared to $8.04 in the prior fiscal year.  R evenue increased 9.9 percent from last\nfiscal year to $262.2 billion.  Gross profit increased 8.0 percent to $9.0 billion due to increases in gross profit in both reportable\nsegments, and an increase in gains from antitrust litigation settlements, partially offset by an increase in LIFO expense in the current\nfiscal year.  Operating expenses increased 11.6 percent primarily due to an increase in distribution, selling, and administrative\nexpenses, amortization expense and restructuring and other expenses, offset in part by a litigation and opioid-related credit in the\ncurrent fiscal year in comparison to an expense in the prior fiscal year and the prior fiscal year included a goodwill impairment.\n Operating income decreased 1.1 percent due to higher operating expenses, largely offset by higher gross profit. ", "original_text": "R evenue increased 9.9 percent from last\nfiscal year to $262.2 billion. ", "page_label": "4", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f44bde3f985336356bade971b98c922e5973f3ae2d8cec22ce6d447de90827b3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1b0ec505-c5f4-4552-b971-2f03fec949f7", "node_type": "1", "metadata": {"window": "Fiscal Y ear 2023 Summar y Results\n\u00a0 GAAP Adjust ed (non-GAAP)\nRevenue $262.2B $262.2B\nGross Pr ofit $9.0B $9.0B\nOperating Expenses $6.6B $5.7B\nOperating Income $2.3B $3.3B\nInterest Expense, Net $229M $229M\nEffectiv e Tax Rat e 19.8% 20.3%\nNet Income A ttributable t o Cencora $1.7B $2.5B\nDilut ed Earnings P er Shar e $8.53 $11.99\nDilut ed Shar es Outstanding 204.6M 204.6M\nSummary Fiscal Y ear GAAP R esults\nIn fiscal year 2023, GAAP diluted EPS was $8.53 compared to $8.04 in the prior fiscal year.  R evenue increased 9.9 percent from last\nfiscal year to $262.2 billion.  Gross profit increased 8.0 percent to $9.0 billion due to increases in gross profit in both reportable\nsegments, and an increase in gains from antitrust litigation settlements, partially offset by an increase in LIFO expense in the current\nfiscal year.  Operating expenses increased 11.6 percent primarily due to an increase in distribution, selling, and administrative\nexpenses, amortization expense and restructuring and other expenses, offset in part by a litigation and opioid-related credit in the\ncurrent fiscal year in comparison to an expense in the prior fiscal year and the prior fiscal year included a goodwill impairment.\n Operating income decreased 1.1 percent due to higher operating expenses, largely offset by higher gross profit.  Diluted weighted\naverage shares outstanding in fiscal 2023 were 204.6 million, down 3.1 percent from the prior fiscal year primarily due to share\nrepurchases.\n Summary Fiscal Y ear Adjusted (non-GAAP) R esults\nIn fiscal year 2023, adjusted diluted EPS was $11.99 compared to $11.03 in the prior fiscal year. ", "original_text": "Operating expenses increased 11.6 percent primarily due to an increase in distribution, selling, and administrative\nexpenses, amortization expense and restructuring and other expenses, offset in part by a litigation and opioid-related credit in the\ncurrent fiscal year in comparison to an expense in the prior fiscal year and the prior fiscal year included a goodwill impairment.\n"}, "hash": "585a059062a32ef0869f8323a30aca1f5315de03ed12d58aa4ed3b82c43e08ab", "class_name": "RelatedNodeInfo"}}, "text": "Gross profit increased 8.0 percent to $9.0 billion due to increases in gross profit in both reportable\nsegments, and an increase in gains from antitrust litigation settlements, partially offset by an increase in LIFO expense in the current\nfiscal year. ", "start_char_idx": 574, "end_char_idx": 827, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1b0ec505-c5f4-4552-b971-2f03fec949f7": {"__data__": {"id_": "1b0ec505-c5f4-4552-b971-2f03fec949f7", "embedding": null, "metadata": {"window": "Fiscal Y ear 2023 Summar y Results\n\u00a0 GAAP Adjust ed (non-GAAP)\nRevenue $262.2B $262.2B\nGross Pr ofit $9.0B $9.0B\nOperating Expenses $6.6B $5.7B\nOperating Income $2.3B $3.3B\nInterest Expense, Net $229M $229M\nEffectiv e Tax Rat e 19.8% 20.3%\nNet Income A ttributable t o Cencora $1.7B $2.5B\nDilut ed Earnings P er Shar e $8.53 $11.99\nDilut ed Shar es Outstanding 204.6M 204.6M\nSummary Fiscal Y ear GAAP R esults\nIn fiscal year 2023, GAAP diluted EPS was $8.53 compared to $8.04 in the prior fiscal year.  R evenue increased 9.9 percent from last\nfiscal year to $262.2 billion.  Gross profit increased 8.0 percent to $9.0 billion due to increases in gross profit in both reportable\nsegments, and an increase in gains from antitrust litigation settlements, partially offset by an increase in LIFO expense in the current\nfiscal year.  Operating expenses increased 11.6 percent primarily due to an increase in distribution, selling, and administrative\nexpenses, amortization expense and restructuring and other expenses, offset in part by a litigation and opioid-related credit in the\ncurrent fiscal year in comparison to an expense in the prior fiscal year and the prior fiscal year included a goodwill impairment.\n Operating income decreased 1.1 percent due to higher operating expenses, largely offset by higher gross profit.  Diluted weighted\naverage shares outstanding in fiscal 2023 were 204.6 million, down 3.1 percent from the prior fiscal year primarily due to share\nrepurchases.\n Summary Fiscal Y ear Adjusted (non-GAAP) R esults\nIn fiscal year 2023, adjusted diluted EPS was $11.99 compared to $11.03 in the prior fiscal year. ", "original_text": "Operating expenses increased 11.6 percent primarily due to an increase in distribution, selling, and administrative\nexpenses, amortization expense and restructuring and other expenses, offset in part by a litigation and opioid-related credit in the\ncurrent fiscal year in comparison to an expense in the prior fiscal year and the prior fiscal year included a goodwill impairment.\n", "page_label": "4", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8e5f2760-457b-40e5-a61e-1e4e45be6670", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d18904d15a84570bc399063d573c66e340fe992cd76a358f1983a6e01aaa7815", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9e30dfe7-40bf-4712-a46c-914d67d7c02f", "node_type": "1", "metadata": {"window": "Fiscal Y ear 2023 Summar y Results\n\u00a0 GAAP Adjust ed (non-GAAP)\nRevenue $262.2B $262.2B\nGross Pr ofit $9.0B $9.0B\nOperating Expenses $6.6B $5.7B\nOperating Income $2.3B $3.3B\nInterest Expense, Net $229M $229M\nEffectiv e Tax Rat e 19.8% 20.3%\nNet Income A ttributable t o Cencora $1.7B $2.5B\nDilut ed Earnings P er Shar e $8.53 $11.99\nDilut ed Shar es Outstanding 204.6M 204.6M\nSummary Fiscal Y ear GAAP R esults\nIn fiscal year 2023, GAAP diluted EPS was $8.53 compared to $8.04 in the prior fiscal year.  R evenue increased 9.9 percent from last\nfiscal year to $262.2 billion.  Gross profit increased 8.0 percent to $9.0 billion due to increases in gross profit in both reportable\nsegments, and an increase in gains from antitrust litigation settlements, partially offset by an increase in LIFO expense in the current\nfiscal year.  Operating expenses increased 11.6 percent primarily due to an increase in distribution, selling, and administrative\nexpenses, amortization expense and restructuring and other expenses, offset in part by a litigation and opioid-related credit in the\ncurrent fiscal year in comparison to an expense in the prior fiscal year and the prior fiscal year included a goodwill impairment.\n Operating income decreased 1.1 percent due to higher operating expenses, largely offset by higher gross profit.  Diluted weighted\naverage shares outstanding in fiscal 2023 were 204.6 million, down 3.1 percent from the prior fiscal year primarily due to share\nrepurchases.\n", "original_text": "Gross profit increased 8.0 percent to $9.0 billion due to increases in gross profit in both reportable\nsegments, and an increase in gains from antitrust litigation settlements, partially offset by an increase in LIFO expense in the current\nfiscal year. ", "page_label": "4", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cd6da9ae2ba53c80fe9b076ef1f5b2199c39c595d18cb3fe97b8ffd0a286dd48", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a04bcd75-74d2-47df-8a16-ce31e74c6ae2", "node_type": "1", "metadata": {"window": "R evenue increased 9.9 percent from last\nfiscal year to $262.2 billion.  Gross profit increased 8.0 percent to $9.0 billion due to increases in gross profit in both reportable\nsegments, and an increase in gains from antitrust litigation settlements, partially offset by an increase in LIFO expense in the current\nfiscal year.  Operating expenses increased 11.6 percent primarily due to an increase in distribution, selling, and administrative\nexpenses, amortization expense and restructuring and other expenses, offset in part by a litigation and opioid-related credit in the\ncurrent fiscal year in comparison to an expense in the prior fiscal year and the prior fiscal year included a goodwill impairment.\n Operating income decreased 1.1 percent due to higher operating expenses, largely offset by higher gross profit.  Diluted weighted\naverage shares outstanding in fiscal 2023 were 204.6 million, down 3.1 percent from the prior fiscal year primarily due to share\nrepurchases.\n Summary Fiscal Y ear Adjusted (non-GAAP) R esults\nIn fiscal year 2023, adjusted diluted EPS was $11.99 compared to $11.03 in the prior fiscal year.  R evenue increased 9.9 percent to\n$262.2 billion. ", "original_text": "Operating income decreased 1.1 percent due to higher operating expenses, largely offset by higher gross profit. "}, "hash": "6422aec80d8757bdfd8a1686aca9e1d79f906df6fc7e8c2633487bcdcd1dc7fc", "class_name": "RelatedNodeInfo"}}, "text": "Operating expenses increased 11.6 percent primarily due to an increase in distribution, selling, and administrative\nexpenses, amortization expense and restructuring and other expenses, offset in part by a litigation and opioid-related credit in the\ncurrent fiscal year in comparison to an expense in the prior fiscal year and the prior fiscal year included a goodwill impairment.\n", "start_char_idx": 827, "end_char_idx": 1207, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a04bcd75-74d2-47df-8a16-ce31e74c6ae2": {"__data__": {"id_": "a04bcd75-74d2-47df-8a16-ce31e74c6ae2", "embedding": null, "metadata": {"window": "R evenue increased 9.9 percent from last\nfiscal year to $262.2 billion.  Gross profit increased 8.0 percent to $9.0 billion due to increases in gross profit in both reportable\nsegments, and an increase in gains from antitrust litigation settlements, partially offset by an increase in LIFO expense in the current\nfiscal year.  Operating expenses increased 11.6 percent primarily due to an increase in distribution, selling, and administrative\nexpenses, amortization expense and restructuring and other expenses, offset in part by a litigation and opioid-related credit in the\ncurrent fiscal year in comparison to an expense in the prior fiscal year and the prior fiscal year included a goodwill impairment.\n Operating income decreased 1.1 percent due to higher operating expenses, largely offset by higher gross profit.  Diluted weighted\naverage shares outstanding in fiscal 2023 were 204.6 million, down 3.1 percent from the prior fiscal year primarily due to share\nrepurchases.\n Summary Fiscal Y ear Adjusted (non-GAAP) R esults\nIn fiscal year 2023, adjusted diluted EPS was $11.99 compared to $11.03 in the prior fiscal year.  R evenue increased 9.9 percent to\n$262.2 billion. ", "original_text": "Operating income decreased 1.1 percent due to higher operating expenses, largely offset by higher gross profit. ", "page_label": "4", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8e5f2760-457b-40e5-a61e-1e4e45be6670", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d18904d15a84570bc399063d573c66e340fe992cd76a358f1983a6e01aaa7815", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1b0ec505-c5f4-4552-b971-2f03fec949f7", "node_type": "1", "metadata": {"window": "Fiscal Y ear 2023 Summar y Results\n\u00a0 GAAP Adjust ed (non-GAAP)\nRevenue $262.2B $262.2B\nGross Pr ofit $9.0B $9.0B\nOperating Expenses $6.6B $5.7B\nOperating Income $2.3B $3.3B\nInterest Expense, Net $229M $229M\nEffectiv e Tax Rat e 19.8% 20.3%\nNet Income A ttributable t o Cencora $1.7B $2.5B\nDilut ed Earnings P er Shar e $8.53 $11.99\nDilut ed Shar es Outstanding 204.6M 204.6M\nSummary Fiscal Y ear GAAP R esults\nIn fiscal year 2023, GAAP diluted EPS was $8.53 compared to $8.04 in the prior fiscal year.  R evenue increased 9.9 percent from last\nfiscal year to $262.2 billion.  Gross profit increased 8.0 percent to $9.0 billion due to increases in gross profit in both reportable\nsegments, and an increase in gains from antitrust litigation settlements, partially offset by an increase in LIFO expense in the current\nfiscal year.  Operating expenses increased 11.6 percent primarily due to an increase in distribution, selling, and administrative\nexpenses, amortization expense and restructuring and other expenses, offset in part by a litigation and opioid-related credit in the\ncurrent fiscal year in comparison to an expense in the prior fiscal year and the prior fiscal year included a goodwill impairment.\n Operating income decreased 1.1 percent due to higher operating expenses, largely offset by higher gross profit.  Diluted weighted\naverage shares outstanding in fiscal 2023 were 204.6 million, down 3.1 percent from the prior fiscal year primarily due to share\nrepurchases.\n Summary Fiscal Y ear Adjusted (non-GAAP) R esults\nIn fiscal year 2023, adjusted diluted EPS was $11.99 compared to $11.03 in the prior fiscal year. ", "original_text": "Operating expenses increased 11.6 percent primarily due to an increase in distribution, selling, and administrative\nexpenses, amortization expense and restructuring and other expenses, offset in part by a litigation and opioid-related credit in the\ncurrent fiscal year in comparison to an expense in the prior fiscal year and the prior fiscal year included a goodwill impairment.\n", "page_label": "4", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d6806a1f840657c54e512676632b2efe796816b566d2e3a6ad10edd82b37eb18", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c8319ec6-016e-4491-bf1c-3cf1e4768fc9", "node_type": "1", "metadata": {"window": "Gross profit increased 8.0 percent to $9.0 billion due to increases in gross profit in both reportable\nsegments, and an increase in gains from antitrust litigation settlements, partially offset by an increase in LIFO expense in the current\nfiscal year.  Operating expenses increased 11.6 percent primarily due to an increase in distribution, selling, and administrative\nexpenses, amortization expense and restructuring and other expenses, offset in part by a litigation and opioid-related credit in the\ncurrent fiscal year in comparison to an expense in the prior fiscal year and the prior fiscal year included a goodwill impairment.\n Operating income decreased 1.1 percent due to higher operating expenses, largely offset by higher gross profit.  Diluted weighted\naverage shares outstanding in fiscal 2023 were 204.6 million, down 3.1 percent from the prior fiscal year primarily due to share\nrepurchases.\n Summary Fiscal Y ear Adjusted (non-GAAP) R esults\nIn fiscal year 2023, adjusted diluted EPS was $11.99 compared to $11.03 in the prior fiscal year.  R evenue increased 9.9 percent to\n$262.2 billion.  Adjusted gross profit increased 7.3 percent to $9.0 billion due to the increases in gross profit in both reportable\nsegments. ", "original_text": "Diluted weighted\naverage shares outstanding in fiscal 2023 were 204.6 million, down 3.1 percent from the prior fiscal year primarily due to share\nrepurchases.\n"}, "hash": "0e4200fbfa15ddf36c110e170ab0e8581013aa589f0cb3b0d3e43c3e0572776e", "class_name": "RelatedNodeInfo"}}, "text": "Operating income decreased 1.1 percent due to higher operating expenses, largely offset by higher gross profit. ", "start_char_idx": 1207, "end_char_idx": 1319, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c8319ec6-016e-4491-bf1c-3cf1e4768fc9": {"__data__": {"id_": "c8319ec6-016e-4491-bf1c-3cf1e4768fc9", "embedding": null, "metadata": {"window": "Gross profit increased 8.0 percent to $9.0 billion due to increases in gross profit in both reportable\nsegments, and an increase in gains from antitrust litigation settlements, partially offset by an increase in LIFO expense in the current\nfiscal year.  Operating expenses increased 11.6 percent primarily due to an increase in distribution, selling, and administrative\nexpenses, amortization expense and restructuring and other expenses, offset in part by a litigation and opioid-related credit in the\ncurrent fiscal year in comparison to an expense in the prior fiscal year and the prior fiscal year included a goodwill impairment.\n Operating income decreased 1.1 percent due to higher operating expenses, largely offset by higher gross profit.  Diluted weighted\naverage shares outstanding in fiscal 2023 were 204.6 million, down 3.1 percent from the prior fiscal year primarily due to share\nrepurchases.\n Summary Fiscal Y ear Adjusted (non-GAAP) R esults\nIn fiscal year 2023, adjusted diluted EPS was $11.99 compared to $11.03 in the prior fiscal year.  R evenue increased 9.9 percent to\n$262.2 billion.  Adjusted gross profit increased 7.3 percent to $9.0 billion due to the increases in gross profit in both reportable\nsegments. ", "original_text": "Diluted weighted\naverage shares outstanding in fiscal 2023 were 204.6 million, down 3.1 percent from the prior fiscal year primarily due to share\nrepurchases.\n", "page_label": "4", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8e5f2760-457b-40e5-a61e-1e4e45be6670", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d18904d15a84570bc399063d573c66e340fe992cd76a358f1983a6e01aaa7815", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a04bcd75-74d2-47df-8a16-ce31e74c6ae2", "node_type": "1", "metadata": {"window": "R evenue increased 9.9 percent from last\nfiscal year to $262.2 billion.  Gross profit increased 8.0 percent to $9.0 billion due to increases in gross profit in both reportable\nsegments, and an increase in gains from antitrust litigation settlements, partially offset by an increase in LIFO expense in the current\nfiscal year.  Operating expenses increased 11.6 percent primarily due to an increase in distribution, selling, and administrative\nexpenses, amortization expense and restructuring and other expenses, offset in part by a litigation and opioid-related credit in the\ncurrent fiscal year in comparison to an expense in the prior fiscal year and the prior fiscal year included a goodwill impairment.\n Operating income decreased 1.1 percent due to higher operating expenses, largely offset by higher gross profit.  Diluted weighted\naverage shares outstanding in fiscal 2023 were 204.6 million, down 3.1 percent from the prior fiscal year primarily due to share\nrepurchases.\n Summary Fiscal Y ear Adjusted (non-GAAP) R esults\nIn fiscal year 2023, adjusted diluted EPS was $11.99 compared to $11.03 in the prior fiscal year.  R evenue increased 9.9 percent to\n$262.2 billion. ", "original_text": "Operating income decreased 1.1 percent due to higher operating expenses, largely offset by higher gross profit. ", "page_label": "4", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fa64941356ac8ea87c3d5cdded7e1e5c055f83bed9920b2999b4a8a90948f7ed", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aa8c2c8c-269a-4459-ab0d-f5c5db8f2c49", "node_type": "1", "metadata": {"window": "Operating expenses increased 11.6 percent primarily due to an increase in distribution, selling, and administrative\nexpenses, amortization expense and restructuring and other expenses, offset in part by a litigation and opioid-related credit in the\ncurrent fiscal year in comparison to an expense in the prior fiscal year and the prior fiscal year included a goodwill impairment.\n Operating income decreased 1.1 percent due to higher operating expenses, largely offset by higher gross profit.  Diluted weighted\naverage shares outstanding in fiscal 2023 were 204.6 million, down 3.1 percent from the prior fiscal year primarily due to share\nrepurchases.\n Summary Fiscal Y ear Adjusted (non-GAAP) R esults\nIn fiscal year 2023, adjusted diluted EPS was $11.99 compared to $11.03 in the prior fiscal year.  R evenue increased 9.9 percent to\n$262.2 billion.  Adjusted gross profit increased 7.3 percent to $9.0 billion due to the increases in gross profit in both reportable\nsegments.  Adjusted operating expenses increased 9.2 percent to $5.7 billion primarily due to an increase in distribution, selling, and\nadministrative expenses. ", "original_text": "Summary Fiscal Y ear Adjusted (non-GAAP) R esults\nIn fiscal year 2023, adjusted diluted EPS was $11.99 compared to $11.03 in the prior fiscal year. "}, "hash": "10c8da571ce0950b0e7e9c79dcb00ea1419196e6207bc7b7d3447fb2cdff7263", "class_name": "RelatedNodeInfo"}}, "text": "Diluted weighted\naverage shares outstanding in fiscal 2023 were 204.6 million, down 3.1 percent from the prior fiscal year primarily due to share\nrepurchases.\n", "start_char_idx": 1319, "end_char_idx": 1478, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aa8c2c8c-269a-4459-ab0d-f5c5db8f2c49": {"__data__": {"id_": "aa8c2c8c-269a-4459-ab0d-f5c5db8f2c49", "embedding": null, "metadata": {"window": "Operating expenses increased 11.6 percent primarily due to an increase in distribution, selling, and administrative\nexpenses, amortization expense and restructuring and other expenses, offset in part by a litigation and opioid-related credit in the\ncurrent fiscal year in comparison to an expense in the prior fiscal year and the prior fiscal year included a goodwill impairment.\n Operating income decreased 1.1 percent due to higher operating expenses, largely offset by higher gross profit.  Diluted weighted\naverage shares outstanding in fiscal 2023 were 204.6 million, down 3.1 percent from the prior fiscal year primarily due to share\nrepurchases.\n Summary Fiscal Y ear Adjusted (non-GAAP) R esults\nIn fiscal year 2023, adjusted diluted EPS was $11.99 compared to $11.03 in the prior fiscal year.  R evenue increased 9.9 percent to\n$262.2 billion.  Adjusted gross profit increased 7.3 percent to $9.0 billion due to the increases in gross profit in both reportable\nsegments.  Adjusted operating expenses increased 9.2 percent to $5.7 billion primarily due to an increase in distribution, selling, and\nadministrative expenses. ", "original_text": "Summary Fiscal Y ear Adjusted (non-GAAP) R esults\nIn fiscal year 2023, adjusted diluted EPS was $11.99 compared to $11.03 in the prior fiscal year. ", "page_label": "4", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8e5f2760-457b-40e5-a61e-1e4e45be6670", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d18904d15a84570bc399063d573c66e340fe992cd76a358f1983a6e01aaa7815", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c8319ec6-016e-4491-bf1c-3cf1e4768fc9", "node_type": "1", "metadata": {"window": "Gross profit increased 8.0 percent to $9.0 billion due to increases in gross profit in both reportable\nsegments, and an increase in gains from antitrust litigation settlements, partially offset by an increase in LIFO expense in the current\nfiscal year.  Operating expenses increased 11.6 percent primarily due to an increase in distribution, selling, and administrative\nexpenses, amortization expense and restructuring and other expenses, offset in part by a litigation and opioid-related credit in the\ncurrent fiscal year in comparison to an expense in the prior fiscal year and the prior fiscal year included a goodwill impairment.\n Operating income decreased 1.1 percent due to higher operating expenses, largely offset by higher gross profit.  Diluted weighted\naverage shares outstanding in fiscal 2023 were 204.6 million, down 3.1 percent from the prior fiscal year primarily due to share\nrepurchases.\n Summary Fiscal Y ear Adjusted (non-GAAP) R esults\nIn fiscal year 2023, adjusted diluted EPS was $11.99 compared to $11.03 in the prior fiscal year.  R evenue increased 9.9 percent to\n$262.2 billion.  Adjusted gross profit increased 7.3 percent to $9.0 billion due to the increases in gross profit in both reportable\nsegments. ", "original_text": "Diluted weighted\naverage shares outstanding in fiscal 2023 were 204.6 million, down 3.1 percent from the prior fiscal year primarily due to share\nrepurchases.\n", "page_label": "4", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "034b2868107d8d116a3bc331cd2c67bbb2e22eec5268e8f9120cf132625dea2e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "394f2a48-85d2-45e6-a05a-ea3a59d66657", "node_type": "1", "metadata": {"window": "Operating income decreased 1.1 percent due to higher operating expenses, largely offset by higher gross profit.  Diluted weighted\naverage shares outstanding in fiscal 2023 were 204.6 million, down 3.1 percent from the prior fiscal year primarily due to share\nrepurchases.\n Summary Fiscal Y ear Adjusted (non-GAAP) R esults\nIn fiscal year 2023, adjusted diluted EPS was $11.99 compared to $11.03 in the prior fiscal year.  R evenue increased 9.9 percent to\n$262.2 billion.  Adjusted gross profit increased 7.3 percent to $9.0 billion due to the increases in gross profit in both reportable\nsegments.  Adjusted operating expenses increased 9.2 percent to $5.7 billion primarily due to an increase in distribution, selling, and\nadministrative expenses.  Adjusted operating income increased 4.0 percent to $3.3 billion due to increases in gross profit in both\nreportable segments, offset in part by increased operating expenses. ", "original_text": "R evenue increased 9.9 percent to\n$262.2 billion. "}, "hash": "f563bc932339e6209c4a2895f7b8fcd097ba04fdd56b43bce3a0aa2d2ccc2344", "class_name": "RelatedNodeInfo"}}, "text": "Summary Fiscal Y ear Adjusted (non-GAAP) R esults\nIn fiscal year 2023, adjusted diluted EPS was $11.99 compared to $11.03 in the prior fiscal year. ", "start_char_idx": 1478, "end_char_idx": 1626, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "394f2a48-85d2-45e6-a05a-ea3a59d66657": {"__data__": {"id_": "394f2a48-85d2-45e6-a05a-ea3a59d66657", "embedding": null, "metadata": {"window": "Operating income decreased 1.1 percent due to higher operating expenses, largely offset by higher gross profit.  Diluted weighted\naverage shares outstanding in fiscal 2023 were 204.6 million, down 3.1 percent from the prior fiscal year primarily due to share\nrepurchases.\n Summary Fiscal Y ear Adjusted (non-GAAP) R esults\nIn fiscal year 2023, adjusted diluted EPS was $11.99 compared to $11.03 in the prior fiscal year.  R evenue increased 9.9 percent to\n$262.2 billion.  Adjusted gross profit increased 7.3 percent to $9.0 billion due to the increases in gross profit in both reportable\nsegments.  Adjusted operating expenses increased 9.2 percent to $5.7 billion primarily due to an increase in distribution, selling, and\nadministrative expenses.  Adjusted operating income increased 4.0 percent to $3.3 billion due to increases in gross profit in both\nreportable segments, offset in part by increased operating expenses. ", "original_text": "R evenue increased 9.9 percent to\n$262.2 billion. ", "page_label": "4", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8e5f2760-457b-40e5-a61e-1e4e45be6670", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d18904d15a84570bc399063d573c66e340fe992cd76a358f1983a6e01aaa7815", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aa8c2c8c-269a-4459-ab0d-f5c5db8f2c49", "node_type": "1", "metadata": {"window": "Operating expenses increased 11.6 percent primarily due to an increase in distribution, selling, and administrative\nexpenses, amortization expense and restructuring and other expenses, offset in part by a litigation and opioid-related credit in the\ncurrent fiscal year in comparison to an expense in the prior fiscal year and the prior fiscal year included a goodwill impairment.\n Operating income decreased 1.1 percent due to higher operating expenses, largely offset by higher gross profit.  Diluted weighted\naverage shares outstanding in fiscal 2023 were 204.6 million, down 3.1 percent from the prior fiscal year primarily due to share\nrepurchases.\n Summary Fiscal Y ear Adjusted (non-GAAP) R esults\nIn fiscal year 2023, adjusted diluted EPS was $11.99 compared to $11.03 in the prior fiscal year.  R evenue increased 9.9 percent to\n$262.2 billion.  Adjusted gross profit increased 7.3 percent to $9.0 billion due to the increases in gross profit in both reportable\nsegments.  Adjusted operating expenses increased 9.2 percent to $5.7 billion primarily due to an increase in distribution, selling, and\nadministrative expenses. ", "original_text": "Summary Fiscal Y ear Adjusted (non-GAAP) R esults\nIn fiscal year 2023, adjusted diluted EPS was $11.99 compared to $11.03 in the prior fiscal year. ", "page_label": "4", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "caad3cf9bcb5ad84bb5e810c7aa5009109b1e5365c7575859646437aecd8cf6a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "45745af8-b062-45a6-bc77-cf9a4a846fbc", "node_type": "1", "metadata": {"window": "Diluted weighted\naverage shares outstanding in fiscal 2023 were 204.6 million, down 3.1 percent from the prior fiscal year primarily due to share\nrepurchases.\n Summary Fiscal Y ear Adjusted (non-GAAP) R esults\nIn fiscal year 2023, adjusted diluted EPS was $11.99 compared to $11.03 in the prior fiscal year.  R evenue increased 9.9 percent to\n$262.2 billion.  Adjusted gross profit increased 7.3 percent to $9.0 billion due to the increases in gross profit in both reportable\nsegments.  Adjusted operating expenses increased 9.2 percent to $5.7 billion primarily due to an increase in distribution, selling, and\nadministrative expenses.  Adjusted operating income increased 4.0 percent to $3.3 billion due to increases in gross profit in both\nreportable segments, offset in part by increased operating expenses.  Adjusted operating income margin decreased by 8 basis points\nto 1.25 percent, primarily due to increased sales of sales of products labeled for diabetes and/or weight loss in the GLP-1 class,\nwhich have lower gross profit margins, and lower sales of government-owned C OVID-19 treatments, which have higher gross profit\nmargins, and a negative impact of foreign currency rates in comparison to the prior fiscal year. ", "original_text": "Adjusted gross profit increased 7.3 percent to $9.0 billion due to the increases in gross profit in both reportable\nsegments. "}, "hash": "4175338884e5cede96b46e838ec184232ef2a31454fe727c8cc365dd6e5db85c", "class_name": "RelatedNodeInfo"}}, "text": "R evenue increased 9.9 percent to\n$262.2 billion. ", "start_char_idx": 1626, "end_char_idx": 1676, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "45745af8-b062-45a6-bc77-cf9a4a846fbc": {"__data__": {"id_": "45745af8-b062-45a6-bc77-cf9a4a846fbc", "embedding": null, "metadata": {"window": "Diluted weighted\naverage shares outstanding in fiscal 2023 were 204.6 million, down 3.1 percent from the prior fiscal year primarily due to share\nrepurchases.\n Summary Fiscal Y ear Adjusted (non-GAAP) R esults\nIn fiscal year 2023, adjusted diluted EPS was $11.99 compared to $11.03 in the prior fiscal year.  R evenue increased 9.9 percent to\n$262.2 billion.  Adjusted gross profit increased 7.3 percent to $9.0 billion due to the increases in gross profit in both reportable\nsegments.  Adjusted operating expenses increased 9.2 percent to $5.7 billion primarily due to an increase in distribution, selling, and\nadministrative expenses.  Adjusted operating income increased 4.0 percent to $3.3 billion due to increases in gross profit in both\nreportable segments, offset in part by increased operating expenses.  Adjusted operating income margin decreased by 8 basis points\nto 1.25 percent, primarily due to increased sales of sales of products labeled for diabetes and/or weight loss in the GLP-1 class,\nwhich have lower gross profit margins, and lower sales of government-owned C OVID-19 treatments, which have higher gross profit\nmargins, and a negative impact of foreign currency rates in comparison to the prior fiscal year. ", "original_text": "Adjusted gross profit increased 7.3 percent to $9.0 billion due to the increases in gross profit in both reportable\nsegments. ", "page_label": "4", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8e5f2760-457b-40e5-a61e-1e4e45be6670", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d18904d15a84570bc399063d573c66e340fe992cd76a358f1983a6e01aaa7815", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "394f2a48-85d2-45e6-a05a-ea3a59d66657", "node_type": "1", "metadata": {"window": "Operating income decreased 1.1 percent due to higher operating expenses, largely offset by higher gross profit.  Diluted weighted\naverage shares outstanding in fiscal 2023 were 204.6 million, down 3.1 percent from the prior fiscal year primarily due to share\nrepurchases.\n Summary Fiscal Y ear Adjusted (non-GAAP) R esults\nIn fiscal year 2023, adjusted diluted EPS was $11.99 compared to $11.03 in the prior fiscal year.  R evenue increased 9.9 percent to\n$262.2 billion.  Adjusted gross profit increased 7.3 percent to $9.0 billion due to the increases in gross profit in both reportable\nsegments.  Adjusted operating expenses increased 9.2 percent to $5.7 billion primarily due to an increase in distribution, selling, and\nadministrative expenses.  Adjusted operating income increased 4.0 percent to $3.3 billion due to increases in gross profit in both\nreportable segments, offset in part by increased operating expenses. ", "original_text": "R evenue increased 9.9 percent to\n$262.2 billion. ", "page_label": "4", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b06caabedc80080c5b0554d3c4a0158fe74491af6eca2b37ffe5c9e5662c2bb7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "379d0b65-26fe-4570-a4c1-bfd84462d224", "node_type": "1", "metadata": {"window": "Summary Fiscal Y ear Adjusted (non-GAAP) R esults\nIn fiscal year 2023, adjusted diluted EPS was $11.99 compared to $11.03 in the prior fiscal year.  R evenue increased 9.9 percent to\n$262.2 billion.  Adjusted gross profit increased 7.3 percent to $9.0 billion due to the increases in gross profit in both reportable\nsegments.  Adjusted operating expenses increased 9.2 percent to $5.7 billion primarily due to an increase in distribution, selling, and\nadministrative expenses.  Adjusted operating income increased 4.0 percent to $3.3 billion due to increases in gross profit in both\nreportable segments, offset in part by increased operating expenses.  Adjusted operating income margin decreased by 8 basis points\nto 1.25 percent, primarily due to increased sales of sales of products labeled for diabetes and/or weight loss in the GLP-1 class,\nwhich have lower gross profit margins, and lower sales of government-owned C OVID-19 treatments, which have higher gross profit\nmargins, and a negative impact of foreign currency rates in comparison to the prior fiscal year.  On a constant currency basis,\nrevenue and adjusted operating income grew 10.9 percent and 6.0 percent, respectively.\n", "original_text": "Adjusted operating expenses increased 9.2 percent to $5.7 billion primarily due to an increase in distribution, selling, and\nadministrative expenses. "}, "hash": "0f91dfdebf0fe432434d539ba0455044adcfd6d0e3bb147be19e48f7b923b7e7", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted gross profit increased 7.3 percent to $9.0 billion due to the increases in gross profit in both reportable\nsegments. ", "start_char_idx": 1676, "end_char_idx": 1802, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "379d0b65-26fe-4570-a4c1-bfd84462d224": {"__data__": {"id_": "379d0b65-26fe-4570-a4c1-bfd84462d224", "embedding": null, "metadata": {"window": "Summary Fiscal Y ear Adjusted (non-GAAP) R esults\nIn fiscal year 2023, adjusted diluted EPS was $11.99 compared to $11.03 in the prior fiscal year.  R evenue increased 9.9 percent to\n$262.2 billion.  Adjusted gross profit increased 7.3 percent to $9.0 billion due to the increases in gross profit in both reportable\nsegments.  Adjusted operating expenses increased 9.2 percent to $5.7 billion primarily due to an increase in distribution, selling, and\nadministrative expenses.  Adjusted operating income increased 4.0 percent to $3.3 billion due to increases in gross profit in both\nreportable segments, offset in part by increased operating expenses.  Adjusted operating income margin decreased by 8 basis points\nto 1.25 percent, primarily due to increased sales of sales of products labeled for diabetes and/or weight loss in the GLP-1 class,\nwhich have lower gross profit margins, and lower sales of government-owned C OVID-19 treatments, which have higher gross profit\nmargins, and a negative impact of foreign currency rates in comparison to the prior fiscal year.  On a constant currency basis,\nrevenue and adjusted operating income grew 10.9 percent and 6.0 percent, respectively.\n", "original_text": "Adjusted operating expenses increased 9.2 percent to $5.7 billion primarily due to an increase in distribution, selling, and\nadministrative expenses. ", "page_label": "4", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8e5f2760-457b-40e5-a61e-1e4e45be6670", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d18904d15a84570bc399063d573c66e340fe992cd76a358f1983a6e01aaa7815", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "45745af8-b062-45a6-bc77-cf9a4a846fbc", "node_type": "1", "metadata": {"window": "Diluted weighted\naverage shares outstanding in fiscal 2023 were 204.6 million, down 3.1 percent from the prior fiscal year primarily due to share\nrepurchases.\n Summary Fiscal Y ear Adjusted (non-GAAP) R esults\nIn fiscal year 2023, adjusted diluted EPS was $11.99 compared to $11.03 in the prior fiscal year.  R evenue increased 9.9 percent to\n$262.2 billion.  Adjusted gross profit increased 7.3 percent to $9.0 billion due to the increases in gross profit in both reportable\nsegments.  Adjusted operating expenses increased 9.2 percent to $5.7 billion primarily due to an increase in distribution, selling, and\nadministrative expenses.  Adjusted operating income increased 4.0 percent to $3.3 billion due to increases in gross profit in both\nreportable segments, offset in part by increased operating expenses.  Adjusted operating income margin decreased by 8 basis points\nto 1.25 percent, primarily due to increased sales of sales of products labeled for diabetes and/or weight loss in the GLP-1 class,\nwhich have lower gross profit margins, and lower sales of government-owned C OVID-19 treatments, which have higher gross profit\nmargins, and a negative impact of foreign currency rates in comparison to the prior fiscal year. ", "original_text": "Adjusted gross profit increased 7.3 percent to $9.0 billion due to the increases in gross profit in both reportable\nsegments. ", "page_label": "4", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5cb5af730c641d2e4eb3dae196efeafceb6677a356b15db681dbe1ea4dc58a4b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "56a348c4-3e00-480a-b890-dd04a4a8dd24", "node_type": "1", "metadata": {"window": "R evenue increased 9.9 percent to\n$262.2 billion.  Adjusted gross profit increased 7.3 percent to $9.0 billion due to the increases in gross profit in both reportable\nsegments.  Adjusted operating expenses increased 9.2 percent to $5.7 billion primarily due to an increase in distribution, selling, and\nadministrative expenses.  Adjusted operating income increased 4.0 percent to $3.3 billion due to increases in gross profit in both\nreportable segments, offset in part by increased operating expenses.  Adjusted operating income margin decreased by 8 basis points\nto 1.25 percent, primarily due to increased sales of sales of products labeled for diabetes and/or weight loss in the GLP-1 class,\nwhich have lower gross profit margins, and lower sales of government-owned C OVID-19 treatments, which have higher gross profit\nmargins, and a negative impact of foreign currency rates in comparison to the prior fiscal year.  On a constant currency basis,\nrevenue and adjusted operating income grew 10.9 percent and 6.0 percent, respectively.\n Recent Comp any Highlights & Milest ones\nCencora completed its name change from AmerisourceBergen and began trading under the ticker symbol \u201cC OR\u201d on the New\n4", "original_text": "Adjusted operating income increased 4.0 percent to $3.3 billion due to increases in gross profit in both\nreportable segments, offset in part by increased operating expenses. "}, "hash": "e133fd00f2b8b33d151358ecb700d2b8a95457dbbbc4b191b3f5041e244b5e40", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operating expenses increased 9.2 percent to $5.7 billion primarily due to an increase in distribution, selling, and\nadministrative expenses. ", "start_char_idx": 1802, "end_char_idx": 1952, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "56a348c4-3e00-480a-b890-dd04a4a8dd24": {"__data__": {"id_": "56a348c4-3e00-480a-b890-dd04a4a8dd24", "embedding": null, "metadata": {"window": "R evenue increased 9.9 percent to\n$262.2 billion.  Adjusted gross profit increased 7.3 percent to $9.0 billion due to the increases in gross profit in both reportable\nsegments.  Adjusted operating expenses increased 9.2 percent to $5.7 billion primarily due to an increase in distribution, selling, and\nadministrative expenses.  Adjusted operating income increased 4.0 percent to $3.3 billion due to increases in gross profit in both\nreportable segments, offset in part by increased operating expenses.  Adjusted operating income margin decreased by 8 basis points\nto 1.25 percent, primarily due to increased sales of sales of products labeled for diabetes and/or weight loss in the GLP-1 class,\nwhich have lower gross profit margins, and lower sales of government-owned C OVID-19 treatments, which have higher gross profit\nmargins, and a negative impact of foreign currency rates in comparison to the prior fiscal year.  On a constant currency basis,\nrevenue and adjusted operating income grew 10.9 percent and 6.0 percent, respectively.\n Recent Comp any Highlights & Milest ones\nCencora completed its name change from AmerisourceBergen and began trading under the ticker symbol \u201cC OR\u201d on the New\n4", "original_text": "Adjusted operating income increased 4.0 percent to $3.3 billion due to increases in gross profit in both\nreportable segments, offset in part by increased operating expenses. ", "page_label": "4", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8e5f2760-457b-40e5-a61e-1e4e45be6670", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d18904d15a84570bc399063d573c66e340fe992cd76a358f1983a6e01aaa7815", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "379d0b65-26fe-4570-a4c1-bfd84462d224", "node_type": "1", "metadata": {"window": "Summary Fiscal Y ear Adjusted (non-GAAP) R esults\nIn fiscal year 2023, adjusted diluted EPS was $11.99 compared to $11.03 in the prior fiscal year.  R evenue increased 9.9 percent to\n$262.2 billion.  Adjusted gross profit increased 7.3 percent to $9.0 billion due to the increases in gross profit in both reportable\nsegments.  Adjusted operating expenses increased 9.2 percent to $5.7 billion primarily due to an increase in distribution, selling, and\nadministrative expenses.  Adjusted operating income increased 4.0 percent to $3.3 billion due to increases in gross profit in both\nreportable segments, offset in part by increased operating expenses.  Adjusted operating income margin decreased by 8 basis points\nto 1.25 percent, primarily due to increased sales of sales of products labeled for diabetes and/or weight loss in the GLP-1 class,\nwhich have lower gross profit margins, and lower sales of government-owned C OVID-19 treatments, which have higher gross profit\nmargins, and a negative impact of foreign currency rates in comparison to the prior fiscal year.  On a constant currency basis,\nrevenue and adjusted operating income grew 10.9 percent and 6.0 percent, respectively.\n", "original_text": "Adjusted operating expenses increased 9.2 percent to $5.7 billion primarily due to an increase in distribution, selling, and\nadministrative expenses. ", "page_label": "4", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c059e1a605a0d8894bcd843fb5edcd41baa369f254ae218015fe09c79cc1e9ca", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5106d744-fed0-4cc2-91a0-bf7d7470f8ed", "node_type": "1", "metadata": {"window": "Adjusted gross profit increased 7.3 percent to $9.0 billion due to the increases in gross profit in both reportable\nsegments.  Adjusted operating expenses increased 9.2 percent to $5.7 billion primarily due to an increase in distribution, selling, and\nadministrative expenses.  Adjusted operating income increased 4.0 percent to $3.3 billion due to increases in gross profit in both\nreportable segments, offset in part by increased operating expenses.  Adjusted operating income margin decreased by 8 basis points\nto 1.25 percent, primarily due to increased sales of sales of products labeled for diabetes and/or weight loss in the GLP-1 class,\nwhich have lower gross profit margins, and lower sales of government-owned C OVID-19 treatments, which have higher gross profit\nmargins, and a negative impact of foreign currency rates in comparison to the prior fiscal year.  On a constant currency basis,\nrevenue and adjusted operating income grew 10.9 percent and 6.0 percent, respectively.\n Recent Comp any Highlights & Milest ones\nCencora completed its name change from AmerisourceBergen and began trading under the ticker symbol \u201cC OR\u201d on the New\n4", "original_text": "Adjusted operating income margin decreased by 8 basis points\nto 1.25 percent, primarily due to increased sales of sales of products labeled for diabetes and/or weight loss in the GLP-1 class,\nwhich have lower gross profit margins, and lower sales of government-owned C OVID-19 treatments, which have higher gross profit\nmargins, and a negative impact of foreign currency rates in comparison to the prior fiscal year. "}, "hash": "bdf419b9a59cae0f121b076f79faf9300974f5020e03cdfc03c1d5e47f64804f", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operating income increased 4.0 percent to $3.3 billion due to increases in gross profit in both\nreportable segments, offset in part by increased operating expenses. ", "start_char_idx": 1952, "end_char_idx": 2126, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5106d744-fed0-4cc2-91a0-bf7d7470f8ed": {"__data__": {"id_": "5106d744-fed0-4cc2-91a0-bf7d7470f8ed", "embedding": null, "metadata": {"window": "Adjusted gross profit increased 7.3 percent to $9.0 billion due to the increases in gross profit in both reportable\nsegments.  Adjusted operating expenses increased 9.2 percent to $5.7 billion primarily due to an increase in distribution, selling, and\nadministrative expenses.  Adjusted operating income increased 4.0 percent to $3.3 billion due to increases in gross profit in both\nreportable segments, offset in part by increased operating expenses.  Adjusted operating income margin decreased by 8 basis points\nto 1.25 percent, primarily due to increased sales of sales of products labeled for diabetes and/or weight loss in the GLP-1 class,\nwhich have lower gross profit margins, and lower sales of government-owned C OVID-19 treatments, which have higher gross profit\nmargins, and a negative impact of foreign currency rates in comparison to the prior fiscal year.  On a constant currency basis,\nrevenue and adjusted operating income grew 10.9 percent and 6.0 percent, respectively.\n Recent Comp any Highlights & Milest ones\nCencora completed its name change from AmerisourceBergen and began trading under the ticker symbol \u201cC OR\u201d on the New\n4", "original_text": "Adjusted operating income margin decreased by 8 basis points\nto 1.25 percent, primarily due to increased sales of sales of products labeled for diabetes and/or weight loss in the GLP-1 class,\nwhich have lower gross profit margins, and lower sales of government-owned C OVID-19 treatments, which have higher gross profit\nmargins, and a negative impact of foreign currency rates in comparison to the prior fiscal year. ", "page_label": "4", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8e5f2760-457b-40e5-a61e-1e4e45be6670", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d18904d15a84570bc399063d573c66e340fe992cd76a358f1983a6e01aaa7815", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "56a348c4-3e00-480a-b890-dd04a4a8dd24", "node_type": "1", "metadata": {"window": "R evenue increased 9.9 percent to\n$262.2 billion.  Adjusted gross profit increased 7.3 percent to $9.0 billion due to the increases in gross profit in both reportable\nsegments.  Adjusted operating expenses increased 9.2 percent to $5.7 billion primarily due to an increase in distribution, selling, and\nadministrative expenses.  Adjusted operating income increased 4.0 percent to $3.3 billion due to increases in gross profit in both\nreportable segments, offset in part by increased operating expenses.  Adjusted operating income margin decreased by 8 basis points\nto 1.25 percent, primarily due to increased sales of sales of products labeled for diabetes and/or weight loss in the GLP-1 class,\nwhich have lower gross profit margins, and lower sales of government-owned C OVID-19 treatments, which have higher gross profit\nmargins, and a negative impact of foreign currency rates in comparison to the prior fiscal year.  On a constant currency basis,\nrevenue and adjusted operating income grew 10.9 percent and 6.0 percent, respectively.\n Recent Comp any Highlights & Milest ones\nCencora completed its name change from AmerisourceBergen and began trading under the ticker symbol \u201cC OR\u201d on the New\n4", "original_text": "Adjusted operating income increased 4.0 percent to $3.3 billion due to increases in gross profit in both\nreportable segments, offset in part by increased operating expenses. ", "page_label": "4", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4746792165b9803eef1f52474139e538dc1afaf2c988120594543ccefcd85040", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9899eb1c-28ed-413f-a253-390b677c3f37", "node_type": "1", "metadata": {"window": "Adjusted operating expenses increased 9.2 percent to $5.7 billion primarily due to an increase in distribution, selling, and\nadministrative expenses.  Adjusted operating income increased 4.0 percent to $3.3 billion due to increases in gross profit in both\nreportable segments, offset in part by increased operating expenses.  Adjusted operating income margin decreased by 8 basis points\nto 1.25 percent, primarily due to increased sales of sales of products labeled for diabetes and/or weight loss in the GLP-1 class,\nwhich have lower gross profit margins, and lower sales of government-owned C OVID-19 treatments, which have higher gross profit\nmargins, and a negative impact of foreign currency rates in comparison to the prior fiscal year.  On a constant currency basis,\nrevenue and adjusted operating income grew 10.9 percent and 6.0 percent, respectively.\n Recent Comp any Highlights & Milest ones\nCencora completed its name change from AmerisourceBergen and began trading under the ticker symbol \u201cC OR\u201d on the New\n4", "original_text": "On a constant currency basis,\nrevenue and adjusted operating income grew 10.9 percent and 6.0 percent, respectively.\n"}, "hash": "e6f744a01c4a2ea799042b9bd9e1940cb85313eb54e1cb35b8393abdebe0c82b", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operating income margin decreased by 8 basis points\nto 1.25 percent, primarily due to increased sales of sales of products labeled for diabetes and/or weight loss in the GLP-1 class,\nwhich have lower gross profit margins, and lower sales of government-owned C OVID-19 treatments, which have higher gross profit\nmargins, and a negative impact of foreign currency rates in comparison to the prior fiscal year. ", "start_char_idx": 2126, "end_char_idx": 2543, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9899eb1c-28ed-413f-a253-390b677c3f37": {"__data__": {"id_": "9899eb1c-28ed-413f-a253-390b677c3f37", "embedding": null, "metadata": {"window": "Adjusted operating expenses increased 9.2 percent to $5.7 billion primarily due to an increase in distribution, selling, and\nadministrative expenses.  Adjusted operating income increased 4.0 percent to $3.3 billion due to increases in gross profit in both\nreportable segments, offset in part by increased operating expenses.  Adjusted operating income margin decreased by 8 basis points\nto 1.25 percent, primarily due to increased sales of sales of products labeled for diabetes and/or weight loss in the GLP-1 class,\nwhich have lower gross profit margins, and lower sales of government-owned C OVID-19 treatments, which have higher gross profit\nmargins, and a negative impact of foreign currency rates in comparison to the prior fiscal year.  On a constant currency basis,\nrevenue and adjusted operating income grew 10.9 percent and 6.0 percent, respectively.\n Recent Comp any Highlights & Milest ones\nCencora completed its name change from AmerisourceBergen and began trading under the ticker symbol \u201cC OR\u201d on the New\n4", "original_text": "On a constant currency basis,\nrevenue and adjusted operating income grew 10.9 percent and 6.0 percent, respectively.\n", "page_label": "4", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8e5f2760-457b-40e5-a61e-1e4e45be6670", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d18904d15a84570bc399063d573c66e340fe992cd76a358f1983a6e01aaa7815", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5106d744-fed0-4cc2-91a0-bf7d7470f8ed", "node_type": "1", "metadata": {"window": "Adjusted gross profit increased 7.3 percent to $9.0 billion due to the increases in gross profit in both reportable\nsegments.  Adjusted operating expenses increased 9.2 percent to $5.7 billion primarily due to an increase in distribution, selling, and\nadministrative expenses.  Adjusted operating income increased 4.0 percent to $3.3 billion due to increases in gross profit in both\nreportable segments, offset in part by increased operating expenses.  Adjusted operating income margin decreased by 8 basis points\nto 1.25 percent, primarily due to increased sales of sales of products labeled for diabetes and/or weight loss in the GLP-1 class,\nwhich have lower gross profit margins, and lower sales of government-owned C OVID-19 treatments, which have higher gross profit\nmargins, and a negative impact of foreign currency rates in comparison to the prior fiscal year.  On a constant currency basis,\nrevenue and adjusted operating income grew 10.9 percent and 6.0 percent, respectively.\n Recent Comp any Highlights & Milest ones\nCencora completed its name change from AmerisourceBergen and began trading under the ticker symbol \u201cC OR\u201d on the New\n4", "original_text": "Adjusted operating income margin decreased by 8 basis points\nto 1.25 percent, primarily due to increased sales of sales of products labeled for diabetes and/or weight loss in the GLP-1 class,\nwhich have lower gross profit margins, and lower sales of government-owned C OVID-19 treatments, which have higher gross profit\nmargins, and a negative impact of foreign currency rates in comparison to the prior fiscal year. ", "page_label": "4", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "31ac4e68d023eb4168bf74aba890fc4a2f7021c18b342a0cf00007e1cf331754", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9123c6e0-22af-44f5-8ddc-ccf3dd25ef28", "node_type": "1", "metadata": {"window": "Adjusted operating income increased 4.0 percent to $3.3 billion due to increases in gross profit in both\nreportable segments, offset in part by increased operating expenses.  Adjusted operating income margin decreased by 8 basis points\nto 1.25 percent, primarily due to increased sales of sales of products labeled for diabetes and/or weight loss in the GLP-1 class,\nwhich have lower gross profit margins, and lower sales of government-owned C OVID-19 treatments, which have higher gross profit\nmargins, and a negative impact of foreign currency rates in comparison to the prior fiscal year.  On a constant currency basis,\nrevenue and adjusted operating income grew 10.9 percent and 6.0 percent, respectively.\n Recent Comp any Highlights & Milest ones\nCencora completed its name change from AmerisourceBergen and began trading under the ticker symbol \u201cC OR\u201d on the New\n4", "original_text": "Recent Comp any Highlights & Milest ones\nCencora completed its name change from AmerisourceBergen and began trading under the ticker symbol \u201cC OR\u201d on the New\n4"}, "hash": "5d54a6e4e734af7f48d178846e215304d2895afaa209ec38462f87ad8ebb5e2d", "class_name": "RelatedNodeInfo"}}, "text": "On a constant currency basis,\nrevenue and adjusted operating income grew 10.9 percent and 6.0 percent, respectively.\n", "start_char_idx": 2543, "end_char_idx": 2660, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9123c6e0-22af-44f5-8ddc-ccf3dd25ef28": {"__data__": {"id_": "9123c6e0-22af-44f5-8ddc-ccf3dd25ef28", "embedding": null, "metadata": {"window": "Adjusted operating income increased 4.0 percent to $3.3 billion due to increases in gross profit in both\nreportable segments, offset in part by increased operating expenses.  Adjusted operating income margin decreased by 8 basis points\nto 1.25 percent, primarily due to increased sales of sales of products labeled for diabetes and/or weight loss in the GLP-1 class,\nwhich have lower gross profit margins, and lower sales of government-owned C OVID-19 treatments, which have higher gross profit\nmargins, and a negative impact of foreign currency rates in comparison to the prior fiscal year.  On a constant currency basis,\nrevenue and adjusted operating income grew 10.9 percent and 6.0 percent, respectively.\n Recent Comp any Highlights & Milest ones\nCencora completed its name change from AmerisourceBergen and began trading under the ticker symbol \u201cC OR\u201d on the New\n4", "original_text": "Recent Comp any Highlights & Milest ones\nCencora completed its name change from AmerisourceBergen and began trading under the ticker symbol \u201cC OR\u201d on the New\n4", "page_label": "4", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8e5f2760-457b-40e5-a61e-1e4e45be6670", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d18904d15a84570bc399063d573c66e340fe992cd76a358f1983a6e01aaa7815", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9899eb1c-28ed-413f-a253-390b677c3f37", "node_type": "1", "metadata": {"window": "Adjusted operating expenses increased 9.2 percent to $5.7 billion primarily due to an increase in distribution, selling, and\nadministrative expenses.  Adjusted operating income increased 4.0 percent to $3.3 billion due to increases in gross profit in both\nreportable segments, offset in part by increased operating expenses.  Adjusted operating income margin decreased by 8 basis points\nto 1.25 percent, primarily due to increased sales of sales of products labeled for diabetes and/or weight loss in the GLP-1 class,\nwhich have lower gross profit margins, and lower sales of government-owned C OVID-19 treatments, which have higher gross profit\nmargins, and a negative impact of foreign currency rates in comparison to the prior fiscal year.  On a constant currency basis,\nrevenue and adjusted operating income grew 10.9 percent and 6.0 percent, respectively.\n Recent Comp any Highlights & Milest ones\nCencora completed its name change from AmerisourceBergen and began trading under the ticker symbol \u201cC OR\u201d on the New\n4", "original_text": "On a constant currency basis,\nrevenue and adjusted operating income grew 10.9 percent and 6.0 percent, respectively.\n", "page_label": "4", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f02deaa2106231d9348346aeda8461de5819b8f89e9799dbfff8ba3d860caef3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1aaff62b-c0f3-437e-91de-ac7a34422f60", "node_type": "1", "metadata": {"window": "York S tock Exchange on August 30, 2023.  The new name underscores Cencora's experience and vision when it comes to\nconnecting manufacturers, providers, pharmacies and patients, and ensuring the consistent, reliable flow of treatments to\nthose who need them at a time of growing complexity.\n Good Neighbor Pharmacy, Cencora's national independent pharmacy network, convened nearly 5,000 independent pharmacy\nowners and other partners to celebrate its annual ThoughtSpot tradeshow and conference.  The event showcased the\nextraordinary collaboration, commitment and perseverance of the Good Neighbor Pharmacy network of pharmacists\ndedicated to improving community health.\n", "original_text": "York S tock Exchange on August 30, 2023. "}, "hash": "dde2d584a47f94a0b676ae2850c6b5cb7ecbd38f05fd6684f5c689b32f3cff70", "class_name": "RelatedNodeInfo"}}, "text": "Recent Comp any Highlights & Milest ones\nCencora completed its name change from AmerisourceBergen and began trading under the ticker symbol \u201cC OR\u201d on the New\n4", "start_char_idx": 2660, "end_char_idx": 2819, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1aaff62b-c0f3-437e-91de-ac7a34422f60": {"__data__": {"id_": "1aaff62b-c0f3-437e-91de-ac7a34422f60", "embedding": null, "metadata": {"window": "York S tock Exchange on August 30, 2023.  The new name underscores Cencora's experience and vision when it comes to\nconnecting manufacturers, providers, pharmacies and patients, and ensuring the consistent, reliable flow of treatments to\nthose who need them at a time of growing complexity.\n Good Neighbor Pharmacy, Cencora's national independent pharmacy network, convened nearly 5,000 independent pharmacy\nowners and other partners to celebrate its annual ThoughtSpot tradeshow and conference.  The event showcased the\nextraordinary collaboration, commitment and perseverance of the Good Neighbor Pharmacy network of pharmacists\ndedicated to improving community health.\n", "original_text": "York S tock Exchange on August 30, 2023. ", "page_label": "5", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7021eca0-c10a-4441-addb-9b3d939e9002", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e911791c4b83e35d703be25839ee3ca91e7a1fc4836d0c645c62d4442711582d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9123c6e0-22af-44f5-8ddc-ccf3dd25ef28", "node_type": "1", "metadata": {"window": "Adjusted operating income increased 4.0 percent to $3.3 billion due to increases in gross profit in both\nreportable segments, offset in part by increased operating expenses.  Adjusted operating income margin decreased by 8 basis points\nto 1.25 percent, primarily due to increased sales of sales of products labeled for diabetes and/or weight loss in the GLP-1 class,\nwhich have lower gross profit margins, and lower sales of government-owned C OVID-19 treatments, which have higher gross profit\nmargins, and a negative impact of foreign currency rates in comparison to the prior fiscal year.  On a constant currency basis,\nrevenue and adjusted operating income grew 10.9 percent and 6.0 percent, respectively.\n Recent Comp any Highlights & Milest ones\nCencora completed its name change from AmerisourceBergen and began trading under the ticker symbol \u201cC OR\u201d on the New\n4", "original_text": "Recent Comp any Highlights & Milest ones\nCencora completed its name change from AmerisourceBergen and began trading under the ticker symbol \u201cC OR\u201d on the New\n4", "page_label": "4", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "56cff847620f0d755e5fb4d8e2f20e538b701f6585cd89573db930ca57e721f3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5da41669-b80c-4152-93af-2e075e09d67c", "node_type": "1", "metadata": {"window": "York S tock Exchange on August 30, 2023.  The new name underscores Cencora's experience and vision when it comes to\nconnecting manufacturers, providers, pharmacies and patients, and ensuring the consistent, reliable flow of treatments to\nthose who need them at a time of growing complexity.\n Good Neighbor Pharmacy, Cencora's national independent pharmacy network, convened nearly 5,000 independent pharmacy\nowners and other partners to celebrate its annual ThoughtSpot tradeshow and conference.  The event showcased the\nextraordinary collaboration, commitment and perseverance of the Good Neighbor Pharmacy network of pharmacists\ndedicated to improving community health.\n Dividend Declaration\nOn November 1, 2023, the Company's Board of Directors declared a quarterly dividend of $0.51 per common share, an increase in\nits quarterly dividend rate from $0.485 per common share. ", "original_text": "The new name underscores Cencora's experience and vision when it comes to\nconnecting manufacturers, providers, pharmacies and patients, and ensuring the consistent, reliable flow of treatments to\nthose who need them at a time of growing complexity.\n"}, "hash": "514b52d024ce87f1590c41c745a9bfa02f37bd45bc0318552c4270ad01f359a3", "class_name": "RelatedNodeInfo"}}, "text": "York S tock Exchange on August 30, 2023. ", "start_char_idx": 0, "end_char_idx": 41, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5da41669-b80c-4152-93af-2e075e09d67c": {"__data__": {"id_": "5da41669-b80c-4152-93af-2e075e09d67c", "embedding": null, "metadata": {"window": "York S tock Exchange on August 30, 2023.  The new name underscores Cencora's experience and vision when it comes to\nconnecting manufacturers, providers, pharmacies and patients, and ensuring the consistent, reliable flow of treatments to\nthose who need them at a time of growing complexity.\n Good Neighbor Pharmacy, Cencora's national independent pharmacy network, convened nearly 5,000 independent pharmacy\nowners and other partners to celebrate its annual ThoughtSpot tradeshow and conference.  The event showcased the\nextraordinary collaboration, commitment and perseverance of the Good Neighbor Pharmacy network of pharmacists\ndedicated to improving community health.\n Dividend Declaration\nOn November 1, 2023, the Company's Board of Directors declared a quarterly dividend of $0.51 per common share, an increase in\nits quarterly dividend rate from $0.485 per common share. ", "original_text": "The new name underscores Cencora's experience and vision when it comes to\nconnecting manufacturers, providers, pharmacies and patients, and ensuring the consistent, reliable flow of treatments to\nthose who need them at a time of growing complexity.\n", "page_label": "5", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7021eca0-c10a-4441-addb-9b3d939e9002", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e911791c4b83e35d703be25839ee3ca91e7a1fc4836d0c645c62d4442711582d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1aaff62b-c0f3-437e-91de-ac7a34422f60", "node_type": "1", "metadata": {"window": "York S tock Exchange on August 30, 2023.  The new name underscores Cencora's experience and vision when it comes to\nconnecting manufacturers, providers, pharmacies and patients, and ensuring the consistent, reliable flow of treatments to\nthose who need them at a time of growing complexity.\n Good Neighbor Pharmacy, Cencora's national independent pharmacy network, convened nearly 5,000 independent pharmacy\nowners and other partners to celebrate its annual ThoughtSpot tradeshow and conference.  The event showcased the\nextraordinary collaboration, commitment and perseverance of the Good Neighbor Pharmacy network of pharmacists\ndedicated to improving community health.\n", "original_text": "York S tock Exchange on August 30, 2023. ", "page_label": "5", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c5082e7686dec43a11aa9327f5ff61b6e3b7d9d2d85fb22bee0051d86d632850", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7c92cd3c-0d31-4e81-8289-ddd45669b851", "node_type": "1", "metadata": {"window": "York S tock Exchange on August 30, 2023.  The new name underscores Cencora's experience and vision when it comes to\nconnecting manufacturers, providers, pharmacies and patients, and ensuring the consistent, reliable flow of treatments to\nthose who need them at a time of growing complexity.\n Good Neighbor Pharmacy, Cencora's national independent pharmacy network, convened nearly 5,000 independent pharmacy\nowners and other partners to celebrate its annual ThoughtSpot tradeshow and conference.  The event showcased the\nextraordinary collaboration, commitment and perseverance of the Good Neighbor Pharmacy network of pharmacists\ndedicated to improving community health.\n Dividend Declaration\nOn November 1, 2023, the Company's Board of Directors declared a quarterly dividend of $0.51 per common share, an increase in\nits quarterly dividend rate from $0.485 per common share.  The quarterly dividend of $0.51 per common share will be payable\nNovember 27, 2023, to stockholders of record at the close of business on November 13, 2023.\n", "original_text": "Good Neighbor Pharmacy, Cencora's national independent pharmacy network, convened nearly 5,000 independent pharmacy\nowners and other partners to celebrate its annual ThoughtSpot tradeshow and conference. "}, "hash": "e1443120e05006a44a9f43ebf0fce078165fe97605a8d248d04f5c5a74f1fd76", "class_name": "RelatedNodeInfo"}}, "text": "The new name underscores Cencora's experience and vision when it comes to\nconnecting manufacturers, providers, pharmacies and patients, and ensuring the consistent, reliable flow of treatments to\nthose who need them at a time of growing complexity.\n", "start_char_idx": 41, "end_char_idx": 290, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7c92cd3c-0d31-4e81-8289-ddd45669b851": {"__data__": {"id_": "7c92cd3c-0d31-4e81-8289-ddd45669b851", "embedding": null, "metadata": {"window": "York S tock Exchange on August 30, 2023.  The new name underscores Cencora's experience and vision when it comes to\nconnecting manufacturers, providers, pharmacies and patients, and ensuring the consistent, reliable flow of treatments to\nthose who need them at a time of growing complexity.\n Good Neighbor Pharmacy, Cencora's national independent pharmacy network, convened nearly 5,000 independent pharmacy\nowners and other partners to celebrate its annual ThoughtSpot tradeshow and conference.  The event showcased the\nextraordinary collaboration, commitment and perseverance of the Good Neighbor Pharmacy network of pharmacists\ndedicated to improving community health.\n Dividend Declaration\nOn November 1, 2023, the Company's Board of Directors declared a quarterly dividend of $0.51 per common share, an increase in\nits quarterly dividend rate from $0.485 per common share.  The quarterly dividend of $0.51 per common share will be payable\nNovember 27, 2023, to stockholders of record at the close of business on November 13, 2023.\n", "original_text": "Good Neighbor Pharmacy, Cencora's national independent pharmacy network, convened nearly 5,000 independent pharmacy\nowners and other partners to celebrate its annual ThoughtSpot tradeshow and conference. ", "page_label": "5", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7021eca0-c10a-4441-addb-9b3d939e9002", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e911791c4b83e35d703be25839ee3ca91e7a1fc4836d0c645c62d4442711582d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5da41669-b80c-4152-93af-2e075e09d67c", "node_type": "1", "metadata": {"window": "York S tock Exchange on August 30, 2023.  The new name underscores Cencora's experience and vision when it comes to\nconnecting manufacturers, providers, pharmacies and patients, and ensuring the consistent, reliable flow of treatments to\nthose who need them at a time of growing complexity.\n Good Neighbor Pharmacy, Cencora's national independent pharmacy network, convened nearly 5,000 independent pharmacy\nowners and other partners to celebrate its annual ThoughtSpot tradeshow and conference.  The event showcased the\nextraordinary collaboration, commitment and perseverance of the Good Neighbor Pharmacy network of pharmacists\ndedicated to improving community health.\n Dividend Declaration\nOn November 1, 2023, the Company's Board of Directors declared a quarterly dividend of $0.51 per common share, an increase in\nits quarterly dividend rate from $0.485 per common share. ", "original_text": "The new name underscores Cencora's experience and vision when it comes to\nconnecting manufacturers, providers, pharmacies and patients, and ensuring the consistent, reliable flow of treatments to\nthose who need them at a time of growing complexity.\n", "page_label": "5", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "250ce2eedabbc49f6c9c577408df871635cf4404ff69a29786cddad461648df3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f0555b4c-b814-4525-adb1-503fe9cea80c", "node_type": "1", "metadata": {"window": "York S tock Exchange on August 30, 2023.  The new name underscores Cencora's experience and vision when it comes to\nconnecting manufacturers, providers, pharmacies and patients, and ensuring the consistent, reliable flow of treatments to\nthose who need them at a time of growing complexity.\n Good Neighbor Pharmacy, Cencora's national independent pharmacy network, convened nearly 5,000 independent pharmacy\nowners and other partners to celebrate its annual ThoughtSpot tradeshow and conference.  The event showcased the\nextraordinary collaboration, commitment and perseverance of the Good Neighbor Pharmacy network of pharmacists\ndedicated to improving community health.\n Dividend Declaration\nOn November 1, 2023, the Company's Board of Directors declared a quarterly dividend of $0.51 per common share, an increase in\nits quarterly dividend rate from $0.485 per common share.  The quarterly dividend of $0.51 per common share will be payable\nNovember 27, 2023, to stockholders of record at the close of business on November 13, 2023.\n Fiscal Y ear 2024 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available and cannot be reasonably estimated. ", "original_text": "The event showcased the\nextraordinary collaboration, commitment and perseverance of the Good Neighbor Pharmacy network of pharmacists\ndedicated to improving community health.\n"}, "hash": "5e781dbb73659f6f04c788a72adc41ead6529c707083c7473ad386152e8b815e", "class_name": "RelatedNodeInfo"}}, "text": "Good Neighbor Pharmacy, Cencora's national independent pharmacy network, convened nearly 5,000 independent pharmacy\nowners and other partners to celebrate its annual ThoughtSpot tradeshow and conference. ", "start_char_idx": 290, "end_char_idx": 494, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f0555b4c-b814-4525-adb1-503fe9cea80c": {"__data__": {"id_": "f0555b4c-b814-4525-adb1-503fe9cea80c", "embedding": null, "metadata": {"window": "York S tock Exchange on August 30, 2023.  The new name underscores Cencora's experience and vision when it comes to\nconnecting manufacturers, providers, pharmacies and patients, and ensuring the consistent, reliable flow of treatments to\nthose who need them at a time of growing complexity.\n Good Neighbor Pharmacy, Cencora's national independent pharmacy network, convened nearly 5,000 independent pharmacy\nowners and other partners to celebrate its annual ThoughtSpot tradeshow and conference.  The event showcased the\nextraordinary collaboration, commitment and perseverance of the Good Neighbor Pharmacy network of pharmacists\ndedicated to improving community health.\n Dividend Declaration\nOn November 1, 2023, the Company's Board of Directors declared a quarterly dividend of $0.51 per common share, an increase in\nits quarterly dividend rate from $0.485 per common share.  The quarterly dividend of $0.51 per common share will be payable\nNovember 27, 2023, to stockholders of record at the close of business on November 13, 2023.\n Fiscal Y ear 2024 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available and cannot be reasonably estimated. ", "original_text": "The event showcased the\nextraordinary collaboration, commitment and perseverance of the Good Neighbor Pharmacy network of pharmacists\ndedicated to improving community health.\n", "page_label": "5", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7021eca0-c10a-4441-addb-9b3d939e9002", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e911791c4b83e35d703be25839ee3ca91e7a1fc4836d0c645c62d4442711582d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7c92cd3c-0d31-4e81-8289-ddd45669b851", "node_type": "1", "metadata": {"window": "York S tock Exchange on August 30, 2023.  The new name underscores Cencora's experience and vision when it comes to\nconnecting manufacturers, providers, pharmacies and patients, and ensuring the consistent, reliable flow of treatments to\nthose who need them at a time of growing complexity.\n Good Neighbor Pharmacy, Cencora's national independent pharmacy network, convened nearly 5,000 independent pharmacy\nowners and other partners to celebrate its annual ThoughtSpot tradeshow and conference.  The event showcased the\nextraordinary collaboration, commitment and perseverance of the Good Neighbor Pharmacy network of pharmacists\ndedicated to improving community health.\n Dividend Declaration\nOn November 1, 2023, the Company's Board of Directors declared a quarterly dividend of $0.51 per common share, an increase in\nits quarterly dividend rate from $0.485 per common share.  The quarterly dividend of $0.51 per common share will be payable\nNovember 27, 2023, to stockholders of record at the close of business on November 13, 2023.\n", "original_text": "Good Neighbor Pharmacy, Cencora's national independent pharmacy network, convened nearly 5,000 independent pharmacy\nowners and other partners to celebrate its annual ThoughtSpot tradeshow and conference. ", "page_label": "5", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "067c137397a446d29da9e31d092ab87e1e4d1513a810e5698cbd797b8e5b278c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "af8ad45f-afbb-40a7-a712-322dc752edfc", "node_type": "1", "metadata": {"window": "The new name underscores Cencora's experience and vision when it comes to\nconnecting manufacturers, providers, pharmacies and patients, and ensuring the consistent, reliable flow of treatments to\nthose who need them at a time of growing complexity.\n Good Neighbor Pharmacy, Cencora's national independent pharmacy network, convened nearly 5,000 independent pharmacy\nowners and other partners to celebrate its annual ThoughtSpot tradeshow and conference.  The event showcased the\nextraordinary collaboration, commitment and perseverance of the Good Neighbor Pharmacy network of pharmacists\ndedicated to improving community health.\n Dividend Declaration\nOn November 1, 2023, the Company's Board of Directors declared a quarterly dividend of $0.51 per common share, an increase in\nits quarterly dividend rate from $0.485 per common share.  The quarterly dividend of $0.51 per common share will be payable\nNovember 27, 2023, to stockholders of record at the close of business on November 13, 2023.\n Fiscal Y ear 2024 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available and cannot be reasonably estimated.  Please refer to the Supplemental\nInformation R egarding Non-GAAP Financial Measures following the tables for additional information.\n", "original_text": "Dividend Declaration\nOn November 1, 2023, the Company's Board of Directors declared a quarterly dividend of $0.51 per common share, an increase in\nits quarterly dividend rate from $0.485 per common share. "}, "hash": "b0d170421cfd5a41aa2848731a0c3c0f5d36ac58f3a1fa539c664a656d99dbbc", "class_name": "RelatedNodeInfo"}}, "text": "The event showcased the\nextraordinary collaboration, commitment and perseverance of the Good Neighbor Pharmacy network of pharmacists\ndedicated to improving community health.\n", "start_char_idx": 494, "end_char_idx": 669, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "af8ad45f-afbb-40a7-a712-322dc752edfc": {"__data__": {"id_": "af8ad45f-afbb-40a7-a712-322dc752edfc", "embedding": null, "metadata": {"window": "The new name underscores Cencora's experience and vision when it comes to\nconnecting manufacturers, providers, pharmacies and patients, and ensuring the consistent, reliable flow of treatments to\nthose who need them at a time of growing complexity.\n Good Neighbor Pharmacy, Cencora's national independent pharmacy network, convened nearly 5,000 independent pharmacy\nowners and other partners to celebrate its annual ThoughtSpot tradeshow and conference.  The event showcased the\nextraordinary collaboration, commitment and perseverance of the Good Neighbor Pharmacy network of pharmacists\ndedicated to improving community health.\n Dividend Declaration\nOn November 1, 2023, the Company's Board of Directors declared a quarterly dividend of $0.51 per common share, an increase in\nits quarterly dividend rate from $0.485 per common share.  The quarterly dividend of $0.51 per common share will be payable\nNovember 27, 2023, to stockholders of record at the close of business on November 13, 2023.\n Fiscal Y ear 2024 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available and cannot be reasonably estimated.  Please refer to the Supplemental\nInformation R egarding Non-GAAP Financial Measures following the tables for additional information.\n", "original_text": "Dividend Declaration\nOn November 1, 2023, the Company's Board of Directors declared a quarterly dividend of $0.51 per common share, an increase in\nits quarterly dividend rate from $0.485 per common share. ", "page_label": "5", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7021eca0-c10a-4441-addb-9b3d939e9002", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e911791c4b83e35d703be25839ee3ca91e7a1fc4836d0c645c62d4442711582d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f0555b4c-b814-4525-adb1-503fe9cea80c", "node_type": "1", "metadata": {"window": "York S tock Exchange on August 30, 2023.  The new name underscores Cencora's experience and vision when it comes to\nconnecting manufacturers, providers, pharmacies and patients, and ensuring the consistent, reliable flow of treatments to\nthose who need them at a time of growing complexity.\n Good Neighbor Pharmacy, Cencora's national independent pharmacy network, convened nearly 5,000 independent pharmacy\nowners and other partners to celebrate its annual ThoughtSpot tradeshow and conference.  The event showcased the\nextraordinary collaboration, commitment and perseverance of the Good Neighbor Pharmacy network of pharmacists\ndedicated to improving community health.\n Dividend Declaration\nOn November 1, 2023, the Company's Board of Directors declared a quarterly dividend of $0.51 per common share, an increase in\nits quarterly dividend rate from $0.485 per common share.  The quarterly dividend of $0.51 per common share will be payable\nNovember 27, 2023, to stockholders of record at the close of business on November 13, 2023.\n Fiscal Y ear 2024 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available and cannot be reasonably estimated. ", "original_text": "The event showcased the\nextraordinary collaboration, commitment and perseverance of the Good Neighbor Pharmacy network of pharmacists\ndedicated to improving community health.\n", "page_label": "5", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5fe67616e07981c9f4de5a7c51d0a487a67f9fab6419f2e1ad44167be36d108e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6d522625-770c-411f-b56d-5a7f64c4cae7", "node_type": "1", "metadata": {"window": "Good Neighbor Pharmacy, Cencora's national independent pharmacy network, convened nearly 5,000 independent pharmacy\nowners and other partners to celebrate its annual ThoughtSpot tradeshow and conference.  The event showcased the\nextraordinary collaboration, commitment and perseverance of the Good Neighbor Pharmacy network of pharmacists\ndedicated to improving community health.\n Dividend Declaration\nOn November 1, 2023, the Company's Board of Directors declared a quarterly dividend of $0.51 per common share, an increase in\nits quarterly dividend rate from $0.485 per common share.  The quarterly dividend of $0.51 per common share will be payable\nNovember 27, 2023, to stockholders of record at the close of business on November 13, 2023.\n Fiscal Y ear 2024 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available and cannot be reasonably estimated.  Please refer to the Supplemental\nInformation R egarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2024 Expectations on an Adjust ed (non-GAAP) Basis\nCencora has introduced its fiscal year 2024 financial guidance. ", "original_text": "The quarterly dividend of $0.51 per common share will be payable\nNovember 27, 2023, to stockholders of record at the close of business on November 13, 2023.\n"}, "hash": "5a4ba1f80eec5d4a28782ba106abb2511c1177f2b83887d5d534020a3438c13a", "class_name": "RelatedNodeInfo"}}, "text": "Dividend Declaration\nOn November 1, 2023, the Company's Board of Directors declared a quarterly dividend of $0.51 per common share, an increase in\nits quarterly dividend rate from $0.485 per common share. ", "start_char_idx": 669, "end_char_idx": 874, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6d522625-770c-411f-b56d-5a7f64c4cae7": {"__data__": {"id_": "6d522625-770c-411f-b56d-5a7f64c4cae7", "embedding": null, "metadata": {"window": "Good Neighbor Pharmacy, Cencora's national independent pharmacy network, convened nearly 5,000 independent pharmacy\nowners and other partners to celebrate its annual ThoughtSpot tradeshow and conference.  The event showcased the\nextraordinary collaboration, commitment and perseverance of the Good Neighbor Pharmacy network of pharmacists\ndedicated to improving community health.\n Dividend Declaration\nOn November 1, 2023, the Company's Board of Directors declared a quarterly dividend of $0.51 per common share, an increase in\nits quarterly dividend rate from $0.485 per common share.  The quarterly dividend of $0.51 per common share will be payable\nNovember 27, 2023, to stockholders of record at the close of business on November 13, 2023.\n Fiscal Y ear 2024 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available and cannot be reasonably estimated.  Please refer to the Supplemental\nInformation R egarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2024 Expectations on an Adjust ed (non-GAAP) Basis\nCencora has introduced its fiscal year 2024 financial guidance. ", "original_text": "The quarterly dividend of $0.51 per common share will be payable\nNovember 27, 2023, to stockholders of record at the close of business on November 13, 2023.\n", "page_label": "5", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7021eca0-c10a-4441-addb-9b3d939e9002", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e911791c4b83e35d703be25839ee3ca91e7a1fc4836d0c645c62d4442711582d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "af8ad45f-afbb-40a7-a712-322dc752edfc", "node_type": "1", "metadata": {"window": "The new name underscores Cencora's experience and vision when it comes to\nconnecting manufacturers, providers, pharmacies and patients, and ensuring the consistent, reliable flow of treatments to\nthose who need them at a time of growing complexity.\n Good Neighbor Pharmacy, Cencora's national independent pharmacy network, convened nearly 5,000 independent pharmacy\nowners and other partners to celebrate its annual ThoughtSpot tradeshow and conference.  The event showcased the\nextraordinary collaboration, commitment and perseverance of the Good Neighbor Pharmacy network of pharmacists\ndedicated to improving community health.\n Dividend Declaration\nOn November 1, 2023, the Company's Board of Directors declared a quarterly dividend of $0.51 per common share, an increase in\nits quarterly dividend rate from $0.485 per common share.  The quarterly dividend of $0.51 per common share will be payable\nNovember 27, 2023, to stockholders of record at the close of business on November 13, 2023.\n Fiscal Y ear 2024 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available and cannot be reasonably estimated.  Please refer to the Supplemental\nInformation R egarding Non-GAAP Financial Measures following the tables for additional information.\n", "original_text": "Dividend Declaration\nOn November 1, 2023, the Company's Board of Directors declared a quarterly dividend of $0.51 per common share, an increase in\nits quarterly dividend rate from $0.485 per common share. ", "page_label": "5", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "843906116bc9e2f3efef9e2dfa05604d2bc3899281adbc0378eff0fa9ea99af4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c7d6bb0f-dc03-4e33-951b-51326bccdbba", "node_type": "1", "metadata": {"window": "The event showcased the\nextraordinary collaboration, commitment and perseverance of the Good Neighbor Pharmacy network of pharmacists\ndedicated to improving community health.\n Dividend Declaration\nOn November 1, 2023, the Company's Board of Directors declared a quarterly dividend of $0.51 per common share, an increase in\nits quarterly dividend rate from $0.485 per common share.  The quarterly dividend of $0.51 per common share will be payable\nNovember 27, 2023, to stockholders of record at the close of business on November 13, 2023.\n Fiscal Y ear 2024 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available and cannot be reasonably estimated.  Please refer to the Supplemental\nInformation R egarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2024 Expectations on an Adjust ed (non-GAAP) Basis\nCencora has introduced its fiscal year 2024 financial guidance.  The Company continues to provide \"ex-C OVID\" growth guidance to\nnormalize for contributions related to exclusive C OVID products, which are government-owned treatments. ", "original_text": "Fiscal Y ear 2024 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available and cannot be reasonably estimated. "}, "hash": "9c1bfcf4a66c46f1a65bac490fa196d7e2805ec6c43714f76ca69f67c374966e", "class_name": "RelatedNodeInfo"}}, "text": "The quarterly dividend of $0.51 per common share will be payable\nNovember 27, 2023, to stockholders of record at the close of business on November 13, 2023.\n", "start_char_idx": 874, "end_char_idx": 1031, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c7d6bb0f-dc03-4e33-951b-51326bccdbba": {"__data__": {"id_": "c7d6bb0f-dc03-4e33-951b-51326bccdbba", "embedding": null, "metadata": {"window": "The event showcased the\nextraordinary collaboration, commitment and perseverance of the Good Neighbor Pharmacy network of pharmacists\ndedicated to improving community health.\n Dividend Declaration\nOn November 1, 2023, the Company's Board of Directors declared a quarterly dividend of $0.51 per common share, an increase in\nits quarterly dividend rate from $0.485 per common share.  The quarterly dividend of $0.51 per common share will be payable\nNovember 27, 2023, to stockholders of record at the close of business on November 13, 2023.\n Fiscal Y ear 2024 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available and cannot be reasonably estimated.  Please refer to the Supplemental\nInformation R egarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2024 Expectations on an Adjust ed (non-GAAP) Basis\nCencora has introduced its fiscal year 2024 financial guidance.  The Company continues to provide \"ex-C OVID\" growth guidance to\nnormalize for contributions related to exclusive C OVID products, which are government-owned treatments. ", "original_text": "Fiscal Y ear 2024 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available and cannot be reasonably estimated. ", "page_label": "5", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7021eca0-c10a-4441-addb-9b3d939e9002", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e911791c4b83e35d703be25839ee3ca91e7a1fc4836d0c645c62d4442711582d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6d522625-770c-411f-b56d-5a7f64c4cae7", "node_type": "1", "metadata": {"window": "Good Neighbor Pharmacy, Cencora's national independent pharmacy network, convened nearly 5,000 independent pharmacy\nowners and other partners to celebrate its annual ThoughtSpot tradeshow and conference.  The event showcased the\nextraordinary collaboration, commitment and perseverance of the Good Neighbor Pharmacy network of pharmacists\ndedicated to improving community health.\n Dividend Declaration\nOn November 1, 2023, the Company's Board of Directors declared a quarterly dividend of $0.51 per common share, an increase in\nits quarterly dividend rate from $0.485 per common share.  The quarterly dividend of $0.51 per common share will be payable\nNovember 27, 2023, to stockholders of record at the close of business on November 13, 2023.\n Fiscal Y ear 2024 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available and cannot be reasonably estimated.  Please refer to the Supplemental\nInformation R egarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2024 Expectations on an Adjust ed (non-GAAP) Basis\nCencora has introduced its fiscal year 2024 financial guidance. ", "original_text": "The quarterly dividend of $0.51 per common share will be payable\nNovember 27, 2023, to stockholders of record at the close of business on November 13, 2023.\n", "page_label": "5", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9a32309b8a50d76999c4cc8c25ceb4d8f450561876f940a4da53ed30e848e156", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ebabf343-3bed-421e-8343-38a689291029", "node_type": "1", "metadata": {"window": "Dividend Declaration\nOn November 1, 2023, the Company's Board of Directors declared a quarterly dividend of $0.51 per common share, an increase in\nits quarterly dividend rate from $0.485 per common share.  The quarterly dividend of $0.51 per common share will be payable\nNovember 27, 2023, to stockholders of record at the close of business on November 13, 2023.\n Fiscal Y ear 2024 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available and cannot be reasonably estimated.  Please refer to the Supplemental\nInformation R egarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2024 Expectations on an Adjust ed (non-GAAP) Basis\nCencora has introduced its fiscal year 2024 financial guidance.  The Company continues to provide \"ex-C OVID\" growth guidance to\nnormalize for contributions related to exclusive C OVID products, which are government-owned treatments.  The Company does not\nexpect a material contribution from exclusive C OVID products beyond the fiscal 2024 first quarter. ", "original_text": "Please refer to the Supplemental\nInformation R egarding Non-GAAP Financial Measures following the tables for additional information.\n"}, "hash": "1bc02f597604fae420fe6d96e96ac8bf5978e00e9bb65f5245644882ac010a9c", "class_name": "RelatedNodeInfo"}}, "text": "Fiscal Y ear 2024 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available and cannot be reasonably estimated. ", "start_char_idx": 1031, "end_char_idx": 1276, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ebabf343-3bed-421e-8343-38a689291029": {"__data__": {"id_": "ebabf343-3bed-421e-8343-38a689291029", "embedding": null, "metadata": {"window": "Dividend Declaration\nOn November 1, 2023, the Company's Board of Directors declared a quarterly dividend of $0.51 per common share, an increase in\nits quarterly dividend rate from $0.485 per common share.  The quarterly dividend of $0.51 per common share will be payable\nNovember 27, 2023, to stockholders of record at the close of business on November 13, 2023.\n Fiscal Y ear 2024 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available and cannot be reasonably estimated.  Please refer to the Supplemental\nInformation R egarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2024 Expectations on an Adjust ed (non-GAAP) Basis\nCencora has introduced its fiscal year 2024 financial guidance.  The Company continues to provide \"ex-C OVID\" growth guidance to\nnormalize for contributions related to exclusive C OVID products, which are government-owned treatments.  The Company does not\nexpect a material contribution from exclusive C OVID products beyond the fiscal 2024 first quarter. ", "original_text": "Please refer to the Supplemental\nInformation R egarding Non-GAAP Financial Measures following the tables for additional information.\n", "page_label": "5", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7021eca0-c10a-4441-addb-9b3d939e9002", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e911791c4b83e35d703be25839ee3ca91e7a1fc4836d0c645c62d4442711582d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c7d6bb0f-dc03-4e33-951b-51326bccdbba", "node_type": "1", "metadata": {"window": "The event showcased the\nextraordinary collaboration, commitment and perseverance of the Good Neighbor Pharmacy network of pharmacists\ndedicated to improving community health.\n Dividend Declaration\nOn November 1, 2023, the Company's Board of Directors declared a quarterly dividend of $0.51 per common share, an increase in\nits quarterly dividend rate from $0.485 per common share.  The quarterly dividend of $0.51 per common share will be payable\nNovember 27, 2023, to stockholders of record at the close of business on November 13, 2023.\n Fiscal Y ear 2024 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available and cannot be reasonably estimated.  Please refer to the Supplemental\nInformation R egarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2024 Expectations on an Adjust ed (non-GAAP) Basis\nCencora has introduced its fiscal year 2024 financial guidance.  The Company continues to provide \"ex-C OVID\" growth guidance to\nnormalize for contributions related to exclusive C OVID products, which are government-owned treatments. ", "original_text": "Fiscal Y ear 2024 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available and cannot be reasonably estimated. ", "page_label": "5", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cf30d3e7acbf39594846680bc32200e9f1d6b33823eb48ed020b51e8691e0698", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "593f5a56-e89b-414f-8b0c-c5172d09fe1b", "node_type": "1", "metadata": {"window": "The quarterly dividend of $0.51 per common share will be payable\nNovember 27, 2023, to stockholders of record at the close of business on November 13, 2023.\n Fiscal Y ear 2024 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available and cannot be reasonably estimated.  Please refer to the Supplemental\nInformation R egarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2024 Expectations on an Adjust ed (non-GAAP) Basis\nCencora has introduced its fiscal year 2024 financial guidance.  The Company continues to provide \"ex-C OVID\" growth guidance to\nnormalize for contributions related to exclusive C OVID products, which are government-owned treatments.  The Company does not\nexpect a material contribution from exclusive C OVID products beyond the fiscal 2024 first quarter.  Commercial C OVID products,\nincluding newly commercial C OVID vaccines, are not excluded. ", "original_text": "Fiscal Y ear 2024 Expectations on an Adjust ed (non-GAAP) Basis\nCencora has introduced its fiscal year 2024 financial guidance. "}, "hash": "49b9f4709d375b580858a215f6e2235d66d719b29a32aa2be67ada047bbc1ec9", "class_name": "RelatedNodeInfo"}}, "text": "Please refer to the Supplemental\nInformation R egarding Non-GAAP Financial Measures following the tables for additional information.\n", "start_char_idx": 1276, "end_char_idx": 1409, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "593f5a56-e89b-414f-8b0c-c5172d09fe1b": {"__data__": {"id_": "593f5a56-e89b-414f-8b0c-c5172d09fe1b", "embedding": null, "metadata": {"window": "The quarterly dividend of $0.51 per common share will be payable\nNovember 27, 2023, to stockholders of record at the close of business on November 13, 2023.\n Fiscal Y ear 2024 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available and cannot be reasonably estimated.  Please refer to the Supplemental\nInformation R egarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2024 Expectations on an Adjust ed (non-GAAP) Basis\nCencora has introduced its fiscal year 2024 financial guidance.  The Company continues to provide \"ex-C OVID\" growth guidance to\nnormalize for contributions related to exclusive C OVID products, which are government-owned treatments.  The Company does not\nexpect a material contribution from exclusive C OVID products beyond the fiscal 2024 first quarter.  Commercial C OVID products,\nincluding newly commercial C OVID vaccines, are not excluded. ", "original_text": "Fiscal Y ear 2024 Expectations on an Adjust ed (non-GAAP) Basis\nCencora has introduced its fiscal year 2024 financial guidance. ", "page_label": "5", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7021eca0-c10a-4441-addb-9b3d939e9002", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e911791c4b83e35d703be25839ee3ca91e7a1fc4836d0c645c62d4442711582d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ebabf343-3bed-421e-8343-38a689291029", "node_type": "1", "metadata": {"window": "Dividend Declaration\nOn November 1, 2023, the Company's Board of Directors declared a quarterly dividend of $0.51 per common share, an increase in\nits quarterly dividend rate from $0.485 per common share.  The quarterly dividend of $0.51 per common share will be payable\nNovember 27, 2023, to stockholders of record at the close of business on November 13, 2023.\n Fiscal Y ear 2024 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available and cannot be reasonably estimated.  Please refer to the Supplemental\nInformation R egarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2024 Expectations on an Adjust ed (non-GAAP) Basis\nCencora has introduced its fiscal year 2024 financial guidance.  The Company continues to provide \"ex-C OVID\" growth guidance to\nnormalize for contributions related to exclusive C OVID products, which are government-owned treatments.  The Company does not\nexpect a material contribution from exclusive C OVID products beyond the fiscal 2024 first quarter. ", "original_text": "Please refer to the Supplemental\nInformation R egarding Non-GAAP Financial Measures following the tables for additional information.\n", "page_label": "5", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "569348c56daaf775636a6b33e0b0a70ef494549cb4677e87ffd05e2b0dc6c888", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6d25a7d1-bea9-4282-a236-0a4d93b064fd", "node_type": "1", "metadata": {"window": "Fiscal Y ear 2024 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available and cannot be reasonably estimated.  Please refer to the Supplemental\nInformation R egarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2024 Expectations on an Adjust ed (non-GAAP) Basis\nCencora has introduced its fiscal year 2024 financial guidance.  The Company continues to provide \"ex-C OVID\" growth guidance to\nnormalize for contributions related to exclusive C OVID products, which are government-owned treatments.  The Company does not\nexpect a material contribution from exclusive C OVID products beyond the fiscal 2024 first quarter.  Commercial C OVID products,\nincluding newly commercial C OVID vaccines, are not excluded.  The Company expects:\nRevenue growth to be in the range of 7 to 10 percent;\nOn a constant currency basis, revenue growth to be in the range of 7 to 10 percent;\nU.S. ", "original_text": "The Company continues to provide \"ex-C OVID\" growth guidance to\nnormalize for contributions related to exclusive C OVID products, which are government-owned treatments. "}, "hash": "ace9dbf347a97ada15da26dfe751be998c3a63bd58148d762d29cf30994f5adb", "class_name": "RelatedNodeInfo"}}, "text": "Fiscal Y ear 2024 Expectations on an Adjust ed (non-GAAP) Basis\nCencora has introduced its fiscal year 2024 financial guidance. ", "start_char_idx": 1409, "end_char_idx": 1537, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6d25a7d1-bea9-4282-a236-0a4d93b064fd": {"__data__": {"id_": "6d25a7d1-bea9-4282-a236-0a4d93b064fd", "embedding": null, "metadata": {"window": "Fiscal Y ear 2024 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available and cannot be reasonably estimated.  Please refer to the Supplemental\nInformation R egarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2024 Expectations on an Adjust ed (non-GAAP) Basis\nCencora has introduced its fiscal year 2024 financial guidance.  The Company continues to provide \"ex-C OVID\" growth guidance to\nnormalize for contributions related to exclusive C OVID products, which are government-owned treatments.  The Company does not\nexpect a material contribution from exclusive C OVID products beyond the fiscal 2024 first quarter.  Commercial C OVID products,\nincluding newly commercial C OVID vaccines, are not excluded.  The Company expects:\nRevenue growth to be in the range of 7 to 10 percent;\nOn a constant currency basis, revenue growth to be in the range of 7 to 10 percent;\nU.S. ", "original_text": "The Company continues to provide \"ex-C OVID\" growth guidance to\nnormalize for contributions related to exclusive C OVID products, which are government-owned treatments. ", "page_label": "5", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7021eca0-c10a-4441-addb-9b3d939e9002", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e911791c4b83e35d703be25839ee3ca91e7a1fc4836d0c645c62d4442711582d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "593f5a56-e89b-414f-8b0c-c5172d09fe1b", "node_type": "1", "metadata": {"window": "The quarterly dividend of $0.51 per common share will be payable\nNovember 27, 2023, to stockholders of record at the close of business on November 13, 2023.\n Fiscal Y ear 2024 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available and cannot be reasonably estimated.  Please refer to the Supplemental\nInformation R egarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2024 Expectations on an Adjust ed (non-GAAP) Basis\nCencora has introduced its fiscal year 2024 financial guidance.  The Company continues to provide \"ex-C OVID\" growth guidance to\nnormalize for contributions related to exclusive C OVID products, which are government-owned treatments.  The Company does not\nexpect a material contribution from exclusive C OVID products beyond the fiscal 2024 first quarter.  Commercial C OVID products,\nincluding newly commercial C OVID vaccines, are not excluded. ", "original_text": "Fiscal Y ear 2024 Expectations on an Adjust ed (non-GAAP) Basis\nCencora has introduced its fiscal year 2024 financial guidance. ", "page_label": "5", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f4a56bc089020c7cbbe6c31e32444a241943a9460a8e715bb0e52133fb52309c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "650ec3b3-e222-4d07-ac94-dc21fa6d165e", "node_type": "1", "metadata": {"window": "Please refer to the Supplemental\nInformation R egarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2024 Expectations on an Adjust ed (non-GAAP) Basis\nCencora has introduced its fiscal year 2024 financial guidance.  The Company continues to provide \"ex-C OVID\" growth guidance to\nnormalize for contributions related to exclusive C OVID products, which are government-owned treatments.  The Company does not\nexpect a material contribution from exclusive C OVID products beyond the fiscal 2024 first quarter.  Commercial C OVID products,\nincluding newly commercial C OVID vaccines, are not excluded.  The Company expects:\nRevenue growth to be in the range of 7 to 10 percent;\nOn a constant currency basis, revenue growth to be in the range of 7 to 10 percent;\nU.S.  Healthcare Solutions revenue growth to be in the range of 7 to 10 percent;\nInternational Healthcare Solutions revenue growth to be in the range of 4 to 8 percent;\nInternational Healthcare Solutions constant currency revenue growth to be in the range of 7 to 11 percent;\nAdjusted diluted earnings per share to be in the range of $12.70 to $13.00.\n", "original_text": "The Company does not\nexpect a material contribution from exclusive C OVID products beyond the fiscal 2024 first quarter. "}, "hash": "7df051d61afe2214b5155a91a61e7b80ba8b5bc2769683486952ab059d4571fb", "class_name": "RelatedNodeInfo"}}, "text": "The Company continues to provide \"ex-C OVID\" growth guidance to\nnormalize for contributions related to exclusive C OVID products, which are government-owned treatments. ", "start_char_idx": 1537, "end_char_idx": 1706, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "650ec3b3-e222-4d07-ac94-dc21fa6d165e": {"__data__": {"id_": "650ec3b3-e222-4d07-ac94-dc21fa6d165e", "embedding": null, "metadata": {"window": "Please refer to the Supplemental\nInformation R egarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2024 Expectations on an Adjust ed (non-GAAP) Basis\nCencora has introduced its fiscal year 2024 financial guidance.  The Company continues to provide \"ex-C OVID\" growth guidance to\nnormalize for contributions related to exclusive C OVID products, which are government-owned treatments.  The Company does not\nexpect a material contribution from exclusive C OVID products beyond the fiscal 2024 first quarter.  Commercial C OVID products,\nincluding newly commercial C OVID vaccines, are not excluded.  The Company expects:\nRevenue growth to be in the range of 7 to 10 percent;\nOn a constant currency basis, revenue growth to be in the range of 7 to 10 percent;\nU.S.  Healthcare Solutions revenue growth to be in the range of 7 to 10 percent;\nInternational Healthcare Solutions revenue growth to be in the range of 4 to 8 percent;\nInternational Healthcare Solutions constant currency revenue growth to be in the range of 7 to 11 percent;\nAdjusted diluted earnings per share to be in the range of $12.70 to $13.00.\n", "original_text": "The Company does not\nexpect a material contribution from exclusive C OVID products beyond the fiscal 2024 first quarter. ", "page_label": "5", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7021eca0-c10a-4441-addb-9b3d939e9002", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e911791c4b83e35d703be25839ee3ca91e7a1fc4836d0c645c62d4442711582d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6d25a7d1-bea9-4282-a236-0a4d93b064fd", "node_type": "1", "metadata": {"window": "Fiscal Y ear 2024 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available and cannot be reasonably estimated.  Please refer to the Supplemental\nInformation R egarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2024 Expectations on an Adjust ed (non-GAAP) Basis\nCencora has introduced its fiscal year 2024 financial guidance.  The Company continues to provide \"ex-C OVID\" growth guidance to\nnormalize for contributions related to exclusive C OVID products, which are government-owned treatments.  The Company does not\nexpect a material contribution from exclusive C OVID products beyond the fiscal 2024 first quarter.  Commercial C OVID products,\nincluding newly commercial C OVID vaccines, are not excluded.  The Company expects:\nRevenue growth to be in the range of 7 to 10 percent;\nOn a constant currency basis, revenue growth to be in the range of 7 to 10 percent;\nU.S. ", "original_text": "The Company continues to provide \"ex-C OVID\" growth guidance to\nnormalize for contributions related to exclusive C OVID products, which are government-owned treatments. ", "page_label": "5", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a97c980a255de94ac8609cfa159e65aadd81fa6ecdbdeb5dfc75aeb379f0510f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ec4747f5-1878-4e7b-9572-08ed0e5af519", "node_type": "1", "metadata": {"window": "Fiscal Y ear 2024 Expectations on an Adjust ed (non-GAAP) Basis\nCencora has introduced its fiscal year 2024 financial guidance.  The Company continues to provide \"ex-C OVID\" growth guidance to\nnormalize for contributions related to exclusive C OVID products, which are government-owned treatments.  The Company does not\nexpect a material contribution from exclusive C OVID products beyond the fiscal 2024 first quarter.  Commercial C OVID products,\nincluding newly commercial C OVID vaccines, are not excluded.  The Company expects:\nRevenue growth to be in the range of 7 to 10 percent;\nOn a constant currency basis, revenue growth to be in the range of 7 to 10 percent;\nU.S.  Healthcare Solutions revenue growth to be in the range of 7 to 10 percent;\nInternational Healthcare Solutions revenue growth to be in the range of 4 to 8 percent;\nInternational Healthcare Solutions constant currency revenue growth to be in the range of 7 to 11 percent;\nAdjusted diluted earnings per share to be in the range of $12.70 to $13.00.\n Additional expectations include:\nAdjusted operating income growth to be in the range of 4 to 6 percent;\nOn a constant currency basis, adjusted operating income growth to be in the range of 5 to 7 percent;\nExcluding contributions related to C OVID-19, adjusted operating income growth to be in the range of 7 to 9 percent;\nOn a constant currency basis, excluding contributions related to C OVID-19, adjusted operating income growth\nto be in the range of 8 to 10 percent;\nU.S. ", "original_text": "Commercial C OVID products,\nincluding newly commercial C OVID vaccines, are not excluded. "}, "hash": "034c9bb56c3d6d218e94265b8270deba1bdd4b050580931d277c43357337b26b", "class_name": "RelatedNodeInfo"}}, "text": "The Company does not\nexpect a material contribution from exclusive C OVID products beyond the fiscal 2024 first quarter. ", "start_char_idx": 1706, "end_char_idx": 1827, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ec4747f5-1878-4e7b-9572-08ed0e5af519": {"__data__": {"id_": "ec4747f5-1878-4e7b-9572-08ed0e5af519", "embedding": null, "metadata": {"window": "Fiscal Y ear 2024 Expectations on an Adjust ed (non-GAAP) Basis\nCencora has introduced its fiscal year 2024 financial guidance.  The Company continues to provide \"ex-C OVID\" growth guidance to\nnormalize for contributions related to exclusive C OVID products, which are government-owned treatments.  The Company does not\nexpect a material contribution from exclusive C OVID products beyond the fiscal 2024 first quarter.  Commercial C OVID products,\nincluding newly commercial C OVID vaccines, are not excluded.  The Company expects:\nRevenue growth to be in the range of 7 to 10 percent;\nOn a constant currency basis, revenue growth to be in the range of 7 to 10 percent;\nU.S.  Healthcare Solutions revenue growth to be in the range of 7 to 10 percent;\nInternational Healthcare Solutions revenue growth to be in the range of 4 to 8 percent;\nInternational Healthcare Solutions constant currency revenue growth to be in the range of 7 to 11 percent;\nAdjusted diluted earnings per share to be in the range of $12.70 to $13.00.\n Additional expectations include:\nAdjusted operating income growth to be in the range of 4 to 6 percent;\nOn a constant currency basis, adjusted operating income growth to be in the range of 5 to 7 percent;\nExcluding contributions related to C OVID-19, adjusted operating income growth to be in the range of 7 to 9 percent;\nOn a constant currency basis, excluding contributions related to C OVID-19, adjusted operating income growth\nto be in the range of 8 to 10 percent;\nU.S. ", "original_text": "Commercial C OVID products,\nincluding newly commercial C OVID vaccines, are not excluded. ", "page_label": "5", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7021eca0-c10a-4441-addb-9b3d939e9002", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e911791c4b83e35d703be25839ee3ca91e7a1fc4836d0c645c62d4442711582d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "650ec3b3-e222-4d07-ac94-dc21fa6d165e", "node_type": "1", "metadata": {"window": "Please refer to the Supplemental\nInformation R egarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2024 Expectations on an Adjust ed (non-GAAP) Basis\nCencora has introduced its fiscal year 2024 financial guidance.  The Company continues to provide \"ex-C OVID\" growth guidance to\nnormalize for contributions related to exclusive C OVID products, which are government-owned treatments.  The Company does not\nexpect a material contribution from exclusive C OVID products beyond the fiscal 2024 first quarter.  Commercial C OVID products,\nincluding newly commercial C OVID vaccines, are not excluded.  The Company expects:\nRevenue growth to be in the range of 7 to 10 percent;\nOn a constant currency basis, revenue growth to be in the range of 7 to 10 percent;\nU.S.  Healthcare Solutions revenue growth to be in the range of 7 to 10 percent;\nInternational Healthcare Solutions revenue growth to be in the range of 4 to 8 percent;\nInternational Healthcare Solutions constant currency revenue growth to be in the range of 7 to 11 percent;\nAdjusted diluted earnings per share to be in the range of $12.70 to $13.00.\n", "original_text": "The Company does not\nexpect a material contribution from exclusive C OVID products beyond the fiscal 2024 first quarter. ", "page_label": "5", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f1bb7a4325365b090448ee7b529c7b4fcc187013fcb2a00b3e52dfcd028e1e8f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eba75f04-d448-4b48-8f12-e125ed0d45f1", "node_type": "1", "metadata": {"window": "The Company continues to provide \"ex-C OVID\" growth guidance to\nnormalize for contributions related to exclusive C OVID products, which are government-owned treatments.  The Company does not\nexpect a material contribution from exclusive C OVID products beyond the fiscal 2024 first quarter.  Commercial C OVID products,\nincluding newly commercial C OVID vaccines, are not excluded.  The Company expects:\nRevenue growth to be in the range of 7 to 10 percent;\nOn a constant currency basis, revenue growth to be in the range of 7 to 10 percent;\nU.S.  Healthcare Solutions revenue growth to be in the range of 7 to 10 percent;\nInternational Healthcare Solutions revenue growth to be in the range of 4 to 8 percent;\nInternational Healthcare Solutions constant currency revenue growth to be in the range of 7 to 11 percent;\nAdjusted diluted earnings per share to be in the range of $12.70 to $13.00.\n Additional expectations include:\nAdjusted operating income growth to be in the range of 4 to 6 percent;\nOn a constant currency basis, adjusted operating income growth to be in the range of 5 to 7 percent;\nExcluding contributions related to C OVID-19, adjusted operating income growth to be in the range of 7 to 9 percent;\nOn a constant currency basis, excluding contributions related to C OVID-19, adjusted operating income growth\nto be in the range of 8 to 10 percent;\nU.S.  Healthcare Solutions segment operating income growth to be in the range of 4 to 7 percent;\nExcluding contributions related to C OVID-19, U.S. ", "original_text": "The Company expects:\nRevenue growth to be in the range of 7 to 10 percent;\nOn a constant currency basis, revenue growth to be in the range of 7 to 10 percent;\nU.S. "}, "hash": "f5fd6df0a0a3d6d8dc0f3175630ece70dfbba56686f80d431828e09e29c69c14", "class_name": "RelatedNodeInfo"}}, "text": "Commercial C OVID products,\nincluding newly commercial C OVID vaccines, are not excluded. ", "start_char_idx": 1827, "end_char_idx": 1917, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eba75f04-d448-4b48-8f12-e125ed0d45f1": {"__data__": {"id_": "eba75f04-d448-4b48-8f12-e125ed0d45f1", "embedding": null, "metadata": {"window": "The Company continues to provide \"ex-C OVID\" growth guidance to\nnormalize for contributions related to exclusive C OVID products, which are government-owned treatments.  The Company does not\nexpect a material contribution from exclusive C OVID products beyond the fiscal 2024 first quarter.  Commercial C OVID products,\nincluding newly commercial C OVID vaccines, are not excluded.  The Company expects:\nRevenue growth to be in the range of 7 to 10 percent;\nOn a constant currency basis, revenue growth to be in the range of 7 to 10 percent;\nU.S.  Healthcare Solutions revenue growth to be in the range of 7 to 10 percent;\nInternational Healthcare Solutions revenue growth to be in the range of 4 to 8 percent;\nInternational Healthcare Solutions constant currency revenue growth to be in the range of 7 to 11 percent;\nAdjusted diluted earnings per share to be in the range of $12.70 to $13.00.\n Additional expectations include:\nAdjusted operating income growth to be in the range of 4 to 6 percent;\nOn a constant currency basis, adjusted operating income growth to be in the range of 5 to 7 percent;\nExcluding contributions related to C OVID-19, adjusted operating income growth to be in the range of 7 to 9 percent;\nOn a constant currency basis, excluding contributions related to C OVID-19, adjusted operating income growth\nto be in the range of 8 to 10 percent;\nU.S.  Healthcare Solutions segment operating income growth to be in the range of 4 to 7 percent;\nExcluding contributions related to C OVID-19, U.S. ", "original_text": "The Company expects:\nRevenue growth to be in the range of 7 to 10 percent;\nOn a constant currency basis, revenue growth to be in the range of 7 to 10 percent;\nU.S. ", "page_label": "5", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7021eca0-c10a-4441-addb-9b3d939e9002", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e911791c4b83e35d703be25839ee3ca91e7a1fc4836d0c645c62d4442711582d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ec4747f5-1878-4e7b-9572-08ed0e5af519", "node_type": "1", "metadata": {"window": "Fiscal Y ear 2024 Expectations on an Adjust ed (non-GAAP) Basis\nCencora has introduced its fiscal year 2024 financial guidance.  The Company continues to provide \"ex-C OVID\" growth guidance to\nnormalize for contributions related to exclusive C OVID products, which are government-owned treatments.  The Company does not\nexpect a material contribution from exclusive C OVID products beyond the fiscal 2024 first quarter.  Commercial C OVID products,\nincluding newly commercial C OVID vaccines, are not excluded.  The Company expects:\nRevenue growth to be in the range of 7 to 10 percent;\nOn a constant currency basis, revenue growth to be in the range of 7 to 10 percent;\nU.S.  Healthcare Solutions revenue growth to be in the range of 7 to 10 percent;\nInternational Healthcare Solutions revenue growth to be in the range of 4 to 8 percent;\nInternational Healthcare Solutions constant currency revenue growth to be in the range of 7 to 11 percent;\nAdjusted diluted earnings per share to be in the range of $12.70 to $13.00.\n Additional expectations include:\nAdjusted operating income growth to be in the range of 4 to 6 percent;\nOn a constant currency basis, adjusted operating income growth to be in the range of 5 to 7 percent;\nExcluding contributions related to C OVID-19, adjusted operating income growth to be in the range of 7 to 9 percent;\nOn a constant currency basis, excluding contributions related to C OVID-19, adjusted operating income growth\nto be in the range of 8 to 10 percent;\nU.S. ", "original_text": "Commercial C OVID products,\nincluding newly commercial C OVID vaccines, are not excluded. ", "page_label": "5", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dc2259efd226626d0aa92121fc7d8d7a7c88bfa347ce260ca88fbe565ac8f5ef", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9d283c3e-80d7-44e0-aa31-cf9611b82b9d", "node_type": "1", "metadata": {"window": "The Company does not\nexpect a material contribution from exclusive C OVID products beyond the fiscal 2024 first quarter.  Commercial C OVID products,\nincluding newly commercial C OVID vaccines, are not excluded.  The Company expects:\nRevenue growth to be in the range of 7 to 10 percent;\nOn a constant currency basis, revenue growth to be in the range of 7 to 10 percent;\nU.S.  Healthcare Solutions revenue growth to be in the range of 7 to 10 percent;\nInternational Healthcare Solutions revenue growth to be in the range of 4 to 8 percent;\nInternational Healthcare Solutions constant currency revenue growth to be in the range of 7 to 11 percent;\nAdjusted diluted earnings per share to be in the range of $12.70 to $13.00.\n Additional expectations include:\nAdjusted operating income growth to be in the range of 4 to 6 percent;\nOn a constant currency basis, adjusted operating income growth to be in the range of 5 to 7 percent;\nExcluding contributions related to C OVID-19, adjusted operating income growth to be in the range of 7 to 9 percent;\nOn a constant currency basis, excluding contributions related to C OVID-19, adjusted operating income growth\nto be in the range of 8 to 10 percent;\nU.S.  Healthcare Solutions segment operating income growth to be in the range of 4 to 7 percent;\nExcluding contributions related to C OVID-19, U.S.  Healthcare Solutions segment operating income growth to be\nin the range of 7 to 10 percent;\nInternational Healthcare Solutions segment operating income growth to be in the range of 1 to 4 percent;\nOn a constant currency basis, International Healthcare Solutions segment operating income growth to be in\nrange of 5 to 8 percent;\nExcluding contributions related to C OVID-19, International Healthcare Solutions segment operating income\ngrowth to be in the range of 3 to 6 percent;\nOn a constant currency basis, excluding contributions related to C OVID-19, International Healthcare\nSolutions segment operating income growth to be in the range of 7 to 10 percent;\n5", "original_text": "Healthcare Solutions revenue growth to be in the range of 7 to 10 percent;\nInternational Healthcare Solutions revenue growth to be in the range of 4 to 8 percent;\nInternational Healthcare Solutions constant currency revenue growth to be in the range of 7 to 11 percent;\nAdjusted diluted earnings per share to be in the range of $12.70 to $13.00.\n"}, "hash": "65191b33b59dbca31d3141d698a065402f2cc08f6eb5697b1d3f4edde3a2c644", "class_name": "RelatedNodeInfo"}}, "text": "The Company expects:\nRevenue growth to be in the range of 7 to 10 percent;\nOn a constant currency basis, revenue growth to be in the range of 7 to 10 percent;\nU.S. ", "start_char_idx": 1917, "end_char_idx": 2081, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9d283c3e-80d7-44e0-aa31-cf9611b82b9d": {"__data__": {"id_": "9d283c3e-80d7-44e0-aa31-cf9611b82b9d", "embedding": null, "metadata": {"window": "The Company does not\nexpect a material contribution from exclusive C OVID products beyond the fiscal 2024 first quarter.  Commercial C OVID products,\nincluding newly commercial C OVID vaccines, are not excluded.  The Company expects:\nRevenue growth to be in the range of 7 to 10 percent;\nOn a constant currency basis, revenue growth to be in the range of 7 to 10 percent;\nU.S.  Healthcare Solutions revenue growth to be in the range of 7 to 10 percent;\nInternational Healthcare Solutions revenue growth to be in the range of 4 to 8 percent;\nInternational Healthcare Solutions constant currency revenue growth to be in the range of 7 to 11 percent;\nAdjusted diluted earnings per share to be in the range of $12.70 to $13.00.\n Additional expectations include:\nAdjusted operating income growth to be in the range of 4 to 6 percent;\nOn a constant currency basis, adjusted operating income growth to be in the range of 5 to 7 percent;\nExcluding contributions related to C OVID-19, adjusted operating income growth to be in the range of 7 to 9 percent;\nOn a constant currency basis, excluding contributions related to C OVID-19, adjusted operating income growth\nto be in the range of 8 to 10 percent;\nU.S.  Healthcare Solutions segment operating income growth to be in the range of 4 to 7 percent;\nExcluding contributions related to C OVID-19, U.S.  Healthcare Solutions segment operating income growth to be\nin the range of 7 to 10 percent;\nInternational Healthcare Solutions segment operating income growth to be in the range of 1 to 4 percent;\nOn a constant currency basis, International Healthcare Solutions segment operating income growth to be in\nrange of 5 to 8 percent;\nExcluding contributions related to C OVID-19, International Healthcare Solutions segment operating income\ngrowth to be in the range of 3 to 6 percent;\nOn a constant currency basis, excluding contributions related to C OVID-19, International Healthcare\nSolutions segment operating income growth to be in the range of 7 to 10 percent;\n5", "original_text": "Healthcare Solutions revenue growth to be in the range of 7 to 10 percent;\nInternational Healthcare Solutions revenue growth to be in the range of 4 to 8 percent;\nInternational Healthcare Solutions constant currency revenue growth to be in the range of 7 to 11 percent;\nAdjusted diluted earnings per share to be in the range of $12.70 to $13.00.\n", "page_label": "5", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7021eca0-c10a-4441-addb-9b3d939e9002", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e911791c4b83e35d703be25839ee3ca91e7a1fc4836d0c645c62d4442711582d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eba75f04-d448-4b48-8f12-e125ed0d45f1", "node_type": "1", "metadata": {"window": "The Company continues to provide \"ex-C OVID\" growth guidance to\nnormalize for contributions related to exclusive C OVID products, which are government-owned treatments.  The Company does not\nexpect a material contribution from exclusive C OVID products beyond the fiscal 2024 first quarter.  Commercial C OVID products,\nincluding newly commercial C OVID vaccines, are not excluded.  The Company expects:\nRevenue growth to be in the range of 7 to 10 percent;\nOn a constant currency basis, revenue growth to be in the range of 7 to 10 percent;\nU.S.  Healthcare Solutions revenue growth to be in the range of 7 to 10 percent;\nInternational Healthcare Solutions revenue growth to be in the range of 4 to 8 percent;\nInternational Healthcare Solutions constant currency revenue growth to be in the range of 7 to 11 percent;\nAdjusted diluted earnings per share to be in the range of $12.70 to $13.00.\n Additional expectations include:\nAdjusted operating income growth to be in the range of 4 to 6 percent;\nOn a constant currency basis, adjusted operating income growth to be in the range of 5 to 7 percent;\nExcluding contributions related to C OVID-19, adjusted operating income growth to be in the range of 7 to 9 percent;\nOn a constant currency basis, excluding contributions related to C OVID-19, adjusted operating income growth\nto be in the range of 8 to 10 percent;\nU.S.  Healthcare Solutions segment operating income growth to be in the range of 4 to 7 percent;\nExcluding contributions related to C OVID-19, U.S. ", "original_text": "The Company expects:\nRevenue growth to be in the range of 7 to 10 percent;\nOn a constant currency basis, revenue growth to be in the range of 7 to 10 percent;\nU.S. ", "page_label": "5", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "be733e64c82e736e99448be4fef43cb2749ed611b1f8b8512c3f4260c403ec4e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1963b9ff-0504-4c52-bd6c-3654fd97a237", "node_type": "1", "metadata": {"window": "Commercial C OVID products,\nincluding newly commercial C OVID vaccines, are not excluded.  The Company expects:\nRevenue growth to be in the range of 7 to 10 percent;\nOn a constant currency basis, revenue growth to be in the range of 7 to 10 percent;\nU.S.  Healthcare Solutions revenue growth to be in the range of 7 to 10 percent;\nInternational Healthcare Solutions revenue growth to be in the range of 4 to 8 percent;\nInternational Healthcare Solutions constant currency revenue growth to be in the range of 7 to 11 percent;\nAdjusted diluted earnings per share to be in the range of $12.70 to $13.00.\n Additional expectations include:\nAdjusted operating income growth to be in the range of 4 to 6 percent;\nOn a constant currency basis, adjusted operating income growth to be in the range of 5 to 7 percent;\nExcluding contributions related to C OVID-19, adjusted operating income growth to be in the range of 7 to 9 percent;\nOn a constant currency basis, excluding contributions related to C OVID-19, adjusted operating income growth\nto be in the range of 8 to 10 percent;\nU.S.  Healthcare Solutions segment operating income growth to be in the range of 4 to 7 percent;\nExcluding contributions related to C OVID-19, U.S.  Healthcare Solutions segment operating income growth to be\nin the range of 7 to 10 percent;\nInternational Healthcare Solutions segment operating income growth to be in the range of 1 to 4 percent;\nOn a constant currency basis, International Healthcare Solutions segment operating income growth to be in\nrange of 5 to 8 percent;\nExcluding contributions related to C OVID-19, International Healthcare Solutions segment operating income\ngrowth to be in the range of 3 to 6 percent;\nOn a constant currency basis, excluding contributions related to C OVID-19, International Healthcare\nSolutions segment operating income growth to be in the range of 7 to 10 percent;\n5", "original_text": "Additional expectations include:\nAdjusted operating income growth to be in the range of 4 to 6 percent;\nOn a constant currency basis, adjusted operating income growth to be in the range of 5 to 7 percent;\nExcluding contributions related to C OVID-19, adjusted operating income growth to be in the range of 7 to 9 percent;\nOn a constant currency basis, excluding contributions related to C OVID-19, adjusted operating income growth\nto be in the range of 8 to 10 percent;\nU.S. "}, "hash": "3c223a8a7754b79efe2e09b4b9980bf2d60fed4f77c9dd857e2d468fe6297a48", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions revenue growth to be in the range of 7 to 10 percent;\nInternational Healthcare Solutions revenue growth to be in the range of 4 to 8 percent;\nInternational Healthcare Solutions constant currency revenue growth to be in the range of 7 to 11 percent;\nAdjusted diluted earnings per share to be in the range of $12.70 to $13.00.\n", "start_char_idx": 2081, "end_char_idx": 2427, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1963b9ff-0504-4c52-bd6c-3654fd97a237": {"__data__": {"id_": "1963b9ff-0504-4c52-bd6c-3654fd97a237", "embedding": null, "metadata": {"window": "Commercial C OVID products,\nincluding newly commercial C OVID vaccines, are not excluded.  The Company expects:\nRevenue growth to be in the range of 7 to 10 percent;\nOn a constant currency basis, revenue growth to be in the range of 7 to 10 percent;\nU.S.  Healthcare Solutions revenue growth to be in the range of 7 to 10 percent;\nInternational Healthcare Solutions revenue growth to be in the range of 4 to 8 percent;\nInternational Healthcare Solutions constant currency revenue growth to be in the range of 7 to 11 percent;\nAdjusted diluted earnings per share to be in the range of $12.70 to $13.00.\n Additional expectations include:\nAdjusted operating income growth to be in the range of 4 to 6 percent;\nOn a constant currency basis, adjusted operating income growth to be in the range of 5 to 7 percent;\nExcluding contributions related to C OVID-19, adjusted operating income growth to be in the range of 7 to 9 percent;\nOn a constant currency basis, excluding contributions related to C OVID-19, adjusted operating income growth\nto be in the range of 8 to 10 percent;\nU.S.  Healthcare Solutions segment operating income growth to be in the range of 4 to 7 percent;\nExcluding contributions related to C OVID-19, U.S.  Healthcare Solutions segment operating income growth to be\nin the range of 7 to 10 percent;\nInternational Healthcare Solutions segment operating income growth to be in the range of 1 to 4 percent;\nOn a constant currency basis, International Healthcare Solutions segment operating income growth to be in\nrange of 5 to 8 percent;\nExcluding contributions related to C OVID-19, International Healthcare Solutions segment operating income\ngrowth to be in the range of 3 to 6 percent;\nOn a constant currency basis, excluding contributions related to C OVID-19, International Healthcare\nSolutions segment operating income growth to be in the range of 7 to 10 percent;\n5", "original_text": "Additional expectations include:\nAdjusted operating income growth to be in the range of 4 to 6 percent;\nOn a constant currency basis, adjusted operating income growth to be in the range of 5 to 7 percent;\nExcluding contributions related to C OVID-19, adjusted operating income growth to be in the range of 7 to 9 percent;\nOn a constant currency basis, excluding contributions related to C OVID-19, adjusted operating income growth\nto be in the range of 8 to 10 percent;\nU.S. ", "page_label": "5", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7021eca0-c10a-4441-addb-9b3d939e9002", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e911791c4b83e35d703be25839ee3ca91e7a1fc4836d0c645c62d4442711582d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9d283c3e-80d7-44e0-aa31-cf9611b82b9d", "node_type": "1", "metadata": {"window": "The Company does not\nexpect a material contribution from exclusive C OVID products beyond the fiscal 2024 first quarter.  Commercial C OVID products,\nincluding newly commercial C OVID vaccines, are not excluded.  The Company expects:\nRevenue growth to be in the range of 7 to 10 percent;\nOn a constant currency basis, revenue growth to be in the range of 7 to 10 percent;\nU.S.  Healthcare Solutions revenue growth to be in the range of 7 to 10 percent;\nInternational Healthcare Solutions revenue growth to be in the range of 4 to 8 percent;\nInternational Healthcare Solutions constant currency revenue growth to be in the range of 7 to 11 percent;\nAdjusted diluted earnings per share to be in the range of $12.70 to $13.00.\n Additional expectations include:\nAdjusted operating income growth to be in the range of 4 to 6 percent;\nOn a constant currency basis, adjusted operating income growth to be in the range of 5 to 7 percent;\nExcluding contributions related to C OVID-19, adjusted operating income growth to be in the range of 7 to 9 percent;\nOn a constant currency basis, excluding contributions related to C OVID-19, adjusted operating income growth\nto be in the range of 8 to 10 percent;\nU.S.  Healthcare Solutions segment operating income growth to be in the range of 4 to 7 percent;\nExcluding contributions related to C OVID-19, U.S.  Healthcare Solutions segment operating income growth to be\nin the range of 7 to 10 percent;\nInternational Healthcare Solutions segment operating income growth to be in the range of 1 to 4 percent;\nOn a constant currency basis, International Healthcare Solutions segment operating income growth to be in\nrange of 5 to 8 percent;\nExcluding contributions related to C OVID-19, International Healthcare Solutions segment operating income\ngrowth to be in the range of 3 to 6 percent;\nOn a constant currency basis, excluding contributions related to C OVID-19, International Healthcare\nSolutions segment operating income growth to be in the range of 7 to 10 percent;\n5", "original_text": "Healthcare Solutions revenue growth to be in the range of 7 to 10 percent;\nInternational Healthcare Solutions revenue growth to be in the range of 4 to 8 percent;\nInternational Healthcare Solutions constant currency revenue growth to be in the range of 7 to 11 percent;\nAdjusted diluted earnings per share to be in the range of $12.70 to $13.00.\n", "page_label": "5", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "154852fab91340e07cffd48c40fe881fad72a86160f4c8b3850fd57099ce0af6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0cbfc5b9-5f87-4fe5-a060-ae3c6a3f0f71", "node_type": "1", "metadata": {"window": "The Company expects:\nRevenue growth to be in the range of 7 to 10 percent;\nOn a constant currency basis, revenue growth to be in the range of 7 to 10 percent;\nU.S.  Healthcare Solutions revenue growth to be in the range of 7 to 10 percent;\nInternational Healthcare Solutions revenue growth to be in the range of 4 to 8 percent;\nInternational Healthcare Solutions constant currency revenue growth to be in the range of 7 to 11 percent;\nAdjusted diluted earnings per share to be in the range of $12.70 to $13.00.\n Additional expectations include:\nAdjusted operating income growth to be in the range of 4 to 6 percent;\nOn a constant currency basis, adjusted operating income growth to be in the range of 5 to 7 percent;\nExcluding contributions related to C OVID-19, adjusted operating income growth to be in the range of 7 to 9 percent;\nOn a constant currency basis, excluding contributions related to C OVID-19, adjusted operating income growth\nto be in the range of 8 to 10 percent;\nU.S.  Healthcare Solutions segment operating income growth to be in the range of 4 to 7 percent;\nExcluding contributions related to C OVID-19, U.S.  Healthcare Solutions segment operating income growth to be\nin the range of 7 to 10 percent;\nInternational Healthcare Solutions segment operating income growth to be in the range of 1 to 4 percent;\nOn a constant currency basis, International Healthcare Solutions segment operating income growth to be in\nrange of 5 to 8 percent;\nExcluding contributions related to C OVID-19, International Healthcare Solutions segment operating income\ngrowth to be in the range of 3 to 6 percent;\nOn a constant currency basis, excluding contributions related to C OVID-19, International Healthcare\nSolutions segment operating income growth to be in the range of 7 to 10 percent;\n5", "original_text": "Healthcare Solutions segment operating income growth to be in the range of 4 to 7 percent;\nExcluding contributions related to C OVID-19, U.S. "}, "hash": "f2734c73e23bbb94f3b541d349679dd960d0b8df6cc0624aee61f625c6956ee0", "class_name": "RelatedNodeInfo"}}, "text": "Additional expectations include:\nAdjusted operating income growth to be in the range of 4 to 6 percent;\nOn a constant currency basis, adjusted operating income growth to be in the range of 5 to 7 percent;\nExcluding contributions related to C OVID-19, adjusted operating income growth to be in the range of 7 to 9 percent;\nOn a constant currency basis, excluding contributions related to C OVID-19, adjusted operating income growth\nto be in the range of 8 to 10 percent;\nU.S. ", "start_char_idx": 2427, "end_char_idx": 2902, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0cbfc5b9-5f87-4fe5-a060-ae3c6a3f0f71": {"__data__": {"id_": "0cbfc5b9-5f87-4fe5-a060-ae3c6a3f0f71", "embedding": null, "metadata": {"window": "The Company expects:\nRevenue growth to be in the range of 7 to 10 percent;\nOn a constant currency basis, revenue growth to be in the range of 7 to 10 percent;\nU.S.  Healthcare Solutions revenue growth to be in the range of 7 to 10 percent;\nInternational Healthcare Solutions revenue growth to be in the range of 4 to 8 percent;\nInternational Healthcare Solutions constant currency revenue growth to be in the range of 7 to 11 percent;\nAdjusted diluted earnings per share to be in the range of $12.70 to $13.00.\n Additional expectations include:\nAdjusted operating income growth to be in the range of 4 to 6 percent;\nOn a constant currency basis, adjusted operating income growth to be in the range of 5 to 7 percent;\nExcluding contributions related to C OVID-19, adjusted operating income growth to be in the range of 7 to 9 percent;\nOn a constant currency basis, excluding contributions related to C OVID-19, adjusted operating income growth\nto be in the range of 8 to 10 percent;\nU.S.  Healthcare Solutions segment operating income growth to be in the range of 4 to 7 percent;\nExcluding contributions related to C OVID-19, U.S.  Healthcare Solutions segment operating income growth to be\nin the range of 7 to 10 percent;\nInternational Healthcare Solutions segment operating income growth to be in the range of 1 to 4 percent;\nOn a constant currency basis, International Healthcare Solutions segment operating income growth to be in\nrange of 5 to 8 percent;\nExcluding contributions related to C OVID-19, International Healthcare Solutions segment operating income\ngrowth to be in the range of 3 to 6 percent;\nOn a constant currency basis, excluding contributions related to C OVID-19, International Healthcare\nSolutions segment operating income growth to be in the range of 7 to 10 percent;\n5", "original_text": "Healthcare Solutions segment operating income growth to be in the range of 4 to 7 percent;\nExcluding contributions related to C OVID-19, U.S. ", "page_label": "5", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7021eca0-c10a-4441-addb-9b3d939e9002", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e911791c4b83e35d703be25839ee3ca91e7a1fc4836d0c645c62d4442711582d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1963b9ff-0504-4c52-bd6c-3654fd97a237", "node_type": "1", "metadata": {"window": "Commercial C OVID products,\nincluding newly commercial C OVID vaccines, are not excluded.  The Company expects:\nRevenue growth to be in the range of 7 to 10 percent;\nOn a constant currency basis, revenue growth to be in the range of 7 to 10 percent;\nU.S.  Healthcare Solutions revenue growth to be in the range of 7 to 10 percent;\nInternational Healthcare Solutions revenue growth to be in the range of 4 to 8 percent;\nInternational Healthcare Solutions constant currency revenue growth to be in the range of 7 to 11 percent;\nAdjusted diluted earnings per share to be in the range of $12.70 to $13.00.\n Additional expectations include:\nAdjusted operating income growth to be in the range of 4 to 6 percent;\nOn a constant currency basis, adjusted operating income growth to be in the range of 5 to 7 percent;\nExcluding contributions related to C OVID-19, adjusted operating income growth to be in the range of 7 to 9 percent;\nOn a constant currency basis, excluding contributions related to C OVID-19, adjusted operating income growth\nto be in the range of 8 to 10 percent;\nU.S.  Healthcare Solutions segment operating income growth to be in the range of 4 to 7 percent;\nExcluding contributions related to C OVID-19, U.S.  Healthcare Solutions segment operating income growth to be\nin the range of 7 to 10 percent;\nInternational Healthcare Solutions segment operating income growth to be in the range of 1 to 4 percent;\nOn a constant currency basis, International Healthcare Solutions segment operating income growth to be in\nrange of 5 to 8 percent;\nExcluding contributions related to C OVID-19, International Healthcare Solutions segment operating income\ngrowth to be in the range of 3 to 6 percent;\nOn a constant currency basis, excluding contributions related to C OVID-19, International Healthcare\nSolutions segment operating income growth to be in the range of 7 to 10 percent;\n5", "original_text": "Additional expectations include:\nAdjusted operating income growth to be in the range of 4 to 6 percent;\nOn a constant currency basis, adjusted operating income growth to be in the range of 5 to 7 percent;\nExcluding contributions related to C OVID-19, adjusted operating income growth to be in the range of 7 to 9 percent;\nOn a constant currency basis, excluding contributions related to C OVID-19, adjusted operating income growth\nto be in the range of 8 to 10 percent;\nU.S. ", "page_label": "5", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fd3b68310bd91f479d778640fd69748f4f6588d7241cdd3b6612102b3385612e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4b46fbd2-318c-4850-b3c7-230296a11fdc", "node_type": "1", "metadata": {"window": "Healthcare Solutions revenue growth to be in the range of 7 to 10 percent;\nInternational Healthcare Solutions revenue growth to be in the range of 4 to 8 percent;\nInternational Healthcare Solutions constant currency revenue growth to be in the range of 7 to 11 percent;\nAdjusted diluted earnings per share to be in the range of $12.70 to $13.00.\n Additional expectations include:\nAdjusted operating income growth to be in the range of 4 to 6 percent;\nOn a constant currency basis, adjusted operating income growth to be in the range of 5 to 7 percent;\nExcluding contributions related to C OVID-19, adjusted operating income growth to be in the range of 7 to 9 percent;\nOn a constant currency basis, excluding contributions related to C OVID-19, adjusted operating income growth\nto be in the range of 8 to 10 percent;\nU.S.  Healthcare Solutions segment operating income growth to be in the range of 4 to 7 percent;\nExcluding contributions related to C OVID-19, U.S.  Healthcare Solutions segment operating income growth to be\nin the range of 7 to 10 percent;\nInternational Healthcare Solutions segment operating income growth to be in the range of 1 to 4 percent;\nOn a constant currency basis, International Healthcare Solutions segment operating income growth to be in\nrange of 5 to 8 percent;\nExcluding contributions related to C OVID-19, International Healthcare Solutions segment operating income\ngrowth to be in the range of 3 to 6 percent;\nOn a constant currency basis, excluding contributions related to C OVID-19, International Healthcare\nSolutions segment operating income growth to be in the range of 7 to 10 percent;\n5", "original_text": "Healthcare Solutions segment operating income growth to be\nin the range of 7 to 10 percent;\nInternational Healthcare Solutions segment operating income growth to be in the range of 1 to 4 percent;\nOn a constant currency basis, International Healthcare Solutions segment operating income growth to be in\nrange of 5 to 8 percent;\nExcluding contributions related to C OVID-19, International Healthcare Solutions segment operating income\ngrowth to be in the range of 3 to 6 percent;\nOn a constant currency basis, excluding contributions related to C OVID-19, International Healthcare\nSolutions segment operating income growth to be in the range of 7 to 10 percent;\n5"}, "hash": "ea6edfdb987ed3df8b63bc000ef2d11208869b08d6cb52bed1ccb4d490c1dd57", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions segment operating income growth to be in the range of 4 to 7 percent;\nExcluding contributions related to C OVID-19, U.S. ", "start_char_idx": 2902, "end_char_idx": 3044, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4b46fbd2-318c-4850-b3c7-230296a11fdc": {"__data__": {"id_": "4b46fbd2-318c-4850-b3c7-230296a11fdc", "embedding": null, "metadata": {"window": "Healthcare Solutions revenue growth to be in the range of 7 to 10 percent;\nInternational Healthcare Solutions revenue growth to be in the range of 4 to 8 percent;\nInternational Healthcare Solutions constant currency revenue growth to be in the range of 7 to 11 percent;\nAdjusted diluted earnings per share to be in the range of $12.70 to $13.00.\n Additional expectations include:\nAdjusted operating income growth to be in the range of 4 to 6 percent;\nOn a constant currency basis, adjusted operating income growth to be in the range of 5 to 7 percent;\nExcluding contributions related to C OVID-19, adjusted operating income growth to be in the range of 7 to 9 percent;\nOn a constant currency basis, excluding contributions related to C OVID-19, adjusted operating income growth\nto be in the range of 8 to 10 percent;\nU.S.  Healthcare Solutions segment operating income growth to be in the range of 4 to 7 percent;\nExcluding contributions related to C OVID-19, U.S.  Healthcare Solutions segment operating income growth to be\nin the range of 7 to 10 percent;\nInternational Healthcare Solutions segment operating income growth to be in the range of 1 to 4 percent;\nOn a constant currency basis, International Healthcare Solutions segment operating income growth to be in\nrange of 5 to 8 percent;\nExcluding contributions related to C OVID-19, International Healthcare Solutions segment operating income\ngrowth to be in the range of 3 to 6 percent;\nOn a constant currency basis, excluding contributions related to C OVID-19, International Healthcare\nSolutions segment operating income growth to be in the range of 7 to 10 percent;\n5", "original_text": "Healthcare Solutions segment operating income growth to be\nin the range of 7 to 10 percent;\nInternational Healthcare Solutions segment operating income growth to be in the range of 1 to 4 percent;\nOn a constant currency basis, International Healthcare Solutions segment operating income growth to be in\nrange of 5 to 8 percent;\nExcluding contributions related to C OVID-19, International Healthcare Solutions segment operating income\ngrowth to be in the range of 3 to 6 percent;\nOn a constant currency basis, excluding contributions related to C OVID-19, International Healthcare\nSolutions segment operating income growth to be in the range of 7 to 10 percent;\n5", "page_label": "5", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7021eca0-c10a-4441-addb-9b3d939e9002", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e911791c4b83e35d703be25839ee3ca91e7a1fc4836d0c645c62d4442711582d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0cbfc5b9-5f87-4fe5-a060-ae3c6a3f0f71", "node_type": "1", "metadata": {"window": "The Company expects:\nRevenue growth to be in the range of 7 to 10 percent;\nOn a constant currency basis, revenue growth to be in the range of 7 to 10 percent;\nU.S.  Healthcare Solutions revenue growth to be in the range of 7 to 10 percent;\nInternational Healthcare Solutions revenue growth to be in the range of 4 to 8 percent;\nInternational Healthcare Solutions constant currency revenue growth to be in the range of 7 to 11 percent;\nAdjusted diluted earnings per share to be in the range of $12.70 to $13.00.\n Additional expectations include:\nAdjusted operating income growth to be in the range of 4 to 6 percent;\nOn a constant currency basis, adjusted operating income growth to be in the range of 5 to 7 percent;\nExcluding contributions related to C OVID-19, adjusted operating income growth to be in the range of 7 to 9 percent;\nOn a constant currency basis, excluding contributions related to C OVID-19, adjusted operating income growth\nto be in the range of 8 to 10 percent;\nU.S.  Healthcare Solutions segment operating income growth to be in the range of 4 to 7 percent;\nExcluding contributions related to C OVID-19, U.S.  Healthcare Solutions segment operating income growth to be\nin the range of 7 to 10 percent;\nInternational Healthcare Solutions segment operating income growth to be in the range of 1 to 4 percent;\nOn a constant currency basis, International Healthcare Solutions segment operating income growth to be in\nrange of 5 to 8 percent;\nExcluding contributions related to C OVID-19, International Healthcare Solutions segment operating income\ngrowth to be in the range of 3 to 6 percent;\nOn a constant currency basis, excluding contributions related to C OVID-19, International Healthcare\nSolutions segment operating income growth to be in the range of 7 to 10 percent;\n5", "original_text": "Healthcare Solutions segment operating income growth to be in the range of 4 to 7 percent;\nExcluding contributions related to C OVID-19, U.S. ", "page_label": "5", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "988c235ccbefac181b69df64e789b1d695e4e8770cf03f25f411ee51092fb8de", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "acc51638-1ece-4e8d-b742-4f5c194d2aca", "node_type": "1", "metadata": {"window": "Interest expense to be in the range of $210 million to $230 million;\nAdjusted effective tax rate to be approximately 20 percent to 21 percent;\nAdjusted free cash flow to be approximately $2.5 billion;\nCapital expenditures in the $500 million range; and\nWeighted average diluted shares outstanding are expected to be approximately 200 to 202 million for the fiscal year.\n For additional details on EPS growth rate excluding C OVID-19 contributions, please refer to our slide presentation for investors.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on November 2, 2023. ", "original_text": "Interest expense to be in the range of $210 million to $230 million;\nAdjusted effective tax rate to be approximately 20 percent to 21 percent;\nAdjusted free cash flow to be approximately $2.5 billion;\nCapital expenditures in the $500 million range; and\nWeighted average diluted shares outstanding are expected to be approximately 200 to 202 million for the fiscal year.\n"}, "hash": "f045437656c156ac16d38f522560d1ddc790b51f9d806f5583eb379178c8939c", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions segment operating income growth to be\nin the range of 7 to 10 percent;\nInternational Healthcare Solutions segment operating income growth to be in the range of 1 to 4 percent;\nOn a constant currency basis, International Healthcare Solutions segment operating income growth to be in\nrange of 5 to 8 percent;\nExcluding contributions related to C OVID-19, International Healthcare Solutions segment operating income\ngrowth to be in the range of 3 to 6 percent;\nOn a constant currency basis, excluding contributions related to C OVID-19, International Healthcare\nSolutions segment operating income growth to be in the range of 7 to 10 percent;\n5", "start_char_idx": 3044, "end_char_idx": 3706, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "acc51638-1ece-4e8d-b742-4f5c194d2aca": {"__data__": {"id_": "acc51638-1ece-4e8d-b742-4f5c194d2aca", "embedding": null, "metadata": {"window": "Interest expense to be in the range of $210 million to $230 million;\nAdjusted effective tax rate to be approximately 20 percent to 21 percent;\nAdjusted free cash flow to be approximately $2.5 billion;\nCapital expenditures in the $500 million range; and\nWeighted average diluted shares outstanding are expected to be approximately 200 to 202 million for the fiscal year.\n For additional details on EPS growth rate excluding C OVID-19 contributions, please refer to our slide presentation for investors.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on November 2, 2023. ", "original_text": "Interest expense to be in the range of $210 million to $230 million;\nAdjusted effective tax rate to be approximately 20 percent to 21 percent;\nAdjusted free cash flow to be approximately $2.5 billion;\nCapital expenditures in the $500 million range; and\nWeighted average diluted shares outstanding are expected to be approximately 200 to 202 million for the fiscal year.\n", "page_label": "6", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b76ad0b5-6e11-4d6c-9702-c56141c82238", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e00f6220ccf1d8d27c6f56f54e65359f917ceb7a0fbd989e9b94774f82ab4cea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4b46fbd2-318c-4850-b3c7-230296a11fdc", "node_type": "1", "metadata": {"window": "Healthcare Solutions revenue growth to be in the range of 7 to 10 percent;\nInternational Healthcare Solutions revenue growth to be in the range of 4 to 8 percent;\nInternational Healthcare Solutions constant currency revenue growth to be in the range of 7 to 11 percent;\nAdjusted diluted earnings per share to be in the range of $12.70 to $13.00.\n Additional expectations include:\nAdjusted operating income growth to be in the range of 4 to 6 percent;\nOn a constant currency basis, adjusted operating income growth to be in the range of 5 to 7 percent;\nExcluding contributions related to C OVID-19, adjusted operating income growth to be in the range of 7 to 9 percent;\nOn a constant currency basis, excluding contributions related to C OVID-19, adjusted operating income growth\nto be in the range of 8 to 10 percent;\nU.S.  Healthcare Solutions segment operating income growth to be in the range of 4 to 7 percent;\nExcluding contributions related to C OVID-19, U.S.  Healthcare Solutions segment operating income growth to be\nin the range of 7 to 10 percent;\nInternational Healthcare Solutions segment operating income growth to be in the range of 1 to 4 percent;\nOn a constant currency basis, International Healthcare Solutions segment operating income growth to be in\nrange of 5 to 8 percent;\nExcluding contributions related to C OVID-19, International Healthcare Solutions segment operating income\ngrowth to be in the range of 3 to 6 percent;\nOn a constant currency basis, excluding contributions related to C OVID-19, International Healthcare\nSolutions segment operating income growth to be in the range of 7 to 10 percent;\n5", "original_text": "Healthcare Solutions segment operating income growth to be\nin the range of 7 to 10 percent;\nInternational Healthcare Solutions segment operating income growth to be in the range of 1 to 4 percent;\nOn a constant currency basis, International Healthcare Solutions segment operating income growth to be in\nrange of 5 to 8 percent;\nExcluding contributions related to C OVID-19, International Healthcare Solutions segment operating income\ngrowth to be in the range of 3 to 6 percent;\nOn a constant currency basis, excluding contributions related to C OVID-19, International Healthcare\nSolutions segment operating income growth to be in the range of 7 to 10 percent;\n5", "page_label": "5", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5b379400de4fc40ae919c405e2cd23b53a436d354ba6cf1e1f0e11cbaa09876d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "164516b5-4570-476c-8d01-637990852562", "node_type": "1", "metadata": {"window": "Interest expense to be in the range of $210 million to $230 million;\nAdjusted effective tax rate to be approximately 20 percent to 21 percent;\nAdjusted free cash flow to be approximately $2.5 billion;\nCapital expenditures in the $500 million range; and\nWeighted average diluted shares outstanding are expected to be approximately 200 to 202 million for the fiscal year.\n For additional details on EPS growth rate excluding C OVID-19 contributions, please refer to our slide presentation for investors.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on November 2, 2023.  A slide presentation for\ninvestors has also been posted on the Company's website at investor.cencora.com. ", "original_text": "For additional details on EPS growth rate excluding C OVID-19 contributions, please refer to our slide presentation for investors.\n"}, "hash": "98e0376c199cea64f2c567f8d4677a3e699edc1deacab902fc4eba789980d37b", "class_name": "RelatedNodeInfo"}}, "text": "Interest expense to be in the range of $210 million to $230 million;\nAdjusted effective tax rate to be approximately 20 percent to 21 percent;\nAdjusted free cash flow to be approximately $2.5 billion;\nCapital expenditures in the $500 million range; and\nWeighted average diluted shares outstanding are expected to be approximately 200 to 202 million for the fiscal year.\n", "start_char_idx": 0, "end_char_idx": 370, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "164516b5-4570-476c-8d01-637990852562": {"__data__": {"id_": "164516b5-4570-476c-8d01-637990852562", "embedding": null, "metadata": {"window": "Interest expense to be in the range of $210 million to $230 million;\nAdjusted effective tax rate to be approximately 20 percent to 21 percent;\nAdjusted free cash flow to be approximately $2.5 billion;\nCapital expenditures in the $500 million range; and\nWeighted average diluted shares outstanding are expected to be approximately 200 to 202 million for the fiscal year.\n For additional details on EPS growth rate excluding C OVID-19 contributions, please refer to our slide presentation for investors.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on November 2, 2023.  A slide presentation for\ninvestors has also been posted on the Company's website at investor.cencora.com. ", "original_text": "For additional details on EPS growth rate excluding C OVID-19 contributions, please refer to our slide presentation for investors.\n", "page_label": "6", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b76ad0b5-6e11-4d6c-9702-c56141c82238", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e00f6220ccf1d8d27c6f56f54e65359f917ceb7a0fbd989e9b94774f82ab4cea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "acc51638-1ece-4e8d-b742-4f5c194d2aca", "node_type": "1", "metadata": {"window": "Interest expense to be in the range of $210 million to $230 million;\nAdjusted effective tax rate to be approximately 20 percent to 21 percent;\nAdjusted free cash flow to be approximately $2.5 billion;\nCapital expenditures in the $500 million range; and\nWeighted average diluted shares outstanding are expected to be approximately 200 to 202 million for the fiscal year.\n For additional details on EPS growth rate excluding C OVID-19 contributions, please refer to our slide presentation for investors.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on November 2, 2023. ", "original_text": "Interest expense to be in the range of $210 million to $230 million;\nAdjusted effective tax rate to be approximately 20 percent to 21 percent;\nAdjusted free cash flow to be approximately $2.5 billion;\nCapital expenditures in the $500 million range; and\nWeighted average diluted shares outstanding are expected to be approximately 200 to 202 million for the fiscal year.\n", "page_label": "6", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "af60e82f77f9e1c54c3ae0ffb83cba047159d6490d2be03fe32982a1fcbb08dc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b43b47de-31b6-4866-bb31-3203346eb62f", "node_type": "1", "metadata": {"window": "Interest expense to be in the range of $210 million to $230 million;\nAdjusted effective tax rate to be approximately 20 percent to 21 percent;\nAdjusted free cash flow to be approximately $2.5 billion;\nCapital expenditures in the $500 million range; and\nWeighted average diluted shares outstanding are expected to be approximately 200 to 202 million for the fiscal year.\n For additional details on EPS growth rate excluding C OVID-19 contributions, please refer to our slide presentation for investors.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on November 2, 2023.  A slide presentation for\ninvestors has also been posted on the Company's website at investor.cencora.com.  P articipating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (833) 470-1428. ", "original_text": "Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m. "}, "hash": "2d4e354a33c86e403b2cfdeea0b9006bc3c3239ba27917f07a131d70ab827a8c", "class_name": "RelatedNodeInfo"}}, "text": "For additional details on EPS growth rate excluding C OVID-19 contributions, please refer to our slide presentation for investors.\n", "start_char_idx": 370, "end_char_idx": 501, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b43b47de-31b6-4866-bb31-3203346eb62f": {"__data__": {"id_": "b43b47de-31b6-4866-bb31-3203346eb62f", "embedding": null, "metadata": {"window": "Interest expense to be in the range of $210 million to $230 million;\nAdjusted effective tax rate to be approximately 20 percent to 21 percent;\nAdjusted free cash flow to be approximately $2.5 billion;\nCapital expenditures in the $500 million range; and\nWeighted average diluted shares outstanding are expected to be approximately 200 to 202 million for the fiscal year.\n For additional details on EPS growth rate excluding C OVID-19 contributions, please refer to our slide presentation for investors.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on November 2, 2023.  A slide presentation for\ninvestors has also been posted on the Company's website at investor.cencora.com.  P articipating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (833) 470-1428. ", "original_text": "Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m. ", "page_label": "6", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b76ad0b5-6e11-4d6c-9702-c56141c82238", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e00f6220ccf1d8d27c6f56f54e65359f917ceb7a0fbd989e9b94774f82ab4cea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "164516b5-4570-476c-8d01-637990852562", "node_type": "1", "metadata": {"window": "Interest expense to be in the range of $210 million to $230 million;\nAdjusted effective tax rate to be approximately 20 percent to 21 percent;\nAdjusted free cash flow to be approximately $2.5 billion;\nCapital expenditures in the $500 million range; and\nWeighted average diluted shares outstanding are expected to be approximately 200 to 202 million for the fiscal year.\n For additional details on EPS growth rate excluding C OVID-19 contributions, please refer to our slide presentation for investors.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on November 2, 2023.  A slide presentation for\ninvestors has also been posted on the Company's website at investor.cencora.com. ", "original_text": "For additional details on EPS growth rate excluding C OVID-19 contributions, please refer to our slide presentation for investors.\n", "page_label": "6", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cd1c43b5ddec095be5704961fad9ee446439a2a40e58bed1093786b19d3d1f1c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d0ee62d1-f6ff-4cef-9786-a6254177c4c2", "node_type": "1", "metadata": {"window": "Interest expense to be in the range of $210 million to $230 million;\nAdjusted effective tax rate to be approximately 20 percent to 21 percent;\nAdjusted free cash flow to be approximately $2.5 billion;\nCapital expenditures in the $500 million range; and\nWeighted average diluted shares outstanding are expected to be approximately 200 to 202 million for the fiscal year.\n For additional details on EPS growth rate excluding C OVID-19 contributions, please refer to our slide presentation for investors.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on November 2, 2023.  A slide presentation for\ninvestors has also been posted on the Company's website at investor.cencora.com.  P articipating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (833) 470-1428.  From outside the United S tates and Canada, dial +1 (404) 975-4839. ", "original_text": "ET on November 2, 2023. "}, "hash": "b56509c98c9542a7840bb774c37aa8748c4e7694ef492d5c08c9b4edcb18de16", "class_name": "RelatedNodeInfo"}}, "text": "Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m. ", "start_char_idx": 501, "end_char_idx": 616, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d0ee62d1-f6ff-4cef-9786-a6254177c4c2": {"__data__": {"id_": "d0ee62d1-f6ff-4cef-9786-a6254177c4c2", "embedding": null, "metadata": {"window": "Interest expense to be in the range of $210 million to $230 million;\nAdjusted effective tax rate to be approximately 20 percent to 21 percent;\nAdjusted free cash flow to be approximately $2.5 billion;\nCapital expenditures in the $500 million range; and\nWeighted average diluted shares outstanding are expected to be approximately 200 to 202 million for the fiscal year.\n For additional details on EPS growth rate excluding C OVID-19 contributions, please refer to our slide presentation for investors.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on November 2, 2023.  A slide presentation for\ninvestors has also been posted on the Company's website at investor.cencora.com.  P articipating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (833) 470-1428.  From outside the United S tates and Canada, dial +1 (404) 975-4839. ", "original_text": "ET on November 2, 2023. ", "page_label": "6", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b76ad0b5-6e11-4d6c-9702-c56141c82238", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e00f6220ccf1d8d27c6f56f54e65359f917ceb7a0fbd989e9b94774f82ab4cea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b43b47de-31b6-4866-bb31-3203346eb62f", "node_type": "1", "metadata": {"window": "Interest expense to be in the range of $210 million to $230 million;\nAdjusted effective tax rate to be approximately 20 percent to 21 percent;\nAdjusted free cash flow to be approximately $2.5 billion;\nCapital expenditures in the $500 million range; and\nWeighted average diluted shares outstanding are expected to be approximately 200 to 202 million for the fiscal year.\n For additional details on EPS growth rate excluding C OVID-19 contributions, please refer to our slide presentation for investors.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on November 2, 2023.  A slide presentation for\ninvestors has also been posted on the Company's website at investor.cencora.com.  P articipating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (833) 470-1428. ", "original_text": "Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m. ", "page_label": "6", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7df4585b1013df3357443be9d14f24948d3ca7cb1b9405a4b2b61e25c794991f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "395f431b-e4fa-43cd-9ae1-fee8293c7008", "node_type": "1", "metadata": {"window": "For additional details on EPS growth rate excluding C OVID-19 contributions, please refer to our slide presentation for investors.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on November 2, 2023.  A slide presentation for\ninvestors has also been posted on the Company's website at investor.cencora.com.  P articipating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (833) 470-1428.  From outside the United S tates and Canada, dial +1 (404) 975-4839.  The\naccess code for the call will be 016298. ", "original_text": "A slide presentation for\ninvestors has also been posted on the Company's website at investor.cencora.com. "}, "hash": "af4a35e6f9b2cf51fb728877bb7758bd00b11ee1ed4fe39aad6398d9f65cd506", "class_name": "RelatedNodeInfo"}}, "text": "ET on November 2, 2023. ", "start_char_idx": 616, "end_char_idx": 640, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "395f431b-e4fa-43cd-9ae1-fee8293c7008": {"__data__": {"id_": "395f431b-e4fa-43cd-9ae1-fee8293c7008", "embedding": null, "metadata": {"window": "For additional details on EPS growth rate excluding C OVID-19 contributions, please refer to our slide presentation for investors.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on November 2, 2023.  A slide presentation for\ninvestors has also been posted on the Company's website at investor.cencora.com.  P articipating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (833) 470-1428.  From outside the United S tates and Canada, dial +1 (404) 975-4839.  The\naccess code for the call will be 016298. ", "original_text": "A slide presentation for\ninvestors has also been posted on the Company's website at investor.cencora.com. ", "page_label": "6", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b76ad0b5-6e11-4d6c-9702-c56141c82238", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e00f6220ccf1d8d27c6f56f54e65359f917ceb7a0fbd989e9b94774f82ab4cea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d0ee62d1-f6ff-4cef-9786-a6254177c4c2", "node_type": "1", "metadata": {"window": "Interest expense to be in the range of $210 million to $230 million;\nAdjusted effective tax rate to be approximately 20 percent to 21 percent;\nAdjusted free cash flow to be approximately $2.5 billion;\nCapital expenditures in the $500 million range; and\nWeighted average diluted shares outstanding are expected to be approximately 200 to 202 million for the fiscal year.\n For additional details on EPS growth rate excluding C OVID-19 contributions, please refer to our slide presentation for investors.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on November 2, 2023.  A slide presentation for\ninvestors has also been posted on the Company's website at investor.cencora.com.  P articipating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (833) 470-1428.  From outside the United S tates and Canada, dial +1 (404) 975-4839. ", "original_text": "ET on November 2, 2023. ", "page_label": "6", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8270707bcfa82edcf7c2524154bee13a4ea9f8ceb20ad7b7a729f49ca682c4e2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fc7f59c6-baab-49ec-a06c-ee63ce9002e3", "node_type": "1", "metadata": {"window": "Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on November 2, 2023.  A slide presentation for\ninvestors has also been posted on the Company's website at investor.cencora.com.  P articipating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (833) 470-1428.  From outside the United S tates and Canada, dial +1 (404) 975-4839.  The\naccess code for the call will be 016298.  The live call will also be webcast via the Company\u2019s website at investor.cencora.com. ", "original_text": "P articipating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (833) 470-1428. "}, "hash": "8ac9f772e1a92ea043a7ea414ab7493a22868768d818cb7eec04308e25886493", "class_name": "RelatedNodeInfo"}}, "text": "A slide presentation for\ninvestors has also been posted on the Company's website at investor.cencora.com. ", "start_char_idx": 640, "end_char_idx": 746, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fc7f59c6-baab-49ec-a06c-ee63ce9002e3": {"__data__": {"id_": "fc7f59c6-baab-49ec-a06c-ee63ce9002e3", "embedding": null, "metadata": {"window": "Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on November 2, 2023.  A slide presentation for\ninvestors has also been posted on the Company's website at investor.cencora.com.  P articipating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (833) 470-1428.  From outside the United S tates and Canada, dial +1 (404) 975-4839.  The\naccess code for the call will be 016298.  The live call will also be webcast via the Company\u2019s website at investor.cencora.com. ", "original_text": "P articipating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (833) 470-1428. ", "page_label": "6", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b76ad0b5-6e11-4d6c-9702-c56141c82238", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e00f6220ccf1d8d27c6f56f54e65359f917ceb7a0fbd989e9b94774f82ab4cea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "395f431b-e4fa-43cd-9ae1-fee8293c7008", "node_type": "1", "metadata": {"window": "For additional details on EPS growth rate excluding C OVID-19 contributions, please refer to our slide presentation for investors.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on November 2, 2023.  A slide presentation for\ninvestors has also been posted on the Company's website at investor.cencora.com.  P articipating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (833) 470-1428.  From outside the United S tates and Canada, dial +1 (404) 975-4839.  The\naccess code for the call will be 016298. ", "original_text": "A slide presentation for\ninvestors has also been posted on the Company's website at investor.cencora.com. ", "page_label": "6", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cd48d35478e43b007311990f48d70ca8fde2009afac5c142828b21211c0bdb59", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "84979e79-43fc-426e-9dcf-76e7920aaaa2", "node_type": "1", "metadata": {"window": "ET on November 2, 2023.  A slide presentation for\ninvestors has also been posted on the Company's website at investor.cencora.com.  P articipating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (833) 470-1428.  From outside the United S tates and Canada, dial +1 (404) 975-4839.  The\naccess code for the call will be 016298.  The live call will also be webcast via the Company\u2019s website at investor.cencora.com.  Users\nare encouraged to log on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n", "original_text": "From outside the United S tates and Canada, dial +1 (404) 975-4839. "}, "hash": "1ade0eb9fef4e9fc6075287583e7ecff196e34fea7f3596a18c2d85c2a803c1e", "class_name": "RelatedNodeInfo"}}, "text": "P articipating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (833) 470-1428. ", "start_char_idx": 746, "end_char_idx": 986, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "84979e79-43fc-426e-9dcf-76e7920aaaa2": {"__data__": {"id_": "84979e79-43fc-426e-9dcf-76e7920aaaa2", "embedding": null, "metadata": {"window": "ET on November 2, 2023.  A slide presentation for\ninvestors has also been posted on the Company's website at investor.cencora.com.  P articipating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (833) 470-1428.  From outside the United S tates and Canada, dial +1 (404) 975-4839.  The\naccess code for the call will be 016298.  The live call will also be webcast via the Company\u2019s website at investor.cencora.com.  Users\nare encouraged to log on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n", "original_text": "From outside the United S tates and Canada, dial +1 (404) 975-4839. ", "page_label": "6", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b76ad0b5-6e11-4d6c-9702-c56141c82238", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e00f6220ccf1d8d27c6f56f54e65359f917ceb7a0fbd989e9b94774f82ab4cea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fc7f59c6-baab-49ec-a06c-ee63ce9002e3", "node_type": "1", "metadata": {"window": "Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on November 2, 2023.  A slide presentation for\ninvestors has also been posted on the Company's website at investor.cencora.com.  P articipating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (833) 470-1428.  From outside the United S tates and Canada, dial +1 (404) 975-4839.  The\naccess code for the call will be 016298.  The live call will also be webcast via the Company\u2019s website at investor.cencora.com. ", "original_text": "P articipating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (833) 470-1428. ", "page_label": "6", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "88df3aeea207519b707375af8494ae800382d8423c360743deb0ed7270b3086c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5a2d9499-b19f-4303-bd2c-a75dbb757efb", "node_type": "1", "metadata": {"window": "A slide presentation for\ninvestors has also been posted on the Company's website at investor.cencora.com.  P articipating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (833) 470-1428.  From outside the United S tates and Canada, dial +1 (404) 975-4839.  The\naccess code for the call will be 016298.  The live call will also be webcast via the Company\u2019s website at investor.cencora.com.  Users\nare encouraged to log on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast. ", "original_text": "The\naccess code for the call will be 016298. "}, "hash": "f1266120d2259ecb09596a0e7f540fec6369abde339199a346bb048db8786b1e", "class_name": "RelatedNodeInfo"}}, "text": "From outside the United S tates and Canada, dial +1 (404) 975-4839. ", "start_char_idx": 986, "end_char_idx": 1054, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5a2d9499-b19f-4303-bd2c-a75dbb757efb": {"__data__": {"id_": "5a2d9499-b19f-4303-bd2c-a75dbb757efb", "embedding": null, "metadata": {"window": "A slide presentation for\ninvestors has also been posted on the Company's website at investor.cencora.com.  P articipating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (833) 470-1428.  From outside the United S tates and Canada, dial +1 (404) 975-4839.  The\naccess code for the call will be 016298.  The live call will also be webcast via the Company\u2019s website at investor.cencora.com.  Users\nare encouraged to log on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast. ", "original_text": "The\naccess code for the call will be 016298. ", "page_label": "6", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b76ad0b5-6e11-4d6c-9702-c56141c82238", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e00f6220ccf1d8d27c6f56f54e65359f917ceb7a0fbd989e9b94774f82ab4cea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "84979e79-43fc-426e-9dcf-76e7920aaaa2", "node_type": "1", "metadata": {"window": "ET on November 2, 2023.  A slide presentation for\ninvestors has also been posted on the Company's website at investor.cencora.com.  P articipating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (833) 470-1428.  From outside the United S tates and Canada, dial +1 (404) 975-4839.  The\naccess code for the call will be 016298.  The live call will also be webcast via the Company\u2019s website at investor.cencora.com.  Users\nare encouraged to log on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n", "original_text": "From outside the United S tates and Canada, dial +1 (404) 975-4839. ", "page_label": "6", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "af88eac7d1e0572051e2491c670f978a64a7de955923eba824741fd0d6a59cb4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1a9d4052-997d-4092-a57b-3225a635d218", "node_type": "1", "metadata": {"window": "P articipating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (833) 470-1428.  From outside the United S tates and Canada, dial +1 (404) 975-4839.  The\naccess code for the call will be 016298.  The live call will also be webcast via the Company\u2019s website at investor.cencora.com.  Users\nare encouraged to log on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on investor.cencora.com\napproximately one hour after the completion of the call and will remain available for one year. ", "original_text": "The live call will also be webcast via the Company\u2019s website at investor.cencora.com. "}, "hash": "0893ca9fc590f709a1c8ed5ff38bf7820d729f4180eb3497f16a472fbdacdde5", "class_name": "RelatedNodeInfo"}}, "text": "The\naccess code for the call will be 016298. ", "start_char_idx": 1054, "end_char_idx": 1099, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1a9d4052-997d-4092-a57b-3225a635d218": {"__data__": {"id_": "1a9d4052-997d-4092-a57b-3225a635d218", "embedding": null, "metadata": {"window": "P articipating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (833) 470-1428.  From outside the United S tates and Canada, dial +1 (404) 975-4839.  The\naccess code for the call will be 016298.  The live call will also be webcast via the Company\u2019s website at investor.cencora.com.  Users\nare encouraged to log on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on investor.cencora.com\napproximately one hour after the completion of the call and will remain available for one year. ", "original_text": "The live call will also be webcast via the Company\u2019s website at investor.cencora.com. ", "page_label": "6", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b76ad0b5-6e11-4d6c-9702-c56141c82238", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e00f6220ccf1d8d27c6f56f54e65359f917ceb7a0fbd989e9b94774f82ab4cea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5a2d9499-b19f-4303-bd2c-a75dbb757efb", "node_type": "1", "metadata": {"window": "A slide presentation for\ninvestors has also been posted on the Company's website at investor.cencora.com.  P articipating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (833) 470-1428.  From outside the United S tates and Canada, dial +1 (404) 975-4839.  The\naccess code for the call will be 016298.  The live call will also be webcast via the Company\u2019s website at investor.cencora.com.  Users\nare encouraged to log on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast. ", "original_text": "The\naccess code for the call will be 016298. ", "page_label": "6", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "83eeed288f6891f3567ee5e95f79eed2586323964c56624d9917cd6f815a3f85", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "67ed5f87-fb0b-4361-8c73-c0dfe3fc9fbc", "node_type": "1", "metadata": {"window": "From outside the United S tates and Canada, dial +1 (404) 975-4839.  The\naccess code for the call will be 016298.  The live call will also be webcast via the Company\u2019s website at investor.cencora.com.  Users\nare encouraged to log on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on investor.cencora.com\napproximately one hour after the completion of the call and will remain available for one year.  The telephone replay will also be\navailable approximately one hour after the completion of the call and will remain available for seven days. ", "original_text": "Users\nare encouraged to log on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n"}, "hash": "388078b6a5bfaf0cd04047bca34eb65c83b9b82e5dbdd8f1f1b9c7ce79c4941d", "class_name": "RelatedNodeInfo"}}, "text": "The live call will also be webcast via the Company\u2019s website at investor.cencora.com. ", "start_char_idx": 1099, "end_char_idx": 1185, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "67ed5f87-fb0b-4361-8c73-c0dfe3fc9fbc": {"__data__": {"id_": "67ed5f87-fb0b-4361-8c73-c0dfe3fc9fbc", "embedding": null, "metadata": {"window": "From outside the United S tates and Canada, dial +1 (404) 975-4839.  The\naccess code for the call will be 016298.  The live call will also be webcast via the Company\u2019s website at investor.cencora.com.  Users\nare encouraged to log on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on investor.cencora.com\napproximately one hour after the completion of the call and will remain available for one year.  The telephone replay will also be\navailable approximately one hour after the completion of the call and will remain available for seven days. ", "original_text": "Users\nare encouraged to log on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n", "page_label": "6", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b76ad0b5-6e11-4d6c-9702-c56141c82238", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e00f6220ccf1d8d27c6f56f54e65359f917ceb7a0fbd989e9b94774f82ab4cea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1a9d4052-997d-4092-a57b-3225a635d218", "node_type": "1", "metadata": {"window": "P articipating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (833) 470-1428.  From outside the United S tates and Canada, dial +1 (404) 975-4839.  The\naccess code for the call will be 016298.  The live call will also be webcast via the Company\u2019s website at investor.cencora.com.  Users\nare encouraged to log on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on investor.cencora.com\napproximately one hour after the completion of the call and will remain available for one year. ", "original_text": "The live call will also be webcast via the Company\u2019s website at investor.cencora.com. ", "page_label": "6", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7de8bbf534518e9df4251ea0131938059c068e152dda3764462eaa3003f87fe6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "55f793dc-d0e9-43b4-a1bc-d69e6a613f59", "node_type": "1", "metadata": {"window": "The\naccess code for the call will be 016298.  The live call will also be webcast via the Company\u2019s website at investor.cencora.com.  Users\nare encouraged to log on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on investor.cencora.com\napproximately one hour after the completion of the call and will remain available for one year.  The telephone replay will also be\navailable approximately one hour after the completion of the call and will remain available for seven days.  T o access the telephone\nreplay from within the U.S. ", "original_text": "Replays of the call will be made available via telephone and webcast. "}, "hash": "a05cffda7f1f90528f07264e8bdf169ef64ce41c4a32e3926e9285c42058bb09", "class_name": "RelatedNodeInfo"}}, "text": "Users\nare encouraged to log on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n", "start_char_idx": 1185, "end_char_idx": 1308, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "55f793dc-d0e9-43b4-a1bc-d69e6a613f59": {"__data__": {"id_": "55f793dc-d0e9-43b4-a1bc-d69e6a613f59", "embedding": null, "metadata": {"window": "The\naccess code for the call will be 016298.  The live call will also be webcast via the Company\u2019s website at investor.cencora.com.  Users\nare encouraged to log on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on investor.cencora.com\napproximately one hour after the completion of the call and will remain available for one year.  The telephone replay will also be\navailable approximately one hour after the completion of the call and will remain available for seven days.  T o access the telephone\nreplay from within the U.S. ", "original_text": "Replays of the call will be made available via telephone and webcast. ", "page_label": "6", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b76ad0b5-6e11-4d6c-9702-c56141c82238", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e00f6220ccf1d8d27c6f56f54e65359f917ceb7a0fbd989e9b94774f82ab4cea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "67ed5f87-fb0b-4361-8c73-c0dfe3fc9fbc", "node_type": "1", "metadata": {"window": "From outside the United S tates and Canada, dial +1 (404) 975-4839.  The\naccess code for the call will be 016298.  The live call will also be webcast via the Company\u2019s website at investor.cencora.com.  Users\nare encouraged to log on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on investor.cencora.com\napproximately one hour after the completion of the call and will remain available for one year.  The telephone replay will also be\navailable approximately one hour after the completion of the call and will remain available for seven days. ", "original_text": "Users\nare encouraged to log on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n", "page_label": "6", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "201129093d2fced1036c129ce3fbd938bf1ca84b9af3d2c0a2692e63a4f68b01", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "40ebe93e-7201-4dd5-9782-f90b1d485e26", "node_type": "1", "metadata": {"window": "The live call will also be webcast via the Company\u2019s website at investor.cencora.com.  Users\nare encouraged to log on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on investor.cencora.com\napproximately one hour after the completion of the call and will remain available for one year.  The telephone replay will also be\navailable approximately one hour after the completion of the call and will remain available for seven days.  T o access the telephone\nreplay from within the U.S.  and Canada, dial (866) 813-9403. ", "original_text": "A replay of the webcast will be posted on investor.cencora.com\napproximately one hour after the completion of the call and will remain available for one year. "}, "hash": "14b6a35172d25bc1bee11031e6c7c281c41c0ed6dac049807095184d0e5d89c4", "class_name": "RelatedNodeInfo"}}, "text": "Replays of the call will be made available via telephone and webcast. ", "start_char_idx": 1308, "end_char_idx": 1378, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "40ebe93e-7201-4dd5-9782-f90b1d485e26": {"__data__": {"id_": "40ebe93e-7201-4dd5-9782-f90b1d485e26", "embedding": null, "metadata": {"window": "The live call will also be webcast via the Company\u2019s website at investor.cencora.com.  Users\nare encouraged to log on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on investor.cencora.com\napproximately one hour after the completion of the call and will remain available for one year.  The telephone replay will also be\navailable approximately one hour after the completion of the call and will remain available for seven days.  T o access the telephone\nreplay from within the U.S.  and Canada, dial (866) 813-9403. ", "original_text": "A replay of the webcast will be posted on investor.cencora.com\napproximately one hour after the completion of the call and will remain available for one year. ", "page_label": "6", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b76ad0b5-6e11-4d6c-9702-c56141c82238", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e00f6220ccf1d8d27c6f56f54e65359f917ceb7a0fbd989e9b94774f82ab4cea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "55f793dc-d0e9-43b4-a1bc-d69e6a613f59", "node_type": "1", "metadata": {"window": "The\naccess code for the call will be 016298.  The live call will also be webcast via the Company\u2019s website at investor.cencora.com.  Users\nare encouraged to log on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on investor.cencora.com\napproximately one hour after the completion of the call and will remain available for one year.  The telephone replay will also be\navailable approximately one hour after the completion of the call and will remain available for seven days.  T o access the telephone\nreplay from within the U.S. ", "original_text": "Replays of the call will be made available via telephone and webcast. ", "page_label": "6", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "be24644151ddfde643eab4cc207427f2c3d78fe716888499ba1232c87a3c74b1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ef91abbc-8c32-4466-b42e-72bb1d637b17", "node_type": "1", "metadata": {"window": "Users\nare encouraged to log on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on investor.cencora.com\napproximately one hour after the completion of the call and will remain available for one year.  The telephone replay will also be\navailable approximately one hour after the completion of the call and will remain available for seven days.  T o access the telephone\nreplay from within the U.S.  and Canada, dial (866) 813-9403.  From outside the U.S. ", "original_text": "The telephone replay will also be\navailable approximately one hour after the completion of the call and will remain available for seven days. "}, "hash": "fa57f8da47b13613573d00e66edd0c9158e8223719cfc1c7124415b7835eccb5", "class_name": "RelatedNodeInfo"}}, "text": "A replay of the webcast will be posted on investor.cencora.com\napproximately one hour after the completion of the call and will remain available for one year. ", "start_char_idx": 1378, "end_char_idx": 1537, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ef91abbc-8c32-4466-b42e-72bb1d637b17": {"__data__": {"id_": "ef91abbc-8c32-4466-b42e-72bb1d637b17", "embedding": null, "metadata": {"window": "Users\nare encouraged to log on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on investor.cencora.com\napproximately one hour after the completion of the call and will remain available for one year.  The telephone replay will also be\navailable approximately one hour after the completion of the call and will remain available for seven days.  T o access the telephone\nreplay from within the U.S.  and Canada, dial (866) 813-9403.  From outside the U.S. ", "original_text": "The telephone replay will also be\navailable approximately one hour after the completion of the call and will remain available for seven days. ", "page_label": "6", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b76ad0b5-6e11-4d6c-9702-c56141c82238", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e00f6220ccf1d8d27c6f56f54e65359f917ceb7a0fbd989e9b94774f82ab4cea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "40ebe93e-7201-4dd5-9782-f90b1d485e26", "node_type": "1", "metadata": {"window": "The live call will also be webcast via the Company\u2019s website at investor.cencora.com.  Users\nare encouraged to log on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on investor.cencora.com\napproximately one hour after the completion of the call and will remain available for one year.  The telephone replay will also be\navailable approximately one hour after the completion of the call and will remain available for seven days.  T o access the telephone\nreplay from within the U.S.  and Canada, dial (866) 813-9403. ", "original_text": "A replay of the webcast will be posted on investor.cencora.com\napproximately one hour after the completion of the call and will remain available for one year. ", "page_label": "6", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dec3076436ffa7b25cafd797051f113b69d6dde952ebad434de805ffe19be60f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1e885e91-955e-444c-84d3-73c154db6f53", "node_type": "1", "metadata": {"window": "Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on investor.cencora.com\napproximately one hour after the completion of the call and will remain available for one year.  The telephone replay will also be\navailable approximately one hour after the completion of the call and will remain available for seven days.  T o access the telephone\nreplay from within the U.S.  and Canada, dial (866) 813-9403.  From outside the U.S.  and Canada, dial +1 (929) 458-6194. ", "original_text": "T o access the telephone\nreplay from within the U.S. "}, "hash": "59092adc202494deb295f8567cc2f9742dea271991f4e494eda7cea90c2d491f", "class_name": "RelatedNodeInfo"}}, "text": "The telephone replay will also be\navailable approximately one hour after the completion of the call and will remain available for seven days. ", "start_char_idx": 1537, "end_char_idx": 1679, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1e885e91-955e-444c-84d3-73c154db6f53": {"__data__": {"id_": "1e885e91-955e-444c-84d3-73c154db6f53", "embedding": null, "metadata": {"window": "Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on investor.cencora.com\napproximately one hour after the completion of the call and will remain available for one year.  The telephone replay will also be\navailable approximately one hour after the completion of the call and will remain available for seven days.  T o access the telephone\nreplay from within the U.S.  and Canada, dial (866) 813-9403.  From outside the U.S.  and Canada, dial +1 (929) 458-6194. ", "original_text": "T o access the telephone\nreplay from within the U.S. ", "page_label": "6", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b76ad0b5-6e11-4d6c-9702-c56141c82238", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e00f6220ccf1d8d27c6f56f54e65359f917ceb7a0fbd989e9b94774f82ab4cea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ef91abbc-8c32-4466-b42e-72bb1d637b17", "node_type": "1", "metadata": {"window": "Users\nare encouraged to log on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on investor.cencora.com\napproximately one hour after the completion of the call and will remain available for one year.  The telephone replay will also be\navailable approximately one hour after the completion of the call and will remain available for seven days.  T o access the telephone\nreplay from within the U.S.  and Canada, dial (866) 813-9403.  From outside the U.S. ", "original_text": "The telephone replay will also be\navailable approximately one hour after the completion of the call and will remain available for seven days. ", "page_label": "6", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "20062d419a399aeb34c81a51f10a36d0e47ccc06f7a2806e48a99ac2d615d748", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "080b129c-c6a3-4cb5-9307-91c5081b2547", "node_type": "1", "metadata": {"window": "A replay of the webcast will be posted on investor.cencora.com\napproximately one hour after the completion of the call and will remain available for one year.  The telephone replay will also be\navailable approximately one hour after the completion of the call and will remain available for seven days.  T o access the telephone\nreplay from within the U.S.  and Canada, dial (866) 813-9403.  From outside the U.S.  and Canada, dial +1 (929) 458-6194.  The access\ncode for the replay is 205780.\n", "original_text": "and Canada, dial (866) 813-9403. "}, "hash": "49f20d24a9b4f0c6e3e3c8d08f924e8b067ded306d9de8e9b3260d3422959e9c", "class_name": "RelatedNodeInfo"}}, "text": "T o access the telephone\nreplay from within the U.S. ", "start_char_idx": 1679, "end_char_idx": 1732, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "080b129c-c6a3-4cb5-9307-91c5081b2547": {"__data__": {"id_": "080b129c-c6a3-4cb5-9307-91c5081b2547", "embedding": null, "metadata": {"window": "A replay of the webcast will be posted on investor.cencora.com\napproximately one hour after the completion of the call and will remain available for one year.  The telephone replay will also be\navailable approximately one hour after the completion of the call and will remain available for seven days.  T o access the telephone\nreplay from within the U.S.  and Canada, dial (866) 813-9403.  From outside the U.S.  and Canada, dial +1 (929) 458-6194.  The access\ncode for the replay is 205780.\n", "original_text": "and Canada, dial (866) 813-9403. ", "page_label": "6", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b76ad0b5-6e11-4d6c-9702-c56141c82238", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e00f6220ccf1d8d27c6f56f54e65359f917ceb7a0fbd989e9b94774f82ab4cea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1e885e91-955e-444c-84d3-73c154db6f53", "node_type": "1", "metadata": {"window": "Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on investor.cencora.com\napproximately one hour after the completion of the call and will remain available for one year.  The telephone replay will also be\navailable approximately one hour after the completion of the call and will remain available for seven days.  T o access the telephone\nreplay from within the U.S.  and Canada, dial (866) 813-9403.  From outside the U.S.  and Canada, dial +1 (929) 458-6194. ", "original_text": "T o access the telephone\nreplay from within the U.S. ", "page_label": "6", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1ab44df5483a4978e9a5fa4d3e37d732d9ec6ff4d7d30aacfc6fa81051c31fa1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b1caa64f-00c4-4c16-a518-0927a9d765fc", "node_type": "1", "metadata": {"window": "The telephone replay will also be\navailable approximately one hour after the completion of the call and will remain available for seven days.  T o access the telephone\nreplay from within the U.S.  and Canada, dial (866) 813-9403.  From outside the U.S.  and Canada, dial +1 (929) 458-6194.  The access\ncode for the replay is 205780.\n Upcoming Inv estor Ev ents\nCencora management will be attending the following investor conference in the coming months:\nJ.P. ", "original_text": "From outside the U.S. "}, "hash": "71fef2e70d4b3f0bd517f0445c9b53a9354200645f009f7de3a85f1b217816f8", "class_name": "RelatedNodeInfo"}}, "text": "and Canada, dial (866) 813-9403. ", "start_char_idx": 1732, "end_char_idx": 1765, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b1caa64f-00c4-4c16-a518-0927a9d765fc": {"__data__": {"id_": "b1caa64f-00c4-4c16-a518-0927a9d765fc", "embedding": null, "metadata": {"window": "The telephone replay will also be\navailable approximately one hour after the completion of the call and will remain available for seven days.  T o access the telephone\nreplay from within the U.S.  and Canada, dial (866) 813-9403.  From outside the U.S.  and Canada, dial +1 (929) 458-6194.  The access\ncode for the replay is 205780.\n Upcoming Inv estor Ev ents\nCencora management will be attending the following investor conference in the coming months:\nJ.P. ", "original_text": "From outside the U.S. ", "page_label": "6", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b76ad0b5-6e11-4d6c-9702-c56141c82238", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e00f6220ccf1d8d27c6f56f54e65359f917ceb7a0fbd989e9b94774f82ab4cea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "080b129c-c6a3-4cb5-9307-91c5081b2547", "node_type": "1", "metadata": {"window": "A replay of the webcast will be posted on investor.cencora.com\napproximately one hour after the completion of the call and will remain available for one year.  The telephone replay will also be\navailable approximately one hour after the completion of the call and will remain available for seven days.  T o access the telephone\nreplay from within the U.S.  and Canada, dial (866) 813-9403.  From outside the U.S.  and Canada, dial +1 (929) 458-6194.  The access\ncode for the replay is 205780.\n", "original_text": "and Canada, dial (866) 813-9403. ", "page_label": "6", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "56b596672e5d5e383f637a191cdfcde65142299c9c4d1da2aab50bab318185ee", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a308398a-e3f6-434f-a38c-c76923306fc8", "node_type": "1", "metadata": {"window": "T o access the telephone\nreplay from within the U.S.  and Canada, dial (866) 813-9403.  From outside the U.S.  and Canada, dial +1 (929) 458-6194.  The access\ncode for the replay is 205780.\n Upcoming Inv estor Ev ents\nCencora management will be attending the following investor conference in the coming months:\nJ.P.  Morgan Healthcare Conference, January 8-11, 2024.\n", "original_text": "and Canada, dial +1 (929) 458-6194. "}, "hash": "db5c03f041ab21a167b04a9ac4788738578f38cf9d1779f330d15f155e394049", "class_name": "RelatedNodeInfo"}}, "text": "From outside the U.S. ", "start_char_idx": 1765, "end_char_idx": 1787, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a308398a-e3f6-434f-a38c-c76923306fc8": {"__data__": {"id_": "a308398a-e3f6-434f-a38c-c76923306fc8", "embedding": null, "metadata": {"window": "T o access the telephone\nreplay from within the U.S.  and Canada, dial (866) 813-9403.  From outside the U.S.  and Canada, dial +1 (929) 458-6194.  The access\ncode for the replay is 205780.\n Upcoming Inv estor Ev ents\nCencora management will be attending the following investor conference in the coming months:\nJ.P.  Morgan Healthcare Conference, January 8-11, 2024.\n", "original_text": "and Canada, dial +1 (929) 458-6194. ", "page_label": "6", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b76ad0b5-6e11-4d6c-9702-c56141c82238", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e00f6220ccf1d8d27c6f56f54e65359f917ceb7a0fbd989e9b94774f82ab4cea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b1caa64f-00c4-4c16-a518-0927a9d765fc", "node_type": "1", "metadata": {"window": "The telephone replay will also be\navailable approximately one hour after the completion of the call and will remain available for seven days.  T o access the telephone\nreplay from within the U.S.  and Canada, dial (866) 813-9403.  From outside the U.S.  and Canada, dial +1 (929) 458-6194.  The access\ncode for the replay is 205780.\n Upcoming Inv estor Ev ents\nCencora management will be attending the following investor conference in the coming months:\nJ.P. ", "original_text": "From outside the U.S. ", "page_label": "6", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f2d7ef6968dddb21256f2533c71e10f069aade76e4b5c6554d0e99634d7f52a0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c496d03c-77dc-44a6-be06-b51d8098e051", "node_type": "1", "metadata": {"window": "and Canada, dial (866) 813-9403.  From outside the U.S.  and Canada, dial +1 (929) 458-6194.  The access\ncode for the replay is 205780.\n Upcoming Inv estor Ev ents\nCencora management will be attending the following investor conference in the coming months:\nJ.P.  Morgan Healthcare Conference, January 8-11, 2024.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n", "original_text": "The access\ncode for the replay is 205780.\n"}, "hash": "28c373e9aebe942381f7f4f8f01e4304c58be46e80e92821906cf0f2b236e453", "class_name": "RelatedNodeInfo"}}, "text": "and Canada, dial +1 (929) 458-6194. ", "start_char_idx": 1787, "end_char_idx": 1823, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c496d03c-77dc-44a6-be06-b51d8098e051": {"__data__": {"id_": "c496d03c-77dc-44a6-be06-b51d8098e051", "embedding": null, "metadata": {"window": "and Canada, dial (866) 813-9403.  From outside the U.S.  and Canada, dial +1 (929) 458-6194.  The access\ncode for the replay is 205780.\n Upcoming Inv estor Ev ents\nCencora management will be attending the following investor conference in the coming months:\nJ.P.  Morgan Healthcare Conference, January 8-11, 2024.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n", "original_text": "The access\ncode for the replay is 205780.\n", "page_label": "6", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b76ad0b5-6e11-4d6c-9702-c56141c82238", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e00f6220ccf1d8d27c6f56f54e65359f917ceb7a0fbd989e9b94774f82ab4cea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a308398a-e3f6-434f-a38c-c76923306fc8", "node_type": "1", "metadata": {"window": "T o access the telephone\nreplay from within the U.S.  and Canada, dial (866) 813-9403.  From outside the U.S.  and Canada, dial +1 (929) 458-6194.  The access\ncode for the replay is 205780.\n Upcoming Inv estor Ev ents\nCencora management will be attending the following investor conference in the coming months:\nJ.P.  Morgan Healthcare Conference, January 8-11, 2024.\n", "original_text": "and Canada, dial +1 (929) 458-6194. ", "page_label": "6", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "734ff42a8939c49a9ebe292b2d9e98cc425c6f030b3fead58b6ccb0226d33917", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e3f14a82-a69c-41aa-8901-7b89d6de07e0", "node_type": "1", "metadata": {"window": "From outside the U.S.  and Canada, dial +1 (929) 458-6194.  The access\ncode for the replay is 205780.\n Upcoming Inv estor Ev ents\nCencora management will be attending the following investor conference in the coming months:\nJ.P.  Morgan Healthcare Conference, January 8-11, 2024.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Cencora\nCencora is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals around\nthe world. ", "original_text": "Upcoming Inv estor Ev ents\nCencora management will be attending the following investor conference in the coming months:\nJ.P. "}, "hash": "412f847bfd729b16bec74c7019a1bcd2afef7e877a07bc16e26a764372ed30fc", "class_name": "RelatedNodeInfo"}}, "text": "The access\ncode for the replay is 205780.\n", "start_char_idx": 1823, "end_char_idx": 1865, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e3f14a82-a69c-41aa-8901-7b89d6de07e0": {"__data__": {"id_": "e3f14a82-a69c-41aa-8901-7b89d6de07e0", "embedding": null, "metadata": {"window": "From outside the U.S.  and Canada, dial +1 (929) 458-6194.  The access\ncode for the replay is 205780.\n Upcoming Inv estor Ev ents\nCencora management will be attending the following investor conference in the coming months:\nJ.P.  Morgan Healthcare Conference, January 8-11, 2024.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Cencora\nCencora is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals around\nthe world. ", "original_text": "Upcoming Inv estor Ev ents\nCencora management will be attending the following investor conference in the coming months:\nJ.P. ", "page_label": "6", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b76ad0b5-6e11-4d6c-9702-c56141c82238", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e00f6220ccf1d8d27c6f56f54e65359f917ceb7a0fbd989e9b94774f82ab4cea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c496d03c-77dc-44a6-be06-b51d8098e051", "node_type": "1", "metadata": {"window": "and Canada, dial (866) 813-9403.  From outside the U.S.  and Canada, dial +1 (929) 458-6194.  The access\ncode for the replay is 205780.\n Upcoming Inv estor Ev ents\nCencora management will be attending the following investor conference in the coming months:\nJ.P.  Morgan Healthcare Conference, January 8-11, 2024.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n", "original_text": "The access\ncode for the replay is 205780.\n", "page_label": "6", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e115bfac334d474def541a14d031d8dab04626326791c1ab087601bd2756e814", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fdd2a319-fc98-43bd-9ed8-cf2e7192513c", "node_type": "1", "metadata": {"window": "and Canada, dial +1 (929) 458-6194.  The access\ncode for the replay is 205780.\n Upcoming Inv estor Ev ents\nCencora management will be attending the following investor conference in the coming months:\nJ.P.  Morgan Healthcare Conference, January 8-11, 2024.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Cencora\nCencora is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals around\nthe world.  W e partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to therapies.\n", "original_text": "Morgan Healthcare Conference, January 8-11, 2024.\n"}, "hash": "8ed91fb2a56d8514af04ddbf1ba341e6648809312a031fe78725f88690b4e009", "class_name": "RelatedNodeInfo"}}, "text": "Upcoming Inv estor Ev ents\nCencora management will be attending the following investor conference in the coming months:\nJ.P. ", "start_char_idx": 1865, "end_char_idx": 1990, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fdd2a319-fc98-43bd-9ed8-cf2e7192513c": {"__data__": {"id_": "fdd2a319-fc98-43bd-9ed8-cf2e7192513c", "embedding": null, "metadata": {"window": "and Canada, dial +1 (929) 458-6194.  The access\ncode for the replay is 205780.\n Upcoming Inv estor Ev ents\nCencora management will be attending the following investor conference in the coming months:\nJ.P.  Morgan Healthcare Conference, January 8-11, 2024.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Cencora\nCencora is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals around\nthe world.  W e partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to therapies.\n", "original_text": "Morgan Healthcare Conference, January 8-11, 2024.\n", "page_label": "6", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b76ad0b5-6e11-4d6c-9702-c56141c82238", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e00f6220ccf1d8d27c6f56f54e65359f917ceb7a0fbd989e9b94774f82ab4cea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e3f14a82-a69c-41aa-8901-7b89d6de07e0", "node_type": "1", "metadata": {"window": "From outside the U.S.  and Canada, dial +1 (929) 458-6194.  The access\ncode for the replay is 205780.\n Upcoming Inv estor Ev ents\nCencora management will be attending the following investor conference in the coming months:\nJ.P.  Morgan Healthcare Conference, January 8-11, 2024.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Cencora\nCencora is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals around\nthe world. ", "original_text": "Upcoming Inv estor Ev ents\nCencora management will be attending the following investor conference in the coming months:\nJ.P. ", "page_label": "6", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8775e21a021062f209f5d8f266dee82572c96e7a35b388875f10108e4abc1217", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a4e9816e-cfa4-4526-8eb4-7ed59d5f8c64", "node_type": "1", "metadata": {"window": "The access\ncode for the replay is 205780.\n Upcoming Inv estor Ev ents\nCencora management will be attending the following investor conference in the coming months:\nJ.P.  Morgan Healthcare Conference, January 8-11, 2024.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Cencora\nCencora is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals around\nthe world.  W e partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to therapies.\n Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions. ", "original_text": "Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n"}, "hash": "1512da55d41a51e8c5cce14dbd2a19c3f4a5f30fa4d2b663a08be8070c6ac048", "class_name": "RelatedNodeInfo"}}, "text": "Morgan Healthcare Conference, January 8-11, 2024.\n", "start_char_idx": 1990, "end_char_idx": 2040, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a4e9816e-cfa4-4526-8eb4-7ed59d5f8c64": {"__data__": {"id_": "a4e9816e-cfa4-4526-8eb4-7ed59d5f8c64", "embedding": null, "metadata": {"window": "The access\ncode for the replay is 205780.\n Upcoming Inv estor Ev ents\nCencora management will be attending the following investor conference in the coming months:\nJ.P.  Morgan Healthcare Conference, January 8-11, 2024.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Cencora\nCencora is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals around\nthe world.  W e partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to therapies.\n Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions. ", "original_text": "Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n", "page_label": "6", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b76ad0b5-6e11-4d6c-9702-c56141c82238", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e00f6220ccf1d8d27c6f56f54e65359f917ceb7a0fbd989e9b94774f82ab4cea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fdd2a319-fc98-43bd-9ed8-cf2e7192513c", "node_type": "1", "metadata": {"window": "and Canada, dial +1 (929) 458-6194.  The access\ncode for the replay is 205780.\n Upcoming Inv estor Ev ents\nCencora management will be attending the following investor conference in the coming months:\nJ.P.  Morgan Healthcare Conference, January 8-11, 2024.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Cencora\nCencora is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals around\nthe world.  W e partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to therapies.\n", "original_text": "Morgan Healthcare Conference, January 8-11, 2024.\n", "page_label": "6", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "77e199e89b3b793f8ffd280a6c874fa46b629a5ef6ec8a5829c5eec7db1205ac", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a5984080-42b9-4bc2-a3f1-dad19c0d9662", "node_type": "1", "metadata": {"window": "Upcoming Inv estor Ev ents\nCencora management will be attending the following investor conference in the coming months:\nJ.P.  Morgan Healthcare Conference, January 8-11, 2024.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Cencora\nCencora is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals around\nthe world.  W e partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to therapies.\n Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions.  Our 46,000+\nworldwide team members contribute to positive health outcomes through the power of our purpose: We are united in our\nresponsibility to create healthier futures . ", "original_text": "About Cencora\nCencora is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals around\nthe world. "}, "hash": "a978a1d99ea2ed162c6c586d02b76634e588ea77b45ecdbe58fe26c9cc009bbb", "class_name": "RelatedNodeInfo"}}, "text": "Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n", "start_char_idx": 2040, "end_char_idx": 2169, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a5984080-42b9-4bc2-a3f1-dad19c0d9662": {"__data__": {"id_": "a5984080-42b9-4bc2-a3f1-dad19c0d9662", "embedding": null, "metadata": {"window": "Upcoming Inv estor Ev ents\nCencora management will be attending the following investor conference in the coming months:\nJ.P.  Morgan Healthcare Conference, January 8-11, 2024.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Cencora\nCencora is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals around\nthe world.  W e partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to therapies.\n Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions.  Our 46,000+\nworldwide team members contribute to positive health outcomes through the power of our purpose: We are united in our\nresponsibility to create healthier futures . ", "original_text": "About Cencora\nCencora is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals around\nthe world. ", "page_label": "6", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b76ad0b5-6e11-4d6c-9702-c56141c82238", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e00f6220ccf1d8d27c6f56f54e65359f917ceb7a0fbd989e9b94774f82ab4cea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a4e9816e-cfa4-4526-8eb4-7ed59d5f8c64", "node_type": "1", "metadata": {"window": "The access\ncode for the replay is 205780.\n Upcoming Inv estor Ev ents\nCencora management will be attending the following investor conference in the coming months:\nJ.P.  Morgan Healthcare Conference, January 8-11, 2024.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Cencora\nCencora is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals around\nthe world.  W e partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to therapies.\n Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions. ", "original_text": "Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n", "page_label": "6", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1da6781bd31c61ee49d41018638adec3ab2b542925709e53d0f567e14ba18f71", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0fca344a-1654-4777-8a0f-ad5e4bec0f5f", "node_type": "1", "metadata": {"window": "Morgan Healthcare Conference, January 8-11, 2024.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Cencora\nCencora is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals around\nthe world.  W e partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to therapies.\n Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions.  Our 46,000+\nworldwide team members contribute to positive health outcomes through the power of our purpose: We are united in our\nresponsibility to create healthier futures .  Cencora is ranked #11 on the Fortune 500 and #24 on the Global Fortune 500 with more\nthan $250 billion in annual revenue. ", "original_text": "W e partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to therapies.\n"}, "hash": "47f0dc8458d673696c270a437179d4665be2b75fce82f697da60a276054c4889", "class_name": "RelatedNodeInfo"}}, "text": "About Cencora\nCencora is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals around\nthe world. ", "start_char_idx": 2169, "end_char_idx": 2321, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0fca344a-1654-4777-8a0f-ad5e4bec0f5f": {"__data__": {"id_": "0fca344a-1654-4777-8a0f-ad5e4bec0f5f", "embedding": null, "metadata": {"window": "Morgan Healthcare Conference, January 8-11, 2024.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Cencora\nCencora is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals around\nthe world.  W e partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to therapies.\n Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions.  Our 46,000+\nworldwide team members contribute to positive health outcomes through the power of our purpose: We are united in our\nresponsibility to create healthier futures .  Cencora is ranked #11 on the Fortune 500 and #24 on the Global Fortune 500 with more\nthan $250 billion in annual revenue. ", "original_text": "W e partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to therapies.\n", "page_label": "6", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b76ad0b5-6e11-4d6c-9702-c56141c82238", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e00f6220ccf1d8d27c6f56f54e65359f917ceb7a0fbd989e9b94774f82ab4cea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a5984080-42b9-4bc2-a3f1-dad19c0d9662", "node_type": "1", "metadata": {"window": "Upcoming Inv estor Ev ents\nCencora management will be attending the following investor conference in the coming months:\nJ.P.  Morgan Healthcare Conference, January 8-11, 2024.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Cencora\nCencora is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals around\nthe world.  W e partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to therapies.\n Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions.  Our 46,000+\nworldwide team members contribute to positive health outcomes through the power of our purpose: We are united in our\nresponsibility to create healthier futures . ", "original_text": "About Cencora\nCencora is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals around\nthe world. ", "page_label": "6", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "262f8dc8828046029e9dbb80da21131dc8bb4fe77314513183092c2fb4cf2a64", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "93fdd4bc-6a4b-48ef-b0a8-becdd89088f1", "node_type": "1", "metadata": {"window": "Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Cencora\nCencora is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals around\nthe world.  W e partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to therapies.\n Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions.  Our 46,000+\nworldwide team members contribute to positive health outcomes through the power of our purpose: We are united in our\nresponsibility to create healthier futures .  Cencora is ranked #11 on the Fortune 500 and #24 on the Global Fortune 500 with more\nthan $250 billion in annual revenue.  Learn more at www.investor.cencora.com\nCencora\u2019 s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d). ", "original_text": "Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions. "}, "hash": "42235300003a77734d46f1146fd74e22ed910ddb336ae3ba964898100a80fdf3", "class_name": "RelatedNodeInfo"}}, "text": "W e partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to therapies.\n", "start_char_idx": 2321, "end_char_idx": 2442, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "93fdd4bc-6a4b-48ef-b0a8-becdd89088f1": {"__data__": {"id_": "93fdd4bc-6a4b-48ef-b0a8-becdd89088f1", "embedding": null, "metadata": {"window": "Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Cencora\nCencora is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals around\nthe world.  W e partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to therapies.\n Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions.  Our 46,000+\nworldwide team members contribute to positive health outcomes through the power of our purpose: We are united in our\nresponsibility to create healthier futures .  Cencora is ranked #11 on the Fortune 500 and #24 on the Global Fortune 500 with more\nthan $250 billion in annual revenue.  Learn more at www.investor.cencora.com\nCencora\u2019 s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d). ", "original_text": "Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions. ", "page_label": "6", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b76ad0b5-6e11-4d6c-9702-c56141c82238", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e00f6220ccf1d8d27c6f56f54e65359f917ceb7a0fbd989e9b94774f82ab4cea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0fca344a-1654-4777-8a0f-ad5e4bec0f5f", "node_type": "1", "metadata": {"window": "Morgan Healthcare Conference, January 8-11, 2024.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Cencora\nCencora is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals around\nthe world.  W e partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to therapies.\n Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions.  Our 46,000+\nworldwide team members contribute to positive health outcomes through the power of our purpose: We are united in our\nresponsibility to create healthier futures .  Cencora is ranked #11 on the Fortune 500 and #24 on the Global Fortune 500 with more\nthan $250 billion in annual revenue. ", "original_text": "W e partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to therapies.\n", "page_label": "6", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c1415e72da7127da6a415cdb009e49ab52233473ba9f017d3da60bff8ba97851", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b285c1a0-db9e-4103-bce2-b0ed9ec4d7da", "node_type": "1", "metadata": {"window": "About Cencora\nCencora is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals around\nthe world.  W e partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to therapies.\n Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions.  Our 46,000+\nworldwide team members contribute to positive health outcomes through the power of our purpose: We are united in our\nresponsibility to create healthier futures .  Cencora is ranked #11 on the Fortune 500 and #24 on the Global Fortune 500 with more\nthan $250 billion in annual revenue.  Learn more at www.investor.cencora.com\nCencora\u2019 s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d).  W ords such as \"aim,\" \"anticipate,\" \"believe,\" \"can,\" \"continue,\" \"could,\" \"estimate,\" \"expect,\" \"intend,\" \"may,\" \"might,\" \"on\ntrack,\" \"opportunity,\" \"plan,\" \"possible,\" \"potential,\" \"predict,\" \"project,\u201d \"seek,\" \"should,\" \"strive,\" \"sustain,\" \"synergy,\" \"target,\" \"will,\"\n\"would\" and similar expressions are intended to identify such forward-looking statements, but the absence of these words does not\nmean the statement is not forward-looking. ", "original_text": "Our 46,000+\nworldwide team members contribute to positive health outcomes through the power of our purpose: We are united in our\nresponsibility to create healthier futures . "}, "hash": "286036c56b19c60ca4bf9dd3f26cd4cf6df9366264589edceb3d99abf843c002", "class_name": "RelatedNodeInfo"}}, "text": "Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions. ", "start_char_idx": 2442, "end_char_idx": 2560, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b285c1a0-db9e-4103-bce2-b0ed9ec4d7da": {"__data__": {"id_": "b285c1a0-db9e-4103-bce2-b0ed9ec4d7da", "embedding": null, "metadata": {"window": "About Cencora\nCencora is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals around\nthe world.  W e partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to therapies.\n Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions.  Our 46,000+\nworldwide team members contribute to positive health outcomes through the power of our purpose: We are united in our\nresponsibility to create healthier futures .  Cencora is ranked #11 on the Fortune 500 and #24 on the Global Fortune 500 with more\nthan $250 billion in annual revenue.  Learn more at www.investor.cencora.com\nCencora\u2019 s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d).  W ords such as \"aim,\" \"anticipate,\" \"believe,\" \"can,\" \"continue,\" \"could,\" \"estimate,\" \"expect,\" \"intend,\" \"may,\" \"might,\" \"on\ntrack,\" \"opportunity,\" \"plan,\" \"possible,\" \"potential,\" \"predict,\" \"project,\u201d \"seek,\" \"should,\" \"strive,\" \"sustain,\" \"synergy,\" \"target,\" \"will,\"\n\"would\" and similar expressions are intended to identify such forward-looking statements, but the absence of these words does not\nmean the statement is not forward-looking. ", "original_text": "Our 46,000+\nworldwide team members contribute to positive health outcomes through the power of our purpose: We are united in our\nresponsibility to create healthier futures . ", "page_label": "6", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b76ad0b5-6e11-4d6c-9702-c56141c82238", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e00f6220ccf1d8d27c6f56f54e65359f917ceb7a0fbd989e9b94774f82ab4cea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "93fdd4bc-6a4b-48ef-b0a8-becdd89088f1", "node_type": "1", "metadata": {"window": "Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Cencora\nCencora is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals around\nthe world.  W e partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to therapies.\n Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions.  Our 46,000+\nworldwide team members contribute to positive health outcomes through the power of our purpose: We are united in our\nresponsibility to create healthier futures .  Cencora is ranked #11 on the Fortune 500 and #24 on the Global Fortune 500 with more\nthan $250 billion in annual revenue.  Learn more at www.investor.cencora.com\nCencora\u2019 s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d). ", "original_text": "Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions. ", "page_label": "6", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2090cd034769cb0b2d2b2d0a659f8d83cbe9e2552ec3b80bd14819c3469253f7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "399f52cb-2812-4e0c-b38f-8f3ee8ca20e5", "node_type": "1", "metadata": {"window": "W e partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to therapies.\n Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions.  Our 46,000+\nworldwide team members contribute to positive health outcomes through the power of our purpose: We are united in our\nresponsibility to create healthier futures .  Cencora is ranked #11 on the Fortune 500 and #24 on the Global Fortune 500 with more\nthan $250 billion in annual revenue.  Learn more at www.investor.cencora.com\nCencora\u2019 s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d).  W ords such as \"aim,\" \"anticipate,\" \"believe,\" \"can,\" \"continue,\" \"could,\" \"estimate,\" \"expect,\" \"intend,\" \"may,\" \"might,\" \"on\ntrack,\" \"opportunity,\" \"plan,\" \"possible,\" \"potential,\" \"predict,\" \"project,\u201d \"seek,\" \"should,\" \"strive,\" \"sustain,\" \"synergy,\" \"target,\" \"will,\"\n\"would\" and similar expressions are intended to identify such forward-looking statements, but the absence of these words does not\nmean the statement is not forward-looking.  These statements are based on management\u2019s current expectations and are subject to\n6", "original_text": "Cencora is ranked #11 on the Fortune 500 and #24 on the Global Fortune 500 with more\nthan $250 billion in annual revenue. "}, "hash": "07d0641bd2818d3a33df66bc881c39eb8b9b431edc397c2e32ebab69446a00ac", "class_name": "RelatedNodeInfo"}}, "text": "Our 46,000+\nworldwide team members contribute to positive health outcomes through the power of our purpose: We are united in our\nresponsibility to create healthier futures . ", "start_char_idx": 2560, "end_char_idx": 2734, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "399f52cb-2812-4e0c-b38f-8f3ee8ca20e5": {"__data__": {"id_": "399f52cb-2812-4e0c-b38f-8f3ee8ca20e5", "embedding": null, "metadata": {"window": "W e partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to therapies.\n Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions.  Our 46,000+\nworldwide team members contribute to positive health outcomes through the power of our purpose: We are united in our\nresponsibility to create healthier futures .  Cencora is ranked #11 on the Fortune 500 and #24 on the Global Fortune 500 with more\nthan $250 billion in annual revenue.  Learn more at www.investor.cencora.com\nCencora\u2019 s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d).  W ords such as \"aim,\" \"anticipate,\" \"believe,\" \"can,\" \"continue,\" \"could,\" \"estimate,\" \"expect,\" \"intend,\" \"may,\" \"might,\" \"on\ntrack,\" \"opportunity,\" \"plan,\" \"possible,\" \"potential,\" \"predict,\" \"project,\u201d \"seek,\" \"should,\" \"strive,\" \"sustain,\" \"synergy,\" \"target,\" \"will,\"\n\"would\" and similar expressions are intended to identify such forward-looking statements, but the absence of these words does not\nmean the statement is not forward-looking.  These statements are based on management\u2019s current expectations and are subject to\n6", "original_text": "Cencora is ranked #11 on the Fortune 500 and #24 on the Global Fortune 500 with more\nthan $250 billion in annual revenue. ", "page_label": "6", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b76ad0b5-6e11-4d6c-9702-c56141c82238", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e00f6220ccf1d8d27c6f56f54e65359f917ceb7a0fbd989e9b94774f82ab4cea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b285c1a0-db9e-4103-bce2-b0ed9ec4d7da", "node_type": "1", "metadata": {"window": "About Cencora\nCencora is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals around\nthe world.  W e partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to therapies.\n Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions.  Our 46,000+\nworldwide team members contribute to positive health outcomes through the power of our purpose: We are united in our\nresponsibility to create healthier futures .  Cencora is ranked #11 on the Fortune 500 and #24 on the Global Fortune 500 with more\nthan $250 billion in annual revenue.  Learn more at www.investor.cencora.com\nCencora\u2019 s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d).  W ords such as \"aim,\" \"anticipate,\" \"believe,\" \"can,\" \"continue,\" \"could,\" \"estimate,\" \"expect,\" \"intend,\" \"may,\" \"might,\" \"on\ntrack,\" \"opportunity,\" \"plan,\" \"possible,\" \"potential,\" \"predict,\" \"project,\u201d \"seek,\" \"should,\" \"strive,\" \"sustain,\" \"synergy,\" \"target,\" \"will,\"\n\"would\" and similar expressions are intended to identify such forward-looking statements, but the absence of these words does not\nmean the statement is not forward-looking. ", "original_text": "Our 46,000+\nworldwide team members contribute to positive health outcomes through the power of our purpose: We are united in our\nresponsibility to create healthier futures . ", "page_label": "6", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9efddcade30b058e5c04ec7f2c10f00796f4b023f5ac7b738371e3b8d77e19da", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bcbef95a-1fcf-4e3a-ae91-9edbb24bfd50", "node_type": "1", "metadata": {"window": "Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions.  Our 46,000+\nworldwide team members contribute to positive health outcomes through the power of our purpose: We are united in our\nresponsibility to create healthier futures .  Cencora is ranked #11 on the Fortune 500 and #24 on the Global Fortune 500 with more\nthan $250 billion in annual revenue.  Learn more at www.investor.cencora.com\nCencora\u2019 s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d).  W ords such as \"aim,\" \"anticipate,\" \"believe,\" \"can,\" \"continue,\" \"could,\" \"estimate,\" \"expect,\" \"intend,\" \"may,\" \"might,\" \"on\ntrack,\" \"opportunity,\" \"plan,\" \"possible,\" \"potential,\" \"predict,\" \"project,\u201d \"seek,\" \"should,\" \"strive,\" \"sustain,\" \"synergy,\" \"target,\" \"will,\"\n\"would\" and similar expressions are intended to identify such forward-looking statements, but the absence of these words does not\nmean the statement is not forward-looking.  These statements are based on management\u2019s current expectations and are subject to\n6", "original_text": "Learn more at www.investor.cencora.com\nCencora\u2019 s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d). "}, "hash": "9bc3d0cfa3af48e049cadd8d08591948aefa7416e64e2e5bbfb5b1768646413a", "class_name": "RelatedNodeInfo"}}, "text": "Cencora is ranked #11 on the Fortune 500 and #24 on the Global Fortune 500 with more\nthan $250 billion in annual revenue. ", "start_char_idx": 2734, "end_char_idx": 2856, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bcbef95a-1fcf-4e3a-ae91-9edbb24bfd50": {"__data__": {"id_": "bcbef95a-1fcf-4e3a-ae91-9edbb24bfd50", "embedding": null, "metadata": {"window": "Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions.  Our 46,000+\nworldwide team members contribute to positive health outcomes through the power of our purpose: We are united in our\nresponsibility to create healthier futures .  Cencora is ranked #11 on the Fortune 500 and #24 on the Global Fortune 500 with more\nthan $250 billion in annual revenue.  Learn more at www.investor.cencora.com\nCencora\u2019 s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d).  W ords such as \"aim,\" \"anticipate,\" \"believe,\" \"can,\" \"continue,\" \"could,\" \"estimate,\" \"expect,\" \"intend,\" \"may,\" \"might,\" \"on\ntrack,\" \"opportunity,\" \"plan,\" \"possible,\" \"potential,\" \"predict,\" \"project,\u201d \"seek,\" \"should,\" \"strive,\" \"sustain,\" \"synergy,\" \"target,\" \"will,\"\n\"would\" and similar expressions are intended to identify such forward-looking statements, but the absence of these words does not\nmean the statement is not forward-looking.  These statements are based on management\u2019s current expectations and are subject to\n6", "original_text": "Learn more at www.investor.cencora.com\nCencora\u2019 s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d). ", "page_label": "6", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b76ad0b5-6e11-4d6c-9702-c56141c82238", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e00f6220ccf1d8d27c6f56f54e65359f917ceb7a0fbd989e9b94774f82ab4cea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "399f52cb-2812-4e0c-b38f-8f3ee8ca20e5", "node_type": "1", "metadata": {"window": "W e partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to therapies.\n Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions.  Our 46,000+\nworldwide team members contribute to positive health outcomes through the power of our purpose: We are united in our\nresponsibility to create healthier futures .  Cencora is ranked #11 on the Fortune 500 and #24 on the Global Fortune 500 with more\nthan $250 billion in annual revenue.  Learn more at www.investor.cencora.com\nCencora\u2019 s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d).  W ords such as \"aim,\" \"anticipate,\" \"believe,\" \"can,\" \"continue,\" \"could,\" \"estimate,\" \"expect,\" \"intend,\" \"may,\" \"might,\" \"on\ntrack,\" \"opportunity,\" \"plan,\" \"possible,\" \"potential,\" \"predict,\" \"project,\u201d \"seek,\" \"should,\" \"strive,\" \"sustain,\" \"synergy,\" \"target,\" \"will,\"\n\"would\" and similar expressions are intended to identify such forward-looking statements, but the absence of these words does not\nmean the statement is not forward-looking.  These statements are based on management\u2019s current expectations and are subject to\n6", "original_text": "Cencora is ranked #11 on the Fortune 500 and #24 on the Global Fortune 500 with more\nthan $250 billion in annual revenue. ", "page_label": "6", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "565d672301dc6dba051637a8fd55b1b6bfd2862291e1788240586054b393e673", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b8e1a68d-9c3a-4e8c-b865-9eb8e81a4798", "node_type": "1", "metadata": {"window": "Our 46,000+\nworldwide team members contribute to positive health outcomes through the power of our purpose: We are united in our\nresponsibility to create healthier futures .  Cencora is ranked #11 on the Fortune 500 and #24 on the Global Fortune 500 with more\nthan $250 billion in annual revenue.  Learn more at www.investor.cencora.com\nCencora\u2019 s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d).  W ords such as \"aim,\" \"anticipate,\" \"believe,\" \"can,\" \"continue,\" \"could,\" \"estimate,\" \"expect,\" \"intend,\" \"may,\" \"might,\" \"on\ntrack,\" \"opportunity,\" \"plan,\" \"possible,\" \"potential,\" \"predict,\" \"project,\u201d \"seek,\" \"should,\" \"strive,\" \"sustain,\" \"synergy,\" \"target,\" \"will,\"\n\"would\" and similar expressions are intended to identify such forward-looking statements, but the absence of these words does not\nmean the statement is not forward-looking.  These statements are based on management\u2019s current expectations and are subject to\n6", "original_text": "W ords such as \"aim,\" \"anticipate,\" \"believe,\" \"can,\" \"continue,\" \"could,\" \"estimate,\" \"expect,\" \"intend,\" \"may,\" \"might,\" \"on\ntrack,\" \"opportunity,\" \"plan,\" \"possible,\" \"potential,\" \"predict,\" \"project,\u201d \"seek,\" \"should,\" \"strive,\" \"sustain,\" \"synergy,\" \"target,\" \"will,\"\n\"would\" and similar expressions are intended to identify such forward-looking statements, but the absence of these words does not\nmean the statement is not forward-looking. "}, "hash": "f1804e06d6a74e3333dc16780c4d80b310863e44c8cd0c8f4d8a06c95f89dbce", "class_name": "RelatedNodeInfo"}}, "text": "Learn more at www.investor.cencora.com\nCencora\u2019 s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d). ", "start_char_idx": 2856, "end_char_idx": 3231, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b8e1a68d-9c3a-4e8c-b865-9eb8e81a4798": {"__data__": {"id_": "b8e1a68d-9c3a-4e8c-b865-9eb8e81a4798", "embedding": null, "metadata": {"window": "Our 46,000+\nworldwide team members contribute to positive health outcomes through the power of our purpose: We are united in our\nresponsibility to create healthier futures .  Cencora is ranked #11 on the Fortune 500 and #24 on the Global Fortune 500 with more\nthan $250 billion in annual revenue.  Learn more at www.investor.cencora.com\nCencora\u2019 s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d).  W ords such as \"aim,\" \"anticipate,\" \"believe,\" \"can,\" \"continue,\" \"could,\" \"estimate,\" \"expect,\" \"intend,\" \"may,\" \"might,\" \"on\ntrack,\" \"opportunity,\" \"plan,\" \"possible,\" \"potential,\" \"predict,\" \"project,\u201d \"seek,\" \"should,\" \"strive,\" \"sustain,\" \"synergy,\" \"target,\" \"will,\"\n\"would\" and similar expressions are intended to identify such forward-looking statements, but the absence of these words does not\nmean the statement is not forward-looking.  These statements are based on management\u2019s current expectations and are subject to\n6", "original_text": "W ords such as \"aim,\" \"anticipate,\" \"believe,\" \"can,\" \"continue,\" \"could,\" \"estimate,\" \"expect,\" \"intend,\" \"may,\" \"might,\" \"on\ntrack,\" \"opportunity,\" \"plan,\" \"possible,\" \"potential,\" \"predict,\" \"project,\u201d \"seek,\" \"should,\" \"strive,\" \"sustain,\" \"synergy,\" \"target,\" \"will,\"\n\"would\" and similar expressions are intended to identify such forward-looking statements, but the absence of these words does not\nmean the statement is not forward-looking. ", "page_label": "6", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b76ad0b5-6e11-4d6c-9702-c56141c82238", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e00f6220ccf1d8d27c6f56f54e65359f917ceb7a0fbd989e9b94774f82ab4cea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bcbef95a-1fcf-4e3a-ae91-9edbb24bfd50", "node_type": "1", "metadata": {"window": "Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions.  Our 46,000+\nworldwide team members contribute to positive health outcomes through the power of our purpose: We are united in our\nresponsibility to create healthier futures .  Cencora is ranked #11 on the Fortune 500 and #24 on the Global Fortune 500 with more\nthan $250 billion in annual revenue.  Learn more at www.investor.cencora.com\nCencora\u2019 s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d).  W ords such as \"aim,\" \"anticipate,\" \"believe,\" \"can,\" \"continue,\" \"could,\" \"estimate,\" \"expect,\" \"intend,\" \"may,\" \"might,\" \"on\ntrack,\" \"opportunity,\" \"plan,\" \"possible,\" \"potential,\" \"predict,\" \"project,\u201d \"seek,\" \"should,\" \"strive,\" \"sustain,\" \"synergy,\" \"target,\" \"will,\"\n\"would\" and similar expressions are intended to identify such forward-looking statements, but the absence of these words does not\nmean the statement is not forward-looking.  These statements are based on management\u2019s current expectations and are subject to\n6", "original_text": "Learn more at www.investor.cencora.com\nCencora\u2019 s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d). ", "page_label": "6", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3177925e51443781fb13dc504db5d15dab28ab31f65a6eaa98c14b061c107389", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f0def778-6885-4419-9e00-5a2d4dcecd5a", "node_type": "1", "metadata": {"window": "Cencora is ranked #11 on the Fortune 500 and #24 on the Global Fortune 500 with more\nthan $250 billion in annual revenue.  Learn more at www.investor.cencora.com\nCencora\u2019 s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d).  W ords such as \"aim,\" \"anticipate,\" \"believe,\" \"can,\" \"continue,\" \"could,\" \"estimate,\" \"expect,\" \"intend,\" \"may,\" \"might,\" \"on\ntrack,\" \"opportunity,\" \"plan,\" \"possible,\" \"potential,\" \"predict,\" \"project,\u201d \"seek,\" \"should,\" \"strive,\" \"sustain,\" \"synergy,\" \"target,\" \"will,\"\n\"would\" and similar expressions are intended to identify such forward-looking statements, but the absence of these words does not\nmean the statement is not forward-looking.  These statements are based on management\u2019s current expectations and are subject to\n6", "original_text": "These statements are based on management\u2019s current expectations and are subject to\n6"}, "hash": "782575a570966cbc7b121f7da839635553cef99053f54a2c17f4f3ec0466717c", "class_name": "RelatedNodeInfo"}}, "text": "W ords such as \"aim,\" \"anticipate,\" \"believe,\" \"can,\" \"continue,\" \"could,\" \"estimate,\" \"expect,\" \"intend,\" \"may,\" \"might,\" \"on\ntrack,\" \"opportunity,\" \"plan,\" \"possible,\" \"potential,\" \"predict,\" \"project,\u201d \"seek,\" \"should,\" \"strive,\" \"sustain,\" \"synergy,\" \"target,\" \"will,\"\n\"would\" and similar expressions are intended to identify such forward-looking statements, but the absence of these words does not\nmean the statement is not forward-looking. ", "start_char_idx": 3231, "end_char_idx": 3677, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f0def778-6885-4419-9e00-5a2d4dcecd5a": {"__data__": {"id_": "f0def778-6885-4419-9e00-5a2d4dcecd5a", "embedding": null, "metadata": {"window": "Cencora is ranked #11 on the Fortune 500 and #24 on the Global Fortune 500 with more\nthan $250 billion in annual revenue.  Learn more at www.investor.cencora.com\nCencora\u2019 s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d).  W ords such as \"aim,\" \"anticipate,\" \"believe,\" \"can,\" \"continue,\" \"could,\" \"estimate,\" \"expect,\" \"intend,\" \"may,\" \"might,\" \"on\ntrack,\" \"opportunity,\" \"plan,\" \"possible,\" \"potential,\" \"predict,\" \"project,\u201d \"seek,\" \"should,\" \"strive,\" \"sustain,\" \"synergy,\" \"target,\" \"will,\"\n\"would\" and similar expressions are intended to identify such forward-looking statements, but the absence of these words does not\nmean the statement is not forward-looking.  These statements are based on management\u2019s current expectations and are subject to\n6", "original_text": "These statements are based on management\u2019s current expectations and are subject to\n6", "page_label": "6", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b76ad0b5-6e11-4d6c-9702-c56141c82238", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e00f6220ccf1d8d27c6f56f54e65359f917ceb7a0fbd989e9b94774f82ab4cea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b8e1a68d-9c3a-4e8c-b865-9eb8e81a4798", "node_type": "1", "metadata": {"window": "Our 46,000+\nworldwide team members contribute to positive health outcomes through the power of our purpose: We are united in our\nresponsibility to create healthier futures .  Cencora is ranked #11 on the Fortune 500 and #24 on the Global Fortune 500 with more\nthan $250 billion in annual revenue.  Learn more at www.investor.cencora.com\nCencora\u2019 s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d).  W ords such as \"aim,\" \"anticipate,\" \"believe,\" \"can,\" \"continue,\" \"could,\" \"estimate,\" \"expect,\" \"intend,\" \"may,\" \"might,\" \"on\ntrack,\" \"opportunity,\" \"plan,\" \"possible,\" \"potential,\" \"predict,\" \"project,\u201d \"seek,\" \"should,\" \"strive,\" \"sustain,\" \"synergy,\" \"target,\" \"will,\"\n\"would\" and similar expressions are intended to identify such forward-looking statements, but the absence of these words does not\nmean the statement is not forward-looking.  These statements are based on management\u2019s current expectations and are subject to\n6", "original_text": "W ords such as \"aim,\" \"anticipate,\" \"believe,\" \"can,\" \"continue,\" \"could,\" \"estimate,\" \"expect,\" \"intend,\" \"may,\" \"might,\" \"on\ntrack,\" \"opportunity,\" \"plan,\" \"possible,\" \"potential,\" \"predict,\" \"project,\u201d \"seek,\" \"should,\" \"strive,\" \"sustain,\" \"synergy,\" \"target,\" \"will,\"\n\"would\" and similar expressions are intended to identify such forward-looking statements, but the absence of these words does not\nmean the statement is not forward-looking. ", "page_label": "6", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "33b4c2a76addef93a8759182ba6dae4dd9c9d439c469f360e443085072036dcc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c1e91ae5-3576-44dc-a7d9-d01058db018d", "node_type": "1", "metadata": {"window": "uncertainty and changes in circumstances and speak only as of the date hereof.  These statements are not guarantees of future\nperformance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary materially\nfrom those indicated.  A more detailed discussion of the risks and uncertainties that could cause our actual results to differ materially\nfrom those indicated is included (i) in the \"Risk F actors\" and \"Management's Discussion and Analysis\" sections in the Company\u2019s\nAnnual R eport on Form 10-K for the fiscal year ended September 30, 2022 and elsewhere in that report as supplemented by the\ndescription of business risks described in Item 1A to our form 10-Q for the fiscal quarter ended March 31, 2023, to which mention is\nmade herein and (ii) in other reports filed by the Company pursuant to the Securities Exchange Act.  The Company undertakes no\nobligation to publicly update or revise any forward-looking statements, except as required by the federal securities laws.\n\u00a0\n", "original_text": "uncertainty and changes in circumstances and speak only as of the date hereof. "}, "hash": "737f4fa028bff021c5e9137ecd7f9e431858f77d8212c5effa041c2c0db453d0", "class_name": "RelatedNodeInfo"}}, "text": "These statements are based on management\u2019s current expectations and are subject to\n6", "start_char_idx": 3677, "end_char_idx": 3761, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c1e91ae5-3576-44dc-a7d9-d01058db018d": {"__data__": {"id_": "c1e91ae5-3576-44dc-a7d9-d01058db018d", "embedding": null, "metadata": {"window": "uncertainty and changes in circumstances and speak only as of the date hereof.  These statements are not guarantees of future\nperformance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary materially\nfrom those indicated.  A more detailed discussion of the risks and uncertainties that could cause our actual results to differ materially\nfrom those indicated is included (i) in the \"Risk F actors\" and \"Management's Discussion and Analysis\" sections in the Company\u2019s\nAnnual R eport on Form 10-K for the fiscal year ended September 30, 2022 and elsewhere in that report as supplemented by the\ndescription of business risks described in Item 1A to our form 10-Q for the fiscal quarter ended March 31, 2023, to which mention is\nmade herein and (ii) in other reports filed by the Company pursuant to the Securities Exchange Act.  The Company undertakes no\nobligation to publicly update or revise any forward-looking statements, except as required by the federal securities laws.\n\u00a0\n", "original_text": "uncertainty and changes in circumstances and speak only as of the date hereof. ", "page_label": "7", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a0057cd9-34f8-4acf-817f-87fe57519f5f", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8211f673b6c529451e8ade8932e546afb3e855766054e0484dd401ee46f62bba", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f0def778-6885-4419-9e00-5a2d4dcecd5a", "node_type": "1", "metadata": {"window": "Cencora is ranked #11 on the Fortune 500 and #24 on the Global Fortune 500 with more\nthan $250 billion in annual revenue.  Learn more at www.investor.cencora.com\nCencora\u2019 s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d).  W ords such as \"aim,\" \"anticipate,\" \"believe,\" \"can,\" \"continue,\" \"could,\" \"estimate,\" \"expect,\" \"intend,\" \"may,\" \"might,\" \"on\ntrack,\" \"opportunity,\" \"plan,\" \"possible,\" \"potential,\" \"predict,\" \"project,\u201d \"seek,\" \"should,\" \"strive,\" \"sustain,\" \"synergy,\" \"target,\" \"will,\"\n\"would\" and similar expressions are intended to identify such forward-looking statements, but the absence of these words does not\nmean the statement is not forward-looking.  These statements are based on management\u2019s current expectations and are subject to\n6", "original_text": "These statements are based on management\u2019s current expectations and are subject to\n6", "page_label": "6", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6ce8ab79cc8b28c50bae043312fb7b77a758c332e1578eedbda5a6f69a1eccd2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b4b1710d-f379-4e26-abd9-50c55e6a45a0", "node_type": "1", "metadata": {"window": "uncertainty and changes in circumstances and speak only as of the date hereof.  These statements are not guarantees of future\nperformance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary materially\nfrom those indicated.  A more detailed discussion of the risks and uncertainties that could cause our actual results to differ materially\nfrom those indicated is included (i) in the \"Risk F actors\" and \"Management's Discussion and Analysis\" sections in the Company\u2019s\nAnnual R eport on Form 10-K for the fiscal year ended September 30, 2022 and elsewhere in that report as supplemented by the\ndescription of business risks described in Item 1A to our form 10-Q for the fiscal quarter ended March 31, 2023, to which mention is\nmade herein and (ii) in other reports filed by the Company pursuant to the Securities Exchange Act.  The Company undertakes no\nobligation to publicly update or revise any forward-looking statements, except as required by the federal securities laws.\n\u00a0\n CENC ORA, INC.\n", "original_text": "These statements are not guarantees of future\nperformance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary materially\nfrom those indicated. "}, "hash": "0b3dbc7df781c4748f3e66c509a89ec35162df9459283f943a3c1507c1135cbd", "class_name": "RelatedNodeInfo"}}, "text": "uncertainty and changes in circumstances and speak only as of the date hereof. ", "start_char_idx": 0, "end_char_idx": 79, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b4b1710d-f379-4e26-abd9-50c55e6a45a0": {"__data__": {"id_": "b4b1710d-f379-4e26-abd9-50c55e6a45a0", "embedding": null, "metadata": {"window": "uncertainty and changes in circumstances and speak only as of the date hereof.  These statements are not guarantees of future\nperformance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary materially\nfrom those indicated.  A more detailed discussion of the risks and uncertainties that could cause our actual results to differ materially\nfrom those indicated is included (i) in the \"Risk F actors\" and \"Management's Discussion and Analysis\" sections in the Company\u2019s\nAnnual R eport on Form 10-K for the fiscal year ended September 30, 2022 and elsewhere in that report as supplemented by the\ndescription of business risks described in Item 1A to our form 10-Q for the fiscal quarter ended March 31, 2023, to which mention is\nmade herein and (ii) in other reports filed by the Company pursuant to the Securities Exchange Act.  The Company undertakes no\nobligation to publicly update or revise any forward-looking statements, except as required by the federal securities laws.\n\u00a0\n CENC ORA, INC.\n", "original_text": "These statements are not guarantees of future\nperformance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary materially\nfrom those indicated. ", "page_label": "7", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a0057cd9-34f8-4acf-817f-87fe57519f5f", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8211f673b6c529451e8ade8932e546afb3e855766054e0484dd401ee46f62bba", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c1e91ae5-3576-44dc-a7d9-d01058db018d", "node_type": "1", "metadata": {"window": "uncertainty and changes in circumstances and speak only as of the date hereof.  These statements are not guarantees of future\nperformance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary materially\nfrom those indicated.  A more detailed discussion of the risks and uncertainties that could cause our actual results to differ materially\nfrom those indicated is included (i) in the \"Risk F actors\" and \"Management's Discussion and Analysis\" sections in the Company\u2019s\nAnnual R eport on Form 10-K for the fiscal year ended September 30, 2022 and elsewhere in that report as supplemented by the\ndescription of business risks described in Item 1A to our form 10-Q for the fiscal quarter ended March 31, 2023, to which mention is\nmade herein and (ii) in other reports filed by the Company pursuant to the Securities Exchange Act.  The Company undertakes no\nobligation to publicly update or revise any forward-looking statements, except as required by the federal securities laws.\n\u00a0\n", "original_text": "uncertainty and changes in circumstances and speak only as of the date hereof. ", "page_label": "7", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "158fd039479958ffd2fd11556cb16cf8c7c8eaa76d15d5dfa23f78cad4a546e1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "147b49c5-ed9b-4286-976b-a64286ce7ebd", "node_type": "1", "metadata": {"window": "uncertainty and changes in circumstances and speak only as of the date hereof.  These statements are not guarantees of future\nperformance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary materially\nfrom those indicated.  A more detailed discussion of the risks and uncertainties that could cause our actual results to differ materially\nfrom those indicated is included (i) in the \"Risk F actors\" and \"Management's Discussion and Analysis\" sections in the Company\u2019s\nAnnual R eport on Form 10-K for the fiscal year ended September 30, 2022 and elsewhere in that report as supplemented by the\ndescription of business risks described in Item 1A to our form 10-Q for the fiscal quarter ended March 31, 2023, to which mention is\nmade herein and (ii) in other reports filed by the Company pursuant to the Securities Exchange Act.  The Company undertakes no\nobligation to publicly update or revise any forward-looking statements, except as required by the federal securities laws.\n\u00a0\n CENC ORA, INC.\n FINANCIAL SUMMAR Y\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three \nMonths Ended \nSeptember 30,\n2023 \u00a0% of \n Revenue \u00a0Three \nMonths Ended \nSeptember 30,\n2022 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$68,922,331 \u00a0\u00a0\u00a0 \u00a0$61,174,149 \u00a0\u00a0\u00a0 \u00a012.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a066,668,879 \u00a0\u00a0\u00a0 \u00a0\u00a059,188,590 \u00a0\u00a0\u00a0 \u00a012.6 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a02,253,452 \u00a0\u00a03.27 %\u00a0\u00a01,985,559 \u00a0\u00a03.25 %\u00a013.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a01,393,828 \u00a0\u00a02.02 %\u00a0\u00a01,263,462 \u00a0\u00a02.07 %\u00a010.3 %\nDepreciation and amortization \u00a0\u00a0276,226 \u00a0\u00a00.40 %\u00a0\u00a0170,562 \u00a0\u00a00.28 %\u00a062.0 %\nLitigation and opioid-related expenses \u00a0\u00a013,890 \u00a0\u00a0\u00a0 \u00a0\u00a015,024 \u00a0\u00a0\u00a0 \u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a040,291 \u00a0\u00a0\u00a0 \u00a0\u00a049,851 \u00a0\u00a0\u00a0 \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a052,276 \u00a0\u00a0\u00a0 \u00a0\u00a032,141 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a01,776,511 \u00a0\u00a02.58 %\u00a0\u00a01,531,040 \u00a0\u00a02.50 %\u00a016.0 %\n7", "original_text": "A more detailed discussion of the risks and uncertainties that could cause our actual results to differ materially\nfrom those indicated is included (i) in the \"Risk F actors\" and \"Management's Discussion and Analysis\" sections in the Company\u2019s\nAnnual R eport on Form 10-K for the fiscal year ended September 30, 2022 and elsewhere in that report as supplemented by the\ndescription of business risks described in Item 1A to our form 10-Q for the fiscal quarter ended March 31, 2023, to which mention is\nmade herein and (ii) in other reports filed by the Company pursuant to the Securities Exchange Act. "}, "hash": "be4d273c853fc8da1b19d9babe9b32a74b8179761929af5e3ed26b1c624830d7", "class_name": "RelatedNodeInfo"}}, "text": "These statements are not guarantees of future\nperformance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary materially\nfrom those indicated. ", "start_char_idx": 79, "end_char_idx": 278, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "147b49c5-ed9b-4286-976b-a64286ce7ebd": {"__data__": {"id_": "147b49c5-ed9b-4286-976b-a64286ce7ebd", "embedding": null, "metadata": {"window": "uncertainty and changes in circumstances and speak only as of the date hereof.  These statements are not guarantees of future\nperformance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary materially\nfrom those indicated.  A more detailed discussion of the risks and uncertainties that could cause our actual results to differ materially\nfrom those indicated is included (i) in the \"Risk F actors\" and \"Management's Discussion and Analysis\" sections in the Company\u2019s\nAnnual R eport on Form 10-K for the fiscal year ended September 30, 2022 and elsewhere in that report as supplemented by the\ndescription of business risks described in Item 1A to our form 10-Q for the fiscal quarter ended March 31, 2023, to which mention is\nmade herein and (ii) in other reports filed by the Company pursuant to the Securities Exchange Act.  The Company undertakes no\nobligation to publicly update or revise any forward-looking statements, except as required by the federal securities laws.\n\u00a0\n CENC ORA, INC.\n FINANCIAL SUMMAR Y\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three \nMonths Ended \nSeptember 30,\n2023 \u00a0% of \n Revenue \u00a0Three \nMonths Ended \nSeptember 30,\n2022 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$68,922,331 \u00a0\u00a0\u00a0 \u00a0$61,174,149 \u00a0\u00a0\u00a0 \u00a012.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a066,668,879 \u00a0\u00a0\u00a0 \u00a0\u00a059,188,590 \u00a0\u00a0\u00a0 \u00a012.6 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a02,253,452 \u00a0\u00a03.27 %\u00a0\u00a01,985,559 \u00a0\u00a03.25 %\u00a013.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a01,393,828 \u00a0\u00a02.02 %\u00a0\u00a01,263,462 \u00a0\u00a02.07 %\u00a010.3 %\nDepreciation and amortization \u00a0\u00a0276,226 \u00a0\u00a00.40 %\u00a0\u00a0170,562 \u00a0\u00a00.28 %\u00a062.0 %\nLitigation and opioid-related expenses \u00a0\u00a013,890 \u00a0\u00a0\u00a0 \u00a0\u00a015,024 \u00a0\u00a0\u00a0 \u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a040,291 \u00a0\u00a0\u00a0 \u00a0\u00a049,851 \u00a0\u00a0\u00a0 \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a052,276 \u00a0\u00a0\u00a0 \u00a0\u00a032,141 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a01,776,511 \u00a0\u00a02.58 %\u00a0\u00a01,531,040 \u00a0\u00a02.50 %\u00a016.0 %\n7", "original_text": "A more detailed discussion of the risks and uncertainties that could cause our actual results to differ materially\nfrom those indicated is included (i) in the \"Risk F actors\" and \"Management's Discussion and Analysis\" sections in the Company\u2019s\nAnnual R eport on Form 10-K for the fiscal year ended September 30, 2022 and elsewhere in that report as supplemented by the\ndescription of business risks described in Item 1A to our form 10-Q for the fiscal quarter ended March 31, 2023, to which mention is\nmade herein and (ii) in other reports filed by the Company pursuant to the Securities Exchange Act. ", "page_label": "7", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a0057cd9-34f8-4acf-817f-87fe57519f5f", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8211f673b6c529451e8ade8932e546afb3e855766054e0484dd401ee46f62bba", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b4b1710d-f379-4e26-abd9-50c55e6a45a0", "node_type": "1", "metadata": {"window": "uncertainty and changes in circumstances and speak only as of the date hereof.  These statements are not guarantees of future\nperformance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary materially\nfrom those indicated.  A more detailed discussion of the risks and uncertainties that could cause our actual results to differ materially\nfrom those indicated is included (i) in the \"Risk F actors\" and \"Management's Discussion and Analysis\" sections in the Company\u2019s\nAnnual R eport on Form 10-K for the fiscal year ended September 30, 2022 and elsewhere in that report as supplemented by the\ndescription of business risks described in Item 1A to our form 10-Q for the fiscal quarter ended March 31, 2023, to which mention is\nmade herein and (ii) in other reports filed by the Company pursuant to the Securities Exchange Act.  The Company undertakes no\nobligation to publicly update or revise any forward-looking statements, except as required by the federal securities laws.\n\u00a0\n CENC ORA, INC.\n", "original_text": "These statements are not guarantees of future\nperformance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary materially\nfrom those indicated. ", "page_label": "7", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ac2f8992d966b0173a715e6d9bb20396259ab35401f7872cee0a5caf40f7e2ce", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "af1f7650-a8fc-4f89-881c-9e9cf184b84f", "node_type": "1", "metadata": {"window": "uncertainty and changes in circumstances and speak only as of the date hereof.  These statements are not guarantees of future\nperformance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary materially\nfrom those indicated.  A more detailed discussion of the risks and uncertainties that could cause our actual results to differ materially\nfrom those indicated is included (i) in the \"Risk F actors\" and \"Management's Discussion and Analysis\" sections in the Company\u2019s\nAnnual R eport on Form 10-K for the fiscal year ended September 30, 2022 and elsewhere in that report as supplemented by the\ndescription of business risks described in Item 1A to our form 10-Q for the fiscal quarter ended March 31, 2023, to which mention is\nmade herein and (ii) in other reports filed by the Company pursuant to the Securities Exchange Act.  The Company undertakes no\nobligation to publicly update or revise any forward-looking statements, except as required by the federal securities laws.\n\u00a0\n CENC ORA, INC.\n FINANCIAL SUMMAR Y\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three \nMonths Ended \nSeptember 30,\n2023 \u00a0% of \n Revenue \u00a0Three \nMonths Ended \nSeptember 30,\n2022 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$68,922,331 \u00a0\u00a0\u00a0 \u00a0$61,174,149 \u00a0\u00a0\u00a0 \u00a012.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a066,668,879 \u00a0\u00a0\u00a0 \u00a0\u00a059,188,590 \u00a0\u00a0\u00a0 \u00a012.6 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a02,253,452 \u00a0\u00a03.27 %\u00a0\u00a01,985,559 \u00a0\u00a03.25 %\u00a013.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a01,393,828 \u00a0\u00a02.02 %\u00a0\u00a01,263,462 \u00a0\u00a02.07 %\u00a010.3 %\nDepreciation and amortization \u00a0\u00a0276,226 \u00a0\u00a00.40 %\u00a0\u00a0170,562 \u00a0\u00a00.28 %\u00a062.0 %\nLitigation and opioid-related expenses \u00a0\u00a013,890 \u00a0\u00a0\u00a0 \u00a0\u00a015,024 \u00a0\u00a0\u00a0 \u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a040,291 \u00a0\u00a0\u00a0 \u00a0\u00a049,851 \u00a0\u00a0\u00a0 \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a052,276 \u00a0\u00a0\u00a0 \u00a0\u00a032,141 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a01,776,511 \u00a0\u00a02.58 %\u00a0\u00a01,531,040 \u00a0\u00a02.50 %\u00a016.0 %\n7", "original_text": "The Company undertakes no\nobligation to publicly update or revise any forward-looking statements, except as required by the federal securities laws.\n\u00a0\n"}, "hash": "6da185f8d2f3eb8ab56194fef94ad80858a7e1300fdfe6d2b36b0f682987b790", "class_name": "RelatedNodeInfo"}}, "text": "A more detailed discussion of the risks and uncertainties that could cause our actual results to differ materially\nfrom those indicated is included (i) in the \"Risk F actors\" and \"Management's Discussion and Analysis\" sections in the Company\u2019s\nAnnual R eport on Form 10-K for the fiscal year ended September 30, 2022 and elsewhere in that report as supplemented by the\ndescription of business risks described in Item 1A to our form 10-Q for the fiscal quarter ended March 31, 2023, to which mention is\nmade herein and (ii) in other reports filed by the Company pursuant to the Securities Exchange Act. ", "start_char_idx": 278, "end_char_idx": 880, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "af1f7650-a8fc-4f89-881c-9e9cf184b84f": {"__data__": {"id_": "af1f7650-a8fc-4f89-881c-9e9cf184b84f", "embedding": null, "metadata": {"window": "uncertainty and changes in circumstances and speak only as of the date hereof.  These statements are not guarantees of future\nperformance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary materially\nfrom those indicated.  A more detailed discussion of the risks and uncertainties that could cause our actual results to differ materially\nfrom those indicated is included (i) in the \"Risk F actors\" and \"Management's Discussion and Analysis\" sections in the Company\u2019s\nAnnual R eport on Form 10-K for the fiscal year ended September 30, 2022 and elsewhere in that report as supplemented by the\ndescription of business risks described in Item 1A to our form 10-Q for the fiscal quarter ended March 31, 2023, to which mention is\nmade herein and (ii) in other reports filed by the Company pursuant to the Securities Exchange Act.  The Company undertakes no\nobligation to publicly update or revise any forward-looking statements, except as required by the federal securities laws.\n\u00a0\n CENC ORA, INC.\n FINANCIAL SUMMAR Y\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three \nMonths Ended \nSeptember 30,\n2023 \u00a0% of \n Revenue \u00a0Three \nMonths Ended \nSeptember 30,\n2022 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$68,922,331 \u00a0\u00a0\u00a0 \u00a0$61,174,149 \u00a0\u00a0\u00a0 \u00a012.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a066,668,879 \u00a0\u00a0\u00a0 \u00a0\u00a059,188,590 \u00a0\u00a0\u00a0 \u00a012.6 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a02,253,452 \u00a0\u00a03.27 %\u00a0\u00a01,985,559 \u00a0\u00a03.25 %\u00a013.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a01,393,828 \u00a0\u00a02.02 %\u00a0\u00a01,263,462 \u00a0\u00a02.07 %\u00a010.3 %\nDepreciation and amortization \u00a0\u00a0276,226 \u00a0\u00a00.40 %\u00a0\u00a0170,562 \u00a0\u00a00.28 %\u00a062.0 %\nLitigation and opioid-related expenses \u00a0\u00a013,890 \u00a0\u00a0\u00a0 \u00a0\u00a015,024 \u00a0\u00a0\u00a0 \u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a040,291 \u00a0\u00a0\u00a0 \u00a0\u00a049,851 \u00a0\u00a0\u00a0 \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a052,276 \u00a0\u00a0\u00a0 \u00a0\u00a032,141 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a01,776,511 \u00a0\u00a02.58 %\u00a0\u00a01,531,040 \u00a0\u00a02.50 %\u00a016.0 %\n7", "original_text": "The Company undertakes no\nobligation to publicly update or revise any forward-looking statements, except as required by the federal securities laws.\n\u00a0\n", "page_label": "7", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a0057cd9-34f8-4acf-817f-87fe57519f5f", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8211f673b6c529451e8ade8932e546afb3e855766054e0484dd401ee46f62bba", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "147b49c5-ed9b-4286-976b-a64286ce7ebd", "node_type": "1", "metadata": {"window": "uncertainty and changes in circumstances and speak only as of the date hereof.  These statements are not guarantees of future\nperformance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary materially\nfrom those indicated.  A more detailed discussion of the risks and uncertainties that could cause our actual results to differ materially\nfrom those indicated is included (i) in the \"Risk F actors\" and \"Management's Discussion and Analysis\" sections in the Company\u2019s\nAnnual R eport on Form 10-K for the fiscal year ended September 30, 2022 and elsewhere in that report as supplemented by the\ndescription of business risks described in Item 1A to our form 10-Q for the fiscal quarter ended March 31, 2023, to which mention is\nmade herein and (ii) in other reports filed by the Company pursuant to the Securities Exchange Act.  The Company undertakes no\nobligation to publicly update or revise any forward-looking statements, except as required by the federal securities laws.\n\u00a0\n CENC ORA, INC.\n FINANCIAL SUMMAR Y\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three \nMonths Ended \nSeptember 30,\n2023 \u00a0% of \n Revenue \u00a0Three \nMonths Ended \nSeptember 30,\n2022 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$68,922,331 \u00a0\u00a0\u00a0 \u00a0$61,174,149 \u00a0\u00a0\u00a0 \u00a012.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a066,668,879 \u00a0\u00a0\u00a0 \u00a0\u00a059,188,590 \u00a0\u00a0\u00a0 \u00a012.6 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a02,253,452 \u00a0\u00a03.27 %\u00a0\u00a01,985,559 \u00a0\u00a03.25 %\u00a013.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a01,393,828 \u00a0\u00a02.02 %\u00a0\u00a01,263,462 \u00a0\u00a02.07 %\u00a010.3 %\nDepreciation and amortization \u00a0\u00a0276,226 \u00a0\u00a00.40 %\u00a0\u00a0170,562 \u00a0\u00a00.28 %\u00a062.0 %\nLitigation and opioid-related expenses \u00a0\u00a013,890 \u00a0\u00a0\u00a0 \u00a0\u00a015,024 \u00a0\u00a0\u00a0 \u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a040,291 \u00a0\u00a0\u00a0 \u00a0\u00a049,851 \u00a0\u00a0\u00a0 \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a052,276 \u00a0\u00a0\u00a0 \u00a0\u00a032,141 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a01,776,511 \u00a0\u00a02.58 %\u00a0\u00a01,531,040 \u00a0\u00a02.50 %\u00a016.0 %\n7", "original_text": "A more detailed discussion of the risks and uncertainties that could cause our actual results to differ materially\nfrom those indicated is included (i) in the \"Risk F actors\" and \"Management's Discussion and Analysis\" sections in the Company\u2019s\nAnnual R eport on Form 10-K for the fiscal year ended September 30, 2022 and elsewhere in that report as supplemented by the\ndescription of business risks described in Item 1A to our form 10-Q for the fiscal quarter ended March 31, 2023, to which mention is\nmade herein and (ii) in other reports filed by the Company pursuant to the Securities Exchange Act. ", "page_label": "7", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "63df7f1a924e7f916327bb4dba815b70bd59aededffabe5a52c5169ccbd3ba50", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "062b7a07-76c9-4f1b-9c37-320b6d8ed218", "node_type": "1", "metadata": {"window": "These statements are not guarantees of future\nperformance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary materially\nfrom those indicated.  A more detailed discussion of the risks and uncertainties that could cause our actual results to differ materially\nfrom those indicated is included (i) in the \"Risk F actors\" and \"Management's Discussion and Analysis\" sections in the Company\u2019s\nAnnual R eport on Form 10-K for the fiscal year ended September 30, 2022 and elsewhere in that report as supplemented by the\ndescription of business risks described in Item 1A to our form 10-Q for the fiscal quarter ended March 31, 2023, to which mention is\nmade herein and (ii) in other reports filed by the Company pursuant to the Securities Exchange Act.  The Company undertakes no\nobligation to publicly update or revise any forward-looking statements, except as required by the federal securities laws.\n\u00a0\n CENC ORA, INC.\n FINANCIAL SUMMAR Y\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three \nMonths Ended \nSeptember 30,\n2023 \u00a0% of \n Revenue \u00a0Three \nMonths Ended \nSeptember 30,\n2022 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$68,922,331 \u00a0\u00a0\u00a0 \u00a0$61,174,149 \u00a0\u00a0\u00a0 \u00a012.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a066,668,879 \u00a0\u00a0\u00a0 \u00a0\u00a059,188,590 \u00a0\u00a0\u00a0 \u00a012.6 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a02,253,452 \u00a0\u00a03.27 %\u00a0\u00a01,985,559 \u00a0\u00a03.25 %\u00a013.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a01,393,828 \u00a0\u00a02.02 %\u00a0\u00a01,263,462 \u00a0\u00a02.07 %\u00a010.3 %\nDepreciation and amortization \u00a0\u00a0276,226 \u00a0\u00a00.40 %\u00a0\u00a0170,562 \u00a0\u00a00.28 %\u00a062.0 %\nLitigation and opioid-related expenses \u00a0\u00a013,890 \u00a0\u00a0\u00a0 \u00a0\u00a015,024 \u00a0\u00a0\u00a0 \u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a040,291 \u00a0\u00a0\u00a0 \u00a0\u00a049,851 \u00a0\u00a0\u00a0 \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a052,276 \u00a0\u00a0\u00a0 \u00a0\u00a032,141 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a01,776,511 \u00a0\u00a02.58 %\u00a0\u00a01,531,040 \u00a0\u00a02.50 %\u00a016.0 %\n7", "original_text": "CENC ORA, INC.\n"}, "hash": "890854b8c7ff62462f2819cd11b5456a405bc44a35a575679340672ae8001344", "class_name": "RelatedNodeInfo"}}, "text": "The Company undertakes no\nobligation to publicly update or revise any forward-looking statements, except as required by the federal securities laws.\n\u00a0\n", "start_char_idx": 880, "end_char_idx": 1031, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "062b7a07-76c9-4f1b-9c37-320b6d8ed218": {"__data__": {"id_": "062b7a07-76c9-4f1b-9c37-320b6d8ed218", "embedding": null, "metadata": {"window": "These statements are not guarantees of future\nperformance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary materially\nfrom those indicated.  A more detailed discussion of the risks and uncertainties that could cause our actual results to differ materially\nfrom those indicated is included (i) in the \"Risk F actors\" and \"Management's Discussion and Analysis\" sections in the Company\u2019s\nAnnual R eport on Form 10-K for the fiscal year ended September 30, 2022 and elsewhere in that report as supplemented by the\ndescription of business risks described in Item 1A to our form 10-Q for the fiscal quarter ended March 31, 2023, to which mention is\nmade herein and (ii) in other reports filed by the Company pursuant to the Securities Exchange Act.  The Company undertakes no\nobligation to publicly update or revise any forward-looking statements, except as required by the federal securities laws.\n\u00a0\n CENC ORA, INC.\n FINANCIAL SUMMAR Y\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three \nMonths Ended \nSeptember 30,\n2023 \u00a0% of \n Revenue \u00a0Three \nMonths Ended \nSeptember 30,\n2022 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$68,922,331 \u00a0\u00a0\u00a0 \u00a0$61,174,149 \u00a0\u00a0\u00a0 \u00a012.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a066,668,879 \u00a0\u00a0\u00a0 \u00a0\u00a059,188,590 \u00a0\u00a0\u00a0 \u00a012.6 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a02,253,452 \u00a0\u00a03.27 %\u00a0\u00a01,985,559 \u00a0\u00a03.25 %\u00a013.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a01,393,828 \u00a0\u00a02.02 %\u00a0\u00a01,263,462 \u00a0\u00a02.07 %\u00a010.3 %\nDepreciation and amortization \u00a0\u00a0276,226 \u00a0\u00a00.40 %\u00a0\u00a0170,562 \u00a0\u00a00.28 %\u00a062.0 %\nLitigation and opioid-related expenses \u00a0\u00a013,890 \u00a0\u00a0\u00a0 \u00a0\u00a015,024 \u00a0\u00a0\u00a0 \u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a040,291 \u00a0\u00a0\u00a0 \u00a0\u00a049,851 \u00a0\u00a0\u00a0 \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a052,276 \u00a0\u00a0\u00a0 \u00a0\u00a032,141 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a01,776,511 \u00a0\u00a02.58 %\u00a0\u00a01,531,040 \u00a0\u00a02.50 %\u00a016.0 %\n7", "original_text": "CENC ORA, INC.\n", "page_label": "7", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a0057cd9-34f8-4acf-817f-87fe57519f5f", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8211f673b6c529451e8ade8932e546afb3e855766054e0484dd401ee46f62bba", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "af1f7650-a8fc-4f89-881c-9e9cf184b84f", "node_type": "1", "metadata": {"window": "uncertainty and changes in circumstances and speak only as of the date hereof.  These statements are not guarantees of future\nperformance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary materially\nfrom those indicated.  A more detailed discussion of the risks and uncertainties that could cause our actual results to differ materially\nfrom those indicated is included (i) in the \"Risk F actors\" and \"Management's Discussion and Analysis\" sections in the Company\u2019s\nAnnual R eport on Form 10-K for the fiscal year ended September 30, 2022 and elsewhere in that report as supplemented by the\ndescription of business risks described in Item 1A to our form 10-Q for the fiscal quarter ended March 31, 2023, to which mention is\nmade herein and (ii) in other reports filed by the Company pursuant to the Securities Exchange Act.  The Company undertakes no\nobligation to publicly update or revise any forward-looking statements, except as required by the federal securities laws.\n\u00a0\n CENC ORA, INC.\n FINANCIAL SUMMAR Y\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three \nMonths Ended \nSeptember 30,\n2023 \u00a0% of \n Revenue \u00a0Three \nMonths Ended \nSeptember 30,\n2022 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$68,922,331 \u00a0\u00a0\u00a0 \u00a0$61,174,149 \u00a0\u00a0\u00a0 \u00a012.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a066,668,879 \u00a0\u00a0\u00a0 \u00a0\u00a059,188,590 \u00a0\u00a0\u00a0 \u00a012.6 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a02,253,452 \u00a0\u00a03.27 %\u00a0\u00a01,985,559 \u00a0\u00a03.25 %\u00a013.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a01,393,828 \u00a0\u00a02.02 %\u00a0\u00a01,263,462 \u00a0\u00a02.07 %\u00a010.3 %\nDepreciation and amortization \u00a0\u00a0276,226 \u00a0\u00a00.40 %\u00a0\u00a0170,562 \u00a0\u00a00.28 %\u00a062.0 %\nLitigation and opioid-related expenses \u00a0\u00a013,890 \u00a0\u00a0\u00a0 \u00a0\u00a015,024 \u00a0\u00a0\u00a0 \u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a040,291 \u00a0\u00a0\u00a0 \u00a0\u00a049,851 \u00a0\u00a0\u00a0 \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a052,276 \u00a0\u00a0\u00a0 \u00a0\u00a032,141 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a01,776,511 \u00a0\u00a02.58 %\u00a0\u00a01,531,040 \u00a0\u00a02.50 %\u00a016.0 %\n7", "original_text": "The Company undertakes no\nobligation to publicly update or revise any forward-looking statements, except as required by the federal securities laws.\n\u00a0\n", "page_label": "7", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bc9a3cad0e2ccc2433b8c75fbea652c62c03424af4a6654d861a89ccdcd82864", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "73ef7261-d311-4089-9728-290a02cf957f", "node_type": "1", "metadata": {"window": "A more detailed discussion of the risks and uncertainties that could cause our actual results to differ materially\nfrom those indicated is included (i) in the \"Risk F actors\" and \"Management's Discussion and Analysis\" sections in the Company\u2019s\nAnnual R eport on Form 10-K for the fiscal year ended September 30, 2022 and elsewhere in that report as supplemented by the\ndescription of business risks described in Item 1A to our form 10-Q for the fiscal quarter ended March 31, 2023, to which mention is\nmade herein and (ii) in other reports filed by the Company pursuant to the Securities Exchange Act.  The Company undertakes no\nobligation to publicly update or revise any forward-looking statements, except as required by the federal securities laws.\n\u00a0\n CENC ORA, INC.\n FINANCIAL SUMMAR Y\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three \nMonths Ended \nSeptember 30,\n2023 \u00a0% of \n Revenue \u00a0Three \nMonths Ended \nSeptember 30,\n2022 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$68,922,331 \u00a0\u00a0\u00a0 \u00a0$61,174,149 \u00a0\u00a0\u00a0 \u00a012.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a066,668,879 \u00a0\u00a0\u00a0 \u00a0\u00a059,188,590 \u00a0\u00a0\u00a0 \u00a012.6 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a02,253,452 \u00a0\u00a03.27 %\u00a0\u00a01,985,559 \u00a0\u00a03.25 %\u00a013.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a01,393,828 \u00a0\u00a02.02 %\u00a0\u00a01,263,462 \u00a0\u00a02.07 %\u00a010.3 %\nDepreciation and amortization \u00a0\u00a0276,226 \u00a0\u00a00.40 %\u00a0\u00a0170,562 \u00a0\u00a00.28 %\u00a062.0 %\nLitigation and opioid-related expenses \u00a0\u00a013,890 \u00a0\u00a0\u00a0 \u00a0\u00a015,024 \u00a0\u00a0\u00a0 \u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a040,291 \u00a0\u00a0\u00a0 \u00a0\u00a049,851 \u00a0\u00a0\u00a0 \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a052,276 \u00a0\u00a0\u00a0 \u00a0\u00a032,141 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a01,776,511 \u00a0\u00a02.58 %\u00a0\u00a01,531,040 \u00a0\u00a02.50 %\u00a016.0 %\n7", "original_text": "FINANCIAL SUMMAR Y\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three \nMonths Ended \nSeptember 30,\n2023 \u00a0% of \n Revenue \u00a0Three \nMonths Ended \nSeptember 30,\n2022 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$68,922,331 \u00a0\u00a0\u00a0 \u00a0$61,174,149 \u00a0\u00a0\u00a0 \u00a012.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a066,668,879 \u00a0\u00a0\u00a0 \u00a0\u00a059,188,590 \u00a0\u00a0\u00a0 \u00a012.6 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a02,253,452 \u00a0\u00a03.27 %\u00a0\u00a01,985,559 \u00a0\u00a03.25 %\u00a013.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a01,393,828 \u00a0\u00a02.02 %\u00a0\u00a01,263,462 \u00a0\u00a02.07 %\u00a010.3 %\nDepreciation and amortization \u00a0\u00a0276,226 \u00a0\u00a00.40 %\u00a0\u00a0170,562 \u00a0\u00a00.28 %\u00a062.0 %\nLitigation and opioid-related expenses \u00a0\u00a013,890 \u00a0\u00a0\u00a0 \u00a0\u00a015,024 \u00a0\u00a0\u00a0 \u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a040,291 \u00a0\u00a0\u00a0 \u00a0\u00a049,851 \u00a0\u00a0\u00a0 \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a052,276 \u00a0\u00a0\u00a0 \u00a0\u00a032,141 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a01,776,511 \u00a0\u00a02.58 %\u00a0\u00a01,531,040 \u00a0\u00a02.50 %\u00a016.0 %\n7"}, "hash": "d3b78a751fbc3c7bd44adf43a32fc34a621b558aa20573357d2a278cf5f4b3e8", "class_name": "RelatedNodeInfo"}}, "text": "CENC ORA, INC.\n", "start_char_idx": 1031, "end_char_idx": 1046, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "73ef7261-d311-4089-9728-290a02cf957f": {"__data__": {"id_": "73ef7261-d311-4089-9728-290a02cf957f", "embedding": null, "metadata": {"window": "A more detailed discussion of the risks and uncertainties that could cause our actual results to differ materially\nfrom those indicated is included (i) in the \"Risk F actors\" and \"Management's Discussion and Analysis\" sections in the Company\u2019s\nAnnual R eport on Form 10-K for the fiscal year ended September 30, 2022 and elsewhere in that report as supplemented by the\ndescription of business risks described in Item 1A to our form 10-Q for the fiscal quarter ended March 31, 2023, to which mention is\nmade herein and (ii) in other reports filed by the Company pursuant to the Securities Exchange Act.  The Company undertakes no\nobligation to publicly update or revise any forward-looking statements, except as required by the federal securities laws.\n\u00a0\n CENC ORA, INC.\n FINANCIAL SUMMAR Y\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three \nMonths Ended \nSeptember 30,\n2023 \u00a0% of \n Revenue \u00a0Three \nMonths Ended \nSeptember 30,\n2022 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$68,922,331 \u00a0\u00a0\u00a0 \u00a0$61,174,149 \u00a0\u00a0\u00a0 \u00a012.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a066,668,879 \u00a0\u00a0\u00a0 \u00a0\u00a059,188,590 \u00a0\u00a0\u00a0 \u00a012.6 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a02,253,452 \u00a0\u00a03.27 %\u00a0\u00a01,985,559 \u00a0\u00a03.25 %\u00a013.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a01,393,828 \u00a0\u00a02.02 %\u00a0\u00a01,263,462 \u00a0\u00a02.07 %\u00a010.3 %\nDepreciation and amortization \u00a0\u00a0276,226 \u00a0\u00a00.40 %\u00a0\u00a0170,562 \u00a0\u00a00.28 %\u00a062.0 %\nLitigation and opioid-related expenses \u00a0\u00a013,890 \u00a0\u00a0\u00a0 \u00a0\u00a015,024 \u00a0\u00a0\u00a0 \u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a040,291 \u00a0\u00a0\u00a0 \u00a0\u00a049,851 \u00a0\u00a0\u00a0 \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a052,276 \u00a0\u00a0\u00a0 \u00a0\u00a032,141 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a01,776,511 \u00a0\u00a02.58 %\u00a0\u00a01,531,040 \u00a0\u00a02.50 %\u00a016.0 %\n7", "original_text": "FINANCIAL SUMMAR Y\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three \nMonths Ended \nSeptember 30,\n2023 \u00a0% of \n Revenue \u00a0Three \nMonths Ended \nSeptember 30,\n2022 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$68,922,331 \u00a0\u00a0\u00a0 \u00a0$61,174,149 \u00a0\u00a0\u00a0 \u00a012.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a066,668,879 \u00a0\u00a0\u00a0 \u00a0\u00a059,188,590 \u00a0\u00a0\u00a0 \u00a012.6 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a02,253,452 \u00a0\u00a03.27 %\u00a0\u00a01,985,559 \u00a0\u00a03.25 %\u00a013.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a01,393,828 \u00a0\u00a02.02 %\u00a0\u00a01,263,462 \u00a0\u00a02.07 %\u00a010.3 %\nDepreciation and amortization \u00a0\u00a0276,226 \u00a0\u00a00.40 %\u00a0\u00a0170,562 \u00a0\u00a00.28 %\u00a062.0 %\nLitigation and opioid-related expenses \u00a0\u00a013,890 \u00a0\u00a0\u00a0 \u00a0\u00a015,024 \u00a0\u00a0\u00a0 \u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a040,291 \u00a0\u00a0\u00a0 \u00a0\u00a049,851 \u00a0\u00a0\u00a0 \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a052,276 \u00a0\u00a0\u00a0 \u00a0\u00a032,141 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a01,776,511 \u00a0\u00a02.58 %\u00a0\u00a01,531,040 \u00a0\u00a02.50 %\u00a016.0 %\n7", "page_label": "7", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a0057cd9-34f8-4acf-817f-87fe57519f5f", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8211f673b6c529451e8ade8932e546afb3e855766054e0484dd401ee46f62bba", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "062b7a07-76c9-4f1b-9c37-320b6d8ed218", "node_type": "1", "metadata": {"window": "These statements are not guarantees of future\nperformance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary materially\nfrom those indicated.  A more detailed discussion of the risks and uncertainties that could cause our actual results to differ materially\nfrom those indicated is included (i) in the \"Risk F actors\" and \"Management's Discussion and Analysis\" sections in the Company\u2019s\nAnnual R eport on Form 10-K for the fiscal year ended September 30, 2022 and elsewhere in that report as supplemented by the\ndescription of business risks described in Item 1A to our form 10-Q for the fiscal quarter ended March 31, 2023, to which mention is\nmade herein and (ii) in other reports filed by the Company pursuant to the Securities Exchange Act.  The Company undertakes no\nobligation to publicly update or revise any forward-looking statements, except as required by the federal securities laws.\n\u00a0\n CENC ORA, INC.\n FINANCIAL SUMMAR Y\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three \nMonths Ended \nSeptember 30,\n2023 \u00a0% of \n Revenue \u00a0Three \nMonths Ended \nSeptember 30,\n2022 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$68,922,331 \u00a0\u00a0\u00a0 \u00a0$61,174,149 \u00a0\u00a0\u00a0 \u00a012.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a066,668,879 \u00a0\u00a0\u00a0 \u00a0\u00a059,188,590 \u00a0\u00a0\u00a0 \u00a012.6 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a02,253,452 \u00a0\u00a03.27 %\u00a0\u00a01,985,559 \u00a0\u00a03.25 %\u00a013.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a01,393,828 \u00a0\u00a02.02 %\u00a0\u00a01,263,462 \u00a0\u00a02.07 %\u00a010.3 %\nDepreciation and amortization \u00a0\u00a0276,226 \u00a0\u00a00.40 %\u00a0\u00a0170,562 \u00a0\u00a00.28 %\u00a062.0 %\nLitigation and opioid-related expenses \u00a0\u00a013,890 \u00a0\u00a0\u00a0 \u00a0\u00a015,024 \u00a0\u00a0\u00a0 \u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a040,291 \u00a0\u00a0\u00a0 \u00a0\u00a049,851 \u00a0\u00a0\u00a0 \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a052,276 \u00a0\u00a0\u00a0 \u00a0\u00a032,141 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a01,776,511 \u00a0\u00a02.58 %\u00a0\u00a01,531,040 \u00a0\u00a02.50 %\u00a016.0 %\n7", "original_text": "CENC ORA, INC.\n", "page_label": "7", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8ac15e27f2dcfa7a71607da4d9c899284f267804332ad92e5de96c0abee83797", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "93ff4593-5398-4e1a-8d7a-c8166313cc2f", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a0476,941 \u00a0\u00a00.69 %\u00a0\u00a0454,519 \u00a0\u00a00.74 %\u00a04.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther (income) loss, net 2 \u00a0\u00a0(30,424 )\u00a0\u00a0 \u00a0\u00a020,656 \u00a0\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a060,942 \u00a0\u00a0\u00a0 \u00a0\u00a051,523 \u00a0\u00a0\u00a0 \u00a018.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a0446,423 \u00a0\u00a00.65 %\u00a0\u00a0382,340 \u00a0\u00a00.63 %\u00a016.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a097,443 \u00a0\u00a0\u00a0 \u00a0\u00a083,664 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a0348,980 \u00a0\u00a00.51 %\u00a0\u00a0298,676 \u00a0\u00a00.49 %\u00a016.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss (income) attributable to noncontrolling\ninterests \u00a0\u00a01,585 \u00a0\u00a0\u00a0 \u00a0\u00a0(3,939 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to Cencora, Inc. \u00a0 $350,565 \u00a0\u00a00.51 %\u00a0$294,737 \u00a0\u00a00.48 %\u00a018.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$1.74 \u00a0\u00a0\u00a0 \u00a0$1.42 \u00a0\u00a0\u00a0 \u00a022.5 %\nDiluted \u00a0$1.72 \u00a0\u00a0\u00a0 \u00a0$1.40 \u00a0\u00a0\u00a0 \u00a022.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0201,338 \u00a0\u00a0\u00a0 \u00a0\u00a0207,222 \u00a0\u00a0\u00a0 \u00a0(2.8 )%\nDiluted \u00a0\u00a0203,395 \u00a0\u00a0\u00a0 \u00a0\u00a0209,961 \u00a0\u00a0\u00a0 \u00a0(3.1 )%\n__________________________________________\n1Includes a $70.6 million gain from antitrust litigation settlements, a $90.3 million LIFO expense, and Turkey foreign currency\nremeasurement expense of $27.9 million in the three months ended September 30, 2023.  Includes a $104.8 million LIFO expense\ndTkfi f$124illi ihh h ddS b302022\n8", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a0476,941 \u00a0\u00a00.69 %\u00a0\u00a0454,519 \u00a0\u00a00.74 %\u00a04.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther (income) loss, net 2 \u00a0\u00a0(30,424 )\u00a0\u00a0 \u00a0\u00a020,656 \u00a0\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a060,942 \u00a0\u00a0\u00a0 \u00a0\u00a051,523 \u00a0\u00a0\u00a0 \u00a018.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a0446,423 \u00a0\u00a00.65 %\u00a0\u00a0382,340 \u00a0\u00a00.63 %\u00a016.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a097,443 \u00a0\u00a0\u00a0 \u00a0\u00a083,664 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a0348,980 \u00a0\u00a00.51 %\u00a0\u00a0298,676 \u00a0\u00a00.49 %\u00a016.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss (income) attributable to noncontrolling\ninterests \u00a0\u00a01,585 \u00a0\u00a0\u00a0 \u00a0\u00a0(3,939 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to Cencora, Inc. \u00a0"}, "hash": "06e6e7e244947617c1e5753adb28ffdd3afdd1bc5347765df334bf3e42fa27e5", "class_name": "RelatedNodeInfo"}}, "text": "FINANCIAL SUMMAR Y\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three \nMonths Ended \nSeptember 30,\n2023 \u00a0% of \n Revenue \u00a0Three \nMonths Ended \nSeptember 30,\n2022 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$68,922,331 \u00a0\u00a0\u00a0 \u00a0$61,174,149 \u00a0\u00a0\u00a0 \u00a012.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a066,668,879 \u00a0\u00a0\u00a0 \u00a0\u00a059,188,590 \u00a0\u00a0\u00a0 \u00a012.6 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a02,253,452 \u00a0\u00a03.27 %\u00a0\u00a01,985,559 \u00a0\u00a03.25 %\u00a013.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a01,393,828 \u00a0\u00a02.02 %\u00a0\u00a01,263,462 \u00a0\u00a02.07 %\u00a010.3 %\nDepreciation and amortization \u00a0\u00a0276,226 \u00a0\u00a00.40 %\u00a0\u00a0170,562 \u00a0\u00a00.28 %\u00a062.0 %\nLitigation and opioid-related expenses \u00a0\u00a013,890 \u00a0\u00a0\u00a0 \u00a0\u00a015,024 \u00a0\u00a0\u00a0 \u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a040,291 \u00a0\u00a0\u00a0 \u00a0\u00a049,851 \u00a0\u00a0\u00a0 \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a052,276 \u00a0\u00a0\u00a0 \u00a0\u00a032,141 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a01,776,511 \u00a0\u00a02.58 %\u00a0\u00a01,531,040 \u00a0\u00a02.50 %\u00a016.0 %\n7", "start_char_idx": 1046, "end_char_idx": 1952, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "93ff4593-5398-4e1a-8d7a-c8166313cc2f": {"__data__": {"id_": "93ff4593-5398-4e1a-8d7a-c8166313cc2f", "embedding": null, "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a0476,941 \u00a0\u00a00.69 %\u00a0\u00a0454,519 \u00a0\u00a00.74 %\u00a04.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther (income) loss, net 2 \u00a0\u00a0(30,424 )\u00a0\u00a0 \u00a0\u00a020,656 \u00a0\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a060,942 \u00a0\u00a0\u00a0 \u00a0\u00a051,523 \u00a0\u00a0\u00a0 \u00a018.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a0446,423 \u00a0\u00a00.65 %\u00a0\u00a0382,340 \u00a0\u00a00.63 %\u00a016.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a097,443 \u00a0\u00a0\u00a0 \u00a0\u00a083,664 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a0348,980 \u00a0\u00a00.51 %\u00a0\u00a0298,676 \u00a0\u00a00.49 %\u00a016.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss (income) attributable to noncontrolling\ninterests \u00a0\u00a01,585 \u00a0\u00a0\u00a0 \u00a0\u00a0(3,939 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to Cencora, Inc. \u00a0 $350,565 \u00a0\u00a00.51 %\u00a0$294,737 \u00a0\u00a00.48 %\u00a018.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$1.74 \u00a0\u00a0\u00a0 \u00a0$1.42 \u00a0\u00a0\u00a0 \u00a022.5 %\nDiluted \u00a0$1.72 \u00a0\u00a0\u00a0 \u00a0$1.40 \u00a0\u00a0\u00a0 \u00a022.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0201,338 \u00a0\u00a0\u00a0 \u00a0\u00a0207,222 \u00a0\u00a0\u00a0 \u00a0(2.8 )%\nDiluted \u00a0\u00a0203,395 \u00a0\u00a0\u00a0 \u00a0\u00a0209,961 \u00a0\u00a0\u00a0 \u00a0(3.1 )%\n__________________________________________\n1Includes a $70.6 million gain from antitrust litigation settlements, a $90.3 million LIFO expense, and Turkey foreign currency\nremeasurement expense of $27.9 million in the three months ended September 30, 2023.  Includes a $104.8 million LIFO expense\ndTkfi f$124illi ihh h ddS b302022\n8", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a0476,941 \u00a0\u00a00.69 %\u00a0\u00a0454,519 \u00a0\u00a00.74 %\u00a04.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther (income) loss, net 2 \u00a0\u00a0(30,424 )\u00a0\u00a0 \u00a0\u00a020,656 \u00a0\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a060,942 \u00a0\u00a0\u00a0 \u00a0\u00a051,523 \u00a0\u00a0\u00a0 \u00a018.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a0446,423 \u00a0\u00a00.65 %\u00a0\u00a0382,340 \u00a0\u00a00.63 %\u00a016.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a097,443 \u00a0\u00a0\u00a0 \u00a0\u00a083,664 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a0348,980 \u00a0\u00a00.51 %\u00a0\u00a0298,676 \u00a0\u00a00.49 %\u00a016.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss (income) attributable to noncontrolling\ninterests \u00a0\u00a01,585 \u00a0\u00a0\u00a0 \u00a0\u00a0(3,939 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to Cencora, Inc. \u00a0", "page_label": "8", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5f73e483-71bf-4e05-8224-0c0ee9ff3a42", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "31c3e951bb5e55d92d8ff775d4ec23372903752cab2964cb2ddacfd299d1aa50", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "73ef7261-d311-4089-9728-290a02cf957f", "node_type": "1", "metadata": {"window": "A more detailed discussion of the risks and uncertainties that could cause our actual results to differ materially\nfrom those indicated is included (i) in the \"Risk F actors\" and \"Management's Discussion and Analysis\" sections in the Company\u2019s\nAnnual R eport on Form 10-K for the fiscal year ended September 30, 2022 and elsewhere in that report as supplemented by the\ndescription of business risks described in Item 1A to our form 10-Q for the fiscal quarter ended March 31, 2023, to which mention is\nmade herein and (ii) in other reports filed by the Company pursuant to the Securities Exchange Act.  The Company undertakes no\nobligation to publicly update or revise any forward-looking statements, except as required by the federal securities laws.\n\u00a0\n CENC ORA, INC.\n FINANCIAL SUMMAR Y\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three \nMonths Ended \nSeptember 30,\n2023 \u00a0% of \n Revenue \u00a0Three \nMonths Ended \nSeptember 30,\n2022 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$68,922,331 \u00a0\u00a0\u00a0 \u00a0$61,174,149 \u00a0\u00a0\u00a0 \u00a012.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a066,668,879 \u00a0\u00a0\u00a0 \u00a0\u00a059,188,590 \u00a0\u00a0\u00a0 \u00a012.6 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a02,253,452 \u00a0\u00a03.27 %\u00a0\u00a01,985,559 \u00a0\u00a03.25 %\u00a013.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a01,393,828 \u00a0\u00a02.02 %\u00a0\u00a01,263,462 \u00a0\u00a02.07 %\u00a010.3 %\nDepreciation and amortization \u00a0\u00a0276,226 \u00a0\u00a00.40 %\u00a0\u00a0170,562 \u00a0\u00a00.28 %\u00a062.0 %\nLitigation and opioid-related expenses \u00a0\u00a013,890 \u00a0\u00a0\u00a0 \u00a0\u00a015,024 \u00a0\u00a0\u00a0 \u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a040,291 \u00a0\u00a0\u00a0 \u00a0\u00a049,851 \u00a0\u00a0\u00a0 \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a052,276 \u00a0\u00a0\u00a0 \u00a0\u00a032,141 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a01,776,511 \u00a0\u00a02.58 %\u00a0\u00a01,531,040 \u00a0\u00a02.50 %\u00a016.0 %\n7", "original_text": "FINANCIAL SUMMAR Y\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three \nMonths Ended \nSeptember 30,\n2023 \u00a0% of \n Revenue \u00a0Three \nMonths Ended \nSeptember 30,\n2022 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$68,922,331 \u00a0\u00a0\u00a0 \u00a0$61,174,149 \u00a0\u00a0\u00a0 \u00a012.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a066,668,879 \u00a0\u00a0\u00a0 \u00a0\u00a059,188,590 \u00a0\u00a0\u00a0 \u00a012.6 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a02,253,452 \u00a0\u00a03.27 %\u00a0\u00a01,985,559 \u00a0\u00a03.25 %\u00a013.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a01,393,828 \u00a0\u00a02.02 %\u00a0\u00a01,263,462 \u00a0\u00a02.07 %\u00a010.3 %\nDepreciation and amortization \u00a0\u00a0276,226 \u00a0\u00a00.40 %\u00a0\u00a0170,562 \u00a0\u00a00.28 %\u00a062.0 %\nLitigation and opioid-related expenses \u00a0\u00a013,890 \u00a0\u00a0\u00a0 \u00a0\u00a015,024 \u00a0\u00a0\u00a0 \u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a040,291 \u00a0\u00a0\u00a0 \u00a0\u00a049,851 \u00a0\u00a0\u00a0 \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a052,276 \u00a0\u00a0\u00a0 \u00a0\u00a032,141 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a01,776,511 \u00a0\u00a02.58 %\u00a0\u00a01,531,040 \u00a0\u00a02.50 %\u00a016.0 %\n7", "page_label": "7", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "645c39d507ff213ce74d7424624f477a803ee9af57a3bb88df65012bdda779b8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d5d1ef16-3c0a-4c63-82db-0a82fdce7bea", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a0476,941 \u00a0\u00a00.69 %\u00a0\u00a0454,519 \u00a0\u00a00.74 %\u00a04.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther (income) loss, net 2 \u00a0\u00a0(30,424 )\u00a0\u00a0 \u00a0\u00a020,656 \u00a0\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a060,942 \u00a0\u00a0\u00a0 \u00a0\u00a051,523 \u00a0\u00a0\u00a0 \u00a018.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a0446,423 \u00a0\u00a00.65 %\u00a0\u00a0382,340 \u00a0\u00a00.63 %\u00a016.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a097,443 \u00a0\u00a0\u00a0 \u00a0\u00a083,664 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a0348,980 \u00a0\u00a00.51 %\u00a0\u00a0298,676 \u00a0\u00a00.49 %\u00a016.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss (income) attributable to noncontrolling\ninterests \u00a0\u00a01,585 \u00a0\u00a0\u00a0 \u00a0\u00a0(3,939 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to Cencora, Inc. \u00a0 $350,565 \u00a0\u00a00.51 %\u00a0$294,737 \u00a0\u00a00.48 %\u00a018.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$1.74 \u00a0\u00a0\u00a0 \u00a0$1.42 \u00a0\u00a0\u00a0 \u00a022.5 %\nDiluted \u00a0$1.72 \u00a0\u00a0\u00a0 \u00a0$1.40 \u00a0\u00a0\u00a0 \u00a022.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0201,338 \u00a0\u00a0\u00a0 \u00a0\u00a0207,222 \u00a0\u00a0\u00a0 \u00a0(2.8 )%\nDiluted \u00a0\u00a0203,395 \u00a0\u00a0\u00a0 \u00a0\u00a0209,961 \u00a0\u00a0\u00a0 \u00a0(3.1 )%\n__________________________________________\n1Includes a $70.6 million gain from antitrust litigation settlements, a $90.3 million LIFO expense, and Turkey foreign currency\nremeasurement expense of $27.9 million in the three months ended September 30, 2023.  Includes a $104.8 million LIFO expense\ndTkfi f$124illi ihh h ddS b302022\n8", "original_text": "$350,565 \u00a0\u00a00.51 %\u00a0$294,737 \u00a0\u00a00.48 %\u00a018.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$1.74 \u00a0\u00a0\u00a0 \u00a0$1.42 \u00a0\u00a0\u00a0 \u00a022.5 %\nDiluted \u00a0$1.72 \u00a0\u00a0\u00a0 \u00a0$1.40 \u00a0\u00a0\u00a0 \u00a022.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0201,338 \u00a0\u00a0\u00a0 \u00a0\u00a0207,222 \u00a0\u00a0\u00a0 \u00a0(2.8 )%\nDiluted \u00a0\u00a0203,395 \u00a0\u00a0\u00a0 \u00a0\u00a0209,961 \u00a0\u00a0\u00a0 \u00a0(3.1 )%\n__________________________________________\n1Includes a $70.6 million gain from antitrust litigation settlements, a $90.3 million LIFO expense, and Turkey foreign currency\nremeasurement expense of $27.9 million in the three months ended September 30, 2023. "}, "hash": "211b4e44a47c54badf481c49a445439c3a94103ecc6add3c7e43143136f004ec", "class_name": "RelatedNodeInfo"}}, "text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a0476,941 \u00a0\u00a00.69 %\u00a0\u00a0454,519 \u00a0\u00a00.74 %\u00a04.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther (income) loss, net 2 \u00a0\u00a0(30,424 )\u00a0\u00a0 \u00a0\u00a020,656 \u00a0\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a060,942 \u00a0\u00a0\u00a0 \u00a0\u00a051,523 \u00a0\u00a0\u00a0 \u00a018.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a0446,423 \u00a0\u00a00.65 %\u00a0\u00a0382,340 \u00a0\u00a00.63 %\u00a016.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a097,443 \u00a0\u00a0\u00a0 \u00a0\u00a083,664 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a0348,980 \u00a0\u00a00.51 %\u00a0\u00a0298,676 \u00a0\u00a00.49 %\u00a016.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss (income) attributable to noncontrolling\ninterests \u00a0\u00a01,585 \u00a0\u00a0\u00a0 \u00a0\u00a0(3,939 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to Cencora, Inc. \u00a0", "start_char_idx": 0, "end_char_idx": 595, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d5d1ef16-3c0a-4c63-82db-0a82fdce7bea": {"__data__": {"id_": "d5d1ef16-3c0a-4c63-82db-0a82fdce7bea", "embedding": null, "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a0476,941 \u00a0\u00a00.69 %\u00a0\u00a0454,519 \u00a0\u00a00.74 %\u00a04.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther (income) loss, net 2 \u00a0\u00a0(30,424 )\u00a0\u00a0 \u00a0\u00a020,656 \u00a0\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a060,942 \u00a0\u00a0\u00a0 \u00a0\u00a051,523 \u00a0\u00a0\u00a0 \u00a018.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a0446,423 \u00a0\u00a00.65 %\u00a0\u00a0382,340 \u00a0\u00a00.63 %\u00a016.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a097,443 \u00a0\u00a0\u00a0 \u00a0\u00a083,664 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a0348,980 \u00a0\u00a00.51 %\u00a0\u00a0298,676 \u00a0\u00a00.49 %\u00a016.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss (income) attributable to noncontrolling\ninterests \u00a0\u00a01,585 \u00a0\u00a0\u00a0 \u00a0\u00a0(3,939 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to Cencora, Inc. \u00a0 $350,565 \u00a0\u00a00.51 %\u00a0$294,737 \u00a0\u00a00.48 %\u00a018.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$1.74 \u00a0\u00a0\u00a0 \u00a0$1.42 \u00a0\u00a0\u00a0 \u00a022.5 %\nDiluted \u00a0$1.72 \u00a0\u00a0\u00a0 \u00a0$1.40 \u00a0\u00a0\u00a0 \u00a022.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0201,338 \u00a0\u00a0\u00a0 \u00a0\u00a0207,222 \u00a0\u00a0\u00a0 \u00a0(2.8 )%\nDiluted \u00a0\u00a0203,395 \u00a0\u00a0\u00a0 \u00a0\u00a0209,961 \u00a0\u00a0\u00a0 \u00a0(3.1 )%\n__________________________________________\n1Includes a $70.6 million gain from antitrust litigation settlements, a $90.3 million LIFO expense, and Turkey foreign currency\nremeasurement expense of $27.9 million in the three months ended September 30, 2023.  Includes a $104.8 million LIFO expense\ndTkfi f$124illi ihh h ddS b302022\n8", "original_text": "$350,565 \u00a0\u00a00.51 %\u00a0$294,737 \u00a0\u00a00.48 %\u00a018.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$1.74 \u00a0\u00a0\u00a0 \u00a0$1.42 \u00a0\u00a0\u00a0 \u00a022.5 %\nDiluted \u00a0$1.72 \u00a0\u00a0\u00a0 \u00a0$1.40 \u00a0\u00a0\u00a0 \u00a022.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0201,338 \u00a0\u00a0\u00a0 \u00a0\u00a0207,222 \u00a0\u00a0\u00a0 \u00a0(2.8 )%\nDiluted \u00a0\u00a0203,395 \u00a0\u00a0\u00a0 \u00a0\u00a0209,961 \u00a0\u00a0\u00a0 \u00a0(3.1 )%\n__________________________________________\n1Includes a $70.6 million gain from antitrust litigation settlements, a $90.3 million LIFO expense, and Turkey foreign currency\nremeasurement expense of $27.9 million in the three months ended September 30, 2023. ", "page_label": "8", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5f73e483-71bf-4e05-8224-0c0ee9ff3a42", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "31c3e951bb5e55d92d8ff775d4ec23372903752cab2964cb2ddacfd299d1aa50", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "93ff4593-5398-4e1a-8d7a-c8166313cc2f", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a0476,941 \u00a0\u00a00.69 %\u00a0\u00a0454,519 \u00a0\u00a00.74 %\u00a04.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther (income) loss, net 2 \u00a0\u00a0(30,424 )\u00a0\u00a0 \u00a0\u00a020,656 \u00a0\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a060,942 \u00a0\u00a0\u00a0 \u00a0\u00a051,523 \u00a0\u00a0\u00a0 \u00a018.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a0446,423 \u00a0\u00a00.65 %\u00a0\u00a0382,340 \u00a0\u00a00.63 %\u00a016.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a097,443 \u00a0\u00a0\u00a0 \u00a0\u00a083,664 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a0348,980 \u00a0\u00a00.51 %\u00a0\u00a0298,676 \u00a0\u00a00.49 %\u00a016.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss (income) attributable to noncontrolling\ninterests \u00a0\u00a01,585 \u00a0\u00a0\u00a0 \u00a0\u00a0(3,939 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to Cencora, Inc. \u00a0 $350,565 \u00a0\u00a00.51 %\u00a0$294,737 \u00a0\u00a00.48 %\u00a018.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$1.74 \u00a0\u00a0\u00a0 \u00a0$1.42 \u00a0\u00a0\u00a0 \u00a022.5 %\nDiluted \u00a0$1.72 \u00a0\u00a0\u00a0 \u00a0$1.40 \u00a0\u00a0\u00a0 \u00a022.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0201,338 \u00a0\u00a0\u00a0 \u00a0\u00a0207,222 \u00a0\u00a0\u00a0 \u00a0(2.8 )%\nDiluted \u00a0\u00a0203,395 \u00a0\u00a0\u00a0 \u00a0\u00a0209,961 \u00a0\u00a0\u00a0 \u00a0(3.1 )%\n__________________________________________\n1Includes a $70.6 million gain from antitrust litigation settlements, a $90.3 million LIFO expense, and Turkey foreign currency\nremeasurement expense of $27.9 million in the three months ended September 30, 2023.  Includes a $104.8 million LIFO expense\ndTkfi f$124illi ihh h ddS b302022\n8", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a0476,941 \u00a0\u00a00.69 %\u00a0\u00a0454,519 \u00a0\u00a00.74 %\u00a04.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther (income) loss, net 2 \u00a0\u00a0(30,424 )\u00a0\u00a0 \u00a0\u00a020,656 \u00a0\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a060,942 \u00a0\u00a0\u00a0 \u00a0\u00a051,523 \u00a0\u00a0\u00a0 \u00a018.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a0446,423 \u00a0\u00a00.65 %\u00a0\u00a0382,340 \u00a0\u00a00.63 %\u00a016.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a097,443 \u00a0\u00a0\u00a0 \u00a0\u00a083,664 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a0348,980 \u00a0\u00a00.51 %\u00a0\u00a0298,676 \u00a0\u00a00.49 %\u00a016.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss (income) attributable to noncontrolling\ninterests \u00a0\u00a01,585 \u00a0\u00a0\u00a0 \u00a0\u00a0(3,939 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to Cencora, Inc. \u00a0", "page_label": "8", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "982fa19a5486c719b0509452be31d68299738bf2c0d24e19b1dc16ad1703c32d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "afe604d3-f010-4c3e-9c48-ba7557c6362c", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a0476,941 \u00a0\u00a00.69 %\u00a0\u00a0454,519 \u00a0\u00a00.74 %\u00a04.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther (income) loss, net 2 \u00a0\u00a0(30,424 )\u00a0\u00a0 \u00a0\u00a020,656 \u00a0\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a060,942 \u00a0\u00a0\u00a0 \u00a0\u00a051,523 \u00a0\u00a0\u00a0 \u00a018.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a0446,423 \u00a0\u00a00.65 %\u00a0\u00a0382,340 \u00a0\u00a00.63 %\u00a016.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a097,443 \u00a0\u00a0\u00a0 \u00a0\u00a083,664 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a0348,980 \u00a0\u00a00.51 %\u00a0\u00a0298,676 \u00a0\u00a00.49 %\u00a016.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss (income) attributable to noncontrolling\ninterests \u00a0\u00a01,585 \u00a0\u00a0\u00a0 \u00a0\u00a0(3,939 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to Cencora, Inc. \u00a0 $350,565 \u00a0\u00a00.51 %\u00a0$294,737 \u00a0\u00a00.48 %\u00a018.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$1.74 \u00a0\u00a0\u00a0 \u00a0$1.42 \u00a0\u00a0\u00a0 \u00a022.5 %\nDiluted \u00a0$1.72 \u00a0\u00a0\u00a0 \u00a0$1.40 \u00a0\u00a0\u00a0 \u00a022.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0201,338 \u00a0\u00a0\u00a0 \u00a0\u00a0207,222 \u00a0\u00a0\u00a0 \u00a0(2.8 )%\nDiluted \u00a0\u00a0203,395 \u00a0\u00a0\u00a0 \u00a0\u00a0209,961 \u00a0\u00a0\u00a0 \u00a0(3.1 )%\n__________________________________________\n1Includes a $70.6 million gain from antitrust litigation settlements, a $90.3 million LIFO expense, and Turkey foreign currency\nremeasurement expense of $27.9 million in the three months ended September 30, 2023.  Includes a $104.8 million LIFO expense\ndTkfi f$124illi ihh h ddS b302022\n8", "original_text": "Includes a $104.8 million LIFO expense\ndTkfi f$124illi ihh h ddS b302022\n8"}, "hash": "15a4cb49ea0da161fbffdd9086f83cda836a24ffbd972e521c933511f196d3b2", "class_name": "RelatedNodeInfo"}}, "text": "$350,565 \u00a0\u00a00.51 %\u00a0$294,737 \u00a0\u00a00.48 %\u00a018.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$1.74 \u00a0\u00a0\u00a0 \u00a0$1.42 \u00a0\u00a0\u00a0 \u00a022.5 %\nDiluted \u00a0$1.72 \u00a0\u00a0\u00a0 \u00a0$1.40 \u00a0\u00a0\u00a0 \u00a022.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0201,338 \u00a0\u00a0\u00a0 \u00a0\u00a0207,222 \u00a0\u00a0\u00a0 \u00a0(2.8 )%\nDiluted \u00a0\u00a0203,395 \u00a0\u00a0\u00a0 \u00a0\u00a0209,961 \u00a0\u00a0\u00a0 \u00a0(3.1 )%\n__________________________________________\n1Includes a $70.6 million gain from antitrust litigation settlements, a $90.3 million LIFO expense, and Turkey foreign currency\nremeasurement expense of $27.9 million in the three months ended September 30, 2023. ", "start_char_idx": 595, "end_char_idx": 1184, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "afe604d3-f010-4c3e-9c48-ba7557c6362c": {"__data__": {"id_": "afe604d3-f010-4c3e-9c48-ba7557c6362c", "embedding": null, "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a0476,941 \u00a0\u00a00.69 %\u00a0\u00a0454,519 \u00a0\u00a00.74 %\u00a04.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther (income) loss, net 2 \u00a0\u00a0(30,424 )\u00a0\u00a0 \u00a0\u00a020,656 \u00a0\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a060,942 \u00a0\u00a0\u00a0 \u00a0\u00a051,523 \u00a0\u00a0\u00a0 \u00a018.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a0446,423 \u00a0\u00a00.65 %\u00a0\u00a0382,340 \u00a0\u00a00.63 %\u00a016.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a097,443 \u00a0\u00a0\u00a0 \u00a0\u00a083,664 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a0348,980 \u00a0\u00a00.51 %\u00a0\u00a0298,676 \u00a0\u00a00.49 %\u00a016.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss (income) attributable to noncontrolling\ninterests \u00a0\u00a01,585 \u00a0\u00a0\u00a0 \u00a0\u00a0(3,939 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to Cencora, Inc. \u00a0 $350,565 \u00a0\u00a00.51 %\u00a0$294,737 \u00a0\u00a00.48 %\u00a018.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$1.74 \u00a0\u00a0\u00a0 \u00a0$1.42 \u00a0\u00a0\u00a0 \u00a022.5 %\nDiluted \u00a0$1.72 \u00a0\u00a0\u00a0 \u00a0$1.40 \u00a0\u00a0\u00a0 \u00a022.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0201,338 \u00a0\u00a0\u00a0 \u00a0\u00a0207,222 \u00a0\u00a0\u00a0 \u00a0(2.8 )%\nDiluted \u00a0\u00a0203,395 \u00a0\u00a0\u00a0 \u00a0\u00a0209,961 \u00a0\u00a0\u00a0 \u00a0(3.1 )%\n__________________________________________\n1Includes a $70.6 million gain from antitrust litigation settlements, a $90.3 million LIFO expense, and Turkey foreign currency\nremeasurement expense of $27.9 million in the three months ended September 30, 2023.  Includes a $104.8 million LIFO expense\ndTkfi f$124illi ihh h ddS b302022\n8", "original_text": "Includes a $104.8 million LIFO expense\ndTkfi f$124illi ihh h ddS b302022\n8", "page_label": "8", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5f73e483-71bf-4e05-8224-0c0ee9ff3a42", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "31c3e951bb5e55d92d8ff775d4ec23372903752cab2964cb2ddacfd299d1aa50", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d5d1ef16-3c0a-4c63-82db-0a82fdce7bea", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a0476,941 \u00a0\u00a00.69 %\u00a0\u00a0454,519 \u00a0\u00a00.74 %\u00a04.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther (income) loss, net 2 \u00a0\u00a0(30,424 )\u00a0\u00a0 \u00a0\u00a020,656 \u00a0\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a060,942 \u00a0\u00a0\u00a0 \u00a0\u00a051,523 \u00a0\u00a0\u00a0 \u00a018.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a0446,423 \u00a0\u00a00.65 %\u00a0\u00a0382,340 \u00a0\u00a00.63 %\u00a016.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a097,443 \u00a0\u00a0\u00a0 \u00a0\u00a083,664 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a0348,980 \u00a0\u00a00.51 %\u00a0\u00a0298,676 \u00a0\u00a00.49 %\u00a016.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss (income) attributable to noncontrolling\ninterests \u00a0\u00a01,585 \u00a0\u00a0\u00a0 \u00a0\u00a0(3,939 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to Cencora, Inc. \u00a0 $350,565 \u00a0\u00a00.51 %\u00a0$294,737 \u00a0\u00a00.48 %\u00a018.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$1.74 \u00a0\u00a0\u00a0 \u00a0$1.42 \u00a0\u00a0\u00a0 \u00a022.5 %\nDiluted \u00a0$1.72 \u00a0\u00a0\u00a0 \u00a0$1.40 \u00a0\u00a0\u00a0 \u00a022.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0201,338 \u00a0\u00a0\u00a0 \u00a0\u00a0207,222 \u00a0\u00a0\u00a0 \u00a0(2.8 )%\nDiluted \u00a0\u00a0203,395 \u00a0\u00a0\u00a0 \u00a0\u00a0209,961 \u00a0\u00a0\u00a0 \u00a0(3.1 )%\n__________________________________________\n1Includes a $70.6 million gain from antitrust litigation settlements, a $90.3 million LIFO expense, and Turkey foreign currency\nremeasurement expense of $27.9 million in the three months ended September 30, 2023.  Includes a $104.8 million LIFO expense\ndTkfi f$124illi ihh h ddS b302022\n8", "original_text": "$350,565 \u00a0\u00a00.51 %\u00a0$294,737 \u00a0\u00a00.48 %\u00a018.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$1.74 \u00a0\u00a0\u00a0 \u00a0$1.42 \u00a0\u00a0\u00a0 \u00a022.5 %\nDiluted \u00a0$1.72 \u00a0\u00a0\u00a0 \u00a0$1.40 \u00a0\u00a0\u00a0 \u00a022.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0201,338 \u00a0\u00a0\u00a0 \u00a0\u00a0207,222 \u00a0\u00a0\u00a0 \u00a0(2.8 )%\nDiluted \u00a0\u00a0203,395 \u00a0\u00a0\u00a0 \u00a0\u00a0209,961 \u00a0\u00a0\u00a0 \u00a0(3.1 )%\n__________________________________________\n1Includes a $70.6 million gain from antitrust litigation settlements, a $90.3 million LIFO expense, and Turkey foreign currency\nremeasurement expense of $27.9 million in the three months ended September 30, 2023. ", "page_label": "8", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "545f2fb4e4382f7cb78dc6c6c0b676bea28b89a9b408afafce30f83a2ecae342", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0468fa44-af41-4032-8bb6-6ed24d1f82fa", "node_type": "1", "metadata": {"window": "and Turkey foreign currency remeasurement expense of $12.4 million in the three months ended September 30, 2022.\n\u00a0\n 2Includes a $40.7 million gain on the divestiture of non-core businesses in the three months September 30, 2023.\n CENC ORA, INC.\n FINANCIAL SUMMAR Y\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended \nSeptember 30,\n2023 \u00a0% of \n Revenue \u00a0Fiscal Y ear Ended \nSeptember 30, 2022 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$262,173,411 \u00a0\u00a0\u00a0 \u00a0$238,587,006 \u00a0\u00a0\u00a0 \u00a09.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a0253,213,918 \u00a0\u00a0\u00a0 \u00a0\u00a0230,290,639 \u00a0\u00a0\u00a0 \u00a010.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a08,959,493 \u00a0\u00a03.42 %\u00a0\u00a08,296,367 \u00a0\u00a03.48 %\u00a08.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a05,309,984 \u00a0\u00a02.03 %\u00a0\u00a04,848,962 \u00a0\u00a02.03 %\u00a09.5 %\nDepreciation and amortization \u00a0\u00a0963,904 \u00a0\u00a00.37 %\u00a0\u00a0693,895 \u00a0\u00a00.29 %\u00a038.9 %\nLitigation and opioid-related (credit) expenses 2\u00a0\u00a0(24,693 )\u00a0\u00a0 \u00a0\u00a0123,191 \u00a0\u00a0\u00a0 \u00a0\u00a0\nAcquisition-related deal and integration\nexpenses \u00a0\u00a0139,683 \u00a0\u00a0\u00a0 \u00a0\u00a0119,561 \u00a0\u00a0\u00a0 \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0229,884 \u00a0\u00a0\u00a0 \u00a0\u00a063,498 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of assets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a04,946 \u00a0\u00a0\u00a0 \u00a0\u00a0\nGoodwill impairment 3 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a075,936 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a06,618,762 \u00a0\u00a02.52 %\u00a0\u00a05,929,989 \u00a0\u00a02.49 %\u00a011.6 %\n9", "original_text": "and Turkey foreign currency remeasurement expense of $12.4 million in the three months ended September 30, 2022.\n\u00a0\n"}, "hash": "97faf42291fa213ef303a9a8ccb8408b1131afd256bf2a53598f2db182cb90b6", "class_name": "RelatedNodeInfo"}}, "text": "Includes a $104.8 million LIFO expense\ndTkfi f$124illi ihh h ddS b302022\n8", "start_char_idx": 1184, "end_char_idx": 1258, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0468fa44-af41-4032-8bb6-6ed24d1f82fa": {"__data__": {"id_": "0468fa44-af41-4032-8bb6-6ed24d1f82fa", "embedding": null, "metadata": {"window": "and Turkey foreign currency remeasurement expense of $12.4 million in the three months ended September 30, 2022.\n\u00a0\n 2Includes a $40.7 million gain on the divestiture of non-core businesses in the three months September 30, 2023.\n CENC ORA, INC.\n FINANCIAL SUMMAR Y\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended \nSeptember 30,\n2023 \u00a0% of \n Revenue \u00a0Fiscal Y ear Ended \nSeptember 30, 2022 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$262,173,411 \u00a0\u00a0\u00a0 \u00a0$238,587,006 \u00a0\u00a0\u00a0 \u00a09.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a0253,213,918 \u00a0\u00a0\u00a0 \u00a0\u00a0230,290,639 \u00a0\u00a0\u00a0 \u00a010.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a08,959,493 \u00a0\u00a03.42 %\u00a0\u00a08,296,367 \u00a0\u00a03.48 %\u00a08.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a05,309,984 \u00a0\u00a02.03 %\u00a0\u00a04,848,962 \u00a0\u00a02.03 %\u00a09.5 %\nDepreciation and amortization \u00a0\u00a0963,904 \u00a0\u00a00.37 %\u00a0\u00a0693,895 \u00a0\u00a00.29 %\u00a038.9 %\nLitigation and opioid-related (credit) expenses 2\u00a0\u00a0(24,693 )\u00a0\u00a0 \u00a0\u00a0123,191 \u00a0\u00a0\u00a0 \u00a0\u00a0\nAcquisition-related deal and integration\nexpenses \u00a0\u00a0139,683 \u00a0\u00a0\u00a0 \u00a0\u00a0119,561 \u00a0\u00a0\u00a0 \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0229,884 \u00a0\u00a0\u00a0 \u00a0\u00a063,498 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of assets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a04,946 \u00a0\u00a0\u00a0 \u00a0\u00a0\nGoodwill impairment 3 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a075,936 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a06,618,762 \u00a0\u00a02.52 %\u00a0\u00a05,929,989 \u00a0\u00a02.49 %\u00a011.6 %\n9", "original_text": "and Turkey foreign currency remeasurement expense of $12.4 million in the three months ended September 30, 2022.\n\u00a0\n", "page_label": "9", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e9de2252-bf7e-4d19-b8c6-e6603420689c", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6f25a6a1e79e99ef709fac344d7664ada28c7ff0e4aad925d6232c163ea91102", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "afe604d3-f010-4c3e-9c48-ba7557c6362c", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a0476,941 \u00a0\u00a00.69 %\u00a0\u00a0454,519 \u00a0\u00a00.74 %\u00a04.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther (income) loss, net 2 \u00a0\u00a0(30,424 )\u00a0\u00a0 \u00a0\u00a020,656 \u00a0\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a060,942 \u00a0\u00a0\u00a0 \u00a0\u00a051,523 \u00a0\u00a0\u00a0 \u00a018.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a0446,423 \u00a0\u00a00.65 %\u00a0\u00a0382,340 \u00a0\u00a00.63 %\u00a016.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a097,443 \u00a0\u00a0\u00a0 \u00a0\u00a083,664 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a0348,980 \u00a0\u00a00.51 %\u00a0\u00a0298,676 \u00a0\u00a00.49 %\u00a016.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss (income) attributable to noncontrolling\ninterests \u00a0\u00a01,585 \u00a0\u00a0\u00a0 \u00a0\u00a0(3,939 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to Cencora, Inc. \u00a0 $350,565 \u00a0\u00a00.51 %\u00a0$294,737 \u00a0\u00a00.48 %\u00a018.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$1.74 \u00a0\u00a0\u00a0 \u00a0$1.42 \u00a0\u00a0\u00a0 \u00a022.5 %\nDiluted \u00a0$1.72 \u00a0\u00a0\u00a0 \u00a0$1.40 \u00a0\u00a0\u00a0 \u00a022.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0201,338 \u00a0\u00a0\u00a0 \u00a0\u00a0207,222 \u00a0\u00a0\u00a0 \u00a0(2.8 )%\nDiluted \u00a0\u00a0203,395 \u00a0\u00a0\u00a0 \u00a0\u00a0209,961 \u00a0\u00a0\u00a0 \u00a0(3.1 )%\n__________________________________________\n1Includes a $70.6 million gain from antitrust litigation settlements, a $90.3 million LIFO expense, and Turkey foreign currency\nremeasurement expense of $27.9 million in the three months ended September 30, 2023.  Includes a $104.8 million LIFO expense\ndTkfi f$124illi ihh h ddS b302022\n8", "original_text": "Includes a $104.8 million LIFO expense\ndTkfi f$124illi ihh h ddS b302022\n8", "page_label": "8", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1c241327f07865826bdfee8cb4d4f97ac52d4f947f29f4b5c13f30d93c8be254", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "12099117-1ec9-4b8b-89d5-663f1923e346", "node_type": "1", "metadata": {"window": "and Turkey foreign currency remeasurement expense of $12.4 million in the three months ended September 30, 2022.\n\u00a0\n 2Includes a $40.7 million gain on the divestiture of non-core businesses in the three months September 30, 2023.\n CENC ORA, INC.\n FINANCIAL SUMMAR Y\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended \nSeptember 30,\n2023 \u00a0% of \n Revenue \u00a0Fiscal Y ear Ended \nSeptember 30, 2022 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$262,173,411 \u00a0\u00a0\u00a0 \u00a0$238,587,006 \u00a0\u00a0\u00a0 \u00a09.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a0253,213,918 \u00a0\u00a0\u00a0 \u00a0\u00a0230,290,639 \u00a0\u00a0\u00a0 \u00a010.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a08,959,493 \u00a0\u00a03.42 %\u00a0\u00a08,296,367 \u00a0\u00a03.48 %\u00a08.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a05,309,984 \u00a0\u00a02.03 %\u00a0\u00a04,848,962 \u00a0\u00a02.03 %\u00a09.5 %\nDepreciation and amortization \u00a0\u00a0963,904 \u00a0\u00a00.37 %\u00a0\u00a0693,895 \u00a0\u00a00.29 %\u00a038.9 %\nLitigation and opioid-related (credit) expenses 2\u00a0\u00a0(24,693 )\u00a0\u00a0 \u00a0\u00a0123,191 \u00a0\u00a0\u00a0 \u00a0\u00a0\nAcquisition-related deal and integration\nexpenses \u00a0\u00a0139,683 \u00a0\u00a0\u00a0 \u00a0\u00a0119,561 \u00a0\u00a0\u00a0 \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0229,884 \u00a0\u00a0\u00a0 \u00a0\u00a063,498 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of assets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a04,946 \u00a0\u00a0\u00a0 \u00a0\u00a0\nGoodwill impairment 3 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a075,936 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a06,618,762 \u00a0\u00a02.52 %\u00a0\u00a05,929,989 \u00a0\u00a02.49 %\u00a011.6 %\n9", "original_text": "2Includes a $40.7 million gain on the divestiture of non-core businesses in the three months September 30, 2023.\n"}, "hash": "80cc701ed9a614e9c08bad390800f4636a34cb2e322809095fb04666327849f5", "class_name": "RelatedNodeInfo"}}, "text": "and Turkey foreign currency remeasurement expense of $12.4 million in the three months ended September 30, 2022.\n\u00a0\n", "start_char_idx": 0, "end_char_idx": 115, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "12099117-1ec9-4b8b-89d5-663f1923e346": {"__data__": {"id_": "12099117-1ec9-4b8b-89d5-663f1923e346", "embedding": null, "metadata": {"window": "and Turkey foreign currency remeasurement expense of $12.4 million in the three months ended September 30, 2022.\n\u00a0\n 2Includes a $40.7 million gain on the divestiture of non-core businesses in the three months September 30, 2023.\n CENC ORA, INC.\n FINANCIAL SUMMAR Y\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended \nSeptember 30,\n2023 \u00a0% of \n Revenue \u00a0Fiscal Y ear Ended \nSeptember 30, 2022 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$262,173,411 \u00a0\u00a0\u00a0 \u00a0$238,587,006 \u00a0\u00a0\u00a0 \u00a09.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a0253,213,918 \u00a0\u00a0\u00a0 \u00a0\u00a0230,290,639 \u00a0\u00a0\u00a0 \u00a010.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a08,959,493 \u00a0\u00a03.42 %\u00a0\u00a08,296,367 \u00a0\u00a03.48 %\u00a08.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a05,309,984 \u00a0\u00a02.03 %\u00a0\u00a04,848,962 \u00a0\u00a02.03 %\u00a09.5 %\nDepreciation and amortization \u00a0\u00a0963,904 \u00a0\u00a00.37 %\u00a0\u00a0693,895 \u00a0\u00a00.29 %\u00a038.9 %\nLitigation and opioid-related (credit) expenses 2\u00a0\u00a0(24,693 )\u00a0\u00a0 \u00a0\u00a0123,191 \u00a0\u00a0\u00a0 \u00a0\u00a0\nAcquisition-related deal and integration\nexpenses \u00a0\u00a0139,683 \u00a0\u00a0\u00a0 \u00a0\u00a0119,561 \u00a0\u00a0\u00a0 \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0229,884 \u00a0\u00a0\u00a0 \u00a0\u00a063,498 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of assets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a04,946 \u00a0\u00a0\u00a0 \u00a0\u00a0\nGoodwill impairment 3 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a075,936 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a06,618,762 \u00a0\u00a02.52 %\u00a0\u00a05,929,989 \u00a0\u00a02.49 %\u00a011.6 %\n9", "original_text": "2Includes a $40.7 million gain on the divestiture of non-core businesses in the three months September 30, 2023.\n", "page_label": "9", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e9de2252-bf7e-4d19-b8c6-e6603420689c", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6f25a6a1e79e99ef709fac344d7664ada28c7ff0e4aad925d6232c163ea91102", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0468fa44-af41-4032-8bb6-6ed24d1f82fa", "node_type": "1", "metadata": {"window": "and Turkey foreign currency remeasurement expense of $12.4 million in the three months ended September 30, 2022.\n\u00a0\n 2Includes a $40.7 million gain on the divestiture of non-core businesses in the three months September 30, 2023.\n CENC ORA, INC.\n FINANCIAL SUMMAR Y\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended \nSeptember 30,\n2023 \u00a0% of \n Revenue \u00a0Fiscal Y ear Ended \nSeptember 30, 2022 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$262,173,411 \u00a0\u00a0\u00a0 \u00a0$238,587,006 \u00a0\u00a0\u00a0 \u00a09.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a0253,213,918 \u00a0\u00a0\u00a0 \u00a0\u00a0230,290,639 \u00a0\u00a0\u00a0 \u00a010.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a08,959,493 \u00a0\u00a03.42 %\u00a0\u00a08,296,367 \u00a0\u00a03.48 %\u00a08.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a05,309,984 \u00a0\u00a02.03 %\u00a0\u00a04,848,962 \u00a0\u00a02.03 %\u00a09.5 %\nDepreciation and amortization \u00a0\u00a0963,904 \u00a0\u00a00.37 %\u00a0\u00a0693,895 \u00a0\u00a00.29 %\u00a038.9 %\nLitigation and opioid-related (credit) expenses 2\u00a0\u00a0(24,693 )\u00a0\u00a0 \u00a0\u00a0123,191 \u00a0\u00a0\u00a0 \u00a0\u00a0\nAcquisition-related deal and integration\nexpenses \u00a0\u00a0139,683 \u00a0\u00a0\u00a0 \u00a0\u00a0119,561 \u00a0\u00a0\u00a0 \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0229,884 \u00a0\u00a0\u00a0 \u00a0\u00a063,498 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of assets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a04,946 \u00a0\u00a0\u00a0 \u00a0\u00a0\nGoodwill impairment 3 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a075,936 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a06,618,762 \u00a0\u00a02.52 %\u00a0\u00a05,929,989 \u00a0\u00a02.49 %\u00a011.6 %\n9", "original_text": "and Turkey foreign currency remeasurement expense of $12.4 million in the three months ended September 30, 2022.\n\u00a0\n", "page_label": "9", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "38c8bd71ac89b5d07e08f91a32fc9a5862d62b97e1d7720a49e1e7d2abe86c94", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "66f83426-3722-4e7b-aacb-1f159a3499f9", "node_type": "1", "metadata": {"window": "and Turkey foreign currency remeasurement expense of $12.4 million in the three months ended September 30, 2022.\n\u00a0\n 2Includes a $40.7 million gain on the divestiture of non-core businesses in the three months September 30, 2023.\n CENC ORA, INC.\n FINANCIAL SUMMAR Y\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended \nSeptember 30,\n2023 \u00a0% of \n Revenue \u00a0Fiscal Y ear Ended \nSeptember 30, 2022 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$262,173,411 \u00a0\u00a0\u00a0 \u00a0$238,587,006 \u00a0\u00a0\u00a0 \u00a09.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a0253,213,918 \u00a0\u00a0\u00a0 \u00a0\u00a0230,290,639 \u00a0\u00a0\u00a0 \u00a010.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a08,959,493 \u00a0\u00a03.42 %\u00a0\u00a08,296,367 \u00a0\u00a03.48 %\u00a08.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a05,309,984 \u00a0\u00a02.03 %\u00a0\u00a04,848,962 \u00a0\u00a02.03 %\u00a09.5 %\nDepreciation and amortization \u00a0\u00a0963,904 \u00a0\u00a00.37 %\u00a0\u00a0693,895 \u00a0\u00a00.29 %\u00a038.9 %\nLitigation and opioid-related (credit) expenses 2\u00a0\u00a0(24,693 )\u00a0\u00a0 \u00a0\u00a0123,191 \u00a0\u00a0\u00a0 \u00a0\u00a0\nAcquisition-related deal and integration\nexpenses \u00a0\u00a0139,683 \u00a0\u00a0\u00a0 \u00a0\u00a0119,561 \u00a0\u00a0\u00a0 \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0229,884 \u00a0\u00a0\u00a0 \u00a0\u00a063,498 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of assets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a04,946 \u00a0\u00a0\u00a0 \u00a0\u00a0\nGoodwill impairment 3 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a075,936 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a06,618,762 \u00a0\u00a02.52 %\u00a0\u00a05,929,989 \u00a0\u00a02.49 %\u00a011.6 %\n9", "original_text": "CENC ORA, INC.\n"}, "hash": "228edf73093e2f45fc720404405edf0270b5ffe729c65d0785bf3821ddcd2f2c", "class_name": "RelatedNodeInfo"}}, "text": "2Includes a $40.7 million gain on the divestiture of non-core businesses in the three months September 30, 2023.\n", "start_char_idx": 115, "end_char_idx": 228, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "66f83426-3722-4e7b-aacb-1f159a3499f9": {"__data__": {"id_": "66f83426-3722-4e7b-aacb-1f159a3499f9", "embedding": null, "metadata": {"window": "and Turkey foreign currency remeasurement expense of $12.4 million in the three months ended September 30, 2022.\n\u00a0\n 2Includes a $40.7 million gain on the divestiture of non-core businesses in the three months September 30, 2023.\n CENC ORA, INC.\n FINANCIAL SUMMAR Y\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended \nSeptember 30,\n2023 \u00a0% of \n Revenue \u00a0Fiscal Y ear Ended \nSeptember 30, 2022 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$262,173,411 \u00a0\u00a0\u00a0 \u00a0$238,587,006 \u00a0\u00a0\u00a0 \u00a09.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a0253,213,918 \u00a0\u00a0\u00a0 \u00a0\u00a0230,290,639 \u00a0\u00a0\u00a0 \u00a010.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a08,959,493 \u00a0\u00a03.42 %\u00a0\u00a08,296,367 \u00a0\u00a03.48 %\u00a08.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a05,309,984 \u00a0\u00a02.03 %\u00a0\u00a04,848,962 \u00a0\u00a02.03 %\u00a09.5 %\nDepreciation and amortization \u00a0\u00a0963,904 \u00a0\u00a00.37 %\u00a0\u00a0693,895 \u00a0\u00a00.29 %\u00a038.9 %\nLitigation and opioid-related (credit) expenses 2\u00a0\u00a0(24,693 )\u00a0\u00a0 \u00a0\u00a0123,191 \u00a0\u00a0\u00a0 \u00a0\u00a0\nAcquisition-related deal and integration\nexpenses \u00a0\u00a0139,683 \u00a0\u00a0\u00a0 \u00a0\u00a0119,561 \u00a0\u00a0\u00a0 \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0229,884 \u00a0\u00a0\u00a0 \u00a0\u00a063,498 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of assets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a04,946 \u00a0\u00a0\u00a0 \u00a0\u00a0\nGoodwill impairment 3 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a075,936 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a06,618,762 \u00a0\u00a02.52 %\u00a0\u00a05,929,989 \u00a0\u00a02.49 %\u00a011.6 %\n9", "original_text": "CENC ORA, INC.\n", "page_label": "9", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e9de2252-bf7e-4d19-b8c6-e6603420689c", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6f25a6a1e79e99ef709fac344d7664ada28c7ff0e4aad925d6232c163ea91102", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "12099117-1ec9-4b8b-89d5-663f1923e346", "node_type": "1", "metadata": {"window": "and Turkey foreign currency remeasurement expense of $12.4 million in the three months ended September 30, 2022.\n\u00a0\n 2Includes a $40.7 million gain on the divestiture of non-core businesses in the three months September 30, 2023.\n CENC ORA, INC.\n FINANCIAL SUMMAR Y\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended \nSeptember 30,\n2023 \u00a0% of \n Revenue \u00a0Fiscal Y ear Ended \nSeptember 30, 2022 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$262,173,411 \u00a0\u00a0\u00a0 \u00a0$238,587,006 \u00a0\u00a0\u00a0 \u00a09.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a0253,213,918 \u00a0\u00a0\u00a0 \u00a0\u00a0230,290,639 \u00a0\u00a0\u00a0 \u00a010.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a08,959,493 \u00a0\u00a03.42 %\u00a0\u00a08,296,367 \u00a0\u00a03.48 %\u00a08.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a05,309,984 \u00a0\u00a02.03 %\u00a0\u00a04,848,962 \u00a0\u00a02.03 %\u00a09.5 %\nDepreciation and amortization \u00a0\u00a0963,904 \u00a0\u00a00.37 %\u00a0\u00a0693,895 \u00a0\u00a00.29 %\u00a038.9 %\nLitigation and opioid-related (credit) expenses 2\u00a0\u00a0(24,693 )\u00a0\u00a0 \u00a0\u00a0123,191 \u00a0\u00a0\u00a0 \u00a0\u00a0\nAcquisition-related deal and integration\nexpenses \u00a0\u00a0139,683 \u00a0\u00a0\u00a0 \u00a0\u00a0119,561 \u00a0\u00a0\u00a0 \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0229,884 \u00a0\u00a0\u00a0 \u00a0\u00a063,498 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of assets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a04,946 \u00a0\u00a0\u00a0 \u00a0\u00a0\nGoodwill impairment 3 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a075,936 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a06,618,762 \u00a0\u00a02.52 %\u00a0\u00a05,929,989 \u00a0\u00a02.49 %\u00a011.6 %\n9", "original_text": "2Includes a $40.7 million gain on the divestiture of non-core businesses in the three months September 30, 2023.\n", "page_label": "9", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ea11aa4166b10c2f3081edae1890d6c818e29c53e9aad4bb45b5d8bc80f801f8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fc84f167-b9f4-4a48-a6b8-4d1b330f9471", "node_type": "1", "metadata": {"window": "and Turkey foreign currency remeasurement expense of $12.4 million in the three months ended September 30, 2022.\n\u00a0\n 2Includes a $40.7 million gain on the divestiture of non-core businesses in the three months September 30, 2023.\n CENC ORA, INC.\n FINANCIAL SUMMAR Y\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended \nSeptember 30,\n2023 \u00a0% of \n Revenue \u00a0Fiscal Y ear Ended \nSeptember 30, 2022 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$262,173,411 \u00a0\u00a0\u00a0 \u00a0$238,587,006 \u00a0\u00a0\u00a0 \u00a09.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a0253,213,918 \u00a0\u00a0\u00a0 \u00a0\u00a0230,290,639 \u00a0\u00a0\u00a0 \u00a010.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a08,959,493 \u00a0\u00a03.42 %\u00a0\u00a08,296,367 \u00a0\u00a03.48 %\u00a08.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a05,309,984 \u00a0\u00a02.03 %\u00a0\u00a04,848,962 \u00a0\u00a02.03 %\u00a09.5 %\nDepreciation and amortization \u00a0\u00a0963,904 \u00a0\u00a00.37 %\u00a0\u00a0693,895 \u00a0\u00a00.29 %\u00a038.9 %\nLitigation and opioid-related (credit) expenses 2\u00a0\u00a0(24,693 )\u00a0\u00a0 \u00a0\u00a0123,191 \u00a0\u00a0\u00a0 \u00a0\u00a0\nAcquisition-related deal and integration\nexpenses \u00a0\u00a0139,683 \u00a0\u00a0\u00a0 \u00a0\u00a0119,561 \u00a0\u00a0\u00a0 \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0229,884 \u00a0\u00a0\u00a0 \u00a0\u00a063,498 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of assets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a04,946 \u00a0\u00a0\u00a0 \u00a0\u00a0\nGoodwill impairment 3 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a075,936 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a06,618,762 \u00a0\u00a02.52 %\u00a0\u00a05,929,989 \u00a0\u00a02.49 %\u00a011.6 %\n9", "original_text": "FINANCIAL SUMMAR Y\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended \nSeptember 30,\n2023 \u00a0% of \n Revenue \u00a0Fiscal Y ear Ended \nSeptember 30, 2022 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$262,173,411 \u00a0\u00a0\u00a0 \u00a0$238,587,006 \u00a0\u00a0\u00a0 \u00a09.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a0253,213,918 \u00a0\u00a0\u00a0 \u00a0\u00a0230,290,639 \u00a0\u00a0\u00a0 \u00a010.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a08,959,493 \u00a0\u00a03.42 %\u00a0\u00a08,296,367 \u00a0\u00a03.48 %\u00a08.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a05,309,984 \u00a0\u00a02.03 %\u00a0\u00a04,848,962 \u00a0\u00a02.03 %\u00a09.5 %\nDepreciation and amortization \u00a0\u00a0963,904 \u00a0\u00a00.37 %\u00a0\u00a0693,895 \u00a0\u00a00.29 %\u00a038.9 %\nLitigation and opioid-related (credit) expenses 2\u00a0\u00a0(24,693 )\u00a0\u00a0 \u00a0\u00a0123,191 \u00a0\u00a0\u00a0 \u00a0\u00a0\nAcquisition-related deal and integration\nexpenses \u00a0\u00a0139,683 \u00a0\u00a0\u00a0 \u00a0\u00a0119,561 \u00a0\u00a0\u00a0 \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0229,884 \u00a0\u00a0\u00a0 \u00a0\u00a063,498 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of assets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a04,946 \u00a0\u00a0\u00a0 \u00a0\u00a0\nGoodwill impairment 3 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a075,936 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a06,618,762 \u00a0\u00a02.52 %\u00a0\u00a05,929,989 \u00a0\u00a02.49 %\u00a011.6 %\n9"}, "hash": "cccc248894bd107e00bcdf61eecae66dd852bf0dbaa0b23b6e95f15781ec2469", "class_name": "RelatedNodeInfo"}}, "text": "CENC ORA, INC.\n", "start_char_idx": 228, "end_char_idx": 243, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fc84f167-b9f4-4a48-a6b8-4d1b330f9471": {"__data__": {"id_": "fc84f167-b9f4-4a48-a6b8-4d1b330f9471", "embedding": null, "metadata": {"window": "and Turkey foreign currency remeasurement expense of $12.4 million in the three months ended September 30, 2022.\n\u00a0\n 2Includes a $40.7 million gain on the divestiture of non-core businesses in the three months September 30, 2023.\n CENC ORA, INC.\n FINANCIAL SUMMAR Y\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended \nSeptember 30,\n2023 \u00a0% of \n Revenue \u00a0Fiscal Y ear Ended \nSeptember 30, 2022 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$262,173,411 \u00a0\u00a0\u00a0 \u00a0$238,587,006 \u00a0\u00a0\u00a0 \u00a09.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a0253,213,918 \u00a0\u00a0\u00a0 \u00a0\u00a0230,290,639 \u00a0\u00a0\u00a0 \u00a010.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a08,959,493 \u00a0\u00a03.42 %\u00a0\u00a08,296,367 \u00a0\u00a03.48 %\u00a08.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a05,309,984 \u00a0\u00a02.03 %\u00a0\u00a04,848,962 \u00a0\u00a02.03 %\u00a09.5 %\nDepreciation and amortization \u00a0\u00a0963,904 \u00a0\u00a00.37 %\u00a0\u00a0693,895 \u00a0\u00a00.29 %\u00a038.9 %\nLitigation and opioid-related (credit) expenses 2\u00a0\u00a0(24,693 )\u00a0\u00a0 \u00a0\u00a0123,191 \u00a0\u00a0\u00a0 \u00a0\u00a0\nAcquisition-related deal and integration\nexpenses \u00a0\u00a0139,683 \u00a0\u00a0\u00a0 \u00a0\u00a0119,561 \u00a0\u00a0\u00a0 \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0229,884 \u00a0\u00a0\u00a0 \u00a0\u00a063,498 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of assets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a04,946 \u00a0\u00a0\u00a0 \u00a0\u00a0\nGoodwill impairment 3 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a075,936 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a06,618,762 \u00a0\u00a02.52 %\u00a0\u00a05,929,989 \u00a0\u00a02.49 %\u00a011.6 %\n9", "original_text": "FINANCIAL SUMMAR Y\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended \nSeptember 30,\n2023 \u00a0% of \n Revenue \u00a0Fiscal Y ear Ended \nSeptember 30, 2022 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$262,173,411 \u00a0\u00a0\u00a0 \u00a0$238,587,006 \u00a0\u00a0\u00a0 \u00a09.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a0253,213,918 \u00a0\u00a0\u00a0 \u00a0\u00a0230,290,639 \u00a0\u00a0\u00a0 \u00a010.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a08,959,493 \u00a0\u00a03.42 %\u00a0\u00a08,296,367 \u00a0\u00a03.48 %\u00a08.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a05,309,984 \u00a0\u00a02.03 %\u00a0\u00a04,848,962 \u00a0\u00a02.03 %\u00a09.5 %\nDepreciation and amortization \u00a0\u00a0963,904 \u00a0\u00a00.37 %\u00a0\u00a0693,895 \u00a0\u00a00.29 %\u00a038.9 %\nLitigation and opioid-related (credit) expenses 2\u00a0\u00a0(24,693 )\u00a0\u00a0 \u00a0\u00a0123,191 \u00a0\u00a0\u00a0 \u00a0\u00a0\nAcquisition-related deal and integration\nexpenses \u00a0\u00a0139,683 \u00a0\u00a0\u00a0 \u00a0\u00a0119,561 \u00a0\u00a0\u00a0 \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0229,884 \u00a0\u00a0\u00a0 \u00a0\u00a063,498 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of assets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a04,946 \u00a0\u00a0\u00a0 \u00a0\u00a0\nGoodwill impairment 3 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a075,936 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a06,618,762 \u00a0\u00a02.52 %\u00a0\u00a05,929,989 \u00a0\u00a02.49 %\u00a011.6 %\n9", "page_label": "9", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e9de2252-bf7e-4d19-b8c6-e6603420689c", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6f25a6a1e79e99ef709fac344d7664ada28c7ff0e4aad925d6232c163ea91102", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "66f83426-3722-4e7b-aacb-1f159a3499f9", "node_type": "1", "metadata": {"window": "and Turkey foreign currency remeasurement expense of $12.4 million in the three months ended September 30, 2022.\n\u00a0\n 2Includes a $40.7 million gain on the divestiture of non-core businesses in the three months September 30, 2023.\n CENC ORA, INC.\n FINANCIAL SUMMAR Y\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended \nSeptember 30,\n2023 \u00a0% of \n Revenue \u00a0Fiscal Y ear Ended \nSeptember 30, 2022 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$262,173,411 \u00a0\u00a0\u00a0 \u00a0$238,587,006 \u00a0\u00a0\u00a0 \u00a09.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a0253,213,918 \u00a0\u00a0\u00a0 \u00a0\u00a0230,290,639 \u00a0\u00a0\u00a0 \u00a010.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a08,959,493 \u00a0\u00a03.42 %\u00a0\u00a08,296,367 \u00a0\u00a03.48 %\u00a08.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a05,309,984 \u00a0\u00a02.03 %\u00a0\u00a04,848,962 \u00a0\u00a02.03 %\u00a09.5 %\nDepreciation and amortization \u00a0\u00a0963,904 \u00a0\u00a00.37 %\u00a0\u00a0693,895 \u00a0\u00a00.29 %\u00a038.9 %\nLitigation and opioid-related (credit) expenses 2\u00a0\u00a0(24,693 )\u00a0\u00a0 \u00a0\u00a0123,191 \u00a0\u00a0\u00a0 \u00a0\u00a0\nAcquisition-related deal and integration\nexpenses \u00a0\u00a0139,683 \u00a0\u00a0\u00a0 \u00a0\u00a0119,561 \u00a0\u00a0\u00a0 \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0229,884 \u00a0\u00a0\u00a0 \u00a0\u00a063,498 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of assets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a04,946 \u00a0\u00a0\u00a0 \u00a0\u00a0\nGoodwill impairment 3 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a075,936 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a06,618,762 \u00a0\u00a02.52 %\u00a0\u00a05,929,989 \u00a0\u00a02.49 %\u00a011.6 %\n9", "original_text": "CENC ORA, INC.\n", "page_label": "9", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9a10e70ac77893a9ad72a960b87fa4474542a55027e5b8fd0da24362f0f7e7b0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "354018de-cc27-4988-b5bb-25ed5feb3cec", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a02,340,731 \u00a0\u00a00.89 %\u00a0\u00a02,366,378 \u00a0\u00a00.99 %\u00a0(1.1 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther income, net  4 \u00a0\u00a0(49,036 )\u00a0\u00a0 \u00a0\u00a0(27,352 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a0228,931 \u00a0\u00a0\u00a0 \u00a0\u00a0210,673 \u00a0\u00a0\u00a0 \u00a08.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a02,160,836 \u00a0\u00a00.82 %\u00a0\u00a02,183,057 \u00a0\u00a00.91 %\u00a0(1.0 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a0428,260 \u00a0\u00a0\u00a0 \u00a0\u00a0516,517 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a01,732,576 \u00a0\u00a00.66 %\u00a0\u00a01,666,540 \u00a0\u00a00.70 %\u00a04.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss attributable to noncontrolling interests \u00a0\u00a012,717 \u00a0\u00a0\u00a0 \u00a0\u00a032,280 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to Cencora, Inc. \u00a0 $1,745,293 \u00a0\u00a00.67 %\u00a0$1,698,820 \u00a0\u00a00.71 %\u00a02.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$8.62 \u00a0\u00a0\u00a0 \u00a0$8.15 \u00a0\u00a0\u00a0 \u00a05.8 %\nDiluted \u00a0$8.53 \u00a0\u00a0\u00a0 \u00a0$8.04 \u00a0\u00a0\u00a0 \u00a06.1 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0202,511 \u00a0\u00a0\u00a0 \u00a0\u00a0208,472 \u00a0\u00a0\u00a0 \u00a0(2.9 )%\nDiluted \u00a0\u00a0204,591 \u00a0\u00a0\u00a0 \u00a0\u00a0211,210 \u00a0\u00a0\u00a0 \u00a0(3.1 )%\n___________________________________________\n1Includes a $239.1 million gain from antitrust litigation settlements, a $204.6 million LIFO expense, and Turkey foreign currency\nremeasurement expense of $87.0 million in the fiscal year ended September 30, 2023.  Includes a $1.8 million gain from antitrust\nlitigation settlements, a $67.2 million LIFO expense, and Turkey foreign currency remeasurement expense of $40.0 million in the\nfil ddS b302022\n10", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a02,340,731 \u00a0\u00a00.89 %\u00a0\u00a02,366,378 \u00a0\u00a00.99 %\u00a0(1.1 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther income, net  4 \u00a0\u00a0(49,036 )\u00a0\u00a0 \u00a0\u00a0(27,352 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a0228,931 \u00a0\u00a0\u00a0 \u00a0\u00a0210,673 \u00a0\u00a0\u00a0 \u00a08.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a02,160,836 \u00a0\u00a00.82 %\u00a0\u00a02,183,057 \u00a0\u00a00.91 %\u00a0(1.0 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a0428,260 \u00a0\u00a0\u00a0 \u00a0\u00a0516,517 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a01,732,576 \u00a0\u00a00.66 %\u00a0\u00a01,666,540 \u00a0\u00a00.70 %\u00a04.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss attributable to noncontrolling interests \u00a0\u00a012,717 \u00a0\u00a0\u00a0 \u00a0\u00a032,280 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to Cencora, Inc. \u00a0"}, "hash": "a1b1a557316ecb66f5882338ff8d5620b1c8a73ae8257548fca77e2c5bb31467", "class_name": "RelatedNodeInfo"}}, "text": "FINANCIAL SUMMAR Y\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended \nSeptember 30,\n2023 \u00a0% of \n Revenue \u00a0Fiscal Y ear Ended \nSeptember 30, 2022 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$262,173,411 \u00a0\u00a0\u00a0 \u00a0$238,587,006 \u00a0\u00a0\u00a0 \u00a09.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a0253,213,918 \u00a0\u00a0\u00a0 \u00a0\u00a0230,290,639 \u00a0\u00a0\u00a0 \u00a010.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a08,959,493 \u00a0\u00a03.42 %\u00a0\u00a08,296,367 \u00a0\u00a03.48 %\u00a08.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a05,309,984 \u00a0\u00a02.03 %\u00a0\u00a04,848,962 \u00a0\u00a02.03 %\u00a09.5 %\nDepreciation and amortization \u00a0\u00a0963,904 \u00a0\u00a00.37 %\u00a0\u00a0693,895 \u00a0\u00a00.29 %\u00a038.9 %\nLitigation and opioid-related (credit) expenses 2\u00a0\u00a0(24,693 )\u00a0\u00a0 \u00a0\u00a0123,191 \u00a0\u00a0\u00a0 \u00a0\u00a0\nAcquisition-related deal and integration\nexpenses \u00a0\u00a0139,683 \u00a0\u00a0\u00a0 \u00a0\u00a0119,561 \u00a0\u00a0\u00a0 \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0229,884 \u00a0\u00a0\u00a0 \u00a0\u00a063,498 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of assets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a04,946 \u00a0\u00a0\u00a0 \u00a0\u00a0\nGoodwill impairment 3 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a075,936 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a06,618,762 \u00a0\u00a02.52 %\u00a0\u00a05,929,989 \u00a0\u00a02.49 %\u00a011.6 %\n9", "start_char_idx": 243, "end_char_idx": 1253, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "354018de-cc27-4988-b5bb-25ed5feb3cec": {"__data__": {"id_": "354018de-cc27-4988-b5bb-25ed5feb3cec", "embedding": null, "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a02,340,731 \u00a0\u00a00.89 %\u00a0\u00a02,366,378 \u00a0\u00a00.99 %\u00a0(1.1 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther income, net  4 \u00a0\u00a0(49,036 )\u00a0\u00a0 \u00a0\u00a0(27,352 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a0228,931 \u00a0\u00a0\u00a0 \u00a0\u00a0210,673 \u00a0\u00a0\u00a0 \u00a08.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a02,160,836 \u00a0\u00a00.82 %\u00a0\u00a02,183,057 \u00a0\u00a00.91 %\u00a0(1.0 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a0428,260 \u00a0\u00a0\u00a0 \u00a0\u00a0516,517 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a01,732,576 \u00a0\u00a00.66 %\u00a0\u00a01,666,540 \u00a0\u00a00.70 %\u00a04.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss attributable to noncontrolling interests \u00a0\u00a012,717 \u00a0\u00a0\u00a0 \u00a0\u00a032,280 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to Cencora, Inc. \u00a0 $1,745,293 \u00a0\u00a00.67 %\u00a0$1,698,820 \u00a0\u00a00.71 %\u00a02.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$8.62 \u00a0\u00a0\u00a0 \u00a0$8.15 \u00a0\u00a0\u00a0 \u00a05.8 %\nDiluted \u00a0$8.53 \u00a0\u00a0\u00a0 \u00a0$8.04 \u00a0\u00a0\u00a0 \u00a06.1 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0202,511 \u00a0\u00a0\u00a0 \u00a0\u00a0208,472 \u00a0\u00a0\u00a0 \u00a0(2.9 )%\nDiluted \u00a0\u00a0204,591 \u00a0\u00a0\u00a0 \u00a0\u00a0211,210 \u00a0\u00a0\u00a0 \u00a0(3.1 )%\n___________________________________________\n1Includes a $239.1 million gain from antitrust litigation settlements, a $204.6 million LIFO expense, and Turkey foreign currency\nremeasurement expense of $87.0 million in the fiscal year ended September 30, 2023.  Includes a $1.8 million gain from antitrust\nlitigation settlements, a $67.2 million LIFO expense, and Turkey foreign currency remeasurement expense of $40.0 million in the\nfil ddS b302022\n10", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a02,340,731 \u00a0\u00a00.89 %\u00a0\u00a02,366,378 \u00a0\u00a00.99 %\u00a0(1.1 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther income, net  4 \u00a0\u00a0(49,036 )\u00a0\u00a0 \u00a0\u00a0(27,352 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a0228,931 \u00a0\u00a0\u00a0 \u00a0\u00a0210,673 \u00a0\u00a0\u00a0 \u00a08.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a02,160,836 \u00a0\u00a00.82 %\u00a0\u00a02,183,057 \u00a0\u00a00.91 %\u00a0(1.0 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a0428,260 \u00a0\u00a0\u00a0 \u00a0\u00a0516,517 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a01,732,576 \u00a0\u00a00.66 %\u00a0\u00a01,666,540 \u00a0\u00a00.70 %\u00a04.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss attributable to noncontrolling interests \u00a0\u00a012,717 \u00a0\u00a0\u00a0 \u00a0\u00a032,280 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to Cencora, Inc. \u00a0", "page_label": "10", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e97ebce4-a63a-4d71-a11f-d8f53ae490c7", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6d427608a62732fdd35a8caea0407f154c2e874b451da93b21cfc43412f29edf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fc84f167-b9f4-4a48-a6b8-4d1b330f9471", "node_type": "1", "metadata": {"window": "and Turkey foreign currency remeasurement expense of $12.4 million in the three months ended September 30, 2022.\n\u00a0\n 2Includes a $40.7 million gain on the divestiture of non-core businesses in the three months September 30, 2023.\n CENC ORA, INC.\n FINANCIAL SUMMAR Y\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended \nSeptember 30,\n2023 \u00a0% of \n Revenue \u00a0Fiscal Y ear Ended \nSeptember 30, 2022 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$262,173,411 \u00a0\u00a0\u00a0 \u00a0$238,587,006 \u00a0\u00a0\u00a0 \u00a09.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a0253,213,918 \u00a0\u00a0\u00a0 \u00a0\u00a0230,290,639 \u00a0\u00a0\u00a0 \u00a010.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a08,959,493 \u00a0\u00a03.42 %\u00a0\u00a08,296,367 \u00a0\u00a03.48 %\u00a08.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a05,309,984 \u00a0\u00a02.03 %\u00a0\u00a04,848,962 \u00a0\u00a02.03 %\u00a09.5 %\nDepreciation and amortization \u00a0\u00a0963,904 \u00a0\u00a00.37 %\u00a0\u00a0693,895 \u00a0\u00a00.29 %\u00a038.9 %\nLitigation and opioid-related (credit) expenses 2\u00a0\u00a0(24,693 )\u00a0\u00a0 \u00a0\u00a0123,191 \u00a0\u00a0\u00a0 \u00a0\u00a0\nAcquisition-related deal and integration\nexpenses \u00a0\u00a0139,683 \u00a0\u00a0\u00a0 \u00a0\u00a0119,561 \u00a0\u00a0\u00a0 \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0229,884 \u00a0\u00a0\u00a0 \u00a0\u00a063,498 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of assets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a04,946 \u00a0\u00a0\u00a0 \u00a0\u00a0\nGoodwill impairment 3 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a075,936 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a06,618,762 \u00a0\u00a02.52 %\u00a0\u00a05,929,989 \u00a0\u00a02.49 %\u00a011.6 %\n9", "original_text": "FINANCIAL SUMMAR Y\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended \nSeptember 30,\n2023 \u00a0% of \n Revenue \u00a0Fiscal Y ear Ended \nSeptember 30, 2022 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$262,173,411 \u00a0\u00a0\u00a0 \u00a0$238,587,006 \u00a0\u00a0\u00a0 \u00a09.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a0253,213,918 \u00a0\u00a0\u00a0 \u00a0\u00a0230,290,639 \u00a0\u00a0\u00a0 \u00a010.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a08,959,493 \u00a0\u00a03.42 %\u00a0\u00a08,296,367 \u00a0\u00a03.48 %\u00a08.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a05,309,984 \u00a0\u00a02.03 %\u00a0\u00a04,848,962 \u00a0\u00a02.03 %\u00a09.5 %\nDepreciation and amortization \u00a0\u00a0963,904 \u00a0\u00a00.37 %\u00a0\u00a0693,895 \u00a0\u00a00.29 %\u00a038.9 %\nLitigation and opioid-related (credit) expenses 2\u00a0\u00a0(24,693 )\u00a0\u00a0 \u00a0\u00a0123,191 \u00a0\u00a0\u00a0 \u00a0\u00a0\nAcquisition-related deal and integration\nexpenses \u00a0\u00a0139,683 \u00a0\u00a0\u00a0 \u00a0\u00a0119,561 \u00a0\u00a0\u00a0 \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0229,884 \u00a0\u00a0\u00a0 \u00a0\u00a063,498 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of assets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a04,946 \u00a0\u00a0\u00a0 \u00a0\u00a0\nGoodwill impairment 3 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a075,936 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a06,618,762 \u00a0\u00a02.52 %\u00a0\u00a05,929,989 \u00a0\u00a02.49 %\u00a011.6 %\n9", "page_label": "9", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "61b606b1eedce7f78be877adbcf35b53748e82fe3431a32307b0b570b486f7a5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e6e57f07-e169-4f52-a40c-32a75e6e8777", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a02,340,731 \u00a0\u00a00.89 %\u00a0\u00a02,366,378 \u00a0\u00a00.99 %\u00a0(1.1 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther income, net  4 \u00a0\u00a0(49,036 )\u00a0\u00a0 \u00a0\u00a0(27,352 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a0228,931 \u00a0\u00a0\u00a0 \u00a0\u00a0210,673 \u00a0\u00a0\u00a0 \u00a08.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a02,160,836 \u00a0\u00a00.82 %\u00a0\u00a02,183,057 \u00a0\u00a00.91 %\u00a0(1.0 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a0428,260 \u00a0\u00a0\u00a0 \u00a0\u00a0516,517 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a01,732,576 \u00a0\u00a00.66 %\u00a0\u00a01,666,540 \u00a0\u00a00.70 %\u00a04.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss attributable to noncontrolling interests \u00a0\u00a012,717 \u00a0\u00a0\u00a0 \u00a0\u00a032,280 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to Cencora, Inc. \u00a0 $1,745,293 \u00a0\u00a00.67 %\u00a0$1,698,820 \u00a0\u00a00.71 %\u00a02.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$8.62 \u00a0\u00a0\u00a0 \u00a0$8.15 \u00a0\u00a0\u00a0 \u00a05.8 %\nDiluted \u00a0$8.53 \u00a0\u00a0\u00a0 \u00a0$8.04 \u00a0\u00a0\u00a0 \u00a06.1 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0202,511 \u00a0\u00a0\u00a0 \u00a0\u00a0208,472 \u00a0\u00a0\u00a0 \u00a0(2.9 )%\nDiluted \u00a0\u00a0204,591 \u00a0\u00a0\u00a0 \u00a0\u00a0211,210 \u00a0\u00a0\u00a0 \u00a0(3.1 )%\n___________________________________________\n1Includes a $239.1 million gain from antitrust litigation settlements, a $204.6 million LIFO expense, and Turkey foreign currency\nremeasurement expense of $87.0 million in the fiscal year ended September 30, 2023.  Includes a $1.8 million gain from antitrust\nlitigation settlements, a $67.2 million LIFO expense, and Turkey foreign currency remeasurement expense of $40.0 million in the\nfil ddS b302022\n10", "original_text": "$1,745,293 \u00a0\u00a00.67 %\u00a0$1,698,820 \u00a0\u00a00.71 %\u00a02.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$8.62 \u00a0\u00a0\u00a0 \u00a0$8.15 \u00a0\u00a0\u00a0 \u00a05.8 %\nDiluted \u00a0$8.53 \u00a0\u00a0\u00a0 \u00a0$8.04 \u00a0\u00a0\u00a0 \u00a06.1 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0202,511 \u00a0\u00a0\u00a0 \u00a0\u00a0208,472 \u00a0\u00a0\u00a0 \u00a0(2.9 )%\nDiluted \u00a0\u00a0204,591 \u00a0\u00a0\u00a0 \u00a0\u00a0211,210 \u00a0\u00a0\u00a0 \u00a0(3.1 )%\n___________________________________________\n1Includes a $239.1 million gain from antitrust litigation settlements, a $204.6 million LIFO expense, and Turkey foreign currency\nremeasurement expense of $87.0 million in the fiscal year ended September 30, 2023. "}, "hash": "6984b1ca9404d25028e4cf7c79aa277d4e2bb4be47c838ffcfc2fa56ea6dbbb7", "class_name": "RelatedNodeInfo"}}, "text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a02,340,731 \u00a0\u00a00.89 %\u00a0\u00a02,366,378 \u00a0\u00a00.99 %\u00a0(1.1 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther income, net  4 \u00a0\u00a0(49,036 )\u00a0\u00a0 \u00a0\u00a0(27,352 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a0228,931 \u00a0\u00a0\u00a0 \u00a0\u00a0210,673 \u00a0\u00a0\u00a0 \u00a08.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a02,160,836 \u00a0\u00a00.82 %\u00a0\u00a02,183,057 \u00a0\u00a00.91 %\u00a0(1.0 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a0428,260 \u00a0\u00a0\u00a0 \u00a0\u00a0516,517 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a01,732,576 \u00a0\u00a00.66 %\u00a0\u00a01,666,540 \u00a0\u00a00.70 %\u00a04.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss attributable to noncontrolling interests \u00a0\u00a012,717 \u00a0\u00a0\u00a0 \u00a0\u00a032,280 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to Cencora, Inc. \u00a0", "start_char_idx": 0, "end_char_idx": 599, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e6e57f07-e169-4f52-a40c-32a75e6e8777": {"__data__": {"id_": "e6e57f07-e169-4f52-a40c-32a75e6e8777", "embedding": null, "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a02,340,731 \u00a0\u00a00.89 %\u00a0\u00a02,366,378 \u00a0\u00a00.99 %\u00a0(1.1 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther income, net  4 \u00a0\u00a0(49,036 )\u00a0\u00a0 \u00a0\u00a0(27,352 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a0228,931 \u00a0\u00a0\u00a0 \u00a0\u00a0210,673 \u00a0\u00a0\u00a0 \u00a08.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a02,160,836 \u00a0\u00a00.82 %\u00a0\u00a02,183,057 \u00a0\u00a00.91 %\u00a0(1.0 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a0428,260 \u00a0\u00a0\u00a0 \u00a0\u00a0516,517 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a01,732,576 \u00a0\u00a00.66 %\u00a0\u00a01,666,540 \u00a0\u00a00.70 %\u00a04.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss attributable to noncontrolling interests \u00a0\u00a012,717 \u00a0\u00a0\u00a0 \u00a0\u00a032,280 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to Cencora, Inc. \u00a0 $1,745,293 \u00a0\u00a00.67 %\u00a0$1,698,820 \u00a0\u00a00.71 %\u00a02.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$8.62 \u00a0\u00a0\u00a0 \u00a0$8.15 \u00a0\u00a0\u00a0 \u00a05.8 %\nDiluted \u00a0$8.53 \u00a0\u00a0\u00a0 \u00a0$8.04 \u00a0\u00a0\u00a0 \u00a06.1 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0202,511 \u00a0\u00a0\u00a0 \u00a0\u00a0208,472 \u00a0\u00a0\u00a0 \u00a0(2.9 )%\nDiluted \u00a0\u00a0204,591 \u00a0\u00a0\u00a0 \u00a0\u00a0211,210 \u00a0\u00a0\u00a0 \u00a0(3.1 )%\n___________________________________________\n1Includes a $239.1 million gain from antitrust litigation settlements, a $204.6 million LIFO expense, and Turkey foreign currency\nremeasurement expense of $87.0 million in the fiscal year ended September 30, 2023.  Includes a $1.8 million gain from antitrust\nlitigation settlements, a $67.2 million LIFO expense, and Turkey foreign currency remeasurement expense of $40.0 million in the\nfil ddS b302022\n10", "original_text": "$1,745,293 \u00a0\u00a00.67 %\u00a0$1,698,820 \u00a0\u00a00.71 %\u00a02.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$8.62 \u00a0\u00a0\u00a0 \u00a0$8.15 \u00a0\u00a0\u00a0 \u00a05.8 %\nDiluted \u00a0$8.53 \u00a0\u00a0\u00a0 \u00a0$8.04 \u00a0\u00a0\u00a0 \u00a06.1 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0202,511 \u00a0\u00a0\u00a0 \u00a0\u00a0208,472 \u00a0\u00a0\u00a0 \u00a0(2.9 )%\nDiluted \u00a0\u00a0204,591 \u00a0\u00a0\u00a0 \u00a0\u00a0211,210 \u00a0\u00a0\u00a0 \u00a0(3.1 )%\n___________________________________________\n1Includes a $239.1 million gain from antitrust litigation settlements, a $204.6 million LIFO expense, and Turkey foreign currency\nremeasurement expense of $87.0 million in the fiscal year ended September 30, 2023. ", "page_label": "10", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e97ebce4-a63a-4d71-a11f-d8f53ae490c7", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6d427608a62732fdd35a8caea0407f154c2e874b451da93b21cfc43412f29edf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "354018de-cc27-4988-b5bb-25ed5feb3cec", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a02,340,731 \u00a0\u00a00.89 %\u00a0\u00a02,366,378 \u00a0\u00a00.99 %\u00a0(1.1 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther income, net  4 \u00a0\u00a0(49,036 )\u00a0\u00a0 \u00a0\u00a0(27,352 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a0228,931 \u00a0\u00a0\u00a0 \u00a0\u00a0210,673 \u00a0\u00a0\u00a0 \u00a08.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a02,160,836 \u00a0\u00a00.82 %\u00a0\u00a02,183,057 \u00a0\u00a00.91 %\u00a0(1.0 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a0428,260 \u00a0\u00a0\u00a0 \u00a0\u00a0516,517 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a01,732,576 \u00a0\u00a00.66 %\u00a0\u00a01,666,540 \u00a0\u00a00.70 %\u00a04.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss attributable to noncontrolling interests \u00a0\u00a012,717 \u00a0\u00a0\u00a0 \u00a0\u00a032,280 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to Cencora, Inc. \u00a0 $1,745,293 \u00a0\u00a00.67 %\u00a0$1,698,820 \u00a0\u00a00.71 %\u00a02.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$8.62 \u00a0\u00a0\u00a0 \u00a0$8.15 \u00a0\u00a0\u00a0 \u00a05.8 %\nDiluted \u00a0$8.53 \u00a0\u00a0\u00a0 \u00a0$8.04 \u00a0\u00a0\u00a0 \u00a06.1 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0202,511 \u00a0\u00a0\u00a0 \u00a0\u00a0208,472 \u00a0\u00a0\u00a0 \u00a0(2.9 )%\nDiluted \u00a0\u00a0204,591 \u00a0\u00a0\u00a0 \u00a0\u00a0211,210 \u00a0\u00a0\u00a0 \u00a0(3.1 )%\n___________________________________________\n1Includes a $239.1 million gain from antitrust litigation settlements, a $204.6 million LIFO expense, and Turkey foreign currency\nremeasurement expense of $87.0 million in the fiscal year ended September 30, 2023.  Includes a $1.8 million gain from antitrust\nlitigation settlements, a $67.2 million LIFO expense, and Turkey foreign currency remeasurement expense of $40.0 million in the\nfil ddS b302022\n10", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a02,340,731 \u00a0\u00a00.89 %\u00a0\u00a02,366,378 \u00a0\u00a00.99 %\u00a0(1.1 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther income, net  4 \u00a0\u00a0(49,036 )\u00a0\u00a0 \u00a0\u00a0(27,352 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a0228,931 \u00a0\u00a0\u00a0 \u00a0\u00a0210,673 \u00a0\u00a0\u00a0 \u00a08.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a02,160,836 \u00a0\u00a00.82 %\u00a0\u00a02,183,057 \u00a0\u00a00.91 %\u00a0(1.0 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a0428,260 \u00a0\u00a0\u00a0 \u00a0\u00a0516,517 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a01,732,576 \u00a0\u00a00.66 %\u00a0\u00a01,666,540 \u00a0\u00a00.70 %\u00a04.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss attributable to noncontrolling interests \u00a0\u00a012,717 \u00a0\u00a0\u00a0 \u00a0\u00a032,280 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to Cencora, Inc. \u00a0", "page_label": "10", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d794f2d919e3ac23235b8f63c15a43b51ee5f715c3594859c90b3643491f3c68", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0485a143-3bfe-4233-83bd-8fef6be10b0e", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a02,340,731 \u00a0\u00a00.89 %\u00a0\u00a02,366,378 \u00a0\u00a00.99 %\u00a0(1.1 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther income, net  4 \u00a0\u00a0(49,036 )\u00a0\u00a0 \u00a0\u00a0(27,352 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a0228,931 \u00a0\u00a0\u00a0 \u00a0\u00a0210,673 \u00a0\u00a0\u00a0 \u00a08.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a02,160,836 \u00a0\u00a00.82 %\u00a0\u00a02,183,057 \u00a0\u00a00.91 %\u00a0(1.0 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a0428,260 \u00a0\u00a0\u00a0 \u00a0\u00a0516,517 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a01,732,576 \u00a0\u00a00.66 %\u00a0\u00a01,666,540 \u00a0\u00a00.70 %\u00a04.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss attributable to noncontrolling interests \u00a0\u00a012,717 \u00a0\u00a0\u00a0 \u00a0\u00a032,280 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to Cencora, Inc. \u00a0 $1,745,293 \u00a0\u00a00.67 %\u00a0$1,698,820 \u00a0\u00a00.71 %\u00a02.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$8.62 \u00a0\u00a0\u00a0 \u00a0$8.15 \u00a0\u00a0\u00a0 \u00a05.8 %\nDiluted \u00a0$8.53 \u00a0\u00a0\u00a0 \u00a0$8.04 \u00a0\u00a0\u00a0 \u00a06.1 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0202,511 \u00a0\u00a0\u00a0 \u00a0\u00a0208,472 \u00a0\u00a0\u00a0 \u00a0(2.9 )%\nDiluted \u00a0\u00a0204,591 \u00a0\u00a0\u00a0 \u00a0\u00a0211,210 \u00a0\u00a0\u00a0 \u00a0(3.1 )%\n___________________________________________\n1Includes a $239.1 million gain from antitrust litigation settlements, a $204.6 million LIFO expense, and Turkey foreign currency\nremeasurement expense of $87.0 million in the fiscal year ended September 30, 2023.  Includes a $1.8 million gain from antitrust\nlitigation settlements, a $67.2 million LIFO expense, and Turkey foreign currency remeasurement expense of $40.0 million in the\nfil ddS b302022\n10", "original_text": "Includes a $1.8 million gain from antitrust\nlitigation settlements, a $67.2 million LIFO expense, and Turkey foreign currency remeasurement expense of $40.0 million in the\nfil ddS b302022\n10"}, "hash": "95b2468bf60fd374d3e8f784bc2c681f426668ae3ae21a2b35679649521816c2", "class_name": "RelatedNodeInfo"}}, "text": "$1,745,293 \u00a0\u00a00.67 %\u00a0$1,698,820 \u00a0\u00a00.71 %\u00a02.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$8.62 \u00a0\u00a0\u00a0 \u00a0$8.15 \u00a0\u00a0\u00a0 \u00a05.8 %\nDiluted \u00a0$8.53 \u00a0\u00a0\u00a0 \u00a0$8.04 \u00a0\u00a0\u00a0 \u00a06.1 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0202,511 \u00a0\u00a0\u00a0 \u00a0\u00a0208,472 \u00a0\u00a0\u00a0 \u00a0(2.9 )%\nDiluted \u00a0\u00a0204,591 \u00a0\u00a0\u00a0 \u00a0\u00a0211,210 \u00a0\u00a0\u00a0 \u00a0(3.1 )%\n___________________________________________\n1Includes a $239.1 million gain from antitrust litigation settlements, a $204.6 million LIFO expense, and Turkey foreign currency\nremeasurement expense of $87.0 million in the fiscal year ended September 30, 2023. ", "start_char_idx": 599, "end_char_idx": 1191, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0485a143-3bfe-4233-83bd-8fef6be10b0e": {"__data__": {"id_": "0485a143-3bfe-4233-83bd-8fef6be10b0e", "embedding": null, "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a02,340,731 \u00a0\u00a00.89 %\u00a0\u00a02,366,378 \u00a0\u00a00.99 %\u00a0(1.1 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther income, net  4 \u00a0\u00a0(49,036 )\u00a0\u00a0 \u00a0\u00a0(27,352 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a0228,931 \u00a0\u00a0\u00a0 \u00a0\u00a0210,673 \u00a0\u00a0\u00a0 \u00a08.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a02,160,836 \u00a0\u00a00.82 %\u00a0\u00a02,183,057 \u00a0\u00a00.91 %\u00a0(1.0 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a0428,260 \u00a0\u00a0\u00a0 \u00a0\u00a0516,517 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a01,732,576 \u00a0\u00a00.66 %\u00a0\u00a01,666,540 \u00a0\u00a00.70 %\u00a04.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss attributable to noncontrolling interests \u00a0\u00a012,717 \u00a0\u00a0\u00a0 \u00a0\u00a032,280 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to Cencora, Inc. \u00a0 $1,745,293 \u00a0\u00a00.67 %\u00a0$1,698,820 \u00a0\u00a00.71 %\u00a02.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$8.62 \u00a0\u00a0\u00a0 \u00a0$8.15 \u00a0\u00a0\u00a0 \u00a05.8 %\nDiluted \u00a0$8.53 \u00a0\u00a0\u00a0 \u00a0$8.04 \u00a0\u00a0\u00a0 \u00a06.1 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0202,511 \u00a0\u00a0\u00a0 \u00a0\u00a0208,472 \u00a0\u00a0\u00a0 \u00a0(2.9 )%\nDiluted \u00a0\u00a0204,591 \u00a0\u00a0\u00a0 \u00a0\u00a0211,210 \u00a0\u00a0\u00a0 \u00a0(3.1 )%\n___________________________________________\n1Includes a $239.1 million gain from antitrust litigation settlements, a $204.6 million LIFO expense, and Turkey foreign currency\nremeasurement expense of $87.0 million in the fiscal year ended September 30, 2023.  Includes a $1.8 million gain from antitrust\nlitigation settlements, a $67.2 million LIFO expense, and Turkey foreign currency remeasurement expense of $40.0 million in the\nfil ddS b302022\n10", "original_text": "Includes a $1.8 million gain from antitrust\nlitigation settlements, a $67.2 million LIFO expense, and Turkey foreign currency remeasurement expense of $40.0 million in the\nfil ddS b302022\n10", "page_label": "10", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e97ebce4-a63a-4d71-a11f-d8f53ae490c7", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6d427608a62732fdd35a8caea0407f154c2e874b451da93b21cfc43412f29edf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e6e57f07-e169-4f52-a40c-32a75e6e8777", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a02,340,731 \u00a0\u00a00.89 %\u00a0\u00a02,366,378 \u00a0\u00a00.99 %\u00a0(1.1 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther income, net  4 \u00a0\u00a0(49,036 )\u00a0\u00a0 \u00a0\u00a0(27,352 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a0228,931 \u00a0\u00a0\u00a0 \u00a0\u00a0210,673 \u00a0\u00a0\u00a0 \u00a08.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a02,160,836 \u00a0\u00a00.82 %\u00a0\u00a02,183,057 \u00a0\u00a00.91 %\u00a0(1.0 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a0428,260 \u00a0\u00a0\u00a0 \u00a0\u00a0516,517 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a01,732,576 \u00a0\u00a00.66 %\u00a0\u00a01,666,540 \u00a0\u00a00.70 %\u00a04.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss attributable to noncontrolling interests \u00a0\u00a012,717 \u00a0\u00a0\u00a0 \u00a0\u00a032,280 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to Cencora, Inc. \u00a0 $1,745,293 \u00a0\u00a00.67 %\u00a0$1,698,820 \u00a0\u00a00.71 %\u00a02.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$8.62 \u00a0\u00a0\u00a0 \u00a0$8.15 \u00a0\u00a0\u00a0 \u00a05.8 %\nDiluted \u00a0$8.53 \u00a0\u00a0\u00a0 \u00a0$8.04 \u00a0\u00a0\u00a0 \u00a06.1 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0202,511 \u00a0\u00a0\u00a0 \u00a0\u00a0208,472 \u00a0\u00a0\u00a0 \u00a0(2.9 )%\nDiluted \u00a0\u00a0204,591 \u00a0\u00a0\u00a0 \u00a0\u00a0211,210 \u00a0\u00a0\u00a0 \u00a0(3.1 )%\n___________________________________________\n1Includes a $239.1 million gain from antitrust litigation settlements, a $204.6 million LIFO expense, and Turkey foreign currency\nremeasurement expense of $87.0 million in the fiscal year ended September 30, 2023.  Includes a $1.8 million gain from antitrust\nlitigation settlements, a $67.2 million LIFO expense, and Turkey foreign currency remeasurement expense of $40.0 million in the\nfil ddS b302022\n10", "original_text": "$1,745,293 \u00a0\u00a00.67 %\u00a0$1,698,820 \u00a0\u00a00.71 %\u00a02.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$8.62 \u00a0\u00a0\u00a0 \u00a0$8.15 \u00a0\u00a0\u00a0 \u00a05.8 %\nDiluted \u00a0$8.53 \u00a0\u00a0\u00a0 \u00a0$8.04 \u00a0\u00a0\u00a0 \u00a06.1 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0202,511 \u00a0\u00a0\u00a0 \u00a0\u00a0208,472 \u00a0\u00a0\u00a0 \u00a0(2.9 )%\nDiluted \u00a0\u00a0204,591 \u00a0\u00a0\u00a0 \u00a0\u00a0211,210 \u00a0\u00a0\u00a0 \u00a0(3.1 )%\n___________________________________________\n1Includes a $239.1 million gain from antitrust litigation settlements, a $204.6 million LIFO expense, and Turkey foreign currency\nremeasurement expense of $87.0 million in the fiscal year ended September 30, 2023. ", "page_label": "10", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "346b62529a6f96363234325867c0af280dea4bf62f3a4d8aae70c54063631fb1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9dbf0a8d-6422-4fa5-a626-cea101906a4f", "node_type": "1", "metadata": {"window": "fiscal year ended September 30, 2022.\n\u00a0\n 2Includes the receipt of $83.4 million from the H.D.  Smith opioid litigation indemnity escrow in the fiscal year ended September\n30, 2023.\n\u00a0\n 3The goodwill impairment is related to the Company's less-than-wholly-owned subsidiary in Brazil in the fiscal year ended\nSeptember 30, 2022.\n\u00a0\n", "original_text": "fiscal year ended September 30, 2022.\n\u00a0\n"}, "hash": "55e83047d700b0d13641c1ba3f92190e4620378d76e9941515e660b6d8ca515b", "class_name": "RelatedNodeInfo"}}, "text": "Includes a $1.8 million gain from antitrust\nlitigation settlements, a $67.2 million LIFO expense, and Turkey foreign currency remeasurement expense of $40.0 million in the\nfil ddS b302022\n10", "start_char_idx": 1191, "end_char_idx": 1381, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9dbf0a8d-6422-4fa5-a626-cea101906a4f": {"__data__": {"id_": "9dbf0a8d-6422-4fa5-a626-cea101906a4f", "embedding": null, "metadata": {"window": "fiscal year ended September 30, 2022.\n\u00a0\n 2Includes the receipt of $83.4 million from the H.D.  Smith opioid litigation indemnity escrow in the fiscal year ended September\n30, 2023.\n\u00a0\n 3The goodwill impairment is related to the Company's less-than-wholly-owned subsidiary in Brazil in the fiscal year ended\nSeptember 30, 2022.\n\u00a0\n", "original_text": "fiscal year ended September 30, 2022.\n\u00a0\n", "page_label": "11", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "74a005aa-13c2-4b61-b91f-cb66794507c6", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fa28d56c30bf22bc750a5ec88ca472ebed3d497ea1578b5ad4a5d2fa9228c6a5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0485a143-3bfe-4233-83bd-8fef6be10b0e", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a02,340,731 \u00a0\u00a00.89 %\u00a0\u00a02,366,378 \u00a0\u00a00.99 %\u00a0(1.1 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther income, net  4 \u00a0\u00a0(49,036 )\u00a0\u00a0 \u00a0\u00a0(27,352 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a0228,931 \u00a0\u00a0\u00a0 \u00a0\u00a0210,673 \u00a0\u00a0\u00a0 \u00a08.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a02,160,836 \u00a0\u00a00.82 %\u00a0\u00a02,183,057 \u00a0\u00a00.91 %\u00a0(1.0 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a0428,260 \u00a0\u00a0\u00a0 \u00a0\u00a0516,517 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a01,732,576 \u00a0\u00a00.66 %\u00a0\u00a01,666,540 \u00a0\u00a00.70 %\u00a04.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss attributable to noncontrolling interests \u00a0\u00a012,717 \u00a0\u00a0\u00a0 \u00a0\u00a032,280 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to Cencora, Inc. \u00a0 $1,745,293 \u00a0\u00a00.67 %\u00a0$1,698,820 \u00a0\u00a00.71 %\u00a02.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$8.62 \u00a0\u00a0\u00a0 \u00a0$8.15 \u00a0\u00a0\u00a0 \u00a05.8 %\nDiluted \u00a0$8.53 \u00a0\u00a0\u00a0 \u00a0$8.04 \u00a0\u00a0\u00a0 \u00a06.1 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0202,511 \u00a0\u00a0\u00a0 \u00a0\u00a0208,472 \u00a0\u00a0\u00a0 \u00a0(2.9 )%\nDiluted \u00a0\u00a0204,591 \u00a0\u00a0\u00a0 \u00a0\u00a0211,210 \u00a0\u00a0\u00a0 \u00a0(3.1 )%\n___________________________________________\n1Includes a $239.1 million gain from antitrust litigation settlements, a $204.6 million LIFO expense, and Turkey foreign currency\nremeasurement expense of $87.0 million in the fiscal year ended September 30, 2023.  Includes a $1.8 million gain from antitrust\nlitigation settlements, a $67.2 million LIFO expense, and Turkey foreign currency remeasurement expense of $40.0 million in the\nfil ddS b302022\n10", "original_text": "Includes a $1.8 million gain from antitrust\nlitigation settlements, a $67.2 million LIFO expense, and Turkey foreign currency remeasurement expense of $40.0 million in the\nfil ddS b302022\n10", "page_label": "10", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8ef24b480908329310eb191341e9c1ccda6726721df97b57ce38a53a70354b52", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a7c29e41-e536-4cde-8243-b820b76112dd", "node_type": "1", "metadata": {"window": "fiscal year ended September 30, 2022.\n\u00a0\n 2Includes the receipt of $83.4 million from the H.D.  Smith opioid litigation indemnity escrow in the fiscal year ended September\n30, 2023.\n\u00a0\n 3The goodwill impairment is related to the Company's less-than-wholly-owned subsidiary in Brazil in the fiscal year ended\nSeptember 30, 2022.\n\u00a0\n 4Includes a $40.7 million gain on the divestiture of non-core businesses in the fiscal year ended September 30, 2023. ", "original_text": "2Includes the receipt of $83.4 million from the H.D. "}, "hash": "5473fe522d388e91ac4267b2670dde0177e13947ef20d93a7f45fe2dad3ab61c", "class_name": "RelatedNodeInfo"}}, "text": "fiscal year ended September 30, 2022.\n\u00a0\n", "start_char_idx": 0, "end_char_idx": 40, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a7c29e41-e536-4cde-8243-b820b76112dd": {"__data__": {"id_": "a7c29e41-e536-4cde-8243-b820b76112dd", "embedding": null, "metadata": {"window": "fiscal year ended September 30, 2022.\n\u00a0\n 2Includes the receipt of $83.4 million from the H.D.  Smith opioid litigation indemnity escrow in the fiscal year ended September\n30, 2023.\n\u00a0\n 3The goodwill impairment is related to the Company's less-than-wholly-owned subsidiary in Brazil in the fiscal year ended\nSeptember 30, 2022.\n\u00a0\n 4Includes a $40.7 million gain on the divestiture of non-core businesses in the fiscal year ended September 30, 2023. ", "original_text": "2Includes the receipt of $83.4 million from the H.D. ", "page_label": "11", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "74a005aa-13c2-4b61-b91f-cb66794507c6", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fa28d56c30bf22bc750a5ec88ca472ebed3d497ea1578b5ad4a5d2fa9228c6a5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9dbf0a8d-6422-4fa5-a626-cea101906a4f", "node_type": "1", "metadata": {"window": "fiscal year ended September 30, 2022.\n\u00a0\n 2Includes the receipt of $83.4 million from the H.D.  Smith opioid litigation indemnity escrow in the fiscal year ended September\n30, 2023.\n\u00a0\n 3The goodwill impairment is related to the Company's less-than-wholly-owned subsidiary in Brazil in the fiscal year ended\nSeptember 30, 2022.\n\u00a0\n", "original_text": "fiscal year ended September 30, 2022.\n\u00a0\n", "page_label": "11", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c57fc9b5cfcc597ad3abee37f18e25e9e9681601e83c57fa2223548952b9254f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dacc8784-3f19-4045-9365-99ff57382b08", "node_type": "1", "metadata": {"window": "fiscal year ended September 30, 2022.\n\u00a0\n 2Includes the receipt of $83.4 million from the H.D.  Smith opioid litigation indemnity escrow in the fiscal year ended September\n30, 2023.\n\u00a0\n 3The goodwill impairment is related to the Company's less-than-wholly-owned subsidiary in Brazil in the fiscal year ended\nSeptember 30, 2022.\n\u00a0\n 4Includes a $40.7 million gain on the divestiture of non-core businesses in the fiscal year ended September 30, 2023.  Includes a\n56.2 million gain on the divestiture of non-core businesses in the fiscal year ended September 30, 2022.\n\u00a0\n", "original_text": "Smith opioid litigation indemnity escrow in the fiscal year ended September\n30, 2023.\n\u00a0\n"}, "hash": "0a99a60a6fee880d6f8dd7f22183256c9d4cba1079772be12a2f2696af17bc93", "class_name": "RelatedNodeInfo"}}, "text": "2Includes the receipt of $83.4 million from the H.D. ", "start_char_idx": 40, "end_char_idx": 93, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dacc8784-3f19-4045-9365-99ff57382b08": {"__data__": {"id_": "dacc8784-3f19-4045-9365-99ff57382b08", "embedding": null, "metadata": {"window": "fiscal year ended September 30, 2022.\n\u00a0\n 2Includes the receipt of $83.4 million from the H.D.  Smith opioid litigation indemnity escrow in the fiscal year ended September\n30, 2023.\n\u00a0\n 3The goodwill impairment is related to the Company's less-than-wholly-owned subsidiary in Brazil in the fiscal year ended\nSeptember 30, 2022.\n\u00a0\n 4Includes a $40.7 million gain on the divestiture of non-core businesses in the fiscal year ended September 30, 2023.  Includes a\n56.2 million gain on the divestiture of non-core businesses in the fiscal year ended September 30, 2022.\n\u00a0\n", "original_text": "Smith opioid litigation indemnity escrow in the fiscal year ended September\n30, 2023.\n\u00a0\n", "page_label": "11", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "74a005aa-13c2-4b61-b91f-cb66794507c6", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fa28d56c30bf22bc750a5ec88ca472ebed3d497ea1578b5ad4a5d2fa9228c6a5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a7c29e41-e536-4cde-8243-b820b76112dd", "node_type": "1", "metadata": {"window": "fiscal year ended September 30, 2022.\n\u00a0\n 2Includes the receipt of $83.4 million from the H.D.  Smith opioid litigation indemnity escrow in the fiscal year ended September\n30, 2023.\n\u00a0\n 3The goodwill impairment is related to the Company's less-than-wholly-owned subsidiary in Brazil in the fiscal year ended\nSeptember 30, 2022.\n\u00a0\n 4Includes a $40.7 million gain on the divestiture of non-core businesses in the fiscal year ended September 30, 2023. ", "original_text": "2Includes the receipt of $83.4 million from the H.D. ", "page_label": "11", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6dcd18d38565af581117465ec6712878f1370b87cfdd5c57bba7bc71a11fb2e8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "150b7a09-cfe6-49db-88bb-21d8a41ba45a", "node_type": "1", "metadata": {"window": "fiscal year ended September 30, 2022.\n\u00a0\n 2Includes the receipt of $83.4 million from the H.D.  Smith opioid litigation indemnity escrow in the fiscal year ended September\n30, 2023.\n\u00a0\n 3The goodwill impairment is related to the Company's less-than-wholly-owned subsidiary in Brazil in the fiscal year ended\nSeptember 30, 2022.\n\u00a0\n 4Includes a $40.7 million gain on the divestiture of non-core businesses in the fiscal year ended September 30, 2023.  Includes a\n56.2 million gain on the divestiture of non-core businesses in the fiscal year ended September 30, 2022.\n\u00a0\n CENC ORA, INC.\n", "original_text": "3The goodwill impairment is related to the Company's less-than-wholly-owned subsidiary in Brazil in the fiscal year ended\nSeptember 30, 2022.\n\u00a0\n"}, "hash": "a97d5fd8b2e216fe6a8dbce13a61a2a31e58cf57c740580593aea66027a586a9", "class_name": "RelatedNodeInfo"}}, "text": "Smith opioid litigation indemnity escrow in the fiscal year ended September\n30, 2023.\n\u00a0\n", "start_char_idx": 93, "end_char_idx": 181, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "150b7a09-cfe6-49db-88bb-21d8a41ba45a": {"__data__": {"id_": "150b7a09-cfe6-49db-88bb-21d8a41ba45a", "embedding": null, "metadata": {"window": "fiscal year ended September 30, 2022.\n\u00a0\n 2Includes the receipt of $83.4 million from the H.D.  Smith opioid litigation indemnity escrow in the fiscal year ended September\n30, 2023.\n\u00a0\n 3The goodwill impairment is related to the Company's less-than-wholly-owned subsidiary in Brazil in the fiscal year ended\nSeptember 30, 2022.\n\u00a0\n 4Includes a $40.7 million gain on the divestiture of non-core businesses in the fiscal year ended September 30, 2023.  Includes a\n56.2 million gain on the divestiture of non-core businesses in the fiscal year ended September 30, 2022.\n\u00a0\n CENC ORA, INC.\n", "original_text": "3The goodwill impairment is related to the Company's less-than-wholly-owned subsidiary in Brazil in the fiscal year ended\nSeptember 30, 2022.\n\u00a0\n", "page_label": "11", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "74a005aa-13c2-4b61-b91f-cb66794507c6", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fa28d56c30bf22bc750a5ec88ca472ebed3d497ea1578b5ad4a5d2fa9228c6a5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dacc8784-3f19-4045-9365-99ff57382b08", "node_type": "1", "metadata": {"window": "fiscal year ended September 30, 2022.\n\u00a0\n 2Includes the receipt of $83.4 million from the H.D.  Smith opioid litigation indemnity escrow in the fiscal year ended September\n30, 2023.\n\u00a0\n 3The goodwill impairment is related to the Company's less-than-wholly-owned subsidiary in Brazil in the fiscal year ended\nSeptember 30, 2022.\n\u00a0\n 4Includes a $40.7 million gain on the divestiture of non-core businesses in the fiscal year ended September 30, 2023.  Includes a\n56.2 million gain on the divestiture of non-core businesses in the fiscal year ended September 30, 2022.\n\u00a0\n", "original_text": "Smith opioid litigation indemnity escrow in the fiscal year ended September\n30, 2023.\n\u00a0\n", "page_label": "11", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cbede31757b40fa95f12145825f6f37819d323d41ac779383eac9ae74eba9de7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fceda422-ad25-44cb-a0e1-1bd9574f57c2", "node_type": "1", "metadata": {"window": "2Includes the receipt of $83.4 million from the H.D.  Smith opioid litigation indemnity escrow in the fiscal year ended September\n30, 2023.\n\u00a0\n 3The goodwill impairment is related to the Company's less-than-wholly-owned subsidiary in Brazil in the fiscal year ended\nSeptember 30, 2022.\n\u00a0\n 4Includes a $40.7 million gain on the divestiture of non-core businesses in the fiscal year ended September 30, 2023.  Includes a\n56.2 million gain on the divestiture of non-core businesses in the fiscal year ended September 30, 2022.\n\u00a0\n CENC ORA, INC.\n GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30, 2023 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n Expenses \u00a0Operating\nIncome \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto \n Cencora \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$2,253,452 \u00a0\u00a0$1,776,511 \u00a0\u00a0$476,941 \u00a0\u00a0$446,423 \u00a0\u00a0$97,443 \u00a0\u00a0$1,585 \u00a0\u00a0$350,565 \u00a0\u00a0$1.72 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(70,582 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(70,582 )\u00a0\u00a0(70,582 )\u00a0\u00a0(16,719 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(53,863 )\u00a0\u00a0(0.26 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a090,323 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a090,323 \u00a0\u00a0\u00a090,323 \u00a0\u00a0\u00a021,264 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a069,056 \u00a0\u00a0\u00a00.34 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\ninflationary\ni 27948 27948 29916 29916 015\n11", "original_text": "4Includes a $40.7 million gain on the divestiture of non-core businesses in the fiscal year ended September 30, 2023. "}, "hash": "d22946a248ca28d7222246b2ba527a5750ce4b3927f975136cbf2c9c01a85e8a", "class_name": "RelatedNodeInfo"}}, "text": "3The goodwill impairment is related to the Company's less-than-wholly-owned subsidiary in Brazil in the fiscal year ended\nSeptember 30, 2022.\n\u00a0\n", "start_char_idx": 181, "end_char_idx": 325, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fceda422-ad25-44cb-a0e1-1bd9574f57c2": {"__data__": {"id_": "fceda422-ad25-44cb-a0e1-1bd9574f57c2", "embedding": null, "metadata": {"window": "2Includes the receipt of $83.4 million from the H.D.  Smith opioid litigation indemnity escrow in the fiscal year ended September\n30, 2023.\n\u00a0\n 3The goodwill impairment is related to the Company's less-than-wholly-owned subsidiary in Brazil in the fiscal year ended\nSeptember 30, 2022.\n\u00a0\n 4Includes a $40.7 million gain on the divestiture of non-core businesses in the fiscal year ended September 30, 2023.  Includes a\n56.2 million gain on the divestiture of non-core businesses in the fiscal year ended September 30, 2022.\n\u00a0\n CENC ORA, INC.\n GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30, 2023 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n Expenses \u00a0Operating\nIncome \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto \n Cencora \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$2,253,452 \u00a0\u00a0$1,776,511 \u00a0\u00a0$476,941 \u00a0\u00a0$446,423 \u00a0\u00a0$97,443 \u00a0\u00a0$1,585 \u00a0\u00a0$350,565 \u00a0\u00a0$1.72 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(70,582 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(70,582 )\u00a0\u00a0(70,582 )\u00a0\u00a0(16,719 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(53,863 )\u00a0\u00a0(0.26 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a090,323 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a090,323 \u00a0\u00a0\u00a090,323 \u00a0\u00a0\u00a021,264 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a069,056 \u00a0\u00a0\u00a00.34 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\ninflationary\ni 27948 27948 29916 29916 015\n11", "original_text": "4Includes a $40.7 million gain on the divestiture of non-core businesses in the fiscal year ended September 30, 2023. ", "page_label": "11", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "74a005aa-13c2-4b61-b91f-cb66794507c6", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fa28d56c30bf22bc750a5ec88ca472ebed3d497ea1578b5ad4a5d2fa9228c6a5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "150b7a09-cfe6-49db-88bb-21d8a41ba45a", "node_type": "1", "metadata": {"window": "fiscal year ended September 30, 2022.\n\u00a0\n 2Includes the receipt of $83.4 million from the H.D.  Smith opioid litigation indemnity escrow in the fiscal year ended September\n30, 2023.\n\u00a0\n 3The goodwill impairment is related to the Company's less-than-wholly-owned subsidiary in Brazil in the fiscal year ended\nSeptember 30, 2022.\n\u00a0\n 4Includes a $40.7 million gain on the divestiture of non-core businesses in the fiscal year ended September 30, 2023.  Includes a\n56.2 million gain on the divestiture of non-core businesses in the fiscal year ended September 30, 2022.\n\u00a0\n CENC ORA, INC.\n", "original_text": "3The goodwill impairment is related to the Company's less-than-wholly-owned subsidiary in Brazil in the fiscal year ended\nSeptember 30, 2022.\n\u00a0\n", "page_label": "11", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9c268f132bb4edfad4958ea1d4cfc137c46f9acc357d11977420d6d5f5a37503", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fd435bae-8805-4a51-8a3d-5bac7b59bb36", "node_type": "1", "metadata": {"window": "Smith opioid litigation indemnity escrow in the fiscal year ended September\n30, 2023.\n\u00a0\n 3The goodwill impairment is related to the Company's less-than-wholly-owned subsidiary in Brazil in the fiscal year ended\nSeptember 30, 2022.\n\u00a0\n 4Includes a $40.7 million gain on the divestiture of non-core businesses in the fiscal year ended September 30, 2023.  Includes a\n56.2 million gain on the divestiture of non-core businesses in the fiscal year ended September 30, 2022.\n\u00a0\n CENC ORA, INC.\n GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30, 2023 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n Expenses \u00a0Operating\nIncome \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto \n Cencora \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$2,253,452 \u00a0\u00a0$1,776,511 \u00a0\u00a0$476,941 \u00a0\u00a0$446,423 \u00a0\u00a0$97,443 \u00a0\u00a0$1,585 \u00a0\u00a0$350,565 \u00a0\u00a0$1.72 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(70,582 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(70,582 )\u00a0\u00a0(70,582 )\u00a0\u00a0(16,719 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(53,863 )\u00a0\u00a0(0.26 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a090,323 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a090,323 \u00a0\u00a0\u00a090,323 \u00a0\u00a0\u00a021,264 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a069,056 \u00a0\u00a0\u00a00.34 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\ninflationary\ni 27948 27948 29916 29916 015\n11", "original_text": "Includes a\n56.2 million gain on the divestiture of non-core businesses in the fiscal year ended September 30, 2022.\n\u00a0\n"}, "hash": "d457ea568ef99fb2101c0f1d405d8b0ded4d601086a202a0c8f6426c45c2651d", "class_name": "RelatedNodeInfo"}}, "text": "4Includes a $40.7 million gain on the divestiture of non-core businesses in the fiscal year ended September 30, 2023. ", "start_char_idx": 325, "end_char_idx": 443, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fd435bae-8805-4a51-8a3d-5bac7b59bb36": {"__data__": {"id_": "fd435bae-8805-4a51-8a3d-5bac7b59bb36", "embedding": null, "metadata": {"window": "Smith opioid litigation indemnity escrow in the fiscal year ended September\n30, 2023.\n\u00a0\n 3The goodwill impairment is related to the Company's less-than-wholly-owned subsidiary in Brazil in the fiscal year ended\nSeptember 30, 2022.\n\u00a0\n 4Includes a $40.7 million gain on the divestiture of non-core businesses in the fiscal year ended September 30, 2023.  Includes a\n56.2 million gain on the divestiture of non-core businesses in the fiscal year ended September 30, 2022.\n\u00a0\n CENC ORA, INC.\n GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30, 2023 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n Expenses \u00a0Operating\nIncome \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto \n Cencora \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$2,253,452 \u00a0\u00a0$1,776,511 \u00a0\u00a0$476,941 \u00a0\u00a0$446,423 \u00a0\u00a0$97,443 \u00a0\u00a0$1,585 \u00a0\u00a0$350,565 \u00a0\u00a0$1.72 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(70,582 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(70,582 )\u00a0\u00a0(70,582 )\u00a0\u00a0(16,719 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(53,863 )\u00a0\u00a0(0.26 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a090,323 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a090,323 \u00a0\u00a0\u00a090,323 \u00a0\u00a0\u00a021,264 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a069,056 \u00a0\u00a0\u00a00.34 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\ninflationary\ni 27948 27948 29916 29916 015\n11", "original_text": "Includes a\n56.2 million gain on the divestiture of non-core businesses in the fiscal year ended September 30, 2022.\n\u00a0\n", "page_label": "11", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "74a005aa-13c2-4b61-b91f-cb66794507c6", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fa28d56c30bf22bc750a5ec88ca472ebed3d497ea1578b5ad4a5d2fa9228c6a5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fceda422-ad25-44cb-a0e1-1bd9574f57c2", "node_type": "1", "metadata": {"window": "2Includes the receipt of $83.4 million from the H.D.  Smith opioid litigation indemnity escrow in the fiscal year ended September\n30, 2023.\n\u00a0\n 3The goodwill impairment is related to the Company's less-than-wholly-owned subsidiary in Brazil in the fiscal year ended\nSeptember 30, 2022.\n\u00a0\n 4Includes a $40.7 million gain on the divestiture of non-core businesses in the fiscal year ended September 30, 2023.  Includes a\n56.2 million gain on the divestiture of non-core businesses in the fiscal year ended September 30, 2022.\n\u00a0\n CENC ORA, INC.\n GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30, 2023 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n Expenses \u00a0Operating\nIncome \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto \n Cencora \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$2,253,452 \u00a0\u00a0$1,776,511 \u00a0\u00a0$476,941 \u00a0\u00a0$446,423 \u00a0\u00a0$97,443 \u00a0\u00a0$1,585 \u00a0\u00a0$350,565 \u00a0\u00a0$1.72 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(70,582 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(70,582 )\u00a0\u00a0(70,582 )\u00a0\u00a0(16,719 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(53,863 )\u00a0\u00a0(0.26 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a090,323 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a090,323 \u00a0\u00a0\u00a090,323 \u00a0\u00a0\u00a021,264 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a069,056 \u00a0\u00a0\u00a00.34 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\ninflationary\ni 27948 27948 29916 29916 015\n11", "original_text": "4Includes a $40.7 million gain on the divestiture of non-core businesses in the fiscal year ended September 30, 2023. ", "page_label": "11", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ed174e695213d3695cd0260f57c02e74b7283b64d05b47f49ee8cba71e8d83a3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9a4c662d-70a8-4a74-8004-abd375696f3d", "node_type": "1", "metadata": {"window": "3The goodwill impairment is related to the Company's less-than-wholly-owned subsidiary in Brazil in the fiscal year ended\nSeptember 30, 2022.\n\u00a0\n 4Includes a $40.7 million gain on the divestiture of non-core businesses in the fiscal year ended September 30, 2023.  Includes a\n56.2 million gain on the divestiture of non-core businesses in the fiscal year ended September 30, 2022.\n\u00a0\n CENC ORA, INC.\n GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30, 2023 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n Expenses \u00a0Operating\nIncome \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto \n Cencora \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$2,253,452 \u00a0\u00a0$1,776,511 \u00a0\u00a0$476,941 \u00a0\u00a0$446,423 \u00a0\u00a0$97,443 \u00a0\u00a0$1,585 \u00a0\u00a0$350,565 \u00a0\u00a0$1.72 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(70,582 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(70,582 )\u00a0\u00a0(70,582 )\u00a0\u00a0(16,719 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(53,863 )\u00a0\u00a0(0.26 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a090,323 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a090,323 \u00a0\u00a0\u00a090,323 \u00a0\u00a0\u00a021,264 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a069,056 \u00a0\u00a0\u00a00.34 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\ninflationary\ni 27948 27948 29916 29916 015\n11", "original_text": "CENC ORA, INC.\n"}, "hash": "31db2554b001ebe2282190d072a4dce4d9f1d3040349679bb6280f4f3cfc142f", "class_name": "RelatedNodeInfo"}}, "text": "Includes a\n56.2 million gain on the divestiture of non-core businesses in the fiscal year ended September 30, 2022.\n\u00a0\n", "start_char_idx": 443, "end_char_idx": 561, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9a4c662d-70a8-4a74-8004-abd375696f3d": {"__data__": {"id_": "9a4c662d-70a8-4a74-8004-abd375696f3d", "embedding": null, "metadata": {"window": "3The goodwill impairment is related to the Company's less-than-wholly-owned subsidiary in Brazil in the fiscal year ended\nSeptember 30, 2022.\n\u00a0\n 4Includes a $40.7 million gain on the divestiture of non-core businesses in the fiscal year ended September 30, 2023.  Includes a\n56.2 million gain on the divestiture of non-core businesses in the fiscal year ended September 30, 2022.\n\u00a0\n CENC ORA, INC.\n GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30, 2023 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n Expenses \u00a0Operating\nIncome \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto \n Cencora \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$2,253,452 \u00a0\u00a0$1,776,511 \u00a0\u00a0$476,941 \u00a0\u00a0$446,423 \u00a0\u00a0$97,443 \u00a0\u00a0$1,585 \u00a0\u00a0$350,565 \u00a0\u00a0$1.72 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(70,582 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(70,582 )\u00a0\u00a0(70,582 )\u00a0\u00a0(16,719 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(53,863 )\u00a0\u00a0(0.26 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a090,323 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a090,323 \u00a0\u00a0\u00a090,323 \u00a0\u00a0\u00a021,264 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a069,056 \u00a0\u00a0\u00a00.34 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\ninflationary\ni 27948 27948 29916 29916 015\n11", "original_text": "CENC ORA, INC.\n", "page_label": "11", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "74a005aa-13c2-4b61-b91f-cb66794507c6", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fa28d56c30bf22bc750a5ec88ca472ebed3d497ea1578b5ad4a5d2fa9228c6a5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fd435bae-8805-4a51-8a3d-5bac7b59bb36", "node_type": "1", "metadata": {"window": "Smith opioid litigation indemnity escrow in the fiscal year ended September\n30, 2023.\n\u00a0\n 3The goodwill impairment is related to the Company's less-than-wholly-owned subsidiary in Brazil in the fiscal year ended\nSeptember 30, 2022.\n\u00a0\n 4Includes a $40.7 million gain on the divestiture of non-core businesses in the fiscal year ended September 30, 2023.  Includes a\n56.2 million gain on the divestiture of non-core businesses in the fiscal year ended September 30, 2022.\n\u00a0\n CENC ORA, INC.\n GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30, 2023 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n Expenses \u00a0Operating\nIncome \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto \n Cencora \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$2,253,452 \u00a0\u00a0$1,776,511 \u00a0\u00a0$476,941 \u00a0\u00a0$446,423 \u00a0\u00a0$97,443 \u00a0\u00a0$1,585 \u00a0\u00a0$350,565 \u00a0\u00a0$1.72 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(70,582 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(70,582 )\u00a0\u00a0(70,582 )\u00a0\u00a0(16,719 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(53,863 )\u00a0\u00a0(0.26 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a090,323 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a090,323 \u00a0\u00a0\u00a090,323 \u00a0\u00a0\u00a021,264 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a069,056 \u00a0\u00a0\u00a00.34 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\ninflationary\ni 27948 27948 29916 29916 015\n11", "original_text": "Includes a\n56.2 million gain on the divestiture of non-core businesses in the fiscal year ended September 30, 2022.\n\u00a0\n", "page_label": "11", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "31b034e9b9aff9a7c3d03b5c3e1989e231321f75de2441e95fc35bfc7937518c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b07a9a92-6d07-4d54-9af8-b566d43c04e9", "node_type": "1", "metadata": {"window": "4Includes a $40.7 million gain on the divestiture of non-core businesses in the fiscal year ended September 30, 2023.  Includes a\n56.2 million gain on the divestiture of non-core businesses in the fiscal year ended September 30, 2022.\n\u00a0\n CENC ORA, INC.\n GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30, 2023 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n Expenses \u00a0Operating\nIncome \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto \n Cencora \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$2,253,452 \u00a0\u00a0$1,776,511 \u00a0\u00a0$476,941 \u00a0\u00a0$446,423 \u00a0\u00a0$97,443 \u00a0\u00a0$1,585 \u00a0\u00a0$350,565 \u00a0\u00a0$1.72 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(70,582 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(70,582 )\u00a0\u00a0(70,582 )\u00a0\u00a0(16,719 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(53,863 )\u00a0\u00a0(0.26 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a090,323 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a090,323 \u00a0\u00a0\u00a090,323 \u00a0\u00a0\u00a021,264 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a069,056 \u00a0\u00a0\u00a00.34 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\ninflationary\ni 27948 27948 29916 29916 015\n11", "original_text": "GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30, 2023 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n Expenses \u00a0Operating\nIncome \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto \n Cencora \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$2,253,452 \u00a0\u00a0$1,776,511 \u00a0\u00a0$476,941 \u00a0\u00a0$446,423 \u00a0\u00a0$97,443 \u00a0\u00a0$1,585 \u00a0\u00a0$350,565 \u00a0\u00a0$1.72 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(70,582 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(70,582 )\u00a0\u00a0(70,582 )\u00a0\u00a0(16,719 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(53,863 )\u00a0\u00a0(0.26 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a090,323 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a090,323 \u00a0\u00a0\u00a090,323 \u00a0\u00a0\u00a021,264 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a069,056 \u00a0\u00a0\u00a00.34 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\ninflationary\ni 27948 27948 29916 29916 015\n11"}, "hash": "949d1e8816b73da3cc38fddbc15f4ac59e56b5f270cad4c29791ed0ae62bd608", "class_name": "RelatedNodeInfo"}}, "text": "CENC ORA, INC.\n", "start_char_idx": 561, "end_char_idx": 576, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b07a9a92-6d07-4d54-9af8-b566d43c04e9": {"__data__": {"id_": "b07a9a92-6d07-4d54-9af8-b566d43c04e9", "embedding": null, "metadata": {"window": "4Includes a $40.7 million gain on the divestiture of non-core businesses in the fiscal year ended September 30, 2023.  Includes a\n56.2 million gain on the divestiture of non-core businesses in the fiscal year ended September 30, 2022.\n\u00a0\n CENC ORA, INC.\n GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30, 2023 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n Expenses \u00a0Operating\nIncome \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto \n Cencora \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$2,253,452 \u00a0\u00a0$1,776,511 \u00a0\u00a0$476,941 \u00a0\u00a0$446,423 \u00a0\u00a0$97,443 \u00a0\u00a0$1,585 \u00a0\u00a0$350,565 \u00a0\u00a0$1.72 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(70,582 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(70,582 )\u00a0\u00a0(70,582 )\u00a0\u00a0(16,719 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(53,863 )\u00a0\u00a0(0.26 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a090,323 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a090,323 \u00a0\u00a0\u00a090,323 \u00a0\u00a0\u00a021,264 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a069,056 \u00a0\u00a0\u00a00.34 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\ninflationary\ni 27948 27948 29916 29916 015\n11", "original_text": "GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30, 2023 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n Expenses \u00a0Operating\nIncome \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto \n Cencora \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$2,253,452 \u00a0\u00a0$1,776,511 \u00a0\u00a0$476,941 \u00a0\u00a0$446,423 \u00a0\u00a0$97,443 \u00a0\u00a0$1,585 \u00a0\u00a0$350,565 \u00a0\u00a0$1.72 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(70,582 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(70,582 )\u00a0\u00a0(70,582 )\u00a0\u00a0(16,719 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(53,863 )\u00a0\u00a0(0.26 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a090,323 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a090,323 \u00a0\u00a0\u00a090,323 \u00a0\u00a0\u00a021,264 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a069,056 \u00a0\u00a0\u00a00.34 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\ninflationary\ni 27948 27948 29916 29916 015\n11", "page_label": "11", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "74a005aa-13c2-4b61-b91f-cb66794507c6", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fa28d56c30bf22bc750a5ec88ca472ebed3d497ea1578b5ad4a5d2fa9228c6a5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9a4c662d-70a8-4a74-8004-abd375696f3d", "node_type": "1", "metadata": {"window": "3The goodwill impairment is related to the Company's less-than-wholly-owned subsidiary in Brazil in the fiscal year ended\nSeptember 30, 2022.\n\u00a0\n 4Includes a $40.7 million gain on the divestiture of non-core businesses in the fiscal year ended September 30, 2023.  Includes a\n56.2 million gain on the divestiture of non-core businesses in the fiscal year ended September 30, 2022.\n\u00a0\n CENC ORA, INC.\n GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30, 2023 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n Expenses \u00a0Operating\nIncome \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto \n Cencora \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$2,253,452 \u00a0\u00a0$1,776,511 \u00a0\u00a0$476,941 \u00a0\u00a0$446,423 \u00a0\u00a0$97,443 \u00a0\u00a0$1,585 \u00a0\u00a0$350,565 \u00a0\u00a0$1.72 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(70,582 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(70,582 )\u00a0\u00a0(70,582 )\u00a0\u00a0(16,719 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(53,863 )\u00a0\u00a0(0.26 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a090,323 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a090,323 \u00a0\u00a0\u00a090,323 \u00a0\u00a0\u00a021,264 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a069,056 \u00a0\u00a0\u00a00.34 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\ninflationary\ni 27948 27948 29916 29916 015\n11", "original_text": "CENC ORA, INC.\n", "page_label": "11", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7cfbf2be9514f19d09ce57c3f056ba3b99cb34c5e6bfc96b2a9ee3261da25076", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cd3132de-f420-415e-9eb6-5d1f90858d55", "node_type": "1", "metadata": {"window": "impact \u00a0\u00a027,948 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a027,948 \u00a0\u00a0\u00a029,916 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a029,916 \u00a0\u00a0\u00a00.15 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(169,900 )\u00a0\u00a0169,900 \u00a0\u00a0\u00a0169,900 \u00a0\u00a0\u00a040,214 \u00a0\u00a0\u00a0(968 )\u00a0\u00a0128,718 \u00a0\u00a0\u00a00.63 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(13,890 )\u00a0\u00a013,890 \u00a0\u00a0\u00a013,890 \u00a0\u00a0\u00a03,305 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a010,585 \u00a0\u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated deal and\nintegration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(40,291 )\u00a0\u00a040,291 \u00a0\u00a0\u00a040,291 \u00a0\u00a0\u00a09,548 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a030,743 \u00a0\u00a0\u00a00.15 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring\nand other\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(52,276 )\u00a0\u00a052,276 \u00a0\u00a0\u00a052,276 \u00a0\u00a0\u00a012,452 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a039,824 \u00a0\u00a0\u00a00.20 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on\ndivestiture of\nnon-core\nbusinesses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(40,665 )\u00a0\u00a01,035 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(41,700 )\u00a0\u00a0(0.21 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nOther, net \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a04,310 \u00a0\u00a0\u00a0781 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a03,529 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a04,824 \u00a0\u00a0\u00a0(8,931 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a013,755 \u00a0\u00a0\u00a00.07 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$2,301,141 \u00a0\u00a0$1,500,154 \u00a0\u00a0$800,987 \u00a0\u00a0$740,906 \u00a0\u00a0$160,392 \u00a0\u00a0$617 \u00a0\u00a0$581,131 \u00a0\u00a0$2.86 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP % change\nvs.  prior year\nquarter \u00a0\u00a09.4 %\u00a0\u00a010.2 %\u00a0\u00a08.0 %\u00a0\u00a08.6 %\u00a0\u00a018.7 %\u00a0\u00a0 \u00a0\u00a06.5 %\u00a0\u00a010.0 %\u00a0\n12", "original_text": "impact \u00a0\u00a027,948 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a027,948 \u00a0\u00a0\u00a029,916 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a029,916 \u00a0\u00a0\u00a00.15 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(169,900 )\u00a0\u00a0169,900 \u00a0\u00a0\u00a0169,900 \u00a0\u00a0\u00a040,214 \u00a0\u00a0\u00a0(968 )\u00a0\u00a0128,718 \u00a0\u00a0\u00a00.63 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(13,890 )\u00a0\u00a013,890 \u00a0\u00a0\u00a013,890 \u00a0\u00a0\u00a03,305 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a010,585 \u00a0\u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated deal and\nintegration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(40,291 )\u00a0\u00a040,291 \u00a0\u00a0\u00a040,291 \u00a0\u00a0\u00a09,548 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a030,743 \u00a0\u00a0\u00a00.15 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring\nand other\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(52,276 )\u00a0\u00a052,276 \u00a0\u00a0\u00a052,276 \u00a0\u00a0\u00a012,452 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a039,824 \u00a0\u00a0\u00a00.20 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on\ndivestiture of\nnon-core\nbusinesses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(40,665 )\u00a0\u00a01,035 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(41,700 )\u00a0\u00a0(0.21 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nOther, net \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a04,310 \u00a0\u00a0\u00a0781 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a03,529 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a04,824 \u00a0\u00a0\u00a0(8,931 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a013,755 \u00a0\u00a0\u00a00.07 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$2,301,141 \u00a0\u00a0$1,500,154 \u00a0\u00a0$800,987 \u00a0\u00a0$740,906 \u00a0\u00a0$160,392 \u00a0\u00a0$617 \u00a0\u00a0$581,131 \u00a0\u00a0$2.86 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP % change\nvs. "}, "hash": "63c709523f680950108f39d6a58e89bf5cb1dadc1cba4978dc450d2b77b8b63c", "class_name": "RelatedNodeInfo"}}, "text": "GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30, 2023 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n Expenses \u00a0Operating\nIncome \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto \n Cencora \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$2,253,452 \u00a0\u00a0$1,776,511 \u00a0\u00a0$476,941 \u00a0\u00a0$446,423 \u00a0\u00a0$97,443 \u00a0\u00a0$1,585 \u00a0\u00a0$350,565 \u00a0\u00a0$1.72 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(70,582 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(70,582 )\u00a0\u00a0(70,582 )\u00a0\u00a0(16,719 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(53,863 )\u00a0\u00a0(0.26 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a090,323 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a090,323 \u00a0\u00a0\u00a090,323 \u00a0\u00a0\u00a021,264 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a069,056 \u00a0\u00a0\u00a00.34 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\ninflationary\ni 27948 27948 29916 29916 015\n11", "start_char_idx": 576, "end_char_idx": 1384, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cd3132de-f420-415e-9eb6-5d1f90858d55": {"__data__": {"id_": "cd3132de-f420-415e-9eb6-5d1f90858d55", "embedding": null, "metadata": {"window": "impact \u00a0\u00a027,948 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a027,948 \u00a0\u00a0\u00a029,916 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a029,916 \u00a0\u00a0\u00a00.15 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(169,900 )\u00a0\u00a0169,900 \u00a0\u00a0\u00a0169,900 \u00a0\u00a0\u00a040,214 \u00a0\u00a0\u00a0(968 )\u00a0\u00a0128,718 \u00a0\u00a0\u00a00.63 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(13,890 )\u00a0\u00a013,890 \u00a0\u00a0\u00a013,890 \u00a0\u00a0\u00a03,305 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a010,585 \u00a0\u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated deal and\nintegration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(40,291 )\u00a0\u00a040,291 \u00a0\u00a0\u00a040,291 \u00a0\u00a0\u00a09,548 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a030,743 \u00a0\u00a0\u00a00.15 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring\nand other\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(52,276 )\u00a0\u00a052,276 \u00a0\u00a0\u00a052,276 \u00a0\u00a0\u00a012,452 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a039,824 \u00a0\u00a0\u00a00.20 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on\ndivestiture of\nnon-core\nbusinesses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(40,665 )\u00a0\u00a01,035 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(41,700 )\u00a0\u00a0(0.21 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nOther, net \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a04,310 \u00a0\u00a0\u00a0781 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a03,529 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a04,824 \u00a0\u00a0\u00a0(8,931 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a013,755 \u00a0\u00a0\u00a00.07 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$2,301,141 \u00a0\u00a0$1,500,154 \u00a0\u00a0$800,987 \u00a0\u00a0$740,906 \u00a0\u00a0$160,392 \u00a0\u00a0$617 \u00a0\u00a0$581,131 \u00a0\u00a0$2.86 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP % change\nvs.  prior year\nquarter \u00a0\u00a09.4 %\u00a0\u00a010.2 %\u00a0\u00a08.0 %\u00a0\u00a08.6 %\u00a0\u00a018.7 %\u00a0\u00a0 \u00a0\u00a06.5 %\u00a0\u00a010.0 %\u00a0\n12", "original_text": "impact \u00a0\u00a027,948 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a027,948 \u00a0\u00a0\u00a029,916 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a029,916 \u00a0\u00a0\u00a00.15 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(169,900 )\u00a0\u00a0169,900 \u00a0\u00a0\u00a0169,900 \u00a0\u00a0\u00a040,214 \u00a0\u00a0\u00a0(968 )\u00a0\u00a0128,718 \u00a0\u00a0\u00a00.63 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(13,890 )\u00a0\u00a013,890 \u00a0\u00a0\u00a013,890 \u00a0\u00a0\u00a03,305 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a010,585 \u00a0\u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated deal and\nintegration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(40,291 )\u00a0\u00a040,291 \u00a0\u00a0\u00a040,291 \u00a0\u00a0\u00a09,548 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a030,743 \u00a0\u00a0\u00a00.15 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring\nand other\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(52,276 )\u00a0\u00a052,276 \u00a0\u00a0\u00a052,276 \u00a0\u00a0\u00a012,452 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a039,824 \u00a0\u00a0\u00a00.20 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on\ndivestiture of\nnon-core\nbusinesses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(40,665 )\u00a0\u00a01,035 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(41,700 )\u00a0\u00a0(0.21 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nOther, net \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a04,310 \u00a0\u00a0\u00a0781 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a03,529 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a04,824 \u00a0\u00a0\u00a0(8,931 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a013,755 \u00a0\u00a0\u00a00.07 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$2,301,141 \u00a0\u00a0$1,500,154 \u00a0\u00a0$800,987 \u00a0\u00a0$740,906 \u00a0\u00a0$160,392 \u00a0\u00a0$617 \u00a0\u00a0$581,131 \u00a0\u00a0$2.86 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP % change\nvs. ", "page_label": "12", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "900b71f9-2b71-4a5a-8a64-9f2cd416280f", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2624fa9645d00bf66d0e09130dd6ff0ce122de10cdcdfd0367af5758993f75a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b07a9a92-6d07-4d54-9af8-b566d43c04e9", "node_type": "1", "metadata": {"window": "4Includes a $40.7 million gain on the divestiture of non-core businesses in the fiscal year ended September 30, 2023.  Includes a\n56.2 million gain on the divestiture of non-core businesses in the fiscal year ended September 30, 2022.\n\u00a0\n CENC ORA, INC.\n GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30, 2023 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n Expenses \u00a0Operating\nIncome \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto \n Cencora \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$2,253,452 \u00a0\u00a0$1,776,511 \u00a0\u00a0$476,941 \u00a0\u00a0$446,423 \u00a0\u00a0$97,443 \u00a0\u00a0$1,585 \u00a0\u00a0$350,565 \u00a0\u00a0$1.72 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(70,582 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(70,582 )\u00a0\u00a0(70,582 )\u00a0\u00a0(16,719 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(53,863 )\u00a0\u00a0(0.26 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a090,323 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a090,323 \u00a0\u00a0\u00a090,323 \u00a0\u00a0\u00a021,264 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a069,056 \u00a0\u00a0\u00a00.34 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\ninflationary\ni 27948 27948 29916 29916 015\n11", "original_text": "GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30, 2023 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n Expenses \u00a0Operating\nIncome \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto \n Cencora \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$2,253,452 \u00a0\u00a0$1,776,511 \u00a0\u00a0$476,941 \u00a0\u00a0$446,423 \u00a0\u00a0$97,443 \u00a0\u00a0$1,585 \u00a0\u00a0$350,565 \u00a0\u00a0$1.72 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(70,582 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(70,582 )\u00a0\u00a0(70,582 )\u00a0\u00a0(16,719 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(53,863 )\u00a0\u00a0(0.26 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a090,323 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a090,323 \u00a0\u00a0\u00a090,323 \u00a0\u00a0\u00a021,264 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a069,056 \u00a0\u00a0\u00a00.34 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\ninflationary\ni 27948 27948 29916 29916 015\n11", "page_label": "11", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "32abee5e39f750e2b6b902e26a45183fe9d1086763927568faba178f8fa01f91", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b52a0b30-431c-4e4b-bea1-72d05389730f", "node_type": "1", "metadata": {"window": "impact \u00a0\u00a027,948 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a027,948 \u00a0\u00a0\u00a029,916 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a029,916 \u00a0\u00a0\u00a00.15 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(169,900 )\u00a0\u00a0169,900 \u00a0\u00a0\u00a0169,900 \u00a0\u00a0\u00a040,214 \u00a0\u00a0\u00a0(968 )\u00a0\u00a0128,718 \u00a0\u00a0\u00a00.63 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(13,890 )\u00a0\u00a013,890 \u00a0\u00a0\u00a013,890 \u00a0\u00a0\u00a03,305 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a010,585 \u00a0\u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated deal and\nintegration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(40,291 )\u00a0\u00a040,291 \u00a0\u00a0\u00a040,291 \u00a0\u00a0\u00a09,548 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a030,743 \u00a0\u00a0\u00a00.15 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring\nand other\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(52,276 )\u00a0\u00a052,276 \u00a0\u00a0\u00a052,276 \u00a0\u00a0\u00a012,452 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a039,824 \u00a0\u00a0\u00a00.20 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on\ndivestiture of\nnon-core\nbusinesses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(40,665 )\u00a0\u00a01,035 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(41,700 )\u00a0\u00a0(0.21 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nOther, net \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a04,310 \u00a0\u00a0\u00a0781 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a03,529 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a04,824 \u00a0\u00a0\u00a0(8,931 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a013,755 \u00a0\u00a0\u00a00.07 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$2,301,141 \u00a0\u00a0$1,500,154 \u00a0\u00a0$800,987 \u00a0\u00a0$740,906 \u00a0\u00a0$160,392 \u00a0\u00a0$617 \u00a0\u00a0$581,131 \u00a0\u00a0$2.86 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP % change\nvs.  prior year\nquarter \u00a0\u00a09.4 %\u00a0\u00a010.2 %\u00a0\u00a08.0 %\u00a0\u00a08.6 %\u00a0\u00a018.7 %\u00a0\u00a0 \u00a0\u00a06.5 %\u00a0\u00a010.0 %\u00a0\n12", "original_text": "prior year\nquarter \u00a0\u00a09.4 %\u00a0\u00a010.2 %\u00a0\u00a08.0 %\u00a0\u00a08.6 %\u00a0\u00a018.7 %\u00a0\u00a0 \u00a0\u00a06.5 %\u00a0\u00a010.0 %\u00a0\n12"}, "hash": "4bcf7f964be31604aad22e6bec5f1a7ad09c0f595ede58c36b91b92b7d470a01", "class_name": "RelatedNodeInfo"}}, "text": "impact \u00a0\u00a027,948 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a027,948 \u00a0\u00a0\u00a029,916 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a029,916 \u00a0\u00a0\u00a00.15 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(169,900 )\u00a0\u00a0169,900 \u00a0\u00a0\u00a0169,900 \u00a0\u00a0\u00a040,214 \u00a0\u00a0\u00a0(968 )\u00a0\u00a0128,718 \u00a0\u00a0\u00a00.63 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(13,890 )\u00a0\u00a013,890 \u00a0\u00a0\u00a013,890 \u00a0\u00a0\u00a03,305 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a010,585 \u00a0\u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated deal and\nintegration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(40,291 )\u00a0\u00a040,291 \u00a0\u00a0\u00a040,291 \u00a0\u00a0\u00a09,548 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a030,743 \u00a0\u00a0\u00a00.15 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring\nand other\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(52,276 )\u00a0\u00a052,276 \u00a0\u00a0\u00a052,276 \u00a0\u00a0\u00a012,452 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a039,824 \u00a0\u00a0\u00a00.20 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on\ndivestiture of\nnon-core\nbusinesses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(40,665 )\u00a0\u00a01,035 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(41,700 )\u00a0\u00a0(0.21 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nOther, net \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a04,310 \u00a0\u00a0\u00a0781 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a03,529 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a04,824 \u00a0\u00a0\u00a0(8,931 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a013,755 \u00a0\u00a0\u00a00.07 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$2,301,141 \u00a0\u00a0$1,500,154 \u00a0\u00a0$800,987 \u00a0\u00a0$740,906 \u00a0\u00a0$160,392 \u00a0\u00a0$617 \u00a0\u00a0$581,131 \u00a0\u00a0$2.86 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP % change\nvs. ", "start_char_idx": 0, "end_char_idx": 1163, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b52a0b30-431c-4e4b-bea1-72d05389730f": {"__data__": {"id_": "b52a0b30-431c-4e4b-bea1-72d05389730f", "embedding": null, "metadata": {"window": "impact \u00a0\u00a027,948 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a027,948 \u00a0\u00a0\u00a029,916 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a029,916 \u00a0\u00a0\u00a00.15 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(169,900 )\u00a0\u00a0169,900 \u00a0\u00a0\u00a0169,900 \u00a0\u00a0\u00a040,214 \u00a0\u00a0\u00a0(968 )\u00a0\u00a0128,718 \u00a0\u00a0\u00a00.63 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(13,890 )\u00a0\u00a013,890 \u00a0\u00a0\u00a013,890 \u00a0\u00a0\u00a03,305 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a010,585 \u00a0\u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated deal and\nintegration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(40,291 )\u00a0\u00a040,291 \u00a0\u00a0\u00a040,291 \u00a0\u00a0\u00a09,548 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a030,743 \u00a0\u00a0\u00a00.15 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring\nand other\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(52,276 )\u00a0\u00a052,276 \u00a0\u00a0\u00a052,276 \u00a0\u00a0\u00a012,452 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a039,824 \u00a0\u00a0\u00a00.20 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on\ndivestiture of\nnon-core\nbusinesses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(40,665 )\u00a0\u00a01,035 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(41,700 )\u00a0\u00a0(0.21 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nOther, net \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a04,310 \u00a0\u00a0\u00a0781 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a03,529 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a04,824 \u00a0\u00a0\u00a0(8,931 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a013,755 \u00a0\u00a0\u00a00.07 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$2,301,141 \u00a0\u00a0$1,500,154 \u00a0\u00a0$800,987 \u00a0\u00a0$740,906 \u00a0\u00a0$160,392 \u00a0\u00a0$617 \u00a0\u00a0$581,131 \u00a0\u00a0$2.86 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP % change\nvs.  prior year\nquarter \u00a0\u00a09.4 %\u00a0\u00a010.2 %\u00a0\u00a08.0 %\u00a0\u00a08.6 %\u00a0\u00a018.7 %\u00a0\u00a0 \u00a0\u00a06.5 %\u00a0\u00a010.0 %\u00a0\n12", "original_text": "prior year\nquarter \u00a0\u00a09.4 %\u00a0\u00a010.2 %\u00a0\u00a08.0 %\u00a0\u00a08.6 %\u00a0\u00a018.7 %\u00a0\u00a0 \u00a0\u00a06.5 %\u00a0\u00a010.0 %\u00a0\n12", "page_label": "12", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "900b71f9-2b71-4a5a-8a64-9f2cd416280f", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2624fa9645d00bf66d0e09130dd6ff0ce122de10cdcdfd0367af5758993f75a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cd3132de-f420-415e-9eb6-5d1f90858d55", "node_type": "1", "metadata": {"window": "impact \u00a0\u00a027,948 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a027,948 \u00a0\u00a0\u00a029,916 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a029,916 \u00a0\u00a0\u00a00.15 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(169,900 )\u00a0\u00a0169,900 \u00a0\u00a0\u00a0169,900 \u00a0\u00a0\u00a040,214 \u00a0\u00a0\u00a0(968 )\u00a0\u00a0128,718 \u00a0\u00a0\u00a00.63 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(13,890 )\u00a0\u00a013,890 \u00a0\u00a0\u00a013,890 \u00a0\u00a0\u00a03,305 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a010,585 \u00a0\u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated deal and\nintegration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(40,291 )\u00a0\u00a040,291 \u00a0\u00a0\u00a040,291 \u00a0\u00a0\u00a09,548 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a030,743 \u00a0\u00a0\u00a00.15 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring\nand other\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(52,276 )\u00a0\u00a052,276 \u00a0\u00a0\u00a052,276 \u00a0\u00a0\u00a012,452 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a039,824 \u00a0\u00a0\u00a00.20 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on\ndivestiture of\nnon-core\nbusinesses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(40,665 )\u00a0\u00a01,035 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(41,700 )\u00a0\u00a0(0.21 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nOther, net \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a04,310 \u00a0\u00a0\u00a0781 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a03,529 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a04,824 \u00a0\u00a0\u00a0(8,931 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a013,755 \u00a0\u00a0\u00a00.07 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$2,301,141 \u00a0\u00a0$1,500,154 \u00a0\u00a0$800,987 \u00a0\u00a0$740,906 \u00a0\u00a0$160,392 \u00a0\u00a0$617 \u00a0\u00a0$581,131 \u00a0\u00a0$2.86 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP % change\nvs.  prior year\nquarter \u00a0\u00a09.4 %\u00a0\u00a010.2 %\u00a0\u00a08.0 %\u00a0\u00a08.6 %\u00a0\u00a018.7 %\u00a0\u00a0 \u00a0\u00a06.5 %\u00a0\u00a010.0 %\u00a0\n12", "original_text": "impact \u00a0\u00a027,948 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a027,948 \u00a0\u00a0\u00a029,916 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a029,916 \u00a0\u00a0\u00a00.15 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(169,900 )\u00a0\u00a0169,900 \u00a0\u00a0\u00a0169,900 \u00a0\u00a0\u00a040,214 \u00a0\u00a0\u00a0(968 )\u00a0\u00a0128,718 \u00a0\u00a0\u00a00.63 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(13,890 )\u00a0\u00a013,890 \u00a0\u00a0\u00a013,890 \u00a0\u00a0\u00a03,305 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a010,585 \u00a0\u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated deal and\nintegration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(40,291 )\u00a0\u00a040,291 \u00a0\u00a0\u00a040,291 \u00a0\u00a0\u00a09,548 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a030,743 \u00a0\u00a0\u00a00.15 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring\nand other\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(52,276 )\u00a0\u00a052,276 \u00a0\u00a0\u00a052,276 \u00a0\u00a0\u00a012,452 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a039,824 \u00a0\u00a0\u00a00.20 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on\ndivestiture of\nnon-core\nbusinesses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(40,665 )\u00a0\u00a01,035 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(41,700 )\u00a0\u00a0(0.21 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nOther, net \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a04,310 \u00a0\u00a0\u00a0781 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a03,529 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a04,824 \u00a0\u00a0\u00a0(8,931 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a013,755 \u00a0\u00a0\u00a00.07 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$2,301,141 \u00a0\u00a0$1,500,154 \u00a0\u00a0$800,987 \u00a0\u00a0$740,906 \u00a0\u00a0$160,392 \u00a0\u00a0$617 \u00a0\u00a0$581,131 \u00a0\u00a0$2.86 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP % change\nvs. ", "page_label": "12", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0c5f334e8d975de7dfa76bb51615f23b2a89e95fa7f7796015aba8867e59f029", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4297ebdd-81e9-4a34-b0f7-356d3db7cf88", "node_type": "1", "metadata": {"window": "Percentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.27% \u00a03.34%\nOperating expenses \u00a02.58% \u00a02.18%\nOperating income \u00a00.69% \u00a01.16%\n______________________________________\n1Includes tax expense relating to 2020 S wiss tax reform and a gain on the currency remeasurement of the related deferred tax\nassets, the latter of which is recorded within Other (Income) Loss, Net.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n CENC ORA, INC.\n GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto \n Cencora \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$1,985,559 \u00a0$1,531,040 \u00a0\u00a0$454,519 \u00a0$382,340 \u00a0\u00a0$83,664 \u00a0\u00a0$(3,939 )\u00a0$294,737 \u00a0\u00a0$1.40 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from antitrust\nlitigation settlements \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a079 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(79 )\u00a0\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a0104,839 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0104,839 \u00a0\u00a0104,839 \u00a0\u00a0\u00a024,943 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a079,896 \u00a0\u00a0\u00a00.38 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n13", "original_text": "Percentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.27% \u00a03.34%\nOperating expenses \u00a02.58% \u00a02.18%\nOperating income \u00a00.69% \u00a01.16%\n______________________________________\n1Includes tax expense relating to 2020 S wiss tax reform and a gain on the currency remeasurement of the related deferred tax\nassets, the latter of which is recorded within Other (Income) Loss, Net.\n\u00a0\n"}, "hash": "9246ec1d52a43c4dc32491be8cf2ef5af71826ad35d509eaec6af0d02ee9af5b", "class_name": "RelatedNodeInfo"}}, "text": "prior year\nquarter \u00a0\u00a09.4 %\u00a0\u00a010.2 %\u00a0\u00a08.0 %\u00a0\u00a08.6 %\u00a0\u00a018.7 %\u00a0\u00a0 \u00a0\u00a06.5 %\u00a0\u00a010.0 %\u00a0\n12", "start_char_idx": 1163, "end_char_idx": 1241, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4297ebdd-81e9-4a34-b0f7-356d3db7cf88": {"__data__": {"id_": "4297ebdd-81e9-4a34-b0f7-356d3db7cf88", "embedding": null, "metadata": {"window": "Percentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.27% \u00a03.34%\nOperating expenses \u00a02.58% \u00a02.18%\nOperating income \u00a00.69% \u00a01.16%\n______________________________________\n1Includes tax expense relating to 2020 S wiss tax reform and a gain on the currency remeasurement of the related deferred tax\nassets, the latter of which is recorded within Other (Income) Loss, Net.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n CENC ORA, INC.\n GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto \n Cencora \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$1,985,559 \u00a0$1,531,040 \u00a0\u00a0$454,519 \u00a0$382,340 \u00a0\u00a0$83,664 \u00a0\u00a0$(3,939 )\u00a0$294,737 \u00a0\u00a0$1.40 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from antitrust\nlitigation settlements \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a079 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(79 )\u00a0\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a0104,839 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0104,839 \u00a0\u00a0104,839 \u00a0\u00a0\u00a024,943 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a079,896 \u00a0\u00a0\u00a00.38 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n13", "original_text": "Percentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.27% \u00a03.34%\nOperating expenses \u00a02.58% \u00a02.18%\nOperating income \u00a00.69% \u00a01.16%\n______________________________________\n1Includes tax expense relating to 2020 S wiss tax reform and a gain on the currency remeasurement of the related deferred tax\nassets, the latter of which is recorded within Other (Income) Loss, Net.\n\u00a0\n", "page_label": "13", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "47ecf181-4191-4aae-9b54-bb362f13435b", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e5692c984c12d431b12dc50555beeeded466d676457ea61530bdf564c6cd22a0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b52a0b30-431c-4e4b-bea1-72d05389730f", "node_type": "1", "metadata": {"window": "impact \u00a0\u00a027,948 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a027,948 \u00a0\u00a0\u00a029,916 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a029,916 \u00a0\u00a0\u00a00.15 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(169,900 )\u00a0\u00a0169,900 \u00a0\u00a0\u00a0169,900 \u00a0\u00a0\u00a040,214 \u00a0\u00a0\u00a0(968 )\u00a0\u00a0128,718 \u00a0\u00a0\u00a00.63 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(13,890 )\u00a0\u00a013,890 \u00a0\u00a0\u00a013,890 \u00a0\u00a0\u00a03,305 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a010,585 \u00a0\u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated deal and\nintegration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(40,291 )\u00a0\u00a040,291 \u00a0\u00a0\u00a040,291 \u00a0\u00a0\u00a09,548 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a030,743 \u00a0\u00a0\u00a00.15 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring\nand other\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(52,276 )\u00a0\u00a052,276 \u00a0\u00a0\u00a052,276 \u00a0\u00a0\u00a012,452 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a039,824 \u00a0\u00a0\u00a00.20 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on\ndivestiture of\nnon-core\nbusinesses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(40,665 )\u00a0\u00a01,035 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(41,700 )\u00a0\u00a0(0.21 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nOther, net \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a04,310 \u00a0\u00a0\u00a0781 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a03,529 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a04,824 \u00a0\u00a0\u00a0(8,931 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a013,755 \u00a0\u00a0\u00a00.07 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$2,301,141 \u00a0\u00a0$1,500,154 \u00a0\u00a0$800,987 \u00a0\u00a0$740,906 \u00a0\u00a0$160,392 \u00a0\u00a0$617 \u00a0\u00a0$581,131 \u00a0\u00a0$2.86 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP % change\nvs.  prior year\nquarter \u00a0\u00a09.4 %\u00a0\u00a010.2 %\u00a0\u00a08.0 %\u00a0\u00a08.6 %\u00a0\u00a018.7 %\u00a0\u00a0 \u00a0\u00a06.5 %\u00a0\u00a010.0 %\u00a0\n12", "original_text": "prior year\nquarter \u00a0\u00a09.4 %\u00a0\u00a010.2 %\u00a0\u00a08.0 %\u00a0\u00a08.6 %\u00a0\u00a018.7 %\u00a0\u00a0 \u00a0\u00a06.5 %\u00a0\u00a010.0 %\u00a0\n12", "page_label": "12", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b74087741b3051efe8c9c0f2eb8111876ad84ec1ea8314bd733c7b838322845f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "be4a1ec7-bc56-43f1-b531-6c2b13ddd65b", "node_type": "1", "metadata": {"window": "Percentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.27% \u00a03.34%\nOperating expenses \u00a02.58% \u00a02.18%\nOperating income \u00a00.69% \u00a01.16%\n______________________________________\n1Includes tax expense relating to 2020 S wiss tax reform and a gain on the currency remeasurement of the related deferred tax\nassets, the latter of which is recorded within Other (Income) Loss, Net.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n CENC ORA, INC.\n GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto \n Cencora \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$1,985,559 \u00a0$1,531,040 \u00a0\u00a0$454,519 \u00a0$382,340 \u00a0\u00a0$83,664 \u00a0\u00a0$(3,939 )\u00a0$294,737 \u00a0\u00a0$1.40 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from antitrust\nlitigation settlements \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a079 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(79 )\u00a0\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a0104,839 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0104,839 \u00a0\u00a0104,839 \u00a0\u00a0\u00a024,943 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a079,896 \u00a0\u00a0\u00a00.38 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n13", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n"}, "hash": "3d9c639cd3027f28065bdab352d729da77aea8f1bc5a23c6ca5ecbec11d3c562", "class_name": "RelatedNodeInfo"}}, "text": "Percentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.27% \u00a03.34%\nOperating expenses \u00a02.58% \u00a02.18%\nOperating income \u00a00.69% \u00a01.16%\n______________________________________\n1Includes tax expense relating to 2020 S wiss tax reform and a gain on the currency remeasurement of the related deferred tax\nassets, the latter of which is recorded within Other (Income) Loss, Net.\n\u00a0\n", "start_char_idx": 0, "end_char_idx": 384, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "be4a1ec7-bc56-43f1-b531-6c2b13ddd65b": {"__data__": {"id_": "be4a1ec7-bc56-43f1-b531-6c2b13ddd65b", "embedding": null, "metadata": {"window": "Percentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.27% \u00a03.34%\nOperating expenses \u00a02.58% \u00a02.18%\nOperating income \u00a00.69% \u00a01.16%\n______________________________________\n1Includes tax expense relating to 2020 S wiss tax reform and a gain on the currency remeasurement of the related deferred tax\nassets, the latter of which is recorded within Other (Income) Loss, Net.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n CENC ORA, INC.\n GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto \n Cencora \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$1,985,559 \u00a0$1,531,040 \u00a0\u00a0$454,519 \u00a0$382,340 \u00a0\u00a0$83,664 \u00a0\u00a0$(3,939 )\u00a0$294,737 \u00a0\u00a0$1.40 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from antitrust\nlitigation settlements \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a079 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(79 )\u00a0\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a0104,839 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0104,839 \u00a0\u00a0104,839 \u00a0\u00a0\u00a024,943 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a079,896 \u00a0\u00a0\u00a00.38 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n13", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "13", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "47ecf181-4191-4aae-9b54-bb362f13435b", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e5692c984c12d431b12dc50555beeeded466d676457ea61530bdf564c6cd22a0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4297ebdd-81e9-4a34-b0f7-356d3db7cf88", "node_type": "1", "metadata": {"window": "Percentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.27% \u00a03.34%\nOperating expenses \u00a02.58% \u00a02.18%\nOperating income \u00a00.69% \u00a01.16%\n______________________________________\n1Includes tax expense relating to 2020 S wiss tax reform and a gain on the currency remeasurement of the related deferred tax\nassets, the latter of which is recorded within Other (Income) Loss, Net.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n CENC ORA, INC.\n GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto \n Cencora \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$1,985,559 \u00a0$1,531,040 \u00a0\u00a0$454,519 \u00a0$382,340 \u00a0\u00a0$83,664 \u00a0\u00a0$(3,939 )\u00a0$294,737 \u00a0\u00a0$1.40 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from antitrust\nlitigation settlements \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a079 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(79 )\u00a0\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a0104,839 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0104,839 \u00a0\u00a0104,839 \u00a0\u00a0\u00a024,943 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a079,896 \u00a0\u00a0\u00a00.38 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n13", "original_text": "Percentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.27% \u00a03.34%\nOperating expenses \u00a02.58% \u00a02.18%\nOperating income \u00a00.69% \u00a01.16%\n______________________________________\n1Includes tax expense relating to 2020 S wiss tax reform and a gain on the currency remeasurement of the related deferred tax\nassets, the latter of which is recorded within Other (Income) Loss, Net.\n\u00a0\n", "page_label": "13", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "55c6b550fab6fd475688d7c746811607a54b94aed6575e798703c558fb099c8c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0370dc29-6276-4578-9d3c-77d35999b3cf", "node_type": "1", "metadata": {"window": "Percentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.27% \u00a03.34%\nOperating expenses \u00a02.58% \u00a02.18%\nOperating income \u00a00.69% \u00a01.16%\n______________________________________\n1Includes tax expense relating to 2020 S wiss tax reform and a gain on the currency remeasurement of the related deferred tax\nassets, the latter of which is recorded within Other (Income) Loss, Net.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n CENC ORA, INC.\n GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto \n Cencora \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$1,985,559 \u00a0$1,531,040 \u00a0\u00a0$454,519 \u00a0$382,340 \u00a0\u00a0$83,664 \u00a0\u00a0$(3,939 )\u00a0$294,737 \u00a0\u00a0$1.40 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from antitrust\nlitigation settlements \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a079 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(79 )\u00a0\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a0104,839 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0104,839 \u00a0\u00a0104,839 \u00a0\u00a0\u00a024,943 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a079,896 \u00a0\u00a0\u00a00.38 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n13", "original_text": "CENC ORA, INC.\n"}, "hash": "f4300c601056313fdbc70b2ecb3c3333bb2870888ac6ecc59a4ec0d39572a7f2", "class_name": "RelatedNodeInfo"}}, "text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "start_char_idx": 384, "end_char_idx": 561, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0370dc29-6276-4578-9d3c-77d35999b3cf": {"__data__": {"id_": "0370dc29-6276-4578-9d3c-77d35999b3cf", "embedding": null, "metadata": {"window": "Percentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.27% \u00a03.34%\nOperating expenses \u00a02.58% \u00a02.18%\nOperating income \u00a00.69% \u00a01.16%\n______________________________________\n1Includes tax expense relating to 2020 S wiss tax reform and a gain on the currency remeasurement of the related deferred tax\nassets, the latter of which is recorded within Other (Income) Loss, Net.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n CENC ORA, INC.\n GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto \n Cencora \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$1,985,559 \u00a0$1,531,040 \u00a0\u00a0$454,519 \u00a0$382,340 \u00a0\u00a0$83,664 \u00a0\u00a0$(3,939 )\u00a0$294,737 \u00a0\u00a0$1.40 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from antitrust\nlitigation settlements \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a079 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(79 )\u00a0\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a0104,839 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0104,839 \u00a0\u00a0104,839 \u00a0\u00a0\u00a024,943 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a079,896 \u00a0\u00a0\u00a00.38 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n13", "original_text": "CENC ORA, INC.\n", "page_label": "13", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "47ecf181-4191-4aae-9b54-bb362f13435b", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e5692c984c12d431b12dc50555beeeded466d676457ea61530bdf564c6cd22a0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "be4a1ec7-bc56-43f1-b531-6c2b13ddd65b", "node_type": "1", "metadata": {"window": "Percentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.27% \u00a03.34%\nOperating expenses \u00a02.58% \u00a02.18%\nOperating income \u00a00.69% \u00a01.16%\n______________________________________\n1Includes tax expense relating to 2020 S wiss tax reform and a gain on the currency remeasurement of the related deferred tax\nassets, the latter of which is recorded within Other (Income) Loss, Net.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n CENC ORA, INC.\n GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto \n Cencora \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$1,985,559 \u00a0$1,531,040 \u00a0\u00a0$454,519 \u00a0$382,340 \u00a0\u00a0$83,664 \u00a0\u00a0$(3,939 )\u00a0$294,737 \u00a0\u00a0$1.40 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from antitrust\nlitigation settlements \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a079 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(79 )\u00a0\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a0104,839 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0104,839 \u00a0\u00a0104,839 \u00a0\u00a0\u00a024,943 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a079,896 \u00a0\u00a0\u00a00.38 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n13", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "13", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "15d5feadcc743f1f1863328082594b85c7ac7870cac8f66a586418dc81ffb15b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eeee86b3-07be-4780-b03f-d68db68a4001", "node_type": "1", "metadata": {"window": "Percentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.27% \u00a03.34%\nOperating expenses \u00a02.58% \u00a02.18%\nOperating income \u00a00.69% \u00a01.16%\n______________________________________\n1Includes tax expense relating to 2020 S wiss tax reform and a gain on the currency remeasurement of the related deferred tax\nassets, the latter of which is recorded within Other (Income) Loss, Net.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n CENC ORA, INC.\n GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto \n Cencora \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$1,985,559 \u00a0$1,531,040 \u00a0\u00a0$454,519 \u00a0$382,340 \u00a0\u00a0$83,664 \u00a0\u00a0$(3,939 )\u00a0$294,737 \u00a0\u00a0$1.40 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from antitrust\nlitigation settlements \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a079 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(79 )\u00a0\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a0104,839 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0104,839 \u00a0\u00a0104,839 \u00a0\u00a0\u00a024,943 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a079,896 \u00a0\u00a0\u00a00.38 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n13", "original_text": "GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto \n Cencora \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$1,985,559 \u00a0$1,531,040 \u00a0\u00a0$454,519 \u00a0$382,340 \u00a0\u00a0$83,664 \u00a0\u00a0$(3,939 )\u00a0$294,737 \u00a0\u00a0$1.40 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from antitrust\nlitigation settlements \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a079 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(79 )\u00a0\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a0104,839 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0104,839 \u00a0\u00a0104,839 \u00a0\u00a0\u00a024,943 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a079,896 \u00a0\u00a0\u00a00.38 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n13"}, "hash": "76eb50ce1cebdf331e724b110f3bf3897513e19f8e1e1a1c11b3831b883830e7", "class_name": "RelatedNodeInfo"}}, "text": "CENC ORA, INC.\n", "start_char_idx": 561, "end_char_idx": 576, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eeee86b3-07be-4780-b03f-d68db68a4001": {"__data__": {"id_": "eeee86b3-07be-4780-b03f-d68db68a4001", "embedding": null, "metadata": {"window": "Percentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.27% \u00a03.34%\nOperating expenses \u00a02.58% \u00a02.18%\nOperating income \u00a00.69% \u00a01.16%\n______________________________________\n1Includes tax expense relating to 2020 S wiss tax reform and a gain on the currency remeasurement of the related deferred tax\nassets, the latter of which is recorded within Other (Income) Loss, Net.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n CENC ORA, INC.\n GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto \n Cencora \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$1,985,559 \u00a0$1,531,040 \u00a0\u00a0$454,519 \u00a0$382,340 \u00a0\u00a0$83,664 \u00a0\u00a0$(3,939 )\u00a0$294,737 \u00a0\u00a0$1.40 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from antitrust\nlitigation settlements \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a079 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(79 )\u00a0\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a0104,839 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0104,839 \u00a0\u00a0104,839 \u00a0\u00a0\u00a024,943 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a079,896 \u00a0\u00a0\u00a00.38 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n13", "original_text": "GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto \n Cencora \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$1,985,559 \u00a0$1,531,040 \u00a0\u00a0$454,519 \u00a0$382,340 \u00a0\u00a0$83,664 \u00a0\u00a0$(3,939 )\u00a0$294,737 \u00a0\u00a0$1.40 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from antitrust\nlitigation settlements \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a079 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(79 )\u00a0\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a0104,839 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0104,839 \u00a0\u00a0104,839 \u00a0\u00a0\u00a024,943 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a079,896 \u00a0\u00a0\u00a00.38 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n13", "page_label": "13", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "47ecf181-4191-4aae-9b54-bb362f13435b", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e5692c984c12d431b12dc50555beeeded466d676457ea61530bdf564c6cd22a0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0370dc29-6276-4578-9d3c-77d35999b3cf", "node_type": "1", "metadata": {"window": "Percentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.27% \u00a03.34%\nOperating expenses \u00a02.58% \u00a02.18%\nOperating income \u00a00.69% \u00a01.16%\n______________________________________\n1Includes tax expense relating to 2020 S wiss tax reform and a gain on the currency remeasurement of the related deferred tax\nassets, the latter of which is recorded within Other (Income) Loss, Net.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n CENC ORA, INC.\n GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto \n Cencora \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$1,985,559 \u00a0$1,531,040 \u00a0\u00a0$454,519 \u00a0$382,340 \u00a0\u00a0$83,664 \u00a0\u00a0$(3,939 )\u00a0$294,737 \u00a0\u00a0$1.40 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from antitrust\nlitigation settlements \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a079 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(79 )\u00a0\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a0104,839 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0104,839 \u00a0\u00a0104,839 \u00a0\u00a0\u00a024,943 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a079,896 \u00a0\u00a0\u00a00.38 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n13", "original_text": "CENC ORA, INC.\n", "page_label": "13", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "671b50dc4b70c9c9a6553b2bf0f3552148e4f4d6d4d2970ab270738496d74e75", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b99353c1-918b-4e60-988a-553d058656b6", "node_type": "1", "metadata": {"window": "Turkey highly\ninflationary impact \u00a0\u00a012,415 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a012,415 \u00a0\u00a018,543 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a018,543 \u00a0\u00a0\u00a00.09 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0(72,685 )\u00a0\u00a072,685 \u00a0\u00a072,685 \u00a0\u00a0\u00a06,194 \u00a0\u00a0\u00a0(1,127 )\u00a0\u00a065,364 \u00a0\u00a0\u00a00.31 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and opioid-\nrelated expenses \u00a0\u00a0\u2014 \u00a0\u00a0(15,024 )\u00a0\u00a015,024 \u00a0\u00a015,024 \u00a0\u00a0\u00a05,106 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a09,918 \u00a0\u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\ndeal and integration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0(49,851 )\u00a0\u00a049,851 \u00a0\u00a049,851 \u00a0\u00a0\u00a04,894 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a044,957 \u00a0\u00a0\u00a00.21 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring and\nother expenses \u00a0\u00a0\u2014 \u00a0\u00a0(32,141 )\u00a0\u00a032,141 \u00a0\u00a032,141 \u00a0\u00a0\u00a04,104 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a028,037 \u00a0\u00a0\u00a00.13 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on\nremeasurement of\nequity investment \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0(4,834 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,834 )\u00a0\u00a0(0.02 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLoss on divestiture of\nnon-core businesses \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a03,745 \u00a0\u00a0\u00a02,821 \u00a0\u00a0\u00a03,618 \u00a0\u00a0\u00a04,542 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain discrete tax\nbenefits \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a09,302 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(9,302 )\u00a0\u00a0(0.04 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a08,127 \u00a0\u00a0\u00a0(5,951 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a014,078 \u00a0\u00a0\u00a00.07 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-GAAP \u00a0$2,102,813 \u00a0$1,361,339 \u00a0\u00a0$741,474 \u00a0$682,461 \u00a0\u00a0$135,156 \u00a0\u00a0$(1,448 )\u00a0$545,857 \u00a0\u00a0$2.60 \u00a0\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.25% \u00a03.44%\n14", "original_text": "Turkey highly\ninflationary impact \u00a0\u00a012,415 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a012,415 \u00a0\u00a018,543 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a018,543 \u00a0\u00a0\u00a00.09 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0(72,685 )\u00a0\u00a072,685 \u00a0\u00a072,685 \u00a0\u00a0\u00a06,194 \u00a0\u00a0\u00a0(1,127 )\u00a0\u00a065,364 \u00a0\u00a0\u00a00.31 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and opioid-\nrelated expenses \u00a0\u00a0\u2014 \u00a0\u00a0(15,024 )\u00a0\u00a015,024 \u00a0\u00a015,024 \u00a0\u00a0\u00a05,106 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a09,918 \u00a0\u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\ndeal and integration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0(49,851 )\u00a0\u00a049,851 \u00a0\u00a049,851 \u00a0\u00a0\u00a04,894 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a044,957 \u00a0\u00a0\u00a00.21 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring and\nother expenses \u00a0\u00a0\u2014 \u00a0\u00a0(32,141 )\u00a0\u00a032,141 \u00a0\u00a032,141 \u00a0\u00a0\u00a04,104 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a028,037 \u00a0\u00a0\u00a00.13 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on\nremeasurement of\nequity investment \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0(4,834 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,834 )\u00a0\u00a0(0.02 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLoss on divestiture of\nnon-core businesses \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a03,745 \u00a0\u00a0\u00a02,821 \u00a0\u00a0\u00a03,618 \u00a0\u00a0\u00a04,542 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain discrete tax\nbenefits \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a09,302 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(9,302 )\u00a0\u00a0(0.04 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a08,127 \u00a0\u00a0\u00a0(5,951 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a014,078 \u00a0\u00a0\u00a00.07 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-GAAP \u00a0$2,102,813 \u00a0$1,361,339 \u00a0\u00a0$741,474 \u00a0$682,461 \u00a0\u00a0$135,156 \u00a0\u00a0$(1,448 )\u00a0$545,857 \u00a0\u00a0$2.60 \u00a0\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.25% \u00a03.44%\n14"}, "hash": "63b8bddc85f9d739ab74c1d2af6e2d53137a9a3c1b582d0f8096c90a618c9df1", "class_name": "RelatedNodeInfo"}}, "text": "GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto \n Cencora \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$1,985,559 \u00a0$1,531,040 \u00a0\u00a0$454,519 \u00a0$382,340 \u00a0\u00a0$83,664 \u00a0\u00a0$(3,939 )\u00a0$294,737 \u00a0\u00a0$1.40 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from antitrust\nlitigation settlements \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a079 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(79 )\u00a0\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a0104,839 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0104,839 \u00a0\u00a0104,839 \u00a0\u00a0\u00a024,943 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a079,896 \u00a0\u00a0\u00a00.38 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n13", "start_char_idx": 576, "end_char_idx": 1292, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b99353c1-918b-4e60-988a-553d058656b6": {"__data__": {"id_": "b99353c1-918b-4e60-988a-553d058656b6", "embedding": null, "metadata": {"window": "Turkey highly\ninflationary impact \u00a0\u00a012,415 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a012,415 \u00a0\u00a018,543 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a018,543 \u00a0\u00a0\u00a00.09 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0(72,685 )\u00a0\u00a072,685 \u00a0\u00a072,685 \u00a0\u00a0\u00a06,194 \u00a0\u00a0\u00a0(1,127 )\u00a0\u00a065,364 \u00a0\u00a0\u00a00.31 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and opioid-\nrelated expenses \u00a0\u00a0\u2014 \u00a0\u00a0(15,024 )\u00a0\u00a015,024 \u00a0\u00a015,024 \u00a0\u00a0\u00a05,106 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a09,918 \u00a0\u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\ndeal and integration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0(49,851 )\u00a0\u00a049,851 \u00a0\u00a049,851 \u00a0\u00a0\u00a04,894 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a044,957 \u00a0\u00a0\u00a00.21 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring and\nother expenses \u00a0\u00a0\u2014 \u00a0\u00a0(32,141 )\u00a0\u00a032,141 \u00a0\u00a032,141 \u00a0\u00a0\u00a04,104 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a028,037 \u00a0\u00a0\u00a00.13 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on\nremeasurement of\nequity investment \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0(4,834 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,834 )\u00a0\u00a0(0.02 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLoss on divestiture of\nnon-core businesses \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a03,745 \u00a0\u00a0\u00a02,821 \u00a0\u00a0\u00a03,618 \u00a0\u00a0\u00a04,542 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain discrete tax\nbenefits \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a09,302 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(9,302 )\u00a0\u00a0(0.04 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a08,127 \u00a0\u00a0\u00a0(5,951 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a014,078 \u00a0\u00a0\u00a00.07 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-GAAP \u00a0$2,102,813 \u00a0$1,361,339 \u00a0\u00a0$741,474 \u00a0$682,461 \u00a0\u00a0$135,156 \u00a0\u00a0$(1,448 )\u00a0$545,857 \u00a0\u00a0$2.60 \u00a0\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.25% \u00a03.44%\n14", "original_text": "Turkey highly\ninflationary impact \u00a0\u00a012,415 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a012,415 \u00a0\u00a018,543 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a018,543 \u00a0\u00a0\u00a00.09 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0(72,685 )\u00a0\u00a072,685 \u00a0\u00a072,685 \u00a0\u00a0\u00a06,194 \u00a0\u00a0\u00a0(1,127 )\u00a0\u00a065,364 \u00a0\u00a0\u00a00.31 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and opioid-\nrelated expenses \u00a0\u00a0\u2014 \u00a0\u00a0(15,024 )\u00a0\u00a015,024 \u00a0\u00a015,024 \u00a0\u00a0\u00a05,106 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a09,918 \u00a0\u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\ndeal and integration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0(49,851 )\u00a0\u00a049,851 \u00a0\u00a049,851 \u00a0\u00a0\u00a04,894 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a044,957 \u00a0\u00a0\u00a00.21 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring and\nother expenses \u00a0\u00a0\u2014 \u00a0\u00a0(32,141 )\u00a0\u00a032,141 \u00a0\u00a032,141 \u00a0\u00a0\u00a04,104 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a028,037 \u00a0\u00a0\u00a00.13 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on\nremeasurement of\nequity investment \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0(4,834 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,834 )\u00a0\u00a0(0.02 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLoss on divestiture of\nnon-core businesses \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a03,745 \u00a0\u00a0\u00a02,821 \u00a0\u00a0\u00a03,618 \u00a0\u00a0\u00a04,542 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain discrete tax\nbenefits \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a09,302 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(9,302 )\u00a0\u00a0(0.04 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a08,127 \u00a0\u00a0\u00a0(5,951 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a014,078 \u00a0\u00a0\u00a00.07 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-GAAP \u00a0$2,102,813 \u00a0$1,361,339 \u00a0\u00a0$741,474 \u00a0$682,461 \u00a0\u00a0$135,156 \u00a0\u00a0$(1,448 )\u00a0$545,857 \u00a0\u00a0$2.60 \u00a0\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.25% \u00a03.44%\n14", "page_label": "14", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "55d70abf-7bc2-4c52-a77a-3f390d38d9a5", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0dec592023da51ab8371dd9dc8b68707ad619136fc9c8a9e6795044afa7bdd4a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eeee86b3-07be-4780-b03f-d68db68a4001", "node_type": "1", "metadata": {"window": "Percentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.27% \u00a03.34%\nOperating expenses \u00a02.58% \u00a02.18%\nOperating income \u00a00.69% \u00a01.16%\n______________________________________\n1Includes tax expense relating to 2020 S wiss tax reform and a gain on the currency remeasurement of the related deferred tax\nassets, the latter of which is recorded within Other (Income) Loss, Net.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n CENC ORA, INC.\n GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto \n Cencora \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$1,985,559 \u00a0$1,531,040 \u00a0\u00a0$454,519 \u00a0$382,340 \u00a0\u00a0$83,664 \u00a0\u00a0$(3,939 )\u00a0$294,737 \u00a0\u00a0$1.40 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from antitrust\nlitigation settlements \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a079 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(79 )\u00a0\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a0104,839 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0104,839 \u00a0\u00a0104,839 \u00a0\u00a0\u00a024,943 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a079,896 \u00a0\u00a0\u00a00.38 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n13", "original_text": "GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto \n Cencora \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$1,985,559 \u00a0$1,531,040 \u00a0\u00a0$454,519 \u00a0$382,340 \u00a0\u00a0$83,664 \u00a0\u00a0$(3,939 )\u00a0$294,737 \u00a0\u00a0$1.40 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from antitrust\nlitigation settlements \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a079 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(79 )\u00a0\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a0104,839 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0104,839 \u00a0\u00a0104,839 \u00a0\u00a0\u00a024,943 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a079,896 \u00a0\u00a0\u00a00.38 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n13", "page_label": "13", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ef603178a72354cbdf635daffb00c9c7b61df8a73d9b842388cd1294e0499476", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a47af973-ef33-4a6e-9416-eba14e4e46ef", "node_type": "1", "metadata": {"window": "Operating expenses \u00a02.50% \u00a02.23%\nOperating income \u00a00.74% \u00a01.21%\n______________________________________\n1Includes tax expense relating to S wiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nthe latter of which is recorded within Other (Income) Loss, Net.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n\u00a0\n CENC ORA, INC.\n GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30, 2023 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Loss \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto \n Cencora \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$8,959,493 \u00a0\u00a0$6,618,762 \u00a0\u00a0$2,340,731 \u00a0\u00a0$2,160,836 \u00a0\u00a0$428,260 \u00a0\u00a0$12,717 \u00a0\u00a0$1,745,293 \u00a0\u00a0$8.53 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(239,092 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(239,092 )\u00a0\u00a0(239,092 )\u00a0\u00a0(55,894 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(183,198 )\u00a0\u00a0(0.90 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a0204,595 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0204,595 \u00a0\u00a0\u00a0204,595 \u00a0\u00a0\u00a047,830 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0156,765 \u00a0\u00a0\u00a00.77 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\nifli\n15", "original_text": "Operating expenses \u00a02.50% \u00a02.23%\nOperating income \u00a00.74% \u00a01.21%\n______________________________________\n1Includes tax expense relating to S wiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nthe latter of which is recorded within Other (Income) Loss, Net.\n\u00a0\n"}, "hash": "166fb8b3f5addd6dbe8b40a0df9367b437159216aefdaeb6d5e2a48bc0cee355", "class_name": "RelatedNodeInfo"}}, "text": "Turkey highly\ninflationary impact \u00a0\u00a012,415 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a012,415 \u00a0\u00a018,543 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a018,543 \u00a0\u00a0\u00a00.09 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0(72,685 )\u00a0\u00a072,685 \u00a0\u00a072,685 \u00a0\u00a0\u00a06,194 \u00a0\u00a0\u00a0(1,127 )\u00a0\u00a065,364 \u00a0\u00a0\u00a00.31 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and opioid-\nrelated expenses \u00a0\u00a0\u2014 \u00a0\u00a0(15,024 )\u00a0\u00a015,024 \u00a0\u00a015,024 \u00a0\u00a0\u00a05,106 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a09,918 \u00a0\u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\ndeal and integration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0(49,851 )\u00a0\u00a049,851 \u00a0\u00a049,851 \u00a0\u00a0\u00a04,894 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a044,957 \u00a0\u00a0\u00a00.21 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring and\nother expenses \u00a0\u00a0\u2014 \u00a0\u00a0(32,141 )\u00a0\u00a032,141 \u00a0\u00a032,141 \u00a0\u00a0\u00a04,104 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a028,037 \u00a0\u00a0\u00a00.13 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on\nremeasurement of\nequity investment \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0(4,834 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,834 )\u00a0\u00a0(0.02 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLoss on divestiture of\nnon-core businesses \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a03,745 \u00a0\u00a0\u00a02,821 \u00a0\u00a0\u00a03,618 \u00a0\u00a0\u00a04,542 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain discrete tax\nbenefits \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a09,302 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(9,302 )\u00a0\u00a0(0.04 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a08,127 \u00a0\u00a0\u00a0(5,951 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a014,078 \u00a0\u00a0\u00a00.07 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-GAAP \u00a0$2,102,813 \u00a0$1,361,339 \u00a0\u00a0$741,474 \u00a0$682,461 \u00a0\u00a0$135,156 \u00a0\u00a0$(1,448 )\u00a0$545,857 \u00a0\u00a0$2.60 \u00a0\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.25% \u00a03.44%\n14", "start_char_idx": 0, "end_char_idx": 1333, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a47af973-ef33-4a6e-9416-eba14e4e46ef": {"__data__": {"id_": "a47af973-ef33-4a6e-9416-eba14e4e46ef", "embedding": null, "metadata": {"window": "Operating expenses \u00a02.50% \u00a02.23%\nOperating income \u00a00.74% \u00a01.21%\n______________________________________\n1Includes tax expense relating to S wiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nthe latter of which is recorded within Other (Income) Loss, Net.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n\u00a0\n CENC ORA, INC.\n GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30, 2023 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Loss \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto \n Cencora \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$8,959,493 \u00a0\u00a0$6,618,762 \u00a0\u00a0$2,340,731 \u00a0\u00a0$2,160,836 \u00a0\u00a0$428,260 \u00a0\u00a0$12,717 \u00a0\u00a0$1,745,293 \u00a0\u00a0$8.53 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(239,092 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(239,092 )\u00a0\u00a0(239,092 )\u00a0\u00a0(55,894 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(183,198 )\u00a0\u00a0(0.90 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a0204,595 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0204,595 \u00a0\u00a0\u00a0204,595 \u00a0\u00a0\u00a047,830 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0156,765 \u00a0\u00a0\u00a00.77 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\nifli\n15", "original_text": "Operating expenses \u00a02.50% \u00a02.23%\nOperating income \u00a00.74% \u00a01.21%\n______________________________________\n1Includes tax expense relating to S wiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nthe latter of which is recorded within Other (Income) Loss, Net.\n\u00a0\n", "page_label": "15", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9785e97e-c48b-4791-bd32-a25b463008af", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5d5946375e4ba4ac94f9ef47768bcd9acc01ff5dc8bebc365239e1c497ff2850", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b99353c1-918b-4e60-988a-553d058656b6", "node_type": "1", "metadata": {"window": "Turkey highly\ninflationary impact \u00a0\u00a012,415 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a012,415 \u00a0\u00a018,543 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a018,543 \u00a0\u00a0\u00a00.09 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0(72,685 )\u00a0\u00a072,685 \u00a0\u00a072,685 \u00a0\u00a0\u00a06,194 \u00a0\u00a0\u00a0(1,127 )\u00a0\u00a065,364 \u00a0\u00a0\u00a00.31 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and opioid-\nrelated expenses \u00a0\u00a0\u2014 \u00a0\u00a0(15,024 )\u00a0\u00a015,024 \u00a0\u00a015,024 \u00a0\u00a0\u00a05,106 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a09,918 \u00a0\u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\ndeal and integration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0(49,851 )\u00a0\u00a049,851 \u00a0\u00a049,851 \u00a0\u00a0\u00a04,894 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a044,957 \u00a0\u00a0\u00a00.21 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring and\nother expenses \u00a0\u00a0\u2014 \u00a0\u00a0(32,141 )\u00a0\u00a032,141 \u00a0\u00a032,141 \u00a0\u00a0\u00a04,104 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a028,037 \u00a0\u00a0\u00a00.13 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on\nremeasurement of\nequity investment \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0(4,834 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,834 )\u00a0\u00a0(0.02 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLoss on divestiture of\nnon-core businesses \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a03,745 \u00a0\u00a0\u00a02,821 \u00a0\u00a0\u00a03,618 \u00a0\u00a0\u00a04,542 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain discrete tax\nbenefits \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a09,302 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(9,302 )\u00a0\u00a0(0.04 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a08,127 \u00a0\u00a0\u00a0(5,951 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a014,078 \u00a0\u00a0\u00a00.07 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-GAAP \u00a0$2,102,813 \u00a0$1,361,339 \u00a0\u00a0$741,474 \u00a0$682,461 \u00a0\u00a0$135,156 \u00a0\u00a0$(1,448 )\u00a0$545,857 \u00a0\u00a0$2.60 \u00a0\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.25% \u00a03.44%\n14", "original_text": "Turkey highly\ninflationary impact \u00a0\u00a012,415 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a012,415 \u00a0\u00a018,543 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a018,543 \u00a0\u00a0\u00a00.09 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0(72,685 )\u00a0\u00a072,685 \u00a0\u00a072,685 \u00a0\u00a0\u00a06,194 \u00a0\u00a0\u00a0(1,127 )\u00a0\u00a065,364 \u00a0\u00a0\u00a00.31 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and opioid-\nrelated expenses \u00a0\u00a0\u2014 \u00a0\u00a0(15,024 )\u00a0\u00a015,024 \u00a0\u00a015,024 \u00a0\u00a0\u00a05,106 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a09,918 \u00a0\u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\ndeal and integration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0(49,851 )\u00a0\u00a049,851 \u00a0\u00a049,851 \u00a0\u00a0\u00a04,894 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a044,957 \u00a0\u00a0\u00a00.21 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring and\nother expenses \u00a0\u00a0\u2014 \u00a0\u00a0(32,141 )\u00a0\u00a032,141 \u00a0\u00a032,141 \u00a0\u00a0\u00a04,104 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a028,037 \u00a0\u00a0\u00a00.13 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on\nremeasurement of\nequity investment \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0(4,834 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,834 )\u00a0\u00a0(0.02 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLoss on divestiture of\nnon-core businesses \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a03,745 \u00a0\u00a0\u00a02,821 \u00a0\u00a0\u00a03,618 \u00a0\u00a0\u00a04,542 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain discrete tax\nbenefits \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a09,302 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(9,302 )\u00a0\u00a0(0.04 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a08,127 \u00a0\u00a0\u00a0(5,951 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a014,078 \u00a0\u00a0\u00a00.07 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-GAAP \u00a0$2,102,813 \u00a0$1,361,339 \u00a0\u00a0$741,474 \u00a0$682,461 \u00a0\u00a0$135,156 \u00a0\u00a0$(1,448 )\u00a0$545,857 \u00a0\u00a0$2.60 \u00a0\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.25% \u00a03.44%\n14", "page_label": "14", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "34370f9f33638dde9903a873b70d1bf47589778e1969ac7e1066ba0842d82e0b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4cee3074-85fd-43e7-8b9d-f3e8292d6629", "node_type": "1", "metadata": {"window": "Operating expenses \u00a02.50% \u00a02.23%\nOperating income \u00a00.74% \u00a01.21%\n______________________________________\n1Includes tax expense relating to S wiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nthe latter of which is recorded within Other (Income) Loss, Net.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n\u00a0\n CENC ORA, INC.\n GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30, 2023 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Loss \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto \n Cencora \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$8,959,493 \u00a0\u00a0$6,618,762 \u00a0\u00a0$2,340,731 \u00a0\u00a0$2,160,836 \u00a0\u00a0$428,260 \u00a0\u00a0$12,717 \u00a0\u00a0$1,745,293 \u00a0\u00a0$8.53 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(239,092 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(239,092 )\u00a0\u00a0(239,092 )\u00a0\u00a0(55,894 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(183,198 )\u00a0\u00a0(0.90 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a0204,595 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0204,595 \u00a0\u00a0\u00a0204,595 \u00a0\u00a0\u00a047,830 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0156,765 \u00a0\u00a0\u00a00.77 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\nifli\n15", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n\u00a0\n"}, "hash": "7c970fa403a08767361ad65e3ba92ae68cb6245e274a9d09234b974e2bf79bfc", "class_name": "RelatedNodeInfo"}}, "text": "Operating expenses \u00a02.50% \u00a02.23%\nOperating income \u00a00.74% \u00a01.21%\n______________________________________\n1Includes tax expense relating to S wiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nthe latter of which is recorded within Other (Income) Loss, Net.\n\u00a0\n", "start_char_idx": 0, "end_char_idx": 299, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4cee3074-85fd-43e7-8b9d-f3e8292d6629": {"__data__": {"id_": "4cee3074-85fd-43e7-8b9d-f3e8292d6629", "embedding": null, "metadata": {"window": "Operating expenses \u00a02.50% \u00a02.23%\nOperating income \u00a00.74% \u00a01.21%\n______________________________________\n1Includes tax expense relating to S wiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nthe latter of which is recorded within Other (Income) Loss, Net.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n\u00a0\n CENC ORA, INC.\n GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30, 2023 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Loss \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto \n Cencora \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$8,959,493 \u00a0\u00a0$6,618,762 \u00a0\u00a0$2,340,731 \u00a0\u00a0$2,160,836 \u00a0\u00a0$428,260 \u00a0\u00a0$12,717 \u00a0\u00a0$1,745,293 \u00a0\u00a0$8.53 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(239,092 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(239,092 )\u00a0\u00a0(239,092 )\u00a0\u00a0(55,894 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(183,198 )\u00a0\u00a0(0.90 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a0204,595 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0204,595 \u00a0\u00a0\u00a0204,595 \u00a0\u00a0\u00a047,830 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0156,765 \u00a0\u00a0\u00a00.77 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\nifli\n15", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n\u00a0\n", "page_label": "15", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9785e97e-c48b-4791-bd32-a25b463008af", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5d5946375e4ba4ac94f9ef47768bcd9acc01ff5dc8bebc365239e1c497ff2850", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a47af973-ef33-4a6e-9416-eba14e4e46ef", "node_type": "1", "metadata": {"window": "Operating expenses \u00a02.50% \u00a02.23%\nOperating income \u00a00.74% \u00a01.21%\n______________________________________\n1Includes tax expense relating to S wiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nthe latter of which is recorded within Other (Income) Loss, Net.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n\u00a0\n CENC ORA, INC.\n GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30, 2023 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Loss \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto \n Cencora \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$8,959,493 \u00a0\u00a0$6,618,762 \u00a0\u00a0$2,340,731 \u00a0\u00a0$2,160,836 \u00a0\u00a0$428,260 \u00a0\u00a0$12,717 \u00a0\u00a0$1,745,293 \u00a0\u00a0$8.53 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(239,092 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(239,092 )\u00a0\u00a0(239,092 )\u00a0\u00a0(55,894 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(183,198 )\u00a0\u00a0(0.90 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a0204,595 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0204,595 \u00a0\u00a0\u00a0204,595 \u00a0\u00a0\u00a047,830 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0156,765 \u00a0\u00a0\u00a00.77 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\nifli\n15", "original_text": "Operating expenses \u00a02.50% \u00a02.23%\nOperating income \u00a00.74% \u00a01.21%\n______________________________________\n1Includes tax expense relating to S wiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nthe latter of which is recorded within Other (Income) Loss, Net.\n\u00a0\n", "page_label": "15", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1124b4301096b592625ebbe6810abcfbc3f0b8574e9d93adf4efa51045ab5a5b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "90eafdd0-d4cf-409e-b270-6ca4a53dcd1d", "node_type": "1", "metadata": {"window": "Operating expenses \u00a02.50% \u00a02.23%\nOperating income \u00a00.74% \u00a01.21%\n______________________________________\n1Includes tax expense relating to S wiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nthe latter of which is recorded within Other (Income) Loss, Net.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n\u00a0\n CENC ORA, INC.\n GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30, 2023 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Loss \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto \n Cencora \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$8,959,493 \u00a0\u00a0$6,618,762 \u00a0\u00a0$2,340,731 \u00a0\u00a0$2,160,836 \u00a0\u00a0$428,260 \u00a0\u00a0$12,717 \u00a0\u00a0$1,745,293 \u00a0\u00a0$8.53 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(239,092 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(239,092 )\u00a0\u00a0(239,092 )\u00a0\u00a0(55,894 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(183,198 )\u00a0\u00a0(0.90 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a0204,595 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0204,595 \u00a0\u00a0\u00a0204,595 \u00a0\u00a0\u00a047,830 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0156,765 \u00a0\u00a0\u00a00.77 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\nifli\n15", "original_text": "CENC ORA, INC.\n"}, "hash": "3e591d89d3a5e8e8e5ae521601db59fedcce07135f2ebe174c58f6f514064984", "class_name": "RelatedNodeInfo"}}, "text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n\u00a0\n", "start_char_idx": 299, "end_char_idx": 478, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "90eafdd0-d4cf-409e-b270-6ca4a53dcd1d": {"__data__": {"id_": "90eafdd0-d4cf-409e-b270-6ca4a53dcd1d", "embedding": null, "metadata": {"window": "Operating expenses \u00a02.50% \u00a02.23%\nOperating income \u00a00.74% \u00a01.21%\n______________________________________\n1Includes tax expense relating to S wiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nthe latter of which is recorded within Other (Income) Loss, Net.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n\u00a0\n CENC ORA, INC.\n GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30, 2023 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Loss \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto \n Cencora \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$8,959,493 \u00a0\u00a0$6,618,762 \u00a0\u00a0$2,340,731 \u00a0\u00a0$2,160,836 \u00a0\u00a0$428,260 \u00a0\u00a0$12,717 \u00a0\u00a0$1,745,293 \u00a0\u00a0$8.53 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(239,092 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(239,092 )\u00a0\u00a0(239,092 )\u00a0\u00a0(55,894 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(183,198 )\u00a0\u00a0(0.90 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a0204,595 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0204,595 \u00a0\u00a0\u00a0204,595 \u00a0\u00a0\u00a047,830 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0156,765 \u00a0\u00a0\u00a00.77 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\nifli\n15", "original_text": "CENC ORA, INC.\n", "page_label": "15", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9785e97e-c48b-4791-bd32-a25b463008af", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5d5946375e4ba4ac94f9ef47768bcd9acc01ff5dc8bebc365239e1c497ff2850", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4cee3074-85fd-43e7-8b9d-f3e8292d6629", "node_type": "1", "metadata": {"window": "Operating expenses \u00a02.50% \u00a02.23%\nOperating income \u00a00.74% \u00a01.21%\n______________________________________\n1Includes tax expense relating to S wiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nthe latter of which is recorded within Other (Income) Loss, Net.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n\u00a0\n CENC ORA, INC.\n GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30, 2023 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Loss \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto \n Cencora \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$8,959,493 \u00a0\u00a0$6,618,762 \u00a0\u00a0$2,340,731 \u00a0\u00a0$2,160,836 \u00a0\u00a0$428,260 \u00a0\u00a0$12,717 \u00a0\u00a0$1,745,293 \u00a0\u00a0$8.53 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(239,092 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(239,092 )\u00a0\u00a0(239,092 )\u00a0\u00a0(55,894 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(183,198 )\u00a0\u00a0(0.90 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a0204,595 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0204,595 \u00a0\u00a0\u00a0204,595 \u00a0\u00a0\u00a047,830 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0156,765 \u00a0\u00a0\u00a00.77 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\nifli\n15", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n\u00a0\n", "page_label": "15", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aff16f7e35de3fb904095c43cc6c644750b0bc30b5c1df5dfce6a2b4015aab63", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "529ceb12-632b-4b43-9ee8-caddc677a932", "node_type": "1", "metadata": {"window": "Operating expenses \u00a02.50% \u00a02.23%\nOperating income \u00a00.74% \u00a01.21%\n______________________________________\n1Includes tax expense relating to S wiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nthe latter of which is recorded within Other (Income) Loss, Net.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n\u00a0\n CENC ORA, INC.\n GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30, 2023 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Loss \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto \n Cencora \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$8,959,493 \u00a0\u00a0$6,618,762 \u00a0\u00a0$2,340,731 \u00a0\u00a0$2,160,836 \u00a0\u00a0$428,260 \u00a0\u00a0$12,717 \u00a0\u00a0$1,745,293 \u00a0\u00a0$8.53 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(239,092 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(239,092 )\u00a0\u00a0(239,092 )\u00a0\u00a0(55,894 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(183,198 )\u00a0\u00a0(0.90 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a0204,595 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0204,595 \u00a0\u00a0\u00a0204,595 \u00a0\u00a0\u00a047,830 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0156,765 \u00a0\u00a0\u00a00.77 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\nifli\n15", "original_text": "GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30, 2023 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Loss \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto \n Cencora \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$8,959,493 \u00a0\u00a0$6,618,762 \u00a0\u00a0$2,340,731 \u00a0\u00a0$2,160,836 \u00a0\u00a0$428,260 \u00a0\u00a0$12,717 \u00a0\u00a0$1,745,293 \u00a0\u00a0$8.53 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(239,092 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(239,092 )\u00a0\u00a0(239,092 )\u00a0\u00a0(55,894 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(183,198 )\u00a0\u00a0(0.90 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a0204,595 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0204,595 \u00a0\u00a0\u00a0204,595 \u00a0\u00a0\u00a047,830 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0156,765 \u00a0\u00a0\u00a00.77 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\nifli\n15"}, "hash": "d14c3d05b8dfab3b6cb753376ac7dddc8f65d7a5f7ef6cacd386063ae700d8db", "class_name": "RelatedNodeInfo"}}, "text": "CENC ORA, INC.\n", "start_char_idx": 478, "end_char_idx": 493, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "529ceb12-632b-4b43-9ee8-caddc677a932": {"__data__": {"id_": "529ceb12-632b-4b43-9ee8-caddc677a932", "embedding": null, "metadata": {"window": "Operating expenses \u00a02.50% \u00a02.23%\nOperating income \u00a00.74% \u00a01.21%\n______________________________________\n1Includes tax expense relating to S wiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nthe latter of which is recorded within Other (Income) Loss, Net.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n\u00a0\n CENC ORA, INC.\n GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30, 2023 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Loss \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto \n Cencora \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$8,959,493 \u00a0\u00a0$6,618,762 \u00a0\u00a0$2,340,731 \u00a0\u00a0$2,160,836 \u00a0\u00a0$428,260 \u00a0\u00a0$12,717 \u00a0\u00a0$1,745,293 \u00a0\u00a0$8.53 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(239,092 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(239,092 )\u00a0\u00a0(239,092 )\u00a0\u00a0(55,894 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(183,198 )\u00a0\u00a0(0.90 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a0204,595 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0204,595 \u00a0\u00a0\u00a0204,595 \u00a0\u00a0\u00a047,830 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0156,765 \u00a0\u00a0\u00a00.77 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\nifli\n15", "original_text": "GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30, 2023 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Loss \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto \n Cencora \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$8,959,493 \u00a0\u00a0$6,618,762 \u00a0\u00a0$2,340,731 \u00a0\u00a0$2,160,836 \u00a0\u00a0$428,260 \u00a0\u00a0$12,717 \u00a0\u00a0$1,745,293 \u00a0\u00a0$8.53 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(239,092 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(239,092 )\u00a0\u00a0(239,092 )\u00a0\u00a0(55,894 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(183,198 )\u00a0\u00a0(0.90 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a0204,595 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0204,595 \u00a0\u00a0\u00a0204,595 \u00a0\u00a0\u00a047,830 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0156,765 \u00a0\u00a0\u00a00.77 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\nifli\n15", "page_label": "15", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9785e97e-c48b-4791-bd32-a25b463008af", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5d5946375e4ba4ac94f9ef47768bcd9acc01ff5dc8bebc365239e1c497ff2850", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "90eafdd0-d4cf-409e-b270-6ca4a53dcd1d", "node_type": "1", "metadata": {"window": "Operating expenses \u00a02.50% \u00a02.23%\nOperating income \u00a00.74% \u00a01.21%\n______________________________________\n1Includes tax expense relating to S wiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nthe latter of which is recorded within Other (Income) Loss, Net.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n\u00a0\n CENC ORA, INC.\n GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30, 2023 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Loss \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto \n Cencora \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$8,959,493 \u00a0\u00a0$6,618,762 \u00a0\u00a0$2,340,731 \u00a0\u00a0$2,160,836 \u00a0\u00a0$428,260 \u00a0\u00a0$12,717 \u00a0\u00a0$1,745,293 \u00a0\u00a0$8.53 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(239,092 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(239,092 )\u00a0\u00a0(239,092 )\u00a0\u00a0(55,894 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(183,198 )\u00a0\u00a0(0.90 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a0204,595 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0204,595 \u00a0\u00a0\u00a0204,595 \u00a0\u00a0\u00a047,830 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0156,765 \u00a0\u00a0\u00a00.77 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\nifli\n15", "original_text": "CENC ORA, INC.\n", "page_label": "15", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "992c9c1584b04c4ecc44b9cfb18cf90a6a9e56933513863fa08a9ed337b222fa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8bcbfe9a-5c0f-42a3-ace5-a66d8d8b31fe", "node_type": "1", "metadata": {"window": "inflationary\nimpact \u00a0\u00a086,967 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a086,967 \u00a0\u00a0\u00a095,938 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a095,938 \u00a0\u00a0\u00a00.47 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(551,046 )\u00a0\u00a0551,046 \u00a0\u00a0\u00a0551,046 \u00a0\u00a0\u00a0128,823 \u00a0\u00a0\u00a0(4,079 )\u00a0\u00a0418,144 \u00a0\u00a0\u00a02.04 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation\nand opioid-\nrelated\ncredit, net 1\u00a0\u00a0\u2014 \u00a0\u00a0\u00a024,693 \u00a0\u00a0\u00a0(24,693 )\u00a0\u00a0(24,693 )\u00a0\u00a013,717 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(38,410 )\u00a0\u00a0(0.19 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated deal\nand\nintegration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(139,683 )\u00a0\u00a0139,683 \u00a0\u00a0\u00a0139,683 \u00a0\u00a0\u00a032,655 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0107,028 \u00a0\u00a0\u00a00.52 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring\nand other\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(229,884 )\u00a0\u00a0229,884 \u00a0\u00a0\u00a0229,884 \u00a0\u00a0\u00a053,742 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0176,142 \u00a0\u00a0\u00a00.86 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on\ndivestiture of\nnon-core\nbusinesses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(40,665 )\u00a0\u00a01,035 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(41,700 )\u00a0\u00a0(0.20 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nOther, net \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(5,501 )\u00a0\u00a0781 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(6,282 )\u00a0\u00a0(0.03 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 2\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(6,638 )\u00a0\u00a0(29,287 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a022,649 \u00a0\u00a0\u00a00.11 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$9,011,963 \u00a0\u00a0$5,722,842 \u00a0\u00a0$3,289,121 \u00a0\u00a0$3,065,393 \u00a0\u00a0$621,662 \u00a0\u00a0$8,638 \u00a0\u00a0$2,452,369 \u00a0\u00a0$11.99 \u00a03\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP %\nchange vs.\n prior year \u00a0\u00a07.3 %\u00a0\u00a09.2 %\u00a0\u00a04.0 %\u00a0\u00a04.1 %\u00a0\u00a02.5 %\u00a0\u00a0 \u00a0\u00a05.3 %\u00a0\u00a08.7 %\u00a0\n16", "original_text": "inflationary\nimpact \u00a0\u00a086,967 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a086,967 \u00a0\u00a0\u00a095,938 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a095,938 \u00a0\u00a0\u00a00.47 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(551,046 )\u00a0\u00a0551,046 \u00a0\u00a0\u00a0551,046 \u00a0\u00a0\u00a0128,823 \u00a0\u00a0\u00a0(4,079 )\u00a0\u00a0418,144 \u00a0\u00a0\u00a02.04 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation\nand opioid-\nrelated\ncredit, net 1\u00a0\u00a0\u2014 \u00a0\u00a0\u00a024,693 \u00a0\u00a0\u00a0(24,693 )\u00a0\u00a0(24,693 )\u00a0\u00a013,717 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(38,410 )\u00a0\u00a0(0.19 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated deal\nand\nintegration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(139,683 )\u00a0\u00a0139,683 \u00a0\u00a0\u00a0139,683 \u00a0\u00a0\u00a032,655 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0107,028 \u00a0\u00a0\u00a00.52 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring\nand other\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(229,884 )\u00a0\u00a0229,884 \u00a0\u00a0\u00a0229,884 \u00a0\u00a0\u00a053,742 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0176,142 \u00a0\u00a0\u00a00.86 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on\ndivestiture of\nnon-core\nbusinesses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(40,665 )\u00a0\u00a01,035 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(41,700 )\u00a0\u00a0(0.20 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nOther, net \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(5,501 )\u00a0\u00a0781 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(6,282 )\u00a0\u00a0(0.03 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 2\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(6,638 )\u00a0\u00a0(29,287 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a022,649 \u00a0\u00a0\u00a00.11 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$9,011,963 \u00a0\u00a0$5,722,842 \u00a0\u00a0$3,289,121 \u00a0\u00a0$3,065,393 \u00a0\u00a0$621,662 \u00a0\u00a0$8,638 \u00a0\u00a0$2,452,369 \u00a0\u00a0$11.99 \u00a03\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP %\nchange vs.\n"}, "hash": "60fb559a032bbd8cde9081086f864604fdbc9396d32c0c8382ebedbb529d27b8", "class_name": "RelatedNodeInfo"}}, "text": "GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30, 2023 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Loss \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto \n Cencora \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$8,959,493 \u00a0\u00a0$6,618,762 \u00a0\u00a0$2,340,731 \u00a0\u00a0$2,160,836 \u00a0\u00a0$428,260 \u00a0\u00a0$12,717 \u00a0\u00a0$1,745,293 \u00a0\u00a0$8.53 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(239,092 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(239,092 )\u00a0\u00a0(239,092 )\u00a0\u00a0(55,894 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(183,198 )\u00a0\u00a0(0.90 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a0204,595 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0204,595 \u00a0\u00a0\u00a0204,595 \u00a0\u00a0\u00a047,830 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0156,765 \u00a0\u00a0\u00a00.77 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\nifli\n15", "start_char_idx": 493, "end_char_idx": 1279, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8bcbfe9a-5c0f-42a3-ace5-a66d8d8b31fe": {"__data__": {"id_": "8bcbfe9a-5c0f-42a3-ace5-a66d8d8b31fe", "embedding": null, "metadata": {"window": "inflationary\nimpact \u00a0\u00a086,967 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a086,967 \u00a0\u00a0\u00a095,938 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a095,938 \u00a0\u00a0\u00a00.47 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(551,046 )\u00a0\u00a0551,046 \u00a0\u00a0\u00a0551,046 \u00a0\u00a0\u00a0128,823 \u00a0\u00a0\u00a0(4,079 )\u00a0\u00a0418,144 \u00a0\u00a0\u00a02.04 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation\nand opioid-\nrelated\ncredit, net 1\u00a0\u00a0\u2014 \u00a0\u00a0\u00a024,693 \u00a0\u00a0\u00a0(24,693 )\u00a0\u00a0(24,693 )\u00a0\u00a013,717 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(38,410 )\u00a0\u00a0(0.19 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated deal\nand\nintegration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(139,683 )\u00a0\u00a0139,683 \u00a0\u00a0\u00a0139,683 \u00a0\u00a0\u00a032,655 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0107,028 \u00a0\u00a0\u00a00.52 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring\nand other\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(229,884 )\u00a0\u00a0229,884 \u00a0\u00a0\u00a0229,884 \u00a0\u00a0\u00a053,742 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0176,142 \u00a0\u00a0\u00a00.86 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on\ndivestiture of\nnon-core\nbusinesses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(40,665 )\u00a0\u00a01,035 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(41,700 )\u00a0\u00a0(0.20 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nOther, net \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(5,501 )\u00a0\u00a0781 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(6,282 )\u00a0\u00a0(0.03 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 2\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(6,638 )\u00a0\u00a0(29,287 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a022,649 \u00a0\u00a0\u00a00.11 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$9,011,963 \u00a0\u00a0$5,722,842 \u00a0\u00a0$3,289,121 \u00a0\u00a0$3,065,393 \u00a0\u00a0$621,662 \u00a0\u00a0$8,638 \u00a0\u00a0$2,452,369 \u00a0\u00a0$11.99 \u00a03\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP %\nchange vs.\n prior year \u00a0\u00a07.3 %\u00a0\u00a09.2 %\u00a0\u00a04.0 %\u00a0\u00a04.1 %\u00a0\u00a02.5 %\u00a0\u00a0 \u00a0\u00a05.3 %\u00a0\u00a08.7 %\u00a0\n16", "original_text": "inflationary\nimpact \u00a0\u00a086,967 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a086,967 \u00a0\u00a0\u00a095,938 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a095,938 \u00a0\u00a0\u00a00.47 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(551,046 )\u00a0\u00a0551,046 \u00a0\u00a0\u00a0551,046 \u00a0\u00a0\u00a0128,823 \u00a0\u00a0\u00a0(4,079 )\u00a0\u00a0418,144 \u00a0\u00a0\u00a02.04 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation\nand opioid-\nrelated\ncredit, net 1\u00a0\u00a0\u2014 \u00a0\u00a0\u00a024,693 \u00a0\u00a0\u00a0(24,693 )\u00a0\u00a0(24,693 )\u00a0\u00a013,717 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(38,410 )\u00a0\u00a0(0.19 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated deal\nand\nintegration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(139,683 )\u00a0\u00a0139,683 \u00a0\u00a0\u00a0139,683 \u00a0\u00a0\u00a032,655 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0107,028 \u00a0\u00a0\u00a00.52 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring\nand other\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(229,884 )\u00a0\u00a0229,884 \u00a0\u00a0\u00a0229,884 \u00a0\u00a0\u00a053,742 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0176,142 \u00a0\u00a0\u00a00.86 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on\ndivestiture of\nnon-core\nbusinesses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(40,665 )\u00a0\u00a01,035 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(41,700 )\u00a0\u00a0(0.20 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nOther, net \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(5,501 )\u00a0\u00a0781 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(6,282 )\u00a0\u00a0(0.03 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 2\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(6,638 )\u00a0\u00a0(29,287 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a022,649 \u00a0\u00a0\u00a00.11 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$9,011,963 \u00a0\u00a0$5,722,842 \u00a0\u00a0$3,289,121 \u00a0\u00a0$3,065,393 \u00a0\u00a0$621,662 \u00a0\u00a0$8,638 \u00a0\u00a0$2,452,369 \u00a0\u00a0$11.99 \u00a03\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP %\nchange vs.\n", "page_label": "16", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "098da69f-b690-4ed8-8161-c74e17402e46", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0143eacc2a32c3ebc0e0e25536e7069eed9e8affbfdf622df89adfdc68ad7206", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "529ceb12-632b-4b43-9ee8-caddc677a932", "node_type": "1", "metadata": {"window": "Operating expenses \u00a02.50% \u00a02.23%\nOperating income \u00a00.74% \u00a01.21%\n______________________________________\n1Includes tax expense relating to S wiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nthe latter of which is recorded within Other (Income) Loss, Net.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n\u00a0\n CENC ORA, INC.\n GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30, 2023 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Loss \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto \n Cencora \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$8,959,493 \u00a0\u00a0$6,618,762 \u00a0\u00a0$2,340,731 \u00a0\u00a0$2,160,836 \u00a0\u00a0$428,260 \u00a0\u00a0$12,717 \u00a0\u00a0$1,745,293 \u00a0\u00a0$8.53 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(239,092 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(239,092 )\u00a0\u00a0(239,092 )\u00a0\u00a0(55,894 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(183,198 )\u00a0\u00a0(0.90 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a0204,595 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0204,595 \u00a0\u00a0\u00a0204,595 \u00a0\u00a0\u00a047,830 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0156,765 \u00a0\u00a0\u00a00.77 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\nifli\n15", "original_text": "GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30, 2023 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Loss \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto \n Cencora \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$8,959,493 \u00a0\u00a0$6,618,762 \u00a0\u00a0$2,340,731 \u00a0\u00a0$2,160,836 \u00a0\u00a0$428,260 \u00a0\u00a0$12,717 \u00a0\u00a0$1,745,293 \u00a0\u00a0$8.53 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(239,092 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(239,092 )\u00a0\u00a0(239,092 )\u00a0\u00a0(55,894 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(183,198 )\u00a0\u00a0(0.90 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a0204,595 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0204,595 \u00a0\u00a0\u00a0204,595 \u00a0\u00a0\u00a047,830 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0156,765 \u00a0\u00a0\u00a00.77 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\nifli\n15", "page_label": "15", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "51f2e83f5a35511d63163c60677b26fa3780319399cb4a69aa78c43aaf558ac8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1c776028-7dd6-4b00-87c0-4ef41edf3bfa", "node_type": "1", "metadata": {"window": "inflationary\nimpact \u00a0\u00a086,967 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a086,967 \u00a0\u00a0\u00a095,938 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a095,938 \u00a0\u00a0\u00a00.47 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(551,046 )\u00a0\u00a0551,046 \u00a0\u00a0\u00a0551,046 \u00a0\u00a0\u00a0128,823 \u00a0\u00a0\u00a0(4,079 )\u00a0\u00a0418,144 \u00a0\u00a0\u00a02.04 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation\nand opioid-\nrelated\ncredit, net 1\u00a0\u00a0\u2014 \u00a0\u00a0\u00a024,693 \u00a0\u00a0\u00a0(24,693 )\u00a0\u00a0(24,693 )\u00a0\u00a013,717 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(38,410 )\u00a0\u00a0(0.19 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated deal\nand\nintegration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(139,683 )\u00a0\u00a0139,683 \u00a0\u00a0\u00a0139,683 \u00a0\u00a0\u00a032,655 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0107,028 \u00a0\u00a0\u00a00.52 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring\nand other\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(229,884 )\u00a0\u00a0229,884 \u00a0\u00a0\u00a0229,884 \u00a0\u00a0\u00a053,742 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0176,142 \u00a0\u00a0\u00a00.86 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on\ndivestiture of\nnon-core\nbusinesses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(40,665 )\u00a0\u00a01,035 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(41,700 )\u00a0\u00a0(0.20 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nOther, net \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(5,501 )\u00a0\u00a0781 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(6,282 )\u00a0\u00a0(0.03 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 2\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(6,638 )\u00a0\u00a0(29,287 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a022,649 \u00a0\u00a0\u00a00.11 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$9,011,963 \u00a0\u00a0$5,722,842 \u00a0\u00a0$3,289,121 \u00a0\u00a0$3,065,393 \u00a0\u00a0$621,662 \u00a0\u00a0$8,638 \u00a0\u00a0$2,452,369 \u00a0\u00a0$11.99 \u00a03\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP %\nchange vs.\n prior year \u00a0\u00a07.3 %\u00a0\u00a09.2 %\u00a0\u00a04.0 %\u00a0\u00a04.1 %\u00a0\u00a02.5 %\u00a0\u00a0 \u00a0\u00a05.3 %\u00a0\u00a08.7 %\u00a0\n16", "original_text": "prior year \u00a0\u00a07.3 %\u00a0\u00a09.2 %\u00a0\u00a04.0 %\u00a0\u00a04.1 %\u00a0\u00a02.5 %\u00a0\u00a0 \u00a0\u00a05.3 %\u00a0\u00a08.7 %\u00a0\n16"}, "hash": "84eaed48a6a78c3a800b71a9a98ffbd4801a06ef3f63ab42a72d200ef62808d8", "class_name": "RelatedNodeInfo"}}, "text": "inflationary\nimpact \u00a0\u00a086,967 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a086,967 \u00a0\u00a0\u00a095,938 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a095,938 \u00a0\u00a0\u00a00.47 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(551,046 )\u00a0\u00a0551,046 \u00a0\u00a0\u00a0551,046 \u00a0\u00a0\u00a0128,823 \u00a0\u00a0\u00a0(4,079 )\u00a0\u00a0418,144 \u00a0\u00a0\u00a02.04 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation\nand opioid-\nrelated\ncredit, net 1\u00a0\u00a0\u2014 \u00a0\u00a0\u00a024,693 \u00a0\u00a0\u00a0(24,693 )\u00a0\u00a0(24,693 )\u00a0\u00a013,717 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(38,410 )\u00a0\u00a0(0.19 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated deal\nand\nintegration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(139,683 )\u00a0\u00a0139,683 \u00a0\u00a0\u00a0139,683 \u00a0\u00a0\u00a032,655 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0107,028 \u00a0\u00a0\u00a00.52 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring\nand other\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(229,884 )\u00a0\u00a0229,884 \u00a0\u00a0\u00a0229,884 \u00a0\u00a0\u00a053,742 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0176,142 \u00a0\u00a0\u00a00.86 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on\ndivestiture of\nnon-core\nbusinesses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(40,665 )\u00a0\u00a01,035 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(41,700 )\u00a0\u00a0(0.20 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nOther, net \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(5,501 )\u00a0\u00a0781 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(6,282 )\u00a0\u00a0(0.03 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 2\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(6,638 )\u00a0\u00a0(29,287 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a022,649 \u00a0\u00a0\u00a00.11 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$9,011,963 \u00a0\u00a0$5,722,842 \u00a0\u00a0$3,289,121 \u00a0\u00a0$3,065,393 \u00a0\u00a0$621,662 \u00a0\u00a0$8,638 \u00a0\u00a0$2,452,369 \u00a0\u00a0$11.99 \u00a03\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP %\nchange vs.\n", "start_char_idx": 0, "end_char_idx": 1208, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1c776028-7dd6-4b00-87c0-4ef41edf3bfa": {"__data__": {"id_": "1c776028-7dd6-4b00-87c0-4ef41edf3bfa", "embedding": null, "metadata": {"window": "inflationary\nimpact \u00a0\u00a086,967 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a086,967 \u00a0\u00a0\u00a095,938 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a095,938 \u00a0\u00a0\u00a00.47 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(551,046 )\u00a0\u00a0551,046 \u00a0\u00a0\u00a0551,046 \u00a0\u00a0\u00a0128,823 \u00a0\u00a0\u00a0(4,079 )\u00a0\u00a0418,144 \u00a0\u00a0\u00a02.04 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation\nand opioid-\nrelated\ncredit, net 1\u00a0\u00a0\u2014 \u00a0\u00a0\u00a024,693 \u00a0\u00a0\u00a0(24,693 )\u00a0\u00a0(24,693 )\u00a0\u00a013,717 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(38,410 )\u00a0\u00a0(0.19 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated deal\nand\nintegration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(139,683 )\u00a0\u00a0139,683 \u00a0\u00a0\u00a0139,683 \u00a0\u00a0\u00a032,655 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0107,028 \u00a0\u00a0\u00a00.52 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring\nand other\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(229,884 )\u00a0\u00a0229,884 \u00a0\u00a0\u00a0229,884 \u00a0\u00a0\u00a053,742 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0176,142 \u00a0\u00a0\u00a00.86 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on\ndivestiture of\nnon-core\nbusinesses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(40,665 )\u00a0\u00a01,035 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(41,700 )\u00a0\u00a0(0.20 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nOther, net \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(5,501 )\u00a0\u00a0781 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(6,282 )\u00a0\u00a0(0.03 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 2\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(6,638 )\u00a0\u00a0(29,287 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a022,649 \u00a0\u00a0\u00a00.11 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$9,011,963 \u00a0\u00a0$5,722,842 \u00a0\u00a0$3,289,121 \u00a0\u00a0$3,065,393 \u00a0\u00a0$621,662 \u00a0\u00a0$8,638 \u00a0\u00a0$2,452,369 \u00a0\u00a0$11.99 \u00a03\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP %\nchange vs.\n prior year \u00a0\u00a07.3 %\u00a0\u00a09.2 %\u00a0\u00a04.0 %\u00a0\u00a04.1 %\u00a0\u00a02.5 %\u00a0\u00a0 \u00a0\u00a05.3 %\u00a0\u00a08.7 %\u00a0\n16", "original_text": "prior year \u00a0\u00a07.3 %\u00a0\u00a09.2 %\u00a0\u00a04.0 %\u00a0\u00a04.1 %\u00a0\u00a02.5 %\u00a0\u00a0 \u00a0\u00a05.3 %\u00a0\u00a08.7 %\u00a0\n16", "page_label": "16", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "098da69f-b690-4ed8-8161-c74e17402e46", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0143eacc2a32c3ebc0e0e25536e7069eed9e8affbfdf622df89adfdc68ad7206", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8bcbfe9a-5c0f-42a3-ace5-a66d8d8b31fe", "node_type": "1", "metadata": {"window": "inflationary\nimpact \u00a0\u00a086,967 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a086,967 \u00a0\u00a0\u00a095,938 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a095,938 \u00a0\u00a0\u00a00.47 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(551,046 )\u00a0\u00a0551,046 \u00a0\u00a0\u00a0551,046 \u00a0\u00a0\u00a0128,823 \u00a0\u00a0\u00a0(4,079 )\u00a0\u00a0418,144 \u00a0\u00a0\u00a02.04 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation\nand opioid-\nrelated\ncredit, net 1\u00a0\u00a0\u2014 \u00a0\u00a0\u00a024,693 \u00a0\u00a0\u00a0(24,693 )\u00a0\u00a0(24,693 )\u00a0\u00a013,717 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(38,410 )\u00a0\u00a0(0.19 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated deal\nand\nintegration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(139,683 )\u00a0\u00a0139,683 \u00a0\u00a0\u00a0139,683 \u00a0\u00a0\u00a032,655 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0107,028 \u00a0\u00a0\u00a00.52 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring\nand other\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(229,884 )\u00a0\u00a0229,884 \u00a0\u00a0\u00a0229,884 \u00a0\u00a0\u00a053,742 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0176,142 \u00a0\u00a0\u00a00.86 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on\ndivestiture of\nnon-core\nbusinesses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(40,665 )\u00a0\u00a01,035 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(41,700 )\u00a0\u00a0(0.20 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nOther, net \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(5,501 )\u00a0\u00a0781 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(6,282 )\u00a0\u00a0(0.03 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 2\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(6,638 )\u00a0\u00a0(29,287 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a022,649 \u00a0\u00a0\u00a00.11 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$9,011,963 \u00a0\u00a0$5,722,842 \u00a0\u00a0$3,289,121 \u00a0\u00a0$3,065,393 \u00a0\u00a0$621,662 \u00a0\u00a0$8,638 \u00a0\u00a0$2,452,369 \u00a0\u00a0$11.99 \u00a03\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP %\nchange vs.\n prior year \u00a0\u00a07.3 %\u00a0\u00a09.2 %\u00a0\u00a04.0 %\u00a0\u00a04.1 %\u00a0\u00a02.5 %\u00a0\u00a0 \u00a0\u00a05.3 %\u00a0\u00a08.7 %\u00a0\n16", "original_text": "inflationary\nimpact \u00a0\u00a086,967 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a086,967 \u00a0\u00a0\u00a095,938 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a095,938 \u00a0\u00a0\u00a00.47 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(551,046 )\u00a0\u00a0551,046 \u00a0\u00a0\u00a0551,046 \u00a0\u00a0\u00a0128,823 \u00a0\u00a0\u00a0(4,079 )\u00a0\u00a0418,144 \u00a0\u00a0\u00a02.04 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation\nand opioid-\nrelated\ncredit, net 1\u00a0\u00a0\u2014 \u00a0\u00a0\u00a024,693 \u00a0\u00a0\u00a0(24,693 )\u00a0\u00a0(24,693 )\u00a0\u00a013,717 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(38,410 )\u00a0\u00a0(0.19 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated deal\nand\nintegration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(139,683 )\u00a0\u00a0139,683 \u00a0\u00a0\u00a0139,683 \u00a0\u00a0\u00a032,655 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0107,028 \u00a0\u00a0\u00a00.52 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring\nand other\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(229,884 )\u00a0\u00a0229,884 \u00a0\u00a0\u00a0229,884 \u00a0\u00a0\u00a053,742 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0176,142 \u00a0\u00a0\u00a00.86 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on\ndivestiture of\nnon-core\nbusinesses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(40,665 )\u00a0\u00a01,035 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(41,700 )\u00a0\u00a0(0.20 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nOther, net \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(5,501 )\u00a0\u00a0781 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(6,282 )\u00a0\u00a0(0.03 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 2\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(6,638 )\u00a0\u00a0(29,287 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a022,649 \u00a0\u00a0\u00a00.11 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$9,011,963 \u00a0\u00a0$5,722,842 \u00a0\u00a0$3,289,121 \u00a0\u00a0$3,065,393 \u00a0\u00a0$621,662 \u00a0\u00a0$8,638 \u00a0\u00a0$2,452,369 \u00a0\u00a0$11.99 \u00a03\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP %\nchange vs.\n", "page_label": "16", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c8f9033a44f20c177c699a5ff8c032d538f77c70a68a1a38738edf239b6ea7f7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6a2cca4c-4d9a-4e19-a2c1-3ddac456ad55", "node_type": "1", "metadata": {"window": "Percentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.42% \u00a03.44%\nOperating expenses \u00a02.52% \u00a02.18%\nOperating income \u00a00.89% \u00a01.25%\n________________________________________\n1Includes the receipt of $83.4 million from the H.D.  Smith opioid litigation indemnity escrow.\n\u00a0\n 2Tax expense relating to 2020 S wiss tax reform and a gain on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Income, Net.\n\u00a0\n 3The sum of the components does not equal the total due to rounding.\n\u00a0\n", "original_text": "Percentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.42% \u00a03.44%\nOperating expenses \u00a02.52% \u00a02.18%\nOperating income \u00a00.89% \u00a01.25%\n________________________________________\n1Includes the receipt of $83.4 million from the H.D. "}, "hash": "bb7cf73515572b2b012818bee23e0a035cbc93fc31ecde90d728896ca6a9d21c", "class_name": "RelatedNodeInfo"}}, "text": "prior year \u00a0\u00a07.3 %\u00a0\u00a09.2 %\u00a0\u00a04.0 %\u00a0\u00a04.1 %\u00a0\u00a02.5 %\u00a0\u00a0 \u00a0\u00a05.3 %\u00a0\u00a08.7 %\u00a0\n16", "start_char_idx": 1208, "end_char_idx": 1275, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6a2cca4c-4d9a-4e19-a2c1-3ddac456ad55": {"__data__": {"id_": "6a2cca4c-4d9a-4e19-a2c1-3ddac456ad55", "embedding": null, "metadata": {"window": "Percentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.42% \u00a03.44%\nOperating expenses \u00a02.52% \u00a02.18%\nOperating income \u00a00.89% \u00a01.25%\n________________________________________\n1Includes the receipt of $83.4 million from the H.D.  Smith opioid litigation indemnity escrow.\n\u00a0\n 2Tax expense relating to 2020 S wiss tax reform and a gain on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Income, Net.\n\u00a0\n 3The sum of the components does not equal the total due to rounding.\n\u00a0\n", "original_text": "Percentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.42% \u00a03.44%\nOperating expenses \u00a02.52% \u00a02.18%\nOperating income \u00a00.89% \u00a01.25%\n________________________________________\n1Includes the receipt of $83.4 million from the H.D. ", "page_label": "17", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ca2098f-d703-48bf-aaf4-056d3a914929", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2a441578acdef52fa5afa738f62c65b7efaba4044c84bd23e783675cd513bb61", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1c776028-7dd6-4b00-87c0-4ef41edf3bfa", "node_type": "1", "metadata": {"window": "inflationary\nimpact \u00a0\u00a086,967 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a086,967 \u00a0\u00a0\u00a095,938 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a095,938 \u00a0\u00a0\u00a00.47 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(551,046 )\u00a0\u00a0551,046 \u00a0\u00a0\u00a0551,046 \u00a0\u00a0\u00a0128,823 \u00a0\u00a0\u00a0(4,079 )\u00a0\u00a0418,144 \u00a0\u00a0\u00a02.04 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation\nand opioid-\nrelated\ncredit, net 1\u00a0\u00a0\u2014 \u00a0\u00a0\u00a024,693 \u00a0\u00a0\u00a0(24,693 )\u00a0\u00a0(24,693 )\u00a0\u00a013,717 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(38,410 )\u00a0\u00a0(0.19 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated deal\nand\nintegration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(139,683 )\u00a0\u00a0139,683 \u00a0\u00a0\u00a0139,683 \u00a0\u00a0\u00a032,655 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0107,028 \u00a0\u00a0\u00a00.52 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring\nand other\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(229,884 )\u00a0\u00a0229,884 \u00a0\u00a0\u00a0229,884 \u00a0\u00a0\u00a053,742 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0176,142 \u00a0\u00a0\u00a00.86 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on\ndivestiture of\nnon-core\nbusinesses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(40,665 )\u00a0\u00a01,035 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(41,700 )\u00a0\u00a0(0.20 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nOther, net \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(5,501 )\u00a0\u00a0781 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(6,282 )\u00a0\u00a0(0.03 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 2\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(6,638 )\u00a0\u00a0(29,287 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a022,649 \u00a0\u00a0\u00a00.11 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$9,011,963 \u00a0\u00a0$5,722,842 \u00a0\u00a0$3,289,121 \u00a0\u00a0$3,065,393 \u00a0\u00a0$621,662 \u00a0\u00a0$8,638 \u00a0\u00a0$2,452,369 \u00a0\u00a0$11.99 \u00a03\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP %\nchange vs.\n prior year \u00a0\u00a07.3 %\u00a0\u00a09.2 %\u00a0\u00a04.0 %\u00a0\u00a04.1 %\u00a0\u00a02.5 %\u00a0\u00a0 \u00a0\u00a05.3 %\u00a0\u00a08.7 %\u00a0\n16", "original_text": "prior year \u00a0\u00a07.3 %\u00a0\u00a09.2 %\u00a0\u00a04.0 %\u00a0\u00a04.1 %\u00a0\u00a02.5 %\u00a0\u00a0 \u00a0\u00a05.3 %\u00a0\u00a08.7 %\u00a0\n16", "page_label": "16", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e2a736e6d5941e0a22fffb15af8f7440d246c7fd7f8c2822ffc26333f9cace40", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0660e4f9-0bc2-46eb-bd18-c9ed8939a477", "node_type": "1", "metadata": {"window": "Percentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.42% \u00a03.44%\nOperating expenses \u00a02.52% \u00a02.18%\nOperating income \u00a00.89% \u00a01.25%\n________________________________________\n1Includes the receipt of $83.4 million from the H.D.  Smith opioid litigation indemnity escrow.\n\u00a0\n 2Tax expense relating to 2020 S wiss tax reform and a gain on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Income, Net.\n\u00a0\n 3The sum of the components does not equal the total due to rounding.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n\u00a0\n", "original_text": "Smith opioid litigation indemnity escrow.\n\u00a0\n"}, "hash": "c0f2ecae03027f52f761fd79c38c27c1ec7337d7af6fbaa3d6b25b77eb5293fe", "class_name": "RelatedNodeInfo"}}, "text": "Percentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.42% \u00a03.44%\nOperating expenses \u00a02.52% \u00a02.18%\nOperating income \u00a00.89% \u00a01.25%\n________________________________________\n1Includes the receipt of $83.4 million from the H.D. ", "start_char_idx": 0, "end_char_idx": 238, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0660e4f9-0bc2-46eb-bd18-c9ed8939a477": {"__data__": {"id_": "0660e4f9-0bc2-46eb-bd18-c9ed8939a477", "embedding": null, "metadata": {"window": "Percentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.42% \u00a03.44%\nOperating expenses \u00a02.52% \u00a02.18%\nOperating income \u00a00.89% \u00a01.25%\n________________________________________\n1Includes the receipt of $83.4 million from the H.D.  Smith opioid litigation indemnity escrow.\n\u00a0\n 2Tax expense relating to 2020 S wiss tax reform and a gain on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Income, Net.\n\u00a0\n 3The sum of the components does not equal the total due to rounding.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n\u00a0\n", "original_text": "Smith opioid litigation indemnity escrow.\n\u00a0\n", "page_label": "17", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ca2098f-d703-48bf-aaf4-056d3a914929", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2a441578acdef52fa5afa738f62c65b7efaba4044c84bd23e783675cd513bb61", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6a2cca4c-4d9a-4e19-a2c1-3ddac456ad55", "node_type": "1", "metadata": {"window": "Percentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.42% \u00a03.44%\nOperating expenses \u00a02.52% \u00a02.18%\nOperating income \u00a00.89% \u00a01.25%\n________________________________________\n1Includes the receipt of $83.4 million from the H.D.  Smith opioid litigation indemnity escrow.\n\u00a0\n 2Tax expense relating to 2020 S wiss tax reform and a gain on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Income, Net.\n\u00a0\n 3The sum of the components does not equal the total due to rounding.\n\u00a0\n", "original_text": "Percentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.42% \u00a03.44%\nOperating expenses \u00a02.52% \u00a02.18%\nOperating income \u00a00.89% \u00a01.25%\n________________________________________\n1Includes the receipt of $83.4 million from the H.D. ", "page_label": "17", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c0336b9f2b589dbd096ae4fd6c24597d8fef1acdc70bc096bc5a5cdc24460bd5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "12cf498e-a392-4a89-a9cf-f193bd09439b", "node_type": "1", "metadata": {"window": "Percentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.42% \u00a03.44%\nOperating expenses \u00a02.52% \u00a02.18%\nOperating income \u00a00.89% \u00a01.25%\n________________________________________\n1Includes the receipt of $83.4 million from the H.D.  Smith opioid litigation indemnity escrow.\n\u00a0\n 2Tax expense relating to 2020 S wiss tax reform and a gain on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Income, Net.\n\u00a0\n 3The sum of the components does not equal the total due to rounding.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n\u00a0\n CENC ORA, INC.\n", "original_text": "2Tax expense relating to 2020 S wiss tax reform and a gain on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Income, Net.\n\u00a0\n"}, "hash": "662baf405ceb1a37193a7ae8f78393ebd72b43ff220bcd8cdaea72736ccd9737", "class_name": "RelatedNodeInfo"}}, "text": "Smith opioid litigation indemnity escrow.\n\u00a0\n", "start_char_idx": 238, "end_char_idx": 282, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "12cf498e-a392-4a89-a9cf-f193bd09439b": {"__data__": {"id_": "12cf498e-a392-4a89-a9cf-f193bd09439b", "embedding": null, "metadata": {"window": "Percentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.42% \u00a03.44%\nOperating expenses \u00a02.52% \u00a02.18%\nOperating income \u00a00.89% \u00a01.25%\n________________________________________\n1Includes the receipt of $83.4 million from the H.D.  Smith opioid litigation indemnity escrow.\n\u00a0\n 2Tax expense relating to 2020 S wiss tax reform and a gain on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Income, Net.\n\u00a0\n 3The sum of the components does not equal the total due to rounding.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n\u00a0\n CENC ORA, INC.\n", "original_text": "2Tax expense relating to 2020 S wiss tax reform and a gain on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Income, Net.\n\u00a0\n", "page_label": "17", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ca2098f-d703-48bf-aaf4-056d3a914929", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2a441578acdef52fa5afa738f62c65b7efaba4044c84bd23e783675cd513bb61", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0660e4f9-0bc2-46eb-bd18-c9ed8939a477", "node_type": "1", "metadata": {"window": "Percentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.42% \u00a03.44%\nOperating expenses \u00a02.52% \u00a02.18%\nOperating income \u00a00.89% \u00a01.25%\n________________________________________\n1Includes the receipt of $83.4 million from the H.D.  Smith opioid litigation indemnity escrow.\n\u00a0\n 2Tax expense relating to 2020 S wiss tax reform and a gain on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Income, Net.\n\u00a0\n 3The sum of the components does not equal the total due to rounding.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n\u00a0\n", "original_text": "Smith opioid litigation indemnity escrow.\n\u00a0\n", "page_label": "17", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "96291ab2f3b56a4f84cfb650e886e9ad26f47df533ad4c029376d0b8549cd16b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6c50def7-f43b-4dd9-95ea-96466c882d59", "node_type": "1", "metadata": {"window": "Percentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.42% \u00a03.44%\nOperating expenses \u00a02.52% \u00a02.18%\nOperating income \u00a00.89% \u00a01.25%\n________________________________________\n1Includes the receipt of $83.4 million from the H.D.  Smith opioid litigation indemnity escrow.\n\u00a0\n 2Tax expense relating to 2020 S wiss tax reform and a gain on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Income, Net.\n\u00a0\n 3The sum of the components does not equal the total due to rounding.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n\u00a0\n CENC ORA, INC.\n GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Loss \n (Income) \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto \n Cencora \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\n17", "original_text": "3The sum of the components does not equal the total due to rounding.\n\u00a0\n"}, "hash": "4cf9560da3f1f9f83eefaf4fe6ad6af62c493f7cfdd11775a6ed766f354e4148", "class_name": "RelatedNodeInfo"}}, "text": "2Tax expense relating to 2020 S wiss tax reform and a gain on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Income, Net.\n\u00a0\n", "start_char_idx": 282, "end_char_idx": 467, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6c50def7-f43b-4dd9-95ea-96466c882d59": {"__data__": {"id_": "6c50def7-f43b-4dd9-95ea-96466c882d59", "embedding": null, "metadata": {"window": "Percentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.42% \u00a03.44%\nOperating expenses \u00a02.52% \u00a02.18%\nOperating income \u00a00.89% \u00a01.25%\n________________________________________\n1Includes the receipt of $83.4 million from the H.D.  Smith opioid litigation indemnity escrow.\n\u00a0\n 2Tax expense relating to 2020 S wiss tax reform and a gain on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Income, Net.\n\u00a0\n 3The sum of the components does not equal the total due to rounding.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n\u00a0\n CENC ORA, INC.\n GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Loss \n (Income) \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto \n Cencora \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\n17", "original_text": "3The sum of the components does not equal the total due to rounding.\n\u00a0\n", "page_label": "17", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ca2098f-d703-48bf-aaf4-056d3a914929", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2a441578acdef52fa5afa738f62c65b7efaba4044c84bd23e783675cd513bb61", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "12cf498e-a392-4a89-a9cf-f193bd09439b", "node_type": "1", "metadata": {"window": "Percentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.42% \u00a03.44%\nOperating expenses \u00a02.52% \u00a02.18%\nOperating income \u00a00.89% \u00a01.25%\n________________________________________\n1Includes the receipt of $83.4 million from the H.D.  Smith opioid litigation indemnity escrow.\n\u00a0\n 2Tax expense relating to 2020 S wiss tax reform and a gain on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Income, Net.\n\u00a0\n 3The sum of the components does not equal the total due to rounding.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n\u00a0\n CENC ORA, INC.\n", "original_text": "2Tax expense relating to 2020 S wiss tax reform and a gain on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Income, Net.\n\u00a0\n", "page_label": "17", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "629808ebbad2fefd47cb4977d991d004e8188205a497a071e5ef3d7452c74acb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e1560151-fc00-46e8-b967-4756bbdebd44", "node_type": "1", "metadata": {"window": "Smith opioid litigation indemnity escrow.\n\u00a0\n 2Tax expense relating to 2020 S wiss tax reform and a gain on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Income, Net.\n\u00a0\n 3The sum of the components does not equal the total due to rounding.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n\u00a0\n CENC ORA, INC.\n GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Loss \n (Income) \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto \n Cencora \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\n17", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n\u00a0\n"}, "hash": "c70cafec439a4c97ef54706da730c48ffe79c92af272d43dad2e6b1dcace10d3", "class_name": "RelatedNodeInfo"}}, "text": "3The sum of the components does not equal the total due to rounding.\n\u00a0\n", "start_char_idx": 467, "end_char_idx": 538, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e1560151-fc00-46e8-b967-4756bbdebd44": {"__data__": {"id_": "e1560151-fc00-46e8-b967-4756bbdebd44", "embedding": null, "metadata": {"window": "Smith opioid litigation indemnity escrow.\n\u00a0\n 2Tax expense relating to 2020 S wiss tax reform and a gain on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Income, Net.\n\u00a0\n 3The sum of the components does not equal the total due to rounding.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n\u00a0\n CENC ORA, INC.\n GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Loss \n (Income) \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto \n Cencora \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\n17", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n\u00a0\n", "page_label": "17", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ca2098f-d703-48bf-aaf4-056d3a914929", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2a441578acdef52fa5afa738f62c65b7efaba4044c84bd23e783675cd513bb61", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6c50def7-f43b-4dd9-95ea-96466c882d59", "node_type": "1", "metadata": {"window": "Percentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.42% \u00a03.44%\nOperating expenses \u00a02.52% \u00a02.18%\nOperating income \u00a00.89% \u00a01.25%\n________________________________________\n1Includes the receipt of $83.4 million from the H.D.  Smith opioid litigation indemnity escrow.\n\u00a0\n 2Tax expense relating to 2020 S wiss tax reform and a gain on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Income, Net.\n\u00a0\n 3The sum of the components does not equal the total due to rounding.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n\u00a0\n CENC ORA, INC.\n GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Loss \n (Income) \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto \n Cencora \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\n17", "original_text": "3The sum of the components does not equal the total due to rounding.\n\u00a0\n", "page_label": "17", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2905fcca889c488a379847bb4380a26c08e8299b8f48d14f62d2b61d418d29f6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6590dd88-2631-443a-b00e-eb2c95f0e522", "node_type": "1", "metadata": {"window": "2Tax expense relating to 2020 S wiss tax reform and a gain on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Income, Net.\n\u00a0\n 3The sum of the components does not equal the total due to rounding.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n\u00a0\n CENC ORA, INC.\n GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Loss \n (Income) \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto \n Cencora \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\n17", "original_text": "CENC ORA, INC.\n"}, "hash": "a2a7732d1df949d3c4dfc72d4a3b5ed9a7f69a0dacc01524b1ff180497b715f7", "class_name": "RelatedNodeInfo"}}, "text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n\u00a0\n", "start_char_idx": 538, "end_char_idx": 717, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6590dd88-2631-443a-b00e-eb2c95f0e522": {"__data__": {"id_": "6590dd88-2631-443a-b00e-eb2c95f0e522", "embedding": null, "metadata": {"window": "2Tax expense relating to 2020 S wiss tax reform and a gain on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Income, Net.\n\u00a0\n 3The sum of the components does not equal the total due to rounding.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n\u00a0\n CENC ORA, INC.\n GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Loss \n (Income) \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto \n Cencora \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\n17", "original_text": "CENC ORA, INC.\n", "page_label": "17", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ca2098f-d703-48bf-aaf4-056d3a914929", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2a441578acdef52fa5afa738f62c65b7efaba4044c84bd23e783675cd513bb61", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e1560151-fc00-46e8-b967-4756bbdebd44", "node_type": "1", "metadata": {"window": "Smith opioid litigation indemnity escrow.\n\u00a0\n 2Tax expense relating to 2020 S wiss tax reform and a gain on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Income, Net.\n\u00a0\n 3The sum of the components does not equal the total due to rounding.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n\u00a0\n CENC ORA, INC.\n GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Loss \n (Income) \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto \n Cencora \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\n17", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n\u00a0\n", "page_label": "17", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "34a346f89fa2efb634a98acbda5bfc2d2f6b34c08008c9da40e1a3d2bf83584e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8ff78fe4-9b70-4405-a1bc-e87aad6e9559", "node_type": "1", "metadata": {"window": "3The sum of the components does not equal the total due to rounding.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n\u00a0\n CENC ORA, INC.\n GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Loss \n (Income) \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto \n Cencora \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\n17", "original_text": "GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Loss \n (Income) \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto \n Cencora \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\n17"}, "hash": "857d21a7f12d7f8b11b81a1f8040e5120b3d680b3fd0b1428a0529e7b8df03f1", "class_name": "RelatedNodeInfo"}}, "text": "CENC ORA, INC.\n", "start_char_idx": 717, "end_char_idx": 732, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8ff78fe4-9b70-4405-a1bc-e87aad6e9559": {"__data__": {"id_": "8ff78fe4-9b70-4405-a1bc-e87aad6e9559", "embedding": null, "metadata": {"window": "3The sum of the components does not equal the total due to rounding.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n\u00a0\n CENC ORA, INC.\n GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Loss \n (Income) \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto \n Cencora \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\n17", "original_text": "GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Loss \n (Income) \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto \n Cencora \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\n17", "page_label": "17", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ca2098f-d703-48bf-aaf4-056d3a914929", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2a441578acdef52fa5afa738f62c65b7efaba4044c84bd23e783675cd513bb61", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6590dd88-2631-443a-b00e-eb2c95f0e522", "node_type": "1", "metadata": {"window": "2Tax expense relating to 2020 S wiss tax reform and a gain on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Income, Net.\n\u00a0\n 3The sum of the components does not equal the total due to rounding.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n\u00a0\n CENC ORA, INC.\n GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Loss \n (Income) \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto \n Cencora \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\n17", "original_text": "CENC ORA, INC.\n", "page_label": "17", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "152b4c0420420aa32935bac0baa113077a1b301e2a59e715ddc711b5ff6b3406", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c60198a0-42db-4b15-bc58-f61fad7aabbc", "node_type": "1", "metadata": {"window": "GAAP \u00a0$8,296,367 \u00a0\u00a0$5,929,989 \u00a0\u00a0$2,366,378 \u00a0\u00a0$2,183,057 \u00a0\u00a0$516,517 \u00a0\u00a0$32,280 \u00a0\u00a0$1,698,820 \u00a0\u00a0$8.04 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust litigation\nsettlements \u00a0\u00a0(1,835 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,835 )\u00a0\u00a0(1,835 )\u00a0\u00a0(408 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,427 )\u00a0\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a067,171 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a067,171 \u00a0\u00a0\u00a067,171 \u00a0\u00a0\u00a014,943 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a052,228 \u00a0\u00a0\u00a00.25 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\ninflationary impact \u00a0\u00a040,033 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a040,033 \u00a0\u00a0\u00a051,966 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a051,966 \u00a0\u00a0\u00a00.25 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(304,551 )\u00a0\u00a0304,551 \u00a0\u00a0\u00a0304,551 \u00a0\u00a0\u00a067,749 \u00a0\u00a0\u00a0(5,219 )\u00a0\u00a0231,583 \u00a0\u00a0\u00a01.10 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(123,191 )\u00a0\u00a0123,191 \u00a0\u00a0\u00a0123,191 \u00a0\u00a0\u00a024,111 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a099,080 \u00a0\u00a0\u00a00.47 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\ndeal and\nintegration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(119,561 )\u00a0\u00a0119,561 \u00a0\u00a0\u00a0119,561 \u00a0\u00a0\u00a023,401 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a096,160 \u00a0\u00a0\u00a00.46 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring and\nother expenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(63,498 )\u00a0\u00a063,498 \u00a0\u00a0\u00a063,498 \u00a0\u00a0\u00a012,428 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a051,070 \u00a0\u00a0\u00a00.24 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on\nremeasurement of\nequity investment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,834 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,834 )\u00a0\u00a0(0.02 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGoodwill\nimpairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(75,936 )\u00a0\u00a075,936 \u00a0\u00a0\u00a075,936 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(47,004 )\u00a0\u00a028,932 \u00a0\u00a0\u00a00.14 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nassets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,946 )\u00a0\u00a04,946 \u00a0\u00a0\u00a04,946 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a04,946 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n18", "original_text": "GAAP \u00a0$8,296,367 \u00a0\u00a0$5,929,989 \u00a0\u00a0$2,366,378 \u00a0\u00a0$2,183,057 \u00a0\u00a0$516,517 \u00a0\u00a0$32,280 \u00a0\u00a0$1,698,820 \u00a0\u00a0$8.04 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust litigation\nsettlements \u00a0\u00a0(1,835 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,835 )\u00a0\u00a0(1,835 )\u00a0\u00a0(408 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,427 )\u00a0\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a067,171 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a067,171 \u00a0\u00a0\u00a067,171 \u00a0\u00a0\u00a014,943 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a052,228 \u00a0\u00a0\u00a00.25 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\ninflationary impact \u00a0\u00a040,033 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a040,033 \u00a0\u00a0\u00a051,966 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a051,966 \u00a0\u00a0\u00a00.25 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(304,551 )\u00a0\u00a0304,551 \u00a0\u00a0\u00a0304,551 \u00a0\u00a0\u00a067,749 \u00a0\u00a0\u00a0(5,219 )\u00a0\u00a0231,583 \u00a0\u00a0\u00a01.10 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(123,191 )\u00a0\u00a0123,191 \u00a0\u00a0\u00a0123,191 \u00a0\u00a0\u00a024,111 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a099,080 \u00a0\u00a0\u00a00.47 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\ndeal and\nintegration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(119,561 )\u00a0\u00a0119,561 \u00a0\u00a0\u00a0119,561 \u00a0\u00a0\u00a023,401 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a096,160 \u00a0\u00a0\u00a00.46 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring and\nother expenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(63,498 )\u00a0\u00a063,498 \u00a0\u00a0\u00a063,498 \u00a0\u00a0\u00a012,428 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a051,070 \u00a0\u00a0\u00a00.24 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on\nremeasurement of\nequity investment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,834 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,834 )\u00a0\u00a0(0.02 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGoodwill\nimpairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(75,936 )\u00a0\u00a075,936 \u00a0\u00a0\u00a075,936 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(47,004 )\u00a0\u00a028,932 \u00a0\u00a0\u00a00.14 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nassets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,946 )\u00a0\u00a04,946 \u00a0\u00a0\u00a04,946 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a04,946 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n18"}, "hash": "b15a9043f7f81ee74389ed0d0fc43d92a6b95a6af67f2a0af5702384e70cd008", "class_name": "RelatedNodeInfo"}}, "text": "GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Loss \n (Income) \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto \n Cencora \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\n17", "start_char_idx": 732, "end_char_idx": 1110, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c60198a0-42db-4b15-bc58-f61fad7aabbc": {"__data__": {"id_": "c60198a0-42db-4b15-bc58-f61fad7aabbc", "embedding": null, "metadata": {"window": "GAAP \u00a0$8,296,367 \u00a0\u00a0$5,929,989 \u00a0\u00a0$2,366,378 \u00a0\u00a0$2,183,057 \u00a0\u00a0$516,517 \u00a0\u00a0$32,280 \u00a0\u00a0$1,698,820 \u00a0\u00a0$8.04 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust litigation\nsettlements \u00a0\u00a0(1,835 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,835 )\u00a0\u00a0(1,835 )\u00a0\u00a0(408 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,427 )\u00a0\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a067,171 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a067,171 \u00a0\u00a0\u00a067,171 \u00a0\u00a0\u00a014,943 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a052,228 \u00a0\u00a0\u00a00.25 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\ninflationary impact \u00a0\u00a040,033 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a040,033 \u00a0\u00a0\u00a051,966 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a051,966 \u00a0\u00a0\u00a00.25 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(304,551 )\u00a0\u00a0304,551 \u00a0\u00a0\u00a0304,551 \u00a0\u00a0\u00a067,749 \u00a0\u00a0\u00a0(5,219 )\u00a0\u00a0231,583 \u00a0\u00a0\u00a01.10 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(123,191 )\u00a0\u00a0123,191 \u00a0\u00a0\u00a0123,191 \u00a0\u00a0\u00a024,111 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a099,080 \u00a0\u00a0\u00a00.47 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\ndeal and\nintegration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(119,561 )\u00a0\u00a0119,561 \u00a0\u00a0\u00a0119,561 \u00a0\u00a0\u00a023,401 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a096,160 \u00a0\u00a0\u00a00.46 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring and\nother expenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(63,498 )\u00a0\u00a063,498 \u00a0\u00a0\u00a063,498 \u00a0\u00a0\u00a012,428 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a051,070 \u00a0\u00a0\u00a00.24 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on\nremeasurement of\nequity investment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,834 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,834 )\u00a0\u00a0(0.02 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGoodwill\nimpairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(75,936 )\u00a0\u00a075,936 \u00a0\u00a0\u00a075,936 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(47,004 )\u00a0\u00a028,932 \u00a0\u00a0\u00a00.14 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nassets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,946 )\u00a0\u00a04,946 \u00a0\u00a0\u00a04,946 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a04,946 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n18", "original_text": "GAAP \u00a0$8,296,367 \u00a0\u00a0$5,929,989 \u00a0\u00a0$2,366,378 \u00a0\u00a0$2,183,057 \u00a0\u00a0$516,517 \u00a0\u00a0$32,280 \u00a0\u00a0$1,698,820 \u00a0\u00a0$8.04 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust litigation\nsettlements \u00a0\u00a0(1,835 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,835 )\u00a0\u00a0(1,835 )\u00a0\u00a0(408 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,427 )\u00a0\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a067,171 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a067,171 \u00a0\u00a0\u00a067,171 \u00a0\u00a0\u00a014,943 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a052,228 \u00a0\u00a0\u00a00.25 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\ninflationary impact \u00a0\u00a040,033 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a040,033 \u00a0\u00a0\u00a051,966 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a051,966 \u00a0\u00a0\u00a00.25 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(304,551 )\u00a0\u00a0304,551 \u00a0\u00a0\u00a0304,551 \u00a0\u00a0\u00a067,749 \u00a0\u00a0\u00a0(5,219 )\u00a0\u00a0231,583 \u00a0\u00a0\u00a01.10 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(123,191 )\u00a0\u00a0123,191 \u00a0\u00a0\u00a0123,191 \u00a0\u00a0\u00a024,111 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a099,080 \u00a0\u00a0\u00a00.47 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\ndeal and\nintegration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(119,561 )\u00a0\u00a0119,561 \u00a0\u00a0\u00a0119,561 \u00a0\u00a0\u00a023,401 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a096,160 \u00a0\u00a0\u00a00.46 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring and\nother expenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(63,498 )\u00a0\u00a063,498 \u00a0\u00a0\u00a063,498 \u00a0\u00a0\u00a012,428 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a051,070 \u00a0\u00a0\u00a00.24 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on\nremeasurement of\nequity investment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,834 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,834 )\u00a0\u00a0(0.02 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGoodwill\nimpairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(75,936 )\u00a0\u00a075,936 \u00a0\u00a0\u00a075,936 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(47,004 )\u00a0\u00a028,932 \u00a0\u00a0\u00a00.14 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nassets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,946 )\u00a0\u00a04,946 \u00a0\u00a0\u00a04,946 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a04,946 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n18", "page_label": "18", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f8f15bb5-391f-4efd-bf98-ba9769c0c274", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f24debad9dbf26e8197a2f26b7c3d2a3fef8c90ed7b8e16ac6826f7c7d433a21", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8ff78fe4-9b70-4405-a1bc-e87aad6e9559", "node_type": "1", "metadata": {"window": "3The sum of the components does not equal the total due to rounding.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n\u00a0\n CENC ORA, INC.\n GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Loss \n (Income) \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto \n Cencora \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\n17", "original_text": "GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Loss \n (Income) \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto \n Cencora \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\n17", "page_label": "17", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4d42328e4185051888d8e2193c3c7d07d799b990e8e4070325bafb2e34cbb0f0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3b4f5756-11a9-4d10-9c4c-56cada2502fa", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on divestiture\nof non-core\nbusinesses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(56,228 )\u00a0\u00a0(10,372 )\u00a0\u00a03,618 \u00a0\u00a0\u00a0(42,238 )\u00a0\u00a0(0.20 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain discrete tax\nbenefits \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(9,677 )\u00a0\u00a06,840 \u00a0\u00a0\u00a016,517 \u00a0\u00a0\u00a00.08 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a014,443 \u00a0\u00a0\u00a0(32,109 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a046,552 \u00a0\u00a0\u00a00.22 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$8,401,736 \u00a0\u00a0$5,238,306 \u00a0\u00a0$3,163,430 \u00a0\u00a0$2,945,423 \u00a0\u00a0$606,583 \u00a0\u00a0$(9,485 )\u00a0$2,329,355 \u00a0\u00a0$11.03 \u00a02\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.48% \u00a03.52%\nOperating expenses \u00a02.49% \u00a02.20%\nOperating income \u00a00.99% \u00a01.33%\n________________________________________\n1Includes tax expense relating to S wiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nthe latter of which is recorded within Other Income, Net.\n\u00a0\n 2The sum of the components does not equal the total due to rounding\n\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n CENC ORA, INC.\n SUMMAR Y SEGMENT INFORMA TION\n19", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on divestiture\nof non-core\nbusinesses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(56,228 )\u00a0\u00a0(10,372 )\u00a0\u00a03,618 \u00a0\u00a0\u00a0(42,238 )\u00a0\u00a0(0.20 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain discrete tax\nbenefits \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(9,677 )\u00a0\u00a06,840 \u00a0\u00a0\u00a016,517 \u00a0\u00a0\u00a00.08 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a014,443 \u00a0\u00a0\u00a0(32,109 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a046,552 \u00a0\u00a0\u00a00.22 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$8,401,736 \u00a0\u00a0$5,238,306 \u00a0\u00a0$3,163,430 \u00a0\u00a0$2,945,423 \u00a0\u00a0$606,583 \u00a0\u00a0$(9,485 )\u00a0$2,329,355 \u00a0\u00a0$11.03 \u00a02\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.48% \u00a03.52%\nOperating expenses \u00a02.49% \u00a02.20%\nOperating income \u00a00.99% \u00a01.33%\n________________________________________\n1Includes tax expense relating to S wiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nthe latter of which is recorded within Other Income, Net.\n\u00a0\n"}, "hash": "f69acb565ec26a41b7e0632d5813ccf5ea8108c9d5c99d35b1462b8ca01323dd", "class_name": "RelatedNodeInfo"}}, "text": "GAAP \u00a0$8,296,367 \u00a0\u00a0$5,929,989 \u00a0\u00a0$2,366,378 \u00a0\u00a0$2,183,057 \u00a0\u00a0$516,517 \u00a0\u00a0$32,280 \u00a0\u00a0$1,698,820 \u00a0\u00a0$8.04 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust litigation\nsettlements \u00a0\u00a0(1,835 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,835 )\u00a0\u00a0(1,835 )\u00a0\u00a0(408 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,427 )\u00a0\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a067,171 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a067,171 \u00a0\u00a0\u00a067,171 \u00a0\u00a0\u00a014,943 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a052,228 \u00a0\u00a0\u00a00.25 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\ninflationary impact \u00a0\u00a040,033 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a040,033 \u00a0\u00a0\u00a051,966 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a051,966 \u00a0\u00a0\u00a00.25 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(304,551 )\u00a0\u00a0304,551 \u00a0\u00a0\u00a0304,551 \u00a0\u00a0\u00a067,749 \u00a0\u00a0\u00a0(5,219 )\u00a0\u00a0231,583 \u00a0\u00a0\u00a01.10 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(123,191 )\u00a0\u00a0123,191 \u00a0\u00a0\u00a0123,191 \u00a0\u00a0\u00a024,111 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a099,080 \u00a0\u00a0\u00a00.47 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\ndeal and\nintegration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(119,561 )\u00a0\u00a0119,561 \u00a0\u00a0\u00a0119,561 \u00a0\u00a0\u00a023,401 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a096,160 \u00a0\u00a0\u00a00.46 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring and\nother expenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(63,498 )\u00a0\u00a063,498 \u00a0\u00a0\u00a063,498 \u00a0\u00a0\u00a012,428 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a051,070 \u00a0\u00a0\u00a00.24 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on\nremeasurement of\nequity investment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,834 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,834 )\u00a0\u00a0(0.02 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGoodwill\nimpairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(75,936 )\u00a0\u00a075,936 \u00a0\u00a0\u00a075,936 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(47,004 )\u00a0\u00a028,932 \u00a0\u00a0\u00a00.14 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nassets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,946 )\u00a0\u00a04,946 \u00a0\u00a0\u00a04,946 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a04,946 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n18", "start_char_idx": 0, "end_char_idx": 1418, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3b4f5756-11a9-4d10-9c4c-56cada2502fa": {"__data__": {"id_": "3b4f5756-11a9-4d10-9c4c-56cada2502fa", "embedding": null, "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on divestiture\nof non-core\nbusinesses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(56,228 )\u00a0\u00a0(10,372 )\u00a0\u00a03,618 \u00a0\u00a0\u00a0(42,238 )\u00a0\u00a0(0.20 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain discrete tax\nbenefits \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(9,677 )\u00a0\u00a06,840 \u00a0\u00a0\u00a016,517 \u00a0\u00a0\u00a00.08 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a014,443 \u00a0\u00a0\u00a0(32,109 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a046,552 \u00a0\u00a0\u00a00.22 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$8,401,736 \u00a0\u00a0$5,238,306 \u00a0\u00a0$3,163,430 \u00a0\u00a0$2,945,423 \u00a0\u00a0$606,583 \u00a0\u00a0$(9,485 )\u00a0$2,329,355 \u00a0\u00a0$11.03 \u00a02\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.48% \u00a03.52%\nOperating expenses \u00a02.49% \u00a02.20%\nOperating income \u00a00.99% \u00a01.33%\n________________________________________\n1Includes tax expense relating to S wiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nthe latter of which is recorded within Other Income, Net.\n\u00a0\n 2The sum of the components does not equal the total due to rounding\n\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n CENC ORA, INC.\n SUMMAR Y SEGMENT INFORMA TION\n19", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on divestiture\nof non-core\nbusinesses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(56,228 )\u00a0\u00a0(10,372 )\u00a0\u00a03,618 \u00a0\u00a0\u00a0(42,238 )\u00a0\u00a0(0.20 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain discrete tax\nbenefits \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(9,677 )\u00a0\u00a06,840 \u00a0\u00a0\u00a016,517 \u00a0\u00a0\u00a00.08 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a014,443 \u00a0\u00a0\u00a0(32,109 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a046,552 \u00a0\u00a0\u00a00.22 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$8,401,736 \u00a0\u00a0$5,238,306 \u00a0\u00a0$3,163,430 \u00a0\u00a0$2,945,423 \u00a0\u00a0$606,583 \u00a0\u00a0$(9,485 )\u00a0$2,329,355 \u00a0\u00a0$11.03 \u00a02\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.48% \u00a03.52%\nOperating expenses \u00a02.49% \u00a02.20%\nOperating income \u00a00.99% \u00a01.33%\n________________________________________\n1Includes tax expense relating to S wiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nthe latter of which is recorded within Other Income, Net.\n\u00a0\n", "page_label": "19", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "03c39f7a-d6b2-42a0-86c6-b60a33129345", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "868ced4081c36a268ac5592eb66b6e6d2e4a7a24c0c640bdc557ee001dd8460e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c60198a0-42db-4b15-bc58-f61fad7aabbc", "node_type": "1", "metadata": {"window": "GAAP \u00a0$8,296,367 \u00a0\u00a0$5,929,989 \u00a0\u00a0$2,366,378 \u00a0\u00a0$2,183,057 \u00a0\u00a0$516,517 \u00a0\u00a0$32,280 \u00a0\u00a0$1,698,820 \u00a0\u00a0$8.04 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust litigation\nsettlements \u00a0\u00a0(1,835 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,835 )\u00a0\u00a0(1,835 )\u00a0\u00a0(408 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,427 )\u00a0\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a067,171 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a067,171 \u00a0\u00a0\u00a067,171 \u00a0\u00a0\u00a014,943 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a052,228 \u00a0\u00a0\u00a00.25 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\ninflationary impact \u00a0\u00a040,033 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a040,033 \u00a0\u00a0\u00a051,966 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a051,966 \u00a0\u00a0\u00a00.25 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(304,551 )\u00a0\u00a0304,551 \u00a0\u00a0\u00a0304,551 \u00a0\u00a0\u00a067,749 \u00a0\u00a0\u00a0(5,219 )\u00a0\u00a0231,583 \u00a0\u00a0\u00a01.10 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(123,191 )\u00a0\u00a0123,191 \u00a0\u00a0\u00a0123,191 \u00a0\u00a0\u00a024,111 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a099,080 \u00a0\u00a0\u00a00.47 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\ndeal and\nintegration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(119,561 )\u00a0\u00a0119,561 \u00a0\u00a0\u00a0119,561 \u00a0\u00a0\u00a023,401 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a096,160 \u00a0\u00a0\u00a00.46 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring and\nother expenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(63,498 )\u00a0\u00a063,498 \u00a0\u00a0\u00a063,498 \u00a0\u00a0\u00a012,428 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a051,070 \u00a0\u00a0\u00a00.24 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on\nremeasurement of\nequity investment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,834 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,834 )\u00a0\u00a0(0.02 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGoodwill\nimpairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(75,936 )\u00a0\u00a075,936 \u00a0\u00a0\u00a075,936 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(47,004 )\u00a0\u00a028,932 \u00a0\u00a0\u00a00.14 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nassets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,946 )\u00a0\u00a04,946 \u00a0\u00a0\u00a04,946 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a04,946 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n18", "original_text": "GAAP \u00a0$8,296,367 \u00a0\u00a0$5,929,989 \u00a0\u00a0$2,366,378 \u00a0\u00a0$2,183,057 \u00a0\u00a0$516,517 \u00a0\u00a0$32,280 \u00a0\u00a0$1,698,820 \u00a0\u00a0$8.04 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust litigation\nsettlements \u00a0\u00a0(1,835 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,835 )\u00a0\u00a0(1,835 )\u00a0\u00a0(408 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,427 )\u00a0\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a067,171 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a067,171 \u00a0\u00a0\u00a067,171 \u00a0\u00a0\u00a014,943 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a052,228 \u00a0\u00a0\u00a00.25 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\ninflationary impact \u00a0\u00a040,033 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a040,033 \u00a0\u00a0\u00a051,966 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a051,966 \u00a0\u00a0\u00a00.25 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(304,551 )\u00a0\u00a0304,551 \u00a0\u00a0\u00a0304,551 \u00a0\u00a0\u00a067,749 \u00a0\u00a0\u00a0(5,219 )\u00a0\u00a0231,583 \u00a0\u00a0\u00a01.10 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(123,191 )\u00a0\u00a0123,191 \u00a0\u00a0\u00a0123,191 \u00a0\u00a0\u00a024,111 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a099,080 \u00a0\u00a0\u00a00.47 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\ndeal and\nintegration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(119,561 )\u00a0\u00a0119,561 \u00a0\u00a0\u00a0119,561 \u00a0\u00a0\u00a023,401 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a096,160 \u00a0\u00a0\u00a00.46 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring and\nother expenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(63,498 )\u00a0\u00a063,498 \u00a0\u00a0\u00a063,498 \u00a0\u00a0\u00a012,428 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a051,070 \u00a0\u00a0\u00a00.24 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on\nremeasurement of\nequity investment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,834 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,834 )\u00a0\u00a0(0.02 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGoodwill\nimpairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(75,936 )\u00a0\u00a075,936 \u00a0\u00a0\u00a075,936 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(47,004 )\u00a0\u00a028,932 \u00a0\u00a0\u00a00.14 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nassets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,946 )\u00a0\u00a04,946 \u00a0\u00a0\u00a04,946 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a04,946 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n18", "page_label": "18", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aaf92f210079977b96be58702c6737db626e4c2f3f2a2662c6d064aec57f48ba", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "de15a7c2-12c5-4e6c-8ea7-9526ecf30309", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on divestiture\nof non-core\nbusinesses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(56,228 )\u00a0\u00a0(10,372 )\u00a0\u00a03,618 \u00a0\u00a0\u00a0(42,238 )\u00a0\u00a0(0.20 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain discrete tax\nbenefits \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(9,677 )\u00a0\u00a06,840 \u00a0\u00a0\u00a016,517 \u00a0\u00a0\u00a00.08 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a014,443 \u00a0\u00a0\u00a0(32,109 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a046,552 \u00a0\u00a0\u00a00.22 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$8,401,736 \u00a0\u00a0$5,238,306 \u00a0\u00a0$3,163,430 \u00a0\u00a0$2,945,423 \u00a0\u00a0$606,583 \u00a0\u00a0$(9,485 )\u00a0$2,329,355 \u00a0\u00a0$11.03 \u00a02\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.48% \u00a03.52%\nOperating expenses \u00a02.49% \u00a02.20%\nOperating income \u00a00.99% \u00a01.33%\n________________________________________\n1Includes tax expense relating to S wiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nthe latter of which is recorded within Other Income, Net.\n\u00a0\n 2The sum of the components does not equal the total due to rounding\n\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n CENC ORA, INC.\n SUMMAR Y SEGMENT INFORMA TION\n19", "original_text": "2The sum of the components does not equal the total due to rounding\n\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n"}, "hash": "0f1e3479b01394e2b0596cfc07bbf74f8d2001ae2ba3014c47886c3d050134de", "class_name": "RelatedNodeInfo"}}, "text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on divestiture\nof non-core\nbusinesses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(56,228 )\u00a0\u00a0(10,372 )\u00a0\u00a03,618 \u00a0\u00a0\u00a0(42,238 )\u00a0\u00a0(0.20 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain discrete tax\nbenefits \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(9,677 )\u00a0\u00a06,840 \u00a0\u00a0\u00a016,517 \u00a0\u00a0\u00a00.08 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a014,443 \u00a0\u00a0\u00a0(32,109 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a046,552 \u00a0\u00a0\u00a00.22 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$8,401,736 \u00a0\u00a0$5,238,306 \u00a0\u00a0$3,163,430 \u00a0\u00a0$2,945,423 \u00a0\u00a0$606,583 \u00a0\u00a0$(9,485 )\u00a0$2,329,355 \u00a0\u00a0$11.03 \u00a02\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.48% \u00a03.52%\nOperating expenses \u00a02.49% \u00a02.20%\nOperating income \u00a00.99% \u00a01.33%\n________________________________________\n1Includes tax expense relating to S wiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nthe latter of which is recorded within Other Income, Net.\n\u00a0\n", "start_char_idx": 0, "end_char_idx": 876, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "de15a7c2-12c5-4e6c-8ea7-9526ecf30309": {"__data__": {"id_": "de15a7c2-12c5-4e6c-8ea7-9526ecf30309", "embedding": null, "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on divestiture\nof non-core\nbusinesses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(56,228 )\u00a0\u00a0(10,372 )\u00a0\u00a03,618 \u00a0\u00a0\u00a0(42,238 )\u00a0\u00a0(0.20 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain discrete tax\nbenefits \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(9,677 )\u00a0\u00a06,840 \u00a0\u00a0\u00a016,517 \u00a0\u00a0\u00a00.08 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a014,443 \u00a0\u00a0\u00a0(32,109 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a046,552 \u00a0\u00a0\u00a00.22 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$8,401,736 \u00a0\u00a0$5,238,306 \u00a0\u00a0$3,163,430 \u00a0\u00a0$2,945,423 \u00a0\u00a0$606,583 \u00a0\u00a0$(9,485 )\u00a0$2,329,355 \u00a0\u00a0$11.03 \u00a02\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.48% \u00a03.52%\nOperating expenses \u00a02.49% \u00a02.20%\nOperating income \u00a00.99% \u00a01.33%\n________________________________________\n1Includes tax expense relating to S wiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nthe latter of which is recorded within Other Income, Net.\n\u00a0\n 2The sum of the components does not equal the total due to rounding\n\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n CENC ORA, INC.\n SUMMAR Y SEGMENT INFORMA TION\n19", "original_text": "2The sum of the components does not equal the total due to rounding\n\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "19", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "03c39f7a-d6b2-42a0-86c6-b60a33129345", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "868ced4081c36a268ac5592eb66b6e6d2e4a7a24c0c640bdc557ee001dd8460e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3b4f5756-11a9-4d10-9c4c-56cada2502fa", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on divestiture\nof non-core\nbusinesses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(56,228 )\u00a0\u00a0(10,372 )\u00a0\u00a03,618 \u00a0\u00a0\u00a0(42,238 )\u00a0\u00a0(0.20 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain discrete tax\nbenefits \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(9,677 )\u00a0\u00a06,840 \u00a0\u00a0\u00a016,517 \u00a0\u00a0\u00a00.08 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a014,443 \u00a0\u00a0\u00a0(32,109 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a046,552 \u00a0\u00a0\u00a00.22 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$8,401,736 \u00a0\u00a0$5,238,306 \u00a0\u00a0$3,163,430 \u00a0\u00a0$2,945,423 \u00a0\u00a0$606,583 \u00a0\u00a0$(9,485 )\u00a0$2,329,355 \u00a0\u00a0$11.03 \u00a02\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.48% \u00a03.52%\nOperating expenses \u00a02.49% \u00a02.20%\nOperating income \u00a00.99% \u00a01.33%\n________________________________________\n1Includes tax expense relating to S wiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nthe latter of which is recorded within Other Income, Net.\n\u00a0\n 2The sum of the components does not equal the total due to rounding\n\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n CENC ORA, INC.\n SUMMAR Y SEGMENT INFORMA TION\n19", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on divestiture\nof non-core\nbusinesses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(56,228 )\u00a0\u00a0(10,372 )\u00a0\u00a03,618 \u00a0\u00a0\u00a0(42,238 )\u00a0\u00a0(0.20 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain discrete tax\nbenefits \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(9,677 )\u00a0\u00a06,840 \u00a0\u00a0\u00a016,517 \u00a0\u00a0\u00a00.08 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a014,443 \u00a0\u00a0\u00a0(32,109 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a046,552 \u00a0\u00a0\u00a00.22 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$8,401,736 \u00a0\u00a0$5,238,306 \u00a0\u00a0$3,163,430 \u00a0\u00a0$2,945,423 \u00a0\u00a0$606,583 \u00a0\u00a0$(9,485 )\u00a0$2,329,355 \u00a0\u00a0$11.03 \u00a02\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.48% \u00a03.52%\nOperating expenses \u00a02.49% \u00a02.20%\nOperating income \u00a00.99% \u00a01.33%\n________________________________________\n1Includes tax expense relating to S wiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nthe latter of which is recorded within Other Income, Net.\n\u00a0\n", "page_label": "19", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "21ae3519cdf8388962ce68873cd84cf50de1cb515d7d71b1cfa799b0c66bcd65", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a637f339-4214-46b0-8c6d-d67fcc3408d1", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on divestiture\nof non-core\nbusinesses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(56,228 )\u00a0\u00a0(10,372 )\u00a0\u00a03,618 \u00a0\u00a0\u00a0(42,238 )\u00a0\u00a0(0.20 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain discrete tax\nbenefits \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(9,677 )\u00a0\u00a06,840 \u00a0\u00a0\u00a016,517 \u00a0\u00a0\u00a00.08 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a014,443 \u00a0\u00a0\u00a0(32,109 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a046,552 \u00a0\u00a0\u00a00.22 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$8,401,736 \u00a0\u00a0$5,238,306 \u00a0\u00a0$3,163,430 \u00a0\u00a0$2,945,423 \u00a0\u00a0$606,583 \u00a0\u00a0$(9,485 )\u00a0$2,329,355 \u00a0\u00a0$11.03 \u00a02\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.48% \u00a03.52%\nOperating expenses \u00a02.49% \u00a02.20%\nOperating income \u00a00.99% \u00a01.33%\n________________________________________\n1Includes tax expense relating to S wiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nthe latter of which is recorded within Other Income, Net.\n\u00a0\n 2The sum of the components does not equal the total due to rounding\n\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n CENC ORA, INC.\n SUMMAR Y SEGMENT INFORMA TION\n19", "original_text": "CENC ORA, INC.\n"}, "hash": "fae171f0349f189e2f1bf23324fae81a75564fa1218229127e35f73a360c03c1", "class_name": "RelatedNodeInfo"}}, "text": "2The sum of the components does not equal the total due to rounding\n\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "start_char_idx": 876, "end_char_idx": 1123, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a637f339-4214-46b0-8c6d-d67fcc3408d1": {"__data__": {"id_": "a637f339-4214-46b0-8c6d-d67fcc3408d1", "embedding": null, "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on divestiture\nof non-core\nbusinesses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(56,228 )\u00a0\u00a0(10,372 )\u00a0\u00a03,618 \u00a0\u00a0\u00a0(42,238 )\u00a0\u00a0(0.20 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain discrete tax\nbenefits \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(9,677 )\u00a0\u00a06,840 \u00a0\u00a0\u00a016,517 \u00a0\u00a0\u00a00.08 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a014,443 \u00a0\u00a0\u00a0(32,109 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a046,552 \u00a0\u00a0\u00a00.22 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$8,401,736 \u00a0\u00a0$5,238,306 \u00a0\u00a0$3,163,430 \u00a0\u00a0$2,945,423 \u00a0\u00a0$606,583 \u00a0\u00a0$(9,485 )\u00a0$2,329,355 \u00a0\u00a0$11.03 \u00a02\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.48% \u00a03.52%\nOperating expenses \u00a02.49% \u00a02.20%\nOperating income \u00a00.99% \u00a01.33%\n________________________________________\n1Includes tax expense relating to S wiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nthe latter of which is recorded within Other Income, Net.\n\u00a0\n 2The sum of the components does not equal the total due to rounding\n\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n CENC ORA, INC.\n SUMMAR Y SEGMENT INFORMA TION\n19", "original_text": "CENC ORA, INC.\n", "page_label": "19", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "03c39f7a-d6b2-42a0-86c6-b60a33129345", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "868ced4081c36a268ac5592eb66b6e6d2e4a7a24c0c640bdc557ee001dd8460e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "de15a7c2-12c5-4e6c-8ea7-9526ecf30309", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on divestiture\nof non-core\nbusinesses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(56,228 )\u00a0\u00a0(10,372 )\u00a0\u00a03,618 \u00a0\u00a0\u00a0(42,238 )\u00a0\u00a0(0.20 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain discrete tax\nbenefits \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(9,677 )\u00a0\u00a06,840 \u00a0\u00a0\u00a016,517 \u00a0\u00a0\u00a00.08 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a014,443 \u00a0\u00a0\u00a0(32,109 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a046,552 \u00a0\u00a0\u00a00.22 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$8,401,736 \u00a0\u00a0$5,238,306 \u00a0\u00a0$3,163,430 \u00a0\u00a0$2,945,423 \u00a0\u00a0$606,583 \u00a0\u00a0$(9,485 )\u00a0$2,329,355 \u00a0\u00a0$11.03 \u00a02\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.48% \u00a03.52%\nOperating expenses \u00a02.49% \u00a02.20%\nOperating income \u00a00.99% \u00a01.33%\n________________________________________\n1Includes tax expense relating to S wiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nthe latter of which is recorded within Other Income, Net.\n\u00a0\n 2The sum of the components does not equal the total due to rounding\n\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n CENC ORA, INC.\n SUMMAR Y SEGMENT INFORMA TION\n19", "original_text": "2The sum of the components does not equal the total due to rounding\n\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "19", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "21102fd36f6de8eb4ee209867fd3b69581cb13fea87b3fc05ca81eaf7eab9236", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "01390958-41be-403b-9794-c956a19e5be3", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on divestiture\nof non-core\nbusinesses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(56,228 )\u00a0\u00a0(10,372 )\u00a0\u00a03,618 \u00a0\u00a0\u00a0(42,238 )\u00a0\u00a0(0.20 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain discrete tax\nbenefits \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(9,677 )\u00a0\u00a06,840 \u00a0\u00a0\u00a016,517 \u00a0\u00a0\u00a00.08 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a014,443 \u00a0\u00a0\u00a0(32,109 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a046,552 \u00a0\u00a0\u00a00.22 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$8,401,736 \u00a0\u00a0$5,238,306 \u00a0\u00a0$3,163,430 \u00a0\u00a0$2,945,423 \u00a0\u00a0$606,583 \u00a0\u00a0$(9,485 )\u00a0$2,329,355 \u00a0\u00a0$11.03 \u00a02\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.48% \u00a03.52%\nOperating expenses \u00a02.49% \u00a02.20%\nOperating income \u00a00.99% \u00a01.33%\n________________________________________\n1Includes tax expense relating to S wiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nthe latter of which is recorded within Other Income, Net.\n\u00a0\n 2The sum of the components does not equal the total due to rounding\n\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n CENC ORA, INC.\n SUMMAR Y SEGMENT INFORMA TION\n19", "original_text": "SUMMAR Y SEGMENT INFORMA TION\n19"}, "hash": "dfba0f6777a8578f0bc661ef91f7bd70cecf7eddc75e3fa19b2c2efd77f59ddf", "class_name": "RelatedNodeInfo"}}, "text": "CENC ORA, INC.\n", "start_char_idx": 1123, "end_char_idx": 1138, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "01390958-41be-403b-9794-c956a19e5be3": {"__data__": {"id_": "01390958-41be-403b-9794-c956a19e5be3", "embedding": null, "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on divestiture\nof non-core\nbusinesses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(56,228 )\u00a0\u00a0(10,372 )\u00a0\u00a03,618 \u00a0\u00a0\u00a0(42,238 )\u00a0\u00a0(0.20 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain discrete tax\nbenefits \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(9,677 )\u00a0\u00a06,840 \u00a0\u00a0\u00a016,517 \u00a0\u00a0\u00a00.08 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a014,443 \u00a0\u00a0\u00a0(32,109 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a046,552 \u00a0\u00a0\u00a00.22 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$8,401,736 \u00a0\u00a0$5,238,306 \u00a0\u00a0$3,163,430 \u00a0\u00a0$2,945,423 \u00a0\u00a0$606,583 \u00a0\u00a0$(9,485 )\u00a0$2,329,355 \u00a0\u00a0$11.03 \u00a02\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.48% \u00a03.52%\nOperating expenses \u00a02.49% \u00a02.20%\nOperating income \u00a00.99% \u00a01.33%\n________________________________________\n1Includes tax expense relating to S wiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nthe latter of which is recorded within Other Income, Net.\n\u00a0\n 2The sum of the components does not equal the total due to rounding\n\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n CENC ORA, INC.\n SUMMAR Y SEGMENT INFORMA TION\n19", "original_text": "SUMMAR Y SEGMENT INFORMA TION\n19", "page_label": "19", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "03c39f7a-d6b2-42a0-86c6-b60a33129345", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "868ced4081c36a268ac5592eb66b6e6d2e4a7a24c0c640bdc557ee001dd8460e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a637f339-4214-46b0-8c6d-d67fcc3408d1", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on divestiture\nof non-core\nbusinesses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(56,228 )\u00a0\u00a0(10,372 )\u00a0\u00a03,618 \u00a0\u00a0\u00a0(42,238 )\u00a0\u00a0(0.20 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain discrete tax\nbenefits \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(9,677 )\u00a0\u00a06,840 \u00a0\u00a0\u00a016,517 \u00a0\u00a0\u00a00.08 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a014,443 \u00a0\u00a0\u00a0(32,109 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a046,552 \u00a0\u00a0\u00a00.22 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$8,401,736 \u00a0\u00a0$5,238,306 \u00a0\u00a0$3,163,430 \u00a0\u00a0$2,945,423 \u00a0\u00a0$606,583 \u00a0\u00a0$(9,485 )\u00a0$2,329,355 \u00a0\u00a0$11.03 \u00a02\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.48% \u00a03.52%\nOperating expenses \u00a02.49% \u00a02.20%\nOperating income \u00a00.99% \u00a01.33%\n________________________________________\n1Includes tax expense relating to S wiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nthe latter of which is recorded within Other Income, Net.\n\u00a0\n 2The sum of the components does not equal the total due to rounding\n\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n CENC ORA, INC.\n SUMMAR Y SEGMENT INFORMA TION\n19", "original_text": "CENC ORA, INC.\n", "page_label": "19", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "57e2ac4dce9dee66bcf84ee127efd116c212ac76965ad91f1fdaa77a49030601", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "63a67739-a037-4018-a397-fd761133090d", "node_type": "1", "metadata": {"window": "(dollars in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30,\nRevenue \u00a0\u00a02023 \u00a0\u00a0\u00a02022 \u00a0\u00a0%\nChange\nU.S.  Healthcare Solutions \u00a0$61,928,984 \u00a0\u00a0$54,788,447 \u00a0\u00a013.0 %\nInternational Healthcare Solutions \u00a0\u00a06,994,689 \u00a0\u00a0\u00a06,387,474 \u00a0\u00a09.5 %\nIntersegment eliminations \u00a0\u00a0(1,342 )\u00a0\u00a0(1,772 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$68,922,331 \u00a0\u00a0$61,174,149 \u00a0\u00a012.7 %\n\u00a0 \u00a0Three Months Ended Sept ember 30,\nOperating income \u00a0\u00a02023 \u00a0\u00a0\u00a02022 \u00a0\u00a0%\nChange\nU.S.  Healthcare Solutions \u00a0$632,830 \u00a0\u00a0$578,416 \u00a0\u00a09.4 %\nInternational Healthcare Solutions \u00a0\u00a0168,157 \u00a0\u00a0\u00a0163,058 \u00a0\u00a03.1 %\nTotal segment operating income \u00a0\u00a0800,987 \u00a0\u00a0\u00a0741,474 \u00a0\u00a08.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation\nsettlements \u00a0\u00a070,582 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nLIFO expense \u00a0\u00a0(90,323 )\u00a0\u00a0(104,839 )\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(27,948 )\u00a0\u00a0(12,415 )\u00a0\u00a0\nAcquisition-related intangibles\namortization \u00a0\u00a0(169,900 )\u00a0\u00a0(72,685 )\u00a0\u00a0\nLitigation and opioid-related expenses \u00a0\u00a0(13,890 )\u00a0\u00a0(15,024 )\u00a0\u00a0\nAcquisition-related deal and\nintegration expenses \u00a0\u00a0(40,291 )\u00a0\u00a0(49,851 )\u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(52,276 )\u00a0\u00a0(32,141 )\u00a0\u00a0\n20", "original_text": "(dollars in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30,\nRevenue \u00a0\u00a02023 \u00a0\u00a0\u00a02022 \u00a0\u00a0%\nChange\nU.S. "}, "hash": "e41abc194409c60c02fb5c770c3d84df605a1ad1f5a09add4f25d5fd424afcf2", "class_name": "RelatedNodeInfo"}}, "text": "SUMMAR Y SEGMENT INFORMA TION\n19", "start_char_idx": 1138, "end_char_idx": 1170, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "63a67739-a037-4018-a397-fd761133090d": {"__data__": {"id_": "63a67739-a037-4018-a397-fd761133090d", "embedding": null, "metadata": {"window": "(dollars in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30,\nRevenue \u00a0\u00a02023 \u00a0\u00a0\u00a02022 \u00a0\u00a0%\nChange\nU.S.  Healthcare Solutions \u00a0$61,928,984 \u00a0\u00a0$54,788,447 \u00a0\u00a013.0 %\nInternational Healthcare Solutions \u00a0\u00a06,994,689 \u00a0\u00a0\u00a06,387,474 \u00a0\u00a09.5 %\nIntersegment eliminations \u00a0\u00a0(1,342 )\u00a0\u00a0(1,772 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$68,922,331 \u00a0\u00a0$61,174,149 \u00a0\u00a012.7 %\n\u00a0 \u00a0Three Months Ended Sept ember 30,\nOperating income \u00a0\u00a02023 \u00a0\u00a0\u00a02022 \u00a0\u00a0%\nChange\nU.S.  Healthcare Solutions \u00a0$632,830 \u00a0\u00a0$578,416 \u00a0\u00a09.4 %\nInternational Healthcare Solutions \u00a0\u00a0168,157 \u00a0\u00a0\u00a0163,058 \u00a0\u00a03.1 %\nTotal segment operating income \u00a0\u00a0800,987 \u00a0\u00a0\u00a0741,474 \u00a0\u00a08.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation\nsettlements \u00a0\u00a070,582 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nLIFO expense \u00a0\u00a0(90,323 )\u00a0\u00a0(104,839 )\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(27,948 )\u00a0\u00a0(12,415 )\u00a0\u00a0\nAcquisition-related intangibles\namortization \u00a0\u00a0(169,900 )\u00a0\u00a0(72,685 )\u00a0\u00a0\nLitigation and opioid-related expenses \u00a0\u00a0(13,890 )\u00a0\u00a0(15,024 )\u00a0\u00a0\nAcquisition-related deal and\nintegration expenses \u00a0\u00a0(40,291 )\u00a0\u00a0(49,851 )\u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(52,276 )\u00a0\u00a0(32,141 )\u00a0\u00a0\n20", "original_text": "(dollars in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30,\nRevenue \u00a0\u00a02023 \u00a0\u00a0\u00a02022 \u00a0\u00a0%\nChange\nU.S. ", "page_label": "20", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "13556533-f636-4043-b74e-d5777dc1f94c", "node_type": "4", "metadata": {"page_label": "20", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "71adb01ff09f7179281e852239635c53e67340f863777e55544b8f0e9da9b0a1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "01390958-41be-403b-9794-c956a19e5be3", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on divestiture\nof non-core\nbusinesses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(56,228 )\u00a0\u00a0(10,372 )\u00a0\u00a03,618 \u00a0\u00a0\u00a0(42,238 )\u00a0\u00a0(0.20 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain discrete tax\nbenefits \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(9,677 )\u00a0\u00a06,840 \u00a0\u00a0\u00a016,517 \u00a0\u00a0\u00a00.08 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a014,443 \u00a0\u00a0\u00a0(32,109 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a046,552 \u00a0\u00a0\u00a00.22 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$8,401,736 \u00a0\u00a0$5,238,306 \u00a0\u00a0$3,163,430 \u00a0\u00a0$2,945,423 \u00a0\u00a0$606,583 \u00a0\u00a0$(9,485 )\u00a0$2,329,355 \u00a0\u00a0$11.03 \u00a02\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.48% \u00a03.52%\nOperating expenses \u00a02.49% \u00a02.20%\nOperating income \u00a00.99% \u00a01.33%\n________________________________________\n1Includes tax expense relating to S wiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nthe latter of which is recorded within Other Income, Net.\n\u00a0\n 2The sum of the components does not equal the total due to rounding\n\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n CENC ORA, INC.\n SUMMAR Y SEGMENT INFORMA TION\n19", "original_text": "SUMMAR Y SEGMENT INFORMA TION\n19", "page_label": "19", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "50064476237dbcc22794963e23efe08d87305927a836c825bc2a755f802cc36a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "509d48a6-c5d0-49d0-a1fd-00dbf3e83d05", "node_type": "1", "metadata": {"window": "(dollars in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30,\nRevenue \u00a0\u00a02023 \u00a0\u00a0\u00a02022 \u00a0\u00a0%\nChange\nU.S.  Healthcare Solutions \u00a0$61,928,984 \u00a0\u00a0$54,788,447 \u00a0\u00a013.0 %\nInternational Healthcare Solutions \u00a0\u00a06,994,689 \u00a0\u00a0\u00a06,387,474 \u00a0\u00a09.5 %\nIntersegment eliminations \u00a0\u00a0(1,342 )\u00a0\u00a0(1,772 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$68,922,331 \u00a0\u00a0$61,174,149 \u00a0\u00a012.7 %\n\u00a0 \u00a0Three Months Ended Sept ember 30,\nOperating income \u00a0\u00a02023 \u00a0\u00a0\u00a02022 \u00a0\u00a0%\nChange\nU.S.  Healthcare Solutions \u00a0$632,830 \u00a0\u00a0$578,416 \u00a0\u00a09.4 %\nInternational Healthcare Solutions \u00a0\u00a0168,157 \u00a0\u00a0\u00a0163,058 \u00a0\u00a03.1 %\nTotal segment operating income \u00a0\u00a0800,987 \u00a0\u00a0\u00a0741,474 \u00a0\u00a08.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation\nsettlements \u00a0\u00a070,582 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nLIFO expense \u00a0\u00a0(90,323 )\u00a0\u00a0(104,839 )\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(27,948 )\u00a0\u00a0(12,415 )\u00a0\u00a0\nAcquisition-related intangibles\namortization \u00a0\u00a0(169,900 )\u00a0\u00a0(72,685 )\u00a0\u00a0\nLitigation and opioid-related expenses \u00a0\u00a0(13,890 )\u00a0\u00a0(15,024 )\u00a0\u00a0\nAcquisition-related deal and\nintegration expenses \u00a0\u00a0(40,291 )\u00a0\u00a0(49,851 )\u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(52,276 )\u00a0\u00a0(32,141 )\u00a0\u00a0\n20", "original_text": "Healthcare Solutions \u00a0$61,928,984 \u00a0\u00a0$54,788,447 \u00a0\u00a013.0 %\nInternational Healthcare Solutions \u00a0\u00a06,994,689 \u00a0\u00a0\u00a06,387,474 \u00a0\u00a09.5 %\nIntersegment eliminations \u00a0\u00a0(1,342 )\u00a0\u00a0(1,772 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$68,922,331 \u00a0\u00a0$61,174,149 \u00a0\u00a012.7 %\n\u00a0 \u00a0Three Months Ended Sept ember 30,\nOperating income \u00a0\u00a02023 \u00a0\u00a0\u00a02022 \u00a0\u00a0%\nChange\nU.S. "}, "hash": "63a72a9b3f9c6c9d57757cc22391840c51934fb2c0a1394694a809bbd87661ad", "class_name": "RelatedNodeInfo"}}, "text": "(dollars in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30,\nRevenue \u00a0\u00a02023 \u00a0\u00a0\u00a02022 \u00a0\u00a0%\nChange\nU.S. ", "start_char_idx": 0, "end_char_idx": 113, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "509d48a6-c5d0-49d0-a1fd-00dbf3e83d05": {"__data__": {"id_": "509d48a6-c5d0-49d0-a1fd-00dbf3e83d05", "embedding": null, "metadata": {"window": "(dollars in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30,\nRevenue \u00a0\u00a02023 \u00a0\u00a0\u00a02022 \u00a0\u00a0%\nChange\nU.S.  Healthcare Solutions \u00a0$61,928,984 \u00a0\u00a0$54,788,447 \u00a0\u00a013.0 %\nInternational Healthcare Solutions \u00a0\u00a06,994,689 \u00a0\u00a0\u00a06,387,474 \u00a0\u00a09.5 %\nIntersegment eliminations \u00a0\u00a0(1,342 )\u00a0\u00a0(1,772 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$68,922,331 \u00a0\u00a0$61,174,149 \u00a0\u00a012.7 %\n\u00a0 \u00a0Three Months Ended Sept ember 30,\nOperating income \u00a0\u00a02023 \u00a0\u00a0\u00a02022 \u00a0\u00a0%\nChange\nU.S.  Healthcare Solutions \u00a0$632,830 \u00a0\u00a0$578,416 \u00a0\u00a09.4 %\nInternational Healthcare Solutions \u00a0\u00a0168,157 \u00a0\u00a0\u00a0163,058 \u00a0\u00a03.1 %\nTotal segment operating income \u00a0\u00a0800,987 \u00a0\u00a0\u00a0741,474 \u00a0\u00a08.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation\nsettlements \u00a0\u00a070,582 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nLIFO expense \u00a0\u00a0(90,323 )\u00a0\u00a0(104,839 )\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(27,948 )\u00a0\u00a0(12,415 )\u00a0\u00a0\nAcquisition-related intangibles\namortization \u00a0\u00a0(169,900 )\u00a0\u00a0(72,685 )\u00a0\u00a0\nLitigation and opioid-related expenses \u00a0\u00a0(13,890 )\u00a0\u00a0(15,024 )\u00a0\u00a0\nAcquisition-related deal and\nintegration expenses \u00a0\u00a0(40,291 )\u00a0\u00a0(49,851 )\u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(52,276 )\u00a0\u00a0(32,141 )\u00a0\u00a0\n20", "original_text": "Healthcare Solutions \u00a0$61,928,984 \u00a0\u00a0$54,788,447 \u00a0\u00a013.0 %\nInternational Healthcare Solutions \u00a0\u00a06,994,689 \u00a0\u00a0\u00a06,387,474 \u00a0\u00a09.5 %\nIntersegment eliminations \u00a0\u00a0(1,342 )\u00a0\u00a0(1,772 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$68,922,331 \u00a0\u00a0$61,174,149 \u00a0\u00a012.7 %\n\u00a0 \u00a0Three Months Ended Sept ember 30,\nOperating income \u00a0\u00a02023 \u00a0\u00a0\u00a02022 \u00a0\u00a0%\nChange\nU.S. ", "page_label": "20", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "13556533-f636-4043-b74e-d5777dc1f94c", "node_type": "4", "metadata": {"page_label": "20", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "71adb01ff09f7179281e852239635c53e67340f863777e55544b8f0e9da9b0a1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "63a67739-a037-4018-a397-fd761133090d", "node_type": "1", "metadata": {"window": "(dollars in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30,\nRevenue \u00a0\u00a02023 \u00a0\u00a0\u00a02022 \u00a0\u00a0%\nChange\nU.S.  Healthcare Solutions \u00a0$61,928,984 \u00a0\u00a0$54,788,447 \u00a0\u00a013.0 %\nInternational Healthcare Solutions \u00a0\u00a06,994,689 \u00a0\u00a0\u00a06,387,474 \u00a0\u00a09.5 %\nIntersegment eliminations \u00a0\u00a0(1,342 )\u00a0\u00a0(1,772 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$68,922,331 \u00a0\u00a0$61,174,149 \u00a0\u00a012.7 %\n\u00a0 \u00a0Three Months Ended Sept ember 30,\nOperating income \u00a0\u00a02023 \u00a0\u00a0\u00a02022 \u00a0\u00a0%\nChange\nU.S.  Healthcare Solutions \u00a0$632,830 \u00a0\u00a0$578,416 \u00a0\u00a09.4 %\nInternational Healthcare Solutions \u00a0\u00a0168,157 \u00a0\u00a0\u00a0163,058 \u00a0\u00a03.1 %\nTotal segment operating income \u00a0\u00a0800,987 \u00a0\u00a0\u00a0741,474 \u00a0\u00a08.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation\nsettlements \u00a0\u00a070,582 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nLIFO expense \u00a0\u00a0(90,323 )\u00a0\u00a0(104,839 )\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(27,948 )\u00a0\u00a0(12,415 )\u00a0\u00a0\nAcquisition-related intangibles\namortization \u00a0\u00a0(169,900 )\u00a0\u00a0(72,685 )\u00a0\u00a0\nLitigation and opioid-related expenses \u00a0\u00a0(13,890 )\u00a0\u00a0(15,024 )\u00a0\u00a0\nAcquisition-related deal and\nintegration expenses \u00a0\u00a0(40,291 )\u00a0\u00a0(49,851 )\u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(52,276 )\u00a0\u00a0(32,141 )\u00a0\u00a0\n20", "original_text": "(dollars in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30,\nRevenue \u00a0\u00a02023 \u00a0\u00a0\u00a02022 \u00a0\u00a0%\nChange\nU.S. ", "page_label": "20", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3487784cbf2a9954dc0068bafff29287e021d76d0d9e3615f7fb968f91a6ac45", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9e08675f-319f-48f5-a2ab-72f93a678932", "node_type": "1", "metadata": {"window": "(dollars in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30,\nRevenue \u00a0\u00a02023 \u00a0\u00a0\u00a02022 \u00a0\u00a0%\nChange\nU.S.  Healthcare Solutions \u00a0$61,928,984 \u00a0\u00a0$54,788,447 \u00a0\u00a013.0 %\nInternational Healthcare Solutions \u00a0\u00a06,994,689 \u00a0\u00a0\u00a06,387,474 \u00a0\u00a09.5 %\nIntersegment eliminations \u00a0\u00a0(1,342 )\u00a0\u00a0(1,772 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$68,922,331 \u00a0\u00a0$61,174,149 \u00a0\u00a012.7 %\n\u00a0 \u00a0Three Months Ended Sept ember 30,\nOperating income \u00a0\u00a02023 \u00a0\u00a0\u00a02022 \u00a0\u00a0%\nChange\nU.S.  Healthcare Solutions \u00a0$632,830 \u00a0\u00a0$578,416 \u00a0\u00a09.4 %\nInternational Healthcare Solutions \u00a0\u00a0168,157 \u00a0\u00a0\u00a0163,058 \u00a0\u00a03.1 %\nTotal segment operating income \u00a0\u00a0800,987 \u00a0\u00a0\u00a0741,474 \u00a0\u00a08.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation\nsettlements \u00a0\u00a070,582 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nLIFO expense \u00a0\u00a0(90,323 )\u00a0\u00a0(104,839 )\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(27,948 )\u00a0\u00a0(12,415 )\u00a0\u00a0\nAcquisition-related intangibles\namortization \u00a0\u00a0(169,900 )\u00a0\u00a0(72,685 )\u00a0\u00a0\nLitigation and opioid-related expenses \u00a0\u00a0(13,890 )\u00a0\u00a0(15,024 )\u00a0\u00a0\nAcquisition-related deal and\nintegration expenses \u00a0\u00a0(40,291 )\u00a0\u00a0(49,851 )\u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(52,276 )\u00a0\u00a0(32,141 )\u00a0\u00a0\n20", "original_text": "Healthcare Solutions \u00a0$632,830 \u00a0\u00a0$578,416 \u00a0\u00a09.4 %\nInternational Healthcare Solutions \u00a0\u00a0168,157 \u00a0\u00a0\u00a0163,058 \u00a0\u00a03.1 %\nTotal segment operating income \u00a0\u00a0800,987 \u00a0\u00a0\u00a0741,474 \u00a0\u00a08.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation\nsettlements \u00a0\u00a070,582 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nLIFO expense \u00a0\u00a0(90,323 )\u00a0\u00a0(104,839 )\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(27,948 )\u00a0\u00a0(12,415 )\u00a0\u00a0\nAcquisition-related intangibles\namortization \u00a0\u00a0(169,900 )\u00a0\u00a0(72,685 )\u00a0\u00a0\nLitigation and opioid-related expenses \u00a0\u00a0(13,890 )\u00a0\u00a0(15,024 )\u00a0\u00a0\nAcquisition-related deal and\nintegration expenses \u00a0\u00a0(40,291 )\u00a0\u00a0(49,851 )\u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(52,276 )\u00a0\u00a0(32,141 )\u00a0\u00a0\n20"}, "hash": "b71c6708f9a562774ec17c40898aee1ba5130984e61ddeb4f206ff3e538e2c58", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions \u00a0$61,928,984 \u00a0\u00a0$54,788,447 \u00a0\u00a013.0 %\nInternational Healthcare Solutions \u00a0\u00a06,994,689 \u00a0\u00a0\u00a06,387,474 \u00a0\u00a09.5 %\nIntersegment eliminations \u00a0\u00a0(1,342 )\u00a0\u00a0(1,772 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$68,922,331 \u00a0\u00a0$61,174,149 \u00a0\u00a012.7 %\n\u00a0 \u00a0Three Months Ended Sept ember 30,\nOperating income \u00a0\u00a02023 \u00a0\u00a0\u00a02022 \u00a0\u00a0%\nChange\nU.S. ", "start_char_idx": 113, "end_char_idx": 427, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9e08675f-319f-48f5-a2ab-72f93a678932": {"__data__": {"id_": "9e08675f-319f-48f5-a2ab-72f93a678932", "embedding": null, "metadata": {"window": "(dollars in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30,\nRevenue \u00a0\u00a02023 \u00a0\u00a0\u00a02022 \u00a0\u00a0%\nChange\nU.S.  Healthcare Solutions \u00a0$61,928,984 \u00a0\u00a0$54,788,447 \u00a0\u00a013.0 %\nInternational Healthcare Solutions \u00a0\u00a06,994,689 \u00a0\u00a0\u00a06,387,474 \u00a0\u00a09.5 %\nIntersegment eliminations \u00a0\u00a0(1,342 )\u00a0\u00a0(1,772 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$68,922,331 \u00a0\u00a0$61,174,149 \u00a0\u00a012.7 %\n\u00a0 \u00a0Three Months Ended Sept ember 30,\nOperating income \u00a0\u00a02023 \u00a0\u00a0\u00a02022 \u00a0\u00a0%\nChange\nU.S.  Healthcare Solutions \u00a0$632,830 \u00a0\u00a0$578,416 \u00a0\u00a09.4 %\nInternational Healthcare Solutions \u00a0\u00a0168,157 \u00a0\u00a0\u00a0163,058 \u00a0\u00a03.1 %\nTotal segment operating income \u00a0\u00a0800,987 \u00a0\u00a0\u00a0741,474 \u00a0\u00a08.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation\nsettlements \u00a0\u00a070,582 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nLIFO expense \u00a0\u00a0(90,323 )\u00a0\u00a0(104,839 )\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(27,948 )\u00a0\u00a0(12,415 )\u00a0\u00a0\nAcquisition-related intangibles\namortization \u00a0\u00a0(169,900 )\u00a0\u00a0(72,685 )\u00a0\u00a0\nLitigation and opioid-related expenses \u00a0\u00a0(13,890 )\u00a0\u00a0(15,024 )\u00a0\u00a0\nAcquisition-related deal and\nintegration expenses \u00a0\u00a0(40,291 )\u00a0\u00a0(49,851 )\u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(52,276 )\u00a0\u00a0(32,141 )\u00a0\u00a0\n20", "original_text": "Healthcare Solutions \u00a0$632,830 \u00a0\u00a0$578,416 \u00a0\u00a09.4 %\nInternational Healthcare Solutions \u00a0\u00a0168,157 \u00a0\u00a0\u00a0163,058 \u00a0\u00a03.1 %\nTotal segment operating income \u00a0\u00a0800,987 \u00a0\u00a0\u00a0741,474 \u00a0\u00a08.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation\nsettlements \u00a0\u00a070,582 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nLIFO expense \u00a0\u00a0(90,323 )\u00a0\u00a0(104,839 )\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(27,948 )\u00a0\u00a0(12,415 )\u00a0\u00a0\nAcquisition-related intangibles\namortization \u00a0\u00a0(169,900 )\u00a0\u00a0(72,685 )\u00a0\u00a0\nLitigation and opioid-related expenses \u00a0\u00a0(13,890 )\u00a0\u00a0(15,024 )\u00a0\u00a0\nAcquisition-related deal and\nintegration expenses \u00a0\u00a0(40,291 )\u00a0\u00a0(49,851 )\u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(52,276 )\u00a0\u00a0(32,141 )\u00a0\u00a0\n20", "page_label": "20", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "13556533-f636-4043-b74e-d5777dc1f94c", "node_type": "4", "metadata": {"page_label": "20", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "71adb01ff09f7179281e852239635c53e67340f863777e55544b8f0e9da9b0a1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "509d48a6-c5d0-49d0-a1fd-00dbf3e83d05", "node_type": "1", "metadata": {"window": "(dollars in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30,\nRevenue \u00a0\u00a02023 \u00a0\u00a0\u00a02022 \u00a0\u00a0%\nChange\nU.S.  Healthcare Solutions \u00a0$61,928,984 \u00a0\u00a0$54,788,447 \u00a0\u00a013.0 %\nInternational Healthcare Solutions \u00a0\u00a06,994,689 \u00a0\u00a0\u00a06,387,474 \u00a0\u00a09.5 %\nIntersegment eliminations \u00a0\u00a0(1,342 )\u00a0\u00a0(1,772 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$68,922,331 \u00a0\u00a0$61,174,149 \u00a0\u00a012.7 %\n\u00a0 \u00a0Three Months Ended Sept ember 30,\nOperating income \u00a0\u00a02023 \u00a0\u00a0\u00a02022 \u00a0\u00a0%\nChange\nU.S.  Healthcare Solutions \u00a0$632,830 \u00a0\u00a0$578,416 \u00a0\u00a09.4 %\nInternational Healthcare Solutions \u00a0\u00a0168,157 \u00a0\u00a0\u00a0163,058 \u00a0\u00a03.1 %\nTotal segment operating income \u00a0\u00a0800,987 \u00a0\u00a0\u00a0741,474 \u00a0\u00a08.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation\nsettlements \u00a0\u00a070,582 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nLIFO expense \u00a0\u00a0(90,323 )\u00a0\u00a0(104,839 )\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(27,948 )\u00a0\u00a0(12,415 )\u00a0\u00a0\nAcquisition-related intangibles\namortization \u00a0\u00a0(169,900 )\u00a0\u00a0(72,685 )\u00a0\u00a0\nLitigation and opioid-related expenses \u00a0\u00a0(13,890 )\u00a0\u00a0(15,024 )\u00a0\u00a0\nAcquisition-related deal and\nintegration expenses \u00a0\u00a0(40,291 )\u00a0\u00a0(49,851 )\u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(52,276 )\u00a0\u00a0(32,141 )\u00a0\u00a0\n20", "original_text": "Healthcare Solutions \u00a0$61,928,984 \u00a0\u00a0$54,788,447 \u00a0\u00a013.0 %\nInternational Healthcare Solutions \u00a0\u00a06,994,689 \u00a0\u00a0\u00a06,387,474 \u00a0\u00a09.5 %\nIntersegment eliminations \u00a0\u00a0(1,342 )\u00a0\u00a0(1,772 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$68,922,331 \u00a0\u00a0$61,174,149 \u00a0\u00a012.7 %\n\u00a0 \u00a0Three Months Ended Sept ember 30,\nOperating income \u00a0\u00a02023 \u00a0\u00a0\u00a02022 \u00a0\u00a0%\nChange\nU.S. ", "page_label": "20", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f73278f8525748ce66334f09da91a29af2be985782e1fc0aab87271c951a75af", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5313847b-c593-4b09-bb95-8f35a43ed723", "node_type": "1", "metadata": {"window": "Operating income \u00a0$476,941 \u00a0\u00a0$454,519 \u00a0\u00a04.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.38 %\u00a0\u00a02.53 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.36 %\u00a0\u00a01.47 %\u00a0\u00a0\nOperating income \u00a0\u00a01.02 %\u00a0\u00a01.06 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.84 %\u00a0\u00a011.22 %\u00a0\u00a0\nOperating expenses \u00a0\u00a09.43 %\u00a0\u00a08.67 %\u00a0\u00a0\nOperating income \u00a0\u00a02.40 %\u00a0\u00a02.55 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.27 %\u00a0\u00a03.25 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.58 %\u00a0\u00a02.50 %\u00a0\u00a0\nOperating income \u00a0\u00a00.69 %\u00a0\u00a00.74 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.34 %\u00a0\u00a03.44 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.18 %\u00a0\u00a02.23 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.16 %\u00a0\u00a01.21 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "original_text": "Operating income \u00a0$476,941 \u00a0\u00a0$454,519 \u00a0\u00a04.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S. "}, "hash": "cb2383d8a2d1dcb0850a5736009ce575af561a6f70f90c29d717badc3b0fbdb4", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions \u00a0$632,830 \u00a0\u00a0$578,416 \u00a0\u00a09.4 %\nInternational Healthcare Solutions \u00a0\u00a0168,157 \u00a0\u00a0\u00a0163,058 \u00a0\u00a03.1 %\nTotal segment operating income \u00a0\u00a0800,987 \u00a0\u00a0\u00a0741,474 \u00a0\u00a08.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation\nsettlements \u00a0\u00a070,582 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nLIFO expense \u00a0\u00a0(90,323 )\u00a0\u00a0(104,839 )\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(27,948 )\u00a0\u00a0(12,415 )\u00a0\u00a0\nAcquisition-related intangibles\namortization \u00a0\u00a0(169,900 )\u00a0\u00a0(72,685 )\u00a0\u00a0\nLitigation and opioid-related expenses \u00a0\u00a0(13,890 )\u00a0\u00a0(15,024 )\u00a0\u00a0\nAcquisition-related deal and\nintegration expenses \u00a0\u00a0(40,291 )\u00a0\u00a0(49,851 )\u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(52,276 )\u00a0\u00a0(32,141 )\u00a0\u00a0\n20", "start_char_idx": 427, "end_char_idx": 1042, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5313847b-c593-4b09-bb95-8f35a43ed723": {"__data__": {"id_": "5313847b-c593-4b09-bb95-8f35a43ed723", "embedding": null, "metadata": {"window": "Operating income \u00a0$476,941 \u00a0\u00a0$454,519 \u00a0\u00a04.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.38 %\u00a0\u00a02.53 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.36 %\u00a0\u00a01.47 %\u00a0\u00a0\nOperating income \u00a0\u00a01.02 %\u00a0\u00a01.06 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.84 %\u00a0\u00a011.22 %\u00a0\u00a0\nOperating expenses \u00a0\u00a09.43 %\u00a0\u00a08.67 %\u00a0\u00a0\nOperating income \u00a0\u00a02.40 %\u00a0\u00a02.55 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.27 %\u00a0\u00a03.25 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.58 %\u00a0\u00a02.50 %\u00a0\u00a0\nOperating income \u00a0\u00a00.69 %\u00a0\u00a00.74 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.34 %\u00a0\u00a03.44 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.18 %\u00a0\u00a02.23 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.16 %\u00a0\u00a01.21 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "original_text": "Operating income \u00a0$476,941 \u00a0\u00a0$454,519 \u00a0\u00a04.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S. ", "page_label": "21", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "12de44de-010b-4dbb-ba8c-5cd0a66639dc", "node_type": "4", "metadata": {"page_label": "21", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4fd1655c8966ea5e82d5b74a02ce49a47ea1c1dbe7d85402e40b61b5733472c0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9e08675f-319f-48f5-a2ab-72f93a678932", "node_type": "1", "metadata": {"window": "(dollars in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30,\nRevenue \u00a0\u00a02023 \u00a0\u00a0\u00a02022 \u00a0\u00a0%\nChange\nU.S.  Healthcare Solutions \u00a0$61,928,984 \u00a0\u00a0$54,788,447 \u00a0\u00a013.0 %\nInternational Healthcare Solutions \u00a0\u00a06,994,689 \u00a0\u00a0\u00a06,387,474 \u00a0\u00a09.5 %\nIntersegment eliminations \u00a0\u00a0(1,342 )\u00a0\u00a0(1,772 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$68,922,331 \u00a0\u00a0$61,174,149 \u00a0\u00a012.7 %\n\u00a0 \u00a0Three Months Ended Sept ember 30,\nOperating income \u00a0\u00a02023 \u00a0\u00a0\u00a02022 \u00a0\u00a0%\nChange\nU.S.  Healthcare Solutions \u00a0$632,830 \u00a0\u00a0$578,416 \u00a0\u00a09.4 %\nInternational Healthcare Solutions \u00a0\u00a0168,157 \u00a0\u00a0\u00a0163,058 \u00a0\u00a03.1 %\nTotal segment operating income \u00a0\u00a0800,987 \u00a0\u00a0\u00a0741,474 \u00a0\u00a08.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation\nsettlements \u00a0\u00a070,582 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nLIFO expense \u00a0\u00a0(90,323 )\u00a0\u00a0(104,839 )\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(27,948 )\u00a0\u00a0(12,415 )\u00a0\u00a0\nAcquisition-related intangibles\namortization \u00a0\u00a0(169,900 )\u00a0\u00a0(72,685 )\u00a0\u00a0\nLitigation and opioid-related expenses \u00a0\u00a0(13,890 )\u00a0\u00a0(15,024 )\u00a0\u00a0\nAcquisition-related deal and\nintegration expenses \u00a0\u00a0(40,291 )\u00a0\u00a0(49,851 )\u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(52,276 )\u00a0\u00a0(32,141 )\u00a0\u00a0\n20", "original_text": "Healthcare Solutions \u00a0$632,830 \u00a0\u00a0$578,416 \u00a0\u00a09.4 %\nInternational Healthcare Solutions \u00a0\u00a0168,157 \u00a0\u00a0\u00a0163,058 \u00a0\u00a03.1 %\nTotal segment operating income \u00a0\u00a0800,987 \u00a0\u00a0\u00a0741,474 \u00a0\u00a08.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation\nsettlements \u00a0\u00a070,582 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nLIFO expense \u00a0\u00a0(90,323 )\u00a0\u00a0(104,839 )\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(27,948 )\u00a0\u00a0(12,415 )\u00a0\u00a0\nAcquisition-related intangibles\namortization \u00a0\u00a0(169,900 )\u00a0\u00a0(72,685 )\u00a0\u00a0\nLitigation and opioid-related expenses \u00a0\u00a0(13,890 )\u00a0\u00a0(15,024 )\u00a0\u00a0\nAcquisition-related deal and\nintegration expenses \u00a0\u00a0(40,291 )\u00a0\u00a0(49,851 )\u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(52,276 )\u00a0\u00a0(32,141 )\u00a0\u00a0\n20", "page_label": "20", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d657403454550335a9e47af5141619db33e876da7e8842c857f7021ff41fc935", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "06a6913f-00e1-468b-bea4-bb182b05cb0d", "node_type": "1", "metadata": {"window": "Operating income \u00a0$476,941 \u00a0\u00a0$454,519 \u00a0\u00a04.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.38 %\u00a0\u00a02.53 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.36 %\u00a0\u00a01.47 %\u00a0\u00a0\nOperating income \u00a0\u00a01.02 %\u00a0\u00a01.06 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.84 %\u00a0\u00a011.22 %\u00a0\u00a0\nOperating expenses \u00a0\u00a09.43 %\u00a0\u00a08.67 %\u00a0\u00a0\nOperating income \u00a0\u00a02.40 %\u00a0\u00a02.55 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.27 %\u00a0\u00a03.25 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.58 %\u00a0\u00a02.50 %\u00a0\u00a0\nOperating income \u00a0\u00a00.69 %\u00a0\u00a00.74 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.34 %\u00a0\u00a03.44 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.18 %\u00a0\u00a02.23 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.16 %\u00a0\u00a01.21 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n 21", "original_text": "Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.38 %\u00a0\u00a02.53 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.36 %\u00a0\u00a01.47 %\u00a0\u00a0\nOperating income \u00a0\u00a01.02 %\u00a0\u00a01.06 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.84 %\u00a0\u00a011.22 %\u00a0\u00a0\nOperating expenses \u00a0\u00a09.43 %\u00a0\u00a08.67 %\u00a0\u00a0\nOperating income \u00a0\u00a02.40 %\u00a0\u00a02.55 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc. "}, "hash": "859517afb520e8b405b715a6cef50ed7b77033e12042a240c6c666334fe38914", "class_name": "RelatedNodeInfo"}}, "text": "Operating income \u00a0$476,941 \u00a0\u00a0$454,519 \u00a0\u00a04.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S. ", "start_char_idx": 0, "end_char_idx": 106, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "06a6913f-00e1-468b-bea4-bb182b05cb0d": {"__data__": {"id_": "06a6913f-00e1-468b-bea4-bb182b05cb0d", "embedding": null, "metadata": {"window": "Operating income \u00a0$476,941 \u00a0\u00a0$454,519 \u00a0\u00a04.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.38 %\u00a0\u00a02.53 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.36 %\u00a0\u00a01.47 %\u00a0\u00a0\nOperating income \u00a0\u00a01.02 %\u00a0\u00a01.06 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.84 %\u00a0\u00a011.22 %\u00a0\u00a0\nOperating expenses \u00a0\u00a09.43 %\u00a0\u00a08.67 %\u00a0\u00a0\nOperating income \u00a0\u00a02.40 %\u00a0\u00a02.55 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.27 %\u00a0\u00a03.25 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.58 %\u00a0\u00a02.50 %\u00a0\u00a0\nOperating income \u00a0\u00a00.69 %\u00a0\u00a00.74 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.34 %\u00a0\u00a03.44 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.18 %\u00a0\u00a02.23 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.16 %\u00a0\u00a01.21 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n 21", "original_text": "Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.38 %\u00a0\u00a02.53 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.36 %\u00a0\u00a01.47 %\u00a0\u00a0\nOperating income \u00a0\u00a01.02 %\u00a0\u00a01.06 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.84 %\u00a0\u00a011.22 %\u00a0\u00a0\nOperating expenses \u00a0\u00a09.43 %\u00a0\u00a08.67 %\u00a0\u00a0\nOperating income \u00a0\u00a02.40 %\u00a0\u00a02.55 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc. ", "page_label": "21", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "12de44de-010b-4dbb-ba8c-5cd0a66639dc", "node_type": "4", "metadata": {"page_label": "21", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4fd1655c8966ea5e82d5b74a02ce49a47ea1c1dbe7d85402e40b61b5733472c0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5313847b-c593-4b09-bb95-8f35a43ed723", "node_type": "1", "metadata": {"window": "Operating income \u00a0$476,941 \u00a0\u00a0$454,519 \u00a0\u00a04.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.38 %\u00a0\u00a02.53 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.36 %\u00a0\u00a01.47 %\u00a0\u00a0\nOperating income \u00a0\u00a01.02 %\u00a0\u00a01.06 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.84 %\u00a0\u00a011.22 %\u00a0\u00a0\nOperating expenses \u00a0\u00a09.43 %\u00a0\u00a08.67 %\u00a0\u00a0\nOperating income \u00a0\u00a02.40 %\u00a0\u00a02.55 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.27 %\u00a0\u00a03.25 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.58 %\u00a0\u00a02.50 %\u00a0\u00a0\nOperating income \u00a0\u00a00.69 %\u00a0\u00a00.74 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.34 %\u00a0\u00a03.44 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.18 %\u00a0\u00a02.23 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.16 %\u00a0\u00a01.21 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "original_text": "Operating income \u00a0$476,941 \u00a0\u00a0$454,519 \u00a0\u00a04.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S. ", "page_label": "21", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c0e17a66c17068d68a146848e7dd7c62e81613b4e99f0ba4ebd9f11facd3c7e6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1cb414e1-de55-4b4b-bc0b-8759a5e5cd97", "node_type": "1", "metadata": {"window": "Operating income \u00a0$476,941 \u00a0\u00a0$454,519 \u00a0\u00a04.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.38 %\u00a0\u00a02.53 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.36 %\u00a0\u00a01.47 %\u00a0\u00a0\nOperating income \u00a0\u00a01.02 %\u00a0\u00a01.06 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.84 %\u00a0\u00a011.22 %\u00a0\u00a0\nOperating expenses \u00a0\u00a09.43 %\u00a0\u00a08.67 %\u00a0\u00a0\nOperating income \u00a0\u00a02.40 %\u00a0\u00a02.55 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.27 %\u00a0\u00a03.25 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.58 %\u00a0\u00a02.50 %\u00a0\u00a0\nOperating income \u00a0\u00a00.69 %\u00a0\u00a00.74 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.34 %\u00a0\u00a03.44 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.18 %\u00a0\u00a02.23 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.16 %\u00a0\u00a01.21 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n 21", "original_text": "(GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.27 %\u00a0\u00a03.25 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.58 %\u00a0\u00a02.50 %\u00a0\u00a0\nOperating income \u00a0\u00a00.69 %\u00a0\u00a00.74 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc. "}, "hash": "bbdc872dd2edc954019eb89e1f90c39c90648901cd14713cdeda8aace8e4c8a0", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.38 %\u00a0\u00a02.53 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.36 %\u00a0\u00a01.47 %\u00a0\u00a0\nOperating income \u00a0\u00a01.02 %\u00a0\u00a01.06 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.84 %\u00a0\u00a011.22 %\u00a0\u00a0\nOperating expenses \u00a0\u00a09.43 %\u00a0\u00a08.67 %\u00a0\u00a0\nOperating income \u00a0\u00a02.40 %\u00a0\u00a02.55 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc. ", "start_char_idx": 106, "end_char_idx": 430, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1cb414e1-de55-4b4b-bc0b-8759a5e5cd97": {"__data__": {"id_": "1cb414e1-de55-4b4b-bc0b-8759a5e5cd97", "embedding": null, "metadata": {"window": "Operating income \u00a0$476,941 \u00a0\u00a0$454,519 \u00a0\u00a04.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.38 %\u00a0\u00a02.53 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.36 %\u00a0\u00a01.47 %\u00a0\u00a0\nOperating income \u00a0\u00a01.02 %\u00a0\u00a01.06 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.84 %\u00a0\u00a011.22 %\u00a0\u00a0\nOperating expenses \u00a0\u00a09.43 %\u00a0\u00a08.67 %\u00a0\u00a0\nOperating income \u00a0\u00a02.40 %\u00a0\u00a02.55 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.27 %\u00a0\u00a03.25 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.58 %\u00a0\u00a02.50 %\u00a0\u00a0\nOperating income \u00a0\u00a00.69 %\u00a0\u00a00.74 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.34 %\u00a0\u00a03.44 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.18 %\u00a0\u00a02.23 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.16 %\u00a0\u00a01.21 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n 21", "original_text": "(GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.27 %\u00a0\u00a03.25 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.58 %\u00a0\u00a02.50 %\u00a0\u00a0\nOperating income \u00a0\u00a00.69 %\u00a0\u00a00.74 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc. ", "page_label": "21", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "12de44de-010b-4dbb-ba8c-5cd0a66639dc", "node_type": "4", "metadata": {"page_label": "21", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4fd1655c8966ea5e82d5b74a02ce49a47ea1c1dbe7d85402e40b61b5733472c0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "06a6913f-00e1-468b-bea4-bb182b05cb0d", "node_type": "1", "metadata": {"window": "Operating income \u00a0$476,941 \u00a0\u00a0$454,519 \u00a0\u00a04.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.38 %\u00a0\u00a02.53 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.36 %\u00a0\u00a01.47 %\u00a0\u00a0\nOperating income \u00a0\u00a01.02 %\u00a0\u00a01.06 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.84 %\u00a0\u00a011.22 %\u00a0\u00a0\nOperating expenses \u00a0\u00a09.43 %\u00a0\u00a08.67 %\u00a0\u00a0\nOperating income \u00a0\u00a02.40 %\u00a0\u00a02.55 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.27 %\u00a0\u00a03.25 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.58 %\u00a0\u00a02.50 %\u00a0\u00a0\nOperating income \u00a0\u00a00.69 %\u00a0\u00a00.74 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.34 %\u00a0\u00a03.44 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.18 %\u00a0\u00a02.23 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.16 %\u00a0\u00a01.21 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n 21", "original_text": "Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.38 %\u00a0\u00a02.53 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.36 %\u00a0\u00a01.47 %\u00a0\u00a0\nOperating income \u00a0\u00a01.02 %\u00a0\u00a01.06 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.84 %\u00a0\u00a011.22 %\u00a0\u00a0\nOperating expenses \u00a0\u00a09.43 %\u00a0\u00a08.67 %\u00a0\u00a0\nOperating income \u00a0\u00a02.40 %\u00a0\u00a02.55 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc. ", "page_label": "21", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "308358db28701b395602f0991a9efb8ea851977d24fa88896551b53ad8764d60", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aa23464f-beff-487b-95ff-f8db5c4bf148", "node_type": "1", "metadata": {"window": "Operating income \u00a0$476,941 \u00a0\u00a0$454,519 \u00a0\u00a04.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.38 %\u00a0\u00a02.53 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.36 %\u00a0\u00a01.47 %\u00a0\u00a0\nOperating income \u00a0\u00a01.02 %\u00a0\u00a01.06 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.84 %\u00a0\u00a011.22 %\u00a0\u00a0\nOperating expenses \u00a0\u00a09.43 %\u00a0\u00a08.67 %\u00a0\u00a0\nOperating income \u00a0\u00a02.40 %\u00a0\u00a02.55 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.27 %\u00a0\u00a03.25 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.58 %\u00a0\u00a02.50 %\u00a0\u00a0\nOperating income \u00a0\u00a00.69 %\u00a0\u00a00.74 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.34 %\u00a0\u00a03.44 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.18 %\u00a0\u00a02.23 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.16 %\u00a0\u00a01.21 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n 21", "original_text": "(Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.34 %\u00a0\u00a03.44 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.18 %\u00a0\u00a02.23 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.16 %\u00a0\u00a01.21 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n"}, "hash": "ad0185007be10a96c1a7d850fb7a9589fe834c3d91a9233bd62da1023ac8098b", "class_name": "RelatedNodeInfo"}}, "text": "(GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.27 %\u00a0\u00a03.25 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.58 %\u00a0\u00a02.50 %\u00a0\u00a0\nOperating income \u00a0\u00a00.69 %\u00a0\u00a00.74 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc. ", "start_char_idx": 430, "end_char_idx": 577, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aa23464f-beff-487b-95ff-f8db5c4bf148": {"__data__": {"id_": "aa23464f-beff-487b-95ff-f8db5c4bf148", "embedding": null, "metadata": {"window": "Operating income \u00a0$476,941 \u00a0\u00a0$454,519 \u00a0\u00a04.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.38 %\u00a0\u00a02.53 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.36 %\u00a0\u00a01.47 %\u00a0\u00a0\nOperating income \u00a0\u00a01.02 %\u00a0\u00a01.06 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.84 %\u00a0\u00a011.22 %\u00a0\u00a0\nOperating expenses \u00a0\u00a09.43 %\u00a0\u00a08.67 %\u00a0\u00a0\nOperating income \u00a0\u00a02.40 %\u00a0\u00a02.55 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.27 %\u00a0\u00a03.25 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.58 %\u00a0\u00a02.50 %\u00a0\u00a0\nOperating income \u00a0\u00a00.69 %\u00a0\u00a00.74 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.34 %\u00a0\u00a03.44 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.18 %\u00a0\u00a02.23 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.16 %\u00a0\u00a01.21 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n 21", "original_text": "(Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.34 %\u00a0\u00a03.44 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.18 %\u00a0\u00a02.23 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.16 %\u00a0\u00a01.21 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "21", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "12de44de-010b-4dbb-ba8c-5cd0a66639dc", "node_type": "4", "metadata": {"page_label": "21", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4fd1655c8966ea5e82d5b74a02ce49a47ea1c1dbe7d85402e40b61b5733472c0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1cb414e1-de55-4b4b-bc0b-8759a5e5cd97", "node_type": "1", "metadata": {"window": "Operating income \u00a0$476,941 \u00a0\u00a0$454,519 \u00a0\u00a04.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.38 %\u00a0\u00a02.53 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.36 %\u00a0\u00a01.47 %\u00a0\u00a0\nOperating income \u00a0\u00a01.02 %\u00a0\u00a01.06 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.84 %\u00a0\u00a011.22 %\u00a0\u00a0\nOperating expenses \u00a0\u00a09.43 %\u00a0\u00a08.67 %\u00a0\u00a0\nOperating income \u00a0\u00a02.40 %\u00a0\u00a02.55 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.27 %\u00a0\u00a03.25 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.58 %\u00a0\u00a02.50 %\u00a0\u00a0\nOperating income \u00a0\u00a00.69 %\u00a0\u00a00.74 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.34 %\u00a0\u00a03.44 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.18 %\u00a0\u00a02.23 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.16 %\u00a0\u00a01.21 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n 21", "original_text": "(GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.27 %\u00a0\u00a03.25 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.58 %\u00a0\u00a02.50 %\u00a0\u00a0\nOperating income \u00a0\u00a00.69 %\u00a0\u00a00.74 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc. ", "page_label": "21", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "087a0719f236827e66807825e0ac45ee1c1c4a1082ab5e790dc070433776f9ab", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c7ab1842-3884-4321-9614-005d00308a71", "node_type": "1", "metadata": {"window": "Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.38 %\u00a0\u00a02.53 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.36 %\u00a0\u00a01.47 %\u00a0\u00a0\nOperating income \u00a0\u00a01.02 %\u00a0\u00a01.06 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.84 %\u00a0\u00a011.22 %\u00a0\u00a0\nOperating expenses \u00a0\u00a09.43 %\u00a0\u00a08.67 %\u00a0\u00a0\nOperating income \u00a0\u00a02.40 %\u00a0\u00a02.55 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.27 %\u00a0\u00a03.25 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.58 %\u00a0\u00a02.50 %\u00a0\u00a0\nOperating income \u00a0\u00a00.69 %\u00a0\u00a00.74 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.34 %\u00a0\u00a03.44 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.18 %\u00a0\u00a02.23 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.16 %\u00a0\u00a01.21 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n 21", "original_text": "21"}, "hash": "db10ca13dc01cb21fb0b2288b674decdc88d065e4b027b5845e1718fbf5cd780", "class_name": "RelatedNodeInfo"}}, "text": "(Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.34 %\u00a0\u00a03.44 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.18 %\u00a0\u00a02.23 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.16 %\u00a0\u00a01.21 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "start_char_idx": 577, "end_char_idx": 907, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c7ab1842-3884-4321-9614-005d00308a71": {"__data__": {"id_": "c7ab1842-3884-4321-9614-005d00308a71", "embedding": null, "metadata": {"window": "Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.38 %\u00a0\u00a02.53 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.36 %\u00a0\u00a01.47 %\u00a0\u00a0\nOperating income \u00a0\u00a01.02 %\u00a0\u00a01.06 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.84 %\u00a0\u00a011.22 %\u00a0\u00a0\nOperating expenses \u00a0\u00a09.43 %\u00a0\u00a08.67 %\u00a0\u00a0\nOperating income \u00a0\u00a02.40 %\u00a0\u00a02.55 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.27 %\u00a0\u00a03.25 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.58 %\u00a0\u00a02.50 %\u00a0\u00a0\nOperating income \u00a0\u00a00.69 %\u00a0\u00a00.74 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.34 %\u00a0\u00a03.44 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.18 %\u00a0\u00a02.23 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.16 %\u00a0\u00a01.21 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n 21", "original_text": "21", "page_label": "21", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "12de44de-010b-4dbb-ba8c-5cd0a66639dc", "node_type": "4", "metadata": {"page_label": "21", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4fd1655c8966ea5e82d5b74a02ce49a47ea1c1dbe7d85402e40b61b5733472c0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aa23464f-beff-487b-95ff-f8db5c4bf148", "node_type": "1", "metadata": {"window": "Operating income \u00a0$476,941 \u00a0\u00a0$454,519 \u00a0\u00a04.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.38 %\u00a0\u00a02.53 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.36 %\u00a0\u00a01.47 %\u00a0\u00a0\nOperating income \u00a0\u00a01.02 %\u00a0\u00a01.06 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.84 %\u00a0\u00a011.22 %\u00a0\u00a0\nOperating expenses \u00a0\u00a09.43 %\u00a0\u00a08.67 %\u00a0\u00a0\nOperating income \u00a0\u00a02.40 %\u00a0\u00a02.55 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.27 %\u00a0\u00a03.25 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.58 %\u00a0\u00a02.50 %\u00a0\u00a0\nOperating income \u00a0\u00a00.69 %\u00a0\u00a00.74 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.34 %\u00a0\u00a03.44 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.18 %\u00a0\u00a02.23 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.16 %\u00a0\u00a01.21 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n 21", "original_text": "(Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.34 %\u00a0\u00a03.44 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.18 %\u00a0\u00a02.23 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.16 %\u00a0\u00a01.21 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "21", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "54b6e4e753b0cfb16287e3a0ace6d1059809fe7bd10837585f9e678a2934f31c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4915a2f6-0c42-4e19-a9e4-1c4126df4895", "node_type": "1", "metadata": {"window": "CENC ORA, INC.\n SUMMAR Y SEGMENT INFORMA TION\n(dollars in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30,\nRevenue \u00a0\u00a02023 \u00a0\u00a0\u00a02022 \u00a0\u00a0%\nChange\nU.S.  Healthcare Solutions \u00a0$234,759,218 \u00a0\u00a0$212,100,202 \u00a0\u00a010.7 %\nInternational Healthcare Solutions \u00a0\u00a027,418,679 \u00a0\u00a0\u00a026,491,673 \u00a0\u00a03.5 %\nIntersegment eliminations \u00a0\u00a0(4,486 )\u00a0\u00a0(4,869 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$262,173,411 \u00a0\u00a0$238,587,006 \u00a0\u00a09.9 %\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30,\nOperating income \u00a0\u00a02023 \u00a0\u00a0\u00a02022 \u00a0\u00a0%\nChange\nU.S.  Healthcare Solutions \u00a0$2,596,559 \u00a0\u00a0$2,456,972 \u00a0\u00a05.7 %\nInternational Healthcare Solutions \u00a0\u00a0692,562 \u00a0\u00a0\u00a0706,458 \u00a0\u00a0(2.0 )%\nTotal segment operating income \u00a0\u00a03,289,121 \u00a0\u00a0\u00a03,163,430 \u00a0\u00a04.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation\nsettlements \u00a0\u00a0239,092 \u00a0\u00a0\u00a01,835 \u00a0\u00a0\u00a0\nLIFO expense \u00a0\u00a0(204,595 )\u00a0\u00a0(67,171 )\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(86,967 )\u00a0\u00a0(40,033 )\u00a0\u00a0\nAcquisition-related intangibles\namortization \u00a0\u00a0(551,046 )\u00a0\u00a0(304,551 )\u00a0\u00a0\nLitigation and opioid-related credit\n(expenses) \u00a0\u00a024,693 \u00a0\u00a0\u00a0(123,191 )\u00a0\u00a0\n22", "original_text": "CENC ORA, INC.\n"}, "hash": "2a48f0ea81055220c4ca0467ee943fca0b3bd1bc01947c089e50a41637acd5e5", "class_name": "RelatedNodeInfo"}}, "text": "21", "start_char_idx": 723, "end_char_idx": 725, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4915a2f6-0c42-4e19-a9e4-1c4126df4895": {"__data__": {"id_": "4915a2f6-0c42-4e19-a9e4-1c4126df4895", "embedding": null, "metadata": {"window": "CENC ORA, INC.\n SUMMAR Y SEGMENT INFORMA TION\n(dollars in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30,\nRevenue \u00a0\u00a02023 \u00a0\u00a0\u00a02022 \u00a0\u00a0%\nChange\nU.S.  Healthcare Solutions \u00a0$234,759,218 \u00a0\u00a0$212,100,202 \u00a0\u00a010.7 %\nInternational Healthcare Solutions \u00a0\u00a027,418,679 \u00a0\u00a0\u00a026,491,673 \u00a0\u00a03.5 %\nIntersegment eliminations \u00a0\u00a0(4,486 )\u00a0\u00a0(4,869 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$262,173,411 \u00a0\u00a0$238,587,006 \u00a0\u00a09.9 %\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30,\nOperating income \u00a0\u00a02023 \u00a0\u00a0\u00a02022 \u00a0\u00a0%\nChange\nU.S.  Healthcare Solutions \u00a0$2,596,559 \u00a0\u00a0$2,456,972 \u00a0\u00a05.7 %\nInternational Healthcare Solutions \u00a0\u00a0692,562 \u00a0\u00a0\u00a0706,458 \u00a0\u00a0(2.0 )%\nTotal segment operating income \u00a0\u00a03,289,121 \u00a0\u00a0\u00a03,163,430 \u00a0\u00a04.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation\nsettlements \u00a0\u00a0239,092 \u00a0\u00a0\u00a01,835 \u00a0\u00a0\u00a0\nLIFO expense \u00a0\u00a0(204,595 )\u00a0\u00a0(67,171 )\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(86,967 )\u00a0\u00a0(40,033 )\u00a0\u00a0\nAcquisition-related intangibles\namortization \u00a0\u00a0(551,046 )\u00a0\u00a0(304,551 )\u00a0\u00a0\nLitigation and opioid-related credit\n(expenses) \u00a0\u00a024,693 \u00a0\u00a0\u00a0(123,191 )\u00a0\u00a0\n22", "original_text": "CENC ORA, INC.\n", "page_label": "22", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "eab89660-9e2b-49b6-b6a5-0548492eca3c", "node_type": "4", "metadata": {"page_label": "22", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "52abe11d8b455e048e780a32c07ee21e347444611c299d8b3dbd1e62e6c9c349", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c7ab1842-3884-4321-9614-005d00308a71", "node_type": "1", "metadata": {"window": "Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.38 %\u00a0\u00a02.53 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.36 %\u00a0\u00a01.47 %\u00a0\u00a0\nOperating income \u00a0\u00a01.02 %\u00a0\u00a01.06 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.84 %\u00a0\u00a011.22 %\u00a0\u00a0\nOperating expenses \u00a0\u00a09.43 %\u00a0\u00a08.67 %\u00a0\u00a0\nOperating income \u00a0\u00a02.40 %\u00a0\u00a02.55 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.27 %\u00a0\u00a03.25 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.58 %\u00a0\u00a02.50 %\u00a0\u00a0\nOperating income \u00a0\u00a00.69 %\u00a0\u00a00.74 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.34 %\u00a0\u00a03.44 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.18 %\u00a0\u00a02.23 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.16 %\u00a0\u00a01.21 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n 21", "original_text": "21", "page_label": "21", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "16f617f060e2fa8bd0024b055496525862cb74052d843c3767fd43381ff4cf5c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "31763b9d-6d88-45cb-bb5c-c7158daa935d", "node_type": "1", "metadata": {"window": "CENC ORA, INC.\n SUMMAR Y SEGMENT INFORMA TION\n(dollars in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30,\nRevenue \u00a0\u00a02023 \u00a0\u00a0\u00a02022 \u00a0\u00a0%\nChange\nU.S.  Healthcare Solutions \u00a0$234,759,218 \u00a0\u00a0$212,100,202 \u00a0\u00a010.7 %\nInternational Healthcare Solutions \u00a0\u00a027,418,679 \u00a0\u00a0\u00a026,491,673 \u00a0\u00a03.5 %\nIntersegment eliminations \u00a0\u00a0(4,486 )\u00a0\u00a0(4,869 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$262,173,411 \u00a0\u00a0$238,587,006 \u00a0\u00a09.9 %\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30,\nOperating income \u00a0\u00a02023 \u00a0\u00a0\u00a02022 \u00a0\u00a0%\nChange\nU.S.  Healthcare Solutions \u00a0$2,596,559 \u00a0\u00a0$2,456,972 \u00a0\u00a05.7 %\nInternational Healthcare Solutions \u00a0\u00a0692,562 \u00a0\u00a0\u00a0706,458 \u00a0\u00a0(2.0 )%\nTotal segment operating income \u00a0\u00a03,289,121 \u00a0\u00a0\u00a03,163,430 \u00a0\u00a04.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation\nsettlements \u00a0\u00a0239,092 \u00a0\u00a0\u00a01,835 \u00a0\u00a0\u00a0\nLIFO expense \u00a0\u00a0(204,595 )\u00a0\u00a0(67,171 )\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(86,967 )\u00a0\u00a0(40,033 )\u00a0\u00a0\nAcquisition-related intangibles\namortization \u00a0\u00a0(551,046 )\u00a0\u00a0(304,551 )\u00a0\u00a0\nLitigation and opioid-related credit\n(expenses) \u00a0\u00a024,693 \u00a0\u00a0\u00a0(123,191 )\u00a0\u00a0\n22", "original_text": "SUMMAR Y SEGMENT INFORMA TION\n(dollars in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30,\nRevenue \u00a0\u00a02023 \u00a0\u00a0\u00a02022 \u00a0\u00a0%\nChange\nU.S. "}, "hash": "d214b03d6ffb153603409330ae26467ec24b1c2ee2cc5e39e008807116a6709c", "class_name": "RelatedNodeInfo"}}, "text": "CENC ORA, INC.\n", "start_char_idx": 0, "end_char_idx": 15, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "31763b9d-6d88-45cb-bb5c-c7158daa935d": {"__data__": {"id_": "31763b9d-6d88-45cb-bb5c-c7158daa935d", "embedding": null, "metadata": {"window": "CENC ORA, INC.\n SUMMAR Y SEGMENT INFORMA TION\n(dollars in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30,\nRevenue \u00a0\u00a02023 \u00a0\u00a0\u00a02022 \u00a0\u00a0%\nChange\nU.S.  Healthcare Solutions \u00a0$234,759,218 \u00a0\u00a0$212,100,202 \u00a0\u00a010.7 %\nInternational Healthcare Solutions \u00a0\u00a027,418,679 \u00a0\u00a0\u00a026,491,673 \u00a0\u00a03.5 %\nIntersegment eliminations \u00a0\u00a0(4,486 )\u00a0\u00a0(4,869 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$262,173,411 \u00a0\u00a0$238,587,006 \u00a0\u00a09.9 %\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30,\nOperating income \u00a0\u00a02023 \u00a0\u00a0\u00a02022 \u00a0\u00a0%\nChange\nU.S.  Healthcare Solutions \u00a0$2,596,559 \u00a0\u00a0$2,456,972 \u00a0\u00a05.7 %\nInternational Healthcare Solutions \u00a0\u00a0692,562 \u00a0\u00a0\u00a0706,458 \u00a0\u00a0(2.0 )%\nTotal segment operating income \u00a0\u00a03,289,121 \u00a0\u00a0\u00a03,163,430 \u00a0\u00a04.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation\nsettlements \u00a0\u00a0239,092 \u00a0\u00a0\u00a01,835 \u00a0\u00a0\u00a0\nLIFO expense \u00a0\u00a0(204,595 )\u00a0\u00a0(67,171 )\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(86,967 )\u00a0\u00a0(40,033 )\u00a0\u00a0\nAcquisition-related intangibles\namortization \u00a0\u00a0(551,046 )\u00a0\u00a0(304,551 )\u00a0\u00a0\nLitigation and opioid-related credit\n(expenses) \u00a0\u00a024,693 \u00a0\u00a0\u00a0(123,191 )\u00a0\u00a0\n22", "original_text": "SUMMAR Y SEGMENT INFORMA TION\n(dollars in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30,\nRevenue \u00a0\u00a02023 \u00a0\u00a0\u00a02022 \u00a0\u00a0%\nChange\nU.S. ", "page_label": "22", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "eab89660-9e2b-49b6-b6a5-0548492eca3c", "node_type": "4", "metadata": {"page_label": "22", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "52abe11d8b455e048e780a32c07ee21e347444611c299d8b3dbd1e62e6c9c349", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4915a2f6-0c42-4e19-a9e4-1c4126df4895", "node_type": "1", "metadata": {"window": "CENC ORA, INC.\n SUMMAR Y SEGMENT INFORMA TION\n(dollars in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30,\nRevenue \u00a0\u00a02023 \u00a0\u00a0\u00a02022 \u00a0\u00a0%\nChange\nU.S.  Healthcare Solutions \u00a0$234,759,218 \u00a0\u00a0$212,100,202 \u00a0\u00a010.7 %\nInternational Healthcare Solutions \u00a0\u00a027,418,679 \u00a0\u00a0\u00a026,491,673 \u00a0\u00a03.5 %\nIntersegment eliminations \u00a0\u00a0(4,486 )\u00a0\u00a0(4,869 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$262,173,411 \u00a0\u00a0$238,587,006 \u00a0\u00a09.9 %\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30,\nOperating income \u00a0\u00a02023 \u00a0\u00a0\u00a02022 \u00a0\u00a0%\nChange\nU.S.  Healthcare Solutions \u00a0$2,596,559 \u00a0\u00a0$2,456,972 \u00a0\u00a05.7 %\nInternational Healthcare Solutions \u00a0\u00a0692,562 \u00a0\u00a0\u00a0706,458 \u00a0\u00a0(2.0 )%\nTotal segment operating income \u00a0\u00a03,289,121 \u00a0\u00a0\u00a03,163,430 \u00a0\u00a04.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation\nsettlements \u00a0\u00a0239,092 \u00a0\u00a0\u00a01,835 \u00a0\u00a0\u00a0\nLIFO expense \u00a0\u00a0(204,595 )\u00a0\u00a0(67,171 )\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(86,967 )\u00a0\u00a0(40,033 )\u00a0\u00a0\nAcquisition-related intangibles\namortization \u00a0\u00a0(551,046 )\u00a0\u00a0(304,551 )\u00a0\u00a0\nLitigation and opioid-related credit\n(expenses) \u00a0\u00a024,693 \u00a0\u00a0\u00a0(123,191 )\u00a0\u00a0\n22", "original_text": "CENC ORA, INC.\n", "page_label": "22", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "58a74c1d847d63f91259a73936c02b501552410fb8eca79c01bf5268edb5fafb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9ba4a894-e49e-4a53-9b0a-f5a77dc05bb1", "node_type": "1", "metadata": {"window": "CENC ORA, INC.\n SUMMAR Y SEGMENT INFORMA TION\n(dollars in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30,\nRevenue \u00a0\u00a02023 \u00a0\u00a0\u00a02022 \u00a0\u00a0%\nChange\nU.S.  Healthcare Solutions \u00a0$234,759,218 \u00a0\u00a0$212,100,202 \u00a0\u00a010.7 %\nInternational Healthcare Solutions \u00a0\u00a027,418,679 \u00a0\u00a0\u00a026,491,673 \u00a0\u00a03.5 %\nIntersegment eliminations \u00a0\u00a0(4,486 )\u00a0\u00a0(4,869 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$262,173,411 \u00a0\u00a0$238,587,006 \u00a0\u00a09.9 %\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30,\nOperating income \u00a0\u00a02023 \u00a0\u00a0\u00a02022 \u00a0\u00a0%\nChange\nU.S.  Healthcare Solutions \u00a0$2,596,559 \u00a0\u00a0$2,456,972 \u00a0\u00a05.7 %\nInternational Healthcare Solutions \u00a0\u00a0692,562 \u00a0\u00a0\u00a0706,458 \u00a0\u00a0(2.0 )%\nTotal segment operating income \u00a0\u00a03,289,121 \u00a0\u00a0\u00a03,163,430 \u00a0\u00a04.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation\nsettlements \u00a0\u00a0239,092 \u00a0\u00a0\u00a01,835 \u00a0\u00a0\u00a0\nLIFO expense \u00a0\u00a0(204,595 )\u00a0\u00a0(67,171 )\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(86,967 )\u00a0\u00a0(40,033 )\u00a0\u00a0\nAcquisition-related intangibles\namortization \u00a0\u00a0(551,046 )\u00a0\u00a0(304,551 )\u00a0\u00a0\nLitigation and opioid-related credit\n(expenses) \u00a0\u00a024,693 \u00a0\u00a0\u00a0(123,191 )\u00a0\u00a0\n22", "original_text": "Healthcare Solutions \u00a0$234,759,218 \u00a0\u00a0$212,100,202 \u00a0\u00a010.7 %\nInternational Healthcare Solutions \u00a0\u00a027,418,679 \u00a0\u00a0\u00a026,491,673 \u00a0\u00a03.5 %\nIntersegment eliminations \u00a0\u00a0(4,486 )\u00a0\u00a0(4,869 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$262,173,411 \u00a0\u00a0$238,587,006 \u00a0\u00a09.9 %\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30,\nOperating income \u00a0\u00a02023 \u00a0\u00a0\u00a02022 \u00a0\u00a0%\nChange\nU.S. "}, "hash": "5ee716820d72d07e0cfc92114ac2c3121d7ad194cec252943579b83a4bc9ae46", "class_name": "RelatedNodeInfo"}}, "text": "SUMMAR Y SEGMENT INFORMA TION\n(dollars in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30,\nRevenue \u00a0\u00a02023 \u00a0\u00a0\u00a02022 \u00a0\u00a0%\nChange\nU.S. ", "start_char_idx": 15, "end_char_idx": 158, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9ba4a894-e49e-4a53-9b0a-f5a77dc05bb1": {"__data__": {"id_": "9ba4a894-e49e-4a53-9b0a-f5a77dc05bb1", "embedding": null, "metadata": {"window": "CENC ORA, INC.\n SUMMAR Y SEGMENT INFORMA TION\n(dollars in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30,\nRevenue \u00a0\u00a02023 \u00a0\u00a0\u00a02022 \u00a0\u00a0%\nChange\nU.S.  Healthcare Solutions \u00a0$234,759,218 \u00a0\u00a0$212,100,202 \u00a0\u00a010.7 %\nInternational Healthcare Solutions \u00a0\u00a027,418,679 \u00a0\u00a0\u00a026,491,673 \u00a0\u00a03.5 %\nIntersegment eliminations \u00a0\u00a0(4,486 )\u00a0\u00a0(4,869 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$262,173,411 \u00a0\u00a0$238,587,006 \u00a0\u00a09.9 %\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30,\nOperating income \u00a0\u00a02023 \u00a0\u00a0\u00a02022 \u00a0\u00a0%\nChange\nU.S.  Healthcare Solutions \u00a0$2,596,559 \u00a0\u00a0$2,456,972 \u00a0\u00a05.7 %\nInternational Healthcare Solutions \u00a0\u00a0692,562 \u00a0\u00a0\u00a0706,458 \u00a0\u00a0(2.0 )%\nTotal segment operating income \u00a0\u00a03,289,121 \u00a0\u00a0\u00a03,163,430 \u00a0\u00a04.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation\nsettlements \u00a0\u00a0239,092 \u00a0\u00a0\u00a01,835 \u00a0\u00a0\u00a0\nLIFO expense \u00a0\u00a0(204,595 )\u00a0\u00a0(67,171 )\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(86,967 )\u00a0\u00a0(40,033 )\u00a0\u00a0\nAcquisition-related intangibles\namortization \u00a0\u00a0(551,046 )\u00a0\u00a0(304,551 )\u00a0\u00a0\nLitigation and opioid-related credit\n(expenses) \u00a0\u00a024,693 \u00a0\u00a0\u00a0(123,191 )\u00a0\u00a0\n22", "original_text": "Healthcare Solutions \u00a0$234,759,218 \u00a0\u00a0$212,100,202 \u00a0\u00a010.7 %\nInternational Healthcare Solutions \u00a0\u00a027,418,679 \u00a0\u00a0\u00a026,491,673 \u00a0\u00a03.5 %\nIntersegment eliminations \u00a0\u00a0(4,486 )\u00a0\u00a0(4,869 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$262,173,411 \u00a0\u00a0$238,587,006 \u00a0\u00a09.9 %\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30,\nOperating income \u00a0\u00a02023 \u00a0\u00a0\u00a02022 \u00a0\u00a0%\nChange\nU.S. ", "page_label": "22", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "eab89660-9e2b-49b6-b6a5-0548492eca3c", "node_type": "4", "metadata": {"page_label": "22", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "52abe11d8b455e048e780a32c07ee21e347444611c299d8b3dbd1e62e6c9c349", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "31763b9d-6d88-45cb-bb5c-c7158daa935d", "node_type": "1", "metadata": {"window": "CENC ORA, INC.\n SUMMAR Y SEGMENT INFORMA TION\n(dollars in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30,\nRevenue \u00a0\u00a02023 \u00a0\u00a0\u00a02022 \u00a0\u00a0%\nChange\nU.S.  Healthcare Solutions \u00a0$234,759,218 \u00a0\u00a0$212,100,202 \u00a0\u00a010.7 %\nInternational Healthcare Solutions \u00a0\u00a027,418,679 \u00a0\u00a0\u00a026,491,673 \u00a0\u00a03.5 %\nIntersegment eliminations \u00a0\u00a0(4,486 )\u00a0\u00a0(4,869 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$262,173,411 \u00a0\u00a0$238,587,006 \u00a0\u00a09.9 %\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30,\nOperating income \u00a0\u00a02023 \u00a0\u00a0\u00a02022 \u00a0\u00a0%\nChange\nU.S.  Healthcare Solutions \u00a0$2,596,559 \u00a0\u00a0$2,456,972 \u00a0\u00a05.7 %\nInternational Healthcare Solutions \u00a0\u00a0692,562 \u00a0\u00a0\u00a0706,458 \u00a0\u00a0(2.0 )%\nTotal segment operating income \u00a0\u00a03,289,121 \u00a0\u00a0\u00a03,163,430 \u00a0\u00a04.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation\nsettlements \u00a0\u00a0239,092 \u00a0\u00a0\u00a01,835 \u00a0\u00a0\u00a0\nLIFO expense \u00a0\u00a0(204,595 )\u00a0\u00a0(67,171 )\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(86,967 )\u00a0\u00a0(40,033 )\u00a0\u00a0\nAcquisition-related intangibles\namortization \u00a0\u00a0(551,046 )\u00a0\u00a0(304,551 )\u00a0\u00a0\nLitigation and opioid-related credit\n(expenses) \u00a0\u00a024,693 \u00a0\u00a0\u00a0(123,191 )\u00a0\u00a0\n22", "original_text": "SUMMAR Y SEGMENT INFORMA TION\n(dollars in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30,\nRevenue \u00a0\u00a02023 \u00a0\u00a0\u00a02022 \u00a0\u00a0%\nChange\nU.S. ", "page_label": "22", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8e152456e685017d3d962a1916551916c8ec77d0b98ed3668c4e7832324d9f09", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "63d05847-6bc7-4c4f-af6f-f087465b562c", "node_type": "1", "metadata": {"window": "CENC ORA, INC.\n SUMMAR Y SEGMENT INFORMA TION\n(dollars in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30,\nRevenue \u00a0\u00a02023 \u00a0\u00a0\u00a02022 \u00a0\u00a0%\nChange\nU.S.  Healthcare Solutions \u00a0$234,759,218 \u00a0\u00a0$212,100,202 \u00a0\u00a010.7 %\nInternational Healthcare Solutions \u00a0\u00a027,418,679 \u00a0\u00a0\u00a026,491,673 \u00a0\u00a03.5 %\nIntersegment eliminations \u00a0\u00a0(4,486 )\u00a0\u00a0(4,869 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$262,173,411 \u00a0\u00a0$238,587,006 \u00a0\u00a09.9 %\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30,\nOperating income \u00a0\u00a02023 \u00a0\u00a0\u00a02022 \u00a0\u00a0%\nChange\nU.S.  Healthcare Solutions \u00a0$2,596,559 \u00a0\u00a0$2,456,972 \u00a0\u00a05.7 %\nInternational Healthcare Solutions \u00a0\u00a0692,562 \u00a0\u00a0\u00a0706,458 \u00a0\u00a0(2.0 )%\nTotal segment operating income \u00a0\u00a03,289,121 \u00a0\u00a0\u00a03,163,430 \u00a0\u00a04.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation\nsettlements \u00a0\u00a0239,092 \u00a0\u00a0\u00a01,835 \u00a0\u00a0\u00a0\nLIFO expense \u00a0\u00a0(204,595 )\u00a0\u00a0(67,171 )\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(86,967 )\u00a0\u00a0(40,033 )\u00a0\u00a0\nAcquisition-related intangibles\namortization \u00a0\u00a0(551,046 )\u00a0\u00a0(304,551 )\u00a0\u00a0\nLitigation and opioid-related credit\n(expenses) \u00a0\u00a024,693 \u00a0\u00a0\u00a0(123,191 )\u00a0\u00a0\n22", "original_text": "Healthcare Solutions \u00a0$2,596,559 \u00a0\u00a0$2,456,972 \u00a0\u00a05.7 %\nInternational Healthcare Solutions \u00a0\u00a0692,562 \u00a0\u00a0\u00a0706,458 \u00a0\u00a0(2.0 )%\nTotal segment operating income \u00a0\u00a03,289,121 \u00a0\u00a0\u00a03,163,430 \u00a0\u00a04.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation\nsettlements \u00a0\u00a0239,092 \u00a0\u00a0\u00a01,835 \u00a0\u00a0\u00a0\nLIFO expense \u00a0\u00a0(204,595 )\u00a0\u00a0(67,171 )\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(86,967 )\u00a0\u00a0(40,033 )\u00a0\u00a0\nAcquisition-related intangibles\namortization \u00a0\u00a0(551,046 )\u00a0\u00a0(304,551 )\u00a0\u00a0\nLitigation and opioid-related credit\n(expenses) \u00a0\u00a024,693 \u00a0\u00a0\u00a0(123,191 )\u00a0\u00a0\n22"}, "hash": "b48f78b03cb37ec2c06035e03f0fd33ac5f190552efb990439667e50f2993dd9", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions \u00a0$234,759,218 \u00a0\u00a0$212,100,202 \u00a0\u00a010.7 %\nInternational Healthcare Solutions \u00a0\u00a027,418,679 \u00a0\u00a0\u00a026,491,673 \u00a0\u00a03.5 %\nIntersegment eliminations \u00a0\u00a0(4,486 )\u00a0\u00a0(4,869 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$262,173,411 \u00a0\u00a0$238,587,006 \u00a0\u00a09.9 %\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30,\nOperating income \u00a0\u00a02023 \u00a0\u00a0\u00a02022 \u00a0\u00a0%\nChange\nU.S. ", "start_char_idx": 158, "end_char_idx": 477, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "63d05847-6bc7-4c4f-af6f-f087465b562c": {"__data__": {"id_": "63d05847-6bc7-4c4f-af6f-f087465b562c", "embedding": null, "metadata": {"window": "CENC ORA, INC.\n SUMMAR Y SEGMENT INFORMA TION\n(dollars in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30,\nRevenue \u00a0\u00a02023 \u00a0\u00a0\u00a02022 \u00a0\u00a0%\nChange\nU.S.  Healthcare Solutions \u00a0$234,759,218 \u00a0\u00a0$212,100,202 \u00a0\u00a010.7 %\nInternational Healthcare Solutions \u00a0\u00a027,418,679 \u00a0\u00a0\u00a026,491,673 \u00a0\u00a03.5 %\nIntersegment eliminations \u00a0\u00a0(4,486 )\u00a0\u00a0(4,869 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$262,173,411 \u00a0\u00a0$238,587,006 \u00a0\u00a09.9 %\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30,\nOperating income \u00a0\u00a02023 \u00a0\u00a0\u00a02022 \u00a0\u00a0%\nChange\nU.S.  Healthcare Solutions \u00a0$2,596,559 \u00a0\u00a0$2,456,972 \u00a0\u00a05.7 %\nInternational Healthcare Solutions \u00a0\u00a0692,562 \u00a0\u00a0\u00a0706,458 \u00a0\u00a0(2.0 )%\nTotal segment operating income \u00a0\u00a03,289,121 \u00a0\u00a0\u00a03,163,430 \u00a0\u00a04.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation\nsettlements \u00a0\u00a0239,092 \u00a0\u00a0\u00a01,835 \u00a0\u00a0\u00a0\nLIFO expense \u00a0\u00a0(204,595 )\u00a0\u00a0(67,171 )\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(86,967 )\u00a0\u00a0(40,033 )\u00a0\u00a0\nAcquisition-related intangibles\namortization \u00a0\u00a0(551,046 )\u00a0\u00a0(304,551 )\u00a0\u00a0\nLitigation and opioid-related credit\n(expenses) \u00a0\u00a024,693 \u00a0\u00a0\u00a0(123,191 )\u00a0\u00a0\n22", "original_text": "Healthcare Solutions \u00a0$2,596,559 \u00a0\u00a0$2,456,972 \u00a0\u00a05.7 %\nInternational Healthcare Solutions \u00a0\u00a0692,562 \u00a0\u00a0\u00a0706,458 \u00a0\u00a0(2.0 )%\nTotal segment operating income \u00a0\u00a03,289,121 \u00a0\u00a0\u00a03,163,430 \u00a0\u00a04.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation\nsettlements \u00a0\u00a0239,092 \u00a0\u00a0\u00a01,835 \u00a0\u00a0\u00a0\nLIFO expense \u00a0\u00a0(204,595 )\u00a0\u00a0(67,171 )\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(86,967 )\u00a0\u00a0(40,033 )\u00a0\u00a0\nAcquisition-related intangibles\namortization \u00a0\u00a0(551,046 )\u00a0\u00a0(304,551 )\u00a0\u00a0\nLitigation and opioid-related credit\n(expenses) \u00a0\u00a024,693 \u00a0\u00a0\u00a0(123,191 )\u00a0\u00a0\n22", "page_label": "22", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "eab89660-9e2b-49b6-b6a5-0548492eca3c", "node_type": "4", "metadata": {"page_label": "22", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "52abe11d8b455e048e780a32c07ee21e347444611c299d8b3dbd1e62e6c9c349", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9ba4a894-e49e-4a53-9b0a-f5a77dc05bb1", "node_type": "1", "metadata": {"window": "CENC ORA, INC.\n SUMMAR Y SEGMENT INFORMA TION\n(dollars in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30,\nRevenue \u00a0\u00a02023 \u00a0\u00a0\u00a02022 \u00a0\u00a0%\nChange\nU.S.  Healthcare Solutions \u00a0$234,759,218 \u00a0\u00a0$212,100,202 \u00a0\u00a010.7 %\nInternational Healthcare Solutions \u00a0\u00a027,418,679 \u00a0\u00a0\u00a026,491,673 \u00a0\u00a03.5 %\nIntersegment eliminations \u00a0\u00a0(4,486 )\u00a0\u00a0(4,869 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$262,173,411 \u00a0\u00a0$238,587,006 \u00a0\u00a09.9 %\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30,\nOperating income \u00a0\u00a02023 \u00a0\u00a0\u00a02022 \u00a0\u00a0%\nChange\nU.S.  Healthcare Solutions \u00a0$2,596,559 \u00a0\u00a0$2,456,972 \u00a0\u00a05.7 %\nInternational Healthcare Solutions \u00a0\u00a0692,562 \u00a0\u00a0\u00a0706,458 \u00a0\u00a0(2.0 )%\nTotal segment operating income \u00a0\u00a03,289,121 \u00a0\u00a0\u00a03,163,430 \u00a0\u00a04.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation\nsettlements \u00a0\u00a0239,092 \u00a0\u00a0\u00a01,835 \u00a0\u00a0\u00a0\nLIFO expense \u00a0\u00a0(204,595 )\u00a0\u00a0(67,171 )\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(86,967 )\u00a0\u00a0(40,033 )\u00a0\u00a0\nAcquisition-related intangibles\namortization \u00a0\u00a0(551,046 )\u00a0\u00a0(304,551 )\u00a0\u00a0\nLitigation and opioid-related credit\n(expenses) \u00a0\u00a024,693 \u00a0\u00a0\u00a0(123,191 )\u00a0\u00a0\n22", "original_text": "Healthcare Solutions \u00a0$234,759,218 \u00a0\u00a0$212,100,202 \u00a0\u00a010.7 %\nInternational Healthcare Solutions \u00a0\u00a027,418,679 \u00a0\u00a0\u00a026,491,673 \u00a0\u00a03.5 %\nIntersegment eliminations \u00a0\u00a0(4,486 )\u00a0\u00a0(4,869 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$262,173,411 \u00a0\u00a0$238,587,006 \u00a0\u00a09.9 %\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30,\nOperating income \u00a0\u00a02023 \u00a0\u00a0\u00a02022 \u00a0\u00a0%\nChange\nU.S. ", "page_label": "22", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e6c49e4bea8f3b0ae82d51f7344025db5d7711caff398aadcfe9dabdea240f64", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "00290e2a-a120-4263-9fe1-95f63004c029", "node_type": "1", "metadata": {"window": "Acquisition-related deal and\nintegration expenses \u00a0\u00a0(139,683 )\u00a0\u00a0(119,561 )\u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(229,884 )\u00a0\u00a0(63,498 )\u00a0\u00a0\nGoodwill impairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(75,936 )\u00a0\u00a0\nImpairment of assets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,946 )\u00a0\u00a0\nOperating income \u00a0$2,340,731 \u00a0\u00a0$2,366,378 \u00a0\u00a0(1.1 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.48 %\u00a0\u00a02.57 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.37 %\u00a0\u00a01.41 %\u00a0\u00a0\nOperating income \u00a0\u00a01.11 %\u00a0\u00a01.16 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.64 %\u00a0\u00a011.12 %\u00a0\u00a0\nOperating expenses \u00a0\u00a09.11 %\u00a0\u00a08.46 %\u00a0\u00a0\nOperating income \u00a0\u00a02.53 %\u00a0\u00a02.67 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.42 %\u00a0\u00a03.48 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.52 %\u00a0\u00a02.49 %\u00a0\u00a0\nOperating income \u00a0\u00a00.89 %\u00a0\u00a00.99 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.44 %\u00a0\u00a03.52 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.18 %\u00a0\u00a02.20 %\u00a0\u00a0\n23", "original_text": "Acquisition-related deal and\nintegration expenses \u00a0\u00a0(139,683 )\u00a0\u00a0(119,561 )\u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(229,884 )\u00a0\u00a0(63,498 )\u00a0\u00a0\nGoodwill impairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(75,936 )\u00a0\u00a0\nImpairment of assets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,946 )\u00a0\u00a0\nOperating income \u00a0$2,340,731 \u00a0\u00a0$2,366,378 \u00a0\u00a0(1.1 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S. "}, "hash": "a579c80e898b8a733172128966a924ac8e286241e968c2a934d2ed44b66cdc3a", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions \u00a0$2,596,559 \u00a0\u00a0$2,456,972 \u00a0\u00a05.7 %\nInternational Healthcare Solutions \u00a0\u00a0692,562 \u00a0\u00a0\u00a0706,458 \u00a0\u00a0(2.0 )%\nTotal segment operating income \u00a0\u00a03,289,121 \u00a0\u00a0\u00a03,163,430 \u00a0\u00a04.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation\nsettlements \u00a0\u00a0239,092 \u00a0\u00a0\u00a01,835 \u00a0\u00a0\u00a0\nLIFO expense \u00a0\u00a0(204,595 )\u00a0\u00a0(67,171 )\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(86,967 )\u00a0\u00a0(40,033 )\u00a0\u00a0\nAcquisition-related intangibles\namortization \u00a0\u00a0(551,046 )\u00a0\u00a0(304,551 )\u00a0\u00a0\nLitigation and opioid-related credit\n(expenses) \u00a0\u00a024,693 \u00a0\u00a0\u00a0(123,191 )\u00a0\u00a0\n22", "start_char_idx": 477, "end_char_idx": 984, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "00290e2a-a120-4263-9fe1-95f63004c029": {"__data__": {"id_": "00290e2a-a120-4263-9fe1-95f63004c029", "embedding": null, "metadata": {"window": "Acquisition-related deal and\nintegration expenses \u00a0\u00a0(139,683 )\u00a0\u00a0(119,561 )\u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(229,884 )\u00a0\u00a0(63,498 )\u00a0\u00a0\nGoodwill impairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(75,936 )\u00a0\u00a0\nImpairment of assets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,946 )\u00a0\u00a0\nOperating income \u00a0$2,340,731 \u00a0\u00a0$2,366,378 \u00a0\u00a0(1.1 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.48 %\u00a0\u00a02.57 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.37 %\u00a0\u00a01.41 %\u00a0\u00a0\nOperating income \u00a0\u00a01.11 %\u00a0\u00a01.16 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.64 %\u00a0\u00a011.12 %\u00a0\u00a0\nOperating expenses \u00a0\u00a09.11 %\u00a0\u00a08.46 %\u00a0\u00a0\nOperating income \u00a0\u00a02.53 %\u00a0\u00a02.67 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.42 %\u00a0\u00a03.48 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.52 %\u00a0\u00a02.49 %\u00a0\u00a0\nOperating income \u00a0\u00a00.89 %\u00a0\u00a00.99 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.44 %\u00a0\u00a03.52 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.18 %\u00a0\u00a02.20 %\u00a0\u00a0\n23", "original_text": "Acquisition-related deal and\nintegration expenses \u00a0\u00a0(139,683 )\u00a0\u00a0(119,561 )\u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(229,884 )\u00a0\u00a0(63,498 )\u00a0\u00a0\nGoodwill impairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(75,936 )\u00a0\u00a0\nImpairment of assets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,946 )\u00a0\u00a0\nOperating income \u00a0$2,340,731 \u00a0\u00a0$2,366,378 \u00a0\u00a0(1.1 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S. ", "page_label": "23", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9f8f0848-5179-4290-915a-2ce8e88fd05b", "node_type": "4", "metadata": {"page_label": "23", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dc3a2f9d4e633005f8d93c780ab970d9d03a68f91c1f1a45d2ebf13159277aff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "63d05847-6bc7-4c4f-af6f-f087465b562c", "node_type": "1", "metadata": {"window": "CENC ORA, INC.\n SUMMAR Y SEGMENT INFORMA TION\n(dollars in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30,\nRevenue \u00a0\u00a02023 \u00a0\u00a0\u00a02022 \u00a0\u00a0%\nChange\nU.S.  Healthcare Solutions \u00a0$234,759,218 \u00a0\u00a0$212,100,202 \u00a0\u00a010.7 %\nInternational Healthcare Solutions \u00a0\u00a027,418,679 \u00a0\u00a0\u00a026,491,673 \u00a0\u00a03.5 %\nIntersegment eliminations \u00a0\u00a0(4,486 )\u00a0\u00a0(4,869 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$262,173,411 \u00a0\u00a0$238,587,006 \u00a0\u00a09.9 %\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30,\nOperating income \u00a0\u00a02023 \u00a0\u00a0\u00a02022 \u00a0\u00a0%\nChange\nU.S.  Healthcare Solutions \u00a0$2,596,559 \u00a0\u00a0$2,456,972 \u00a0\u00a05.7 %\nInternational Healthcare Solutions \u00a0\u00a0692,562 \u00a0\u00a0\u00a0706,458 \u00a0\u00a0(2.0 )%\nTotal segment operating income \u00a0\u00a03,289,121 \u00a0\u00a0\u00a03,163,430 \u00a0\u00a04.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation\nsettlements \u00a0\u00a0239,092 \u00a0\u00a0\u00a01,835 \u00a0\u00a0\u00a0\nLIFO expense \u00a0\u00a0(204,595 )\u00a0\u00a0(67,171 )\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(86,967 )\u00a0\u00a0(40,033 )\u00a0\u00a0\nAcquisition-related intangibles\namortization \u00a0\u00a0(551,046 )\u00a0\u00a0(304,551 )\u00a0\u00a0\nLitigation and opioid-related credit\n(expenses) \u00a0\u00a024,693 \u00a0\u00a0\u00a0(123,191 )\u00a0\u00a0\n22", "original_text": "Healthcare Solutions \u00a0$2,596,559 \u00a0\u00a0$2,456,972 \u00a0\u00a05.7 %\nInternational Healthcare Solutions \u00a0\u00a0692,562 \u00a0\u00a0\u00a0706,458 \u00a0\u00a0(2.0 )%\nTotal segment operating income \u00a0\u00a03,289,121 \u00a0\u00a0\u00a03,163,430 \u00a0\u00a04.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation\nsettlements \u00a0\u00a0239,092 \u00a0\u00a0\u00a01,835 \u00a0\u00a0\u00a0\nLIFO expense \u00a0\u00a0(204,595 )\u00a0\u00a0(67,171 )\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(86,967 )\u00a0\u00a0(40,033 )\u00a0\u00a0\nAcquisition-related intangibles\namortization \u00a0\u00a0(551,046 )\u00a0\u00a0(304,551 )\u00a0\u00a0\nLitigation and opioid-related credit\n(expenses) \u00a0\u00a024,693 \u00a0\u00a0\u00a0(123,191 )\u00a0\u00a0\n22", "page_label": "22", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b8e96c83a5e3e31cbb5b802a65f4eb4ce2e4c9703a931f845f3318ba3d40f779", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bc8008ac-d6fb-40d3-a972-f0f5d4ab4fe8", "node_type": "1", "metadata": {"window": "Acquisition-related deal and\nintegration expenses \u00a0\u00a0(139,683 )\u00a0\u00a0(119,561 )\u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(229,884 )\u00a0\u00a0(63,498 )\u00a0\u00a0\nGoodwill impairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(75,936 )\u00a0\u00a0\nImpairment of assets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,946 )\u00a0\u00a0\nOperating income \u00a0$2,340,731 \u00a0\u00a0$2,366,378 \u00a0\u00a0(1.1 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.48 %\u00a0\u00a02.57 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.37 %\u00a0\u00a01.41 %\u00a0\u00a0\nOperating income \u00a0\u00a01.11 %\u00a0\u00a01.16 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.64 %\u00a0\u00a011.12 %\u00a0\u00a0\nOperating expenses \u00a0\u00a09.11 %\u00a0\u00a08.46 %\u00a0\u00a0\nOperating income \u00a0\u00a02.53 %\u00a0\u00a02.67 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.42 %\u00a0\u00a03.48 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.52 %\u00a0\u00a02.49 %\u00a0\u00a0\nOperating income \u00a0\u00a00.89 %\u00a0\u00a00.99 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.44 %\u00a0\u00a03.52 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.18 %\u00a0\u00a02.20 %\u00a0\u00a0\n23", "original_text": "Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.48 %\u00a0\u00a02.57 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.37 %\u00a0\u00a01.41 %\u00a0\u00a0\nOperating income \u00a0\u00a01.11 %\u00a0\u00a01.16 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.64 %\u00a0\u00a011.12 %\u00a0\u00a0\nOperating expenses \u00a0\u00a09.11 %\u00a0\u00a08.46 %\u00a0\u00a0\nOperating income \u00a0\u00a02.53 %\u00a0\u00a02.67 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc. "}, "hash": "287ec8124acbdebd4a65adf73ad0fcf1194a5b0d573c629cdc8ab5a9e8e3690d", "class_name": "RelatedNodeInfo"}}, "text": "Acquisition-related deal and\nintegration expenses \u00a0\u00a0(139,683 )\u00a0\u00a0(119,561 )\u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(229,884 )\u00a0\u00a0(63,498 )\u00a0\u00a0\nGoodwill impairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(75,936 )\u00a0\u00a0\nImpairment of assets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,946 )\u00a0\u00a0\nOperating income \u00a0$2,340,731 \u00a0\u00a0$2,366,378 \u00a0\u00a0(1.1 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S. ", "start_char_idx": 0, "end_char_idx": 326, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bc8008ac-d6fb-40d3-a972-f0f5d4ab4fe8": {"__data__": {"id_": "bc8008ac-d6fb-40d3-a972-f0f5d4ab4fe8", "embedding": null, "metadata": {"window": "Acquisition-related deal and\nintegration expenses \u00a0\u00a0(139,683 )\u00a0\u00a0(119,561 )\u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(229,884 )\u00a0\u00a0(63,498 )\u00a0\u00a0\nGoodwill impairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(75,936 )\u00a0\u00a0\nImpairment of assets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,946 )\u00a0\u00a0\nOperating income \u00a0$2,340,731 \u00a0\u00a0$2,366,378 \u00a0\u00a0(1.1 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.48 %\u00a0\u00a02.57 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.37 %\u00a0\u00a01.41 %\u00a0\u00a0\nOperating income \u00a0\u00a01.11 %\u00a0\u00a01.16 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.64 %\u00a0\u00a011.12 %\u00a0\u00a0\nOperating expenses \u00a0\u00a09.11 %\u00a0\u00a08.46 %\u00a0\u00a0\nOperating income \u00a0\u00a02.53 %\u00a0\u00a02.67 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.42 %\u00a0\u00a03.48 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.52 %\u00a0\u00a02.49 %\u00a0\u00a0\nOperating income \u00a0\u00a00.89 %\u00a0\u00a00.99 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.44 %\u00a0\u00a03.52 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.18 %\u00a0\u00a02.20 %\u00a0\u00a0\n23", "original_text": "Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.48 %\u00a0\u00a02.57 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.37 %\u00a0\u00a01.41 %\u00a0\u00a0\nOperating income \u00a0\u00a01.11 %\u00a0\u00a01.16 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.64 %\u00a0\u00a011.12 %\u00a0\u00a0\nOperating expenses \u00a0\u00a09.11 %\u00a0\u00a08.46 %\u00a0\u00a0\nOperating income \u00a0\u00a02.53 %\u00a0\u00a02.67 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc. ", "page_label": "23", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9f8f0848-5179-4290-915a-2ce8e88fd05b", "node_type": "4", "metadata": {"page_label": "23", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dc3a2f9d4e633005f8d93c780ab970d9d03a68f91c1f1a45d2ebf13159277aff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "00290e2a-a120-4263-9fe1-95f63004c029", "node_type": "1", "metadata": {"window": "Acquisition-related deal and\nintegration expenses \u00a0\u00a0(139,683 )\u00a0\u00a0(119,561 )\u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(229,884 )\u00a0\u00a0(63,498 )\u00a0\u00a0\nGoodwill impairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(75,936 )\u00a0\u00a0\nImpairment of assets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,946 )\u00a0\u00a0\nOperating income \u00a0$2,340,731 \u00a0\u00a0$2,366,378 \u00a0\u00a0(1.1 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.48 %\u00a0\u00a02.57 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.37 %\u00a0\u00a01.41 %\u00a0\u00a0\nOperating income \u00a0\u00a01.11 %\u00a0\u00a01.16 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.64 %\u00a0\u00a011.12 %\u00a0\u00a0\nOperating expenses \u00a0\u00a09.11 %\u00a0\u00a08.46 %\u00a0\u00a0\nOperating income \u00a0\u00a02.53 %\u00a0\u00a02.67 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.42 %\u00a0\u00a03.48 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.52 %\u00a0\u00a02.49 %\u00a0\u00a0\nOperating income \u00a0\u00a00.89 %\u00a0\u00a00.99 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.44 %\u00a0\u00a03.52 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.18 %\u00a0\u00a02.20 %\u00a0\u00a0\n23", "original_text": "Acquisition-related deal and\nintegration expenses \u00a0\u00a0(139,683 )\u00a0\u00a0(119,561 )\u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(229,884 )\u00a0\u00a0(63,498 )\u00a0\u00a0\nGoodwill impairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(75,936 )\u00a0\u00a0\nImpairment of assets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,946 )\u00a0\u00a0\nOperating income \u00a0$2,340,731 \u00a0\u00a0$2,366,378 \u00a0\u00a0(1.1 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S. ", "page_label": "23", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b09835eb648706042b9d0679fb3adabaf48a2527708721ff796794b818a12d93", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "efd7088c-e46d-4c1a-ba7e-25543b139e6b", "node_type": "1", "metadata": {"window": "Acquisition-related deal and\nintegration expenses \u00a0\u00a0(139,683 )\u00a0\u00a0(119,561 )\u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(229,884 )\u00a0\u00a0(63,498 )\u00a0\u00a0\nGoodwill impairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(75,936 )\u00a0\u00a0\nImpairment of assets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,946 )\u00a0\u00a0\nOperating income \u00a0$2,340,731 \u00a0\u00a0$2,366,378 \u00a0\u00a0(1.1 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.48 %\u00a0\u00a02.57 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.37 %\u00a0\u00a01.41 %\u00a0\u00a0\nOperating income \u00a0\u00a01.11 %\u00a0\u00a01.16 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.64 %\u00a0\u00a011.12 %\u00a0\u00a0\nOperating expenses \u00a0\u00a09.11 %\u00a0\u00a08.46 %\u00a0\u00a0\nOperating income \u00a0\u00a02.53 %\u00a0\u00a02.67 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.42 %\u00a0\u00a03.48 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.52 %\u00a0\u00a02.49 %\u00a0\u00a0\nOperating income \u00a0\u00a00.89 %\u00a0\u00a00.99 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.44 %\u00a0\u00a03.52 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.18 %\u00a0\u00a02.20 %\u00a0\u00a0\n23", "original_text": "(GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.42 %\u00a0\u00a03.48 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.52 %\u00a0\u00a02.49 %\u00a0\u00a0\nOperating income \u00a0\u00a00.89 %\u00a0\u00a00.99 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc. "}, "hash": "69d81f8eb4ff932547c4e8c86fd11879458acbe4843497af0a24ea1c3130c24b", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.48 %\u00a0\u00a02.57 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.37 %\u00a0\u00a01.41 %\u00a0\u00a0\nOperating income \u00a0\u00a01.11 %\u00a0\u00a01.16 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.64 %\u00a0\u00a011.12 %\u00a0\u00a0\nOperating expenses \u00a0\u00a09.11 %\u00a0\u00a08.46 %\u00a0\u00a0\nOperating income \u00a0\u00a02.53 %\u00a0\u00a02.67 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc. ", "start_char_idx": 326, "end_char_idx": 650, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "efd7088c-e46d-4c1a-ba7e-25543b139e6b": {"__data__": {"id_": "efd7088c-e46d-4c1a-ba7e-25543b139e6b", "embedding": null, "metadata": {"window": "Acquisition-related deal and\nintegration expenses \u00a0\u00a0(139,683 )\u00a0\u00a0(119,561 )\u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(229,884 )\u00a0\u00a0(63,498 )\u00a0\u00a0\nGoodwill impairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(75,936 )\u00a0\u00a0\nImpairment of assets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,946 )\u00a0\u00a0\nOperating income \u00a0$2,340,731 \u00a0\u00a0$2,366,378 \u00a0\u00a0(1.1 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.48 %\u00a0\u00a02.57 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.37 %\u00a0\u00a01.41 %\u00a0\u00a0\nOperating income \u00a0\u00a01.11 %\u00a0\u00a01.16 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.64 %\u00a0\u00a011.12 %\u00a0\u00a0\nOperating expenses \u00a0\u00a09.11 %\u00a0\u00a08.46 %\u00a0\u00a0\nOperating income \u00a0\u00a02.53 %\u00a0\u00a02.67 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.42 %\u00a0\u00a03.48 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.52 %\u00a0\u00a02.49 %\u00a0\u00a0\nOperating income \u00a0\u00a00.89 %\u00a0\u00a00.99 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.44 %\u00a0\u00a03.52 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.18 %\u00a0\u00a02.20 %\u00a0\u00a0\n23", "original_text": "(GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.42 %\u00a0\u00a03.48 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.52 %\u00a0\u00a02.49 %\u00a0\u00a0\nOperating income \u00a0\u00a00.89 %\u00a0\u00a00.99 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc. ", "page_label": "23", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9f8f0848-5179-4290-915a-2ce8e88fd05b", "node_type": "4", "metadata": {"page_label": "23", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dc3a2f9d4e633005f8d93c780ab970d9d03a68f91c1f1a45d2ebf13159277aff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bc8008ac-d6fb-40d3-a972-f0f5d4ab4fe8", "node_type": "1", "metadata": {"window": "Acquisition-related deal and\nintegration expenses \u00a0\u00a0(139,683 )\u00a0\u00a0(119,561 )\u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(229,884 )\u00a0\u00a0(63,498 )\u00a0\u00a0\nGoodwill impairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(75,936 )\u00a0\u00a0\nImpairment of assets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,946 )\u00a0\u00a0\nOperating income \u00a0$2,340,731 \u00a0\u00a0$2,366,378 \u00a0\u00a0(1.1 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.48 %\u00a0\u00a02.57 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.37 %\u00a0\u00a01.41 %\u00a0\u00a0\nOperating income \u00a0\u00a01.11 %\u00a0\u00a01.16 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.64 %\u00a0\u00a011.12 %\u00a0\u00a0\nOperating expenses \u00a0\u00a09.11 %\u00a0\u00a08.46 %\u00a0\u00a0\nOperating income \u00a0\u00a02.53 %\u00a0\u00a02.67 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.42 %\u00a0\u00a03.48 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.52 %\u00a0\u00a02.49 %\u00a0\u00a0\nOperating income \u00a0\u00a00.89 %\u00a0\u00a00.99 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.44 %\u00a0\u00a03.52 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.18 %\u00a0\u00a02.20 %\u00a0\u00a0\n23", "original_text": "Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.48 %\u00a0\u00a02.57 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.37 %\u00a0\u00a01.41 %\u00a0\u00a0\nOperating income \u00a0\u00a01.11 %\u00a0\u00a01.16 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.64 %\u00a0\u00a011.12 %\u00a0\u00a0\nOperating expenses \u00a0\u00a09.11 %\u00a0\u00a08.46 %\u00a0\u00a0\nOperating income \u00a0\u00a02.53 %\u00a0\u00a02.67 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc. ", "page_label": "23", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a380987a567119c735955873a54544323e463b61b6dd92592735f6bb6a19ad27", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "87539361-2953-426c-9dc7-d6f9578af2d2", "node_type": "1", "metadata": {"window": "Acquisition-related deal and\nintegration expenses \u00a0\u00a0(139,683 )\u00a0\u00a0(119,561 )\u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(229,884 )\u00a0\u00a0(63,498 )\u00a0\u00a0\nGoodwill impairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(75,936 )\u00a0\u00a0\nImpairment of assets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,946 )\u00a0\u00a0\nOperating income \u00a0$2,340,731 \u00a0\u00a0$2,366,378 \u00a0\u00a0(1.1 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.48 %\u00a0\u00a02.57 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.37 %\u00a0\u00a01.41 %\u00a0\u00a0\nOperating income \u00a0\u00a01.11 %\u00a0\u00a01.16 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.64 %\u00a0\u00a011.12 %\u00a0\u00a0\nOperating expenses \u00a0\u00a09.11 %\u00a0\u00a08.46 %\u00a0\u00a0\nOperating income \u00a0\u00a02.53 %\u00a0\u00a02.67 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.42 %\u00a0\u00a03.48 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.52 %\u00a0\u00a02.49 %\u00a0\u00a0\nOperating income \u00a0\u00a00.89 %\u00a0\u00a00.99 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.44 %\u00a0\u00a03.52 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.18 %\u00a0\u00a02.20 %\u00a0\u00a0\n23", "original_text": "(Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.44 %\u00a0\u00a03.52 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.18 %\u00a0\u00a02.20 %\u00a0\u00a0\n23"}, "hash": "603471f8eb0d07d72f7a15731b9c1ffa365feefe8cf240e9befeea9d6a465d93", "class_name": "RelatedNodeInfo"}}, "text": "(GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.42 %\u00a0\u00a03.48 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.52 %\u00a0\u00a02.49 %\u00a0\u00a0\nOperating income \u00a0\u00a00.89 %\u00a0\u00a00.99 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc. ", "start_char_idx": 650, "end_char_idx": 797, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "87539361-2953-426c-9dc7-d6f9578af2d2": {"__data__": {"id_": "87539361-2953-426c-9dc7-d6f9578af2d2", "embedding": null, "metadata": {"window": "Acquisition-related deal and\nintegration expenses \u00a0\u00a0(139,683 )\u00a0\u00a0(119,561 )\u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(229,884 )\u00a0\u00a0(63,498 )\u00a0\u00a0\nGoodwill impairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(75,936 )\u00a0\u00a0\nImpairment of assets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,946 )\u00a0\u00a0\nOperating income \u00a0$2,340,731 \u00a0\u00a0$2,366,378 \u00a0\u00a0(1.1 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.48 %\u00a0\u00a02.57 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.37 %\u00a0\u00a01.41 %\u00a0\u00a0\nOperating income \u00a0\u00a01.11 %\u00a0\u00a01.16 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.64 %\u00a0\u00a011.12 %\u00a0\u00a0\nOperating expenses \u00a0\u00a09.11 %\u00a0\u00a08.46 %\u00a0\u00a0\nOperating income \u00a0\u00a02.53 %\u00a0\u00a02.67 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.42 %\u00a0\u00a03.48 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.52 %\u00a0\u00a02.49 %\u00a0\u00a0\nOperating income \u00a0\u00a00.89 %\u00a0\u00a00.99 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.44 %\u00a0\u00a03.52 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.18 %\u00a0\u00a02.20 %\u00a0\u00a0\n23", "original_text": "(Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.44 %\u00a0\u00a03.52 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.18 %\u00a0\u00a02.20 %\u00a0\u00a0\n23", "page_label": "23", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9f8f0848-5179-4290-915a-2ce8e88fd05b", "node_type": "4", "metadata": {"page_label": "23", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dc3a2f9d4e633005f8d93c780ab970d9d03a68f91c1f1a45d2ebf13159277aff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "efd7088c-e46d-4c1a-ba7e-25543b139e6b", "node_type": "1", "metadata": {"window": "Acquisition-related deal and\nintegration expenses \u00a0\u00a0(139,683 )\u00a0\u00a0(119,561 )\u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(229,884 )\u00a0\u00a0(63,498 )\u00a0\u00a0\nGoodwill impairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(75,936 )\u00a0\u00a0\nImpairment of assets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,946 )\u00a0\u00a0\nOperating income \u00a0$2,340,731 \u00a0\u00a0$2,366,378 \u00a0\u00a0(1.1 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.48 %\u00a0\u00a02.57 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.37 %\u00a0\u00a01.41 %\u00a0\u00a0\nOperating income \u00a0\u00a01.11 %\u00a0\u00a01.16 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.64 %\u00a0\u00a011.12 %\u00a0\u00a0\nOperating expenses \u00a0\u00a09.11 %\u00a0\u00a08.46 %\u00a0\u00a0\nOperating income \u00a0\u00a02.53 %\u00a0\u00a02.67 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.42 %\u00a0\u00a03.48 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.52 %\u00a0\u00a02.49 %\u00a0\u00a0\nOperating income \u00a0\u00a00.89 %\u00a0\u00a00.99 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.44 %\u00a0\u00a03.52 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.18 %\u00a0\u00a02.20 %\u00a0\u00a0\n23", "original_text": "(GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.42 %\u00a0\u00a03.48 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.52 %\u00a0\u00a02.49 %\u00a0\u00a0\nOperating income \u00a0\u00a00.89 %\u00a0\u00a00.99 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc. ", "page_label": "23", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f3bd4d2aa5e423fdf470d17e564cff1e6893b1780f5e91bb0b655ed828ac2a35", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "093bc0cc-2f1c-40ae-99f9-0636341e056c", "node_type": "1", "metadata": {"window": "Adjusted operating income \u00a0\u00a01.25 %\u00a0\u00a01.33 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n CENC ORA, INC.\n CONDENSED C ONSOLID ATED BAL ANCE SHEET S\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 September 30,\n\u00a0 \u00a02023 \u00a0\u00a02022\nASSET S \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $2,592,051 \u00a0$3,388,189\nAccounts receivable, net \u00a020,911,081 \u00a0\u00a018,452,675\nInventories \u00a017,454,768 \u00a0\u00a015,556,394\nRight to recover asset \u00a01,314,857 \u00a0\u00a01,532,061\nPrepaid expenses and other \u00a0526,069 \u00a0\u00a0660,439\nTotal current assets \u00a042,798,826 \u00a0\u00a039,589,758\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net \u00a02,135,171 \u00a0\u00a02,135,003\nGoodwill and other intangible assets \u00a014,005,900 \u00a0\u00a012,836,623\nDeferred income taxes \u00a0200,667 \u00a0\u00a0237,571\nOther long-term assets \u00a03,418,182 \u00a0\u00a01,761,661\n24", "original_text": "Adjusted operating income \u00a0\u00a01.25 %\u00a0\u00a01.33 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n"}, "hash": "a942695797e367cd55dfaaf9994f52c2735beddcdd693f651d23057549364c3d", "class_name": "RelatedNodeInfo"}}, "text": "(Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.44 %\u00a0\u00a03.52 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.18 %\u00a0\u00a02.20 %\u00a0\u00a0\n23", "start_char_idx": 797, "end_char_idx": 907, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "093bc0cc-2f1c-40ae-99f9-0636341e056c": {"__data__": {"id_": "093bc0cc-2f1c-40ae-99f9-0636341e056c", "embedding": null, "metadata": {"window": "Adjusted operating income \u00a0\u00a01.25 %\u00a0\u00a01.33 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n CENC ORA, INC.\n CONDENSED C ONSOLID ATED BAL ANCE SHEET S\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 September 30,\n\u00a0 \u00a02023 \u00a0\u00a02022\nASSET S \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $2,592,051 \u00a0$3,388,189\nAccounts receivable, net \u00a020,911,081 \u00a0\u00a018,452,675\nInventories \u00a017,454,768 \u00a0\u00a015,556,394\nRight to recover asset \u00a01,314,857 \u00a0\u00a01,532,061\nPrepaid expenses and other \u00a0526,069 \u00a0\u00a0660,439\nTotal current assets \u00a042,798,826 \u00a0\u00a039,589,758\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net \u00a02,135,171 \u00a0\u00a02,135,003\nGoodwill and other intangible assets \u00a014,005,900 \u00a0\u00a012,836,623\nDeferred income taxes \u00a0200,667 \u00a0\u00a0237,571\nOther long-term assets \u00a03,418,182 \u00a0\u00a01,761,661\n24", "original_text": "Adjusted operating income \u00a0\u00a01.25 %\u00a0\u00a01.33 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "24", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edcb9b2b-c10b-4f75-af3b-b6097c3b653a", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fa3142068f293709d87d70ec73256a5a277c680cc21d2ac33d67e61665dcbb54", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "87539361-2953-426c-9dc7-d6f9578af2d2", "node_type": "1", "metadata": {"window": "Acquisition-related deal and\nintegration expenses \u00a0\u00a0(139,683 )\u00a0\u00a0(119,561 )\u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(229,884 )\u00a0\u00a0(63,498 )\u00a0\u00a0\nGoodwill impairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(75,936 )\u00a0\u00a0\nImpairment of assets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,946 )\u00a0\u00a0\nOperating income \u00a0$2,340,731 \u00a0\u00a0$2,366,378 \u00a0\u00a0(1.1 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.48 %\u00a0\u00a02.57 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.37 %\u00a0\u00a01.41 %\u00a0\u00a0\nOperating income \u00a0\u00a01.11 %\u00a0\u00a01.16 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.64 %\u00a0\u00a011.12 %\u00a0\u00a0\nOperating expenses \u00a0\u00a09.11 %\u00a0\u00a08.46 %\u00a0\u00a0\nOperating income \u00a0\u00a02.53 %\u00a0\u00a02.67 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.42 %\u00a0\u00a03.48 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.52 %\u00a0\u00a02.49 %\u00a0\u00a0\nOperating income \u00a0\u00a00.89 %\u00a0\u00a00.99 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.44 %\u00a0\u00a03.52 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.18 %\u00a0\u00a02.20 %\u00a0\u00a0\n23", "original_text": "(Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.44 %\u00a0\u00a03.52 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.18 %\u00a0\u00a02.20 %\u00a0\u00a0\n23", "page_label": "23", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b7efc34daa3be4a71242519087241532adbeb5e4d92fa023ee7962cfaa2d86b3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c6a0f1e7-008b-4910-b0bf-cddd6e50b1d2", "node_type": "1", "metadata": {"window": "Adjusted operating income \u00a0\u00a01.25 %\u00a0\u00a01.33 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n CENC ORA, INC.\n CONDENSED C ONSOLID ATED BAL ANCE SHEET S\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 September 30,\n\u00a0 \u00a02023 \u00a0\u00a02022\nASSET S \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $2,592,051 \u00a0$3,388,189\nAccounts receivable, net \u00a020,911,081 \u00a0\u00a018,452,675\nInventories \u00a017,454,768 \u00a0\u00a015,556,394\nRight to recover asset \u00a01,314,857 \u00a0\u00a01,532,061\nPrepaid expenses and other \u00a0526,069 \u00a0\u00a0660,439\nTotal current assets \u00a042,798,826 \u00a0\u00a039,589,758\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net \u00a02,135,171 \u00a0\u00a02,135,003\nGoodwill and other intangible assets \u00a014,005,900 \u00a0\u00a012,836,623\nDeferred income taxes \u00a0200,667 \u00a0\u00a0237,571\nOther long-term assets \u00a03,418,182 \u00a0\u00a01,761,661\n24", "original_text": "CENC ORA, INC.\n"}, "hash": "429fed1853d2430ebd43b705d8cf91ca6df2e516e64fee35712646f9d4f1c878", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operating income \u00a0\u00a01.25 %\u00a0\u00a01.33 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "start_char_idx": 0, "end_char_idx": 222, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c6a0f1e7-008b-4910-b0bf-cddd6e50b1d2": {"__data__": {"id_": "c6a0f1e7-008b-4910-b0bf-cddd6e50b1d2", "embedding": null, "metadata": {"window": "Adjusted operating income \u00a0\u00a01.25 %\u00a0\u00a01.33 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n CENC ORA, INC.\n CONDENSED C ONSOLID ATED BAL ANCE SHEET S\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 September 30,\n\u00a0 \u00a02023 \u00a0\u00a02022\nASSET S \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $2,592,051 \u00a0$3,388,189\nAccounts receivable, net \u00a020,911,081 \u00a0\u00a018,452,675\nInventories \u00a017,454,768 \u00a0\u00a015,556,394\nRight to recover asset \u00a01,314,857 \u00a0\u00a01,532,061\nPrepaid expenses and other \u00a0526,069 \u00a0\u00a0660,439\nTotal current assets \u00a042,798,826 \u00a0\u00a039,589,758\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net \u00a02,135,171 \u00a0\u00a02,135,003\nGoodwill and other intangible assets \u00a014,005,900 \u00a0\u00a012,836,623\nDeferred income taxes \u00a0200,667 \u00a0\u00a0237,571\nOther long-term assets \u00a03,418,182 \u00a0\u00a01,761,661\n24", "original_text": "CENC ORA, INC.\n", "page_label": "24", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edcb9b2b-c10b-4f75-af3b-b6097c3b653a", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fa3142068f293709d87d70ec73256a5a277c680cc21d2ac33d67e61665dcbb54", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "093bc0cc-2f1c-40ae-99f9-0636341e056c", "node_type": "1", "metadata": {"window": "Adjusted operating income \u00a0\u00a01.25 %\u00a0\u00a01.33 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n CENC ORA, INC.\n CONDENSED C ONSOLID ATED BAL ANCE SHEET S\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 September 30,\n\u00a0 \u00a02023 \u00a0\u00a02022\nASSET S \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $2,592,051 \u00a0$3,388,189\nAccounts receivable, net \u00a020,911,081 \u00a0\u00a018,452,675\nInventories \u00a017,454,768 \u00a0\u00a015,556,394\nRight to recover asset \u00a01,314,857 \u00a0\u00a01,532,061\nPrepaid expenses and other \u00a0526,069 \u00a0\u00a0660,439\nTotal current assets \u00a042,798,826 \u00a0\u00a039,589,758\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net \u00a02,135,171 \u00a0\u00a02,135,003\nGoodwill and other intangible assets \u00a014,005,900 \u00a0\u00a012,836,623\nDeferred income taxes \u00a0200,667 \u00a0\u00a0237,571\nOther long-term assets \u00a03,418,182 \u00a0\u00a01,761,661\n24", "original_text": "Adjusted operating income \u00a0\u00a01.25 %\u00a0\u00a01.33 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "24", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "543ef9405ad9d4b20c4a76c955d3fc437d66d3baefc885f8bde0faae8c46b4b2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c16099db-7bac-4548-afa6-84e9d056b986", "node_type": "1", "metadata": {"window": "Adjusted operating income \u00a0\u00a01.25 %\u00a0\u00a01.33 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n CENC ORA, INC.\n CONDENSED C ONSOLID ATED BAL ANCE SHEET S\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 September 30,\n\u00a0 \u00a02023 \u00a0\u00a02022\nASSET S \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $2,592,051 \u00a0$3,388,189\nAccounts receivable, net \u00a020,911,081 \u00a0\u00a018,452,675\nInventories \u00a017,454,768 \u00a0\u00a015,556,394\nRight to recover asset \u00a01,314,857 \u00a0\u00a01,532,061\nPrepaid expenses and other \u00a0526,069 \u00a0\u00a0660,439\nTotal current assets \u00a042,798,826 \u00a0\u00a039,589,758\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net \u00a02,135,171 \u00a0\u00a02,135,003\nGoodwill and other intangible assets \u00a014,005,900 \u00a0\u00a012,836,623\nDeferred income taxes \u00a0200,667 \u00a0\u00a0237,571\nOther long-term assets \u00a03,418,182 \u00a0\u00a01,761,661\n24", "original_text": "CONDENSED C ONSOLID ATED BAL ANCE SHEET S\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 September 30,\n\u00a0 \u00a02023 \u00a0\u00a02022\nASSET S \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $2,592,051 \u00a0$3,388,189\nAccounts receivable, net \u00a020,911,081 \u00a0\u00a018,452,675\nInventories \u00a017,454,768 \u00a0\u00a015,556,394\nRight to recover asset \u00a01,314,857 \u00a0\u00a01,532,061\nPrepaid expenses and other \u00a0526,069 \u00a0\u00a0660,439\nTotal current assets \u00a042,798,826 \u00a0\u00a039,589,758\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net \u00a02,135,171 \u00a0\u00a02,135,003\nGoodwill and other intangible assets \u00a014,005,900 \u00a0\u00a012,836,623\nDeferred income taxes \u00a0200,667 \u00a0\u00a0237,571\nOther long-term assets \u00a03,418,182 \u00a0\u00a01,761,661\n24"}, "hash": "6fc45a92af12e9c1dfa21bf80d8ee56dd1eea71d0e1879114e9e50a2a83355a2", "class_name": "RelatedNodeInfo"}}, "text": "CENC ORA, INC.\n", "start_char_idx": 222, "end_char_idx": 237, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c16099db-7bac-4548-afa6-84e9d056b986": {"__data__": {"id_": "c16099db-7bac-4548-afa6-84e9d056b986", "embedding": null, "metadata": {"window": "Adjusted operating income \u00a0\u00a01.25 %\u00a0\u00a01.33 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n CENC ORA, INC.\n CONDENSED C ONSOLID ATED BAL ANCE SHEET S\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 September 30,\n\u00a0 \u00a02023 \u00a0\u00a02022\nASSET S \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $2,592,051 \u00a0$3,388,189\nAccounts receivable, net \u00a020,911,081 \u00a0\u00a018,452,675\nInventories \u00a017,454,768 \u00a0\u00a015,556,394\nRight to recover asset \u00a01,314,857 \u00a0\u00a01,532,061\nPrepaid expenses and other \u00a0526,069 \u00a0\u00a0660,439\nTotal current assets \u00a042,798,826 \u00a0\u00a039,589,758\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net \u00a02,135,171 \u00a0\u00a02,135,003\nGoodwill and other intangible assets \u00a014,005,900 \u00a0\u00a012,836,623\nDeferred income taxes \u00a0200,667 \u00a0\u00a0237,571\nOther long-term assets \u00a03,418,182 \u00a0\u00a01,761,661\n24", "original_text": "CONDENSED C ONSOLID ATED BAL ANCE SHEET S\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 September 30,\n\u00a0 \u00a02023 \u00a0\u00a02022\nASSET S \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $2,592,051 \u00a0$3,388,189\nAccounts receivable, net \u00a020,911,081 \u00a0\u00a018,452,675\nInventories \u00a017,454,768 \u00a0\u00a015,556,394\nRight to recover asset \u00a01,314,857 \u00a0\u00a01,532,061\nPrepaid expenses and other \u00a0526,069 \u00a0\u00a0660,439\nTotal current assets \u00a042,798,826 \u00a0\u00a039,589,758\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net \u00a02,135,171 \u00a0\u00a02,135,003\nGoodwill and other intangible assets \u00a014,005,900 \u00a0\u00a012,836,623\nDeferred income taxes \u00a0200,667 \u00a0\u00a0237,571\nOther long-term assets \u00a03,418,182 \u00a0\u00a01,761,661\n24", "page_label": "24", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edcb9b2b-c10b-4f75-af3b-b6097c3b653a", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fa3142068f293709d87d70ec73256a5a277c680cc21d2ac33d67e61665dcbb54", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c6a0f1e7-008b-4910-b0bf-cddd6e50b1d2", "node_type": "1", "metadata": {"window": "Adjusted operating income \u00a0\u00a01.25 %\u00a0\u00a01.33 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n CENC ORA, INC.\n CONDENSED C ONSOLID ATED BAL ANCE SHEET S\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 September 30,\n\u00a0 \u00a02023 \u00a0\u00a02022\nASSET S \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $2,592,051 \u00a0$3,388,189\nAccounts receivable, net \u00a020,911,081 \u00a0\u00a018,452,675\nInventories \u00a017,454,768 \u00a0\u00a015,556,394\nRight to recover asset \u00a01,314,857 \u00a0\u00a01,532,061\nPrepaid expenses and other \u00a0526,069 \u00a0\u00a0660,439\nTotal current assets \u00a042,798,826 \u00a0\u00a039,589,758\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net \u00a02,135,171 \u00a0\u00a02,135,003\nGoodwill and other intangible assets \u00a014,005,900 \u00a0\u00a012,836,623\nDeferred income taxes \u00a0200,667 \u00a0\u00a0237,571\nOther long-term assets \u00a03,418,182 \u00a0\u00a01,761,661\n24", "original_text": "CENC ORA, INC.\n", "page_label": "24", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ed36e3fff8e0c373154f860c638e487eb3d00028fe8b963820dd3f90c5332d50", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d2dddc55-c19b-424e-b40e-744d0ff98bbc", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0 \u00a0\u00a0\nTotal assets $62,558,746 \u00a0$56,560,616\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND ST OCKHOLDERS\u2019 EQUIT Y \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $45,836,037 \u00a0$40,192,890\nAccrued expenses and other \u00a02,353,817 \u00a0\u00a02,214,592\nShort-term debt \u00a0641,344 \u00a0\u00a01,070,473\nTotal current liabilities \u00a048,831,198 \u00a0\u00a043,477,955\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt \u00a04,146,113 \u00a0\u00a04,632,360\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes \u00a0310,676 \u00a0\u00a0320,274\nDeferred income taxes \u00a01,657,944 \u00a0\u00a01,620,413\nAccrued litigation liability \u00a05,061,795 \u00a0\u00a05,461,758\nOther long-term liabilities \u00a01,884,733 \u00a0\u00a0976,583\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity \u00a0666,287 \u00a0\u00a071,273\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and stockholders' equity $62,558,746 \u00a0$56,560,616\n\u00a0\nCENC ORA, INC.\n CONDENSED C ONSOLID ATED ST ATEMENT S OF CASH FL OWS\n(in thousands)\n25", "original_text": "\u00a0 \u00a0 \u00a0\u00a0\nTotal assets $62,558,746 \u00a0$56,560,616\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND ST OCKHOLDERS\u2019 EQUIT Y \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $45,836,037 \u00a0$40,192,890\nAccrued expenses and other \u00a02,353,817 \u00a0\u00a02,214,592\nShort-term debt \u00a0641,344 \u00a0\u00a01,070,473\nTotal current liabilities \u00a048,831,198 \u00a0\u00a043,477,955\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt \u00a04,146,113 \u00a0\u00a04,632,360\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes \u00a0310,676 \u00a0\u00a0320,274\nDeferred income taxes \u00a01,657,944 \u00a0\u00a01,620,413\nAccrued litigation liability \u00a05,061,795 \u00a0\u00a05,461,758\nOther long-term liabilities \u00a01,884,733 \u00a0\u00a0976,583\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity \u00a0666,287 \u00a0\u00a071,273\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and stockholders' equity $62,558,746 \u00a0$56,560,616\n\u00a0\nCENC ORA, INC.\n"}, "hash": "478dd9560972016e6b72ea0cbe5dadac192948cc921a04dc0c5722ee34aa0752", "class_name": "RelatedNodeInfo"}}, "text": "CONDENSED C ONSOLID ATED BAL ANCE SHEET S\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 September 30,\n\u00a0 \u00a02023 \u00a0\u00a02022\nASSET S \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $2,592,051 \u00a0$3,388,189\nAccounts receivable, net \u00a020,911,081 \u00a0\u00a018,452,675\nInventories \u00a017,454,768 \u00a0\u00a015,556,394\nRight to recover asset \u00a01,314,857 \u00a0\u00a01,532,061\nPrepaid expenses and other \u00a0526,069 \u00a0\u00a0660,439\nTotal current assets \u00a042,798,826 \u00a0\u00a039,589,758\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net \u00a02,135,171 \u00a0\u00a02,135,003\nGoodwill and other intangible assets \u00a014,005,900 \u00a0\u00a012,836,623\nDeferred income taxes \u00a0200,667 \u00a0\u00a0237,571\nOther long-term assets \u00a03,418,182 \u00a0\u00a01,761,661\n24", "start_char_idx": 237, "end_char_idx": 863, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d2dddc55-c19b-424e-b40e-744d0ff98bbc": {"__data__": {"id_": "d2dddc55-c19b-424e-b40e-744d0ff98bbc", "embedding": null, "metadata": {"window": "\u00a0 \u00a0 \u00a0\u00a0\nTotal assets $62,558,746 \u00a0$56,560,616\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND ST OCKHOLDERS\u2019 EQUIT Y \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $45,836,037 \u00a0$40,192,890\nAccrued expenses and other \u00a02,353,817 \u00a0\u00a02,214,592\nShort-term debt \u00a0641,344 \u00a0\u00a01,070,473\nTotal current liabilities \u00a048,831,198 \u00a0\u00a043,477,955\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt \u00a04,146,113 \u00a0\u00a04,632,360\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes \u00a0310,676 \u00a0\u00a0320,274\nDeferred income taxes \u00a01,657,944 \u00a0\u00a01,620,413\nAccrued litigation liability \u00a05,061,795 \u00a0\u00a05,461,758\nOther long-term liabilities \u00a01,884,733 \u00a0\u00a0976,583\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity \u00a0666,287 \u00a0\u00a071,273\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and stockholders' equity $62,558,746 \u00a0$56,560,616\n\u00a0\nCENC ORA, INC.\n CONDENSED C ONSOLID ATED ST ATEMENT S OF CASH FL OWS\n(in thousands)\n25", "original_text": "\u00a0 \u00a0 \u00a0\u00a0\nTotal assets $62,558,746 \u00a0$56,560,616\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND ST OCKHOLDERS\u2019 EQUIT Y \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $45,836,037 \u00a0$40,192,890\nAccrued expenses and other \u00a02,353,817 \u00a0\u00a02,214,592\nShort-term debt \u00a0641,344 \u00a0\u00a01,070,473\nTotal current liabilities \u00a048,831,198 \u00a0\u00a043,477,955\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt \u00a04,146,113 \u00a0\u00a04,632,360\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes \u00a0310,676 \u00a0\u00a0320,274\nDeferred income taxes \u00a01,657,944 \u00a0\u00a01,620,413\nAccrued litigation liability \u00a05,061,795 \u00a0\u00a05,461,758\nOther long-term liabilities \u00a01,884,733 \u00a0\u00a0976,583\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity \u00a0666,287 \u00a0\u00a071,273\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and stockholders' equity $62,558,746 \u00a0$56,560,616\n\u00a0\nCENC ORA, INC.\n", "page_label": "25", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7e2e8e0c-431c-4289-b30a-2df493dc98b7", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "79f19281876d338fcf3200a889e01dc2d4a1e5aaf2d082304e7a0036f63a89ef", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c16099db-7bac-4548-afa6-84e9d056b986", "node_type": "1", "metadata": {"window": "Adjusted operating income \u00a0\u00a01.25 %\u00a0\u00a01.33 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n CENC ORA, INC.\n CONDENSED C ONSOLID ATED BAL ANCE SHEET S\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 September 30,\n\u00a0 \u00a02023 \u00a0\u00a02022\nASSET S \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $2,592,051 \u00a0$3,388,189\nAccounts receivable, net \u00a020,911,081 \u00a0\u00a018,452,675\nInventories \u00a017,454,768 \u00a0\u00a015,556,394\nRight to recover asset \u00a01,314,857 \u00a0\u00a01,532,061\nPrepaid expenses and other \u00a0526,069 \u00a0\u00a0660,439\nTotal current assets \u00a042,798,826 \u00a0\u00a039,589,758\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net \u00a02,135,171 \u00a0\u00a02,135,003\nGoodwill and other intangible assets \u00a014,005,900 \u00a0\u00a012,836,623\nDeferred income taxes \u00a0200,667 \u00a0\u00a0237,571\nOther long-term assets \u00a03,418,182 \u00a0\u00a01,761,661\n24", "original_text": "CONDENSED C ONSOLID ATED BAL ANCE SHEET S\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 September 30,\n\u00a0 \u00a02023 \u00a0\u00a02022\nASSET S \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $2,592,051 \u00a0$3,388,189\nAccounts receivable, net \u00a020,911,081 \u00a0\u00a018,452,675\nInventories \u00a017,454,768 \u00a0\u00a015,556,394\nRight to recover asset \u00a01,314,857 \u00a0\u00a01,532,061\nPrepaid expenses and other \u00a0526,069 \u00a0\u00a0660,439\nTotal current assets \u00a042,798,826 \u00a0\u00a039,589,758\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net \u00a02,135,171 \u00a0\u00a02,135,003\nGoodwill and other intangible assets \u00a014,005,900 \u00a0\u00a012,836,623\nDeferred income taxes \u00a0200,667 \u00a0\u00a0237,571\nOther long-term assets \u00a03,418,182 \u00a0\u00a01,761,661\n24", "page_label": "24", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f850625145d4bdac1d11d31609d5b597a1e639225ca94cd1bd30bd096500ab01", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "19b9762f-84d2-45a9-b9fd-bbfc144df112", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0 \u00a0\u00a0\nTotal assets $62,558,746 \u00a0$56,560,616\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND ST OCKHOLDERS\u2019 EQUIT Y \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $45,836,037 \u00a0$40,192,890\nAccrued expenses and other \u00a02,353,817 \u00a0\u00a02,214,592\nShort-term debt \u00a0641,344 \u00a0\u00a01,070,473\nTotal current liabilities \u00a048,831,198 \u00a0\u00a043,477,955\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt \u00a04,146,113 \u00a0\u00a04,632,360\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes \u00a0310,676 \u00a0\u00a0320,274\nDeferred income taxes \u00a01,657,944 \u00a0\u00a01,620,413\nAccrued litigation liability \u00a05,061,795 \u00a0\u00a05,461,758\nOther long-term liabilities \u00a01,884,733 \u00a0\u00a0976,583\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity \u00a0666,287 \u00a0\u00a071,273\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and stockholders' equity $62,558,746 \u00a0$56,560,616\n\u00a0\nCENC ORA, INC.\n CONDENSED C ONSOLID ATED ST ATEMENT S OF CASH FL OWS\n(in thousands)\n25", "original_text": "CONDENSED C ONSOLID ATED ST ATEMENT S OF CASH FL OWS\n(in thousands)\n25"}, "hash": "496b0018b86b66f5f5019d556ff508aca946eba1a0e4fa2502a972c88c6ca44b", "class_name": "RelatedNodeInfo"}}, "text": "\u00a0 \u00a0 \u00a0\u00a0\nTotal assets $62,558,746 \u00a0$56,560,616\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND ST OCKHOLDERS\u2019 EQUIT Y \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $45,836,037 \u00a0$40,192,890\nAccrued expenses and other \u00a02,353,817 \u00a0\u00a02,214,592\nShort-term debt \u00a0641,344 \u00a0\u00a01,070,473\nTotal current liabilities \u00a048,831,198 \u00a0\u00a043,477,955\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt \u00a04,146,113 \u00a0\u00a04,632,360\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes \u00a0310,676 \u00a0\u00a0320,274\nDeferred income taxes \u00a01,657,944 \u00a0\u00a01,620,413\nAccrued litigation liability \u00a05,061,795 \u00a0\u00a05,461,758\nOther long-term liabilities \u00a01,884,733 \u00a0\u00a0976,583\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity \u00a0666,287 \u00a0\u00a071,273\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and stockholders' equity $62,558,746 \u00a0$56,560,616\n\u00a0\nCENC ORA, INC.\n", "start_char_idx": 0, "end_char_idx": 677, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "19b9762f-84d2-45a9-b9fd-bbfc144df112": {"__data__": {"id_": "19b9762f-84d2-45a9-b9fd-bbfc144df112", "embedding": null, "metadata": {"window": "\u00a0 \u00a0 \u00a0\u00a0\nTotal assets $62,558,746 \u00a0$56,560,616\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND ST OCKHOLDERS\u2019 EQUIT Y \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $45,836,037 \u00a0$40,192,890\nAccrued expenses and other \u00a02,353,817 \u00a0\u00a02,214,592\nShort-term debt \u00a0641,344 \u00a0\u00a01,070,473\nTotal current liabilities \u00a048,831,198 \u00a0\u00a043,477,955\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt \u00a04,146,113 \u00a0\u00a04,632,360\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes \u00a0310,676 \u00a0\u00a0320,274\nDeferred income taxes \u00a01,657,944 \u00a0\u00a01,620,413\nAccrued litigation liability \u00a05,061,795 \u00a0\u00a05,461,758\nOther long-term liabilities \u00a01,884,733 \u00a0\u00a0976,583\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity \u00a0666,287 \u00a0\u00a071,273\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and stockholders' equity $62,558,746 \u00a0$56,560,616\n\u00a0\nCENC ORA, INC.\n CONDENSED C ONSOLID ATED ST ATEMENT S OF CASH FL OWS\n(in thousands)\n25", "original_text": "CONDENSED C ONSOLID ATED ST ATEMENT S OF CASH FL OWS\n(in thousands)\n25", "page_label": "25", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7e2e8e0c-431c-4289-b30a-2df493dc98b7", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "79f19281876d338fcf3200a889e01dc2d4a1e5aaf2d082304e7a0036f63a89ef", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d2dddc55-c19b-424e-b40e-744d0ff98bbc", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0 \u00a0\u00a0\nTotal assets $62,558,746 \u00a0$56,560,616\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND ST OCKHOLDERS\u2019 EQUIT Y \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $45,836,037 \u00a0$40,192,890\nAccrued expenses and other \u00a02,353,817 \u00a0\u00a02,214,592\nShort-term debt \u00a0641,344 \u00a0\u00a01,070,473\nTotal current liabilities \u00a048,831,198 \u00a0\u00a043,477,955\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt \u00a04,146,113 \u00a0\u00a04,632,360\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes \u00a0310,676 \u00a0\u00a0320,274\nDeferred income taxes \u00a01,657,944 \u00a0\u00a01,620,413\nAccrued litigation liability \u00a05,061,795 \u00a0\u00a05,461,758\nOther long-term liabilities \u00a01,884,733 \u00a0\u00a0976,583\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity \u00a0666,287 \u00a0\u00a071,273\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and stockholders' equity $62,558,746 \u00a0$56,560,616\n\u00a0\nCENC ORA, INC.\n CONDENSED C ONSOLID ATED ST ATEMENT S OF CASH FL OWS\n(in thousands)\n25", "original_text": "\u00a0 \u00a0 \u00a0\u00a0\nTotal assets $62,558,746 \u00a0$56,560,616\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND ST OCKHOLDERS\u2019 EQUIT Y \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $45,836,037 \u00a0$40,192,890\nAccrued expenses and other \u00a02,353,817 \u00a0\u00a02,214,592\nShort-term debt \u00a0641,344 \u00a0\u00a01,070,473\nTotal current liabilities \u00a048,831,198 \u00a0\u00a043,477,955\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt \u00a04,146,113 \u00a0\u00a04,632,360\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes \u00a0310,676 \u00a0\u00a0320,274\nDeferred income taxes \u00a01,657,944 \u00a0\u00a01,620,413\nAccrued litigation liability \u00a05,061,795 \u00a0\u00a05,461,758\nOther long-term liabilities \u00a01,884,733 \u00a0\u00a0976,583\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity \u00a0666,287 \u00a0\u00a071,273\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and stockholders' equity $62,558,746 \u00a0$56,560,616\n\u00a0\nCENC ORA, INC.\n", "page_label": "25", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fe2af242c6c090f2e70e03a39b11f370a8efeec2ef39ce8e56e244b626c0a81b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "512c2c9b-6956-43bf-abf7-13f78971b843", "node_type": "1", "metadata": {"window": "(unaudited)\n\u00a0\n\u00a0Fiscal Y ear Ended\nSeptember 30,\n\u00a0 \u00a02023 \u00a0\u00a0\u00a02022 \u00a0\nOperating Activities: \u00a0 \u00a0\u00a0\nNet income $1,732,576 \u00a0\u00a0$1,666,540 \u00a0\nAdjustments to reconcile net income to net cash provided by operating activities \u00a01,304,216 \u00a0\u00a0\u00a01,176,210 \u00a0\nChanges in operating assets and liabilities, excluding the effects of acquisitions and divestitures: \u00a0 \u00a0\u00a0\nAccounts receivable \u00a0(2,711,786 )\u00a0\u00a0(1,659,525 )\nInventories \u00a0(2,183,368 )\u00a0\u00a0(665,370 )\nAccounts payable \u00a06,103,451 \u00a0\u00a0\u00a03,320,725 \u00a0\nOther, net \u00a0(333,755 )\u00a0\u00a0(1,135,492 )\nNet cash provided by operating activities \u00a03,911,334 \u00a0\u00a0\u00a02,703,088 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures \u00a0(458,359 )\u00a0\u00a0(496,318 )\nCost of acquired companies, net of cash acquired 1 \u00a0(1,409,835 )\u00a0\u00a0(133,814 )\nCost of equity investments 2 \u00a0(743,275 )\u00a0\u00a0(18,491 )\nProceeds from the divestiture of businesses \u00a0\u2014 \u00a0\u00a0\u00a0272,586 \u00a0\nOther, net \u00a09,004 \u00a0\u00a0\u00a07,600 \u00a0\nNet cash used in investing activities \u00a0(2,602,465 )\u00a0\u00a0(368,437 )\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet debt repayments \u00a0(623,258 )\u00a0\u00a0(923,103 )\nPurchases of common stock 3 \u00a0(1,180,728 )\u00a0\u00a0(483,704 )\nExercises of stock options \u00a061,152 \u00a0\u00a0\u00a093,912 \u00a0\nCash dividends on common stock \u00a0(398,752 )\u00a0\u00a0(391,687 )\n26", "original_text": "(unaudited)\n\u00a0\n\u00a0Fiscal Y ear Ended\nSeptember 30,\n\u00a0 \u00a02023 \u00a0\u00a0\u00a02022 \u00a0\nOperating Activities: \u00a0 \u00a0\u00a0\nNet income $1,732,576 \u00a0\u00a0$1,666,540 \u00a0\nAdjustments to reconcile net income to net cash provided by operating activities \u00a01,304,216 \u00a0\u00a0\u00a01,176,210 \u00a0\nChanges in operating assets and liabilities, excluding the effects of acquisitions and divestitures: \u00a0 \u00a0\u00a0\nAccounts receivable \u00a0(2,711,786 )\u00a0\u00a0(1,659,525 )\nInventories \u00a0(2,183,368 )\u00a0\u00a0(665,370 )\nAccounts payable \u00a06,103,451 \u00a0\u00a0\u00a03,320,725 \u00a0\nOther, net \u00a0(333,755 )\u00a0\u00a0(1,135,492 )\nNet cash provided by operating activities \u00a03,911,334 \u00a0\u00a0\u00a02,703,088 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures \u00a0(458,359 )\u00a0\u00a0(496,318 )\nCost of acquired companies, net of cash acquired 1 \u00a0(1,409,835 )\u00a0\u00a0(133,814 )\nCost of equity investments 2 \u00a0(743,275 )\u00a0\u00a0(18,491 )\nProceeds from the divestiture of businesses \u00a0\u2014 \u00a0\u00a0\u00a0272,586 \u00a0\nOther, net \u00a09,004 \u00a0\u00a0\u00a07,600 \u00a0\nNet cash used in investing activities \u00a0(2,602,465 )\u00a0\u00a0(368,437 )\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet debt repayments \u00a0(623,258 )\u00a0\u00a0(923,103 )\nPurchases of common stock 3 \u00a0(1,180,728 )\u00a0\u00a0(483,704 )\nExercises of stock options \u00a061,152 \u00a0\u00a0\u00a093,912 \u00a0\nCash dividends on common stock \u00a0(398,752 )\u00a0\u00a0(391,687 )\n26"}, "hash": "a322ba70e0ea5390cf6ca0ebe92a47b68f511d6fe41afc098e0f9cb4f8f6d897", "class_name": "RelatedNodeInfo"}}, "text": "CONDENSED C ONSOLID ATED ST ATEMENT S OF CASH FL OWS\n(in thousands)\n25", "start_char_idx": 677, "end_char_idx": 747, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "512c2c9b-6956-43bf-abf7-13f78971b843": {"__data__": {"id_": "512c2c9b-6956-43bf-abf7-13f78971b843", "embedding": null, "metadata": {"window": "(unaudited)\n\u00a0\n\u00a0Fiscal Y ear Ended\nSeptember 30,\n\u00a0 \u00a02023 \u00a0\u00a0\u00a02022 \u00a0\nOperating Activities: \u00a0 \u00a0\u00a0\nNet income $1,732,576 \u00a0\u00a0$1,666,540 \u00a0\nAdjustments to reconcile net income to net cash provided by operating activities \u00a01,304,216 \u00a0\u00a0\u00a01,176,210 \u00a0\nChanges in operating assets and liabilities, excluding the effects of acquisitions and divestitures: \u00a0 \u00a0\u00a0\nAccounts receivable \u00a0(2,711,786 )\u00a0\u00a0(1,659,525 )\nInventories \u00a0(2,183,368 )\u00a0\u00a0(665,370 )\nAccounts payable \u00a06,103,451 \u00a0\u00a0\u00a03,320,725 \u00a0\nOther, net \u00a0(333,755 )\u00a0\u00a0(1,135,492 )\nNet cash provided by operating activities \u00a03,911,334 \u00a0\u00a0\u00a02,703,088 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures \u00a0(458,359 )\u00a0\u00a0(496,318 )\nCost of acquired companies, net of cash acquired 1 \u00a0(1,409,835 )\u00a0\u00a0(133,814 )\nCost of equity investments 2 \u00a0(743,275 )\u00a0\u00a0(18,491 )\nProceeds from the divestiture of businesses \u00a0\u2014 \u00a0\u00a0\u00a0272,586 \u00a0\nOther, net \u00a09,004 \u00a0\u00a0\u00a07,600 \u00a0\nNet cash used in investing activities \u00a0(2,602,465 )\u00a0\u00a0(368,437 )\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet debt repayments \u00a0(623,258 )\u00a0\u00a0(923,103 )\nPurchases of common stock 3 \u00a0(1,180,728 )\u00a0\u00a0(483,704 )\nExercises of stock options \u00a061,152 \u00a0\u00a0\u00a093,912 \u00a0\nCash dividends on common stock \u00a0(398,752 )\u00a0\u00a0(391,687 )\n26", "original_text": "(unaudited)\n\u00a0\n\u00a0Fiscal Y ear Ended\nSeptember 30,\n\u00a0 \u00a02023 \u00a0\u00a0\u00a02022 \u00a0\nOperating Activities: \u00a0 \u00a0\u00a0\nNet income $1,732,576 \u00a0\u00a0$1,666,540 \u00a0\nAdjustments to reconcile net income to net cash provided by operating activities \u00a01,304,216 \u00a0\u00a0\u00a01,176,210 \u00a0\nChanges in operating assets and liabilities, excluding the effects of acquisitions and divestitures: \u00a0 \u00a0\u00a0\nAccounts receivable \u00a0(2,711,786 )\u00a0\u00a0(1,659,525 )\nInventories \u00a0(2,183,368 )\u00a0\u00a0(665,370 )\nAccounts payable \u00a06,103,451 \u00a0\u00a0\u00a03,320,725 \u00a0\nOther, net \u00a0(333,755 )\u00a0\u00a0(1,135,492 )\nNet cash provided by operating activities \u00a03,911,334 \u00a0\u00a0\u00a02,703,088 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures \u00a0(458,359 )\u00a0\u00a0(496,318 )\nCost of acquired companies, net of cash acquired 1 \u00a0(1,409,835 )\u00a0\u00a0(133,814 )\nCost of equity investments 2 \u00a0(743,275 )\u00a0\u00a0(18,491 )\nProceeds from the divestiture of businesses \u00a0\u2014 \u00a0\u00a0\u00a0272,586 \u00a0\nOther, net \u00a09,004 \u00a0\u00a0\u00a07,600 \u00a0\nNet cash used in investing activities \u00a0(2,602,465 )\u00a0\u00a0(368,437 )\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet debt repayments \u00a0(623,258 )\u00a0\u00a0(923,103 )\nPurchases of common stock 3 \u00a0(1,180,728 )\u00a0\u00a0(483,704 )\nExercises of stock options \u00a061,152 \u00a0\u00a0\u00a093,912 \u00a0\nCash dividends on common stock \u00a0(398,752 )\u00a0\u00a0(391,687 )\n26", "page_label": "26", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b7f3c838-ea4a-4758-8a6e-83ef3ac74947", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fe52b1fd69ad71f8f6bc505176be19bb022bd93fb887dbe8cae07a2138a40fdf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "19b9762f-84d2-45a9-b9fd-bbfc144df112", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0 \u00a0\u00a0\nTotal assets $62,558,746 \u00a0$56,560,616\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND ST OCKHOLDERS\u2019 EQUIT Y \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $45,836,037 \u00a0$40,192,890\nAccrued expenses and other \u00a02,353,817 \u00a0\u00a02,214,592\nShort-term debt \u00a0641,344 \u00a0\u00a01,070,473\nTotal current liabilities \u00a048,831,198 \u00a0\u00a043,477,955\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt \u00a04,146,113 \u00a0\u00a04,632,360\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes \u00a0310,676 \u00a0\u00a0320,274\nDeferred income taxes \u00a01,657,944 \u00a0\u00a01,620,413\nAccrued litigation liability \u00a05,061,795 \u00a0\u00a05,461,758\nOther long-term liabilities \u00a01,884,733 \u00a0\u00a0976,583\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity \u00a0666,287 \u00a0\u00a071,273\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and stockholders' equity $62,558,746 \u00a0$56,560,616\n\u00a0\nCENC ORA, INC.\n CONDENSED C ONSOLID ATED ST ATEMENT S OF CASH FL OWS\n(in thousands)\n25", "original_text": "CONDENSED C ONSOLID ATED ST ATEMENT S OF CASH FL OWS\n(in thousands)\n25", "page_label": "25", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bd91a1ff8ac830ec58dea0f185524d02a8bc21884943f73012b35c80bf7d8b30", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "081a6624-c870-4e51-a2d3-ff7a8089a4c0", "node_type": "1", "metadata": {"window": "Employee tax withholdings related to restricted share vesting \u00a0(71,279 )\u00a0\u00a0(38,076 )\nOther, net \u00a0(9,413 )\u00a0\u00a0(10,122 )\nNet cash used in financing activities \u00a0(2,222,278 )\u00a0\u00a0(1,752,780 )\n\u00a0 \u00a0 \u00a0\u00a0\nEffect of exchange rate changes on cash, cash equivalents, and restricted cash \u00a072,759 \u00a0\u00a0\u00a0(57,850 )\n\u00a0 \u00a0 \u00a0\u00a0\n(Decrease) increase in cash, cash equivalents, and restricted cash, including cash classified within\nassets held for sale \u00a0(840,650 )\u00a0\u00a0524,021 \u00a0\nLess: Increase in cash classified within assets held for sale \u00a0\u2014 \u00a0\u00a0\u00a0(610 )\n(Decrease) increase in cash, cash equivalents, and restricted cash \u00a0(840,650 )\u00a0\u00a0523,411 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of year 4 \u00a03,593,539 \u00a0\u00a0\u00a03,070,128 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of year 4 $2,752,889 \u00a0\u00a0$3,593,539 \u00a0\n________________________________________\n1Includes $1,406.5 million for the acquisition of PharmaLex.\n\u00a0\n 2Includes a $718.4 million investment in OneOncology.\n\u00a0\n 3Includes $28.4 million of purchases in September 2022 that cash settled in October 2022.\n\u00a0\n 4The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated S tatements of Cash Flows:\n\u00a0 \u00a0September 30,\n(amounts in thousands) \u00a0\u00a02023 \u00a0\u00a02022 \u00a0\u00a02021\n27", "original_text": "Employee tax withholdings related to restricted share vesting \u00a0(71,279 )\u00a0\u00a0(38,076 )\nOther, net \u00a0(9,413 )\u00a0\u00a0(10,122 )\nNet cash used in financing activities \u00a0(2,222,278 )\u00a0\u00a0(1,752,780 )\n\u00a0 \u00a0 \u00a0\u00a0\nEffect of exchange rate changes on cash, cash equivalents, and restricted cash \u00a072,759 \u00a0\u00a0\u00a0(57,850 )\n\u00a0 \u00a0 \u00a0\u00a0\n(Decrease) increase in cash, cash equivalents, and restricted cash, including cash classified within\nassets held for sale \u00a0(840,650 )\u00a0\u00a0524,021 \u00a0\nLess: Increase in cash classified within assets held for sale \u00a0\u2014 \u00a0\u00a0\u00a0(610 )\n(Decrease) increase in cash, cash equivalents, and restricted cash \u00a0(840,650 )\u00a0\u00a0523,411 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of year 4 \u00a03,593,539 \u00a0\u00a0\u00a03,070,128 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of year 4 $2,752,889 \u00a0\u00a0$3,593,539 \u00a0\n________________________________________\n1Includes $1,406.5 million for the acquisition of PharmaLex.\n\u00a0\n"}, "hash": "d781b56b03a9e21296f96525553943461fb584fef0c15f0bdf82a5794dfcbaae", "class_name": "RelatedNodeInfo"}}, "text": "(unaudited)\n\u00a0\n\u00a0Fiscal Y ear Ended\nSeptember 30,\n\u00a0 \u00a02023 \u00a0\u00a0\u00a02022 \u00a0\nOperating Activities: \u00a0 \u00a0\u00a0\nNet income $1,732,576 \u00a0\u00a0$1,666,540 \u00a0\nAdjustments to reconcile net income to net cash provided by operating activities \u00a01,304,216 \u00a0\u00a0\u00a01,176,210 \u00a0\nChanges in operating assets and liabilities, excluding the effects of acquisitions and divestitures: \u00a0 \u00a0\u00a0\nAccounts receivable \u00a0(2,711,786 )\u00a0\u00a0(1,659,525 )\nInventories \u00a0(2,183,368 )\u00a0\u00a0(665,370 )\nAccounts payable \u00a06,103,451 \u00a0\u00a0\u00a03,320,725 \u00a0\nOther, net \u00a0(333,755 )\u00a0\u00a0(1,135,492 )\nNet cash provided by operating activities \u00a03,911,334 \u00a0\u00a0\u00a02,703,088 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures \u00a0(458,359 )\u00a0\u00a0(496,318 )\nCost of acquired companies, net of cash acquired 1 \u00a0(1,409,835 )\u00a0\u00a0(133,814 )\nCost of equity investments 2 \u00a0(743,275 )\u00a0\u00a0(18,491 )\nProceeds from the divestiture of businesses \u00a0\u2014 \u00a0\u00a0\u00a0272,586 \u00a0\nOther, net \u00a09,004 \u00a0\u00a0\u00a07,600 \u00a0\nNet cash used in investing activities \u00a0(2,602,465 )\u00a0\u00a0(368,437 )\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet debt repayments \u00a0(623,258 )\u00a0\u00a0(923,103 )\nPurchases of common stock 3 \u00a0(1,180,728 )\u00a0\u00a0(483,704 )\nExercises of stock options \u00a061,152 \u00a0\u00a0\u00a093,912 \u00a0\nCash dividends on common stock \u00a0(398,752 )\u00a0\u00a0(391,687 )\n26", "start_char_idx": 0, "end_char_idx": 1174, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "081a6624-c870-4e51-a2d3-ff7a8089a4c0": {"__data__": {"id_": "081a6624-c870-4e51-a2d3-ff7a8089a4c0", "embedding": null, "metadata": {"window": "Employee tax withholdings related to restricted share vesting \u00a0(71,279 )\u00a0\u00a0(38,076 )\nOther, net \u00a0(9,413 )\u00a0\u00a0(10,122 )\nNet cash used in financing activities \u00a0(2,222,278 )\u00a0\u00a0(1,752,780 )\n\u00a0 \u00a0 \u00a0\u00a0\nEffect of exchange rate changes on cash, cash equivalents, and restricted cash \u00a072,759 \u00a0\u00a0\u00a0(57,850 )\n\u00a0 \u00a0 \u00a0\u00a0\n(Decrease) increase in cash, cash equivalents, and restricted cash, including cash classified within\nassets held for sale \u00a0(840,650 )\u00a0\u00a0524,021 \u00a0\nLess: Increase in cash classified within assets held for sale \u00a0\u2014 \u00a0\u00a0\u00a0(610 )\n(Decrease) increase in cash, cash equivalents, and restricted cash \u00a0(840,650 )\u00a0\u00a0523,411 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of year 4 \u00a03,593,539 \u00a0\u00a0\u00a03,070,128 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of year 4 $2,752,889 \u00a0\u00a0$3,593,539 \u00a0\n________________________________________\n1Includes $1,406.5 million for the acquisition of PharmaLex.\n\u00a0\n 2Includes a $718.4 million investment in OneOncology.\n\u00a0\n 3Includes $28.4 million of purchases in September 2022 that cash settled in October 2022.\n\u00a0\n 4The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated S tatements of Cash Flows:\n\u00a0 \u00a0September 30,\n(amounts in thousands) \u00a0\u00a02023 \u00a0\u00a02022 \u00a0\u00a02021\n27", "original_text": "Employee tax withholdings related to restricted share vesting \u00a0(71,279 )\u00a0\u00a0(38,076 )\nOther, net \u00a0(9,413 )\u00a0\u00a0(10,122 )\nNet cash used in financing activities \u00a0(2,222,278 )\u00a0\u00a0(1,752,780 )\n\u00a0 \u00a0 \u00a0\u00a0\nEffect of exchange rate changes on cash, cash equivalents, and restricted cash \u00a072,759 \u00a0\u00a0\u00a0(57,850 )\n\u00a0 \u00a0 \u00a0\u00a0\n(Decrease) increase in cash, cash equivalents, and restricted cash, including cash classified within\nassets held for sale \u00a0(840,650 )\u00a0\u00a0524,021 \u00a0\nLess: Increase in cash classified within assets held for sale \u00a0\u2014 \u00a0\u00a0\u00a0(610 )\n(Decrease) increase in cash, cash equivalents, and restricted cash \u00a0(840,650 )\u00a0\u00a0523,411 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of year 4 \u00a03,593,539 \u00a0\u00a0\u00a03,070,128 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of year 4 $2,752,889 \u00a0\u00a0$3,593,539 \u00a0\n________________________________________\n1Includes $1,406.5 million for the acquisition of PharmaLex.\n\u00a0\n", "page_label": "27", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "33c63d93-9b01-43c3-9fc2-750e06a8cd22", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2d386a62a9cb837618ab6c93515d4bbc9c422c2ec91558920e889dbd2beea67e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "512c2c9b-6956-43bf-abf7-13f78971b843", "node_type": "1", "metadata": {"window": "(unaudited)\n\u00a0\n\u00a0Fiscal Y ear Ended\nSeptember 30,\n\u00a0 \u00a02023 \u00a0\u00a0\u00a02022 \u00a0\nOperating Activities: \u00a0 \u00a0\u00a0\nNet income $1,732,576 \u00a0\u00a0$1,666,540 \u00a0\nAdjustments to reconcile net income to net cash provided by operating activities \u00a01,304,216 \u00a0\u00a0\u00a01,176,210 \u00a0\nChanges in operating assets and liabilities, excluding the effects of acquisitions and divestitures: \u00a0 \u00a0\u00a0\nAccounts receivable \u00a0(2,711,786 )\u00a0\u00a0(1,659,525 )\nInventories \u00a0(2,183,368 )\u00a0\u00a0(665,370 )\nAccounts payable \u00a06,103,451 \u00a0\u00a0\u00a03,320,725 \u00a0\nOther, net \u00a0(333,755 )\u00a0\u00a0(1,135,492 )\nNet cash provided by operating activities \u00a03,911,334 \u00a0\u00a0\u00a02,703,088 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures \u00a0(458,359 )\u00a0\u00a0(496,318 )\nCost of acquired companies, net of cash acquired 1 \u00a0(1,409,835 )\u00a0\u00a0(133,814 )\nCost of equity investments 2 \u00a0(743,275 )\u00a0\u00a0(18,491 )\nProceeds from the divestiture of businesses \u00a0\u2014 \u00a0\u00a0\u00a0272,586 \u00a0\nOther, net \u00a09,004 \u00a0\u00a0\u00a07,600 \u00a0\nNet cash used in investing activities \u00a0(2,602,465 )\u00a0\u00a0(368,437 )\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet debt repayments \u00a0(623,258 )\u00a0\u00a0(923,103 )\nPurchases of common stock 3 \u00a0(1,180,728 )\u00a0\u00a0(483,704 )\nExercises of stock options \u00a061,152 \u00a0\u00a0\u00a093,912 \u00a0\nCash dividends on common stock \u00a0(398,752 )\u00a0\u00a0(391,687 )\n26", "original_text": "(unaudited)\n\u00a0\n\u00a0Fiscal Y ear Ended\nSeptember 30,\n\u00a0 \u00a02023 \u00a0\u00a0\u00a02022 \u00a0\nOperating Activities: \u00a0 \u00a0\u00a0\nNet income $1,732,576 \u00a0\u00a0$1,666,540 \u00a0\nAdjustments to reconcile net income to net cash provided by operating activities \u00a01,304,216 \u00a0\u00a0\u00a01,176,210 \u00a0\nChanges in operating assets and liabilities, excluding the effects of acquisitions and divestitures: \u00a0 \u00a0\u00a0\nAccounts receivable \u00a0(2,711,786 )\u00a0\u00a0(1,659,525 )\nInventories \u00a0(2,183,368 )\u00a0\u00a0(665,370 )\nAccounts payable \u00a06,103,451 \u00a0\u00a0\u00a03,320,725 \u00a0\nOther, net \u00a0(333,755 )\u00a0\u00a0(1,135,492 )\nNet cash provided by operating activities \u00a03,911,334 \u00a0\u00a0\u00a02,703,088 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures \u00a0(458,359 )\u00a0\u00a0(496,318 )\nCost of acquired companies, net of cash acquired 1 \u00a0(1,409,835 )\u00a0\u00a0(133,814 )\nCost of equity investments 2 \u00a0(743,275 )\u00a0\u00a0(18,491 )\nProceeds from the divestiture of businesses \u00a0\u2014 \u00a0\u00a0\u00a0272,586 \u00a0\nOther, net \u00a09,004 \u00a0\u00a0\u00a07,600 \u00a0\nNet cash used in investing activities \u00a0(2,602,465 )\u00a0\u00a0(368,437 )\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet debt repayments \u00a0(623,258 )\u00a0\u00a0(923,103 )\nPurchases of common stock 3 \u00a0(1,180,728 )\u00a0\u00a0(483,704 )\nExercises of stock options \u00a061,152 \u00a0\u00a0\u00a093,912 \u00a0\nCash dividends on common stock \u00a0(398,752 )\u00a0\u00a0(391,687 )\n26", "page_label": "26", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ee1b7f05da532a258d69c61d1846cd4ec9a3894f70fc39770b96d9838c142597", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6b8b5f4c-a6ce-44fc-a5b1-55d4d9d84a25", "node_type": "1", "metadata": {"window": "Employee tax withholdings related to restricted share vesting \u00a0(71,279 )\u00a0\u00a0(38,076 )\nOther, net \u00a0(9,413 )\u00a0\u00a0(10,122 )\nNet cash used in financing activities \u00a0(2,222,278 )\u00a0\u00a0(1,752,780 )\n\u00a0 \u00a0 \u00a0\u00a0\nEffect of exchange rate changes on cash, cash equivalents, and restricted cash \u00a072,759 \u00a0\u00a0\u00a0(57,850 )\n\u00a0 \u00a0 \u00a0\u00a0\n(Decrease) increase in cash, cash equivalents, and restricted cash, including cash classified within\nassets held for sale \u00a0(840,650 )\u00a0\u00a0524,021 \u00a0\nLess: Increase in cash classified within assets held for sale \u00a0\u2014 \u00a0\u00a0\u00a0(610 )\n(Decrease) increase in cash, cash equivalents, and restricted cash \u00a0(840,650 )\u00a0\u00a0523,411 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of year 4 \u00a03,593,539 \u00a0\u00a0\u00a03,070,128 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of year 4 $2,752,889 \u00a0\u00a0$3,593,539 \u00a0\n________________________________________\n1Includes $1,406.5 million for the acquisition of PharmaLex.\n\u00a0\n 2Includes a $718.4 million investment in OneOncology.\n\u00a0\n 3Includes $28.4 million of purchases in September 2022 that cash settled in October 2022.\n\u00a0\n 4The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated S tatements of Cash Flows:\n\u00a0 \u00a0September 30,\n(amounts in thousands) \u00a0\u00a02023 \u00a0\u00a02022 \u00a0\u00a02021\n27", "original_text": "2Includes a $718.4 million investment in OneOncology.\n\u00a0\n"}, "hash": "1fe41c5bde8bca6bc38b444fae6af254045f0056306576692d9d3f77e845cb82", "class_name": "RelatedNodeInfo"}}, "text": "Employee tax withholdings related to restricted share vesting \u00a0(71,279 )\u00a0\u00a0(38,076 )\nOther, net \u00a0(9,413 )\u00a0\u00a0(10,122 )\nNet cash used in financing activities \u00a0(2,222,278 )\u00a0\u00a0(1,752,780 )\n\u00a0 \u00a0 \u00a0\u00a0\nEffect of exchange rate changes on cash, cash equivalents, and restricted cash \u00a072,759 \u00a0\u00a0\u00a0(57,850 )\n\u00a0 \u00a0 \u00a0\u00a0\n(Decrease) increase in cash, cash equivalents, and restricted cash, including cash classified within\nassets held for sale \u00a0(840,650 )\u00a0\u00a0524,021 \u00a0\nLess: Increase in cash classified within assets held for sale \u00a0\u2014 \u00a0\u00a0\u00a0(610 )\n(Decrease) increase in cash, cash equivalents, and restricted cash \u00a0(840,650 )\u00a0\u00a0523,411 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of year 4 \u00a03,593,539 \u00a0\u00a0\u00a03,070,128 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of year 4 $2,752,889 \u00a0\u00a0$3,593,539 \u00a0\n________________________________________\n1Includes $1,406.5 million for the acquisition of PharmaLex.\n\u00a0\n", "start_char_idx": 0, "end_char_idx": 904, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6b8b5f4c-a6ce-44fc-a5b1-55d4d9d84a25": {"__data__": {"id_": "6b8b5f4c-a6ce-44fc-a5b1-55d4d9d84a25", "embedding": null, "metadata": {"window": "Employee tax withholdings related to restricted share vesting \u00a0(71,279 )\u00a0\u00a0(38,076 )\nOther, net \u00a0(9,413 )\u00a0\u00a0(10,122 )\nNet cash used in financing activities \u00a0(2,222,278 )\u00a0\u00a0(1,752,780 )\n\u00a0 \u00a0 \u00a0\u00a0\nEffect of exchange rate changes on cash, cash equivalents, and restricted cash \u00a072,759 \u00a0\u00a0\u00a0(57,850 )\n\u00a0 \u00a0 \u00a0\u00a0\n(Decrease) increase in cash, cash equivalents, and restricted cash, including cash classified within\nassets held for sale \u00a0(840,650 )\u00a0\u00a0524,021 \u00a0\nLess: Increase in cash classified within assets held for sale \u00a0\u2014 \u00a0\u00a0\u00a0(610 )\n(Decrease) increase in cash, cash equivalents, and restricted cash \u00a0(840,650 )\u00a0\u00a0523,411 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of year 4 \u00a03,593,539 \u00a0\u00a0\u00a03,070,128 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of year 4 $2,752,889 \u00a0\u00a0$3,593,539 \u00a0\n________________________________________\n1Includes $1,406.5 million for the acquisition of PharmaLex.\n\u00a0\n 2Includes a $718.4 million investment in OneOncology.\n\u00a0\n 3Includes $28.4 million of purchases in September 2022 that cash settled in October 2022.\n\u00a0\n 4The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated S tatements of Cash Flows:\n\u00a0 \u00a0September 30,\n(amounts in thousands) \u00a0\u00a02023 \u00a0\u00a02022 \u00a0\u00a02021\n27", "original_text": "2Includes a $718.4 million investment in OneOncology.\n\u00a0\n", "page_label": "27", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "33c63d93-9b01-43c3-9fc2-750e06a8cd22", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2d386a62a9cb837618ab6c93515d4bbc9c422c2ec91558920e889dbd2beea67e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "081a6624-c870-4e51-a2d3-ff7a8089a4c0", "node_type": "1", "metadata": {"window": "Employee tax withholdings related to restricted share vesting \u00a0(71,279 )\u00a0\u00a0(38,076 )\nOther, net \u00a0(9,413 )\u00a0\u00a0(10,122 )\nNet cash used in financing activities \u00a0(2,222,278 )\u00a0\u00a0(1,752,780 )\n\u00a0 \u00a0 \u00a0\u00a0\nEffect of exchange rate changes on cash, cash equivalents, and restricted cash \u00a072,759 \u00a0\u00a0\u00a0(57,850 )\n\u00a0 \u00a0 \u00a0\u00a0\n(Decrease) increase in cash, cash equivalents, and restricted cash, including cash classified within\nassets held for sale \u00a0(840,650 )\u00a0\u00a0524,021 \u00a0\nLess: Increase in cash classified within assets held for sale \u00a0\u2014 \u00a0\u00a0\u00a0(610 )\n(Decrease) increase in cash, cash equivalents, and restricted cash \u00a0(840,650 )\u00a0\u00a0523,411 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of year 4 \u00a03,593,539 \u00a0\u00a0\u00a03,070,128 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of year 4 $2,752,889 \u00a0\u00a0$3,593,539 \u00a0\n________________________________________\n1Includes $1,406.5 million for the acquisition of PharmaLex.\n\u00a0\n 2Includes a $718.4 million investment in OneOncology.\n\u00a0\n 3Includes $28.4 million of purchases in September 2022 that cash settled in October 2022.\n\u00a0\n 4The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated S tatements of Cash Flows:\n\u00a0 \u00a0September 30,\n(amounts in thousands) \u00a0\u00a02023 \u00a0\u00a02022 \u00a0\u00a02021\n27", "original_text": "Employee tax withholdings related to restricted share vesting \u00a0(71,279 )\u00a0\u00a0(38,076 )\nOther, net \u00a0(9,413 )\u00a0\u00a0(10,122 )\nNet cash used in financing activities \u00a0(2,222,278 )\u00a0\u00a0(1,752,780 )\n\u00a0 \u00a0 \u00a0\u00a0\nEffect of exchange rate changes on cash, cash equivalents, and restricted cash \u00a072,759 \u00a0\u00a0\u00a0(57,850 )\n\u00a0 \u00a0 \u00a0\u00a0\n(Decrease) increase in cash, cash equivalents, and restricted cash, including cash classified within\nassets held for sale \u00a0(840,650 )\u00a0\u00a0524,021 \u00a0\nLess: Increase in cash classified within assets held for sale \u00a0\u2014 \u00a0\u00a0\u00a0(610 )\n(Decrease) increase in cash, cash equivalents, and restricted cash \u00a0(840,650 )\u00a0\u00a0523,411 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of year 4 \u00a03,593,539 \u00a0\u00a0\u00a03,070,128 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of year 4 $2,752,889 \u00a0\u00a0$3,593,539 \u00a0\n________________________________________\n1Includes $1,406.5 million for the acquisition of PharmaLex.\n\u00a0\n", "page_label": "27", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "62c22d017ac4fdc690254a239a8ff47ba38bde98dd5ff19e3c69a7aba85c1aff", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "72d4c6ed-6de5-4018-9f69-928914e7ce5c", "node_type": "1", "metadata": {"window": "Employee tax withholdings related to restricted share vesting \u00a0(71,279 )\u00a0\u00a0(38,076 )\nOther, net \u00a0(9,413 )\u00a0\u00a0(10,122 )\nNet cash used in financing activities \u00a0(2,222,278 )\u00a0\u00a0(1,752,780 )\n\u00a0 \u00a0 \u00a0\u00a0\nEffect of exchange rate changes on cash, cash equivalents, and restricted cash \u00a072,759 \u00a0\u00a0\u00a0(57,850 )\n\u00a0 \u00a0 \u00a0\u00a0\n(Decrease) increase in cash, cash equivalents, and restricted cash, including cash classified within\nassets held for sale \u00a0(840,650 )\u00a0\u00a0524,021 \u00a0\nLess: Increase in cash classified within assets held for sale \u00a0\u2014 \u00a0\u00a0\u00a0(610 )\n(Decrease) increase in cash, cash equivalents, and restricted cash \u00a0(840,650 )\u00a0\u00a0523,411 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of year 4 \u00a03,593,539 \u00a0\u00a0\u00a03,070,128 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of year 4 $2,752,889 \u00a0\u00a0$3,593,539 \u00a0\n________________________________________\n1Includes $1,406.5 million for the acquisition of PharmaLex.\n\u00a0\n 2Includes a $718.4 million investment in OneOncology.\n\u00a0\n 3Includes $28.4 million of purchases in September 2022 that cash settled in October 2022.\n\u00a0\n 4The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated S tatements of Cash Flows:\n\u00a0 \u00a0September 30,\n(amounts in thousands) \u00a0\u00a02023 \u00a0\u00a02022 \u00a0\u00a02021\n27", "original_text": "3Includes $28.4 million of purchases in September 2022 that cash settled in October 2022.\n\u00a0\n"}, "hash": "dcba584e2fe43ff024e7af7bd9bcc18d994bf1dc03d34c1607928ec52a74cb25", "class_name": "RelatedNodeInfo"}}, "text": "2Includes a $718.4 million investment in OneOncology.\n\u00a0\n", "start_char_idx": 904, "end_char_idx": 960, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "72d4c6ed-6de5-4018-9f69-928914e7ce5c": {"__data__": {"id_": "72d4c6ed-6de5-4018-9f69-928914e7ce5c", "embedding": null, "metadata": {"window": "Employee tax withholdings related to restricted share vesting \u00a0(71,279 )\u00a0\u00a0(38,076 )\nOther, net \u00a0(9,413 )\u00a0\u00a0(10,122 )\nNet cash used in financing activities \u00a0(2,222,278 )\u00a0\u00a0(1,752,780 )\n\u00a0 \u00a0 \u00a0\u00a0\nEffect of exchange rate changes on cash, cash equivalents, and restricted cash \u00a072,759 \u00a0\u00a0\u00a0(57,850 )\n\u00a0 \u00a0 \u00a0\u00a0\n(Decrease) increase in cash, cash equivalents, and restricted cash, including cash classified within\nassets held for sale \u00a0(840,650 )\u00a0\u00a0524,021 \u00a0\nLess: Increase in cash classified within assets held for sale \u00a0\u2014 \u00a0\u00a0\u00a0(610 )\n(Decrease) increase in cash, cash equivalents, and restricted cash \u00a0(840,650 )\u00a0\u00a0523,411 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of year 4 \u00a03,593,539 \u00a0\u00a0\u00a03,070,128 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of year 4 $2,752,889 \u00a0\u00a0$3,593,539 \u00a0\n________________________________________\n1Includes $1,406.5 million for the acquisition of PharmaLex.\n\u00a0\n 2Includes a $718.4 million investment in OneOncology.\n\u00a0\n 3Includes $28.4 million of purchases in September 2022 that cash settled in October 2022.\n\u00a0\n 4The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated S tatements of Cash Flows:\n\u00a0 \u00a0September 30,\n(amounts in thousands) \u00a0\u00a02023 \u00a0\u00a02022 \u00a0\u00a02021\n27", "original_text": "3Includes $28.4 million of purchases in September 2022 that cash settled in October 2022.\n\u00a0\n", "page_label": "27", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "33c63d93-9b01-43c3-9fc2-750e06a8cd22", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2d386a62a9cb837618ab6c93515d4bbc9c422c2ec91558920e889dbd2beea67e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6b8b5f4c-a6ce-44fc-a5b1-55d4d9d84a25", "node_type": "1", "metadata": {"window": "Employee tax withholdings related to restricted share vesting \u00a0(71,279 )\u00a0\u00a0(38,076 )\nOther, net \u00a0(9,413 )\u00a0\u00a0(10,122 )\nNet cash used in financing activities \u00a0(2,222,278 )\u00a0\u00a0(1,752,780 )\n\u00a0 \u00a0 \u00a0\u00a0\nEffect of exchange rate changes on cash, cash equivalents, and restricted cash \u00a072,759 \u00a0\u00a0\u00a0(57,850 )\n\u00a0 \u00a0 \u00a0\u00a0\n(Decrease) increase in cash, cash equivalents, and restricted cash, including cash classified within\nassets held for sale \u00a0(840,650 )\u00a0\u00a0524,021 \u00a0\nLess: Increase in cash classified within assets held for sale \u00a0\u2014 \u00a0\u00a0\u00a0(610 )\n(Decrease) increase in cash, cash equivalents, and restricted cash \u00a0(840,650 )\u00a0\u00a0523,411 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of year 4 \u00a03,593,539 \u00a0\u00a0\u00a03,070,128 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of year 4 $2,752,889 \u00a0\u00a0$3,593,539 \u00a0\n________________________________________\n1Includes $1,406.5 million for the acquisition of PharmaLex.\n\u00a0\n 2Includes a $718.4 million investment in OneOncology.\n\u00a0\n 3Includes $28.4 million of purchases in September 2022 that cash settled in October 2022.\n\u00a0\n 4The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated S tatements of Cash Flows:\n\u00a0 \u00a0September 30,\n(amounts in thousands) \u00a0\u00a02023 \u00a0\u00a02022 \u00a0\u00a02021\n27", "original_text": "2Includes a $718.4 million investment in OneOncology.\n\u00a0\n", "page_label": "27", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "017b7fc6d5326bab3694efcfe49d5b6ab34f0476fba6a3436f0a9be8be7fc4fe", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5d299aec-446f-412f-8010-4f3fbc3ae56a", "node_type": "1", "metadata": {"window": "Employee tax withholdings related to restricted share vesting \u00a0(71,279 )\u00a0\u00a0(38,076 )\nOther, net \u00a0(9,413 )\u00a0\u00a0(10,122 )\nNet cash used in financing activities \u00a0(2,222,278 )\u00a0\u00a0(1,752,780 )\n\u00a0 \u00a0 \u00a0\u00a0\nEffect of exchange rate changes on cash, cash equivalents, and restricted cash \u00a072,759 \u00a0\u00a0\u00a0(57,850 )\n\u00a0 \u00a0 \u00a0\u00a0\n(Decrease) increase in cash, cash equivalents, and restricted cash, including cash classified within\nassets held for sale \u00a0(840,650 )\u00a0\u00a0524,021 \u00a0\nLess: Increase in cash classified within assets held for sale \u00a0\u2014 \u00a0\u00a0\u00a0(610 )\n(Decrease) increase in cash, cash equivalents, and restricted cash \u00a0(840,650 )\u00a0\u00a0523,411 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of year 4 \u00a03,593,539 \u00a0\u00a0\u00a03,070,128 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of year 4 $2,752,889 \u00a0\u00a0$3,593,539 \u00a0\n________________________________________\n1Includes $1,406.5 million for the acquisition of PharmaLex.\n\u00a0\n 2Includes a $718.4 million investment in OneOncology.\n\u00a0\n 3Includes $28.4 million of purchases in September 2022 that cash settled in October 2022.\n\u00a0\n 4The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated S tatements of Cash Flows:\n\u00a0 \u00a0September 30,\n(amounts in thousands) \u00a0\u00a02023 \u00a0\u00a02022 \u00a0\u00a02021\n27", "original_text": "4The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated S tatements of Cash Flows:\n\u00a0 \u00a0September 30,\n(amounts in thousands) \u00a0\u00a02023 \u00a0\u00a02022 \u00a0\u00a02021\n27"}, "hash": "c45e4502f2c5663a7f4981c247e5aceb7e1e704ab31aee21e5309b5985d57e5d", "class_name": "RelatedNodeInfo"}}, "text": "3Includes $28.4 million of purchases in September 2022 that cash settled in October 2022.\n\u00a0\n", "start_char_idx": 960, "end_char_idx": 1052, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5d299aec-446f-412f-8010-4f3fbc3ae56a": {"__data__": {"id_": "5d299aec-446f-412f-8010-4f3fbc3ae56a", "embedding": null, "metadata": {"window": "Employee tax withholdings related to restricted share vesting \u00a0(71,279 )\u00a0\u00a0(38,076 )\nOther, net \u00a0(9,413 )\u00a0\u00a0(10,122 )\nNet cash used in financing activities \u00a0(2,222,278 )\u00a0\u00a0(1,752,780 )\n\u00a0 \u00a0 \u00a0\u00a0\nEffect of exchange rate changes on cash, cash equivalents, and restricted cash \u00a072,759 \u00a0\u00a0\u00a0(57,850 )\n\u00a0 \u00a0 \u00a0\u00a0\n(Decrease) increase in cash, cash equivalents, and restricted cash, including cash classified within\nassets held for sale \u00a0(840,650 )\u00a0\u00a0524,021 \u00a0\nLess: Increase in cash classified within assets held for sale \u00a0\u2014 \u00a0\u00a0\u00a0(610 )\n(Decrease) increase in cash, cash equivalents, and restricted cash \u00a0(840,650 )\u00a0\u00a0523,411 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of year 4 \u00a03,593,539 \u00a0\u00a0\u00a03,070,128 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of year 4 $2,752,889 \u00a0\u00a0$3,593,539 \u00a0\n________________________________________\n1Includes $1,406.5 million for the acquisition of PharmaLex.\n\u00a0\n 2Includes a $718.4 million investment in OneOncology.\n\u00a0\n 3Includes $28.4 million of purchases in September 2022 that cash settled in October 2022.\n\u00a0\n 4The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated S tatements of Cash Flows:\n\u00a0 \u00a0September 30,\n(amounts in thousands) \u00a0\u00a02023 \u00a0\u00a02022 \u00a0\u00a02021\n27", "original_text": "4The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated S tatements of Cash Flows:\n\u00a0 \u00a0September 30,\n(amounts in thousands) \u00a0\u00a02023 \u00a0\u00a02022 \u00a0\u00a02021\n27", "page_label": "27", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "33c63d93-9b01-43c3-9fc2-750e06a8cd22", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2d386a62a9cb837618ab6c93515d4bbc9c422c2ec91558920e889dbd2beea67e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "72d4c6ed-6de5-4018-9f69-928914e7ce5c", "node_type": "1", "metadata": {"window": "Employee tax withholdings related to restricted share vesting \u00a0(71,279 )\u00a0\u00a0(38,076 )\nOther, net \u00a0(9,413 )\u00a0\u00a0(10,122 )\nNet cash used in financing activities \u00a0(2,222,278 )\u00a0\u00a0(1,752,780 )\n\u00a0 \u00a0 \u00a0\u00a0\nEffect of exchange rate changes on cash, cash equivalents, and restricted cash \u00a072,759 \u00a0\u00a0\u00a0(57,850 )\n\u00a0 \u00a0 \u00a0\u00a0\n(Decrease) increase in cash, cash equivalents, and restricted cash, including cash classified within\nassets held for sale \u00a0(840,650 )\u00a0\u00a0524,021 \u00a0\nLess: Increase in cash classified within assets held for sale \u00a0\u2014 \u00a0\u00a0\u00a0(610 )\n(Decrease) increase in cash, cash equivalents, and restricted cash \u00a0(840,650 )\u00a0\u00a0523,411 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of year 4 \u00a03,593,539 \u00a0\u00a0\u00a03,070,128 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of year 4 $2,752,889 \u00a0\u00a0$3,593,539 \u00a0\n________________________________________\n1Includes $1,406.5 million for the acquisition of PharmaLex.\n\u00a0\n 2Includes a $718.4 million investment in OneOncology.\n\u00a0\n 3Includes $28.4 million of purchases in September 2022 that cash settled in October 2022.\n\u00a0\n 4The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated S tatements of Cash Flows:\n\u00a0 \u00a0September 30,\n(amounts in thousands) \u00a0\u00a02023 \u00a0\u00a02022 \u00a0\u00a02021\n27", "original_text": "3Includes $28.4 million of purchases in September 2022 that cash settled in October 2022.\n\u00a0\n", "page_label": "27", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7af6efb7cd0f71263fae0e22572f5376c6378313cd9616e97fe2d1ea0b6b7951", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "280c0370-118c-4aeb-ad3d-933b36c88449", "node_type": "1", "metadata": {"window": "Cash and cash equivalents \u00a0$2,592,051 \u00a0$3,388,189 \u00a0$2,547,142\nRestricted cash (included in Prepaid Expenses and Other) \u00a0\u00a097,722 \u00a0\u00a0144,980 \u00a0\u00a0462,986\nRestricted cash (included in Other Assets) \u00a0\u00a063,116 \u00a0\u00a060,370 \u00a0\u00a060,000\nCash, cash equiv alents, and r estrict ed cash \u00a0$2,752,889 \u00a0$3,593,539 \u00a0$3,070,128\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n", "original_text": "Cash and cash equivalents \u00a0$2,592,051 \u00a0$3,388,189 \u00a0$2,547,142\nRestricted cash (included in Prepaid Expenses and Other) \u00a0\u00a097,722 \u00a0\u00a0144,980 \u00a0\u00a0462,986\nRestricted cash (included in Other Assets) \u00a0\u00a063,116 \u00a0\u00a060,370 \u00a0\u00a060,000\nCash, cash equiv alents, and r estrict ed cash \u00a0$2,752,889 \u00a0$3,593,539 \u00a0$3,070,128\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S. "}, "hash": "e3108ce3e2f82f272e5ddbafb2e92cebc92fd0e2da98f0b8b5148098e399dded", "class_name": "RelatedNodeInfo"}}, "text": "4The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated S tatements of Cash Flows:\n\u00a0 \u00a0September 30,\n(amounts in thousands) \u00a0\u00a02023 \u00a0\u00a02022 \u00a0\u00a02021\n27", "start_char_idx": 1052, "end_char_idx": 1341, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "280c0370-118c-4aeb-ad3d-933b36c88449": {"__data__": {"id_": "280c0370-118c-4aeb-ad3d-933b36c88449", "embedding": null, "metadata": {"window": "Cash and cash equivalents \u00a0$2,592,051 \u00a0$3,388,189 \u00a0$2,547,142\nRestricted cash (included in Prepaid Expenses and Other) \u00a0\u00a097,722 \u00a0\u00a0144,980 \u00a0\u00a0462,986\nRestricted cash (included in Other Assets) \u00a0\u00a063,116 \u00a0\u00a060,370 \u00a0\u00a060,000\nCash, cash equiv alents, and r estrict ed cash \u00a0$2,752,889 \u00a0$3,593,539 \u00a0$3,070,128\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n", "original_text": "Cash and cash equivalents \u00a0$2,592,051 \u00a0$3,388,189 \u00a0$2,547,142\nRestricted cash (included in Prepaid Expenses and Other) \u00a0\u00a097,722 \u00a0\u00a0144,980 \u00a0\u00a0462,986\nRestricted cash (included in Other Assets) \u00a0\u00a063,116 \u00a0\u00a060,370 \u00a0\u00a060,000\nCash, cash equiv alents, and r estrict ed cash \u00a0$2,752,889 \u00a0$3,593,539 \u00a0$3,070,128\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S. ", "page_label": "28", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "577e95e3-3be8-440d-a07a-76a197f7dc46", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9e952da639b2c440829a6e14b64d92f7655e92484c6afb2f978ee1e30288d10f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5d299aec-446f-412f-8010-4f3fbc3ae56a", "node_type": "1", "metadata": {"window": "Employee tax withholdings related to restricted share vesting \u00a0(71,279 )\u00a0\u00a0(38,076 )\nOther, net \u00a0(9,413 )\u00a0\u00a0(10,122 )\nNet cash used in financing activities \u00a0(2,222,278 )\u00a0\u00a0(1,752,780 )\n\u00a0 \u00a0 \u00a0\u00a0\nEffect of exchange rate changes on cash, cash equivalents, and restricted cash \u00a072,759 \u00a0\u00a0\u00a0(57,850 )\n\u00a0 \u00a0 \u00a0\u00a0\n(Decrease) increase in cash, cash equivalents, and restricted cash, including cash classified within\nassets held for sale \u00a0(840,650 )\u00a0\u00a0524,021 \u00a0\nLess: Increase in cash classified within assets held for sale \u00a0\u2014 \u00a0\u00a0\u00a0(610 )\n(Decrease) increase in cash, cash equivalents, and restricted cash \u00a0(840,650 )\u00a0\u00a0523,411 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of year 4 \u00a03,593,539 \u00a0\u00a0\u00a03,070,128 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of year 4 $2,752,889 \u00a0\u00a0$3,593,539 \u00a0\n________________________________________\n1Includes $1,406.5 million for the acquisition of PharmaLex.\n\u00a0\n 2Includes a $718.4 million investment in OneOncology.\n\u00a0\n 3Includes $28.4 million of purchases in September 2022 that cash settled in October 2022.\n\u00a0\n 4The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated S tatements of Cash Flows:\n\u00a0 \u00a0September 30,\n(amounts in thousands) \u00a0\u00a02023 \u00a0\u00a02022 \u00a0\u00a02021\n27", "original_text": "4The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated S tatements of Cash Flows:\n\u00a0 \u00a0September 30,\n(amounts in thousands) \u00a0\u00a02023 \u00a0\u00a02022 \u00a0\u00a02021\n27", "page_label": "27", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a95591f82828601e88d6675aad5ed1c4cc25ca553b53ecdcbcbfd19f80cedc57", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a97359e8-4d14-44a8-af3b-f031a0e70269", "node_type": "1", "metadata": {"window": "Cash and cash equivalents \u00a0$2,592,051 \u00a0$3,388,189 \u00a0$2,547,142\nRestricted cash (included in Prepaid Expenses and Other) \u00a0\u00a097,722 \u00a0\u00a0144,980 \u00a0\u00a0462,986\nRestricted cash (included in Other Assets) \u00a0\u00a063,116 \u00a0\u00a060,370 \u00a0\u00a060,000\nCash, cash equiv alents, and r estrict ed cash \u00a0$2,752,889 \u00a0$3,593,539 \u00a0$3,070,128\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation. ", "original_text": "generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below. "}, "hash": "f1d7086041744643868f7a1aff1a03ee0927b2f83968c3921c76abc75aaeed2c", "class_name": "RelatedNodeInfo"}}, "text": "Cash and cash equivalents \u00a0$2,592,051 \u00a0$3,388,189 \u00a0$2,547,142\nRestricted cash (included in Prepaid Expenses and Other) \u00a0\u00a097,722 \u00a0\u00a0144,980 \u00a0\u00a0462,986\nRestricted cash (included in Other Assets) \u00a0\u00a063,116 \u00a0\u00a060,370 \u00a0\u00a060,000\nCash, cash equiv alents, and r estrict ed cash \u00a0$2,752,889 \u00a0$3,593,539 \u00a0$3,070,128\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S. ", "start_char_idx": 0, "end_char_idx": 439, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a97359e8-4d14-44a8-af3b-f031a0e70269": {"__data__": {"id_": "a97359e8-4d14-44a8-af3b-f031a0e70269", "embedding": null, "metadata": {"window": "Cash and cash equivalents \u00a0$2,592,051 \u00a0$3,388,189 \u00a0$2,547,142\nRestricted cash (included in Prepaid Expenses and Other) \u00a0\u00a097,722 \u00a0\u00a0144,980 \u00a0\u00a0462,986\nRestricted cash (included in Other Assets) \u00a0\u00a063,116 \u00a0\u00a060,370 \u00a0\u00a060,000\nCash, cash equiv alents, and r estrict ed cash \u00a0$2,752,889 \u00a0$3,593,539 \u00a0$3,070,128\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation. ", "original_text": "generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below. ", "page_label": "28", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "577e95e3-3be8-440d-a07a-76a197f7dc46", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9e952da639b2c440829a6e14b64d92f7655e92484c6afb2f978ee1e30288d10f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "280c0370-118c-4aeb-ad3d-933b36c88449", "node_type": "1", "metadata": {"window": "Cash and cash equivalents \u00a0$2,592,051 \u00a0$3,388,189 \u00a0$2,547,142\nRestricted cash (included in Prepaid Expenses and Other) \u00a0\u00a097,722 \u00a0\u00a0144,980 \u00a0\u00a0462,986\nRestricted cash (included in Other Assets) \u00a0\u00a063,116 \u00a0\u00a060,370 \u00a0\u00a060,000\nCash, cash equiv alents, and r estrict ed cash \u00a0$2,752,889 \u00a0$3,593,539 \u00a0$3,070,128\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n", "original_text": "Cash and cash equivalents \u00a0$2,592,051 \u00a0$3,388,189 \u00a0$2,547,142\nRestricted cash (included in Prepaid Expenses and Other) \u00a0\u00a097,722 \u00a0\u00a0144,980 \u00a0\u00a0462,986\nRestricted cash (included in Other Assets) \u00a0\u00a063,116 \u00a0\u00a060,370 \u00a0\u00a060,000\nCash, cash equiv alents, and r estrict ed cash \u00a0$2,752,889 \u00a0$3,593,539 \u00a0$3,070,128\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S. ", "page_label": "28", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "adcb37c2a879db62d238ae9751d305d69be008bbcf914461283f1c3760de7065", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a56f2b0e-568b-458b-84a3-8721977473ba", "node_type": "1", "metadata": {"window": "Cash and cash equivalents \u00a0$2,592,051 \u00a0$3,388,189 \u00a0$2,547,142\nRestricted cash (included in Prepaid Expenses and Other) \u00a0\u00a097,722 \u00a0\u00a0144,980 \u00a0\u00a0462,986\nRestricted cash (included in Other Assets) \u00a0\u00a063,116 \u00a0\u00a060,370 \u00a0\u00a060,000\nCash, cash equiv alents, and r estrict ed cash \u00a0$2,752,889 \u00a0$3,593,539 \u00a0$3,070,128\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors. ", "original_text": "The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP. "}, "hash": "de3969daeb5d57cd16e4b6cade0732ecad83a8c69a7b23cbca95a3c98be8b2d0", "class_name": "RelatedNodeInfo"}}, "text": "generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below. ", "start_char_idx": 439, "end_char_idx": 554, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a56f2b0e-568b-458b-84a3-8721977473ba": {"__data__": {"id_": "a56f2b0e-568b-458b-84a3-8721977473ba", "embedding": null, "metadata": {"window": "Cash and cash equivalents \u00a0$2,592,051 \u00a0$3,388,189 \u00a0$2,547,142\nRestricted cash (included in Prepaid Expenses and Other) \u00a0\u00a097,722 \u00a0\u00a0144,980 \u00a0\u00a0462,986\nRestricted cash (included in Other Assets) \u00a0\u00a063,116 \u00a0\u00a060,370 \u00a0\u00a060,000\nCash, cash equiv alents, and r estrict ed cash \u00a0$2,752,889 \u00a0$3,593,539 \u00a0$3,070,128\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors. ", "original_text": "The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP. ", "page_label": "28", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "577e95e3-3be8-440d-a07a-76a197f7dc46", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9e952da639b2c440829a6e14b64d92f7655e92484c6afb2f978ee1e30288d10f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a97359e8-4d14-44a8-af3b-f031a0e70269", "node_type": "1", "metadata": {"window": "Cash and cash equivalents \u00a0$2,592,051 \u00a0$3,388,189 \u00a0$2,547,142\nRestricted cash (included in Prepaid Expenses and Other) \u00a0\u00a097,722 \u00a0\u00a0144,980 \u00a0\u00a0462,986\nRestricted cash (included in Other Assets) \u00a0\u00a063,116 \u00a0\u00a060,370 \u00a0\u00a060,000\nCash, cash equiv alents, and r estrict ed cash \u00a0$2,752,889 \u00a0$3,593,539 \u00a0$3,070,128\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation. ", "original_text": "generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below. ", "page_label": "28", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d0c91a5b2f3804f1ae9f958be6817b0c974ee2e878eebe1569d784abf13f4a96", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "85b6e3c3-db0a-4e97-85e4-e4b52f9b54e0", "node_type": "1", "metadata": {"window": "Cash and cash equivalents \u00a0$2,592,051 \u00a0$3,388,189 \u00a0$2,547,142\nRestricted cash (included in Prepaid Expenses and Other) \u00a0\u00a097,722 \u00a0\u00a0144,980 \u00a0\u00a0462,986\nRestricted cash (included in Other Assets) \u00a0\u00a063,116 \u00a0\u00a060,370 \u00a0\u00a060,000\nCash, cash equiv alents, and r estrict ed cash \u00a0$2,752,889 \u00a0$3,593,539 \u00a0$3,070,128\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash. ", "original_text": "These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n"}, "hash": "cae094acac639e208201ea6cca07f0b9d764ca67a05297fc892cb379bccbb266", "class_name": "RelatedNodeInfo"}}, "text": "The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP. ", "start_char_idx": 554, "end_char_idx": 694, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "85b6e3c3-db0a-4e97-85e4-e4b52f9b54e0": {"__data__": {"id_": "85b6e3c3-db0a-4e97-85e4-e4b52f9b54e0", "embedding": null, "metadata": {"window": "Cash and cash equivalents \u00a0$2,592,051 \u00a0$3,388,189 \u00a0$2,547,142\nRestricted cash (included in Prepaid Expenses and Other) \u00a0\u00a097,722 \u00a0\u00a0144,980 \u00a0\u00a0462,986\nRestricted cash (included in Other Assets) \u00a0\u00a063,116 \u00a0\u00a060,370 \u00a0\u00a060,000\nCash, cash equiv alents, and r estrict ed cash \u00a0$2,752,889 \u00a0$3,593,539 \u00a0$3,070,128\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash. ", "original_text": "These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n", "page_label": "28", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "577e95e3-3be8-440d-a07a-76a197f7dc46", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9e952da639b2c440829a6e14b64d92f7655e92484c6afb2f978ee1e30288d10f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a56f2b0e-568b-458b-84a3-8721977473ba", "node_type": "1", "metadata": {"window": "Cash and cash equivalents \u00a0$2,592,051 \u00a0$3,388,189 \u00a0$2,547,142\nRestricted cash (included in Prepaid Expenses and Other) \u00a0\u00a097,722 \u00a0\u00a0144,980 \u00a0\u00a0462,986\nRestricted cash (included in Other Assets) \u00a0\u00a063,116 \u00a0\u00a060,370 \u00a0\u00a060,000\nCash, cash equiv alents, and r estrict ed cash \u00a0$2,752,889 \u00a0$3,593,539 \u00a0$3,070,128\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors. ", "original_text": "The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP. ", "page_label": "28", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "28e74ef3a970850075ab0994b2900dea17771b6915b46b3f5b9296aa2f9b9e50", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "45782755-5f85-4625-9f3c-62c437d771f6", "node_type": "1", "metadata": {"window": "generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  W e have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact and LIFO expense (credit). ", "original_text": "The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation. "}, "hash": "a29d026357b1fbbcd398553dce6b0f5d6bb8f42675f19df63e9f30c2db225761", "class_name": "RelatedNodeInfo"}}, "text": "These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n", "start_char_idx": 694, "end_char_idx": 813, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "45782755-5f85-4625-9f3c-62c437d771f6": {"__data__": {"id_": "45782755-5f85-4625-9f3c-62c437d771f6", "embedding": null, "metadata": {"window": "generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  W e have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact and LIFO expense (credit). ", "original_text": "The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation. ", "page_label": "28", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "577e95e3-3be8-440d-a07a-76a197f7dc46", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9e952da639b2c440829a6e14b64d92f7655e92484c6afb2f978ee1e30288d10f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "85b6e3c3-db0a-4e97-85e4-e4b52f9b54e0", "node_type": "1", "metadata": {"window": "Cash and cash equivalents \u00a0$2,592,051 \u00a0$3,388,189 \u00a0$2,547,142\nRestricted cash (included in Prepaid Expenses and Other) \u00a0\u00a097,722 \u00a0\u00a0144,980 \u00a0\u00a0462,986\nRestricted cash (included in Other Assets) \u00a0\u00a063,116 \u00a0\u00a060,370 \u00a0\u00a060,000\nCash, cash equiv alents, and r estrict ed cash \u00a0$2,752,889 \u00a0$3,593,539 \u00a0$3,070,128\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash. ", "original_text": "These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n", "page_label": "28", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "690960f8a045246b08a9f886ee9fe0637acba2a2ed56461a63d19ccb96999775", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bc8b899d-5500-4738-91b7-ca996189f9f9", "node_type": "1", "metadata": {"window": "The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  W e have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact and LIFO expense (credit).  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue. ", "original_text": "Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors. "}, "hash": "5603d28dc694df6589f3867481ea3188ee575b9eb84e481789ba37e90fc0fd7b", "class_name": "RelatedNodeInfo"}}, "text": "The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation. ", "start_char_idx": 813, "end_char_idx": 1032, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bc8b899d-5500-4738-91b7-ca996189f9f9": {"__data__": {"id_": "bc8b899d-5500-4738-91b7-ca996189f9f9", "embedding": null, "metadata": {"window": "The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  W e have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact and LIFO expense (credit).  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue. ", "original_text": "Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors. ", "page_label": "28", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "577e95e3-3be8-440d-a07a-76a197f7dc46", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9e952da639b2c440829a6e14b64d92f7655e92484c6afb2f978ee1e30288d10f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "45782755-5f85-4625-9f3c-62c437d771f6", "node_type": "1", "metadata": {"window": "generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  W e have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact and LIFO expense (credit). ", "original_text": "The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation. ", "page_label": "28", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "818316226a32f97f798ac6b6201a6cf57b66b028b30a2f32a03d6cb3682c0be1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e63a11d3-2f7f-400b-9f2a-bac120294f77", "node_type": "1", "metadata": {"window": "These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  W e have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact and LIFO expense (credit).  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance. ", "original_text": "The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash. "}, "hash": "a4b97d59076a25cfbd35a6ea4a7608f3e640e9997b9a077f9cf256924ff5c17f", "class_name": "RelatedNodeInfo"}}, "text": "Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors. ", "start_char_idx": 1032, "end_char_idx": 1214, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e63a11d3-2f7f-400b-9f2a-bac120294f77": {"__data__": {"id_": "e63a11d3-2f7f-400b-9f2a-bac120294f77", "embedding": null, "metadata": {"window": "These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  W e have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact and LIFO expense (credit).  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance. ", "original_text": "The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash. ", "page_label": "28", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "577e95e3-3be8-440d-a07a-76a197f7dc46", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9e952da639b2c440829a6e14b64d92f7655e92484c6afb2f978ee1e30288d10f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bc8b899d-5500-4738-91b7-ca996189f9f9", "node_type": "1", "metadata": {"window": "The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  W e have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact and LIFO expense (credit).  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue. ", "original_text": "Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors. ", "page_label": "28", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b710f7425ac56798fd0cedfbb249b2e9bf54f4d982d23ce137ca9744cc7b3e43", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2e046d66-e957-4a15-8d6b-b44141f79aa1", "node_type": "1", "metadata": {"window": "The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  W e have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact and LIFO expense (credit).  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact and LIFO expense (credit) are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items. ", "original_text": "W e have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact and LIFO expense (credit). "}, "hash": "c0dbb45f343b5d4e27a57e5ffc251148678ec758078b2d88ea04a829868503bd", "class_name": "RelatedNodeInfo"}}, "text": "The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash. ", "start_char_idx": 1214, "end_char_idx": 1495, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2e046d66-e957-4a15-8d6b-b44141f79aa1": {"__data__": {"id_": "2e046d66-e957-4a15-8d6b-b44141f79aa1", "embedding": null, "metadata": {"window": "The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  W e have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact and LIFO expense (credit).  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact and LIFO expense (credit) are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items. ", "original_text": "W e have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact and LIFO expense (credit). ", "page_label": "28", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "577e95e3-3be8-440d-a07a-76a197f7dc46", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9e952da639b2c440829a6e14b64d92f7655e92484c6afb2f978ee1e30288d10f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e63a11d3-2f7f-400b-9f2a-bac120294f77", "node_type": "1", "metadata": {"window": "These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  W e have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact and LIFO expense (credit).  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance. ", "original_text": "The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash. ", "page_label": "28", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "60adf47802a570833c67cc2b12197df5a4800ec6792fb1117b10e85a90e5fe96", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "486479f3-266c-4b4c-a597-50827ef8df24", "node_type": "1", "metadata": {"window": "Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  W e have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact and LIFO expense (credit).  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact and LIFO expense (credit) are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market. ", "original_text": "Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue. "}, "hash": "900e61fb3cee51b7139ecfea1c6fcb3e4c0b9ae3dfffb6239a57eb5533237134", "class_name": "RelatedNodeInfo"}}, "text": "W e have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact and LIFO expense (credit). ", "start_char_idx": 1495, "end_char_idx": 1820, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "486479f3-266c-4b4c-a597-50827ef8df24": {"__data__": {"id_": "486479f3-266c-4b4c-a597-50827ef8df24", "embedding": null, "metadata": {"window": "Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  W e have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact and LIFO expense (credit).  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact and LIFO expense (credit) are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market. ", "original_text": "Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue. ", "page_label": "28", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "577e95e3-3be8-440d-a07a-76a197f7dc46", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9e952da639b2c440829a6e14b64d92f7655e92484c6afb2f978ee1e30288d10f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2e046d66-e957-4a15-8d6b-b44141f79aa1", "node_type": "1", "metadata": {"window": "The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  W e have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact and LIFO expense (credit).  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact and LIFO expense (credit) are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items. ", "original_text": "W e have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact and LIFO expense (credit). ", "page_label": "28", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ae316b29a658880574814e2755d5ae41ab0b09cd12b16afc6a7653984b855ace", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "17483c1b-2f00-45e7-b6ef-3b21d7719345", "node_type": "1", "metadata": {"window": "The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  W e have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact and LIFO expense (credit).  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact and LIFO expense (credit) are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n", "original_text": "Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance. "}, "hash": "590d8d78134c7218ac1b09b10da08872a199c71043868560989c5f4f9dc00bc3", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue. ", "start_char_idx": 1820, "end_char_idx": 1905, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "17483c1b-2f00-45e7-b6ef-3b21d7719345": {"__data__": {"id_": "17483c1b-2f00-45e7-b6ef-3b21d7719345", "embedding": null, "metadata": {"window": "The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  W e have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact and LIFO expense (credit).  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact and LIFO expense (credit) are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n", "original_text": "Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance. ", "page_label": "28", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "577e95e3-3be8-440d-a07a-76a197f7dc46", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9e952da639b2c440829a6e14b64d92f7655e92484c6afb2f978ee1e30288d10f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "486479f3-266c-4b4c-a597-50827ef8df24", "node_type": "1", "metadata": {"window": "Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  W e have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact and LIFO expense (credit).  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact and LIFO expense (credit) are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market. ", "original_text": "Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue. ", "page_label": "28", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8ba6adb4f1ead77132bd9d49325b23b7fbe0df28fe1ddf5200dacd7dc61da6e1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3a537d0f-b1dc-4ebf-9caa-ea6e1da43621", "node_type": "1", "metadata": {"window": "W e have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact and LIFO expense (credit).  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact and LIFO expense (credit) are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses (credit);\nacquisition-related deal and integration expenses; restructuring and other expenses; impairment of assets; and goodwill\nimpairment. ", "original_text": "Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact and LIFO expense (credit) are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items. "}, "hash": "5afefff2aad31741782ebacd633a2bbc6dd18bdc9d5e0edbcdea75b3640bdac7", "class_name": "RelatedNodeInfo"}}, "text": "Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance. ", "start_char_idx": 1905, "end_char_idx": 2062, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3a537d0f-b1dc-4ebf-9caa-ea6e1da43621": {"__data__": {"id_": "3a537d0f-b1dc-4ebf-9caa-ea6e1da43621", "embedding": null, "metadata": {"window": "W e have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact and LIFO expense (credit).  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact and LIFO expense (credit) are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses (credit);\nacquisition-related deal and integration expenses; restructuring and other expenses; impairment of assets; and goodwill\nimpairment. ", "original_text": "Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact and LIFO expense (credit) are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items. ", "page_label": "28", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "577e95e3-3be8-440d-a07a-76a197f7dc46", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9e952da639b2c440829a6e14b64d92f7655e92484c6afb2f978ee1e30288d10f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "17483c1b-2f00-45e7-b6ef-3b21d7719345", "node_type": "1", "metadata": {"window": "The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  W e have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact and LIFO expense (credit).  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact and LIFO expense (credit) are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n", "original_text": "Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance. ", "page_label": "28", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3f25463426ec0f7f827126d727693320560097f83565badfa863c95e3c09a075", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "30855a9d-a778-4906-b0fd-899107dc395b", "node_type": "1", "metadata": {"window": "Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact and LIFO expense (credit) are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses (credit);\nacquisition-related deal and integration expenses; restructuring and other expenses; impairment of assets; and goodwill\nimpairment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue. ", "original_text": "Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market. "}, "hash": "25d958d709404761b1ec1308b9c192b0d037e40b94418b91cd8ad5e4e8c77ce0", "class_name": "RelatedNodeInfo"}}, "text": "Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact and LIFO expense (credit) are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items. ", "start_char_idx": 2062, "end_char_idx": 2264, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "30855a9d-a778-4906-b0fd-899107dc395b": {"__data__": {"id_": "30855a9d-a778-4906-b0fd-899107dc395b", "embedding": null, "metadata": {"window": "Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact and LIFO expense (credit) are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses (credit);\nacquisition-related deal and integration expenses; restructuring and other expenses; impairment of assets; and goodwill\nimpairment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue. ", "original_text": "Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market. ", "page_label": "28", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "577e95e3-3be8-440d-a07a-76a197f7dc46", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9e952da639b2c440829a6e14b64d92f7655e92484c6afb2f978ee1e30288d10f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3a537d0f-b1dc-4ebf-9caa-ea6e1da43621", "node_type": "1", "metadata": {"window": "W e have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact and LIFO expense (credit).  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact and LIFO expense (credit) are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses (credit);\nacquisition-related deal and integration expenses; restructuring and other expenses; impairment of assets; and goodwill\nimpairment. ", "original_text": "Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact and LIFO expense (credit) are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items. ", "page_label": "28", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bf7dc5afaf0ab7e5c0fcfbeeafb58366a1876d3a24fdb100501358e51d51431c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "41c9d689-02e7-48d1-9e76-ef355524b839", "node_type": "1", "metadata": {"window": "Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact and LIFO expense (credit) are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses (credit);\nacquisition-related deal and integration expenses; restructuring and other expenses; impairment of assets; and goodwill\nimpairment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.  Acquisition-\nrelated intangibles amortization is excluded because it is a non-cash item and does not reflect the operating performance of\nthe acquired companies. ", "original_text": "LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n"}, "hash": "152687852b163b1257912e9a16cf1ccaf5a11cb83c23d6004cb894e2533857b0", "class_name": "RelatedNodeInfo"}}, "text": "Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market. ", "start_char_idx": 2264, "end_char_idx": 2560, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "41c9d689-02e7-48d1-9e76-ef355524b839": {"__data__": {"id_": "41c9d689-02e7-48d1-9e76-ef355524b839", "embedding": null, "metadata": {"window": "Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact and LIFO expense (credit) are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses (credit);\nacquisition-related deal and integration expenses; restructuring and other expenses; impairment of assets; and goodwill\nimpairment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.  Acquisition-\nrelated intangibles amortization is excluded because it is a non-cash item and does not reflect the operating performance of\nthe acquired companies. ", "original_text": "LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n", "page_label": "28", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "577e95e3-3be8-440d-a07a-76a197f7dc46", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9e952da639b2c440829a6e14b64d92f7655e92484c6afb2f978ee1e30288d10f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "30855a9d-a778-4906-b0fd-899107dc395b", "node_type": "1", "metadata": {"window": "Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact and LIFO expense (credit) are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses (credit);\nacquisition-related deal and integration expenses; restructuring and other expenses; impairment of assets; and goodwill\nimpairment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue. ", "original_text": "Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market. ", "page_label": "28", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ca5ae6b0bbe914a9ee039058d3b4502f92affe094b88981fba0876da1a2802c4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7dfe1b24-be78-41e6-8095-ef5f22a38ed5", "node_type": "1", "metadata": {"window": "Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact and LIFO expense (credit) are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses (credit);\nacquisition-related deal and integration expenses; restructuring and other expenses; impairment of assets; and goodwill\nimpairment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.  Acquisition-\nrelated intangibles amortization is excluded because it is a non-cash item and does not reflect the operating performance of\nthe acquired companies.  W e exclude acquisition-related deal and integration expenses and restructuring and other expenses\nthat relate to unpredictable and/or non-recurring business activities. ", "original_text": "Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses (credit);\nacquisition-related deal and integration expenses; restructuring and other expenses; impairment of assets; and goodwill\nimpairment. "}, "hash": "df622ca5de2a9f5f75eaaac5cbbac61bde0bb002315fbc2548c633593d5ada63", "class_name": "RelatedNodeInfo"}}, "text": "LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n", "start_char_idx": 2560, "end_char_idx": 2742, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7dfe1b24-be78-41e6-8095-ef5f22a38ed5": {"__data__": {"id_": "7dfe1b24-be78-41e6-8095-ef5f22a38ed5", "embedding": null, "metadata": {"window": "Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact and LIFO expense (credit) are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses (credit);\nacquisition-related deal and integration expenses; restructuring and other expenses; impairment of assets; and goodwill\nimpairment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.  Acquisition-\nrelated intangibles amortization is excluded because it is a non-cash item and does not reflect the operating performance of\nthe acquired companies.  W e exclude acquisition-related deal and integration expenses and restructuring and other expenses\nthat relate to unpredictable and/or non-recurring business activities. ", "original_text": "Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses (credit);\nacquisition-related deal and integration expenses; restructuring and other expenses; impairment of assets; and goodwill\nimpairment. ", "page_label": "28", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "577e95e3-3be8-440d-a07a-76a197f7dc46", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9e952da639b2c440829a6e14b64d92f7655e92484c6afb2f978ee1e30288d10f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "41c9d689-02e7-48d1-9e76-ef355524b839", "node_type": "1", "metadata": {"window": "Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact and LIFO expense (credit) are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses (credit);\nacquisition-related deal and integration expenses; restructuring and other expenses; impairment of assets; and goodwill\nimpairment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.  Acquisition-\nrelated intangibles amortization is excluded because it is a non-cash item and does not reflect the operating performance of\nthe acquired companies. ", "original_text": "LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n", "page_label": "28", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "48c65ddb224c5ad1a2232d43ab6c1416659e207045a89d5375f77f2b66c4cb36", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cbc7f4e0-ecb8-4269-a428-a6c26aeb7ef3", "node_type": "1", "metadata": {"window": "Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses (credit);\nacquisition-related deal and integration expenses; restructuring and other expenses; impairment of assets; and goodwill\nimpairment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.  Acquisition-\nrelated intangibles amortization is excluded because it is a non-cash item and does not reflect the operating performance of\nthe acquired companies.  W e exclude acquisition-related deal and integration expenses and restructuring and other expenses\nthat relate to unpredictable and/or non-recurring business activities.  W e exclude the amount of litigation and opioid-related\nexpenses (credit), and the impairment of assets, including goodwill, that are unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing operational\nperformance.\n", "original_text": "Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue. "}, "hash": "f46d69060bf6829220dc686d014baa23a9ab58f57dfee5af4019e079c789ac77", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses (credit);\nacquisition-related deal and integration expenses; restructuring and other expenses; impairment of assets; and goodwill\nimpairment. ", "start_char_idx": 2742, "end_char_idx": 3110, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cbc7f4e0-ecb8-4269-a428-a6c26aeb7ef3": {"__data__": {"id_": "cbc7f4e0-ecb8-4269-a428-a6c26aeb7ef3", "embedding": null, "metadata": {"window": "Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses (credit);\nacquisition-related deal and integration expenses; restructuring and other expenses; impairment of assets; and goodwill\nimpairment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.  Acquisition-\nrelated intangibles amortization is excluded because it is a non-cash item and does not reflect the operating performance of\nthe acquired companies.  W e exclude acquisition-related deal and integration expenses and restructuring and other expenses\nthat relate to unpredictable and/or non-recurring business activities.  W e exclude the amount of litigation and opioid-related\nexpenses (credit), and the impairment of assets, including goodwill, that are unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing operational\nperformance.\n", "original_text": "Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue. ", "page_label": "28", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "577e95e3-3be8-440d-a07a-76a197f7dc46", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9e952da639b2c440829a6e14b64d92f7655e92484c6afb2f978ee1e30288d10f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7dfe1b24-be78-41e6-8095-ef5f22a38ed5", "node_type": "1", "metadata": {"window": "Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact and LIFO expense (credit) are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses (credit);\nacquisition-related deal and integration expenses; restructuring and other expenses; impairment of assets; and goodwill\nimpairment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.  Acquisition-\nrelated intangibles amortization is excluded because it is a non-cash item and does not reflect the operating performance of\nthe acquired companies.  W e exclude acquisition-related deal and integration expenses and restructuring and other expenses\nthat relate to unpredictable and/or non-recurring business activities. ", "original_text": "Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses (credit);\nacquisition-related deal and integration expenses; restructuring and other expenses; impairment of assets; and goodwill\nimpairment. ", "page_label": "28", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "870feffb37c8dac7e106e43b5724ce3b1b0d368ca9414bfd890bff385b54158c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d23080df-e17b-4048-a273-68a4da838b02", "node_type": "1", "metadata": {"window": "LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses (credit);\nacquisition-related deal and integration expenses; restructuring and other expenses; impairment of assets; and goodwill\nimpairment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.  Acquisition-\nrelated intangibles amortization is excluded because it is a non-cash item and does not reflect the operating performance of\nthe acquired companies.  W e exclude acquisition-related deal and integration expenses and restructuring and other expenses\nthat relate to unpredictable and/or non-recurring business activities.  W e exclude the amount of litigation and opioid-related\nexpenses (credit), and the impairment of assets, including goodwill, that are unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing operational\nperformance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses. ", "original_text": "Acquisition-\nrelated intangibles amortization is excluded because it is a non-cash item and does not reflect the operating performance of\nthe acquired companies. "}, "hash": "5aeadb939b344b939b7b71ab95150f68456f02ca53cd176397924f55fe611ad2", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue. ", "start_char_idx": 3110, "end_char_idx": 3206, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d23080df-e17b-4048-a273-68a4da838b02": {"__data__": {"id_": "d23080df-e17b-4048-a273-68a4da838b02", "embedding": null, "metadata": {"window": "LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses (credit);\nacquisition-related deal and integration expenses; restructuring and other expenses; impairment of assets; and goodwill\nimpairment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.  Acquisition-\nrelated intangibles amortization is excluded because it is a non-cash item and does not reflect the operating performance of\nthe acquired companies.  W e exclude acquisition-related deal and integration expenses and restructuring and other expenses\nthat relate to unpredictable and/or non-recurring business activities.  W e exclude the amount of litigation and opioid-related\nexpenses (credit), and the impairment of assets, including goodwill, that are unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing operational\nperformance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses. ", "original_text": "Acquisition-\nrelated intangibles amortization is excluded because it is a non-cash item and does not reflect the operating performance of\nthe acquired companies. ", "page_label": "28", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "577e95e3-3be8-440d-a07a-76a197f7dc46", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9e952da639b2c440829a6e14b64d92f7655e92484c6afb2f978ee1e30288d10f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cbc7f4e0-ecb8-4269-a428-a6c26aeb7ef3", "node_type": "1", "metadata": {"window": "Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses (credit);\nacquisition-related deal and integration expenses; restructuring and other expenses; impairment of assets; and goodwill\nimpairment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.  Acquisition-\nrelated intangibles amortization is excluded because it is a non-cash item and does not reflect the operating performance of\nthe acquired companies.  W e exclude acquisition-related deal and integration expenses and restructuring and other expenses\nthat relate to unpredictable and/or non-recurring business activities.  W e exclude the amount of litigation and opioid-related\nexpenses (credit), and the impairment of assets, including goodwill, that are unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing operational\nperformance.\n", "original_text": "Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue. ", "page_label": "28", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ac5f1598e2a4b84f8d91a7d756c2291b8f82034a1a68ccaa073cbb1af3a1eff7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9cbc5f78-bc73-4f6f-8544-03c21b1d05c7", "node_type": "1", "metadata": {"window": "Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses (credit);\nacquisition-related deal and integration expenses; restructuring and other expenses; impairment of assets; and goodwill\nimpairment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.  Acquisition-\nrelated intangibles amortization is excluded because it is a non-cash item and does not reflect the operating performance of\nthe acquired companies.  W e exclude acquisition-related deal and integration expenses and restructuring and other expenses\nthat relate to unpredictable and/or non-recurring business activities.  W e exclude the amount of litigation and opioid-related\nexpenses (credit), and the impairment of assets, including goodwill, that are unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing operational\nperformance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n", "original_text": "W e exclude acquisition-related deal and integration expenses and restructuring and other expenses\nthat relate to unpredictable and/or non-recurring business activities. "}, "hash": "21ec04265c0dcaa3e281b726cb2337db1f721368fb0fa12e8ceb29d6f952a4bc", "class_name": "RelatedNodeInfo"}}, "text": "Acquisition-\nrelated intangibles amortization is excluded because it is a non-cash item and does not reflect the operating performance of\nthe acquired companies. ", "start_char_idx": 3206, "end_char_idx": 3368, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9cbc5f78-bc73-4f6f-8544-03c21b1d05c7": {"__data__": {"id_": "9cbc5f78-bc73-4f6f-8544-03c21b1d05c7", "embedding": null, "metadata": {"window": "Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses (credit);\nacquisition-related deal and integration expenses; restructuring and other expenses; impairment of assets; and goodwill\nimpairment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.  Acquisition-\nrelated intangibles amortization is excluded because it is a non-cash item and does not reflect the operating performance of\nthe acquired companies.  W e exclude acquisition-related deal and integration expenses and restructuring and other expenses\nthat relate to unpredictable and/or non-recurring business activities.  W e exclude the amount of litigation and opioid-related\nexpenses (credit), and the impairment of assets, including goodwill, that are unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing operational\nperformance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n", "original_text": "W e exclude acquisition-related deal and integration expenses and restructuring and other expenses\nthat relate to unpredictable and/or non-recurring business activities. ", "page_label": "28", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "577e95e3-3be8-440d-a07a-76a197f7dc46", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9e952da639b2c440829a6e14b64d92f7655e92484c6afb2f978ee1e30288d10f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d23080df-e17b-4048-a273-68a4da838b02", "node_type": "1", "metadata": {"window": "LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses (credit);\nacquisition-related deal and integration expenses; restructuring and other expenses; impairment of assets; and goodwill\nimpairment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.  Acquisition-\nrelated intangibles amortization is excluded because it is a non-cash item and does not reflect the operating performance of\nthe acquired companies.  W e exclude acquisition-related deal and integration expenses and restructuring and other expenses\nthat relate to unpredictable and/or non-recurring business activities.  W e exclude the amount of litigation and opioid-related\nexpenses (credit), and the impairment of assets, including goodwill, that are unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing operational\nperformance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses. ", "original_text": "Acquisition-\nrelated intangibles amortization is excluded because it is a non-cash item and does not reflect the operating performance of\nthe acquired companies. ", "page_label": "28", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5a8c246f63b18127f42b3042dec57b534b92b527a9d711bdfa7a167d133dfc9e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "36a00b13-e8b9-417b-9cb0-ea04653cb2df", "node_type": "1", "metadata": {"window": "Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.  Acquisition-\nrelated intangibles amortization is excluded because it is a non-cash item and does not reflect the operating performance of\nthe acquired companies.  W e exclude acquisition-related deal and integration expenses and restructuring and other expenses\nthat relate to unpredictable and/or non-recurring business activities.  W e exclude the amount of litigation and opioid-related\nexpenses (credit), and the impairment of assets, including goodwill, that are unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing operational\nperformance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n", "original_text": "W e exclude the amount of litigation and opioid-related\nexpenses (credit), and the impairment of assets, including goodwill, that are unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing operational\nperformance.\n"}, "hash": "7f1398ddf5ffb4d3ce77d2552adc65a663add53eba32745f8a9fa9fd0c08fde1", "class_name": "RelatedNodeInfo"}}, "text": "W e exclude acquisition-related deal and integration expenses and restructuring and other expenses\nthat relate to unpredictable and/or non-recurring business activities. ", "start_char_idx": 3368, "end_char_idx": 3538, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "36a00b13-e8b9-417b-9cb0-ea04653cb2df": {"__data__": {"id_": "36a00b13-e8b9-417b-9cb0-ea04653cb2df", "embedding": null, "metadata": {"window": "Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.  Acquisition-\nrelated intangibles amortization is excluded because it is a non-cash item and does not reflect the operating performance of\nthe acquired companies.  W e exclude acquisition-related deal and integration expenses and restructuring and other expenses\nthat relate to unpredictable and/or non-recurring business activities.  W e exclude the amount of litigation and opioid-related\nexpenses (credit), and the impairment of assets, including goodwill, that are unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing operational\nperformance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n", "original_text": "W e exclude the amount of litigation and opioid-related\nexpenses (credit), and the impairment of assets, including goodwill, that are unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing operational\nperformance.\n", "page_label": "28", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "577e95e3-3be8-440d-a07a-76a197f7dc46", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9e952da639b2c440829a6e14b64d92f7655e92484c6afb2f978ee1e30288d10f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9cbc5f78-bc73-4f6f-8544-03c21b1d05c7", "node_type": "1", "metadata": {"window": "Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses (credit);\nacquisition-related deal and integration expenses; restructuring and other expenses; impairment of assets; and goodwill\nimpairment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.  Acquisition-\nrelated intangibles amortization is excluded because it is a non-cash item and does not reflect the operating performance of\nthe acquired companies.  W e exclude acquisition-related deal and integration expenses and restructuring and other expenses\nthat relate to unpredictable and/or non-recurring business activities.  W e exclude the amount of litigation and opioid-related\nexpenses (credit), and the impairment of assets, including goodwill, that are unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing operational\nperformance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n", "original_text": "W e exclude acquisition-related deal and integration expenses and restructuring and other expenses\nthat relate to unpredictable and/or non-recurring business activities. ", "page_label": "28", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fdd6817bcaf61740e7c1bfc4db295696b6c520013c971375beec6871e59d015a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7a54b6b6-6ab4-403b-a336-c44b0136be4d", "node_type": "1", "metadata": {"window": "Acquisition-\nrelated intangibles amortization is excluded because it is a non-cash item and does not reflect the operating performance of\nthe acquired companies.  W e exclude acquisition-related deal and integration expenses and restructuring and other expenses\nthat relate to unpredictable and/or non-recurring business activities.  W e exclude the amount of litigation and opioid-related\nexpenses (credit), and the impairment of assets, including goodwill, that are unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing operational\nperformance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n 28", "original_text": "Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses. "}, "hash": "c498a3324a2e054e9830be807334f7e7e17aa8ba0d07c10567a8ede33254fac8", "class_name": "RelatedNodeInfo"}}, "text": "W e exclude the amount of litigation and opioid-related\nexpenses (credit), and the impairment of assets, including goodwill, that are unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing operational\nperformance.\n", "start_char_idx": 3538, "end_char_idx": 3848, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7a54b6b6-6ab4-403b-a336-c44b0136be4d": {"__data__": {"id_": "7a54b6b6-6ab4-403b-a336-c44b0136be4d", "embedding": null, "metadata": {"window": "Acquisition-\nrelated intangibles amortization is excluded because it is a non-cash item and does not reflect the operating performance of\nthe acquired companies.  W e exclude acquisition-related deal and integration expenses and restructuring and other expenses\nthat relate to unpredictable and/or non-recurring business activities.  W e exclude the amount of litigation and opioid-related\nexpenses (credit), and the impairment of assets, including goodwill, that are unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing operational\nperformance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n 28", "original_text": "Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses. ", "page_label": "28", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "577e95e3-3be8-440d-a07a-76a197f7dc46", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9e952da639b2c440829a6e14b64d92f7655e92484c6afb2f978ee1e30288d10f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "36a00b13-e8b9-417b-9cb0-ea04653cb2df", "node_type": "1", "metadata": {"window": "Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.  Acquisition-\nrelated intangibles amortization is excluded because it is a non-cash item and does not reflect the operating performance of\nthe acquired companies.  W e exclude acquisition-related deal and integration expenses and restructuring and other expenses\nthat relate to unpredictable and/or non-recurring business activities.  W e exclude the amount of litigation and opioid-related\nexpenses (credit), and the impairment of assets, including goodwill, that are unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing operational\nperformance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n", "original_text": "W e exclude the amount of litigation and opioid-related\nexpenses (credit), and the impairment of assets, including goodwill, that are unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing operational\nperformance.\n", "page_label": "28", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3711173f2610dd6e90a1591c0b3fe06546f59a72232deb55ef30aae3787fdfbd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "be9b4b96-464f-46e0-b18c-70cc547e4f95", "node_type": "1", "metadata": {"window": "W e exclude acquisition-related deal and integration expenses and restructuring and other expenses\nthat relate to unpredictable and/or non-recurring business activities.  W e exclude the amount of litigation and opioid-related\nexpenses (credit), and the impairment of assets, including goodwill, that are unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing operational\nperformance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n 28", "original_text": "Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n"}, "hash": "4f18185c995ca48dc0a7f8fe2ee87edf7b64f7783a323e6549ce5f26f3967354", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses. ", "start_char_idx": 3848, "end_char_idx": 4097, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "be9b4b96-464f-46e0-b18c-70cc547e4f95": {"__data__": {"id_": "be9b4b96-464f-46e0-b18c-70cc547e4f95", "embedding": null, "metadata": {"window": "W e exclude acquisition-related deal and integration expenses and restructuring and other expenses\nthat relate to unpredictable and/or non-recurring business activities.  W e exclude the amount of litigation and opioid-related\nexpenses (credit), and the impairment of assets, including goodwill, that are unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing operational\nperformance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n 28", "original_text": "Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n", "page_label": "28", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "577e95e3-3be8-440d-a07a-76a197f7dc46", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9e952da639b2c440829a6e14b64d92f7655e92484c6afb2f978ee1e30288d10f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7a54b6b6-6ab4-403b-a336-c44b0136be4d", "node_type": "1", "metadata": {"window": "Acquisition-\nrelated intangibles amortization is excluded because it is a non-cash item and does not reflect the operating performance of\nthe acquired companies.  W e exclude acquisition-related deal and integration expenses and restructuring and other expenses\nthat relate to unpredictable and/or non-recurring business activities.  W e exclude the amount of litigation and opioid-related\nexpenses (credit), and the impairment of assets, including goodwill, that are unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing operational\nperformance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n 28", "original_text": "Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses. ", "page_label": "28", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c2488a989619efd2b2eb952d5feb1dbce8ee68eb58c0e6aab41cc5398dfb3c10", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8b19d01b-ba69-4c67-bad3-2af44b90b466", "node_type": "1", "metadata": {"window": "W e exclude the amount of litigation and opioid-related\nexpenses (credit), and the impairment of assets, including goodwill, that are unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing operational\nperformance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n 28", "original_text": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n"}, "hash": "bf465a7bad874cdfcb760cbd5635511f84d3c8dc03289f30b2b7dd009be9d9ec", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n", "start_char_idx": 4097, "end_char_idx": 4190, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8b19d01b-ba69-4c67-bad3-2af44b90b466": {"__data__": {"id_": "8b19d01b-ba69-4c67-bad3-2af44b90b466", "embedding": null, "metadata": {"window": "W e exclude the amount of litigation and opioid-related\nexpenses (credit), and the impairment of assets, including goodwill, that are unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing operational\nperformance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n 28", "original_text": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n", "page_label": "28", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "577e95e3-3be8-440d-a07a-76a197f7dc46", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9e952da639b2c440829a6e14b64d92f7655e92484c6afb2f978ee1e30288d10f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "be9b4b96-464f-46e0-b18c-70cc547e4f95", "node_type": "1", "metadata": {"window": "W e exclude acquisition-related deal and integration expenses and restructuring and other expenses\nthat relate to unpredictable and/or non-recurring business activities.  W e exclude the amount of litigation and opioid-related\nexpenses (credit), and the impairment of assets, including goodwill, that are unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing operational\nperformance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n 28", "original_text": "Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n", "page_label": "28", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6b96993c4687482cdbe828acad73b4762761c66f52dd69c77614aafcd7f1c8a3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "71b64171-42c0-4980-b307-64d08eb87ab8", "node_type": "1", "metadata": {"window": "Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n 28", "original_text": "28"}, "hash": "1b480469644c3717ded3a6c44805f3a4cfe09ac5d003098426b2acba5ed588ed", "class_name": "RelatedNodeInfo"}}, "text": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n", "start_char_idx": 4190, "end_char_idx": 4437, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "71b64171-42c0-4980-b307-64d08eb87ab8": {"__data__": {"id_": "71b64171-42c0-4980-b307-64d08eb87ab8", "embedding": null, "metadata": {"window": "Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n 28", "original_text": "28", "page_label": "28", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "577e95e3-3be8-440d-a07a-76a197f7dc46", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9e952da639b2c440829a6e14b64d92f7655e92484c6afb2f978ee1e30288d10f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8b19d01b-ba69-4c67-bad3-2af44b90b466", "node_type": "1", "metadata": {"window": "W e exclude the amount of litigation and opioid-related\nexpenses (credit), and the impairment of assets, including goodwill, that are unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing operational\nperformance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n 28", "original_text": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n", "page_label": "28", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f502185da269735f40edbabd881a6bfde9dfb3d793b7ff7c31932f3c037b96fe", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "16ec3b65-a79b-4ae7-90eb-2d39624eb0cc", "node_type": "1", "metadata": {"window": "Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the gain (loss) on the\ncurrency remeasurement of the deferred tax asset relating to 2020 S wiss tax reform, the gain on the sale of non-core\nbusinesses, and the gain on the remeasurement of an equity investment are excluded from adjusted income before income\ntaxes because these amounts are unusual, non-operating, and/or non-recurring.  Management believes that this non-GAAP\nfinancial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes. ", "original_text": "Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income. "}, "hash": "408d9e128487176c1d8fe02fa3bac128464ad08b93df6b0b5141ce36ab5be509", "class_name": "RelatedNodeInfo"}}, "text": "28", "start_char_idx": 298, "end_char_idx": 300, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "16ec3b65-a79b-4ae7-90eb-2d39624eb0cc": {"__data__": {"id_": "16ec3b65-a79b-4ae7-90eb-2d39624eb0cc", "embedding": null, "metadata": {"window": "Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the gain (loss) on the\ncurrency remeasurement of the deferred tax asset relating to 2020 S wiss tax reform, the gain on the sale of non-core\nbusinesses, and the gain on the remeasurement of an equity investment are excluded from adjusted income before income\ntaxes because these amounts are unusual, non-operating, and/or non-recurring.  Management believes that this non-GAAP\nfinancial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes. ", "original_text": "Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income. ", "page_label": "29", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b6ce48e9-6291-4029-92f1-4d8ffacab73d", "node_type": "4", "metadata": {"page_label": "29", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c3435c2989c759c74fca82f28d28ffa7f7247066e82f0d6e1b0f1d9cc6e6c3be", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "71b64171-42c0-4980-b307-64d08eb87ab8", "node_type": "1", "metadata": {"window": "Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n 28", "original_text": "28", "page_label": "28", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ac5500720fdbc4cea0f0c4f4a524a1409f2f999fc6f33f9d0ea000e110e29c3b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7bab9e85-82de-4fd7-92c7-e0f400e1e0a6", "node_type": "1", "metadata": {"window": "Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the gain (loss) on the\ncurrency remeasurement of the deferred tax asset relating to 2020 S wiss tax reform, the gain on the sale of non-core\nbusinesses, and the gain on the remeasurement of an equity investment are excluded from adjusted income before income\ntaxes because these amounts are unusual, non-operating, and/or non-recurring.  Management believes that this non-GAAP\nfinancial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes.  Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n", "original_text": "In addition, the gain (loss) on the\ncurrency remeasurement of the deferred tax asset relating to 2020 S wiss tax reform, the gain on the sale of non-core\nbusinesses, and the gain on the remeasurement of an equity investment are excluded from adjusted income before income\ntaxes because these amounts are unusual, non-operating, and/or non-recurring. "}, "hash": "45374af2731859ead81c1f18c9dd0decb250fe399a3f82c3c9e5b500f75ca715", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income. ", "start_char_idx": 0, "end_char_idx": 205, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7bab9e85-82de-4fd7-92c7-e0f400e1e0a6": {"__data__": {"id_": "7bab9e85-82de-4fd7-92c7-e0f400e1e0a6", "embedding": null, "metadata": {"window": "Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the gain (loss) on the\ncurrency remeasurement of the deferred tax asset relating to 2020 S wiss tax reform, the gain on the sale of non-core\nbusinesses, and the gain on the remeasurement of an equity investment are excluded from adjusted income before income\ntaxes because these amounts are unusual, non-operating, and/or non-recurring.  Management believes that this non-GAAP\nfinancial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes.  Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n", "original_text": "In addition, the gain (loss) on the\ncurrency remeasurement of the deferred tax asset relating to 2020 S wiss tax reform, the gain on the sale of non-core\nbusinesses, and the gain on the remeasurement of an equity investment are excluded from adjusted income before income\ntaxes because these amounts are unusual, non-operating, and/or non-recurring. ", "page_label": "29", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b6ce48e9-6291-4029-92f1-4d8ffacab73d", "node_type": "4", "metadata": {"page_label": "29", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c3435c2989c759c74fca82f28d28ffa7f7247066e82f0d6e1b0f1d9cc6e6c3be", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "16ec3b65-a79b-4ae7-90eb-2d39624eb0cc", "node_type": "1", "metadata": {"window": "Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the gain (loss) on the\ncurrency remeasurement of the deferred tax asset relating to 2020 S wiss tax reform, the gain on the sale of non-core\nbusinesses, and the gain on the remeasurement of an equity investment are excluded from adjusted income before income\ntaxes because these amounts are unusual, non-operating, and/or non-recurring.  Management believes that this non-GAAP\nfinancial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes. ", "original_text": "Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income. ", "page_label": "29", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "10c73cec6d006b234082a86a97d21a7a576f24882c7f1104a1de2799833cb618", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ee03e2be-e51c-4c49-92bc-e2bf21431daf", "node_type": "1", "metadata": {"window": "Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the gain (loss) on the\ncurrency remeasurement of the deferred tax asset relating to 2020 S wiss tax reform, the gain on the sale of non-core\nbusinesses, and the gain on the remeasurement of an equity investment are excluded from adjusted income before income\ntaxes because these amounts are unusual, non-operating, and/or non-recurring.  Management believes that this non-GAAP\nfinancial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes.  Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n", "original_text": "Management believes that this non-GAAP\nfinancial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted effective tax rate.\n"}, "hash": "b7733183ee221a3a4a7adf83e1c1139a27419c9815093cb5318862c148608056", "class_name": "RelatedNodeInfo"}}, "text": "In addition, the gain (loss) on the\ncurrency remeasurement of the deferred tax asset relating to 2020 S wiss tax reform, the gain on the sale of non-core\nbusinesses, and the gain on the remeasurement of an equity investment are excluded from adjusted income before income\ntaxes because these amounts are unusual, non-operating, and/or non-recurring. ", "start_char_idx": 205, "end_char_idx": 555, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ee03e2be-e51c-4c49-92bc-e2bf21431daf": {"__data__": {"id_": "ee03e2be-e51c-4c49-92bc-e2bf21431daf", "embedding": null, "metadata": {"window": "Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the gain (loss) on the\ncurrency remeasurement of the deferred tax asset relating to 2020 S wiss tax reform, the gain on the sale of non-core\nbusinesses, and the gain on the remeasurement of an equity investment are excluded from adjusted income before income\ntaxes because these amounts are unusual, non-operating, and/or non-recurring.  Management believes that this non-GAAP\nfinancial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes.  Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n", "original_text": "Management believes that this non-GAAP\nfinancial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted effective tax rate.\n", "page_label": "29", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b6ce48e9-6291-4029-92f1-4d8ffacab73d", "node_type": "4", "metadata": {"page_label": "29", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c3435c2989c759c74fca82f28d28ffa7f7247066e82f0d6e1b0f1d9cc6e6c3be", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7bab9e85-82de-4fd7-92c7-e0f400e1e0a6", "node_type": "1", "metadata": {"window": "Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the gain (loss) on the\ncurrency remeasurement of the deferred tax asset relating to 2020 S wiss tax reform, the gain on the sale of non-core\nbusinesses, and the gain on the remeasurement of an equity investment are excluded from adjusted income before income\ntaxes because these amounts are unusual, non-operating, and/or non-recurring.  Management believes that this non-GAAP\nfinancial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes.  Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n", "original_text": "In addition, the gain (loss) on the\ncurrency remeasurement of the deferred tax asset relating to 2020 S wiss tax reform, the gain on the sale of non-core\nbusinesses, and the gain on the remeasurement of an equity investment are excluded from adjusted income before income\ntaxes because these amounts are unusual, non-operating, and/or non-recurring. ", "page_label": "29", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "969ecdbb7650fdd91c14f3cf8ecee06fef6009b580e9d7aabffa5fd6478160a8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "458f655b-c0d0-4231-93ff-dde3f058eb1c", "node_type": "1", "metadata": {"window": "Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the gain (loss) on the\ncurrency remeasurement of the deferred tax asset relating to 2020 S wiss tax reform, the gain on the sale of non-core\nbusinesses, and the gain on the remeasurement of an equity investment are excluded from adjusted income before income\ntaxes because these amounts are unusual, non-operating, and/or non-recurring.  Management believes that this non-GAAP\nfinancial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes.  Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to foreign valuation allowance adjustments are also excluded from adjusted\nincome tax expense. ", "original_text": "Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes. "}, "hash": "06e11a40f397a4f92680d09b4848e9256cbe6792191a7693359b2bf2add72494", "class_name": "RelatedNodeInfo"}}, "text": "Management believes that this non-GAAP\nfinancial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted effective tax rate.\n", "start_char_idx": 555, "end_char_idx": 720, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "458f655b-c0d0-4231-93ff-dde3f058eb1c": {"__data__": {"id_": "458f655b-c0d0-4231-93ff-dde3f058eb1c", "embedding": null, "metadata": {"window": "Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the gain (loss) on the\ncurrency remeasurement of the deferred tax asset relating to 2020 S wiss tax reform, the gain on the sale of non-core\nbusinesses, and the gain on the remeasurement of an equity investment are excluded from adjusted income before income\ntaxes because these amounts are unusual, non-operating, and/or non-recurring.  Management believes that this non-GAAP\nfinancial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes.  Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to foreign valuation allowance adjustments are also excluded from adjusted\nincome tax expense. ", "original_text": "Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes. ", "page_label": "29", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b6ce48e9-6291-4029-92f1-4d8ffacab73d", "node_type": "4", "metadata": {"page_label": "29", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c3435c2989c759c74fca82f28d28ffa7f7247066e82f0d6e1b0f1d9cc6e6c3be", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ee03e2be-e51c-4c49-92bc-e2bf21431daf", "node_type": "1", "metadata": {"window": "Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the gain (loss) on the\ncurrency remeasurement of the deferred tax asset relating to 2020 S wiss tax reform, the gain on the sale of non-core\nbusinesses, and the gain on the remeasurement of an equity investment are excluded from adjusted income before income\ntaxes because these amounts are unusual, non-operating, and/or non-recurring.  Management believes that this non-GAAP\nfinancial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes.  Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n", "original_text": "Management believes that this non-GAAP\nfinancial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted effective tax rate.\n", "page_label": "29", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "06d38833dc6586aead099e2a6888515ce69441c309a24b1715d9e96367a8cbb5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "71b02232-d5cc-4aee-a942-28c892c46502", "node_type": "1", "metadata": {"window": "In addition, the gain (loss) on the\ncurrency remeasurement of the deferred tax asset relating to 2020 S wiss tax reform, the gain on the sale of non-core\nbusinesses, and the gain on the remeasurement of an equity investment are excluded from adjusted income before income\ntaxes because these amounts are unusual, non-operating, and/or non-recurring.  Management believes that this non-GAAP\nfinancial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes.  Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to foreign valuation allowance adjustments are also excluded from adjusted\nincome tax expense.  Further, certain expenses relating 2020 S wiss tax reform are excluded from adjusted income tax expense.\n", "original_text": "Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n"}, "hash": "89608cfd05d3b4b98809e5b329093fb324acef55f0bd8e41c87ca9c16d826295", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes. ", "start_char_idx": 720, "end_char_idx": 909, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "71b02232-d5cc-4aee-a942-28c892c46502": {"__data__": {"id_": "71b02232-d5cc-4aee-a942-28c892c46502", "embedding": null, "metadata": {"window": "In addition, the gain (loss) on the\ncurrency remeasurement of the deferred tax asset relating to 2020 S wiss tax reform, the gain on the sale of non-core\nbusinesses, and the gain on the remeasurement of an equity investment are excluded from adjusted income before income\ntaxes because these amounts are unusual, non-operating, and/or non-recurring.  Management believes that this non-GAAP\nfinancial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes.  Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to foreign valuation allowance adjustments are also excluded from adjusted\nincome tax expense.  Further, certain expenses relating 2020 S wiss tax reform are excluded from adjusted income tax expense.\n", "original_text": "Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n", "page_label": "29", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b6ce48e9-6291-4029-92f1-4d8ffacab73d", "node_type": "4", "metadata": {"page_label": "29", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c3435c2989c759c74fca82f28d28ffa7f7247066e82f0d6e1b0f1d9cc6e6c3be", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "458f655b-c0d0-4231-93ff-dde3f058eb1c", "node_type": "1", "metadata": {"window": "Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the gain (loss) on the\ncurrency remeasurement of the deferred tax asset relating to 2020 S wiss tax reform, the gain on the sale of non-core\nbusinesses, and the gain on the remeasurement of an equity investment are excluded from adjusted income before income\ntaxes because these amounts are unusual, non-operating, and/or non-recurring.  Management believes that this non-GAAP\nfinancial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes.  Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to foreign valuation allowance adjustments are also excluded from adjusted\nincome tax expense. ", "original_text": "Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes. ", "page_label": "29", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f41c00884c7b155004c65653ff40630ab8fecc6c2aa6518ea127178565fb32c2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "27c84ada-3a05-48fe-bb07-6840f73e746f", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP\nfinancial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes.  Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to foreign valuation allowance adjustments are also excluded from adjusted\nincome tax expense.  Further, certain expenses relating 2020 S wiss tax reform are excluded from adjusted income tax expense.\n Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n", "original_text": "Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n"}, "hash": "9cbb4bcb57f8d6f13656c8138d9438f8575bd62cea382e99aafbb7a22889dd8e", "class_name": "RelatedNodeInfo"}}, "text": "Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n", "start_char_idx": 909, "end_char_idx": 1182, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "27c84ada-3a05-48fe-bb07-6840f73e746f": {"__data__": {"id_": "27c84ada-3a05-48fe-bb07-6840f73e746f", "embedding": null, "metadata": {"window": "Management believes that this non-GAAP\nfinancial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes.  Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to foreign valuation allowance adjustments are also excluded from adjusted\nincome tax expense.  Further, certain expenses relating 2020 S wiss tax reform are excluded from adjusted income tax expense.\n Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n", "original_text": "Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n", "page_label": "29", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b6ce48e9-6291-4029-92f1-4d8ffacab73d", "node_type": "4", "metadata": {"page_label": "29", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c3435c2989c759c74fca82f28d28ffa7f7247066e82f0d6e1b0f1d9cc6e6c3be", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "71b02232-d5cc-4aee-a942-28c892c46502", "node_type": "1", "metadata": {"window": "In addition, the gain (loss) on the\ncurrency remeasurement of the deferred tax asset relating to 2020 S wiss tax reform, the gain on the sale of non-core\nbusinesses, and the gain on the remeasurement of an equity investment are excluded from adjusted income before income\ntaxes because these amounts are unusual, non-operating, and/or non-recurring.  Management believes that this non-GAAP\nfinancial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes.  Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to foreign valuation allowance adjustments are also excluded from adjusted\nincome tax expense.  Further, certain expenses relating 2020 S wiss tax reform are excluded from adjusted income tax expense.\n", "original_text": "Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n", "page_label": "29", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bac2195026208c0e81aa768de63f2bd82e3b66801b56881b11048ca0ec66fd61", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "125c1d80-8fa5-46f6-b252-82fb300d9581", "node_type": "1", "metadata": {"window": "Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes.  Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to foreign valuation allowance adjustments are also excluded from adjusted\nincome tax expense.  Further, certain expenses relating 2020 S wiss tax reform are excluded from adjusted income tax expense.\n Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of the same items described above. ", "original_text": "Certain discrete tax benefits primarily attributable to foreign valuation allowance adjustments are also excluded from adjusted\nincome tax expense. "}, "hash": "3425f289581396ebf935acb7adc0c71970b0b6a7da86e9c5b5068e0e59f1582c", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n", "start_char_idx": 1182, "end_char_idx": 1420, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "125c1d80-8fa5-46f6-b252-82fb300d9581": {"__data__": {"id_": "125c1d80-8fa5-46f6-b252-82fb300d9581", "embedding": null, "metadata": {"window": "Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes.  Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to foreign valuation allowance adjustments are also excluded from adjusted\nincome tax expense.  Further, certain expenses relating 2020 S wiss tax reform are excluded from adjusted income tax expense.\n Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of the same items described above. ", "original_text": "Certain discrete tax benefits primarily attributable to foreign valuation allowance adjustments are also excluded from adjusted\nincome tax expense. ", "page_label": "29", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b6ce48e9-6291-4029-92f1-4d8ffacab73d", "node_type": "4", "metadata": {"page_label": "29", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c3435c2989c759c74fca82f28d28ffa7f7247066e82f0d6e1b0f1d9cc6e6c3be", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "27c84ada-3a05-48fe-bb07-6840f73e746f", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP\nfinancial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes.  Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to foreign valuation allowance adjustments are also excluded from adjusted\nincome tax expense.  Further, certain expenses relating 2020 S wiss tax reform are excluded from adjusted income tax expense.\n Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n", "original_text": "Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n", "page_label": "29", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1c1eb9bea153d4cb226600d8a9284bc09dc081547baac6ab9d5ac833ddebbb60", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eb0ea4a1-1c90-448c-b46b-2695bda5b028", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to foreign valuation allowance adjustments are also excluded from adjusted\nincome tax expense.  Further, certain expenses relating 2020 S wiss tax reform are excluded from adjusted income tax expense.\n Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of the same items described above.  Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n", "original_text": "Further, certain expenses relating 2020 S wiss tax reform are excluded from adjusted income tax expense.\n"}, "hash": "24a0ed5ee3b69c85c2f49fa2700d71303715bfd984c66b43c43fb2f1298cf083", "class_name": "RelatedNodeInfo"}}, "text": "Certain discrete tax benefits primarily attributable to foreign valuation allowance adjustments are also excluded from adjusted\nincome tax expense. ", "start_char_idx": 1420, "end_char_idx": 1568, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eb0ea4a1-1c90-448c-b46b-2695bda5b028": {"__data__": {"id_": "eb0ea4a1-1c90-448c-b46b-2695bda5b028", "embedding": null, "metadata": {"window": "Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to foreign valuation allowance adjustments are also excluded from adjusted\nincome tax expense.  Further, certain expenses relating 2020 S wiss tax reform are excluded from adjusted income tax expense.\n Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of the same items described above.  Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n", "original_text": "Further, certain expenses relating 2020 S wiss tax reform are excluded from adjusted income tax expense.\n", "page_label": "29", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b6ce48e9-6291-4029-92f1-4d8ffacab73d", "node_type": "4", "metadata": {"page_label": "29", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c3435c2989c759c74fca82f28d28ffa7f7247066e82f0d6e1b0f1d9cc6e6c3be", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "125c1d80-8fa5-46f6-b252-82fb300d9581", "node_type": "1", "metadata": {"window": "Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes.  Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to foreign valuation allowance adjustments are also excluded from adjusted\nincome tax expense.  Further, certain expenses relating 2020 S wiss tax reform are excluded from adjusted income tax expense.\n Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of the same items described above. ", "original_text": "Certain discrete tax benefits primarily attributable to foreign valuation allowance adjustments are also excluded from adjusted\nincome tax expense. ", "page_label": "29", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b1ba4e73c327bc59c8553b832b8ac4a4ef4c3f109d61d688b9a28605b25ca9f2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5e70f10b-99c9-4a62-9b2e-83bb8c391a86", "node_type": "1", "metadata": {"window": "Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to foreign valuation allowance adjustments are also excluded from adjusted\nincome tax expense.  Further, certain expenses relating 2020 S wiss tax reform are excluded from adjusted income tax expense.\n Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of the same items described above.  Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above. ", "original_text": "Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n"}, "hash": "53528f32647b155153b4f254e7172348b299628bfa0c5e0f3d6cf86ce862dd78", "class_name": "RelatedNodeInfo"}}, "text": "Further, certain expenses relating 2020 S wiss tax reform are excluded from adjusted income tax expense.\n", "start_char_idx": 1568, "end_char_idx": 1673, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5e70f10b-99c9-4a62-9b2e-83bb8c391a86": {"__data__": {"id_": "5e70f10b-99c9-4a62-9b2e-83bb8c391a86", "embedding": null, "metadata": {"window": "Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to foreign valuation allowance adjustments are also excluded from adjusted\nincome tax expense.  Further, certain expenses relating 2020 S wiss tax reform are excluded from adjusted income tax expense.\n Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of the same items described above.  Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above. ", "original_text": "Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n", "page_label": "29", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b6ce48e9-6291-4029-92f1-4d8ffacab73d", "node_type": "4", "metadata": {"page_label": "29", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c3435c2989c759c74fca82f28d28ffa7f7247066e82f0d6e1b0f1d9cc6e6c3be", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eb0ea4a1-1c90-448c-b46b-2695bda5b028", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to foreign valuation allowance adjustments are also excluded from adjusted\nincome tax expense.  Further, certain expenses relating 2020 S wiss tax reform are excluded from adjusted income tax expense.\n Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of the same items described above.  Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n", "original_text": "Further, certain expenses relating 2020 S wiss tax reform are excluded from adjusted income tax expense.\n", "page_label": "29", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "43662c5dcbfd4702ba1e4354200857206f6ee067fd4bab5def2fe546ce494b1e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "41bb9c0d-9d28-44c5-a6c2-ee2e9d4466cd", "node_type": "1", "metadata": {"window": "Certain discrete tax benefits primarily attributable to foreign valuation allowance adjustments are also excluded from adjusted\nincome tax expense.  Further, certain expenses relating 2020 S wiss tax reform are excluded from adjusted income tax expense.\n Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of the same items described above.  Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company's performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n", "original_text": "Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of the same items described above. "}, "hash": "cf0c0bd27cee03712f6724937afc2090c79a1ae3920135cd99656637649508bb", "class_name": "RelatedNodeInfo"}}, "text": "Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n", "start_char_idx": 1673, "end_char_idx": 1917, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "41bb9c0d-9d28-44c5-a6c2-ee2e9d4466cd": {"__data__": {"id_": "41bb9c0d-9d28-44c5-a6c2-ee2e9d4466cd", "embedding": null, "metadata": {"window": "Certain discrete tax benefits primarily attributable to foreign valuation allowance adjustments are also excluded from adjusted\nincome tax expense.  Further, certain expenses relating 2020 S wiss tax reform are excluded from adjusted income tax expense.\n Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of the same items described above.  Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company's performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n", "original_text": "Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of the same items described above. ", "page_label": "29", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b6ce48e9-6291-4029-92f1-4d8ffacab73d", "node_type": "4", "metadata": {"page_label": "29", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c3435c2989c759c74fca82f28d28ffa7f7247066e82f0d6e1b0f1d9cc6e6c3be", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5e70f10b-99c9-4a62-9b2e-83bb8c391a86", "node_type": "1", "metadata": {"window": "Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to foreign valuation allowance adjustments are also excluded from adjusted\nincome tax expense.  Further, certain expenses relating 2020 S wiss tax reform are excluded from adjusted income tax expense.\n Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of the same items described above.  Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above. ", "original_text": "Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n", "page_label": "29", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "27a6cac0387cf14aedad79c2b88578cfe9f6fe8877a173f42074c913a2e2e290", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9ae155f6-73f4-4fca-a1bc-54db5ec793ae", "node_type": "1", "metadata": {"window": "Further, certain expenses relating 2020 S wiss tax reform are excluded from adjusted income tax expense.\n Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of the same items described above.  Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company's performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense (credit); acquisition-\nrelated intangibles amortization; litigation and opioid expenses (credit); acquisition-related deal and integration expenses;\nrestructuring and other expenses; impairment of assets, including goodwill; the gain on the sale of non-core businesses; the\ngain (loss) on the currency remeasurement related to 2020 S wiss tax reform; and the gain on the remeasurement of an equity\ninvestment, in each case net of the tax effect calculated using the applicable effective tax rate for those items. ", "original_text": "Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n"}, "hash": "eafb99c1c97cab577e999e5153fe7f452287e713c62efd5de175b017c8559ecf", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of the same items described above. ", "start_char_idx": 1917, "end_char_idx": 2129, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9ae155f6-73f4-4fca-a1bc-54db5ec793ae": {"__data__": {"id_": "9ae155f6-73f4-4fca-a1bc-54db5ec793ae", "embedding": null, "metadata": {"window": "Further, certain expenses relating 2020 S wiss tax reform are excluded from adjusted income tax expense.\n Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of the same items described above.  Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company's performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense (credit); acquisition-\nrelated intangibles amortization; litigation and opioid expenses (credit); acquisition-related deal and integration expenses;\nrestructuring and other expenses; impairment of assets, including goodwill; the gain on the sale of non-core businesses; the\ngain (loss) on the currency remeasurement related to 2020 S wiss tax reform; and the gain on the remeasurement of an equity\ninvestment, in each case net of the tax effect calculated using the applicable effective tax rate for those items. ", "original_text": "Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n", "page_label": "29", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b6ce48e9-6291-4029-92f1-4d8ffacab73d", "node_type": "4", "metadata": {"page_label": "29", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c3435c2989c759c74fca82f28d28ffa7f7247066e82f0d6e1b0f1d9cc6e6c3be", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "41bb9c0d-9d28-44c5-a6c2-ee2e9d4466cd", "node_type": "1", "metadata": {"window": "Certain discrete tax benefits primarily attributable to foreign valuation allowance adjustments are also excluded from adjusted\nincome tax expense.  Further, certain expenses relating 2020 S wiss tax reform are excluded from adjusted income tax expense.\n Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of the same items described above.  Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company's performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n", "original_text": "Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of the same items described above. ", "page_label": "29", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6a9a9ebfec5bde8622b2e3dddb0a361fce9ec5c6b949e54a8b52149de61e748e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b56344fe-0076-4d30-af1c-a654dccc3690", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of the same items described above.  Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company's performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense (credit); acquisition-\nrelated intangibles amortization; litigation and opioid expenses (credit); acquisition-related deal and integration expenses;\nrestructuring and other expenses; impairment of assets, including goodwill; the gain on the sale of non-core businesses; the\ngain (loss) on the currency remeasurement related to 2020 S wiss tax reform; and the gain on the remeasurement of an equity\ninvestment, in each case net of the tax effect calculated using the applicable effective tax rate for those items.  In addition, the\nper share impact of certain discrete tax expense primarily attributable to foreign valuation adjustment allowance, and the per\nshare impact of certain expenses related to 2020 S wiss tax reform are also excluded from adjusted diluted earnings per share.\n", "original_text": "Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above. "}, "hash": "fb8c4e36abbc56f07886f191b3d460ced55f4b98b504398fbbe65ac0377d2ac7", "class_name": "RelatedNodeInfo"}}, "text": "Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n", "start_char_idx": 2129, "end_char_idx": 2300, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b56344fe-0076-4d30-af1c-a654dccc3690": {"__data__": {"id_": "b56344fe-0076-4d30-af1c-a654dccc3690", "embedding": null, "metadata": {"window": "Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of the same items described above.  Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company's performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense (credit); acquisition-\nrelated intangibles amortization; litigation and opioid expenses (credit); acquisition-related deal and integration expenses;\nrestructuring and other expenses; impairment of assets, including goodwill; the gain on the sale of non-core businesses; the\ngain (loss) on the currency remeasurement related to 2020 S wiss tax reform; and the gain on the remeasurement of an equity\ninvestment, in each case net of the tax effect calculated using the applicable effective tax rate for those items.  In addition, the\nper share impact of certain discrete tax expense primarily attributable to foreign valuation adjustment allowance, and the per\nshare impact of certain expenses related to 2020 S wiss tax reform are also excluded from adjusted diluted earnings per share.\n", "original_text": "Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above. ", "page_label": "29", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b6ce48e9-6291-4029-92f1-4d8ffacab73d", "node_type": "4", "metadata": {"page_label": "29", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c3435c2989c759c74fca82f28d28ffa7f7247066e82f0d6e1b0f1d9cc6e6c3be", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9ae155f6-73f4-4fca-a1bc-54db5ec793ae", "node_type": "1", "metadata": {"window": "Further, certain expenses relating 2020 S wiss tax reform are excluded from adjusted income tax expense.\n Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of the same items described above.  Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company's performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense (credit); acquisition-\nrelated intangibles amortization; litigation and opioid expenses (credit); acquisition-related deal and integration expenses;\nrestructuring and other expenses; impairment of assets, including goodwill; the gain on the sale of non-core businesses; the\ngain (loss) on the currency remeasurement related to 2020 S wiss tax reform; and the gain on the remeasurement of an equity\ninvestment, in each case net of the tax effect calculated using the applicable effective tax rate for those items. ", "original_text": "Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n", "page_label": "29", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dc9bd9f2945d86dd4c5a4b18cffcab947eb3e759d3bc665e66ad84e4d1b03e10", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ef66c963-4862-4885-90af-49cd3f181809", "node_type": "1", "metadata": {"window": "Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of the same items described above.  Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company's performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense (credit); acquisition-\nrelated intangibles amortization; litigation and opioid expenses (credit); acquisition-related deal and integration expenses;\nrestructuring and other expenses; impairment of assets, including goodwill; the gain on the sale of non-core businesses; the\ngain (loss) on the currency remeasurement related to 2020 S wiss tax reform; and the gain on the remeasurement of an equity\ninvestment, in each case net of the tax effect calculated using the applicable effective tax rate for those items.  In addition, the\nper share impact of certain discrete tax expense primarily attributable to foreign valuation adjustment allowance, and the per\nshare impact of certain expenses related to 2020 S wiss tax reform are also excluded from adjusted diluted earnings per share.\n Management believes that this non-GAAP financial measure is useful to investors because it eliminates the per share impact\nof the items that are outside the control of the Company or that we consider to not be indicative of our ongoing operating\nperformance due to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n", "original_text": "Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company's performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n"}, "hash": "e400d6cb6b5a42ebbe7e69b8c42f58eacfe1d3317349eb41badde7c888e14ab5", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above. ", "start_char_idx": 2300, "end_char_idx": 2485, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ef66c963-4862-4885-90af-49cd3f181809": {"__data__": {"id_": "ef66c963-4862-4885-90af-49cd3f181809", "embedding": null, "metadata": {"window": "Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of the same items described above.  Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company's performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense (credit); acquisition-\nrelated intangibles amortization; litigation and opioid expenses (credit); acquisition-related deal and integration expenses;\nrestructuring and other expenses; impairment of assets, including goodwill; the gain on the sale of non-core businesses; the\ngain (loss) on the currency remeasurement related to 2020 S wiss tax reform; and the gain on the remeasurement of an equity\ninvestment, in each case net of the tax effect calculated using the applicable effective tax rate for those items.  In addition, the\nper share impact of certain discrete tax expense primarily attributable to foreign valuation adjustment allowance, and the per\nshare impact of certain expenses related to 2020 S wiss tax reform are also excluded from adjusted diluted earnings per share.\n Management believes that this non-GAAP financial measure is useful to investors because it eliminates the per share impact\nof the items that are outside the control of the Company or that we consider to not be indicative of our ongoing operating\nperformance due to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n", "original_text": "Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company's performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n", "page_label": "29", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b6ce48e9-6291-4029-92f1-4d8ffacab73d", "node_type": "4", "metadata": {"page_label": "29", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c3435c2989c759c74fca82f28d28ffa7f7247066e82f0d6e1b0f1d9cc6e6c3be", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b56344fe-0076-4d30-af1c-a654dccc3690", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of the same items described above.  Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company's performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense (credit); acquisition-\nrelated intangibles amortization; litigation and opioid expenses (credit); acquisition-related deal and integration expenses;\nrestructuring and other expenses; impairment of assets, including goodwill; the gain on the sale of non-core businesses; the\ngain (loss) on the currency remeasurement related to 2020 S wiss tax reform; and the gain on the remeasurement of an equity\ninvestment, in each case net of the tax effect calculated using the applicable effective tax rate for those items.  In addition, the\nper share impact of certain discrete tax expense primarily attributable to foreign valuation adjustment allowance, and the per\nshare impact of certain expenses related to 2020 S wiss tax reform are also excluded from adjusted diluted earnings per share.\n", "original_text": "Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above. ", "page_label": "29", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "14608ba6c9df650af97a3f6f208c93424242db4c827c8b0df4bc281d080e3a80", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9e95f243-3d53-41bf-8532-5b7d6848c2d7", "node_type": "1", "metadata": {"window": "Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company's performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense (credit); acquisition-\nrelated intangibles amortization; litigation and opioid expenses (credit); acquisition-related deal and integration expenses;\nrestructuring and other expenses; impairment of assets, including goodwill; the gain on the sale of non-core businesses; the\ngain (loss) on the currency remeasurement related to 2020 S wiss tax reform; and the gain on the remeasurement of an equity\ninvestment, in each case net of the tax effect calculated using the applicable effective tax rate for those items.  In addition, the\nper share impact of certain discrete tax expense primarily attributable to foreign valuation adjustment allowance, and the per\nshare impact of certain expenses related to 2020 S wiss tax reform are also excluded from adjusted diluted earnings per share.\n Management believes that this non-GAAP financial measure is useful to investors because it eliminates the per share impact\nof the items that are outside the control of the Company or that we consider to not be indicative of our ongoing operating\nperformance due to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures. ", "original_text": "Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense (credit); acquisition-\nrelated intangibles amortization; litigation and opioid expenses (credit); acquisition-related deal and integration expenses;\nrestructuring and other expenses; impairment of assets, including goodwill; the gain on the sale of non-core businesses; the\ngain (loss) on the currency remeasurement related to 2020 S wiss tax reform; and the gain on the remeasurement of an equity\ninvestment, in each case net of the tax effect calculated using the applicable effective tax rate for those items. "}, "hash": "3781ea627176f5f4d7d7797f44cab98b3d28849ca9bb21bfefe0ae885c148e66", "class_name": "RelatedNodeInfo"}}, "text": "Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company's performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n", "start_char_idx": 2485, "end_char_idx": 2729, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9e95f243-3d53-41bf-8532-5b7d6848c2d7": {"__data__": {"id_": "9e95f243-3d53-41bf-8532-5b7d6848c2d7", "embedding": null, "metadata": {"window": "Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company's performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense (credit); acquisition-\nrelated intangibles amortization; litigation and opioid expenses (credit); acquisition-related deal and integration expenses;\nrestructuring and other expenses; impairment of assets, including goodwill; the gain on the sale of non-core businesses; the\ngain (loss) on the currency remeasurement related to 2020 S wiss tax reform; and the gain on the remeasurement of an equity\ninvestment, in each case net of the tax effect calculated using the applicable effective tax rate for those items.  In addition, the\nper share impact of certain discrete tax expense primarily attributable to foreign valuation adjustment allowance, and the per\nshare impact of certain expenses related to 2020 S wiss tax reform are also excluded from adjusted diluted earnings per share.\n Management believes that this non-GAAP financial measure is useful to investors because it eliminates the per share impact\nof the items that are outside the control of the Company or that we consider to not be indicative of our ongoing operating\nperformance due to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures. ", "original_text": "Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense (credit); acquisition-\nrelated intangibles amortization; litigation and opioid expenses (credit); acquisition-related deal and integration expenses;\nrestructuring and other expenses; impairment of assets, including goodwill; the gain on the sale of non-core businesses; the\ngain (loss) on the currency remeasurement related to 2020 S wiss tax reform; and the gain on the remeasurement of an equity\ninvestment, in each case net of the tax effect calculated using the applicable effective tax rate for those items. ", "page_label": "29", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b6ce48e9-6291-4029-92f1-4d8ffacab73d", "node_type": "4", "metadata": {"page_label": "29", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c3435c2989c759c74fca82f28d28ffa7f7247066e82f0d6e1b0f1d9cc6e6c3be", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ef66c963-4862-4885-90af-49cd3f181809", "node_type": "1", "metadata": {"window": "Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of the same items described above.  Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company's performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense (credit); acquisition-\nrelated intangibles amortization; litigation and opioid expenses (credit); acquisition-related deal and integration expenses;\nrestructuring and other expenses; impairment of assets, including goodwill; the gain on the sale of non-core businesses; the\ngain (loss) on the currency remeasurement related to 2020 S wiss tax reform; and the gain on the remeasurement of an equity\ninvestment, in each case net of the tax effect calculated using the applicable effective tax rate for those items.  In addition, the\nper share impact of certain discrete tax expense primarily attributable to foreign valuation adjustment allowance, and the per\nshare impact of certain expenses related to 2020 S wiss tax reform are also excluded from adjusted diluted earnings per share.\n Management believes that this non-GAAP financial measure is useful to investors because it eliminates the per share impact\nof the items that are outside the control of the Company or that we consider to not be indicative of our ongoing operating\nperformance due to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n", "original_text": "Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company's performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n", "page_label": "29", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "74062b7cde9d50b1227139633255d0fb30d0a08993732a195c7eab4fd09f0147", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c148761a-5b9a-4623-8e9d-4688ad6a2b84", "node_type": "1", "metadata": {"window": "Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company's performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense (credit); acquisition-\nrelated intangibles amortization; litigation and opioid expenses (credit); acquisition-related deal and integration expenses;\nrestructuring and other expenses; impairment of assets, including goodwill; the gain on the sale of non-core businesses; the\ngain (loss) on the currency remeasurement related to 2020 S wiss tax reform; and the gain on the remeasurement of an equity\ninvestment, in each case net of the tax effect calculated using the applicable effective tax rate for those items.  In addition, the\nper share impact of certain discrete tax expense primarily attributable to foreign valuation adjustment allowance, and the per\nshare impact of certain expenses related to 2020 S wiss tax reform are also excluded from adjusted diluted earnings per share.\n Management believes that this non-GAAP financial measure is useful to investors because it eliminates the per share impact\nof the items that are outside the control of the Company or that we consider to not be indicative of our ongoing operating\nperformance due to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows. ", "original_text": "In addition, the\nper share impact of certain discrete tax expense primarily attributable to foreign valuation adjustment allowance, and the per\nshare impact of certain expenses related to 2020 S wiss tax reform are also excluded from adjusted diluted earnings per share.\n"}, "hash": "2122db514203fcb08e5f31f13a153ae3fd382bd401ce25e440fb47bb29549a31", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense (credit); acquisition-\nrelated intangibles amortization; litigation and opioid expenses (credit); acquisition-related deal and integration expenses;\nrestructuring and other expenses; impairment of assets, including goodwill; the gain on the sale of non-core businesses; the\ngain (loss) on the currency remeasurement related to 2020 S wiss tax reform; and the gain on the remeasurement of an equity\ninvestment, in each case net of the tax effect calculated using the applicable effective tax rate for those items. ", "start_char_idx": 2729, "end_char_idx": 3463, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c148761a-5b9a-4623-8e9d-4688ad6a2b84": {"__data__": {"id_": "c148761a-5b9a-4623-8e9d-4688ad6a2b84", "embedding": null, "metadata": {"window": "Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company's performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense (credit); acquisition-\nrelated intangibles amortization; litigation and opioid expenses (credit); acquisition-related deal and integration expenses;\nrestructuring and other expenses; impairment of assets, including goodwill; the gain on the sale of non-core businesses; the\ngain (loss) on the currency remeasurement related to 2020 S wiss tax reform; and the gain on the remeasurement of an equity\ninvestment, in each case net of the tax effect calculated using the applicable effective tax rate for those items.  In addition, the\nper share impact of certain discrete tax expense primarily attributable to foreign valuation adjustment allowance, and the per\nshare impact of certain expenses related to 2020 S wiss tax reform are also excluded from adjusted diluted earnings per share.\n Management believes that this non-GAAP financial measure is useful to investors because it eliminates the per share impact\nof the items that are outside the control of the Company or that we consider to not be indicative of our ongoing operating\nperformance due to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows. ", "original_text": "In addition, the\nper share impact of certain discrete tax expense primarily attributable to foreign valuation adjustment allowance, and the per\nshare impact of certain expenses related to 2020 S wiss tax reform are also excluded from adjusted diluted earnings per share.\n", "page_label": "29", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b6ce48e9-6291-4029-92f1-4d8ffacab73d", "node_type": "4", "metadata": {"page_label": "29", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c3435c2989c759c74fca82f28d28ffa7f7247066e82f0d6e1b0f1d9cc6e6c3be", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9e95f243-3d53-41bf-8532-5b7d6848c2d7", "node_type": "1", "metadata": {"window": "Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company's performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense (credit); acquisition-\nrelated intangibles amortization; litigation and opioid expenses (credit); acquisition-related deal and integration expenses;\nrestructuring and other expenses; impairment of assets, including goodwill; the gain on the sale of non-core businesses; the\ngain (loss) on the currency remeasurement related to 2020 S wiss tax reform; and the gain on the remeasurement of an equity\ninvestment, in each case net of the tax effect calculated using the applicable effective tax rate for those items.  In addition, the\nper share impact of certain discrete tax expense primarily attributable to foreign valuation adjustment allowance, and the per\nshare impact of certain expenses related to 2020 S wiss tax reform are also excluded from adjusted diluted earnings per share.\n Management believes that this non-GAAP financial measure is useful to investors because it eliminates the per share impact\nof the items that are outside the control of the Company or that we consider to not be indicative of our ongoing operating\nperformance due to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures. ", "original_text": "Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense (credit); acquisition-\nrelated intangibles amortization; litigation and opioid expenses (credit); acquisition-related deal and integration expenses;\nrestructuring and other expenses; impairment of assets, including goodwill; the gain on the sale of non-core businesses; the\ngain (loss) on the currency remeasurement related to 2020 S wiss tax reform; and the gain on the remeasurement of an equity\ninvestment, in each case net of the tax effect calculated using the applicable effective tax rate for those items. ", "page_label": "29", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "898611ab6df7e8980d185b748b09b06671a3bac585c49be54a96953d664c687c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e6340bbc-27ab-4211-8bd2-6a7145d5af99", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company's performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense (credit); acquisition-\nrelated intangibles amortization; litigation and opioid expenses (credit); acquisition-related deal and integration expenses;\nrestructuring and other expenses; impairment of assets, including goodwill; the gain on the sale of non-core businesses; the\ngain (loss) on the currency remeasurement related to 2020 S wiss tax reform; and the gain on the remeasurement of an equity\ninvestment, in each case net of the tax effect calculated using the applicable effective tax rate for those items.  In addition, the\nper share impact of certain discrete tax expense primarily attributable to foreign valuation adjustment allowance, and the per\nshare impact of certain expenses related to 2020 S wiss tax reform are also excluded from adjusted diluted earnings per share.\n Management believes that this non-GAAP financial measure is useful to investors because it eliminates the per share impact\nof the items that are outside the control of the Company or that we consider to not be indicative of our ongoing operating\nperformance due to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  For the fiscal year ended September 30, 2023, adjusted free cash flow of $3,130.5 million consisted of net cash\nprovided by operating activities of $3,911.3 million, minus capital expenditures of $458.4 million, the gains from antitrust\nlitigation settlements of $239.1 million, and the receipt of $83.4 million from the H.D. ", "original_text": "Management believes that this non-GAAP financial measure is useful to investors because it eliminates the per share impact\nof the items that are outside the control of the Company or that we consider to not be indicative of our ongoing operating\nperformance due to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n"}, "hash": "d8004ae6b05c5ea88fb1282f5dbf8460a21006abc25bae762aad07bf028d4b7b", "class_name": "RelatedNodeInfo"}}, "text": "In addition, the\nper share impact of certain discrete tax expense primarily attributable to foreign valuation adjustment allowance, and the per\nshare impact of certain expenses related to 2020 S wiss tax reform are also excluded from adjusted diluted earnings per share.\n", "start_char_idx": 3463, "end_char_idx": 3734, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e6340bbc-27ab-4211-8bd2-6a7145d5af99": {"__data__": {"id_": "e6340bbc-27ab-4211-8bd2-6a7145d5af99", "embedding": null, "metadata": {"window": "Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company's performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense (credit); acquisition-\nrelated intangibles amortization; litigation and opioid expenses (credit); acquisition-related deal and integration expenses;\nrestructuring and other expenses; impairment of assets, including goodwill; the gain on the sale of non-core businesses; the\ngain (loss) on the currency remeasurement related to 2020 S wiss tax reform; and the gain on the remeasurement of an equity\ninvestment, in each case net of the tax effect calculated using the applicable effective tax rate for those items.  In addition, the\nper share impact of certain discrete tax expense primarily attributable to foreign valuation adjustment allowance, and the per\nshare impact of certain expenses related to 2020 S wiss tax reform are also excluded from adjusted diluted earnings per share.\n Management believes that this non-GAAP financial measure is useful to investors because it eliminates the per share impact\nof the items that are outside the control of the Company or that we consider to not be indicative of our ongoing operating\nperformance due to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  For the fiscal year ended September 30, 2023, adjusted free cash flow of $3,130.5 million consisted of net cash\nprovided by operating activities of $3,911.3 million, minus capital expenditures of $458.4 million, the gains from antitrust\nlitigation settlements of $239.1 million, and the receipt of $83.4 million from the H.D. ", "original_text": "Management believes that this non-GAAP financial measure is useful to investors because it eliminates the per share impact\nof the items that are outside the control of the Company or that we consider to not be indicative of our ongoing operating\nperformance due to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n", "page_label": "29", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b6ce48e9-6291-4029-92f1-4d8ffacab73d", "node_type": "4", "metadata": {"page_label": "29", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c3435c2989c759c74fca82f28d28ffa7f7247066e82f0d6e1b0f1d9cc6e6c3be", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c148761a-5b9a-4623-8e9d-4688ad6a2b84", "node_type": "1", "metadata": {"window": "Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company's performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense (credit); acquisition-\nrelated intangibles amortization; litigation and opioid expenses (credit); acquisition-related deal and integration expenses;\nrestructuring and other expenses; impairment of assets, including goodwill; the gain on the sale of non-core businesses; the\ngain (loss) on the currency remeasurement related to 2020 S wiss tax reform; and the gain on the remeasurement of an equity\ninvestment, in each case net of the tax effect calculated using the applicable effective tax rate for those items.  In addition, the\nper share impact of certain discrete tax expense primarily attributable to foreign valuation adjustment allowance, and the per\nshare impact of certain expenses related to 2020 S wiss tax reform are also excluded from adjusted diluted earnings per share.\n Management believes that this non-GAAP financial measure is useful to investors because it eliminates the per share impact\nof the items that are outside the control of the Company or that we consider to not be indicative of our ongoing operating\nperformance due to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows. ", "original_text": "In addition, the\nper share impact of certain discrete tax expense primarily attributable to foreign valuation adjustment allowance, and the per\nshare impact of certain expenses related to 2020 S wiss tax reform are also excluded from adjusted diluted earnings per share.\n", "page_label": "29", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4685944d45b696dfff60cdd275e5546f10cc44b1c1934c316b77f19050c39587", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "504caf1e-ffe7-468c-aa7f-9ddb1d4af397", "node_type": "1", "metadata": {"window": "Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense (credit); acquisition-\nrelated intangibles amortization; litigation and opioid expenses (credit); acquisition-related deal and integration expenses;\nrestructuring and other expenses; impairment of assets, including goodwill; the gain on the sale of non-core businesses; the\ngain (loss) on the currency remeasurement related to 2020 S wiss tax reform; and the gain on the remeasurement of an equity\ninvestment, in each case net of the tax effect calculated using the applicable effective tax rate for those items.  In addition, the\nper share impact of certain discrete tax expense primarily attributable to foreign valuation adjustment allowance, and the per\nshare impact of certain expenses related to 2020 S wiss tax reform are also excluded from adjusted diluted earnings per share.\n Management believes that this non-GAAP financial measure is useful to investors because it eliminates the per share impact\nof the items that are outside the control of the Company or that we consider to not be indicative of our ongoing operating\nperformance due to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  For the fiscal year ended September 30, 2023, adjusted free cash flow of $3,130.5 million consisted of net cash\nprovided by operating activities of $3,911.3 million, minus capital expenditures of $458.4 million, the gains from antitrust\nlitigation settlements of $239.1 million, and the receipt of $83.4 million from the H.D.  Smith opioid indemnity escrow. ", "original_text": "Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures. "}, "hash": "e3d30a88b1ca7e84fb4cf825d0d5b011f9431109e585c86e157769ec878b3d35", "class_name": "RelatedNodeInfo"}}, "text": "Management believes that this non-GAAP financial measure is useful to investors because it eliminates the per share impact\nof the items that are outside the control of the Company or that we consider to not be indicative of our ongoing operating\nperformance due to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n", "start_char_idx": 3734, "end_char_idx": 4088, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "504caf1e-ffe7-468c-aa7f-9ddb1d4af397": {"__data__": {"id_": "504caf1e-ffe7-468c-aa7f-9ddb1d4af397", "embedding": null, "metadata": {"window": "Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense (credit); acquisition-\nrelated intangibles amortization; litigation and opioid expenses (credit); acquisition-related deal and integration expenses;\nrestructuring and other expenses; impairment of assets, including goodwill; the gain on the sale of non-core businesses; the\ngain (loss) on the currency remeasurement related to 2020 S wiss tax reform; and the gain on the remeasurement of an equity\ninvestment, in each case net of the tax effect calculated using the applicable effective tax rate for those items.  In addition, the\nper share impact of certain discrete tax expense primarily attributable to foreign valuation adjustment allowance, and the per\nshare impact of certain expenses related to 2020 S wiss tax reform are also excluded from adjusted diluted earnings per share.\n Management believes that this non-GAAP financial measure is useful to investors because it eliminates the per share impact\nof the items that are outside the control of the Company or that we consider to not be indicative of our ongoing operating\nperformance due to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  For the fiscal year ended September 30, 2023, adjusted free cash flow of $3,130.5 million consisted of net cash\nprovided by operating activities of $3,911.3 million, minus capital expenditures of $458.4 million, the gains from antitrust\nlitigation settlements of $239.1 million, and the receipt of $83.4 million from the H.D.  Smith opioid indemnity escrow. ", "original_text": "Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures. ", "page_label": "29", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b6ce48e9-6291-4029-92f1-4d8ffacab73d", "node_type": "4", "metadata": {"page_label": "29", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c3435c2989c759c74fca82f28d28ffa7f7247066e82f0d6e1b0f1d9cc6e6c3be", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e6340bbc-27ab-4211-8bd2-6a7145d5af99", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company's performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense (credit); acquisition-\nrelated intangibles amortization; litigation and opioid expenses (credit); acquisition-related deal and integration expenses;\nrestructuring and other expenses; impairment of assets, including goodwill; the gain on the sale of non-core businesses; the\ngain (loss) on the currency remeasurement related to 2020 S wiss tax reform; and the gain on the remeasurement of an equity\ninvestment, in each case net of the tax effect calculated using the applicable effective tax rate for those items.  In addition, the\nper share impact of certain discrete tax expense primarily attributable to foreign valuation adjustment allowance, and the per\nshare impact of certain expenses related to 2020 S wiss tax reform are also excluded from adjusted diluted earnings per share.\n Management believes that this non-GAAP financial measure is useful to investors because it eliminates the per share impact\nof the items that are outside the control of the Company or that we consider to not be indicative of our ongoing operating\nperformance due to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  For the fiscal year ended September 30, 2023, adjusted free cash flow of $3,130.5 million consisted of net cash\nprovided by operating activities of $3,911.3 million, minus capital expenditures of $458.4 million, the gains from antitrust\nlitigation settlements of $239.1 million, and the receipt of $83.4 million from the H.D. ", "original_text": "Management believes that this non-GAAP financial measure is useful to investors because it eliminates the per share impact\nof the items that are outside the control of the Company or that we consider to not be indicative of our ongoing operating\nperformance due to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n", "page_label": "29", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "71686f3b489bbc2b639e87f5b95735c496d0c92fc9f0d92652f68c014490c55d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e14f3436-eb07-4f72-8feb-7aafb66fdb04", "node_type": "1", "metadata": {"window": "In addition, the\nper share impact of certain discrete tax expense primarily attributable to foreign valuation adjustment allowance, and the per\nshare impact of certain expenses related to 2020 S wiss tax reform are also excluded from adjusted diluted earnings per share.\n Management believes that this non-GAAP financial measure is useful to investors because it eliminates the per share impact\nof the items that are outside the control of the Company or that we consider to not be indicative of our ongoing operating\nperformance due to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  For the fiscal year ended September 30, 2023, adjusted free cash flow of $3,130.5 million consisted of net cash\nprovided by operating activities of $3,911.3 million, minus capital expenditures of $458.4 million, the gains from antitrust\nlitigation settlements of $239.1 million, and the receipt of $83.4 million from the H.D.  Smith opioid indemnity escrow.  The\nCompany does not provide forward looking guidance on a GAAP basis for free cash flow because the timing and amount of\nfavorable and unfavorable settlements excluded from this metric, the probable significance of which cannot be determined,\nare unavailable and cannot be reasonably estimated.\n", "original_text": "Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows. "}, "hash": "438456efd019671abb621e77617a3f2accaf887ff613788e7a815f273a951be8", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures. ", "start_char_idx": 4088, "end_char_idx": 4361, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e14f3436-eb07-4f72-8feb-7aafb66fdb04": {"__data__": {"id_": "e14f3436-eb07-4f72-8feb-7aafb66fdb04", "embedding": null, "metadata": {"window": "In addition, the\nper share impact of certain discrete tax expense primarily attributable to foreign valuation adjustment allowance, and the per\nshare impact of certain expenses related to 2020 S wiss tax reform are also excluded from adjusted diluted earnings per share.\n Management believes that this non-GAAP financial measure is useful to investors because it eliminates the per share impact\nof the items that are outside the control of the Company or that we consider to not be indicative of our ongoing operating\nperformance due to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  For the fiscal year ended September 30, 2023, adjusted free cash flow of $3,130.5 million consisted of net cash\nprovided by operating activities of $3,911.3 million, minus capital expenditures of $458.4 million, the gains from antitrust\nlitigation settlements of $239.1 million, and the receipt of $83.4 million from the H.D.  Smith opioid indemnity escrow.  The\nCompany does not provide forward looking guidance on a GAAP basis for free cash flow because the timing and amount of\nfavorable and unfavorable settlements excluded from this metric, the probable significance of which cannot be determined,\nare unavailable and cannot be reasonably estimated.\n", "original_text": "Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows. ", "page_label": "29", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b6ce48e9-6291-4029-92f1-4d8ffacab73d", "node_type": "4", "metadata": {"page_label": "29", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c3435c2989c759c74fca82f28d28ffa7f7247066e82f0d6e1b0f1d9cc6e6c3be", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "504caf1e-ffe7-468c-aa7f-9ddb1d4af397", "node_type": "1", "metadata": {"window": "Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense (credit); acquisition-\nrelated intangibles amortization; litigation and opioid expenses (credit); acquisition-related deal and integration expenses;\nrestructuring and other expenses; impairment of assets, including goodwill; the gain on the sale of non-core businesses; the\ngain (loss) on the currency remeasurement related to 2020 S wiss tax reform; and the gain on the remeasurement of an equity\ninvestment, in each case net of the tax effect calculated using the applicable effective tax rate for those items.  In addition, the\nper share impact of certain discrete tax expense primarily attributable to foreign valuation adjustment allowance, and the per\nshare impact of certain expenses related to 2020 S wiss tax reform are also excluded from adjusted diluted earnings per share.\n Management believes that this non-GAAP financial measure is useful to investors because it eliminates the per share impact\nof the items that are outside the control of the Company or that we consider to not be indicative of our ongoing operating\nperformance due to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  For the fiscal year ended September 30, 2023, adjusted free cash flow of $3,130.5 million consisted of net cash\nprovided by operating activities of $3,911.3 million, minus capital expenditures of $458.4 million, the gains from antitrust\nlitigation settlements of $239.1 million, and the receipt of $83.4 million from the H.D.  Smith opioid indemnity escrow. ", "original_text": "Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures. ", "page_label": "29", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1ffcceb86a3e5d93b9bf12af40ec5510e95223ce14a15da142e9567333dd15ab", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d77f5401-00df-4ca7-87c4-7e44404488b6", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP financial measure is useful to investors because it eliminates the per share impact\nof the items that are outside the control of the Company or that we consider to not be indicative of our ongoing operating\nperformance due to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  For the fiscal year ended September 30, 2023, adjusted free cash flow of $3,130.5 million consisted of net cash\nprovided by operating activities of $3,911.3 million, minus capital expenditures of $458.4 million, the gains from antitrust\nlitigation settlements of $239.1 million, and the receipt of $83.4 million from the H.D.  Smith opioid indemnity escrow.  The\nCompany does not provide forward looking guidance on a GAAP basis for free cash flow because the timing and amount of\nfavorable and unfavorable settlements excluded from this metric, the probable significance of which cannot be determined,\nare unavailable and cannot be reasonably estimated.\n The Company also presents revenue and operating income on a \u201cconstant currency\u201d basis, which are non-GAAP financial measures.\n", "original_text": "For the fiscal year ended September 30, 2023, adjusted free cash flow of $3,130.5 million consisted of net cash\nprovided by operating activities of $3,911.3 million, minus capital expenditures of $458.4 million, the gains from antitrust\nlitigation settlements of $239.1 million, and the receipt of $83.4 million from the H.D. "}, "hash": "344798d723ea85e2843ce71bb0fbfa5fddffb2ca58e410490acd0f2491a39783", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows. ", "start_char_idx": 4361, "end_char_idx": 4599, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d77f5401-00df-4ca7-87c4-7e44404488b6": {"__data__": {"id_": "d77f5401-00df-4ca7-87c4-7e44404488b6", "embedding": null, "metadata": {"window": "Management believes that this non-GAAP financial measure is useful to investors because it eliminates the per share impact\nof the items that are outside the control of the Company or that we consider to not be indicative of our ongoing operating\nperformance due to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  For the fiscal year ended September 30, 2023, adjusted free cash flow of $3,130.5 million consisted of net cash\nprovided by operating activities of $3,911.3 million, minus capital expenditures of $458.4 million, the gains from antitrust\nlitigation settlements of $239.1 million, and the receipt of $83.4 million from the H.D.  Smith opioid indemnity escrow.  The\nCompany does not provide forward looking guidance on a GAAP basis for free cash flow because the timing and amount of\nfavorable and unfavorable settlements excluded from this metric, the probable significance of which cannot be determined,\nare unavailable and cannot be reasonably estimated.\n The Company also presents revenue and operating income on a \u201cconstant currency\u201d basis, which are non-GAAP financial measures.\n", "original_text": "For the fiscal year ended September 30, 2023, adjusted free cash flow of $3,130.5 million consisted of net cash\nprovided by operating activities of $3,911.3 million, minus capital expenditures of $458.4 million, the gains from antitrust\nlitigation settlements of $239.1 million, and the receipt of $83.4 million from the H.D. ", "page_label": "29", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b6ce48e9-6291-4029-92f1-4d8ffacab73d", "node_type": "4", "metadata": {"page_label": "29", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c3435c2989c759c74fca82f28d28ffa7f7247066e82f0d6e1b0f1d9cc6e6c3be", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e14f3436-eb07-4f72-8feb-7aafb66fdb04", "node_type": "1", "metadata": {"window": "In addition, the\nper share impact of certain discrete tax expense primarily attributable to foreign valuation adjustment allowance, and the per\nshare impact of certain expenses related to 2020 S wiss tax reform are also excluded from adjusted diluted earnings per share.\n Management believes that this non-GAAP financial measure is useful to investors because it eliminates the per share impact\nof the items that are outside the control of the Company or that we consider to not be indicative of our ongoing operating\nperformance due to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  For the fiscal year ended September 30, 2023, adjusted free cash flow of $3,130.5 million consisted of net cash\nprovided by operating activities of $3,911.3 million, minus capital expenditures of $458.4 million, the gains from antitrust\nlitigation settlements of $239.1 million, and the receipt of $83.4 million from the H.D.  Smith opioid indemnity escrow.  The\nCompany does not provide forward looking guidance on a GAAP basis for free cash flow because the timing and amount of\nfavorable and unfavorable settlements excluded from this metric, the probable significance of which cannot be determined,\nare unavailable and cannot be reasonably estimated.\n", "original_text": "Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows. ", "page_label": "29", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "18852fc289e2a541e1d806e12e81d8e2b2bb5b40acdb40b9a48bb6b4078af1c4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f02c7f7b-37f8-460c-bcc5-84ce8c81f486", "node_type": "1", "metadata": {"window": "Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  For the fiscal year ended September 30, 2023, adjusted free cash flow of $3,130.5 million consisted of net cash\nprovided by operating activities of $3,911.3 million, minus capital expenditures of $458.4 million, the gains from antitrust\nlitigation settlements of $239.1 million, and the receipt of $83.4 million from the H.D.  Smith opioid indemnity escrow.  The\nCompany does not provide forward looking guidance on a GAAP basis for free cash flow because the timing and amount of\nfavorable and unfavorable settlements excluded from this metric, the probable significance of which cannot be determined,\nare unavailable and cannot be reasonably estimated.\n The Company also presents revenue and operating income on a \u201cconstant currency\u201d basis, which are non-GAAP financial measures.\n These amounts are calculated by translating current period GAAP results at the foreign currency exchange rates used in the\ncomparable period in the prior year. ", "original_text": "Smith opioid indemnity escrow. "}, "hash": "a15f3e137dd4467e545093761b72324480a7ad274144e4c676c13b43273d0776", "class_name": "RelatedNodeInfo"}}, "text": "For the fiscal year ended September 30, 2023, adjusted free cash flow of $3,130.5 million consisted of net cash\nprovided by operating activities of $3,911.3 million, minus capital expenditures of $458.4 million, the gains from antitrust\nlitigation settlements of $239.1 million, and the receipt of $83.4 million from the H.D. ", "start_char_idx": 4599, "end_char_idx": 4925, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f02c7f7b-37f8-460c-bcc5-84ce8c81f486": {"__data__": {"id_": "f02c7f7b-37f8-460c-bcc5-84ce8c81f486", "embedding": null, "metadata": {"window": "Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  For the fiscal year ended September 30, 2023, adjusted free cash flow of $3,130.5 million consisted of net cash\nprovided by operating activities of $3,911.3 million, minus capital expenditures of $458.4 million, the gains from antitrust\nlitigation settlements of $239.1 million, and the receipt of $83.4 million from the H.D.  Smith opioid indemnity escrow.  The\nCompany does not provide forward looking guidance on a GAAP basis for free cash flow because the timing and amount of\nfavorable and unfavorable settlements excluded from this metric, the probable significance of which cannot be determined,\nare unavailable and cannot be reasonably estimated.\n The Company also presents revenue and operating income on a \u201cconstant currency\u201d basis, which are non-GAAP financial measures.\n These amounts are calculated by translating current period GAAP results at the foreign currency exchange rates used in the\ncomparable period in the prior year. ", "original_text": "Smith opioid indemnity escrow. ", "page_label": "29", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b6ce48e9-6291-4029-92f1-4d8ffacab73d", "node_type": "4", "metadata": {"page_label": "29", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c3435c2989c759c74fca82f28d28ffa7f7247066e82f0d6e1b0f1d9cc6e6c3be", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d77f5401-00df-4ca7-87c4-7e44404488b6", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP financial measure is useful to investors because it eliminates the per share impact\nof the items that are outside the control of the Company or that we consider to not be indicative of our ongoing operating\nperformance due to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  For the fiscal year ended September 30, 2023, adjusted free cash flow of $3,130.5 million consisted of net cash\nprovided by operating activities of $3,911.3 million, minus capital expenditures of $458.4 million, the gains from antitrust\nlitigation settlements of $239.1 million, and the receipt of $83.4 million from the H.D.  Smith opioid indemnity escrow.  The\nCompany does not provide forward looking guidance on a GAAP basis for free cash flow because the timing and amount of\nfavorable and unfavorable settlements excluded from this metric, the probable significance of which cannot be determined,\nare unavailable and cannot be reasonably estimated.\n The Company also presents revenue and operating income on a \u201cconstant currency\u201d basis, which are non-GAAP financial measures.\n", "original_text": "For the fiscal year ended September 30, 2023, adjusted free cash flow of $3,130.5 million consisted of net cash\nprovided by operating activities of $3,911.3 million, minus capital expenditures of $458.4 million, the gains from antitrust\nlitigation settlements of $239.1 million, and the receipt of $83.4 million from the H.D. ", "page_label": "29", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "33f59a9e43e6fad1082b2602e9e8a1d0d34c205a9171781d240ca327c2801eb2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aa602770-38b0-494d-969f-dbd7312a2671", "node_type": "1", "metadata": {"window": "Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  For the fiscal year ended September 30, 2023, adjusted free cash flow of $3,130.5 million consisted of net cash\nprovided by operating activities of $3,911.3 million, minus capital expenditures of $458.4 million, the gains from antitrust\nlitigation settlements of $239.1 million, and the receipt of $83.4 million from the H.D.  Smith opioid indemnity escrow.  The\nCompany does not provide forward looking guidance on a GAAP basis for free cash flow because the timing and amount of\nfavorable and unfavorable settlements excluded from this metric, the probable significance of which cannot be determined,\nare unavailable and cannot be reasonably estimated.\n The Company also presents revenue and operating income on a \u201cconstant currency\u201d basis, which are non-GAAP financial measures.\n These amounts are calculated by translating current period GAAP results at the foreign currency exchange rates used in the\ncomparable period in the prior year.  The Company presents such constant currency financial information because it has significant\n29", "original_text": "The\nCompany does not provide forward looking guidance on a GAAP basis for free cash flow because the timing and amount of\nfavorable and unfavorable settlements excluded from this metric, the probable significance of which cannot be determined,\nare unavailable and cannot be reasonably estimated.\n"}, "hash": "3a2fac1b8ad10314ef32cdae08e638d4b8dcbd28952b5ed82449894eab04daef", "class_name": "RelatedNodeInfo"}}, "text": "Smith opioid indemnity escrow. ", "start_char_idx": 4925, "end_char_idx": 4956, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aa602770-38b0-494d-969f-dbd7312a2671": {"__data__": {"id_": "aa602770-38b0-494d-969f-dbd7312a2671", "embedding": null, "metadata": {"window": "Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  For the fiscal year ended September 30, 2023, adjusted free cash flow of $3,130.5 million consisted of net cash\nprovided by operating activities of $3,911.3 million, minus capital expenditures of $458.4 million, the gains from antitrust\nlitigation settlements of $239.1 million, and the receipt of $83.4 million from the H.D.  Smith opioid indemnity escrow.  The\nCompany does not provide forward looking guidance on a GAAP basis for free cash flow because the timing and amount of\nfavorable and unfavorable settlements excluded from this metric, the probable significance of which cannot be determined,\nare unavailable and cannot be reasonably estimated.\n The Company also presents revenue and operating income on a \u201cconstant currency\u201d basis, which are non-GAAP financial measures.\n These amounts are calculated by translating current period GAAP results at the foreign currency exchange rates used in the\ncomparable period in the prior year.  The Company presents such constant currency financial information because it has significant\n29", "original_text": "The\nCompany does not provide forward looking guidance on a GAAP basis for free cash flow because the timing and amount of\nfavorable and unfavorable settlements excluded from this metric, the probable significance of which cannot be determined,\nare unavailable and cannot be reasonably estimated.\n", "page_label": "29", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b6ce48e9-6291-4029-92f1-4d8ffacab73d", "node_type": "4", "metadata": {"page_label": "29", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c3435c2989c759c74fca82f28d28ffa7f7247066e82f0d6e1b0f1d9cc6e6c3be", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f02c7f7b-37f8-460c-bcc5-84ce8c81f486", "node_type": "1", "metadata": {"window": "Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  For the fiscal year ended September 30, 2023, adjusted free cash flow of $3,130.5 million consisted of net cash\nprovided by operating activities of $3,911.3 million, minus capital expenditures of $458.4 million, the gains from antitrust\nlitigation settlements of $239.1 million, and the receipt of $83.4 million from the H.D.  Smith opioid indemnity escrow.  The\nCompany does not provide forward looking guidance on a GAAP basis for free cash flow because the timing and amount of\nfavorable and unfavorable settlements excluded from this metric, the probable significance of which cannot be determined,\nare unavailable and cannot be reasonably estimated.\n The Company also presents revenue and operating income on a \u201cconstant currency\u201d basis, which are non-GAAP financial measures.\n These amounts are calculated by translating current period GAAP results at the foreign currency exchange rates used in the\ncomparable period in the prior year. ", "original_text": "Smith opioid indemnity escrow. ", "page_label": "29", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d9af68360ef1f6f7340f7440f17a105ba99f7696a94f719aeb7f27e598c467a6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ec136266-5f1f-4dbe-a156-39b40eb370f7", "node_type": "1", "metadata": {"window": "For the fiscal year ended September 30, 2023, adjusted free cash flow of $3,130.5 million consisted of net cash\nprovided by operating activities of $3,911.3 million, minus capital expenditures of $458.4 million, the gains from antitrust\nlitigation settlements of $239.1 million, and the receipt of $83.4 million from the H.D.  Smith opioid indemnity escrow.  The\nCompany does not provide forward looking guidance on a GAAP basis for free cash flow because the timing and amount of\nfavorable and unfavorable settlements excluded from this metric, the probable significance of which cannot be determined,\nare unavailable and cannot be reasonably estimated.\n The Company also presents revenue and operating income on a \u201cconstant currency\u201d basis, which are non-GAAP financial measures.\n These amounts are calculated by translating current period GAAP results at the foreign currency exchange rates used in the\ncomparable period in the prior year.  The Company presents such constant currency financial information because it has significant\n29", "original_text": "The Company also presents revenue and operating income on a \u201cconstant currency\u201d basis, which are non-GAAP financial measures.\n"}, "hash": "b83d4f243bfbfc4204cc59c0422c305a1531e11d50687ae2b5b21fe3d3ccdcb0", "class_name": "RelatedNodeInfo"}}, "text": "The\nCompany does not provide forward looking guidance on a GAAP basis for free cash flow because the timing and amount of\nfavorable and unfavorable settlements excluded from this metric, the probable significance of which cannot be determined,\nare unavailable and cannot be reasonably estimated.\n", "start_char_idx": 4956, "end_char_idx": 5252, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ec136266-5f1f-4dbe-a156-39b40eb370f7": {"__data__": {"id_": "ec136266-5f1f-4dbe-a156-39b40eb370f7", "embedding": null, "metadata": {"window": "For the fiscal year ended September 30, 2023, adjusted free cash flow of $3,130.5 million consisted of net cash\nprovided by operating activities of $3,911.3 million, minus capital expenditures of $458.4 million, the gains from antitrust\nlitigation settlements of $239.1 million, and the receipt of $83.4 million from the H.D.  Smith opioid indemnity escrow.  The\nCompany does not provide forward looking guidance on a GAAP basis for free cash flow because the timing and amount of\nfavorable and unfavorable settlements excluded from this metric, the probable significance of which cannot be determined,\nare unavailable and cannot be reasonably estimated.\n The Company also presents revenue and operating income on a \u201cconstant currency\u201d basis, which are non-GAAP financial measures.\n These amounts are calculated by translating current period GAAP results at the foreign currency exchange rates used in the\ncomparable period in the prior year.  The Company presents such constant currency financial information because it has significant\n29", "original_text": "The Company also presents revenue and operating income on a \u201cconstant currency\u201d basis, which are non-GAAP financial measures.\n", "page_label": "29", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b6ce48e9-6291-4029-92f1-4d8ffacab73d", "node_type": "4", "metadata": {"page_label": "29", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c3435c2989c759c74fca82f28d28ffa7f7247066e82f0d6e1b0f1d9cc6e6c3be", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aa602770-38b0-494d-969f-dbd7312a2671", "node_type": "1", "metadata": {"window": "Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  For the fiscal year ended September 30, 2023, adjusted free cash flow of $3,130.5 million consisted of net cash\nprovided by operating activities of $3,911.3 million, minus capital expenditures of $458.4 million, the gains from antitrust\nlitigation settlements of $239.1 million, and the receipt of $83.4 million from the H.D.  Smith opioid indemnity escrow.  The\nCompany does not provide forward looking guidance on a GAAP basis for free cash flow because the timing and amount of\nfavorable and unfavorable settlements excluded from this metric, the probable significance of which cannot be determined,\nare unavailable and cannot be reasonably estimated.\n The Company also presents revenue and operating income on a \u201cconstant currency\u201d basis, which are non-GAAP financial measures.\n These amounts are calculated by translating current period GAAP results at the foreign currency exchange rates used in the\ncomparable period in the prior year.  The Company presents such constant currency financial information because it has significant\n29", "original_text": "The\nCompany does not provide forward looking guidance on a GAAP basis for free cash flow because the timing and amount of\nfavorable and unfavorable settlements excluded from this metric, the probable significance of which cannot be determined,\nare unavailable and cannot be reasonably estimated.\n", "page_label": "29", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c7af4a74009127141160d3a31987cf41a4d119c4b95b21f00e1a16205b65a285", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "897d7bdd-d77d-4611-8467-c8639437d5dc", "node_type": "1", "metadata": {"window": "Smith opioid indemnity escrow.  The\nCompany does not provide forward looking guidance on a GAAP basis for free cash flow because the timing and amount of\nfavorable and unfavorable settlements excluded from this metric, the probable significance of which cannot be determined,\nare unavailable and cannot be reasonably estimated.\n The Company also presents revenue and operating income on a \u201cconstant currency\u201d basis, which are non-GAAP financial measures.\n These amounts are calculated by translating current period GAAP results at the foreign currency exchange rates used in the\ncomparable period in the prior year.  The Company presents such constant currency financial information because it has significant\n29", "original_text": "These amounts are calculated by translating current period GAAP results at the foreign currency exchange rates used in the\ncomparable period in the prior year. "}, "hash": "6dcd96bda10c2087d18a31073b277f4be72733631a16afe7435b002dafa07ff1", "class_name": "RelatedNodeInfo"}}, "text": "The Company also presents revenue and operating income on a \u201cconstant currency\u201d basis, which are non-GAAP financial measures.\n", "start_char_idx": 5252, "end_char_idx": 5378, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "897d7bdd-d77d-4611-8467-c8639437d5dc": {"__data__": {"id_": "897d7bdd-d77d-4611-8467-c8639437d5dc", "embedding": null, "metadata": {"window": "Smith opioid indemnity escrow.  The\nCompany does not provide forward looking guidance on a GAAP basis for free cash flow because the timing and amount of\nfavorable and unfavorable settlements excluded from this metric, the probable significance of which cannot be determined,\nare unavailable and cannot be reasonably estimated.\n The Company also presents revenue and operating income on a \u201cconstant currency\u201d basis, which are non-GAAP financial measures.\n These amounts are calculated by translating current period GAAP results at the foreign currency exchange rates used in the\ncomparable period in the prior year.  The Company presents such constant currency financial information because it has significant\n29", "original_text": "These amounts are calculated by translating current period GAAP results at the foreign currency exchange rates used in the\ncomparable period in the prior year. ", "page_label": "29", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b6ce48e9-6291-4029-92f1-4d8ffacab73d", "node_type": "4", "metadata": {"page_label": "29", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c3435c2989c759c74fca82f28d28ffa7f7247066e82f0d6e1b0f1d9cc6e6c3be", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ec136266-5f1f-4dbe-a156-39b40eb370f7", "node_type": "1", "metadata": {"window": "For the fiscal year ended September 30, 2023, adjusted free cash flow of $3,130.5 million consisted of net cash\nprovided by operating activities of $3,911.3 million, minus capital expenditures of $458.4 million, the gains from antitrust\nlitigation settlements of $239.1 million, and the receipt of $83.4 million from the H.D.  Smith opioid indemnity escrow.  The\nCompany does not provide forward looking guidance on a GAAP basis for free cash flow because the timing and amount of\nfavorable and unfavorable settlements excluded from this metric, the probable significance of which cannot be determined,\nare unavailable and cannot be reasonably estimated.\n The Company also presents revenue and operating income on a \u201cconstant currency\u201d basis, which are non-GAAP financial measures.\n These amounts are calculated by translating current period GAAP results at the foreign currency exchange rates used in the\ncomparable period in the prior year.  The Company presents such constant currency financial information because it has significant\n29", "original_text": "The Company also presents revenue and operating income on a \u201cconstant currency\u201d basis, which are non-GAAP financial measures.\n", "page_label": "29", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aec163d72282ffb5a7375b663e6486cea09508e680b7d051e2818033e4349768", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "94330c16-fdcb-48b6-aa28-c46b9cdd2e5c", "node_type": "1", "metadata": {"window": "The\nCompany does not provide forward looking guidance on a GAAP basis for free cash flow because the timing and amount of\nfavorable and unfavorable settlements excluded from this metric, the probable significance of which cannot be determined,\nare unavailable and cannot be reasonably estimated.\n The Company also presents revenue and operating income on a \u201cconstant currency\u201d basis, which are non-GAAP financial measures.\n These amounts are calculated by translating current period GAAP results at the foreign currency exchange rates used in the\ncomparable period in the prior year.  The Company presents such constant currency financial information because it has significant\n29", "original_text": "The Company presents such constant currency financial information because it has significant\n29"}, "hash": "d3523440f9a58093542a70c8f2005aae5567a474c659c5d89cd3d0d3563b5c86", "class_name": "RelatedNodeInfo"}}, "text": "These amounts are calculated by translating current period GAAP results at the foreign currency exchange rates used in the\ncomparable period in the prior year. ", "start_char_idx": 5378, "end_char_idx": 5538, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "94330c16-fdcb-48b6-aa28-c46b9cdd2e5c": {"__data__": {"id_": "94330c16-fdcb-48b6-aa28-c46b9cdd2e5c", "embedding": null, "metadata": {"window": "The\nCompany does not provide forward looking guidance on a GAAP basis for free cash flow because the timing and amount of\nfavorable and unfavorable settlements excluded from this metric, the probable significance of which cannot be determined,\nare unavailable and cannot be reasonably estimated.\n The Company also presents revenue and operating income on a \u201cconstant currency\u201d basis, which are non-GAAP financial measures.\n These amounts are calculated by translating current period GAAP results at the foreign currency exchange rates used in the\ncomparable period in the prior year.  The Company presents such constant currency financial information because it has significant\n29", "original_text": "The Company presents such constant currency financial information because it has significant\n29", "page_label": "29", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b6ce48e9-6291-4029-92f1-4d8ffacab73d", "node_type": "4", "metadata": {"page_label": "29", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c3435c2989c759c74fca82f28d28ffa7f7247066e82f0d6e1b0f1d9cc6e6c3be", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "897d7bdd-d77d-4611-8467-c8639437d5dc", "node_type": "1", "metadata": {"window": "Smith opioid indemnity escrow.  The\nCompany does not provide forward looking guidance on a GAAP basis for free cash flow because the timing and amount of\nfavorable and unfavorable settlements excluded from this metric, the probable significance of which cannot be determined,\nare unavailable and cannot be reasonably estimated.\n The Company also presents revenue and operating income on a \u201cconstant currency\u201d basis, which are non-GAAP financial measures.\n These amounts are calculated by translating current period GAAP results at the foreign currency exchange rates used in the\ncomparable period in the prior year.  The Company presents such constant currency financial information because it has significant\n29", "original_text": "These amounts are calculated by translating current period GAAP results at the foreign currency exchange rates used in the\ncomparable period in the prior year. ", "page_label": "29", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "59e6ad9e68201b8781310368b989a1a3f19777f29d81fa593e93d069767e5eee", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "08e62781-d6e8-45fa-a58d-c8dfa11f81f8", "node_type": "1", "metadata": {"window": "operations outside of the United S tates reporting in currencies other than the U.S.  dollar and management believes that this\npresentation provides a framework to assess how its business performed excluding the impact of foreign currency exchange rate\nfluctuations.  For the fourth quarter of fiscal 2023, (i) revenue of $68.9 billion was negatively impacted by foreign currency translation\nof $37.6 million, resulting in revenue on a constant currency basis of $69.0 billion, and (ii) operating income of $801.0 million was\nnegatively impacted by foreign currency translation of $1.5 million, resulting in operating income on a constant currency basis of\n$802.5 million.  For the fourth quarter of fiscal 2023 in the International Healthcare Solutions segment, (i) revenue of $6,994.7 million\nwas negatively impacted by foreign currency translation of $37.6 million, resulting in revenue on a constant currency basis of\n$7,032.3 million, and (ii) operating income of $168.2 million was negatively impacted by foreign currency translation of $1.5 million,\nresulting in operating income on a constant currency basis of $169.6 million. ", "original_text": "operations outside of the United S tates reporting in currencies other than the U.S. "}, "hash": "4fba9d0aa3777ea2147f591c825fa4df174b8aa504ae7af12e2452a703a1212b", "class_name": "RelatedNodeInfo"}}, "text": "The Company presents such constant currency financial information because it has significant\n29", "start_char_idx": 5538, "end_char_idx": 5633, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "08e62781-d6e8-45fa-a58d-c8dfa11f81f8": {"__data__": {"id_": "08e62781-d6e8-45fa-a58d-c8dfa11f81f8", "embedding": null, "metadata": {"window": "operations outside of the United S tates reporting in currencies other than the U.S.  dollar and management believes that this\npresentation provides a framework to assess how its business performed excluding the impact of foreign currency exchange rate\nfluctuations.  For the fourth quarter of fiscal 2023, (i) revenue of $68.9 billion was negatively impacted by foreign currency translation\nof $37.6 million, resulting in revenue on a constant currency basis of $69.0 billion, and (ii) operating income of $801.0 million was\nnegatively impacted by foreign currency translation of $1.5 million, resulting in operating income on a constant currency basis of\n$802.5 million.  For the fourth quarter of fiscal 2023 in the International Healthcare Solutions segment, (i) revenue of $6,994.7 million\nwas negatively impacted by foreign currency translation of $37.6 million, resulting in revenue on a constant currency basis of\n$7,032.3 million, and (ii) operating income of $168.2 million was negatively impacted by foreign currency translation of $1.5 million,\nresulting in operating income on a constant currency basis of $169.6 million. ", "original_text": "operations outside of the United S tates reporting in currencies other than the U.S. ", "page_label": "30", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c37dba28-e111-4586-9210-488c4a7cda52", "node_type": "4", "metadata": {"page_label": "30", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6390196a97d263de8522d5032a6a1904df19ed34645d7c126d9f1697237179d4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "94330c16-fdcb-48b6-aa28-c46b9cdd2e5c", "node_type": "1", "metadata": {"window": "The\nCompany does not provide forward looking guidance on a GAAP basis for free cash flow because the timing and amount of\nfavorable and unfavorable settlements excluded from this metric, the probable significance of which cannot be determined,\nare unavailable and cannot be reasonably estimated.\n The Company also presents revenue and operating income on a \u201cconstant currency\u201d basis, which are non-GAAP financial measures.\n These amounts are calculated by translating current period GAAP results at the foreign currency exchange rates used in the\ncomparable period in the prior year.  The Company presents such constant currency financial information because it has significant\n29", "original_text": "The Company presents such constant currency financial information because it has significant\n29", "page_label": "29", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f31449ad92eddb03032c1f262ef7d4226f1168e9422b61885e9af11ff783a4d0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eb6b779e-96d3-41dc-85fa-0ba472d42497", "node_type": "1", "metadata": {"window": "operations outside of the United S tates reporting in currencies other than the U.S.  dollar and management believes that this\npresentation provides a framework to assess how its business performed excluding the impact of foreign currency exchange rate\nfluctuations.  For the fourth quarter of fiscal 2023, (i) revenue of $68.9 billion was negatively impacted by foreign currency translation\nof $37.6 million, resulting in revenue on a constant currency basis of $69.0 billion, and (ii) operating income of $801.0 million was\nnegatively impacted by foreign currency translation of $1.5 million, resulting in operating income on a constant currency basis of\n$802.5 million.  For the fourth quarter of fiscal 2023 in the International Healthcare Solutions segment, (i) revenue of $6,994.7 million\nwas negatively impacted by foreign currency translation of $37.6 million, resulting in revenue on a constant currency basis of\n$7,032.3 million, and (ii) operating income of $168.2 million was negatively impacted by foreign currency translation of $1.5 million,\nresulting in operating income on a constant currency basis of $169.6 million.  For fiscal 2023, (i) revenue of $262.2 billion was\nnegatively impacted by foreign currency translation of $2.4 billion, resulting in revenue on a constant currency basis of $264.5\nbillion, and (ii) operating income of $3,289.1 million was negatively impacted by foreign currency translation of $63.0 million,\nresulting in operating income on a constant currency basis of $3,352.1 million. ", "original_text": "dollar and management believes that this\npresentation provides a framework to assess how its business performed excluding the impact of foreign currency exchange rate\nfluctuations. "}, "hash": "a1c5153b462cacc7ecdab98b9af4d77cf556222b421265663389f2c866790c91", "class_name": "RelatedNodeInfo"}}, "text": "operations outside of the United S tates reporting in currencies other than the U.S. ", "start_char_idx": 0, "end_char_idx": 85, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eb6b779e-96d3-41dc-85fa-0ba472d42497": {"__data__": {"id_": "eb6b779e-96d3-41dc-85fa-0ba472d42497", "embedding": null, "metadata": {"window": "operations outside of the United S tates reporting in currencies other than the U.S.  dollar and management believes that this\npresentation provides a framework to assess how its business performed excluding the impact of foreign currency exchange rate\nfluctuations.  For the fourth quarter of fiscal 2023, (i) revenue of $68.9 billion was negatively impacted by foreign currency translation\nof $37.6 million, resulting in revenue on a constant currency basis of $69.0 billion, and (ii) operating income of $801.0 million was\nnegatively impacted by foreign currency translation of $1.5 million, resulting in operating income on a constant currency basis of\n$802.5 million.  For the fourth quarter of fiscal 2023 in the International Healthcare Solutions segment, (i) revenue of $6,994.7 million\nwas negatively impacted by foreign currency translation of $37.6 million, resulting in revenue on a constant currency basis of\n$7,032.3 million, and (ii) operating income of $168.2 million was negatively impacted by foreign currency translation of $1.5 million,\nresulting in operating income on a constant currency basis of $169.6 million.  For fiscal 2023, (i) revenue of $262.2 billion was\nnegatively impacted by foreign currency translation of $2.4 billion, resulting in revenue on a constant currency basis of $264.5\nbillion, and (ii) operating income of $3,289.1 million was negatively impacted by foreign currency translation of $63.0 million,\nresulting in operating income on a constant currency basis of $3,352.1 million. ", "original_text": "dollar and management believes that this\npresentation provides a framework to assess how its business performed excluding the impact of foreign currency exchange rate\nfluctuations. ", "page_label": "30", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c37dba28-e111-4586-9210-488c4a7cda52", "node_type": "4", "metadata": {"page_label": "30", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6390196a97d263de8522d5032a6a1904df19ed34645d7c126d9f1697237179d4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "08e62781-d6e8-45fa-a58d-c8dfa11f81f8", "node_type": "1", "metadata": {"window": "operations outside of the United S tates reporting in currencies other than the U.S.  dollar and management believes that this\npresentation provides a framework to assess how its business performed excluding the impact of foreign currency exchange rate\nfluctuations.  For the fourth quarter of fiscal 2023, (i) revenue of $68.9 billion was negatively impacted by foreign currency translation\nof $37.6 million, resulting in revenue on a constant currency basis of $69.0 billion, and (ii) operating income of $801.0 million was\nnegatively impacted by foreign currency translation of $1.5 million, resulting in operating income on a constant currency basis of\n$802.5 million.  For the fourth quarter of fiscal 2023 in the International Healthcare Solutions segment, (i) revenue of $6,994.7 million\nwas negatively impacted by foreign currency translation of $37.6 million, resulting in revenue on a constant currency basis of\n$7,032.3 million, and (ii) operating income of $168.2 million was negatively impacted by foreign currency translation of $1.5 million,\nresulting in operating income on a constant currency basis of $169.6 million. ", "original_text": "operations outside of the United S tates reporting in currencies other than the U.S. ", "page_label": "30", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5a79ee04b82a61d193d77ab2e93f6927d5e35221f05030353c287652d2e03d7f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f3ded855-013d-49f4-9837-9d213fcb0ea5", "node_type": "1", "metadata": {"window": "operations outside of the United S tates reporting in currencies other than the U.S.  dollar and management believes that this\npresentation provides a framework to assess how its business performed excluding the impact of foreign currency exchange rate\nfluctuations.  For the fourth quarter of fiscal 2023, (i) revenue of $68.9 billion was negatively impacted by foreign currency translation\nof $37.6 million, resulting in revenue on a constant currency basis of $69.0 billion, and (ii) operating income of $801.0 million was\nnegatively impacted by foreign currency translation of $1.5 million, resulting in operating income on a constant currency basis of\n$802.5 million.  For the fourth quarter of fiscal 2023 in the International Healthcare Solutions segment, (i) revenue of $6,994.7 million\nwas negatively impacted by foreign currency translation of $37.6 million, resulting in revenue on a constant currency basis of\n$7,032.3 million, and (ii) operating income of $168.2 million was negatively impacted by foreign currency translation of $1.5 million,\nresulting in operating income on a constant currency basis of $169.6 million.  For fiscal 2023, (i) revenue of $262.2 billion was\nnegatively impacted by foreign currency translation of $2.4 billion, resulting in revenue on a constant currency basis of $264.5\nbillion, and (ii) operating income of $3,289.1 million was negatively impacted by foreign currency translation of $63.0 million,\nresulting in operating income on a constant currency basis of $3,352.1 million.  For fiscal 2023 in the International Healthcare\nSolutions segment, (i) revenue of $27.4 billion was negatively impacted by foreign currency translation of $2.4 billion, resulting in\nrevenue on a constant currency basis of $29.8 billion, and (ii) operating income of $692.6 million was negatively impacted by foreign\ncurrency translation of $63.0 million, resulting in operating income on a constant currency basis of $755.6 million.\n", "original_text": "For the fourth quarter of fiscal 2023, (i) revenue of $68.9 billion was negatively impacted by foreign currency translation\nof $37.6 million, resulting in revenue on a constant currency basis of $69.0 billion, and (ii) operating income of $801.0 million was\nnegatively impacted by foreign currency translation of $1.5 million, resulting in operating income on a constant currency basis of\n$802.5 million. "}, "hash": "cb7815dc532421ff5e76e38b2ccecef8429673ad391137865e3441e111b2d715", "class_name": "RelatedNodeInfo"}}, "text": "dollar and management believes that this\npresentation provides a framework to assess how its business performed excluding the impact of foreign currency exchange rate\nfluctuations. ", "start_char_idx": 85, "end_char_idx": 266, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f3ded855-013d-49f4-9837-9d213fcb0ea5": {"__data__": {"id_": "f3ded855-013d-49f4-9837-9d213fcb0ea5", "embedding": null, "metadata": {"window": "operations outside of the United S tates reporting in currencies other than the U.S.  dollar and management believes that this\npresentation provides a framework to assess how its business performed excluding the impact of foreign currency exchange rate\nfluctuations.  For the fourth quarter of fiscal 2023, (i) revenue of $68.9 billion was negatively impacted by foreign currency translation\nof $37.6 million, resulting in revenue on a constant currency basis of $69.0 billion, and (ii) operating income of $801.0 million was\nnegatively impacted by foreign currency translation of $1.5 million, resulting in operating income on a constant currency basis of\n$802.5 million.  For the fourth quarter of fiscal 2023 in the International Healthcare Solutions segment, (i) revenue of $6,994.7 million\nwas negatively impacted by foreign currency translation of $37.6 million, resulting in revenue on a constant currency basis of\n$7,032.3 million, and (ii) operating income of $168.2 million was negatively impacted by foreign currency translation of $1.5 million,\nresulting in operating income on a constant currency basis of $169.6 million.  For fiscal 2023, (i) revenue of $262.2 billion was\nnegatively impacted by foreign currency translation of $2.4 billion, resulting in revenue on a constant currency basis of $264.5\nbillion, and (ii) operating income of $3,289.1 million was negatively impacted by foreign currency translation of $63.0 million,\nresulting in operating income on a constant currency basis of $3,352.1 million.  For fiscal 2023 in the International Healthcare\nSolutions segment, (i) revenue of $27.4 billion was negatively impacted by foreign currency translation of $2.4 billion, resulting in\nrevenue on a constant currency basis of $29.8 billion, and (ii) operating income of $692.6 million was negatively impacted by foreign\ncurrency translation of $63.0 million, resulting in operating income on a constant currency basis of $755.6 million.\n", "original_text": "For the fourth quarter of fiscal 2023, (i) revenue of $68.9 billion was negatively impacted by foreign currency translation\nof $37.6 million, resulting in revenue on a constant currency basis of $69.0 billion, and (ii) operating income of $801.0 million was\nnegatively impacted by foreign currency translation of $1.5 million, resulting in operating income on a constant currency basis of\n$802.5 million. ", "page_label": "30", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c37dba28-e111-4586-9210-488c4a7cda52", "node_type": "4", "metadata": {"page_label": "30", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6390196a97d263de8522d5032a6a1904df19ed34645d7c126d9f1697237179d4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eb6b779e-96d3-41dc-85fa-0ba472d42497", "node_type": "1", "metadata": {"window": "operations outside of the United S tates reporting in currencies other than the U.S.  dollar and management believes that this\npresentation provides a framework to assess how its business performed excluding the impact of foreign currency exchange rate\nfluctuations.  For the fourth quarter of fiscal 2023, (i) revenue of $68.9 billion was negatively impacted by foreign currency translation\nof $37.6 million, resulting in revenue on a constant currency basis of $69.0 billion, and (ii) operating income of $801.0 million was\nnegatively impacted by foreign currency translation of $1.5 million, resulting in operating income on a constant currency basis of\n$802.5 million.  For the fourth quarter of fiscal 2023 in the International Healthcare Solutions segment, (i) revenue of $6,994.7 million\nwas negatively impacted by foreign currency translation of $37.6 million, resulting in revenue on a constant currency basis of\n$7,032.3 million, and (ii) operating income of $168.2 million was negatively impacted by foreign currency translation of $1.5 million,\nresulting in operating income on a constant currency basis of $169.6 million.  For fiscal 2023, (i) revenue of $262.2 billion was\nnegatively impacted by foreign currency translation of $2.4 billion, resulting in revenue on a constant currency basis of $264.5\nbillion, and (ii) operating income of $3,289.1 million was negatively impacted by foreign currency translation of $63.0 million,\nresulting in operating income on a constant currency basis of $3,352.1 million. ", "original_text": "dollar and management believes that this\npresentation provides a framework to assess how its business performed excluding the impact of foreign currency exchange rate\nfluctuations. ", "page_label": "30", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f6a246246e9d9fc74dc1a59fa5ca6f71e1eb9bdbe09abc7383fbf3bee63bb175", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c8f42f9b-eef8-4258-8725-2d5cd66688b7", "node_type": "1", "metadata": {"window": "operations outside of the United S tates reporting in currencies other than the U.S.  dollar and management believes that this\npresentation provides a framework to assess how its business performed excluding the impact of foreign currency exchange rate\nfluctuations.  For the fourth quarter of fiscal 2023, (i) revenue of $68.9 billion was negatively impacted by foreign currency translation\nof $37.6 million, resulting in revenue on a constant currency basis of $69.0 billion, and (ii) operating income of $801.0 million was\nnegatively impacted by foreign currency translation of $1.5 million, resulting in operating income on a constant currency basis of\n$802.5 million.  For the fourth quarter of fiscal 2023 in the International Healthcare Solutions segment, (i) revenue of $6,994.7 million\nwas negatively impacted by foreign currency translation of $37.6 million, resulting in revenue on a constant currency basis of\n$7,032.3 million, and (ii) operating income of $168.2 million was negatively impacted by foreign currency translation of $1.5 million,\nresulting in operating income on a constant currency basis of $169.6 million.  For fiscal 2023, (i) revenue of $262.2 billion was\nnegatively impacted by foreign currency translation of $2.4 billion, resulting in revenue on a constant currency basis of $264.5\nbillion, and (ii) operating income of $3,289.1 million was negatively impacted by foreign currency translation of $63.0 million,\nresulting in operating income on a constant currency basis of $3,352.1 million.  For fiscal 2023 in the International Healthcare\nSolutions segment, (i) revenue of $27.4 billion was negatively impacted by foreign currency translation of $2.4 billion, resulting in\nrevenue on a constant currency basis of $29.8 billion, and (ii) operating income of $692.6 million was negatively impacted by foreign\ncurrency translation of $63.0 million, resulting in operating income on a constant currency basis of $755.6 million.\n In addition, the Company has provided non-GAAP fiscal year 2024 guidance for diluted earnings per share, operating income,\neffective income tax rate and free cash flow that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature. ", "original_text": "For the fourth quarter of fiscal 2023 in the International Healthcare Solutions segment, (i) revenue of $6,994.7 million\nwas negatively impacted by foreign currency translation of $37.6 million, resulting in revenue on a constant currency basis of\n$7,032.3 million, and (ii) operating income of $168.2 million was negatively impacted by foreign currency translation of $1.5 million,\nresulting in operating income on a constant currency basis of $169.6 million. "}, "hash": "67f4795db17ecc80ac4b7cb7e33a674910fe002d26dba1e0e8bbe31cd6339ed9", "class_name": "RelatedNodeInfo"}}, "text": "For the fourth quarter of fiscal 2023, (i) revenue of $68.9 billion was negatively impacted by foreign currency translation\nof $37.6 million, resulting in revenue on a constant currency basis of $69.0 billion, and (ii) operating income of $801.0 million was\nnegatively impacted by foreign currency translation of $1.5 million, resulting in operating income on a constant currency basis of\n$802.5 million. ", "start_char_idx": 266, "end_char_idx": 671, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c8f42f9b-eef8-4258-8725-2d5cd66688b7": {"__data__": {"id_": "c8f42f9b-eef8-4258-8725-2d5cd66688b7", "embedding": null, "metadata": {"window": "operations outside of the United S tates reporting in currencies other than the U.S.  dollar and management believes that this\npresentation provides a framework to assess how its business performed excluding the impact of foreign currency exchange rate\nfluctuations.  For the fourth quarter of fiscal 2023, (i) revenue of $68.9 billion was negatively impacted by foreign currency translation\nof $37.6 million, resulting in revenue on a constant currency basis of $69.0 billion, and (ii) operating income of $801.0 million was\nnegatively impacted by foreign currency translation of $1.5 million, resulting in operating income on a constant currency basis of\n$802.5 million.  For the fourth quarter of fiscal 2023 in the International Healthcare Solutions segment, (i) revenue of $6,994.7 million\nwas negatively impacted by foreign currency translation of $37.6 million, resulting in revenue on a constant currency basis of\n$7,032.3 million, and (ii) operating income of $168.2 million was negatively impacted by foreign currency translation of $1.5 million,\nresulting in operating income on a constant currency basis of $169.6 million.  For fiscal 2023, (i) revenue of $262.2 billion was\nnegatively impacted by foreign currency translation of $2.4 billion, resulting in revenue on a constant currency basis of $264.5\nbillion, and (ii) operating income of $3,289.1 million was negatively impacted by foreign currency translation of $63.0 million,\nresulting in operating income on a constant currency basis of $3,352.1 million.  For fiscal 2023 in the International Healthcare\nSolutions segment, (i) revenue of $27.4 billion was negatively impacted by foreign currency translation of $2.4 billion, resulting in\nrevenue on a constant currency basis of $29.8 billion, and (ii) operating income of $692.6 million was negatively impacted by foreign\ncurrency translation of $63.0 million, resulting in operating income on a constant currency basis of $755.6 million.\n In addition, the Company has provided non-GAAP fiscal year 2024 guidance for diluted earnings per share, operating income,\neffective income tax rate and free cash flow that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature. ", "original_text": "For the fourth quarter of fiscal 2023 in the International Healthcare Solutions segment, (i) revenue of $6,994.7 million\nwas negatively impacted by foreign currency translation of $37.6 million, resulting in revenue on a constant currency basis of\n$7,032.3 million, and (ii) operating income of $168.2 million was negatively impacted by foreign currency translation of $1.5 million,\nresulting in operating income on a constant currency basis of $169.6 million. ", "page_label": "30", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c37dba28-e111-4586-9210-488c4a7cda52", "node_type": "4", "metadata": {"page_label": "30", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6390196a97d263de8522d5032a6a1904df19ed34645d7c126d9f1697237179d4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f3ded855-013d-49f4-9837-9d213fcb0ea5", "node_type": "1", "metadata": {"window": "operations outside of the United S tates reporting in currencies other than the U.S.  dollar and management believes that this\npresentation provides a framework to assess how its business performed excluding the impact of foreign currency exchange rate\nfluctuations.  For the fourth quarter of fiscal 2023, (i) revenue of $68.9 billion was negatively impacted by foreign currency translation\nof $37.6 million, resulting in revenue on a constant currency basis of $69.0 billion, and (ii) operating income of $801.0 million was\nnegatively impacted by foreign currency translation of $1.5 million, resulting in operating income on a constant currency basis of\n$802.5 million.  For the fourth quarter of fiscal 2023 in the International Healthcare Solutions segment, (i) revenue of $6,994.7 million\nwas negatively impacted by foreign currency translation of $37.6 million, resulting in revenue on a constant currency basis of\n$7,032.3 million, and (ii) operating income of $168.2 million was negatively impacted by foreign currency translation of $1.5 million,\nresulting in operating income on a constant currency basis of $169.6 million.  For fiscal 2023, (i) revenue of $262.2 billion was\nnegatively impacted by foreign currency translation of $2.4 billion, resulting in revenue on a constant currency basis of $264.5\nbillion, and (ii) operating income of $3,289.1 million was negatively impacted by foreign currency translation of $63.0 million,\nresulting in operating income on a constant currency basis of $3,352.1 million.  For fiscal 2023 in the International Healthcare\nSolutions segment, (i) revenue of $27.4 billion was negatively impacted by foreign currency translation of $2.4 billion, resulting in\nrevenue on a constant currency basis of $29.8 billion, and (ii) operating income of $692.6 million was negatively impacted by foreign\ncurrency translation of $63.0 million, resulting in operating income on a constant currency basis of $755.6 million.\n", "original_text": "For the fourth quarter of fiscal 2023, (i) revenue of $68.9 billion was negatively impacted by foreign currency translation\nof $37.6 million, resulting in revenue on a constant currency basis of $69.0 billion, and (ii) operating income of $801.0 million was\nnegatively impacted by foreign currency translation of $1.5 million, resulting in operating income on a constant currency basis of\n$802.5 million. ", "page_label": "30", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4caeedb40a394c62fe64a47e81ea7e8fee43caa1e9eaad67a615ccc2a2219ee7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "922ebad1-3d5a-4dbc-a2b7-46e29aef8de4", "node_type": "1", "metadata": {"window": "dollar and management believes that this\npresentation provides a framework to assess how its business performed excluding the impact of foreign currency exchange rate\nfluctuations.  For the fourth quarter of fiscal 2023, (i) revenue of $68.9 billion was negatively impacted by foreign currency translation\nof $37.6 million, resulting in revenue on a constant currency basis of $69.0 billion, and (ii) operating income of $801.0 million was\nnegatively impacted by foreign currency translation of $1.5 million, resulting in operating income on a constant currency basis of\n$802.5 million.  For the fourth quarter of fiscal 2023 in the International Healthcare Solutions segment, (i) revenue of $6,994.7 million\nwas negatively impacted by foreign currency translation of $37.6 million, resulting in revenue on a constant currency basis of\n$7,032.3 million, and (ii) operating income of $168.2 million was negatively impacted by foreign currency translation of $1.5 million,\nresulting in operating income on a constant currency basis of $169.6 million.  For fiscal 2023, (i) revenue of $262.2 billion was\nnegatively impacted by foreign currency translation of $2.4 billion, resulting in revenue on a constant currency basis of $264.5\nbillion, and (ii) operating income of $3,289.1 million was negatively impacted by foreign currency translation of $63.0 million,\nresulting in operating income on a constant currency basis of $3,352.1 million.  For fiscal 2023 in the International Healthcare\nSolutions segment, (i) revenue of $27.4 billion was negatively impacted by foreign currency translation of $2.4 billion, resulting in\nrevenue on a constant currency basis of $29.8 billion, and (ii) operating income of $692.6 million was negatively impacted by foreign\ncurrency translation of $63.0 million, resulting in operating income on a constant currency basis of $755.6 million.\n In addition, the Company has provided non-GAAP fiscal year 2024 guidance for diluted earnings per share, operating income,\neffective income tax rate and free cash flow that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated. ", "original_text": "For fiscal 2023, (i) revenue of $262.2 billion was\nnegatively impacted by foreign currency translation of $2.4 billion, resulting in revenue on a constant currency basis of $264.5\nbillion, and (ii) operating income of $3,289.1 million was negatively impacted by foreign currency translation of $63.0 million,\nresulting in operating income on a constant currency basis of $3,352.1 million. "}, "hash": "993a2e1a0fa452de784828bbc4dc4b239b6caf4dcf29020e4888fb139ce5045f", "class_name": "RelatedNodeInfo"}}, "text": "For the fourth quarter of fiscal 2023 in the International Healthcare Solutions segment, (i) revenue of $6,994.7 million\nwas negatively impacted by foreign currency translation of $37.6 million, resulting in revenue on a constant currency basis of\n$7,032.3 million, and (ii) operating income of $168.2 million was negatively impacted by foreign currency translation of $1.5 million,\nresulting in operating income on a constant currency basis of $169.6 million. ", "start_char_idx": 671, "end_char_idx": 1132, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "922ebad1-3d5a-4dbc-a2b7-46e29aef8de4": {"__data__": {"id_": "922ebad1-3d5a-4dbc-a2b7-46e29aef8de4", "embedding": null, "metadata": {"window": "dollar and management believes that this\npresentation provides a framework to assess how its business performed excluding the impact of foreign currency exchange rate\nfluctuations.  For the fourth quarter of fiscal 2023, (i) revenue of $68.9 billion was negatively impacted by foreign currency translation\nof $37.6 million, resulting in revenue on a constant currency basis of $69.0 billion, and (ii) operating income of $801.0 million was\nnegatively impacted by foreign currency translation of $1.5 million, resulting in operating income on a constant currency basis of\n$802.5 million.  For the fourth quarter of fiscal 2023 in the International Healthcare Solutions segment, (i) revenue of $6,994.7 million\nwas negatively impacted by foreign currency translation of $37.6 million, resulting in revenue on a constant currency basis of\n$7,032.3 million, and (ii) operating income of $168.2 million was negatively impacted by foreign currency translation of $1.5 million,\nresulting in operating income on a constant currency basis of $169.6 million.  For fiscal 2023, (i) revenue of $262.2 billion was\nnegatively impacted by foreign currency translation of $2.4 billion, resulting in revenue on a constant currency basis of $264.5\nbillion, and (ii) operating income of $3,289.1 million was negatively impacted by foreign currency translation of $63.0 million,\nresulting in operating income on a constant currency basis of $3,352.1 million.  For fiscal 2023 in the International Healthcare\nSolutions segment, (i) revenue of $27.4 billion was negatively impacted by foreign currency translation of $2.4 billion, resulting in\nrevenue on a constant currency basis of $29.8 billion, and (ii) operating income of $692.6 million was negatively impacted by foreign\ncurrency translation of $63.0 million, resulting in operating income on a constant currency basis of $755.6 million.\n In addition, the Company has provided non-GAAP fiscal year 2024 guidance for diluted earnings per share, operating income,\neffective income tax rate and free cash flow that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated. ", "original_text": "For fiscal 2023, (i) revenue of $262.2 billion was\nnegatively impacted by foreign currency translation of $2.4 billion, resulting in revenue on a constant currency basis of $264.5\nbillion, and (ii) operating income of $3,289.1 million was negatively impacted by foreign currency translation of $63.0 million,\nresulting in operating income on a constant currency basis of $3,352.1 million. ", "page_label": "30", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c37dba28-e111-4586-9210-488c4a7cda52", "node_type": "4", "metadata": {"page_label": "30", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6390196a97d263de8522d5032a6a1904df19ed34645d7c126d9f1697237179d4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c8f42f9b-eef8-4258-8725-2d5cd66688b7", "node_type": "1", "metadata": {"window": "operations outside of the United S tates reporting in currencies other than the U.S.  dollar and management believes that this\npresentation provides a framework to assess how its business performed excluding the impact of foreign currency exchange rate\nfluctuations.  For the fourth quarter of fiscal 2023, (i) revenue of $68.9 billion was negatively impacted by foreign currency translation\nof $37.6 million, resulting in revenue on a constant currency basis of $69.0 billion, and (ii) operating income of $801.0 million was\nnegatively impacted by foreign currency translation of $1.5 million, resulting in operating income on a constant currency basis of\n$802.5 million.  For the fourth quarter of fiscal 2023 in the International Healthcare Solutions segment, (i) revenue of $6,994.7 million\nwas negatively impacted by foreign currency translation of $37.6 million, resulting in revenue on a constant currency basis of\n$7,032.3 million, and (ii) operating income of $168.2 million was negatively impacted by foreign currency translation of $1.5 million,\nresulting in operating income on a constant currency basis of $169.6 million.  For fiscal 2023, (i) revenue of $262.2 billion was\nnegatively impacted by foreign currency translation of $2.4 billion, resulting in revenue on a constant currency basis of $264.5\nbillion, and (ii) operating income of $3,289.1 million was negatively impacted by foreign currency translation of $63.0 million,\nresulting in operating income on a constant currency basis of $3,352.1 million.  For fiscal 2023 in the International Healthcare\nSolutions segment, (i) revenue of $27.4 billion was negatively impacted by foreign currency translation of $2.4 billion, resulting in\nrevenue on a constant currency basis of $29.8 billion, and (ii) operating income of $692.6 million was negatively impacted by foreign\ncurrency translation of $63.0 million, resulting in operating income on a constant currency basis of $755.6 million.\n In addition, the Company has provided non-GAAP fiscal year 2024 guidance for diluted earnings per share, operating income,\neffective income tax rate and free cash flow that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature. ", "original_text": "For the fourth quarter of fiscal 2023 in the International Healthcare Solutions segment, (i) revenue of $6,994.7 million\nwas negatively impacted by foreign currency translation of $37.6 million, resulting in revenue on a constant currency basis of\n$7,032.3 million, and (ii) operating income of $168.2 million was negatively impacted by foreign currency translation of $1.5 million,\nresulting in operating income on a constant currency basis of $169.6 million. ", "page_label": "30", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "687e77f45cfd70fa68dbc42d84cb4d32ca858c4b01217738017f9486bfe96278", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c93f9df6-c4b2-4dde-97db-52264c50645c", "node_type": "1", "metadata": {"window": "For the fourth quarter of fiscal 2023, (i) revenue of $68.9 billion was negatively impacted by foreign currency translation\nof $37.6 million, resulting in revenue on a constant currency basis of $69.0 billion, and (ii) operating income of $801.0 million was\nnegatively impacted by foreign currency translation of $1.5 million, resulting in operating income on a constant currency basis of\n$802.5 million.  For the fourth quarter of fiscal 2023 in the International Healthcare Solutions segment, (i) revenue of $6,994.7 million\nwas negatively impacted by foreign currency translation of $37.6 million, resulting in revenue on a constant currency basis of\n$7,032.3 million, and (ii) operating income of $168.2 million was negatively impacted by foreign currency translation of $1.5 million,\nresulting in operating income on a constant currency basis of $169.6 million.  For fiscal 2023, (i) revenue of $262.2 billion was\nnegatively impacted by foreign currency translation of $2.4 billion, resulting in revenue on a constant currency basis of $264.5\nbillion, and (ii) operating income of $3,289.1 million was negatively impacted by foreign currency translation of $63.0 million,\nresulting in operating income on a constant currency basis of $3,352.1 million.  For fiscal 2023 in the International Healthcare\nSolutions segment, (i) revenue of $27.4 billion was negatively impacted by foreign currency translation of $2.4 billion, resulting in\nrevenue on a constant currency basis of $29.8 billion, and (ii) operating income of $692.6 million was negatively impacted by foreign\ncurrency translation of $63.0 million, resulting in operating income on a constant currency basis of $755.6 million.\n In addition, the Company has provided non-GAAP fiscal year 2024 guidance for diluted earnings per share, operating income,\neffective income tax rate and free cash flow that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense/credit is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated. ", "original_text": "For fiscal 2023 in the International Healthcare\nSolutions segment, (i) revenue of $27.4 billion was negatively impacted by foreign currency translation of $2.4 billion, resulting in\nrevenue on a constant currency basis of $29.8 billion, and (ii) operating income of $692.6 million was negatively impacted by foreign\ncurrency translation of $63.0 million, resulting in operating income on a constant currency basis of $755.6 million.\n"}, "hash": "01ebb459568a01d553d7d1af822c5558bd17f680426093d13697d3e1d4bb3d7b", "class_name": "RelatedNodeInfo"}}, "text": "For fiscal 2023, (i) revenue of $262.2 billion was\nnegatively impacted by foreign currency translation of $2.4 billion, resulting in revenue on a constant currency basis of $264.5\nbillion, and (ii) operating income of $3,289.1 million was negatively impacted by foreign currency translation of $63.0 million,\nresulting in operating income on a constant currency basis of $3,352.1 million. ", "start_char_idx": 1132, "end_char_idx": 1521, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c93f9df6-c4b2-4dde-97db-52264c50645c": {"__data__": {"id_": "c93f9df6-c4b2-4dde-97db-52264c50645c", "embedding": null, "metadata": {"window": "For the fourth quarter of fiscal 2023, (i) revenue of $68.9 billion was negatively impacted by foreign currency translation\nof $37.6 million, resulting in revenue on a constant currency basis of $69.0 billion, and (ii) operating income of $801.0 million was\nnegatively impacted by foreign currency translation of $1.5 million, resulting in operating income on a constant currency basis of\n$802.5 million.  For the fourth quarter of fiscal 2023 in the International Healthcare Solutions segment, (i) revenue of $6,994.7 million\nwas negatively impacted by foreign currency translation of $37.6 million, resulting in revenue on a constant currency basis of\n$7,032.3 million, and (ii) operating income of $168.2 million was negatively impacted by foreign currency translation of $1.5 million,\nresulting in operating income on a constant currency basis of $169.6 million.  For fiscal 2023, (i) revenue of $262.2 billion was\nnegatively impacted by foreign currency translation of $2.4 billion, resulting in revenue on a constant currency basis of $264.5\nbillion, and (ii) operating income of $3,289.1 million was negatively impacted by foreign currency translation of $63.0 million,\nresulting in operating income on a constant currency basis of $3,352.1 million.  For fiscal 2023 in the International Healthcare\nSolutions segment, (i) revenue of $27.4 billion was negatively impacted by foreign currency translation of $2.4 billion, resulting in\nrevenue on a constant currency basis of $29.8 billion, and (ii) operating income of $692.6 million was negatively impacted by foreign\ncurrency translation of $63.0 million, resulting in operating income on a constant currency basis of $755.6 million.\n In addition, the Company has provided non-GAAP fiscal year 2024 guidance for diluted earnings per share, operating income,\neffective income tax rate and free cash flow that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense/credit is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated. ", "original_text": "For fiscal 2023 in the International Healthcare\nSolutions segment, (i) revenue of $27.4 billion was negatively impacted by foreign currency translation of $2.4 billion, resulting in\nrevenue on a constant currency basis of $29.8 billion, and (ii) operating income of $692.6 million was negatively impacted by foreign\ncurrency translation of $63.0 million, resulting in operating income on a constant currency basis of $755.6 million.\n", "page_label": "30", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c37dba28-e111-4586-9210-488c4a7cda52", "node_type": "4", "metadata": {"page_label": "30", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6390196a97d263de8522d5032a6a1904df19ed34645d7c126d9f1697237179d4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "922ebad1-3d5a-4dbc-a2b7-46e29aef8de4", "node_type": "1", "metadata": {"window": "dollar and management believes that this\npresentation provides a framework to assess how its business performed excluding the impact of foreign currency exchange rate\nfluctuations.  For the fourth quarter of fiscal 2023, (i) revenue of $68.9 billion was negatively impacted by foreign currency translation\nof $37.6 million, resulting in revenue on a constant currency basis of $69.0 billion, and (ii) operating income of $801.0 million was\nnegatively impacted by foreign currency translation of $1.5 million, resulting in operating income on a constant currency basis of\n$802.5 million.  For the fourth quarter of fiscal 2023 in the International Healthcare Solutions segment, (i) revenue of $6,994.7 million\nwas negatively impacted by foreign currency translation of $37.6 million, resulting in revenue on a constant currency basis of\n$7,032.3 million, and (ii) operating income of $168.2 million was negatively impacted by foreign currency translation of $1.5 million,\nresulting in operating income on a constant currency basis of $169.6 million.  For fiscal 2023, (i) revenue of $262.2 billion was\nnegatively impacted by foreign currency translation of $2.4 billion, resulting in revenue on a constant currency basis of $264.5\nbillion, and (ii) operating income of $3,289.1 million was negatively impacted by foreign currency translation of $63.0 million,\nresulting in operating income on a constant currency basis of $3,352.1 million.  For fiscal 2023 in the International Healthcare\nSolutions segment, (i) revenue of $27.4 billion was negatively impacted by foreign currency translation of $2.4 billion, resulting in\nrevenue on a constant currency basis of $29.8 billion, and (ii) operating income of $692.6 million was negatively impacted by foreign\ncurrency translation of $63.0 million, resulting in operating income on a constant currency basis of $755.6 million.\n In addition, the Company has provided non-GAAP fiscal year 2024 guidance for diluted earnings per share, operating income,\neffective income tax rate and free cash flow that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated. ", "original_text": "For fiscal 2023, (i) revenue of $262.2 billion was\nnegatively impacted by foreign currency translation of $2.4 billion, resulting in revenue on a constant currency basis of $264.5\nbillion, and (ii) operating income of $3,289.1 million was negatively impacted by foreign currency translation of $63.0 million,\nresulting in operating income on a constant currency basis of $3,352.1 million. ", "page_label": "30", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "146757e286b9b909a2daba4e7dd6540787df2bb0e241a95e2f06b6cf11dd1135", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cfb39a9c-0d19-4d03-8c82-60c0c093911a", "node_type": "1", "metadata": {"window": "For the fourth quarter of fiscal 2023 in the International Healthcare Solutions segment, (i) revenue of $6,994.7 million\nwas negatively impacted by foreign currency translation of $37.6 million, resulting in revenue on a constant currency basis of\n$7,032.3 million, and (ii) operating income of $168.2 million was negatively impacted by foreign currency translation of $1.5 million,\nresulting in operating income on a constant currency basis of $169.6 million.  For fiscal 2023, (i) revenue of $262.2 billion was\nnegatively impacted by foreign currency translation of $2.4 billion, resulting in revenue on a constant currency basis of $264.5\nbillion, and (ii) operating income of $3,289.1 million was negatively impacted by foreign currency translation of $63.0 million,\nresulting in operating income on a constant currency basis of $3,352.1 million.  For fiscal 2023 in the International Healthcare\nSolutions segment, (i) revenue of $27.4 billion was negatively impacted by foreign currency translation of $2.4 billion, resulting in\nrevenue on a constant currency basis of $29.8 billion, and (ii) operating income of $692.6 million was negatively impacted by foreign\ncurrency translation of $63.0 million, resulting in operating income on a constant currency basis of $755.6 million.\n In addition, the Company has provided non-GAAP fiscal year 2024 guidance for diluted earnings per share, operating income,\neffective income tax rate and free cash flow that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense/credit is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing\nand amount of favorable and unfavorable settlements, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n", "original_text": "In addition, the Company has provided non-GAAP fiscal year 2024 guidance for diluted earnings per share, operating income,\neffective income tax rate and free cash flow that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature. "}, "hash": "1311b26c5b6c3e051747cd9c55ba2af5b7e59decdae98b43a81254ba1da74070", "class_name": "RelatedNodeInfo"}}, "text": "For fiscal 2023 in the International Healthcare\nSolutions segment, (i) revenue of $27.4 billion was negatively impacted by foreign currency translation of $2.4 billion, resulting in\nrevenue on a constant currency basis of $29.8 billion, and (ii) operating income of $692.6 million was negatively impacted by foreign\ncurrency translation of $63.0 million, resulting in operating income on a constant currency basis of $755.6 million.\n", "start_char_idx": 1521, "end_char_idx": 1954, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cfb39a9c-0d19-4d03-8c82-60c0c093911a": {"__data__": {"id_": "cfb39a9c-0d19-4d03-8c82-60c0c093911a", "embedding": null, "metadata": {"window": "For the fourth quarter of fiscal 2023 in the International Healthcare Solutions segment, (i) revenue of $6,994.7 million\nwas negatively impacted by foreign currency translation of $37.6 million, resulting in revenue on a constant currency basis of\n$7,032.3 million, and (ii) operating income of $168.2 million was negatively impacted by foreign currency translation of $1.5 million,\nresulting in operating income on a constant currency basis of $169.6 million.  For fiscal 2023, (i) revenue of $262.2 billion was\nnegatively impacted by foreign currency translation of $2.4 billion, resulting in revenue on a constant currency basis of $264.5\nbillion, and (ii) operating income of $3,289.1 million was negatively impacted by foreign currency translation of $63.0 million,\nresulting in operating income on a constant currency basis of $3,352.1 million.  For fiscal 2023 in the International Healthcare\nSolutions segment, (i) revenue of $27.4 billion was negatively impacted by foreign currency translation of $2.4 billion, resulting in\nrevenue on a constant currency basis of $29.8 billion, and (ii) operating income of $692.6 million was negatively impacted by foreign\ncurrency translation of $63.0 million, resulting in operating income on a constant currency basis of $755.6 million.\n In addition, the Company has provided non-GAAP fiscal year 2024 guidance for diluted earnings per share, operating income,\neffective income tax rate and free cash flow that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense/credit is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing\nand amount of favorable and unfavorable settlements, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n", "original_text": "In addition, the Company has provided non-GAAP fiscal year 2024 guidance for diluted earnings per share, operating income,\neffective income tax rate and free cash flow that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature. ", "page_label": "30", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c37dba28-e111-4586-9210-488c4a7cda52", "node_type": "4", "metadata": {"page_label": "30", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6390196a97d263de8522d5032a6a1904df19ed34645d7c126d9f1697237179d4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c93f9df6-c4b2-4dde-97db-52264c50645c", "node_type": "1", "metadata": {"window": "For the fourth quarter of fiscal 2023, (i) revenue of $68.9 billion was negatively impacted by foreign currency translation\nof $37.6 million, resulting in revenue on a constant currency basis of $69.0 billion, and (ii) operating income of $801.0 million was\nnegatively impacted by foreign currency translation of $1.5 million, resulting in operating income on a constant currency basis of\n$802.5 million.  For the fourth quarter of fiscal 2023 in the International Healthcare Solutions segment, (i) revenue of $6,994.7 million\nwas negatively impacted by foreign currency translation of $37.6 million, resulting in revenue on a constant currency basis of\n$7,032.3 million, and (ii) operating income of $168.2 million was negatively impacted by foreign currency translation of $1.5 million,\nresulting in operating income on a constant currency basis of $169.6 million.  For fiscal 2023, (i) revenue of $262.2 billion was\nnegatively impacted by foreign currency translation of $2.4 billion, resulting in revenue on a constant currency basis of $264.5\nbillion, and (ii) operating income of $3,289.1 million was negatively impacted by foreign currency translation of $63.0 million,\nresulting in operating income on a constant currency basis of $3,352.1 million.  For fiscal 2023 in the International Healthcare\nSolutions segment, (i) revenue of $27.4 billion was negatively impacted by foreign currency translation of $2.4 billion, resulting in\nrevenue on a constant currency basis of $29.8 billion, and (ii) operating income of $692.6 million was negatively impacted by foreign\ncurrency translation of $63.0 million, resulting in operating income on a constant currency basis of $755.6 million.\n In addition, the Company has provided non-GAAP fiscal year 2024 guidance for diluted earnings per share, operating income,\neffective income tax rate and free cash flow that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense/credit is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated. ", "original_text": "For fiscal 2023 in the International Healthcare\nSolutions segment, (i) revenue of $27.4 billion was negatively impacted by foreign currency translation of $2.4 billion, resulting in\nrevenue on a constant currency basis of $29.8 billion, and (ii) operating income of $692.6 million was negatively impacted by foreign\ncurrency translation of $63.0 million, resulting in operating income on a constant currency basis of $755.6 million.\n", "page_label": "30", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e9195e3a093a6171abe437957325e4509bc944f59d11866b979fd517e40b0445", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0aa8a436-e3a9-4829-893e-23d7b4f541a3", "node_type": "1", "metadata": {"window": "For fiscal 2023, (i) revenue of $262.2 billion was\nnegatively impacted by foreign currency translation of $2.4 billion, resulting in revenue on a constant currency basis of $264.5\nbillion, and (ii) operating income of $3,289.1 million was negatively impacted by foreign currency translation of $63.0 million,\nresulting in operating income on a constant currency basis of $3,352.1 million.  For fiscal 2023 in the International Healthcare\nSolutions segment, (i) revenue of $27.4 billion was negatively impacted by foreign currency translation of $2.4 billion, resulting in\nrevenue on a constant currency basis of $29.8 billion, and (ii) operating income of $692.6 million was negatively impacted by foreign\ncurrency translation of $63.0 million, resulting in operating income on a constant currency basis of $755.6 million.\n In addition, the Company has provided non-GAAP fiscal year 2024 guidance for diluted earnings per share, operating income,\neffective income tax rate and free cash flow that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense/credit is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing\nand amount of favorable and unfavorable settlements, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n Bennett S. Murphy \nSenior Vice Pr esident, Head o f Investor Relations and T reasur y \n610-727-3693 \nbennett.murphy@cencora.com\nSource: Cencora\n30", "original_text": "The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated. "}, "hash": "50eb484c598863d13745f4b6dcf4061aea2d05e2eebcc2631e3c2f3682ff6dcd", "class_name": "RelatedNodeInfo"}}, "text": "In addition, the Company has provided non-GAAP fiscal year 2024 guidance for diluted earnings per share, operating income,\neffective income tax rate and free cash flow that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature. ", "start_char_idx": 1954, "end_char_idx": 2402, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0aa8a436-e3a9-4829-893e-23d7b4f541a3": {"__data__": {"id_": "0aa8a436-e3a9-4829-893e-23d7b4f541a3", "embedding": null, "metadata": {"window": "For fiscal 2023, (i) revenue of $262.2 billion was\nnegatively impacted by foreign currency translation of $2.4 billion, resulting in revenue on a constant currency basis of $264.5\nbillion, and (ii) operating income of $3,289.1 million was negatively impacted by foreign currency translation of $63.0 million,\nresulting in operating income on a constant currency basis of $3,352.1 million.  For fiscal 2023 in the International Healthcare\nSolutions segment, (i) revenue of $27.4 billion was negatively impacted by foreign currency translation of $2.4 billion, resulting in\nrevenue on a constant currency basis of $29.8 billion, and (ii) operating income of $692.6 million was negatively impacted by foreign\ncurrency translation of $63.0 million, resulting in operating income on a constant currency basis of $755.6 million.\n In addition, the Company has provided non-GAAP fiscal year 2024 guidance for diluted earnings per share, operating income,\neffective income tax rate and free cash flow that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense/credit is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing\nand amount of favorable and unfavorable settlements, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n Bennett S. Murphy \nSenior Vice Pr esident, Head o f Investor Relations and T reasur y \n610-727-3693 \nbennett.murphy@cencora.com\nSource: Cencora\n30", "original_text": "The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated. ", "page_label": "30", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c37dba28-e111-4586-9210-488c4a7cda52", "node_type": "4", "metadata": {"page_label": "30", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6390196a97d263de8522d5032a6a1904df19ed34645d7c126d9f1697237179d4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cfb39a9c-0d19-4d03-8c82-60c0c093911a", "node_type": "1", "metadata": {"window": "For the fourth quarter of fiscal 2023 in the International Healthcare Solutions segment, (i) revenue of $6,994.7 million\nwas negatively impacted by foreign currency translation of $37.6 million, resulting in revenue on a constant currency basis of\n$7,032.3 million, and (ii) operating income of $168.2 million was negatively impacted by foreign currency translation of $1.5 million,\nresulting in operating income on a constant currency basis of $169.6 million.  For fiscal 2023, (i) revenue of $262.2 billion was\nnegatively impacted by foreign currency translation of $2.4 billion, resulting in revenue on a constant currency basis of $264.5\nbillion, and (ii) operating income of $3,289.1 million was negatively impacted by foreign currency translation of $63.0 million,\nresulting in operating income on a constant currency basis of $3,352.1 million.  For fiscal 2023 in the International Healthcare\nSolutions segment, (i) revenue of $27.4 billion was negatively impacted by foreign currency translation of $2.4 billion, resulting in\nrevenue on a constant currency basis of $29.8 billion, and (ii) operating income of $692.6 million was negatively impacted by foreign\ncurrency translation of $63.0 million, resulting in operating income on a constant currency basis of $755.6 million.\n In addition, the Company has provided non-GAAP fiscal year 2024 guidance for diluted earnings per share, operating income,\neffective income tax rate and free cash flow that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense/credit is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing\nand amount of favorable and unfavorable settlements, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n", "original_text": "In addition, the Company has provided non-GAAP fiscal year 2024 guidance for diluted earnings per share, operating income,\neffective income tax rate and free cash flow that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature. ", "page_label": "30", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8daa5d908312cb6666c435300a6e0fe8e1f08ddf9432313f048388e3313fa606", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3066a540-dcf1-4894-881c-77189419b393", "node_type": "1", "metadata": {"window": "For fiscal 2023 in the International Healthcare\nSolutions segment, (i) revenue of $27.4 billion was negatively impacted by foreign currency translation of $2.4 billion, resulting in\nrevenue on a constant currency basis of $29.8 billion, and (ii) operating income of $692.6 million was negatively impacted by foreign\ncurrency translation of $63.0 million, resulting in operating income on a constant currency basis of $755.6 million.\n In addition, the Company has provided non-GAAP fiscal year 2024 guidance for diluted earnings per share, operating income,\neffective income tax rate and free cash flow that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense/credit is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing\nand amount of favorable and unfavorable settlements, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n Bennett S. Murphy \nSenior Vice Pr esident, Head o f Investor Relations and T reasur y \n610-727-3693 \nbennett.murphy@cencora.com\nSource: Cencora\n30", "original_text": "For example, LIFO expense/credit is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated. "}, "hash": "d41211632d08e1e8912ee4b161016bcd2b4e6f09275adac566b16e29e54aa7e7", "class_name": "RelatedNodeInfo"}}, "text": "The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated. ", "start_char_idx": 2402, "end_char_idx": 2638, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3066a540-dcf1-4894-881c-77189419b393": {"__data__": {"id_": "3066a540-dcf1-4894-881c-77189419b393", "embedding": null, "metadata": {"window": "For fiscal 2023 in the International Healthcare\nSolutions segment, (i) revenue of $27.4 billion was negatively impacted by foreign currency translation of $2.4 billion, resulting in\nrevenue on a constant currency basis of $29.8 billion, and (ii) operating income of $692.6 million was negatively impacted by foreign\ncurrency translation of $63.0 million, resulting in operating income on a constant currency basis of $755.6 million.\n In addition, the Company has provided non-GAAP fiscal year 2024 guidance for diluted earnings per share, operating income,\neffective income tax rate and free cash flow that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense/credit is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing\nand amount of favorable and unfavorable settlements, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n Bennett S. Murphy \nSenior Vice Pr esident, Head o f Investor Relations and T reasur y \n610-727-3693 \nbennett.murphy@cencora.com\nSource: Cencora\n30", "original_text": "For example, LIFO expense/credit is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated. ", "page_label": "30", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c37dba28-e111-4586-9210-488c4a7cda52", "node_type": "4", "metadata": {"page_label": "30", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6390196a97d263de8522d5032a6a1904df19ed34645d7c126d9f1697237179d4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0aa8a436-e3a9-4829-893e-23d7b4f541a3", "node_type": "1", "metadata": {"window": "For fiscal 2023, (i) revenue of $262.2 billion was\nnegatively impacted by foreign currency translation of $2.4 billion, resulting in revenue on a constant currency basis of $264.5\nbillion, and (ii) operating income of $3,289.1 million was negatively impacted by foreign currency translation of $63.0 million,\nresulting in operating income on a constant currency basis of $3,352.1 million.  For fiscal 2023 in the International Healthcare\nSolutions segment, (i) revenue of $27.4 billion was negatively impacted by foreign currency translation of $2.4 billion, resulting in\nrevenue on a constant currency basis of $29.8 billion, and (ii) operating income of $692.6 million was negatively impacted by foreign\ncurrency translation of $63.0 million, resulting in operating income on a constant currency basis of $755.6 million.\n In addition, the Company has provided non-GAAP fiscal year 2024 guidance for diluted earnings per share, operating income,\neffective income tax rate and free cash flow that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense/credit is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing\nand amount of favorable and unfavorable settlements, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n Bennett S. Murphy \nSenior Vice Pr esident, Head o f Investor Relations and T reasur y \n610-727-3693 \nbennett.murphy@cencora.com\nSource: Cencora\n30", "original_text": "The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated. ", "page_label": "30", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "06228690bee6a8509813107d3dc7e647a11e06932e854690359caeca4e60bb7f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "371ebb77-1a11-40f7-a1f1-399c9eb61997", "node_type": "1", "metadata": {"window": "In addition, the Company has provided non-GAAP fiscal year 2024 guidance for diluted earnings per share, operating income,\neffective income tax rate and free cash flow that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense/credit is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing\nand amount of favorable and unfavorable settlements, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n Bennett S. Murphy \nSenior Vice Pr esident, Head o f Investor Relations and T reasur y \n610-727-3693 \nbennett.murphy@cencora.com\nSource: Cencora\n30", "original_text": "Similarly, the timing\nand amount of favorable and unfavorable settlements, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n"}, "hash": "9752e5d0c3d3eb213037f727f57550d6b82bae3e141acebe483ec8831d55026e", "class_name": "RelatedNodeInfo"}}, "text": "For example, LIFO expense/credit is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated. ", "start_char_idx": 2638, "end_char_idx": 2952, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "371ebb77-1a11-40f7-a1f1-399c9eb61997": {"__data__": {"id_": "371ebb77-1a11-40f7-a1f1-399c9eb61997", "embedding": null, "metadata": {"window": "In addition, the Company has provided non-GAAP fiscal year 2024 guidance for diluted earnings per share, operating income,\neffective income tax rate and free cash flow that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense/credit is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing\nand amount of favorable and unfavorable settlements, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n Bennett S. Murphy \nSenior Vice Pr esident, Head o f Investor Relations and T reasur y \n610-727-3693 \nbennett.murphy@cencora.com\nSource: Cencora\n30", "original_text": "Similarly, the timing\nand amount of favorable and unfavorable settlements, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n", "page_label": "30", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c37dba28-e111-4586-9210-488c4a7cda52", "node_type": "4", "metadata": {"page_label": "30", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6390196a97d263de8522d5032a6a1904df19ed34645d7c126d9f1697237179d4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3066a540-dcf1-4894-881c-77189419b393", "node_type": "1", "metadata": {"window": "For fiscal 2023 in the International Healthcare\nSolutions segment, (i) revenue of $27.4 billion was negatively impacted by foreign currency translation of $2.4 billion, resulting in\nrevenue on a constant currency basis of $29.8 billion, and (ii) operating income of $692.6 million was negatively impacted by foreign\ncurrency translation of $63.0 million, resulting in operating income on a constant currency basis of $755.6 million.\n In addition, the Company has provided non-GAAP fiscal year 2024 guidance for diluted earnings per share, operating income,\neffective income tax rate and free cash flow that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense/credit is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing\nand amount of favorable and unfavorable settlements, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n Bennett S. Murphy \nSenior Vice Pr esident, Head o f Investor Relations and T reasur y \n610-727-3693 \nbennett.murphy@cencora.com\nSource: Cencora\n30", "original_text": "For example, LIFO expense/credit is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated. ", "page_label": "30", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "06c84f622219efa780b145682ef278b3644dfea3789463b0876969b4195bba3b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d5bedafa-8c0a-4811-9110-7c731478ae16", "node_type": "1", "metadata": {"window": "The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense/credit is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing\nand amount of favorable and unfavorable settlements, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n Bennett S. Murphy \nSenior Vice Pr esident, Head o f Investor Relations and T reasur y \n610-727-3693 \nbennett.murphy@cencora.com\nSource: Cencora\n30", "original_text": "Bennett S. Murphy \nSenior Vice Pr esident, Head o f Investor Relations and T reasur y \n610-727-3693 \nbennett.murphy@cencora.com\nSource: Cencora\n30"}, "hash": "ddae2478fd7dad234134f67ee423314c23d4ff4686cdbf70050cc373233214c5", "class_name": "RelatedNodeInfo"}}, "text": "Similarly, the timing\nand amount of favorable and unfavorable settlements, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n", "start_char_idx": 2952, "end_char_idx": 3136, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d5bedafa-8c0a-4811-9110-7c731478ae16": {"__data__": {"id_": "d5bedafa-8c0a-4811-9110-7c731478ae16", "embedding": null, "metadata": {"window": "The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense/credit is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing\nand amount of favorable and unfavorable settlements, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n Bennett S. Murphy \nSenior Vice Pr esident, Head o f Investor Relations and T reasur y \n610-727-3693 \nbennett.murphy@cencora.com\nSource: Cencora\n30", "original_text": "Bennett S. Murphy \nSenior Vice Pr esident, Head o f Investor Relations and T reasur y \n610-727-3693 \nbennett.murphy@cencora.com\nSource: Cencora\n30", "page_label": "30", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c37dba28-e111-4586-9210-488c4a7cda52", "node_type": "4", "metadata": {"page_label": "30", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6390196a97d263de8522d5032a6a1904df19ed34645d7c126d9f1697237179d4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "371ebb77-1a11-40f7-a1f1-399c9eb61997", "node_type": "1", "metadata": {"window": "In addition, the Company has provided non-GAAP fiscal year 2024 guidance for diluted earnings per share, operating income,\neffective income tax rate and free cash flow that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense/credit is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing\nand amount of favorable and unfavorable settlements, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n Bennett S. Murphy \nSenior Vice Pr esident, Head o f Investor Relations and T reasur y \n610-727-3693 \nbennett.murphy@cencora.com\nSource: Cencora\n30", "original_text": "Similarly, the timing\nand amount of favorable and unfavorable settlements, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n", "page_label": "30", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6c0a41c0856871c7e3e2bed3ee8b6a3e7378840e1fde7e0f92b79cd97d8d1a89", "class_name": "RelatedNodeInfo"}}, "text": "Bennett S. Murphy \nSenior Vice Pr esident, Head o f Investor Relations and T reasur y \n610-727-3693 \nbennett.murphy@cencora.com\nSource: Cencora\n30", "start_char_idx": 3136, "end_char_idx": 3282, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}}, "docstore/metadata": {"a4454e1f-4542-4e09-a1ce-f78891dd1e8c": {"doc_hash": "f999ac33cc16f5686d5dddafe4bbc4db20a9e326098d5ac9de1382a57c763869", "ref_doc_id": "751beaeb-087d-4f58-8f44-70cbbdf28794"}, "ac252ed7-1453-48e0-b1be-22da698c291f": {"doc_hash": "cb71718c6865a7087ccc65aa153ffd6b7b43b3faa3f47fc17ce8b7c3436cac4c", "ref_doc_id": "751beaeb-087d-4f58-8f44-70cbbdf28794"}, "c466d288-3978-47d6-99b3-d5491119dbca": {"doc_hash": "0176acdd22267b9f2ef333c7e59ecf477e5bbb53f1a775c0c8d2454cd4358821", "ref_doc_id": "751beaeb-087d-4f58-8f44-70cbbdf28794"}, "3ae576b1-521b-4910-b1dd-ac8e054cafc6": {"doc_hash": "96a189e985d5b7b45dc922a044be4e75711d0c92cfb7803f7b79b11399fc3d6f", "ref_doc_id": "751beaeb-087d-4f58-8f44-70cbbdf28794"}, "cc798f13-adad-45d5-a189-950b8a842339": {"doc_hash": "b97817eb572170ab385a5d37b63f65088e431cb28de6fe0fc439d81c341dc589", "ref_doc_id": "751beaeb-087d-4f58-8f44-70cbbdf28794"}, "4942cea5-8069-40be-bad5-0d2307d62baa": {"doc_hash": "642f2a962f17fa927f90e194ddb9e637e329e42df66a82db9a28895082577a46", "ref_doc_id": "751beaeb-087d-4f58-8f44-70cbbdf28794"}, "6b4ecd28-20b9-4081-ad83-8812f65cfd81": {"doc_hash": "989012318bf0bf6c6ffdbc01fdc29a289e07d141184afb94bf48cf09776b9157", "ref_doc_id": "751beaeb-087d-4f58-8f44-70cbbdf28794"}, "45925fee-f88d-4ba3-98ea-f67646da83db": {"doc_hash": "d930f1810813afda82d66a59b5b5138f1c8f0e803367e2008bfa0cbbfebddfa4", "ref_doc_id": "751beaeb-087d-4f58-8f44-70cbbdf28794"}, "7bc3b277-cc63-4abd-a97b-23ce6f9c2744": {"doc_hash": "7609a87072b9e05ebd32114fd73c8c4dd8921076d5a03a1f46c9b02439023499", "ref_doc_id": "751beaeb-087d-4f58-8f44-70cbbdf28794"}, "4c2cde99-63ae-4a6a-9e5b-235f1a62beff": {"doc_hash": "85ea7d8647109c01f0970a08c902d0480f04406140226889691ad07da788d3cb", "ref_doc_id": "751beaeb-087d-4f58-8f44-70cbbdf28794"}, "4f8703b0-ed0a-477e-b757-2d56115db514": {"doc_hash": "41f5c4a76d7846b929f90c0e3488b5d18e415dea3be624f9ac658e7c53315e64", "ref_doc_id": "751beaeb-087d-4f58-8f44-70cbbdf28794"}, "b501d36d-525b-4697-ba72-5e3ea3095340": {"doc_hash": "f8c341eb5968ab0a26f27460b0013154e31fbfb8a892d356cd52dc44bf7b32c2", "ref_doc_id": "751beaeb-087d-4f58-8f44-70cbbdf28794"}, "0bd4223d-52e3-4c0d-9c81-c8d017fc56a6": {"doc_hash": "f60caa8ec5b656ba1955d030ab6d4c7ddb3f0346b7c467fb436ab726bea8b010", "ref_doc_id": "751beaeb-087d-4f58-8f44-70cbbdf28794"}, "1480aff5-c5c0-4511-8879-fd795907f0a9": {"doc_hash": "ee4a99d988c3442bd05fe19d6294f1a47e850433003024de8573fa42d595d8a0", "ref_doc_id": "8d68cffe-a6e2-4827-9f5b-bc33a23ae109"}, "dc4ef9c5-d141-4ae0-b5cf-a94ee37d76c0": {"doc_hash": "e1eae4f3c79fde468d519315aa8d5a00d151fc2078641a41d1c054475d199bc8", "ref_doc_id": "8d68cffe-a6e2-4827-9f5b-bc33a23ae109"}, "9d821aef-9c5c-4c75-ab18-5054e605106d": {"doc_hash": "71fc6e4717b6932dac63607f79f5ee91a2c9e6ac5f179af1559dc856e1465add", "ref_doc_id": "8d68cffe-a6e2-4827-9f5b-bc33a23ae109"}, "8c44791a-2860-406f-a04c-bee689fc5f90": {"doc_hash": "00d1cba302e3f1ef1ff64a5118aa00643db852fb66884c095d9479b0298d9571", "ref_doc_id": "8d68cffe-a6e2-4827-9f5b-bc33a23ae109"}, "013a3f5e-7c5a-41ae-ade5-09699ec5f0db": {"doc_hash": "eb1d83c483abb38381eea1b79292f8d482b1352346cf407caa122353ed326373", "ref_doc_id": "8d68cffe-a6e2-4827-9f5b-bc33a23ae109"}, "1705c2b2-fc15-4cc9-8eac-79d82cab8bbb": {"doc_hash": "4c06a2ddcf10d19f07ceae670b9b991ea2bb927a17cd3d22811663c6ce9c7b7a", "ref_doc_id": "8d68cffe-a6e2-4827-9f5b-bc33a23ae109"}, "1aa202f4-72d5-4766-8e30-cd400fd352b2": {"doc_hash": "bb08dc894eb28b84b0aa611142a2b7cd2a67fa62316f7f08c7608aae2c07ceca", "ref_doc_id": "8d68cffe-a6e2-4827-9f5b-bc33a23ae109"}, "64e46371-4dc8-47ff-984e-f495fb7b5161": {"doc_hash": "b0318efcbc008ef81d9eb6bf042cb5afc14341402a7a5adc9651a9cb339a3aa0", "ref_doc_id": "8d68cffe-a6e2-4827-9f5b-bc33a23ae109"}, "37dceed8-1267-4e8d-ba64-c0a9415b0905": {"doc_hash": "0bf0601a8572f9a1ef89ec40e6ef2732be07489625c26c41fe7f5ead31dc79c2", "ref_doc_id": "8d68cffe-a6e2-4827-9f5b-bc33a23ae109"}, "54fbee63-c89e-4186-b826-7da5fa8bb4cb": {"doc_hash": "93b93980c0b65a8a84723255b222c32bc41fcd6544ad6b9cea1ec1e4efb44cf9", "ref_doc_id": "8d68cffe-a6e2-4827-9f5b-bc33a23ae109"}, "ded1d99d-2cac-4640-b5e1-2b69c9734f9e": {"doc_hash": "035b90da2d8fd9c5aca0caa5c95ffd813e41cf9808756d541d6331817da4d53b", "ref_doc_id": "8d68cffe-a6e2-4827-9f5b-bc33a23ae109"}, "800b856d-6f65-4af6-9281-83c63781d15d": {"doc_hash": "3f53fe68f9d8427c6ead3fc2b389eca2cbe49b8891eb61792fc97bdaff445f9f", "ref_doc_id": "8d68cffe-a6e2-4827-9f5b-bc33a23ae109"}, "d4ebb983-95d2-4cc3-8eeb-d81ec217e66d": {"doc_hash": "4cabe9f654695b3b7520a206dbeaa557ea91f0a95f45e8ab5935405c1494172a", "ref_doc_id": "8d68cffe-a6e2-4827-9f5b-bc33a23ae109"}, "459a00ea-eb96-45ab-85e4-7dd1bd7523f0": {"doc_hash": "8ce2749b6d2699c4ce6a70c7f247c956315748cdfae79f3df35610256257f282", "ref_doc_id": "8d68cffe-a6e2-4827-9f5b-bc33a23ae109"}, "38d550a3-b8d2-4444-9dba-e56a1c8fbcec": {"doc_hash": "9699b108ae0e57e17d1e43be22f33874ff73f9d697271a25b71ad256883be754", "ref_doc_id": "8d68cffe-a6e2-4827-9f5b-bc33a23ae109"}, "d455cd11-d663-48ae-b44d-19048a5ebb5f": {"doc_hash": "110515dd66bd1506d35da052b26e6d49eb1035abc1466e2a2878e90ada860075", "ref_doc_id": "8d68cffe-a6e2-4827-9f5b-bc33a23ae109"}, "62610197-df01-41b8-9ab8-44594b47421c": {"doc_hash": "7237b1f8e02e7c47deb16e4f0386357a953d01b3c6a88202cd13281a63d7e687", "ref_doc_id": "8d68cffe-a6e2-4827-9f5b-bc33a23ae109"}, "efb3776d-dbfa-4152-b65b-f04e1e560f83": {"doc_hash": "09f3356d9acc00c9c1126e8711fa4a41d85e588fab9f9f357fd455f7bc8d19de", "ref_doc_id": "8d68cffe-a6e2-4827-9f5b-bc33a23ae109"}, "d4eb03b6-ef81-4590-bacc-943307f4aab0": {"doc_hash": "1f0a95b7bb4112ec745a0fa7021d372a886dea7c78d917ba4562f5acf7afed95", "ref_doc_id": "8d68cffe-a6e2-4827-9f5b-bc33a23ae109"}, "d258aaca-bc2d-42f2-a50d-8034aac78a11": {"doc_hash": "5fc935d683bb66f2c64c91f9f82ef58ea3ad7cc7e6bde44d74fd69c8592a41c6", "ref_doc_id": "8d68cffe-a6e2-4827-9f5b-bc33a23ae109"}, "3e043939-87a8-458f-bedb-7bab7562332c": {"doc_hash": "9631761adf08fbb91c2eb6ccbcfab4921df949a07e8a0434fc618b70097e962f", "ref_doc_id": "8d68cffe-a6e2-4827-9f5b-bc33a23ae109"}, "f2941e01-d3e5-440e-a914-8562aa337169": {"doc_hash": "2cc5a355a9c667e5b3ccf50f387907e25db3f8975aaf3b9b2e76d5c25720f8e4", "ref_doc_id": "8d68cffe-a6e2-4827-9f5b-bc33a23ae109"}, "01e1be5f-63be-45b5-9902-2e599ac705d9": {"doc_hash": "084047671842dab92bddc4edba838854728984a27e0e8791f50aa6c32cf39049", "ref_doc_id": "20e3d800-bd50-438f-b446-f823062e13e0"}, "89c6a0e3-e830-40a4-b525-e51d25eb8e15": {"doc_hash": "2f6602a51ab52bbafbb969395de10c7485384428e0ff58f7e5ebde2039ad0982", "ref_doc_id": "20e3d800-bd50-438f-b446-f823062e13e0"}, "9e89b35a-0ed1-4f98-b157-5747a429d6cb": {"doc_hash": "6f4ba362ad02624a475d7d513e8ffe732f72e70ed14021937b40588fb4f713c3", "ref_doc_id": "20e3d800-bd50-438f-b446-f823062e13e0"}, "9aaf4b69-e82f-4639-afe5-0601a348e3a7": {"doc_hash": "d2e53a851b9020518ee48191dc8e7a64ad7087f72b3cf7939b09fb0b9704a69d", "ref_doc_id": "20e3d800-bd50-438f-b446-f823062e13e0"}, "4b7ddded-d19c-4b76-9683-80a2e92db665": {"doc_hash": "c42eb677141efe432d0417c1824eea413bd88a6d7a72abe1c97c002fa269d667", "ref_doc_id": "20e3d800-bd50-438f-b446-f823062e13e0"}, "13057d64-5674-4122-adc4-48eae99844d7": {"doc_hash": "283ee95222e88ee1d1c19da7f3923879701cc2020563594d12a4447634610be5", "ref_doc_id": "20e3d800-bd50-438f-b446-f823062e13e0"}, "38ddf0b6-f99d-4c83-afa0-1e4a43cc51e8": {"doc_hash": "763aed3bfd0cdab7dda239a21b3267f977350775c5a6a31016c801899ef26d50", "ref_doc_id": "20e3d800-bd50-438f-b446-f823062e13e0"}, "efe0d55c-07c7-4acc-916d-68a3889bc549": {"doc_hash": "93249e9ba7cd50c6f5061eb4fb5e012e91976d914b9328372c222bfa26469def", "ref_doc_id": "20e3d800-bd50-438f-b446-f823062e13e0"}, "1a04af32-691a-44cd-b80e-78fb931ce9d6": {"doc_hash": "d26c366bc55f1fe9da780321e0fab67dcaaf4dbd080ddeb29ed9d906bcc1c22c", "ref_doc_id": "20e3d800-bd50-438f-b446-f823062e13e0"}, "b9c901e0-fe44-4f9a-9c86-4e9995246faf": {"doc_hash": "16c77f74b2e6c3a501e804cb91e73c6ea9bcb9bdf1ff812f8be47b35e5ad405a", "ref_doc_id": "20e3d800-bd50-438f-b446-f823062e13e0"}, "cf3e3334-ba76-4b6e-9276-ae04cb3b75b3": {"doc_hash": "85dd08710a7889e985cc5284300bb63b52139b03c4526c59686c7560722e00f4", "ref_doc_id": "20e3d800-bd50-438f-b446-f823062e13e0"}, "aee4e122-d26c-4c09-963a-583e370ec4b8": {"doc_hash": "0e29a492747f394e42992ff384cfa26ee359bd5800875ea0ade8cee337ffa5aa", "ref_doc_id": "20e3d800-bd50-438f-b446-f823062e13e0"}, "81b20521-ac95-4d2a-a3e4-d3a983427b1a": {"doc_hash": "96f2ccf63bbb6564a198ae13a027df50ba59c3f6301f008f3fcb5b879a14b9f0", "ref_doc_id": "20e3d800-bd50-438f-b446-f823062e13e0"}, "e1d6b9ca-e518-4470-961c-d0fc19bf6cfe": {"doc_hash": "f0fe55175688714aafa64e39da2eb8f5e5beb3c676353ca504d9bc7b281c15ce", "ref_doc_id": "20e3d800-bd50-438f-b446-f823062e13e0"}, "49787032-84c4-413a-abb6-69ee678443c5": {"doc_hash": "4c862c8910b66a5d2961e4ebec7c97be3a60373d36956a463f3225c4083a5efe", "ref_doc_id": "20e3d800-bd50-438f-b446-f823062e13e0"}, "c9ee42c3-8b51-4d74-9ee6-1a59965a71b1": {"doc_hash": "2697fec7b4cb9cdfc8ba83a0a47db25f1a9a8d2f95f55f2ef7ae366e0a565463", "ref_doc_id": "20e3d800-bd50-438f-b446-f823062e13e0"}, "4eff1dfd-092c-4f1f-bb66-2378a922e541": {"doc_hash": "8b1eb5464afcbc5e9107fb30140c6090a0a301c6508e196b61e6444ab4c54efa", "ref_doc_id": "20e3d800-bd50-438f-b446-f823062e13e0"}, "18a39604-f37f-4f9e-a250-97c6fd2c2b1e": {"doc_hash": "fe5d5af3c8eb2b5612901ca58e15829fbf7625f3e47a6c364cb37a3b6ec3126b", "ref_doc_id": "20e3d800-bd50-438f-b446-f823062e13e0"}, "f9f2b925-03ec-48ad-a9f3-c0636dbd699f": {"doc_hash": "e84a7203e0b58afc8cd5b8bfea7f955912f260e40164b170150709538116c242", "ref_doc_id": "20e3d800-bd50-438f-b446-f823062e13e0"}, "ace5e9f1-6b37-4720-8ea0-dc8440664239": {"doc_hash": "d80e7c0041b43c057bcfa5bce32b2cc3e73e67700e3c410537210b613f584454", "ref_doc_id": "20e3d800-bd50-438f-b446-f823062e13e0"}, "b7c25434-60bc-4fd0-aaaf-72ff812ececf": {"doc_hash": "965c684dd0dcd454a1e42a193ce4f7c4fe5bf7619e6384013a97f1d0ec547dd9", "ref_doc_id": "20e3d800-bd50-438f-b446-f823062e13e0"}, "99ceaa20-7247-4386-8dd0-105da8c3ad3f": {"doc_hash": "1c66dce1c6b152175d69c0775c93b1b64c909244bf4c8bd7e4b8926eb453cb77", "ref_doc_id": "20e3d800-bd50-438f-b446-f823062e13e0"}, "7c9c234f-7b20-4bb2-ade4-469fdf5114c2": {"doc_hash": "e774c2150afbe94826ddd0eff3fa2f2db79da78219d51d4d550611c5d3b6da6b", "ref_doc_id": "20e3d800-bd50-438f-b446-f823062e13e0"}, "0f14efc8-b446-44ee-ac88-8f94fa11ff8f": {"doc_hash": "0bca0fdfab27a6729d63928118ada3619bee3a83d728b793d6812c69c19cd67c", "ref_doc_id": "20e3d800-bd50-438f-b446-f823062e13e0"}, "6686a994-3d07-4d5c-b05f-b9e13d4caca0": {"doc_hash": "926db6ab8bb91f0093fd3c4281143a1c88b84067285cda60171cd511702559e9", "ref_doc_id": "20e3d800-bd50-438f-b446-f823062e13e0"}, "41ee8191-516e-4405-ab00-ac4684af0e4a": {"doc_hash": "3c0f4446bda2955170768d59f7e0813416849f39146e0a070ba52b5fd2d340d6", "ref_doc_id": "20e3d800-bd50-438f-b446-f823062e13e0"}, "2075c00a-57ee-4c6f-ab83-227868e02c10": {"doc_hash": "be272be903a073a9345ccaf4bad5648b6a4812f0edbcca66879ba55f82f49d6d", "ref_doc_id": "20e3d800-bd50-438f-b446-f823062e13e0"}, "dc7e8a9d-e742-4625-9453-8624a32c1c4c": {"doc_hash": "bd5fcfe01cffb69207ebe16b2b4d911da8b2ba57d78e53b9d51469069851593e", "ref_doc_id": "8e5f2760-457b-40e5-a61e-1e4e45be6670"}, "f6acad40-6d7e-400a-9e06-a4f37be68469": {"doc_hash": "f44bde3f985336356bade971b98c922e5973f3ae2d8cec22ce6d447de90827b3", "ref_doc_id": "8e5f2760-457b-40e5-a61e-1e4e45be6670"}, "9e30dfe7-40bf-4712-a46c-914d67d7c02f": {"doc_hash": "cd6da9ae2ba53c80fe9b076ef1f5b2199c39c595d18cb3fe97b8ffd0a286dd48", "ref_doc_id": "8e5f2760-457b-40e5-a61e-1e4e45be6670"}, "1b0ec505-c5f4-4552-b971-2f03fec949f7": {"doc_hash": "d6806a1f840657c54e512676632b2efe796816b566d2e3a6ad10edd82b37eb18", "ref_doc_id": "8e5f2760-457b-40e5-a61e-1e4e45be6670"}, "a04bcd75-74d2-47df-8a16-ce31e74c6ae2": {"doc_hash": "fa64941356ac8ea87c3d5cdded7e1e5c055f83bed9920b2999b4a8a90948f7ed", "ref_doc_id": "8e5f2760-457b-40e5-a61e-1e4e45be6670"}, "c8319ec6-016e-4491-bf1c-3cf1e4768fc9": {"doc_hash": "034b2868107d8d116a3bc331cd2c67bbb2e22eec5268e8f9120cf132625dea2e", "ref_doc_id": "8e5f2760-457b-40e5-a61e-1e4e45be6670"}, "aa8c2c8c-269a-4459-ab0d-f5c5db8f2c49": {"doc_hash": "caad3cf9bcb5ad84bb5e810c7aa5009109b1e5365c7575859646437aecd8cf6a", "ref_doc_id": "8e5f2760-457b-40e5-a61e-1e4e45be6670"}, "394f2a48-85d2-45e6-a05a-ea3a59d66657": {"doc_hash": "b06caabedc80080c5b0554d3c4a0158fe74491af6eca2b37ffe5c9e5662c2bb7", "ref_doc_id": "8e5f2760-457b-40e5-a61e-1e4e45be6670"}, "45745af8-b062-45a6-bc77-cf9a4a846fbc": {"doc_hash": "5cb5af730c641d2e4eb3dae196efeafceb6677a356b15db681dbe1ea4dc58a4b", "ref_doc_id": "8e5f2760-457b-40e5-a61e-1e4e45be6670"}, "379d0b65-26fe-4570-a4c1-bfd84462d224": {"doc_hash": "c059e1a605a0d8894bcd843fb5edcd41baa369f254ae218015fe09c79cc1e9ca", "ref_doc_id": "8e5f2760-457b-40e5-a61e-1e4e45be6670"}, "56a348c4-3e00-480a-b890-dd04a4a8dd24": {"doc_hash": "4746792165b9803eef1f52474139e538dc1afaf2c988120594543ccefcd85040", "ref_doc_id": "8e5f2760-457b-40e5-a61e-1e4e45be6670"}, "5106d744-fed0-4cc2-91a0-bf7d7470f8ed": {"doc_hash": "31ac4e68d023eb4168bf74aba890fc4a2f7021c18b342a0cf00007e1cf331754", "ref_doc_id": "8e5f2760-457b-40e5-a61e-1e4e45be6670"}, "9899eb1c-28ed-413f-a253-390b677c3f37": {"doc_hash": "f02deaa2106231d9348346aeda8461de5819b8f89e9799dbfff8ba3d860caef3", "ref_doc_id": "8e5f2760-457b-40e5-a61e-1e4e45be6670"}, "9123c6e0-22af-44f5-8ddc-ccf3dd25ef28": {"doc_hash": "56cff847620f0d755e5fb4d8e2f20e538b701f6585cd89573db930ca57e721f3", "ref_doc_id": "8e5f2760-457b-40e5-a61e-1e4e45be6670"}, "1aaff62b-c0f3-437e-91de-ac7a34422f60": {"doc_hash": "c5082e7686dec43a11aa9327f5ff61b6e3b7d9d2d85fb22bee0051d86d632850", "ref_doc_id": "7021eca0-c10a-4441-addb-9b3d939e9002"}, "5da41669-b80c-4152-93af-2e075e09d67c": {"doc_hash": "250ce2eedabbc49f6c9c577408df871635cf4404ff69a29786cddad461648df3", "ref_doc_id": "7021eca0-c10a-4441-addb-9b3d939e9002"}, "7c92cd3c-0d31-4e81-8289-ddd45669b851": {"doc_hash": "067c137397a446d29da9e31d092ab87e1e4d1513a810e5698cbd797b8e5b278c", "ref_doc_id": "7021eca0-c10a-4441-addb-9b3d939e9002"}, "f0555b4c-b814-4525-adb1-503fe9cea80c": {"doc_hash": "5fe67616e07981c9f4de5a7c51d0a487a67f9fab6419f2e1ad44167be36d108e", "ref_doc_id": "7021eca0-c10a-4441-addb-9b3d939e9002"}, "af8ad45f-afbb-40a7-a712-322dc752edfc": {"doc_hash": "843906116bc9e2f3efef9e2dfa05604d2bc3899281adbc0378eff0fa9ea99af4", "ref_doc_id": "7021eca0-c10a-4441-addb-9b3d939e9002"}, "6d522625-770c-411f-b56d-5a7f64c4cae7": {"doc_hash": "9a32309b8a50d76999c4cc8c25ceb4d8f450561876f940a4da53ed30e848e156", "ref_doc_id": "7021eca0-c10a-4441-addb-9b3d939e9002"}, "c7d6bb0f-dc03-4e33-951b-51326bccdbba": {"doc_hash": "cf30d3e7acbf39594846680bc32200e9f1d6b33823eb48ed020b51e8691e0698", "ref_doc_id": "7021eca0-c10a-4441-addb-9b3d939e9002"}, "ebabf343-3bed-421e-8343-38a689291029": {"doc_hash": "569348c56daaf775636a6b33e0b0a70ef494549cb4677e87ffd05e2b0dc6c888", "ref_doc_id": "7021eca0-c10a-4441-addb-9b3d939e9002"}, "593f5a56-e89b-414f-8b0c-c5172d09fe1b": {"doc_hash": "f4a56bc089020c7cbbe6c31e32444a241943a9460a8e715bb0e52133fb52309c", "ref_doc_id": "7021eca0-c10a-4441-addb-9b3d939e9002"}, "6d25a7d1-bea9-4282-a236-0a4d93b064fd": {"doc_hash": "a97c980a255de94ac8609cfa159e65aadd81fa6ecdbdeb5dfc75aeb379f0510f", "ref_doc_id": "7021eca0-c10a-4441-addb-9b3d939e9002"}, "650ec3b3-e222-4d07-ac94-dc21fa6d165e": {"doc_hash": "f1bb7a4325365b090448ee7b529c7b4fcc187013fcb2a00b3e52dfcd028e1e8f", "ref_doc_id": "7021eca0-c10a-4441-addb-9b3d939e9002"}, "ec4747f5-1878-4e7b-9572-08ed0e5af519": {"doc_hash": "dc2259efd226626d0aa92121fc7d8d7a7c88bfa347ce260ca88fbe565ac8f5ef", "ref_doc_id": "7021eca0-c10a-4441-addb-9b3d939e9002"}, "eba75f04-d448-4b48-8f12-e125ed0d45f1": {"doc_hash": "be733e64c82e736e99448be4fef43cb2749ed611b1f8b8512c3f4260c403ec4e", "ref_doc_id": "7021eca0-c10a-4441-addb-9b3d939e9002"}, "9d283c3e-80d7-44e0-aa31-cf9611b82b9d": {"doc_hash": "154852fab91340e07cffd48c40fe881fad72a86160f4c8b3850fd57099ce0af6", "ref_doc_id": "7021eca0-c10a-4441-addb-9b3d939e9002"}, "1963b9ff-0504-4c52-bd6c-3654fd97a237": {"doc_hash": "fd3b68310bd91f479d778640fd69748f4f6588d7241cdd3b6612102b3385612e", "ref_doc_id": "7021eca0-c10a-4441-addb-9b3d939e9002"}, "0cbfc5b9-5f87-4fe5-a060-ae3c6a3f0f71": {"doc_hash": "988c235ccbefac181b69df64e789b1d695e4e8770cf03f25f411ee51092fb8de", "ref_doc_id": "7021eca0-c10a-4441-addb-9b3d939e9002"}, "4b46fbd2-318c-4850-b3c7-230296a11fdc": {"doc_hash": "5b379400de4fc40ae919c405e2cd23b53a436d354ba6cf1e1f0e11cbaa09876d", "ref_doc_id": "7021eca0-c10a-4441-addb-9b3d939e9002"}, "acc51638-1ece-4e8d-b742-4f5c194d2aca": {"doc_hash": "af60e82f77f9e1c54c3ae0ffb83cba047159d6490d2be03fe32982a1fcbb08dc", "ref_doc_id": "b76ad0b5-6e11-4d6c-9702-c56141c82238"}, "164516b5-4570-476c-8d01-637990852562": {"doc_hash": "cd1c43b5ddec095be5704961fad9ee446439a2a40e58bed1093786b19d3d1f1c", "ref_doc_id": "b76ad0b5-6e11-4d6c-9702-c56141c82238"}, "b43b47de-31b6-4866-bb31-3203346eb62f": {"doc_hash": "7df4585b1013df3357443be9d14f24948d3ca7cb1b9405a4b2b61e25c794991f", "ref_doc_id": "b76ad0b5-6e11-4d6c-9702-c56141c82238"}, "d0ee62d1-f6ff-4cef-9786-a6254177c4c2": {"doc_hash": "8270707bcfa82edcf7c2524154bee13a4ea9f8ceb20ad7b7a729f49ca682c4e2", "ref_doc_id": "b76ad0b5-6e11-4d6c-9702-c56141c82238"}, "395f431b-e4fa-43cd-9ae1-fee8293c7008": {"doc_hash": "cd48d35478e43b007311990f48d70ca8fde2009afac5c142828b21211c0bdb59", "ref_doc_id": "b76ad0b5-6e11-4d6c-9702-c56141c82238"}, "fc7f59c6-baab-49ec-a06c-ee63ce9002e3": {"doc_hash": "88df3aeea207519b707375af8494ae800382d8423c360743deb0ed7270b3086c", "ref_doc_id": "b76ad0b5-6e11-4d6c-9702-c56141c82238"}, "84979e79-43fc-426e-9dcf-76e7920aaaa2": {"doc_hash": "af88eac7d1e0572051e2491c670f978a64a7de955923eba824741fd0d6a59cb4", "ref_doc_id": "b76ad0b5-6e11-4d6c-9702-c56141c82238"}, "5a2d9499-b19f-4303-bd2c-a75dbb757efb": {"doc_hash": "83eeed288f6891f3567ee5e95f79eed2586323964c56624d9917cd6f815a3f85", "ref_doc_id": "b76ad0b5-6e11-4d6c-9702-c56141c82238"}, "1a9d4052-997d-4092-a57b-3225a635d218": {"doc_hash": "7de8bbf534518e9df4251ea0131938059c068e152dda3764462eaa3003f87fe6", "ref_doc_id": "b76ad0b5-6e11-4d6c-9702-c56141c82238"}, "67ed5f87-fb0b-4361-8c73-c0dfe3fc9fbc": {"doc_hash": "201129093d2fced1036c129ce3fbd938bf1ca84b9af3d2c0a2692e63a4f68b01", "ref_doc_id": "b76ad0b5-6e11-4d6c-9702-c56141c82238"}, "55f793dc-d0e9-43b4-a1bc-d69e6a613f59": {"doc_hash": "be24644151ddfde643eab4cc207427f2c3d78fe716888499ba1232c87a3c74b1", "ref_doc_id": "b76ad0b5-6e11-4d6c-9702-c56141c82238"}, "40ebe93e-7201-4dd5-9782-f90b1d485e26": {"doc_hash": "dec3076436ffa7b25cafd797051f113b69d6dde952ebad434de805ffe19be60f", "ref_doc_id": "b76ad0b5-6e11-4d6c-9702-c56141c82238"}, "ef91abbc-8c32-4466-b42e-72bb1d637b17": {"doc_hash": "20062d419a399aeb34c81a51f10a36d0e47ccc06f7a2806e48a99ac2d615d748", "ref_doc_id": "b76ad0b5-6e11-4d6c-9702-c56141c82238"}, "1e885e91-955e-444c-84d3-73c154db6f53": {"doc_hash": "1ab44df5483a4978e9a5fa4d3e37d732d9ec6ff4d7d30aacfc6fa81051c31fa1", "ref_doc_id": "b76ad0b5-6e11-4d6c-9702-c56141c82238"}, "080b129c-c6a3-4cb5-9307-91c5081b2547": {"doc_hash": "56b596672e5d5e383f637a191cdfcde65142299c9c4d1da2aab50bab318185ee", "ref_doc_id": "b76ad0b5-6e11-4d6c-9702-c56141c82238"}, "b1caa64f-00c4-4c16-a518-0927a9d765fc": {"doc_hash": "f2d7ef6968dddb21256f2533c71e10f069aade76e4b5c6554d0e99634d7f52a0", "ref_doc_id": "b76ad0b5-6e11-4d6c-9702-c56141c82238"}, "a308398a-e3f6-434f-a38c-c76923306fc8": {"doc_hash": "734ff42a8939c49a9ebe292b2d9e98cc425c6f030b3fead58b6ccb0226d33917", "ref_doc_id": "b76ad0b5-6e11-4d6c-9702-c56141c82238"}, "c496d03c-77dc-44a6-be06-b51d8098e051": {"doc_hash": "e115bfac334d474def541a14d031d8dab04626326791c1ab087601bd2756e814", "ref_doc_id": "b76ad0b5-6e11-4d6c-9702-c56141c82238"}, "e3f14a82-a69c-41aa-8901-7b89d6de07e0": {"doc_hash": "8775e21a021062f209f5d8f266dee82572c96e7a35b388875f10108e4abc1217", "ref_doc_id": "b76ad0b5-6e11-4d6c-9702-c56141c82238"}, "fdd2a319-fc98-43bd-9ed8-cf2e7192513c": {"doc_hash": "77e199e89b3b793f8ffd280a6c874fa46b629a5ef6ec8a5829c5eec7db1205ac", "ref_doc_id": "b76ad0b5-6e11-4d6c-9702-c56141c82238"}, "a4e9816e-cfa4-4526-8eb4-7ed59d5f8c64": {"doc_hash": "1da6781bd31c61ee49d41018638adec3ab2b542925709e53d0f567e14ba18f71", "ref_doc_id": "b76ad0b5-6e11-4d6c-9702-c56141c82238"}, "a5984080-42b9-4bc2-a3f1-dad19c0d9662": {"doc_hash": "262f8dc8828046029e9dbb80da21131dc8bb4fe77314513183092c2fb4cf2a64", "ref_doc_id": "b76ad0b5-6e11-4d6c-9702-c56141c82238"}, "0fca344a-1654-4777-8a0f-ad5e4bec0f5f": {"doc_hash": "c1415e72da7127da6a415cdb009e49ab52233473ba9f017d3da60bff8ba97851", "ref_doc_id": "b76ad0b5-6e11-4d6c-9702-c56141c82238"}, "93fdd4bc-6a4b-48ef-b0a8-becdd89088f1": {"doc_hash": "2090cd034769cb0b2d2b2d0a659f8d83cbe9e2552ec3b80bd14819c3469253f7", "ref_doc_id": "b76ad0b5-6e11-4d6c-9702-c56141c82238"}, "b285c1a0-db9e-4103-bce2-b0ed9ec4d7da": {"doc_hash": "9efddcade30b058e5c04ec7f2c10f00796f4b023f5ac7b738371e3b8d77e19da", "ref_doc_id": "b76ad0b5-6e11-4d6c-9702-c56141c82238"}, "399f52cb-2812-4e0c-b38f-8f3ee8ca20e5": {"doc_hash": "565d672301dc6dba051637a8fd55b1b6bfd2862291e1788240586054b393e673", "ref_doc_id": "b76ad0b5-6e11-4d6c-9702-c56141c82238"}, "bcbef95a-1fcf-4e3a-ae91-9edbb24bfd50": {"doc_hash": "3177925e51443781fb13dc504db5d15dab28ab31f65a6eaa98c14b061c107389", "ref_doc_id": "b76ad0b5-6e11-4d6c-9702-c56141c82238"}, "b8e1a68d-9c3a-4e8c-b865-9eb8e81a4798": {"doc_hash": "33b4c2a76addef93a8759182ba6dae4dd9c9d439c469f360e443085072036dcc", "ref_doc_id": "b76ad0b5-6e11-4d6c-9702-c56141c82238"}, "f0def778-6885-4419-9e00-5a2d4dcecd5a": {"doc_hash": "6ce8ab79cc8b28c50bae043312fb7b77a758c332e1578eedbda5a6f69a1eccd2", "ref_doc_id": "b76ad0b5-6e11-4d6c-9702-c56141c82238"}, "c1e91ae5-3576-44dc-a7d9-d01058db018d": {"doc_hash": "158fd039479958ffd2fd11556cb16cf8c7c8eaa76d15d5dfa23f78cad4a546e1", "ref_doc_id": "a0057cd9-34f8-4acf-817f-87fe57519f5f"}, "b4b1710d-f379-4e26-abd9-50c55e6a45a0": {"doc_hash": "ac2f8992d966b0173a715e6d9bb20396259ab35401f7872cee0a5caf40f7e2ce", "ref_doc_id": "a0057cd9-34f8-4acf-817f-87fe57519f5f"}, "147b49c5-ed9b-4286-976b-a64286ce7ebd": {"doc_hash": "63df7f1a924e7f916327bb4dba815b70bd59aededffabe5a52c5169ccbd3ba50", "ref_doc_id": "a0057cd9-34f8-4acf-817f-87fe57519f5f"}, "af1f7650-a8fc-4f89-881c-9e9cf184b84f": {"doc_hash": "bc9a3cad0e2ccc2433b8c75fbea652c62c03424af4a6654d861a89ccdcd82864", "ref_doc_id": "a0057cd9-34f8-4acf-817f-87fe57519f5f"}, "062b7a07-76c9-4f1b-9c37-320b6d8ed218": {"doc_hash": "8ac15e27f2dcfa7a71607da4d9c899284f267804332ad92e5de96c0abee83797", "ref_doc_id": "a0057cd9-34f8-4acf-817f-87fe57519f5f"}, "73ef7261-d311-4089-9728-290a02cf957f": {"doc_hash": "645c39d507ff213ce74d7424624f477a803ee9af57a3bb88df65012bdda779b8", "ref_doc_id": "a0057cd9-34f8-4acf-817f-87fe57519f5f"}, "93ff4593-5398-4e1a-8d7a-c8166313cc2f": {"doc_hash": "982fa19a5486c719b0509452be31d68299738bf2c0d24e19b1dc16ad1703c32d", "ref_doc_id": "5f73e483-71bf-4e05-8224-0c0ee9ff3a42"}, "d5d1ef16-3c0a-4c63-82db-0a82fdce7bea": {"doc_hash": "545f2fb4e4382f7cb78dc6c6c0b676bea28b89a9b408afafce30f83a2ecae342", "ref_doc_id": "5f73e483-71bf-4e05-8224-0c0ee9ff3a42"}, "afe604d3-f010-4c3e-9c48-ba7557c6362c": {"doc_hash": "1c241327f07865826bdfee8cb4d4f97ac52d4f947f29f4b5c13f30d93c8be254", "ref_doc_id": "5f73e483-71bf-4e05-8224-0c0ee9ff3a42"}, "0468fa44-af41-4032-8bb6-6ed24d1f82fa": {"doc_hash": "38c8bd71ac89b5d07e08f91a32fc9a5862d62b97e1d7720a49e1e7d2abe86c94", "ref_doc_id": "e9de2252-bf7e-4d19-b8c6-e6603420689c"}, "12099117-1ec9-4b8b-89d5-663f1923e346": {"doc_hash": "ea11aa4166b10c2f3081edae1890d6c818e29c53e9aad4bb45b5d8bc80f801f8", "ref_doc_id": "e9de2252-bf7e-4d19-b8c6-e6603420689c"}, "66f83426-3722-4e7b-aacb-1f159a3499f9": {"doc_hash": "9a10e70ac77893a9ad72a960b87fa4474542a55027e5b8fd0da24362f0f7e7b0", "ref_doc_id": "e9de2252-bf7e-4d19-b8c6-e6603420689c"}, "fc84f167-b9f4-4a48-a6b8-4d1b330f9471": {"doc_hash": "61b606b1eedce7f78be877adbcf35b53748e82fe3431a32307b0b570b486f7a5", "ref_doc_id": "e9de2252-bf7e-4d19-b8c6-e6603420689c"}, "354018de-cc27-4988-b5bb-25ed5feb3cec": {"doc_hash": "d794f2d919e3ac23235b8f63c15a43b51ee5f715c3594859c90b3643491f3c68", "ref_doc_id": "e97ebce4-a63a-4d71-a11f-d8f53ae490c7"}, "e6e57f07-e169-4f52-a40c-32a75e6e8777": {"doc_hash": "346b62529a6f96363234325867c0af280dea4bf62f3a4d8aae70c54063631fb1", "ref_doc_id": "e97ebce4-a63a-4d71-a11f-d8f53ae490c7"}, "0485a143-3bfe-4233-83bd-8fef6be10b0e": {"doc_hash": "8ef24b480908329310eb191341e9c1ccda6726721df97b57ce38a53a70354b52", "ref_doc_id": "e97ebce4-a63a-4d71-a11f-d8f53ae490c7"}, "9dbf0a8d-6422-4fa5-a626-cea101906a4f": {"doc_hash": "c57fc9b5cfcc597ad3abee37f18e25e9e9681601e83c57fa2223548952b9254f", "ref_doc_id": "74a005aa-13c2-4b61-b91f-cb66794507c6"}, "a7c29e41-e536-4cde-8243-b820b76112dd": {"doc_hash": "6dcd18d38565af581117465ec6712878f1370b87cfdd5c57bba7bc71a11fb2e8", "ref_doc_id": "74a005aa-13c2-4b61-b91f-cb66794507c6"}, "dacc8784-3f19-4045-9365-99ff57382b08": {"doc_hash": "cbede31757b40fa95f12145825f6f37819d323d41ac779383eac9ae74eba9de7", "ref_doc_id": "74a005aa-13c2-4b61-b91f-cb66794507c6"}, "150b7a09-cfe6-49db-88bb-21d8a41ba45a": {"doc_hash": "9c268f132bb4edfad4958ea1d4cfc137c46f9acc357d11977420d6d5f5a37503", "ref_doc_id": "74a005aa-13c2-4b61-b91f-cb66794507c6"}, "fceda422-ad25-44cb-a0e1-1bd9574f57c2": {"doc_hash": "ed174e695213d3695cd0260f57c02e74b7283b64d05b47f49ee8cba71e8d83a3", "ref_doc_id": "74a005aa-13c2-4b61-b91f-cb66794507c6"}, "fd435bae-8805-4a51-8a3d-5bac7b59bb36": {"doc_hash": "31b034e9b9aff9a7c3d03b5c3e1989e231321f75de2441e95fc35bfc7937518c", "ref_doc_id": "74a005aa-13c2-4b61-b91f-cb66794507c6"}, "9a4c662d-70a8-4a74-8004-abd375696f3d": {"doc_hash": "7cfbf2be9514f19d09ce57c3f056ba3b99cb34c5e6bfc96b2a9ee3261da25076", "ref_doc_id": "74a005aa-13c2-4b61-b91f-cb66794507c6"}, "b07a9a92-6d07-4d54-9af8-b566d43c04e9": {"doc_hash": "32abee5e39f750e2b6b902e26a45183fe9d1086763927568faba178f8fa01f91", "ref_doc_id": "74a005aa-13c2-4b61-b91f-cb66794507c6"}, "cd3132de-f420-415e-9eb6-5d1f90858d55": {"doc_hash": "0c5f334e8d975de7dfa76bb51615f23b2a89e95fa7f7796015aba8867e59f029", "ref_doc_id": "900b71f9-2b71-4a5a-8a64-9f2cd416280f"}, "b52a0b30-431c-4e4b-bea1-72d05389730f": {"doc_hash": "b74087741b3051efe8c9c0f2eb8111876ad84ec1ea8314bd733c7b838322845f", "ref_doc_id": "900b71f9-2b71-4a5a-8a64-9f2cd416280f"}, "4297ebdd-81e9-4a34-b0f7-356d3db7cf88": {"doc_hash": "55c6b550fab6fd475688d7c746811607a54b94aed6575e798703c558fb099c8c", "ref_doc_id": "47ecf181-4191-4aae-9b54-bb362f13435b"}, "be4a1ec7-bc56-43f1-b531-6c2b13ddd65b": {"doc_hash": "15d5feadcc743f1f1863328082594b85c7ac7870cac8f66a586418dc81ffb15b", "ref_doc_id": "47ecf181-4191-4aae-9b54-bb362f13435b"}, "0370dc29-6276-4578-9d3c-77d35999b3cf": {"doc_hash": "671b50dc4b70c9c9a6553b2bf0f3552148e4f4d6d4d2970ab270738496d74e75", "ref_doc_id": "47ecf181-4191-4aae-9b54-bb362f13435b"}, "eeee86b3-07be-4780-b03f-d68db68a4001": {"doc_hash": "ef603178a72354cbdf635daffb00c9c7b61df8a73d9b842388cd1294e0499476", "ref_doc_id": "47ecf181-4191-4aae-9b54-bb362f13435b"}, "b99353c1-918b-4e60-988a-553d058656b6": {"doc_hash": "34370f9f33638dde9903a873b70d1bf47589778e1969ac7e1066ba0842d82e0b", "ref_doc_id": "55d70abf-7bc2-4c52-a77a-3f390d38d9a5"}, "a47af973-ef33-4a6e-9416-eba14e4e46ef": {"doc_hash": "1124b4301096b592625ebbe6810abcfbc3f0b8574e9d93adf4efa51045ab5a5b", "ref_doc_id": "9785e97e-c48b-4791-bd32-a25b463008af"}, "4cee3074-85fd-43e7-8b9d-f3e8292d6629": {"doc_hash": "aff16f7e35de3fb904095c43cc6c644750b0bc30b5c1df5dfce6a2b4015aab63", "ref_doc_id": "9785e97e-c48b-4791-bd32-a25b463008af"}, "90eafdd0-d4cf-409e-b270-6ca4a53dcd1d": {"doc_hash": "992c9c1584b04c4ecc44b9cfb18cf90a6a9e56933513863fa08a9ed337b222fa", "ref_doc_id": "9785e97e-c48b-4791-bd32-a25b463008af"}, "529ceb12-632b-4b43-9ee8-caddc677a932": {"doc_hash": "51f2e83f5a35511d63163c60677b26fa3780319399cb4a69aa78c43aaf558ac8", "ref_doc_id": "9785e97e-c48b-4791-bd32-a25b463008af"}, "8bcbfe9a-5c0f-42a3-ace5-a66d8d8b31fe": {"doc_hash": "c8f9033a44f20c177c699a5ff8c032d538f77c70a68a1a38738edf239b6ea7f7", "ref_doc_id": "098da69f-b690-4ed8-8161-c74e17402e46"}, "1c776028-7dd6-4b00-87c0-4ef41edf3bfa": {"doc_hash": "e2a736e6d5941e0a22fffb15af8f7440d246c7fd7f8c2822ffc26333f9cace40", "ref_doc_id": "098da69f-b690-4ed8-8161-c74e17402e46"}, "6a2cca4c-4d9a-4e19-a2c1-3ddac456ad55": {"doc_hash": "c0336b9f2b589dbd096ae4fd6c24597d8fef1acdc70bc096bc5a5cdc24460bd5", "ref_doc_id": "9ca2098f-d703-48bf-aaf4-056d3a914929"}, "0660e4f9-0bc2-46eb-bd18-c9ed8939a477": {"doc_hash": "96291ab2f3b56a4f84cfb650e886e9ad26f47df533ad4c029376d0b8549cd16b", "ref_doc_id": "9ca2098f-d703-48bf-aaf4-056d3a914929"}, "12cf498e-a392-4a89-a9cf-f193bd09439b": {"doc_hash": "629808ebbad2fefd47cb4977d991d004e8188205a497a071e5ef3d7452c74acb", "ref_doc_id": "9ca2098f-d703-48bf-aaf4-056d3a914929"}, "6c50def7-f43b-4dd9-95ea-96466c882d59": {"doc_hash": "2905fcca889c488a379847bb4380a26c08e8299b8f48d14f62d2b61d418d29f6", "ref_doc_id": "9ca2098f-d703-48bf-aaf4-056d3a914929"}, "e1560151-fc00-46e8-b967-4756bbdebd44": {"doc_hash": "34a346f89fa2efb634a98acbda5bfc2d2f6b34c08008c9da40e1a3d2bf83584e", "ref_doc_id": "9ca2098f-d703-48bf-aaf4-056d3a914929"}, "6590dd88-2631-443a-b00e-eb2c95f0e522": {"doc_hash": "152b4c0420420aa32935bac0baa113077a1b301e2a59e715ddc711b5ff6b3406", "ref_doc_id": "9ca2098f-d703-48bf-aaf4-056d3a914929"}, "8ff78fe4-9b70-4405-a1bc-e87aad6e9559": {"doc_hash": "4d42328e4185051888d8e2193c3c7d07d799b990e8e4070325bafb2e34cbb0f0", "ref_doc_id": "9ca2098f-d703-48bf-aaf4-056d3a914929"}, "c60198a0-42db-4b15-bc58-f61fad7aabbc": {"doc_hash": "aaf92f210079977b96be58702c6737db626e4c2f3f2a2662c6d064aec57f48ba", "ref_doc_id": "f8f15bb5-391f-4efd-bf98-ba9769c0c274"}, "3b4f5756-11a9-4d10-9c4c-56cada2502fa": {"doc_hash": "21ae3519cdf8388962ce68873cd84cf50de1cb515d7d71b1cfa799b0c66bcd65", "ref_doc_id": "03c39f7a-d6b2-42a0-86c6-b60a33129345"}, "de15a7c2-12c5-4e6c-8ea7-9526ecf30309": {"doc_hash": "21102fd36f6de8eb4ee209867fd3b69581cb13fea87b3fc05ca81eaf7eab9236", "ref_doc_id": "03c39f7a-d6b2-42a0-86c6-b60a33129345"}, "a637f339-4214-46b0-8c6d-d67fcc3408d1": {"doc_hash": "57e2ac4dce9dee66bcf84ee127efd116c212ac76965ad91f1fdaa77a49030601", "ref_doc_id": "03c39f7a-d6b2-42a0-86c6-b60a33129345"}, "01390958-41be-403b-9794-c956a19e5be3": {"doc_hash": "50064476237dbcc22794963e23efe08d87305927a836c825bc2a755f802cc36a", "ref_doc_id": "03c39f7a-d6b2-42a0-86c6-b60a33129345"}, "63a67739-a037-4018-a397-fd761133090d": {"doc_hash": "3487784cbf2a9954dc0068bafff29287e021d76d0d9e3615f7fb968f91a6ac45", "ref_doc_id": "13556533-f636-4043-b74e-d5777dc1f94c"}, "509d48a6-c5d0-49d0-a1fd-00dbf3e83d05": {"doc_hash": "f73278f8525748ce66334f09da91a29af2be985782e1fc0aab87271c951a75af", "ref_doc_id": "13556533-f636-4043-b74e-d5777dc1f94c"}, "9e08675f-319f-48f5-a2ab-72f93a678932": {"doc_hash": "d657403454550335a9e47af5141619db33e876da7e8842c857f7021ff41fc935", "ref_doc_id": "13556533-f636-4043-b74e-d5777dc1f94c"}, "5313847b-c593-4b09-bb95-8f35a43ed723": {"doc_hash": "c0e17a66c17068d68a146848e7dd7c62e81613b4e99f0ba4ebd9f11facd3c7e6", "ref_doc_id": "12de44de-010b-4dbb-ba8c-5cd0a66639dc"}, "06a6913f-00e1-468b-bea4-bb182b05cb0d": {"doc_hash": "308358db28701b395602f0991a9efb8ea851977d24fa88896551b53ad8764d60", "ref_doc_id": "12de44de-010b-4dbb-ba8c-5cd0a66639dc"}, "1cb414e1-de55-4b4b-bc0b-8759a5e5cd97": {"doc_hash": "087a0719f236827e66807825e0ac45ee1c1c4a1082ab5e790dc070433776f9ab", "ref_doc_id": "12de44de-010b-4dbb-ba8c-5cd0a66639dc"}, "aa23464f-beff-487b-95ff-f8db5c4bf148": {"doc_hash": "54b6e4e753b0cfb16287e3a0ace6d1059809fe7bd10837585f9e678a2934f31c", "ref_doc_id": "12de44de-010b-4dbb-ba8c-5cd0a66639dc"}, "c7ab1842-3884-4321-9614-005d00308a71": {"doc_hash": "16f617f060e2fa8bd0024b055496525862cb74052d843c3767fd43381ff4cf5c", "ref_doc_id": "12de44de-010b-4dbb-ba8c-5cd0a66639dc"}, "4915a2f6-0c42-4e19-a9e4-1c4126df4895": {"doc_hash": "58a74c1d847d63f91259a73936c02b501552410fb8eca79c01bf5268edb5fafb", "ref_doc_id": "eab89660-9e2b-49b6-b6a5-0548492eca3c"}, "31763b9d-6d88-45cb-bb5c-c7158daa935d": {"doc_hash": "8e152456e685017d3d962a1916551916c8ec77d0b98ed3668c4e7832324d9f09", "ref_doc_id": "eab89660-9e2b-49b6-b6a5-0548492eca3c"}, "9ba4a894-e49e-4a53-9b0a-f5a77dc05bb1": {"doc_hash": "e6c49e4bea8f3b0ae82d51f7344025db5d7711caff398aadcfe9dabdea240f64", "ref_doc_id": "eab89660-9e2b-49b6-b6a5-0548492eca3c"}, "63d05847-6bc7-4c4f-af6f-f087465b562c": {"doc_hash": "b8e96c83a5e3e31cbb5b802a65f4eb4ce2e4c9703a931f845f3318ba3d40f779", "ref_doc_id": "eab89660-9e2b-49b6-b6a5-0548492eca3c"}, "00290e2a-a120-4263-9fe1-95f63004c029": {"doc_hash": "b09835eb648706042b9d0679fb3adabaf48a2527708721ff796794b818a12d93", "ref_doc_id": "9f8f0848-5179-4290-915a-2ce8e88fd05b"}, "bc8008ac-d6fb-40d3-a972-f0f5d4ab4fe8": {"doc_hash": "a380987a567119c735955873a54544323e463b61b6dd92592735f6bb6a19ad27", "ref_doc_id": "9f8f0848-5179-4290-915a-2ce8e88fd05b"}, "efd7088c-e46d-4c1a-ba7e-25543b139e6b": {"doc_hash": "f3bd4d2aa5e423fdf470d17e564cff1e6893b1780f5e91bb0b655ed828ac2a35", "ref_doc_id": "9f8f0848-5179-4290-915a-2ce8e88fd05b"}, "87539361-2953-426c-9dc7-d6f9578af2d2": {"doc_hash": "b7efc34daa3be4a71242519087241532adbeb5e4d92fa023ee7962cfaa2d86b3", "ref_doc_id": "9f8f0848-5179-4290-915a-2ce8e88fd05b"}, "093bc0cc-2f1c-40ae-99f9-0636341e056c": {"doc_hash": "543ef9405ad9d4b20c4a76c955d3fc437d66d3baefc885f8bde0faae8c46b4b2", "ref_doc_id": "edcb9b2b-c10b-4f75-af3b-b6097c3b653a"}, "c6a0f1e7-008b-4910-b0bf-cddd6e50b1d2": {"doc_hash": "ed36e3fff8e0c373154f860c638e487eb3d00028fe8b963820dd3f90c5332d50", "ref_doc_id": "edcb9b2b-c10b-4f75-af3b-b6097c3b653a"}, "c16099db-7bac-4548-afa6-84e9d056b986": {"doc_hash": "f850625145d4bdac1d11d31609d5b597a1e639225ca94cd1bd30bd096500ab01", "ref_doc_id": "edcb9b2b-c10b-4f75-af3b-b6097c3b653a"}, "d2dddc55-c19b-424e-b40e-744d0ff98bbc": {"doc_hash": "fe2af242c6c090f2e70e03a39b11f370a8efeec2ef39ce8e56e244b626c0a81b", "ref_doc_id": "7e2e8e0c-431c-4289-b30a-2df493dc98b7"}, "19b9762f-84d2-45a9-b9fd-bbfc144df112": {"doc_hash": "bd91a1ff8ac830ec58dea0f185524d02a8bc21884943f73012b35c80bf7d8b30", "ref_doc_id": "7e2e8e0c-431c-4289-b30a-2df493dc98b7"}, "512c2c9b-6956-43bf-abf7-13f78971b843": {"doc_hash": "ee1b7f05da532a258d69c61d1846cd4ec9a3894f70fc39770b96d9838c142597", "ref_doc_id": "b7f3c838-ea4a-4758-8a6e-83ef3ac74947"}, "081a6624-c870-4e51-a2d3-ff7a8089a4c0": {"doc_hash": "62c22d017ac4fdc690254a239a8ff47ba38bde98dd5ff19e3c69a7aba85c1aff", "ref_doc_id": "33c63d93-9b01-43c3-9fc2-750e06a8cd22"}, "6b8b5f4c-a6ce-44fc-a5b1-55d4d9d84a25": {"doc_hash": "017b7fc6d5326bab3694efcfe49d5b6ab34f0476fba6a3436f0a9be8be7fc4fe", "ref_doc_id": "33c63d93-9b01-43c3-9fc2-750e06a8cd22"}, "72d4c6ed-6de5-4018-9f69-928914e7ce5c": {"doc_hash": "7af6efb7cd0f71263fae0e22572f5376c6378313cd9616e97fe2d1ea0b6b7951", "ref_doc_id": "33c63d93-9b01-43c3-9fc2-750e06a8cd22"}, "5d299aec-446f-412f-8010-4f3fbc3ae56a": {"doc_hash": "a95591f82828601e88d6675aad5ed1c4cc25ca553b53ecdcbcbfd19f80cedc57", "ref_doc_id": "33c63d93-9b01-43c3-9fc2-750e06a8cd22"}, "280c0370-118c-4aeb-ad3d-933b36c88449": {"doc_hash": "adcb37c2a879db62d238ae9751d305d69be008bbcf914461283f1c3760de7065", "ref_doc_id": "577e95e3-3be8-440d-a07a-76a197f7dc46"}, "a97359e8-4d14-44a8-af3b-f031a0e70269": {"doc_hash": "d0c91a5b2f3804f1ae9f958be6817b0c974ee2e878eebe1569d784abf13f4a96", "ref_doc_id": "577e95e3-3be8-440d-a07a-76a197f7dc46"}, "a56f2b0e-568b-458b-84a3-8721977473ba": {"doc_hash": "28e74ef3a970850075ab0994b2900dea17771b6915b46b3f5b9296aa2f9b9e50", "ref_doc_id": "577e95e3-3be8-440d-a07a-76a197f7dc46"}, "85b6e3c3-db0a-4e97-85e4-e4b52f9b54e0": {"doc_hash": "690960f8a045246b08a9f886ee9fe0637acba2a2ed56461a63d19ccb96999775", "ref_doc_id": "577e95e3-3be8-440d-a07a-76a197f7dc46"}, "45782755-5f85-4625-9f3c-62c437d771f6": {"doc_hash": "818316226a32f97f798ac6b6201a6cf57b66b028b30a2f32a03d6cb3682c0be1", "ref_doc_id": "577e95e3-3be8-440d-a07a-76a197f7dc46"}, "bc8b899d-5500-4738-91b7-ca996189f9f9": {"doc_hash": "b710f7425ac56798fd0cedfbb249b2e9bf54f4d982d23ce137ca9744cc7b3e43", "ref_doc_id": "577e95e3-3be8-440d-a07a-76a197f7dc46"}, "e63a11d3-2f7f-400b-9f2a-bac120294f77": {"doc_hash": "60adf47802a570833c67cc2b12197df5a4800ec6792fb1117b10e85a90e5fe96", "ref_doc_id": "577e95e3-3be8-440d-a07a-76a197f7dc46"}, "2e046d66-e957-4a15-8d6b-b44141f79aa1": {"doc_hash": "ae316b29a658880574814e2755d5ae41ab0b09cd12b16afc6a7653984b855ace", "ref_doc_id": "577e95e3-3be8-440d-a07a-76a197f7dc46"}, "486479f3-266c-4b4c-a597-50827ef8df24": {"doc_hash": "8ba6adb4f1ead77132bd9d49325b23b7fbe0df28fe1ddf5200dacd7dc61da6e1", "ref_doc_id": "577e95e3-3be8-440d-a07a-76a197f7dc46"}, "17483c1b-2f00-45e7-b6ef-3b21d7719345": {"doc_hash": "3f25463426ec0f7f827126d727693320560097f83565badfa863c95e3c09a075", "ref_doc_id": "577e95e3-3be8-440d-a07a-76a197f7dc46"}, "3a537d0f-b1dc-4ebf-9caa-ea6e1da43621": {"doc_hash": "bf7dc5afaf0ab7e5c0fcfbeeafb58366a1876d3a24fdb100501358e51d51431c", "ref_doc_id": "577e95e3-3be8-440d-a07a-76a197f7dc46"}, "30855a9d-a778-4906-b0fd-899107dc395b": {"doc_hash": "ca5ae6b0bbe914a9ee039058d3b4502f92affe094b88981fba0876da1a2802c4", "ref_doc_id": "577e95e3-3be8-440d-a07a-76a197f7dc46"}, "41c9d689-02e7-48d1-9e76-ef355524b839": {"doc_hash": "48c65ddb224c5ad1a2232d43ab6c1416659e207045a89d5375f77f2b66c4cb36", "ref_doc_id": "577e95e3-3be8-440d-a07a-76a197f7dc46"}, "7dfe1b24-be78-41e6-8095-ef5f22a38ed5": {"doc_hash": "870feffb37c8dac7e106e43b5724ce3b1b0d368ca9414bfd890bff385b54158c", "ref_doc_id": "577e95e3-3be8-440d-a07a-76a197f7dc46"}, "cbc7f4e0-ecb8-4269-a428-a6c26aeb7ef3": {"doc_hash": "ac5f1598e2a4b84f8d91a7d756c2291b8f82034a1a68ccaa073cbb1af3a1eff7", "ref_doc_id": "577e95e3-3be8-440d-a07a-76a197f7dc46"}, "d23080df-e17b-4048-a273-68a4da838b02": {"doc_hash": "5a8c246f63b18127f42b3042dec57b534b92b527a9d711bdfa7a167d133dfc9e", "ref_doc_id": "577e95e3-3be8-440d-a07a-76a197f7dc46"}, "9cbc5f78-bc73-4f6f-8544-03c21b1d05c7": {"doc_hash": "fdd6817bcaf61740e7c1bfc4db295696b6c520013c971375beec6871e59d015a", "ref_doc_id": "577e95e3-3be8-440d-a07a-76a197f7dc46"}, "36a00b13-e8b9-417b-9cb0-ea04653cb2df": {"doc_hash": "3711173f2610dd6e90a1591c0b3fe06546f59a72232deb55ef30aae3787fdfbd", "ref_doc_id": "577e95e3-3be8-440d-a07a-76a197f7dc46"}, "7a54b6b6-6ab4-403b-a336-c44b0136be4d": {"doc_hash": "c2488a989619efd2b2eb952d5feb1dbce8ee68eb58c0e6aab41cc5398dfb3c10", "ref_doc_id": "577e95e3-3be8-440d-a07a-76a197f7dc46"}, "be9b4b96-464f-46e0-b18c-70cc547e4f95": {"doc_hash": "6b96993c4687482cdbe828acad73b4762761c66f52dd69c77614aafcd7f1c8a3", "ref_doc_id": "577e95e3-3be8-440d-a07a-76a197f7dc46"}, "8b19d01b-ba69-4c67-bad3-2af44b90b466": {"doc_hash": "f502185da269735f40edbabd881a6bfde9dfb3d793b7ff7c31932f3c037b96fe", "ref_doc_id": "577e95e3-3be8-440d-a07a-76a197f7dc46"}, "71b64171-42c0-4980-b307-64d08eb87ab8": {"doc_hash": "ac5500720fdbc4cea0f0c4f4a524a1409f2f999fc6f33f9d0ea000e110e29c3b", "ref_doc_id": "577e95e3-3be8-440d-a07a-76a197f7dc46"}, "16ec3b65-a79b-4ae7-90eb-2d39624eb0cc": {"doc_hash": "10c73cec6d006b234082a86a97d21a7a576f24882c7f1104a1de2799833cb618", "ref_doc_id": "b6ce48e9-6291-4029-92f1-4d8ffacab73d"}, "7bab9e85-82de-4fd7-92c7-e0f400e1e0a6": {"doc_hash": "969ecdbb7650fdd91c14f3cf8ecee06fef6009b580e9d7aabffa5fd6478160a8", "ref_doc_id": "b6ce48e9-6291-4029-92f1-4d8ffacab73d"}, "ee03e2be-e51c-4c49-92bc-e2bf21431daf": {"doc_hash": "06d38833dc6586aead099e2a6888515ce69441c309a24b1715d9e96367a8cbb5", "ref_doc_id": "b6ce48e9-6291-4029-92f1-4d8ffacab73d"}, "458f655b-c0d0-4231-93ff-dde3f058eb1c": {"doc_hash": "f41c00884c7b155004c65653ff40630ab8fecc6c2aa6518ea127178565fb32c2", "ref_doc_id": "b6ce48e9-6291-4029-92f1-4d8ffacab73d"}, "71b02232-d5cc-4aee-a942-28c892c46502": {"doc_hash": "bac2195026208c0e81aa768de63f2bd82e3b66801b56881b11048ca0ec66fd61", "ref_doc_id": "b6ce48e9-6291-4029-92f1-4d8ffacab73d"}, "27c84ada-3a05-48fe-bb07-6840f73e746f": {"doc_hash": "1c1eb9bea153d4cb226600d8a9284bc09dc081547baac6ab9d5ac833ddebbb60", "ref_doc_id": "b6ce48e9-6291-4029-92f1-4d8ffacab73d"}, "125c1d80-8fa5-46f6-b252-82fb300d9581": {"doc_hash": "b1ba4e73c327bc59c8553b832b8ac4a4ef4c3f109d61d688b9a28605b25ca9f2", "ref_doc_id": "b6ce48e9-6291-4029-92f1-4d8ffacab73d"}, "eb0ea4a1-1c90-448c-b46b-2695bda5b028": {"doc_hash": "43662c5dcbfd4702ba1e4354200857206f6ee067fd4bab5def2fe546ce494b1e", "ref_doc_id": "b6ce48e9-6291-4029-92f1-4d8ffacab73d"}, "5e70f10b-99c9-4a62-9b2e-83bb8c391a86": {"doc_hash": "27a6cac0387cf14aedad79c2b88578cfe9f6fe8877a173f42074c913a2e2e290", "ref_doc_id": "b6ce48e9-6291-4029-92f1-4d8ffacab73d"}, "41bb9c0d-9d28-44c5-a6c2-ee2e9d4466cd": {"doc_hash": "6a9a9ebfec5bde8622b2e3dddb0a361fce9ec5c6b949e54a8b52149de61e748e", "ref_doc_id": "b6ce48e9-6291-4029-92f1-4d8ffacab73d"}, "9ae155f6-73f4-4fca-a1bc-54db5ec793ae": {"doc_hash": "dc9bd9f2945d86dd4c5a4b18cffcab947eb3e759d3bc665e66ad84e4d1b03e10", "ref_doc_id": "b6ce48e9-6291-4029-92f1-4d8ffacab73d"}, "b56344fe-0076-4d30-af1c-a654dccc3690": {"doc_hash": "14608ba6c9df650af97a3f6f208c93424242db4c827c8b0df4bc281d080e3a80", "ref_doc_id": "b6ce48e9-6291-4029-92f1-4d8ffacab73d"}, "ef66c963-4862-4885-90af-49cd3f181809": {"doc_hash": "74062b7cde9d50b1227139633255d0fb30d0a08993732a195c7eab4fd09f0147", "ref_doc_id": "b6ce48e9-6291-4029-92f1-4d8ffacab73d"}, "9e95f243-3d53-41bf-8532-5b7d6848c2d7": {"doc_hash": "898611ab6df7e8980d185b748b09b06671a3bac585c49be54a96953d664c687c", "ref_doc_id": "b6ce48e9-6291-4029-92f1-4d8ffacab73d"}, "c148761a-5b9a-4623-8e9d-4688ad6a2b84": {"doc_hash": "4685944d45b696dfff60cdd275e5546f10cc44b1c1934c316b77f19050c39587", "ref_doc_id": "b6ce48e9-6291-4029-92f1-4d8ffacab73d"}, "e6340bbc-27ab-4211-8bd2-6a7145d5af99": {"doc_hash": "71686f3b489bbc2b639e87f5b95735c496d0c92fc9f0d92652f68c014490c55d", "ref_doc_id": "b6ce48e9-6291-4029-92f1-4d8ffacab73d"}, "504caf1e-ffe7-468c-aa7f-9ddb1d4af397": {"doc_hash": "1ffcceb86a3e5d93b9bf12af40ec5510e95223ce14a15da142e9567333dd15ab", "ref_doc_id": "b6ce48e9-6291-4029-92f1-4d8ffacab73d"}, "e14f3436-eb07-4f72-8feb-7aafb66fdb04": {"doc_hash": "18852fc289e2a541e1d806e12e81d8e2b2bb5b40acdb40b9a48bb6b4078af1c4", "ref_doc_id": "b6ce48e9-6291-4029-92f1-4d8ffacab73d"}, "d77f5401-00df-4ca7-87c4-7e44404488b6": {"doc_hash": "33f59a9e43e6fad1082b2602e9e8a1d0d34c205a9171781d240ca327c2801eb2", "ref_doc_id": "b6ce48e9-6291-4029-92f1-4d8ffacab73d"}, "f02c7f7b-37f8-460c-bcc5-84ce8c81f486": {"doc_hash": "d9af68360ef1f6f7340f7440f17a105ba99f7696a94f719aeb7f27e598c467a6", "ref_doc_id": "b6ce48e9-6291-4029-92f1-4d8ffacab73d"}, "aa602770-38b0-494d-969f-dbd7312a2671": {"doc_hash": "c7af4a74009127141160d3a31987cf41a4d119c4b95b21f00e1a16205b65a285", "ref_doc_id": "b6ce48e9-6291-4029-92f1-4d8ffacab73d"}, "ec136266-5f1f-4dbe-a156-39b40eb370f7": {"doc_hash": "aec163d72282ffb5a7375b663e6486cea09508e680b7d051e2818033e4349768", "ref_doc_id": "b6ce48e9-6291-4029-92f1-4d8ffacab73d"}, "897d7bdd-d77d-4611-8467-c8639437d5dc": {"doc_hash": "59e6ad9e68201b8781310368b989a1a3f19777f29d81fa593e93d069767e5eee", "ref_doc_id": "b6ce48e9-6291-4029-92f1-4d8ffacab73d"}, "94330c16-fdcb-48b6-aa28-c46b9cdd2e5c": {"doc_hash": "f31449ad92eddb03032c1f262ef7d4226f1168e9422b61885e9af11ff783a4d0", "ref_doc_id": "b6ce48e9-6291-4029-92f1-4d8ffacab73d"}, "08e62781-d6e8-45fa-a58d-c8dfa11f81f8": {"doc_hash": "5a79ee04b82a61d193d77ab2e93f6927d5e35221f05030353c287652d2e03d7f", "ref_doc_id": "c37dba28-e111-4586-9210-488c4a7cda52"}, "eb6b779e-96d3-41dc-85fa-0ba472d42497": {"doc_hash": "f6a246246e9d9fc74dc1a59fa5ca6f71e1eb9bdbe09abc7383fbf3bee63bb175", "ref_doc_id": "c37dba28-e111-4586-9210-488c4a7cda52"}, "f3ded855-013d-49f4-9837-9d213fcb0ea5": {"doc_hash": "4caeedb40a394c62fe64a47e81ea7e8fee43caa1e9eaad67a615ccc2a2219ee7", "ref_doc_id": "c37dba28-e111-4586-9210-488c4a7cda52"}, "c8f42f9b-eef8-4258-8725-2d5cd66688b7": {"doc_hash": "687e77f45cfd70fa68dbc42d84cb4d32ca858c4b01217738017f9486bfe96278", "ref_doc_id": "c37dba28-e111-4586-9210-488c4a7cda52"}, "922ebad1-3d5a-4dbc-a2b7-46e29aef8de4": {"doc_hash": "146757e286b9b909a2daba4e7dd6540787df2bb0e241a95e2f06b6cf11dd1135", "ref_doc_id": "c37dba28-e111-4586-9210-488c4a7cda52"}, "c93f9df6-c4b2-4dde-97db-52264c50645c": {"doc_hash": "e9195e3a093a6171abe437957325e4509bc944f59d11866b979fd517e40b0445", "ref_doc_id": "c37dba28-e111-4586-9210-488c4a7cda52"}, "cfb39a9c-0d19-4d03-8c82-60c0c093911a": {"doc_hash": "8daa5d908312cb6666c435300a6e0fe8e1f08ddf9432313f048388e3313fa606", "ref_doc_id": "c37dba28-e111-4586-9210-488c4a7cda52"}, "0aa8a436-e3a9-4829-893e-23d7b4f541a3": {"doc_hash": "06228690bee6a8509813107d3dc7e647a11e06932e854690359caeca4e60bb7f", "ref_doc_id": "c37dba28-e111-4586-9210-488c4a7cda52"}, "3066a540-dcf1-4894-881c-77189419b393": {"doc_hash": "06c84f622219efa780b145682ef278b3644dfea3789463b0876969b4195bba3b", "ref_doc_id": "c37dba28-e111-4586-9210-488c4a7cda52"}, "371ebb77-1a11-40f7-a1f1-399c9eb61997": {"doc_hash": "6c0a41c0856871c7e3e2bed3ee8b6a3e7378840e1fde7e0f92b79cd97d8d1a89", "ref_doc_id": "c37dba28-e111-4586-9210-488c4a7cda52"}, "d5bedafa-8c0a-4811-9110-7c731478ae16": {"doc_hash": "87ad9a50dab1f6463e8203199403bd9fe738ee89aa3af4f9a2802b6e71e9c033", "ref_doc_id": "c37dba28-e111-4586-9210-488c4a7cda52"}}, "docstore/ref_doc_info": {"751beaeb-087d-4f58-8f44-70cbbdf28794": {"node_ids": ["a4454e1f-4542-4e09-a1ce-f78891dd1e8c", "ac252ed7-1453-48e0-b1be-22da698c291f", "c466d288-3978-47d6-99b3-d5491119dbca", "3ae576b1-521b-4910-b1dd-ac8e054cafc6", "cc798f13-adad-45d5-a189-950b8a842339", "4942cea5-8069-40be-bad5-0d2307d62baa", "6b4ecd28-20b9-4081-ad83-8812f65cfd81", "45925fee-f88d-4ba3-98ea-f67646da83db", "7bc3b277-cc63-4abd-a97b-23ce6f9c2744", "4c2cde99-63ae-4a6a-9e5b-235f1a62beff", "4f8703b0-ed0a-477e-b757-2d56115db514", "b501d36d-525b-4697-ba72-5e3ea3095340", "0bd4223d-52e3-4c0d-9c81-c8d017fc56a6"], "metadata": {"window": "Cencora R epor ts Fiscal 2023 Four th Quar ter and Y ear End R esults\n11/2/2023\nRevenue of $68.9 Billion for the Fourth Quarter, a 12.7 Percent Year-Over-Year Increase\nFourth Quarter GAAP Diluted EPS of $1.72 and Adjusted Diluted EPS of $2.86\nRevenue of $262.2 Billion for Fiscal Year 2023, a 9.9 Percent Year-Over-Year Increase\nFiscal Year 2023 GAAP Diluted EPS of $8.53 and Adjusted Diluted EPS of $11.99\nCONSHOHOCKEN, P a.--(BUSINESS WIRE)-- Cencora, Inc.  (NYSE: C OR), formerly AmerisourceBergen Corporation, today reported that\nin its fiscal year 2023 fourth quarter ended September 30, 2023, revenue increased 12.7 percent to $68.9 billion.  R evenue increased\n9.9 percent to $262.2 billion for the fiscal year.  On the basis of U.S. ", "original_text": "Cencora R epor ts Fiscal 2023 Four th Quar ter and Y ear End R esults\n11/2/2023\nRevenue of $68.9 Billion for the Fourth Quarter, a 12.7 Percent Year-Over-Year Increase\nFourth Quarter GAAP Diluted EPS of $1.72 and Adjusted Diluted EPS of $2.86\nRevenue of $262.2 Billion for Fiscal Year 2023, a 9.9 Percent Year-Over-Year Increase\nFiscal Year 2023 GAAP Diluted EPS of $8.53 and Adjusted Diluted EPS of $11.99\nCONSHOHOCKEN, P a.--(BUSINESS WIRE)-- Cencora, Inc. ", "page_label": "1", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "8d68cffe-a6e2-4827-9f5b-bc33a23ae109": {"node_ids": ["1480aff5-c5c0-4511-8879-fd795907f0a9", "dc4ef9c5-d141-4ae0-b5cf-a94ee37d76c0", "9d821aef-9c5c-4c75-ab18-5054e605106d", "8c44791a-2860-406f-a04c-bee689fc5f90", "013a3f5e-7c5a-41ae-ade5-09699ec5f0db", "1705c2b2-fc15-4cc9-8eac-79d82cab8bbb", "1aa202f4-72d5-4766-8e30-cd400fd352b2", "64e46371-4dc8-47ff-984e-f495fb7b5161", "37dceed8-1267-4e8d-ba64-c0a9415b0905", "54fbee63-c89e-4186-b826-7da5fa8bb4cb", "ded1d99d-2cac-4640-b5e1-2b69c9734f9e", "800b856d-6f65-4af6-9281-83c63781d15d", "d4ebb983-95d2-4cc3-8eeb-d81ec217e66d", "459a00ea-eb96-45ab-85e4-7dd1bd7523f0", "38d550a3-b8d2-4444-9dba-e56a1c8fbcec", "d455cd11-d663-48ae-b44d-19048a5ebb5f", "62610197-df01-41b8-9ab8-44594b47421c", "efb3776d-dbfa-4152-b65b-f04e1e560f83", "d4eb03b6-ef81-4590-bacc-943307f4aab0", "d258aaca-bc2d-42f2-a50d-8034aac78a11", "3e043939-87a8-458f-bedb-7bab7562332c", "f2941e01-d3e5-440e-a914-8562aa337169"], "metadata": {"window": "Net Income A ttributable t o Cencora $351M $581M\nDilut ed Earnings P er Shar e $1.72 $2.86\nDilut ed Shar es Outstanding 203.4M 203.4M\nBelow, Cencora presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly and fiscal year results.\n In the tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental Information\nRegarding Non-GAAP Financial Measures following the tables.\n Four th Quar ter GAAP R esults\nRevenue:  In the fourth quarter of fiscal 2023, revenue was $68.9 billion, up 12.7 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 13.0 percent increase in revenue within U.S. ", "original_text": "Net Income A ttributable t o Cencora $351M $581M\nDilut ed Earnings P er Shar e $1.72 $2.86\nDilut ed Shar es Outstanding 203.4M 203.4M\nBelow, Cencora presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly and fiscal year results.\n", "page_label": "2", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "20e3d800-bd50-438f-b446-f823062e13e0": {"node_ids": ["01e1be5f-63be-45b5-9902-2e599ac705d9", "89c6a0e3-e830-40a4-b525-e51d25eb8e15", "9e89b35a-0ed1-4f98-b157-5747a429d6cb", "9aaf4b69-e82f-4639-afe5-0601a348e3a7", "4b7ddded-d19c-4b76-9683-80a2e92db665", "13057d64-5674-4122-adc4-48eae99844d7", "38ddf0b6-f99d-4c83-afa0-1e4a43cc51e8", "efe0d55c-07c7-4acc-916d-68a3889bc549", "1a04af32-691a-44cd-b80e-78fb931ce9d6", "b9c901e0-fe44-4f9a-9c86-4e9995246faf", "cf3e3334-ba76-4b6e-9276-ae04cb3b75b3", "aee4e122-d26c-4c09-963a-583e370ec4b8", "81b20521-ac95-4d2a-a3e4-d3a983427b1a", "e1d6b9ca-e518-4470-961c-d0fc19bf6cfe", "49787032-84c4-413a-abb6-69ee678443c5", "c9ee42c3-8b51-4d74-9ee6-1a59965a71b1", "4eff1dfd-092c-4f1f-bb66-2378a922e541", "18a39604-f37f-4f9e-a250-97c6fd2c2b1e", "f9f2b925-03ec-48ad-a9f3-c0636dbd699f", "ace5e9f1-6b37-4720-8ea0-dc8440664239", "b7c25434-60bc-4fd0-aaaf-72ff812ececf", "99ceaa20-7247-4386-8dd0-105da8c3ad3f", "7c9c234f-7b20-4bb2-ade4-469fdf5114c2", "0f14efc8-b446-44ee-ac88-8f94fa11ff8f", "6686a994-3d07-4d5c-b05f-b9e13d4caca0", "41ee8191-516e-4405-ab00-ac4684af0e4a", "2075c00a-57ee-4c6f-ab83-227868e02c10"], "metadata": {"window": "compared to the prior year quarter.  The decrease was due to the decline of U.S.  Healthcare Solutions' gross profit margin as a\nresult of increased sales of products labeled for diabetes and/or weight loss in the GLP-1 class, which have lower gross profit\nmargins, and lower sales of government-owned C OVID-19 treatments, which have higher gross profit margins.\n Adjusted Operating Expenses:  In the fourth quarter of fiscal 2023, adjusted operating expenses were $1.5 billion, an increase\nof 10.2 percent compared to the same period in the previous fiscal year primarily due to an increase in distribution, selling,\nand administrative expenses compared to the prior year quarter. ", "original_text": "compared to the prior year quarter. ", "page_label": "3", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "8e5f2760-457b-40e5-a61e-1e4e45be6670": {"node_ids": ["dc7e8a9d-e742-4625-9453-8624a32c1c4c", "f6acad40-6d7e-400a-9e06-a4f37be68469", "9e30dfe7-40bf-4712-a46c-914d67d7c02f", "1b0ec505-c5f4-4552-b971-2f03fec949f7", "a04bcd75-74d2-47df-8a16-ce31e74c6ae2", "c8319ec6-016e-4491-bf1c-3cf1e4768fc9", "aa8c2c8c-269a-4459-ab0d-f5c5db8f2c49", "394f2a48-85d2-45e6-a05a-ea3a59d66657", "45745af8-b062-45a6-bc77-cf9a4a846fbc", "379d0b65-26fe-4570-a4c1-bfd84462d224", "56a348c4-3e00-480a-b890-dd04a4a8dd24", "5106d744-fed0-4cc2-91a0-bf7d7470f8ed", "9899eb1c-28ed-413f-a253-390b677c3f37", "9123c6e0-22af-44f5-8ddc-ccf3dd25ef28"], "metadata": {"window": "Fiscal Y ear 2023 Summar y Results\n\u00a0 GAAP Adjust ed (non-GAAP)\nRevenue $262.2B $262.2B\nGross Pr ofit $9.0B $9.0B\nOperating Expenses $6.6B $5.7B\nOperating Income $2.3B $3.3B\nInterest Expense, Net $229M $229M\nEffectiv e Tax Rat e 19.8% 20.3%\nNet Income A ttributable t o Cencora $1.7B $2.5B\nDilut ed Earnings P er Shar e $8.53 $11.99\nDilut ed Shar es Outstanding 204.6M 204.6M\nSummary Fiscal Y ear GAAP R esults\nIn fiscal year 2023, GAAP diluted EPS was $8.53 compared to $8.04 in the prior fiscal year.  R evenue increased 9.9 percent from last\nfiscal year to $262.2 billion.  Gross profit increased 8.0 percent to $9.0 billion due to increases in gross profit in both reportable\nsegments, and an increase in gains from antitrust litigation settlements, partially offset by an increase in LIFO expense in the current\nfiscal year.  Operating expenses increased 11.6 percent primarily due to an increase in distribution, selling, and administrative\nexpenses, amortization expense and restructuring and other expenses, offset in part by a litigation and opioid-related credit in the\ncurrent fiscal year in comparison to an expense in the prior fiscal year and the prior fiscal year included a goodwill impairment.\n", "original_text": "Fiscal Y ear 2023 Summar y Results\n\u00a0 GAAP Adjust ed (non-GAAP)\nRevenue $262.2B $262.2B\nGross Pr ofit $9.0B $9.0B\nOperating Expenses $6.6B $5.7B\nOperating Income $2.3B $3.3B\nInterest Expense, Net $229M $229M\nEffectiv e Tax Rat e 19.8% 20.3%\nNet Income A ttributable t o Cencora $1.7B $2.5B\nDilut ed Earnings P er Shar e $8.53 $11.99\nDilut ed Shar es Outstanding 204.6M 204.6M\nSummary Fiscal Y ear GAAP R esults\nIn fiscal year 2023, GAAP diluted EPS was $8.53 compared to $8.04 in the prior fiscal year. ", "page_label": "4", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "7021eca0-c10a-4441-addb-9b3d939e9002": {"node_ids": ["1aaff62b-c0f3-437e-91de-ac7a34422f60", "5da41669-b80c-4152-93af-2e075e09d67c", "7c92cd3c-0d31-4e81-8289-ddd45669b851", "f0555b4c-b814-4525-adb1-503fe9cea80c", "af8ad45f-afbb-40a7-a712-322dc752edfc", "6d522625-770c-411f-b56d-5a7f64c4cae7", "c7d6bb0f-dc03-4e33-951b-51326bccdbba", "ebabf343-3bed-421e-8343-38a689291029", "593f5a56-e89b-414f-8b0c-c5172d09fe1b", "6d25a7d1-bea9-4282-a236-0a4d93b064fd", "650ec3b3-e222-4d07-ac94-dc21fa6d165e", "ec4747f5-1878-4e7b-9572-08ed0e5af519", "eba75f04-d448-4b48-8f12-e125ed0d45f1", "9d283c3e-80d7-44e0-aa31-cf9611b82b9d", "1963b9ff-0504-4c52-bd6c-3654fd97a237", "0cbfc5b9-5f87-4fe5-a060-ae3c6a3f0f71", "4b46fbd2-318c-4850-b3c7-230296a11fdc"], "metadata": {"window": "York S tock Exchange on August 30, 2023.  The new name underscores Cencora's experience and vision when it comes to\nconnecting manufacturers, providers, pharmacies and patients, and ensuring the consistent, reliable flow of treatments to\nthose who need them at a time of growing complexity.\n Good Neighbor Pharmacy, Cencora's national independent pharmacy network, convened nearly 5,000 independent pharmacy\nowners and other partners to celebrate its annual ThoughtSpot tradeshow and conference.  The event showcased the\nextraordinary collaboration, commitment and perseverance of the Good Neighbor Pharmacy network of pharmacists\ndedicated to improving community health.\n", "original_text": "York S tock Exchange on August 30, 2023. ", "page_label": "5", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "b76ad0b5-6e11-4d6c-9702-c56141c82238": {"node_ids": ["acc51638-1ece-4e8d-b742-4f5c194d2aca", "164516b5-4570-476c-8d01-637990852562", "b43b47de-31b6-4866-bb31-3203346eb62f", "d0ee62d1-f6ff-4cef-9786-a6254177c4c2", "395f431b-e4fa-43cd-9ae1-fee8293c7008", "fc7f59c6-baab-49ec-a06c-ee63ce9002e3", "84979e79-43fc-426e-9dcf-76e7920aaaa2", "5a2d9499-b19f-4303-bd2c-a75dbb757efb", "1a9d4052-997d-4092-a57b-3225a635d218", "67ed5f87-fb0b-4361-8c73-c0dfe3fc9fbc", "55f793dc-d0e9-43b4-a1bc-d69e6a613f59", "40ebe93e-7201-4dd5-9782-f90b1d485e26", "ef91abbc-8c32-4466-b42e-72bb1d637b17", "1e885e91-955e-444c-84d3-73c154db6f53", "080b129c-c6a3-4cb5-9307-91c5081b2547", "b1caa64f-00c4-4c16-a518-0927a9d765fc", "a308398a-e3f6-434f-a38c-c76923306fc8", "c496d03c-77dc-44a6-be06-b51d8098e051", "e3f14a82-a69c-41aa-8901-7b89d6de07e0", "fdd2a319-fc98-43bd-9ed8-cf2e7192513c", "a4e9816e-cfa4-4526-8eb4-7ed59d5f8c64", "a5984080-42b9-4bc2-a3f1-dad19c0d9662", "0fca344a-1654-4777-8a0f-ad5e4bec0f5f", "93fdd4bc-6a4b-48ef-b0a8-becdd89088f1", "b285c1a0-db9e-4103-bce2-b0ed9ec4d7da", "399f52cb-2812-4e0c-b38f-8f3ee8ca20e5", "bcbef95a-1fcf-4e3a-ae91-9edbb24bfd50", "b8e1a68d-9c3a-4e8c-b865-9eb8e81a4798", "f0def778-6885-4419-9e00-5a2d4dcecd5a"], "metadata": {"window": "Interest expense to be in the range of $210 million to $230 million;\nAdjusted effective tax rate to be approximately 20 percent to 21 percent;\nAdjusted free cash flow to be approximately $2.5 billion;\nCapital expenditures in the $500 million range; and\nWeighted average diluted shares outstanding are expected to be approximately 200 to 202 million for the fiscal year.\n For additional details on EPS growth rate excluding C OVID-19 contributions, please refer to our slide presentation for investors.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on November 2, 2023. ", "original_text": "Interest expense to be in the range of $210 million to $230 million;\nAdjusted effective tax rate to be approximately 20 percent to 21 percent;\nAdjusted free cash flow to be approximately $2.5 billion;\nCapital expenditures in the $500 million range; and\nWeighted average diluted shares outstanding are expected to be approximately 200 to 202 million for the fiscal year.\n", "page_label": "6", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "a0057cd9-34f8-4acf-817f-87fe57519f5f": {"node_ids": ["c1e91ae5-3576-44dc-a7d9-d01058db018d", "b4b1710d-f379-4e26-abd9-50c55e6a45a0", "147b49c5-ed9b-4286-976b-a64286ce7ebd", "af1f7650-a8fc-4f89-881c-9e9cf184b84f", "062b7a07-76c9-4f1b-9c37-320b6d8ed218", "73ef7261-d311-4089-9728-290a02cf957f"], "metadata": {"window": "uncertainty and changes in circumstances and speak only as of the date hereof.  These statements are not guarantees of future\nperformance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary materially\nfrom those indicated.  A more detailed discussion of the risks and uncertainties that could cause our actual results to differ materially\nfrom those indicated is included (i) in the \"Risk F actors\" and \"Management's Discussion and Analysis\" sections in the Company\u2019s\nAnnual R eport on Form 10-K for the fiscal year ended September 30, 2022 and elsewhere in that report as supplemented by the\ndescription of business risks described in Item 1A to our form 10-Q for the fiscal quarter ended March 31, 2023, to which mention is\nmade herein and (ii) in other reports filed by the Company pursuant to the Securities Exchange Act.  The Company undertakes no\nobligation to publicly update or revise any forward-looking statements, except as required by the federal securities laws.\n\u00a0\n", "original_text": "uncertainty and changes in circumstances and speak only as of the date hereof. ", "page_label": "7", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "5f73e483-71bf-4e05-8224-0c0ee9ff3a42": {"node_ids": ["93ff4593-5398-4e1a-8d7a-c8166313cc2f", "d5d1ef16-3c0a-4c63-82db-0a82fdce7bea", "afe604d3-f010-4c3e-9c48-ba7557c6362c"], "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a0476,941 \u00a0\u00a00.69 %\u00a0\u00a0454,519 \u00a0\u00a00.74 %\u00a04.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther (income) loss, net 2 \u00a0\u00a0(30,424 )\u00a0\u00a0 \u00a0\u00a020,656 \u00a0\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a060,942 \u00a0\u00a0\u00a0 \u00a0\u00a051,523 \u00a0\u00a0\u00a0 \u00a018.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a0446,423 \u00a0\u00a00.65 %\u00a0\u00a0382,340 \u00a0\u00a00.63 %\u00a016.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a097,443 \u00a0\u00a0\u00a0 \u00a0\u00a083,664 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a0348,980 \u00a0\u00a00.51 %\u00a0\u00a0298,676 \u00a0\u00a00.49 %\u00a016.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss (income) attributable to noncontrolling\ninterests \u00a0\u00a01,585 \u00a0\u00a0\u00a0 \u00a0\u00a0(3,939 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to Cencora, Inc. \u00a0 $350,565 \u00a0\u00a00.51 %\u00a0$294,737 \u00a0\u00a00.48 %\u00a018.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$1.74 \u00a0\u00a0\u00a0 \u00a0$1.42 \u00a0\u00a0\u00a0 \u00a022.5 %\nDiluted \u00a0$1.72 \u00a0\u00a0\u00a0 \u00a0$1.40 \u00a0\u00a0\u00a0 \u00a022.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0201,338 \u00a0\u00a0\u00a0 \u00a0\u00a0207,222 \u00a0\u00a0\u00a0 \u00a0(2.8 )%\nDiluted \u00a0\u00a0203,395 \u00a0\u00a0\u00a0 \u00a0\u00a0209,961 \u00a0\u00a0\u00a0 \u00a0(3.1 )%\n__________________________________________\n1Includes a $70.6 million gain from antitrust litigation settlements, a $90.3 million LIFO expense, and Turkey foreign currency\nremeasurement expense of $27.9 million in the three months ended September 30, 2023.  Includes a $104.8 million LIFO expense\ndTkfi f$124illi ihh h ddS b302022\n8", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a0476,941 \u00a0\u00a00.69 %\u00a0\u00a0454,519 \u00a0\u00a00.74 %\u00a04.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther (income) loss, net 2 \u00a0\u00a0(30,424 )\u00a0\u00a0 \u00a0\u00a020,656 \u00a0\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a060,942 \u00a0\u00a0\u00a0 \u00a0\u00a051,523 \u00a0\u00a0\u00a0 \u00a018.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a0446,423 \u00a0\u00a00.65 %\u00a0\u00a0382,340 \u00a0\u00a00.63 %\u00a016.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a097,443 \u00a0\u00a0\u00a0 \u00a0\u00a083,664 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a0348,980 \u00a0\u00a00.51 %\u00a0\u00a0298,676 \u00a0\u00a00.49 %\u00a016.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss (income) attributable to noncontrolling\ninterests \u00a0\u00a01,585 \u00a0\u00a0\u00a0 \u00a0\u00a0(3,939 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to Cencora, Inc. \u00a0", "page_label": "8", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "e9de2252-bf7e-4d19-b8c6-e6603420689c": {"node_ids": ["0468fa44-af41-4032-8bb6-6ed24d1f82fa", "12099117-1ec9-4b8b-89d5-663f1923e346", "66f83426-3722-4e7b-aacb-1f159a3499f9", "fc84f167-b9f4-4a48-a6b8-4d1b330f9471"], "metadata": {"window": "and Turkey foreign currency remeasurement expense of $12.4 million in the three months ended September 30, 2022.\n\u00a0\n 2Includes a $40.7 million gain on the divestiture of non-core businesses in the three months September 30, 2023.\n CENC ORA, INC.\n FINANCIAL SUMMAR Y\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended \nSeptember 30,\n2023 \u00a0% of \n Revenue \u00a0Fiscal Y ear Ended \nSeptember 30, 2022 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$262,173,411 \u00a0\u00a0\u00a0 \u00a0$238,587,006 \u00a0\u00a0\u00a0 \u00a09.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a0253,213,918 \u00a0\u00a0\u00a0 \u00a0\u00a0230,290,639 \u00a0\u00a0\u00a0 \u00a010.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a08,959,493 \u00a0\u00a03.42 %\u00a0\u00a08,296,367 \u00a0\u00a03.48 %\u00a08.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a05,309,984 \u00a0\u00a02.03 %\u00a0\u00a04,848,962 \u00a0\u00a02.03 %\u00a09.5 %\nDepreciation and amortization \u00a0\u00a0963,904 \u00a0\u00a00.37 %\u00a0\u00a0693,895 \u00a0\u00a00.29 %\u00a038.9 %\nLitigation and opioid-related (credit) expenses 2\u00a0\u00a0(24,693 )\u00a0\u00a0 \u00a0\u00a0123,191 \u00a0\u00a0\u00a0 \u00a0\u00a0\nAcquisition-related deal and integration\nexpenses \u00a0\u00a0139,683 \u00a0\u00a0\u00a0 \u00a0\u00a0119,561 \u00a0\u00a0\u00a0 \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0229,884 \u00a0\u00a0\u00a0 \u00a0\u00a063,498 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of assets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a04,946 \u00a0\u00a0\u00a0 \u00a0\u00a0\nGoodwill impairment 3 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a075,936 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a06,618,762 \u00a0\u00a02.52 %\u00a0\u00a05,929,989 \u00a0\u00a02.49 %\u00a011.6 %\n9", "original_text": "and Turkey foreign currency remeasurement expense of $12.4 million in the three months ended September 30, 2022.\n\u00a0\n", "page_label": "9", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "e97ebce4-a63a-4d71-a11f-d8f53ae490c7": {"node_ids": ["354018de-cc27-4988-b5bb-25ed5feb3cec", "e6e57f07-e169-4f52-a40c-32a75e6e8777", "0485a143-3bfe-4233-83bd-8fef6be10b0e"], "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a02,340,731 \u00a0\u00a00.89 %\u00a0\u00a02,366,378 \u00a0\u00a00.99 %\u00a0(1.1 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther income, net  4 \u00a0\u00a0(49,036 )\u00a0\u00a0 \u00a0\u00a0(27,352 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a0228,931 \u00a0\u00a0\u00a0 \u00a0\u00a0210,673 \u00a0\u00a0\u00a0 \u00a08.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a02,160,836 \u00a0\u00a00.82 %\u00a0\u00a02,183,057 \u00a0\u00a00.91 %\u00a0(1.0 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a0428,260 \u00a0\u00a0\u00a0 \u00a0\u00a0516,517 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a01,732,576 \u00a0\u00a00.66 %\u00a0\u00a01,666,540 \u00a0\u00a00.70 %\u00a04.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss attributable to noncontrolling interests \u00a0\u00a012,717 \u00a0\u00a0\u00a0 \u00a0\u00a032,280 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to Cencora, Inc. \u00a0 $1,745,293 \u00a0\u00a00.67 %\u00a0$1,698,820 \u00a0\u00a00.71 %\u00a02.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$8.62 \u00a0\u00a0\u00a0 \u00a0$8.15 \u00a0\u00a0\u00a0 \u00a05.8 %\nDiluted \u00a0$8.53 \u00a0\u00a0\u00a0 \u00a0$8.04 \u00a0\u00a0\u00a0 \u00a06.1 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0202,511 \u00a0\u00a0\u00a0 \u00a0\u00a0208,472 \u00a0\u00a0\u00a0 \u00a0(2.9 )%\nDiluted \u00a0\u00a0204,591 \u00a0\u00a0\u00a0 \u00a0\u00a0211,210 \u00a0\u00a0\u00a0 \u00a0(3.1 )%\n___________________________________________\n1Includes a $239.1 million gain from antitrust litigation settlements, a $204.6 million LIFO expense, and Turkey foreign currency\nremeasurement expense of $87.0 million in the fiscal year ended September 30, 2023.  Includes a $1.8 million gain from antitrust\nlitigation settlements, a $67.2 million LIFO expense, and Turkey foreign currency remeasurement expense of $40.0 million in the\nfil ddS b302022\n10", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a02,340,731 \u00a0\u00a00.89 %\u00a0\u00a02,366,378 \u00a0\u00a00.99 %\u00a0(1.1 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther income, net  4 \u00a0\u00a0(49,036 )\u00a0\u00a0 \u00a0\u00a0(27,352 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a0228,931 \u00a0\u00a0\u00a0 \u00a0\u00a0210,673 \u00a0\u00a0\u00a0 \u00a08.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a02,160,836 \u00a0\u00a00.82 %\u00a0\u00a02,183,057 \u00a0\u00a00.91 %\u00a0(1.0 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a0428,260 \u00a0\u00a0\u00a0 \u00a0\u00a0516,517 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a01,732,576 \u00a0\u00a00.66 %\u00a0\u00a01,666,540 \u00a0\u00a00.70 %\u00a04.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss attributable to noncontrolling interests \u00a0\u00a012,717 \u00a0\u00a0\u00a0 \u00a0\u00a032,280 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to Cencora, Inc. \u00a0", "page_label": "10", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "74a005aa-13c2-4b61-b91f-cb66794507c6": {"node_ids": ["9dbf0a8d-6422-4fa5-a626-cea101906a4f", "a7c29e41-e536-4cde-8243-b820b76112dd", "dacc8784-3f19-4045-9365-99ff57382b08", "150b7a09-cfe6-49db-88bb-21d8a41ba45a", "fceda422-ad25-44cb-a0e1-1bd9574f57c2", "fd435bae-8805-4a51-8a3d-5bac7b59bb36", "9a4c662d-70a8-4a74-8004-abd375696f3d", "b07a9a92-6d07-4d54-9af8-b566d43c04e9"], "metadata": {"window": "fiscal year ended September 30, 2022.\n\u00a0\n 2Includes the receipt of $83.4 million from the H.D.  Smith opioid litigation indemnity escrow in the fiscal year ended September\n30, 2023.\n\u00a0\n 3The goodwill impairment is related to the Company's less-than-wholly-owned subsidiary in Brazil in the fiscal year ended\nSeptember 30, 2022.\n\u00a0\n", "original_text": "fiscal year ended September 30, 2022.\n\u00a0\n", "page_label": "11", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "900b71f9-2b71-4a5a-8a64-9f2cd416280f": {"node_ids": ["cd3132de-f420-415e-9eb6-5d1f90858d55", "b52a0b30-431c-4e4b-bea1-72d05389730f"], "metadata": {"window": "impact \u00a0\u00a027,948 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a027,948 \u00a0\u00a0\u00a029,916 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a029,916 \u00a0\u00a0\u00a00.15 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(169,900 )\u00a0\u00a0169,900 \u00a0\u00a0\u00a0169,900 \u00a0\u00a0\u00a040,214 \u00a0\u00a0\u00a0(968 )\u00a0\u00a0128,718 \u00a0\u00a0\u00a00.63 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(13,890 )\u00a0\u00a013,890 \u00a0\u00a0\u00a013,890 \u00a0\u00a0\u00a03,305 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a010,585 \u00a0\u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated deal and\nintegration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(40,291 )\u00a0\u00a040,291 \u00a0\u00a0\u00a040,291 \u00a0\u00a0\u00a09,548 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a030,743 \u00a0\u00a0\u00a00.15 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring\nand other\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(52,276 )\u00a0\u00a052,276 \u00a0\u00a0\u00a052,276 \u00a0\u00a0\u00a012,452 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a039,824 \u00a0\u00a0\u00a00.20 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on\ndivestiture of\nnon-core\nbusinesses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(40,665 )\u00a0\u00a01,035 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(41,700 )\u00a0\u00a0(0.21 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nOther, net \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a04,310 \u00a0\u00a0\u00a0781 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a03,529 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a04,824 \u00a0\u00a0\u00a0(8,931 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a013,755 \u00a0\u00a0\u00a00.07 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$2,301,141 \u00a0\u00a0$1,500,154 \u00a0\u00a0$800,987 \u00a0\u00a0$740,906 \u00a0\u00a0$160,392 \u00a0\u00a0$617 \u00a0\u00a0$581,131 \u00a0\u00a0$2.86 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP % change\nvs.  prior year\nquarter \u00a0\u00a09.4 %\u00a0\u00a010.2 %\u00a0\u00a08.0 %\u00a0\u00a08.6 %\u00a0\u00a018.7 %\u00a0\u00a0 \u00a0\u00a06.5 %\u00a0\u00a010.0 %\u00a0\n12", "original_text": "impact \u00a0\u00a027,948 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a027,948 \u00a0\u00a0\u00a029,916 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a029,916 \u00a0\u00a0\u00a00.15 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(169,900 )\u00a0\u00a0169,900 \u00a0\u00a0\u00a0169,900 \u00a0\u00a0\u00a040,214 \u00a0\u00a0\u00a0(968 )\u00a0\u00a0128,718 \u00a0\u00a0\u00a00.63 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(13,890 )\u00a0\u00a013,890 \u00a0\u00a0\u00a013,890 \u00a0\u00a0\u00a03,305 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a010,585 \u00a0\u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated deal and\nintegration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(40,291 )\u00a0\u00a040,291 \u00a0\u00a0\u00a040,291 \u00a0\u00a0\u00a09,548 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a030,743 \u00a0\u00a0\u00a00.15 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring\nand other\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(52,276 )\u00a0\u00a052,276 \u00a0\u00a0\u00a052,276 \u00a0\u00a0\u00a012,452 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a039,824 \u00a0\u00a0\u00a00.20 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on\ndivestiture of\nnon-core\nbusinesses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(40,665 )\u00a0\u00a01,035 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(41,700 )\u00a0\u00a0(0.21 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nOther, net \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a04,310 \u00a0\u00a0\u00a0781 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a03,529 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a04,824 \u00a0\u00a0\u00a0(8,931 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a013,755 \u00a0\u00a0\u00a00.07 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$2,301,141 \u00a0\u00a0$1,500,154 \u00a0\u00a0$800,987 \u00a0\u00a0$740,906 \u00a0\u00a0$160,392 \u00a0\u00a0$617 \u00a0\u00a0$581,131 \u00a0\u00a0$2.86 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP % change\nvs. ", "page_label": "12", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "47ecf181-4191-4aae-9b54-bb362f13435b": {"node_ids": ["4297ebdd-81e9-4a34-b0f7-356d3db7cf88", "be4a1ec7-bc56-43f1-b531-6c2b13ddd65b", "0370dc29-6276-4578-9d3c-77d35999b3cf", "eeee86b3-07be-4780-b03f-d68db68a4001"], "metadata": {"window": "Percentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.27% \u00a03.34%\nOperating expenses \u00a02.58% \u00a02.18%\nOperating income \u00a00.69% \u00a01.16%\n______________________________________\n1Includes tax expense relating to 2020 S wiss tax reform and a gain on the currency remeasurement of the related deferred tax\nassets, the latter of which is recorded within Other (Income) Loss, Net.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n CENC ORA, INC.\n GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto \n Cencora \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$1,985,559 \u00a0$1,531,040 \u00a0\u00a0$454,519 \u00a0$382,340 \u00a0\u00a0$83,664 \u00a0\u00a0$(3,939 )\u00a0$294,737 \u00a0\u00a0$1.40 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from antitrust\nlitigation settlements \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a079 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(79 )\u00a0\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a0104,839 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0104,839 \u00a0\u00a0104,839 \u00a0\u00a0\u00a024,943 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a079,896 \u00a0\u00a0\u00a00.38 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n13", "original_text": "Percentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.27% \u00a03.34%\nOperating expenses \u00a02.58% \u00a02.18%\nOperating income \u00a00.69% \u00a01.16%\n______________________________________\n1Includes tax expense relating to 2020 S wiss tax reform and a gain on the currency remeasurement of the related deferred tax\nassets, the latter of which is recorded within Other (Income) Loss, Net.\n\u00a0\n", "page_label": "13", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "55d70abf-7bc2-4c52-a77a-3f390d38d9a5": {"node_ids": ["b99353c1-918b-4e60-988a-553d058656b6"], "metadata": {"window": "Turkey highly\ninflationary impact \u00a0\u00a012,415 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a012,415 \u00a0\u00a018,543 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a018,543 \u00a0\u00a0\u00a00.09 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0(72,685 )\u00a0\u00a072,685 \u00a0\u00a072,685 \u00a0\u00a0\u00a06,194 \u00a0\u00a0\u00a0(1,127 )\u00a0\u00a065,364 \u00a0\u00a0\u00a00.31 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and opioid-\nrelated expenses \u00a0\u00a0\u2014 \u00a0\u00a0(15,024 )\u00a0\u00a015,024 \u00a0\u00a015,024 \u00a0\u00a0\u00a05,106 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a09,918 \u00a0\u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\ndeal and integration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0(49,851 )\u00a0\u00a049,851 \u00a0\u00a049,851 \u00a0\u00a0\u00a04,894 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a044,957 \u00a0\u00a0\u00a00.21 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring and\nother expenses \u00a0\u00a0\u2014 \u00a0\u00a0(32,141 )\u00a0\u00a032,141 \u00a0\u00a032,141 \u00a0\u00a0\u00a04,104 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a028,037 \u00a0\u00a0\u00a00.13 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on\nremeasurement of\nequity investment \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0(4,834 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,834 )\u00a0\u00a0(0.02 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLoss on divestiture of\nnon-core businesses \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a03,745 \u00a0\u00a0\u00a02,821 \u00a0\u00a0\u00a03,618 \u00a0\u00a0\u00a04,542 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain discrete tax\nbenefits \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a09,302 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(9,302 )\u00a0\u00a0(0.04 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a08,127 \u00a0\u00a0\u00a0(5,951 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a014,078 \u00a0\u00a0\u00a00.07 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-GAAP \u00a0$2,102,813 \u00a0$1,361,339 \u00a0\u00a0$741,474 \u00a0$682,461 \u00a0\u00a0$135,156 \u00a0\u00a0$(1,448 )\u00a0$545,857 \u00a0\u00a0$2.60 \u00a0\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.25% \u00a03.44%\n14", "original_text": "Turkey highly\ninflationary impact \u00a0\u00a012,415 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a012,415 \u00a0\u00a018,543 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a018,543 \u00a0\u00a0\u00a00.09 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0(72,685 )\u00a0\u00a072,685 \u00a0\u00a072,685 \u00a0\u00a0\u00a06,194 \u00a0\u00a0\u00a0(1,127 )\u00a0\u00a065,364 \u00a0\u00a0\u00a00.31 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and opioid-\nrelated expenses \u00a0\u00a0\u2014 \u00a0\u00a0(15,024 )\u00a0\u00a015,024 \u00a0\u00a015,024 \u00a0\u00a0\u00a05,106 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a09,918 \u00a0\u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\ndeal and integration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0(49,851 )\u00a0\u00a049,851 \u00a0\u00a049,851 \u00a0\u00a0\u00a04,894 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a044,957 \u00a0\u00a0\u00a00.21 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring and\nother expenses \u00a0\u00a0\u2014 \u00a0\u00a0(32,141 )\u00a0\u00a032,141 \u00a0\u00a032,141 \u00a0\u00a0\u00a04,104 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a028,037 \u00a0\u00a0\u00a00.13 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on\nremeasurement of\nequity investment \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0(4,834 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,834 )\u00a0\u00a0(0.02 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLoss on divestiture of\nnon-core businesses \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a03,745 \u00a0\u00a0\u00a02,821 \u00a0\u00a0\u00a03,618 \u00a0\u00a0\u00a04,542 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain discrete tax\nbenefits \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a09,302 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(9,302 )\u00a0\u00a0(0.04 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a08,127 \u00a0\u00a0\u00a0(5,951 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a014,078 \u00a0\u00a0\u00a00.07 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-GAAP \u00a0$2,102,813 \u00a0$1,361,339 \u00a0\u00a0$741,474 \u00a0$682,461 \u00a0\u00a0$135,156 \u00a0\u00a0$(1,448 )\u00a0$545,857 \u00a0\u00a0$2.60 \u00a0\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.25% \u00a03.44%\n14", "page_label": "14", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "9785e97e-c48b-4791-bd32-a25b463008af": {"node_ids": ["a47af973-ef33-4a6e-9416-eba14e4e46ef", "4cee3074-85fd-43e7-8b9d-f3e8292d6629", "90eafdd0-d4cf-409e-b270-6ca4a53dcd1d", "529ceb12-632b-4b43-9ee8-caddc677a932"], "metadata": {"window": "Operating expenses \u00a02.50% \u00a02.23%\nOperating income \u00a00.74% \u00a01.21%\n______________________________________\n1Includes tax expense relating to S wiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nthe latter of which is recorded within Other (Income) Loss, Net.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n\u00a0\n CENC ORA, INC.\n GAAP T O NON-GAAP REC ONCILIA TIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30, 2023 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Loss \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto \n Cencora \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$8,959,493 \u00a0\u00a0$6,618,762 \u00a0\u00a0$2,340,731 \u00a0\u00a0$2,160,836 \u00a0\u00a0$428,260 \u00a0\u00a0$12,717 \u00a0\u00a0$1,745,293 \u00a0\u00a0$8.53 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(239,092 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(239,092 )\u00a0\u00a0(239,092 )\u00a0\u00a0(55,894 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(183,198 )\u00a0\u00a0(0.90 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a0204,595 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0204,595 \u00a0\u00a0\u00a0204,595 \u00a0\u00a0\u00a047,830 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0156,765 \u00a0\u00a0\u00a00.77 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\nifli\n15", "original_text": "Operating expenses \u00a02.50% \u00a02.23%\nOperating income \u00a00.74% \u00a01.21%\n______________________________________\n1Includes tax expense relating to S wiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nthe latter of which is recorded within Other (Income) Loss, Net.\n\u00a0\n", "page_label": "15", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "098da69f-b690-4ed8-8161-c74e17402e46": {"node_ids": ["8bcbfe9a-5c0f-42a3-ace5-a66d8d8b31fe", "1c776028-7dd6-4b00-87c0-4ef41edf3bfa"], "metadata": {"window": "inflationary\nimpact \u00a0\u00a086,967 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a086,967 \u00a0\u00a0\u00a095,938 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a095,938 \u00a0\u00a0\u00a00.47 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(551,046 )\u00a0\u00a0551,046 \u00a0\u00a0\u00a0551,046 \u00a0\u00a0\u00a0128,823 \u00a0\u00a0\u00a0(4,079 )\u00a0\u00a0418,144 \u00a0\u00a0\u00a02.04 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation\nand opioid-\nrelated\ncredit, net 1\u00a0\u00a0\u2014 \u00a0\u00a0\u00a024,693 \u00a0\u00a0\u00a0(24,693 )\u00a0\u00a0(24,693 )\u00a0\u00a013,717 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(38,410 )\u00a0\u00a0(0.19 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated deal\nand\nintegration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(139,683 )\u00a0\u00a0139,683 \u00a0\u00a0\u00a0139,683 \u00a0\u00a0\u00a032,655 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0107,028 \u00a0\u00a0\u00a00.52 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring\nand other\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(229,884 )\u00a0\u00a0229,884 \u00a0\u00a0\u00a0229,884 \u00a0\u00a0\u00a053,742 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0176,142 \u00a0\u00a0\u00a00.86 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on\ndivestiture of\nnon-core\nbusinesses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(40,665 )\u00a0\u00a01,035 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(41,700 )\u00a0\u00a0(0.20 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nOther, net \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(5,501 )\u00a0\u00a0781 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(6,282 )\u00a0\u00a0(0.03 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 2\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(6,638 )\u00a0\u00a0(29,287 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a022,649 \u00a0\u00a0\u00a00.11 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$9,011,963 \u00a0\u00a0$5,722,842 \u00a0\u00a0$3,289,121 \u00a0\u00a0$3,065,393 \u00a0\u00a0$621,662 \u00a0\u00a0$8,638 \u00a0\u00a0$2,452,369 \u00a0\u00a0$11.99 \u00a03\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP %\nchange vs.\n prior year \u00a0\u00a07.3 %\u00a0\u00a09.2 %\u00a0\u00a04.0 %\u00a0\u00a04.1 %\u00a0\u00a02.5 %\u00a0\u00a0 \u00a0\u00a05.3 %\u00a0\u00a08.7 %\u00a0\n16", "original_text": "inflationary\nimpact \u00a0\u00a086,967 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a086,967 \u00a0\u00a0\u00a095,938 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a095,938 \u00a0\u00a0\u00a00.47 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(551,046 )\u00a0\u00a0551,046 \u00a0\u00a0\u00a0551,046 \u00a0\u00a0\u00a0128,823 \u00a0\u00a0\u00a0(4,079 )\u00a0\u00a0418,144 \u00a0\u00a0\u00a02.04 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation\nand opioid-\nrelated\ncredit, net 1\u00a0\u00a0\u2014 \u00a0\u00a0\u00a024,693 \u00a0\u00a0\u00a0(24,693 )\u00a0\u00a0(24,693 )\u00a0\u00a013,717 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(38,410 )\u00a0\u00a0(0.19 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated deal\nand\nintegration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(139,683 )\u00a0\u00a0139,683 \u00a0\u00a0\u00a0139,683 \u00a0\u00a0\u00a032,655 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0107,028 \u00a0\u00a0\u00a00.52 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring\nand other\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(229,884 )\u00a0\u00a0229,884 \u00a0\u00a0\u00a0229,884 \u00a0\u00a0\u00a053,742 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0176,142 \u00a0\u00a0\u00a00.86 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on\ndivestiture of\nnon-core\nbusinesses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(40,665 )\u00a0\u00a01,035 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(41,700 )\u00a0\u00a0(0.20 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nOther, net \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(5,501 )\u00a0\u00a0781 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(6,282 )\u00a0\u00a0(0.03 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 2\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(6,638 )\u00a0\u00a0(29,287 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a022,649 \u00a0\u00a0\u00a00.11 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$9,011,963 \u00a0\u00a0$5,722,842 \u00a0\u00a0$3,289,121 \u00a0\u00a0$3,065,393 \u00a0\u00a0$621,662 \u00a0\u00a0$8,638 \u00a0\u00a0$2,452,369 \u00a0\u00a0$11.99 \u00a03\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP %\nchange vs.\n", "page_label": "16", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "9ca2098f-d703-48bf-aaf4-056d3a914929": {"node_ids": ["6a2cca4c-4d9a-4e19-a2c1-3ddac456ad55", "0660e4f9-0bc2-46eb-bd18-c9ed8939a477", "12cf498e-a392-4a89-a9cf-f193bd09439b", "6c50def7-f43b-4dd9-95ea-96466c882d59", "e1560151-fc00-46e8-b967-4756bbdebd44", "6590dd88-2631-443a-b00e-eb2c95f0e522", "8ff78fe4-9b70-4405-a1bc-e87aad6e9559"], "metadata": {"window": "Percentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.42% \u00a03.44%\nOperating expenses \u00a02.52% \u00a02.18%\nOperating income \u00a00.89% \u00a01.25%\n________________________________________\n1Includes the receipt of $83.4 million from the H.D.  Smith opioid litigation indemnity escrow.\n\u00a0\n 2Tax expense relating to 2020 S wiss tax reform and a gain on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Income, Net.\n\u00a0\n 3The sum of the components does not equal the total due to rounding.\n\u00a0\n", "original_text": "Percentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.42% \u00a03.44%\nOperating expenses \u00a02.52% \u00a02.18%\nOperating income \u00a00.89% \u00a01.25%\n________________________________________\n1Includes the receipt of $83.4 million from the H.D. ", "page_label": "17", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "f8f15bb5-391f-4efd-bf98-ba9769c0c274": {"node_ids": ["c60198a0-42db-4b15-bc58-f61fad7aabbc"], "metadata": {"window": "GAAP \u00a0$8,296,367 \u00a0\u00a0$5,929,989 \u00a0\u00a0$2,366,378 \u00a0\u00a0$2,183,057 \u00a0\u00a0$516,517 \u00a0\u00a0$32,280 \u00a0\u00a0$1,698,820 \u00a0\u00a0$8.04 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust litigation\nsettlements \u00a0\u00a0(1,835 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,835 )\u00a0\u00a0(1,835 )\u00a0\u00a0(408 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,427 )\u00a0\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a067,171 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a067,171 \u00a0\u00a0\u00a067,171 \u00a0\u00a0\u00a014,943 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a052,228 \u00a0\u00a0\u00a00.25 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\ninflationary impact \u00a0\u00a040,033 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a040,033 \u00a0\u00a0\u00a051,966 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a051,966 \u00a0\u00a0\u00a00.25 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(304,551 )\u00a0\u00a0304,551 \u00a0\u00a0\u00a0304,551 \u00a0\u00a0\u00a067,749 \u00a0\u00a0\u00a0(5,219 )\u00a0\u00a0231,583 \u00a0\u00a0\u00a01.10 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(123,191 )\u00a0\u00a0123,191 \u00a0\u00a0\u00a0123,191 \u00a0\u00a0\u00a024,111 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a099,080 \u00a0\u00a0\u00a00.47 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\ndeal and\nintegration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(119,561 )\u00a0\u00a0119,561 \u00a0\u00a0\u00a0119,561 \u00a0\u00a0\u00a023,401 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a096,160 \u00a0\u00a0\u00a00.46 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring and\nother expenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(63,498 )\u00a0\u00a063,498 \u00a0\u00a0\u00a063,498 \u00a0\u00a0\u00a012,428 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a051,070 \u00a0\u00a0\u00a00.24 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on\nremeasurement of\nequity investment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,834 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,834 )\u00a0\u00a0(0.02 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGoodwill\nimpairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(75,936 )\u00a0\u00a075,936 \u00a0\u00a0\u00a075,936 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(47,004 )\u00a0\u00a028,932 \u00a0\u00a0\u00a00.14 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nassets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,946 )\u00a0\u00a04,946 \u00a0\u00a0\u00a04,946 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a04,946 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n18", "original_text": "GAAP \u00a0$8,296,367 \u00a0\u00a0$5,929,989 \u00a0\u00a0$2,366,378 \u00a0\u00a0$2,183,057 \u00a0\u00a0$516,517 \u00a0\u00a0$32,280 \u00a0\u00a0$1,698,820 \u00a0\u00a0$8.04 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust litigation\nsettlements \u00a0\u00a0(1,835 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,835 )\u00a0\u00a0(1,835 )\u00a0\u00a0(408 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,427 )\u00a0\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a067,171 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a067,171 \u00a0\u00a0\u00a067,171 \u00a0\u00a0\u00a014,943 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a052,228 \u00a0\u00a0\u00a00.25 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\ninflationary impact \u00a0\u00a040,033 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a040,033 \u00a0\u00a0\u00a051,966 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a051,966 \u00a0\u00a0\u00a00.25 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(304,551 )\u00a0\u00a0304,551 \u00a0\u00a0\u00a0304,551 \u00a0\u00a0\u00a067,749 \u00a0\u00a0\u00a0(5,219 )\u00a0\u00a0231,583 \u00a0\u00a0\u00a01.10 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(123,191 )\u00a0\u00a0123,191 \u00a0\u00a0\u00a0123,191 \u00a0\u00a0\u00a024,111 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a099,080 \u00a0\u00a0\u00a00.47 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\ndeal and\nintegration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(119,561 )\u00a0\u00a0119,561 \u00a0\u00a0\u00a0119,561 \u00a0\u00a0\u00a023,401 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a096,160 \u00a0\u00a0\u00a00.46 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring and\nother expenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(63,498 )\u00a0\u00a063,498 \u00a0\u00a0\u00a063,498 \u00a0\u00a0\u00a012,428 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a051,070 \u00a0\u00a0\u00a00.24 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on\nremeasurement of\nequity investment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,834 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,834 )\u00a0\u00a0(0.02 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGoodwill\nimpairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(75,936 )\u00a0\u00a075,936 \u00a0\u00a0\u00a075,936 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(47,004 )\u00a0\u00a028,932 \u00a0\u00a0\u00a00.14 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nassets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,946 )\u00a0\u00a04,946 \u00a0\u00a0\u00a04,946 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a04,946 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n18", "page_label": "18", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "03c39f7a-d6b2-42a0-86c6-b60a33129345": {"node_ids": ["3b4f5756-11a9-4d10-9c4c-56cada2502fa", "de15a7c2-12c5-4e6c-8ea7-9526ecf30309", "a637f339-4214-46b0-8c6d-d67fcc3408d1", "01390958-41be-403b-9794-c956a19e5be3"], "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on divestiture\nof non-core\nbusinesses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(56,228 )\u00a0\u00a0(10,372 )\u00a0\u00a03,618 \u00a0\u00a0\u00a0(42,238 )\u00a0\u00a0(0.20 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain discrete tax\nbenefits \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(9,677 )\u00a0\u00a06,840 \u00a0\u00a0\u00a016,517 \u00a0\u00a0\u00a00.08 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a014,443 \u00a0\u00a0\u00a0(32,109 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a046,552 \u00a0\u00a0\u00a00.22 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$8,401,736 \u00a0\u00a0$5,238,306 \u00a0\u00a0$3,163,430 \u00a0\u00a0$2,945,423 \u00a0\u00a0$606,583 \u00a0\u00a0$(9,485 )\u00a0$2,329,355 \u00a0\u00a0$11.03 \u00a02\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.48% \u00a03.52%\nOperating expenses \u00a02.49% \u00a02.20%\nOperating income \u00a00.99% \u00a01.33%\n________________________________________\n1Includes tax expense relating to S wiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nthe latter of which is recorded within Other Income, Net.\n\u00a0\n 2The sum of the components does not equal the total due to rounding\n\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n CENC ORA, INC.\n SUMMAR Y SEGMENT INFORMA TION\n19", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on divestiture\nof non-core\nbusinesses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(56,228 )\u00a0\u00a0(10,372 )\u00a0\u00a03,618 \u00a0\u00a0\u00a0(42,238 )\u00a0\u00a0(0.20 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain discrete tax\nbenefits \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(9,677 )\u00a0\u00a06,840 \u00a0\u00a0\u00a016,517 \u00a0\u00a0\u00a00.08 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a014,443 \u00a0\u00a0\u00a0(32,109 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a046,552 \u00a0\u00a0\u00a00.22 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$8,401,736 \u00a0\u00a0$5,238,306 \u00a0\u00a0$3,163,430 \u00a0\u00a0$2,945,423 \u00a0\u00a0$606,583 \u00a0\u00a0$(9,485 )\u00a0$2,329,355 \u00a0\u00a0$11.03 \u00a02\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.48% \u00a03.52%\nOperating expenses \u00a02.49% \u00a02.20%\nOperating income \u00a00.99% \u00a01.33%\n________________________________________\n1Includes tax expense relating to S wiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nthe latter of which is recorded within Other Income, Net.\n\u00a0\n", "page_label": "19", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "13556533-f636-4043-b74e-d5777dc1f94c": {"node_ids": ["63a67739-a037-4018-a397-fd761133090d", "509d48a6-c5d0-49d0-a1fd-00dbf3e83d05", "9e08675f-319f-48f5-a2ab-72f93a678932"], "metadata": {"window": "(dollars in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30,\nRevenue \u00a0\u00a02023 \u00a0\u00a0\u00a02022 \u00a0\u00a0%\nChange\nU.S.  Healthcare Solutions \u00a0$61,928,984 \u00a0\u00a0$54,788,447 \u00a0\u00a013.0 %\nInternational Healthcare Solutions \u00a0\u00a06,994,689 \u00a0\u00a0\u00a06,387,474 \u00a0\u00a09.5 %\nIntersegment eliminations \u00a0\u00a0(1,342 )\u00a0\u00a0(1,772 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$68,922,331 \u00a0\u00a0$61,174,149 \u00a0\u00a012.7 %\n\u00a0 \u00a0Three Months Ended Sept ember 30,\nOperating income \u00a0\u00a02023 \u00a0\u00a0\u00a02022 \u00a0\u00a0%\nChange\nU.S.  Healthcare Solutions \u00a0$632,830 \u00a0\u00a0$578,416 \u00a0\u00a09.4 %\nInternational Healthcare Solutions \u00a0\u00a0168,157 \u00a0\u00a0\u00a0163,058 \u00a0\u00a03.1 %\nTotal segment operating income \u00a0\u00a0800,987 \u00a0\u00a0\u00a0741,474 \u00a0\u00a08.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation\nsettlements \u00a0\u00a070,582 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nLIFO expense \u00a0\u00a0(90,323 )\u00a0\u00a0(104,839 )\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(27,948 )\u00a0\u00a0(12,415 )\u00a0\u00a0\nAcquisition-related intangibles\namortization \u00a0\u00a0(169,900 )\u00a0\u00a0(72,685 )\u00a0\u00a0\nLitigation and opioid-related expenses \u00a0\u00a0(13,890 )\u00a0\u00a0(15,024 )\u00a0\u00a0\nAcquisition-related deal and\nintegration expenses \u00a0\u00a0(40,291 )\u00a0\u00a0(49,851 )\u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(52,276 )\u00a0\u00a0(32,141 )\u00a0\u00a0\n20", "original_text": "(dollars in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30,\nRevenue \u00a0\u00a02023 \u00a0\u00a0\u00a02022 \u00a0\u00a0%\nChange\nU.S. ", "page_label": "20", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "12de44de-010b-4dbb-ba8c-5cd0a66639dc": {"node_ids": ["5313847b-c593-4b09-bb95-8f35a43ed723", "06a6913f-00e1-468b-bea4-bb182b05cb0d", "1cb414e1-de55-4b4b-bc0b-8759a5e5cd97", "aa23464f-beff-487b-95ff-f8db5c4bf148", "c7ab1842-3884-4321-9614-005d00308a71"], "metadata": {"window": "Operating income \u00a0$476,941 \u00a0\u00a0$454,519 \u00a0\u00a04.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.38 %\u00a0\u00a02.53 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.36 %\u00a0\u00a01.47 %\u00a0\u00a0\nOperating income \u00a0\u00a01.02 %\u00a0\u00a01.06 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.84 %\u00a0\u00a011.22 %\u00a0\u00a0\nOperating expenses \u00a0\u00a09.43 %\u00a0\u00a08.67 %\u00a0\u00a0\nOperating income \u00a0\u00a02.40 %\u00a0\u00a02.55 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.27 %\u00a0\u00a03.25 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.58 %\u00a0\u00a02.50 %\u00a0\u00a0\nOperating income \u00a0\u00a00.69 %\u00a0\u00a00.74 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.34 %\u00a0\u00a03.44 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.18 %\u00a0\u00a02.23 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.16 %\u00a0\u00a01.21 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "original_text": "Operating income \u00a0$476,941 \u00a0\u00a0$454,519 \u00a0\u00a04.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S. ", "page_label": "21", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "eab89660-9e2b-49b6-b6a5-0548492eca3c": {"node_ids": ["4915a2f6-0c42-4e19-a9e4-1c4126df4895", "31763b9d-6d88-45cb-bb5c-c7158daa935d", "9ba4a894-e49e-4a53-9b0a-f5a77dc05bb1", "63d05847-6bc7-4c4f-af6f-f087465b562c"], "metadata": {"window": "CENC ORA, INC.\n SUMMAR Y SEGMENT INFORMA TION\n(dollars in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30,\nRevenue \u00a0\u00a02023 \u00a0\u00a0\u00a02022 \u00a0\u00a0%\nChange\nU.S.  Healthcare Solutions \u00a0$234,759,218 \u00a0\u00a0$212,100,202 \u00a0\u00a010.7 %\nInternational Healthcare Solutions \u00a0\u00a027,418,679 \u00a0\u00a0\u00a026,491,673 \u00a0\u00a03.5 %\nIntersegment eliminations \u00a0\u00a0(4,486 )\u00a0\u00a0(4,869 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$262,173,411 \u00a0\u00a0$238,587,006 \u00a0\u00a09.9 %\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30,\nOperating income \u00a0\u00a02023 \u00a0\u00a0\u00a02022 \u00a0\u00a0%\nChange\nU.S.  Healthcare Solutions \u00a0$2,596,559 \u00a0\u00a0$2,456,972 \u00a0\u00a05.7 %\nInternational Healthcare Solutions \u00a0\u00a0692,562 \u00a0\u00a0\u00a0706,458 \u00a0\u00a0(2.0 )%\nTotal segment operating income \u00a0\u00a03,289,121 \u00a0\u00a0\u00a03,163,430 \u00a0\u00a04.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation\nsettlements \u00a0\u00a0239,092 \u00a0\u00a0\u00a01,835 \u00a0\u00a0\u00a0\nLIFO expense \u00a0\u00a0(204,595 )\u00a0\u00a0(67,171 )\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(86,967 )\u00a0\u00a0(40,033 )\u00a0\u00a0\nAcquisition-related intangibles\namortization \u00a0\u00a0(551,046 )\u00a0\u00a0(304,551 )\u00a0\u00a0\nLitigation and opioid-related credit\n(expenses) \u00a0\u00a024,693 \u00a0\u00a0\u00a0(123,191 )\u00a0\u00a0\n22", "original_text": "CENC ORA, INC.\n", "page_label": "22", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "9f8f0848-5179-4290-915a-2ce8e88fd05b": {"node_ids": ["00290e2a-a120-4263-9fe1-95f63004c029", "bc8008ac-d6fb-40d3-a972-f0f5d4ab4fe8", "efd7088c-e46d-4c1a-ba7e-25543b139e6b", "87539361-2953-426c-9dc7-d6f9578af2d2"], "metadata": {"window": "Acquisition-related deal and\nintegration expenses \u00a0\u00a0(139,683 )\u00a0\u00a0(119,561 )\u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(229,884 )\u00a0\u00a0(63,498 )\u00a0\u00a0\nGoodwill impairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(75,936 )\u00a0\u00a0\nImpairment of assets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,946 )\u00a0\u00a0\nOperating income \u00a0$2,340,731 \u00a0\u00a0$2,366,378 \u00a0\u00a0(1.1 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.48 %\u00a0\u00a02.57 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.37 %\u00a0\u00a01.41 %\u00a0\u00a0\nOperating income \u00a0\u00a01.11 %\u00a0\u00a01.16 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.64 %\u00a0\u00a011.12 %\u00a0\u00a0\nOperating expenses \u00a0\u00a09.11 %\u00a0\u00a08.46 %\u00a0\u00a0\nOperating income \u00a0\u00a02.53 %\u00a0\u00a02.67 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.42 %\u00a0\u00a03.48 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.52 %\u00a0\u00a02.49 %\u00a0\u00a0\nOperating income \u00a0\u00a00.89 %\u00a0\u00a00.99 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCencora, Inc.  (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.44 %\u00a0\u00a03.52 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.18 %\u00a0\u00a02.20 %\u00a0\u00a0\n23", "original_text": "Acquisition-related deal and\nintegration expenses \u00a0\u00a0(139,683 )\u00a0\u00a0(119,561 )\u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(229,884 )\u00a0\u00a0(63,498 )\u00a0\u00a0\nGoodwill impairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(75,936 )\u00a0\u00a0\nImpairment of assets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,946 )\u00a0\u00a0\nOperating income \u00a0$2,340,731 \u00a0\u00a0$2,366,378 \u00a0\u00a0(1.1 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S. ", "page_label": "23", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "edcb9b2b-c10b-4f75-af3b-b6097c3b653a": {"node_ids": ["093bc0cc-2f1c-40ae-99f9-0636341e056c", "c6a0f1e7-008b-4910-b0bf-cddd6e50b1d2", "c16099db-7bac-4548-afa6-84e9d056b986"], "metadata": {"window": "Adjusted operating income \u00a0\u00a01.25 %\u00a0\u00a01.33 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n CENC ORA, INC.\n CONDENSED C ONSOLID ATED BAL ANCE SHEET S\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 September 30,\n\u00a0 \u00a02023 \u00a0\u00a02022\nASSET S \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $2,592,051 \u00a0$3,388,189\nAccounts receivable, net \u00a020,911,081 \u00a0\u00a018,452,675\nInventories \u00a017,454,768 \u00a0\u00a015,556,394\nRight to recover asset \u00a01,314,857 \u00a0\u00a01,532,061\nPrepaid expenses and other \u00a0526,069 \u00a0\u00a0660,439\nTotal current assets \u00a042,798,826 \u00a0\u00a039,589,758\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net \u00a02,135,171 \u00a0\u00a02,135,003\nGoodwill and other intangible assets \u00a014,005,900 \u00a0\u00a012,836,623\nDeferred income taxes \u00a0200,667 \u00a0\u00a0237,571\nOther long-term assets \u00a03,418,182 \u00a0\u00a01,761,661\n24", "original_text": "Adjusted operating income \u00a0\u00a01.25 %\u00a0\u00a01.33 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "24", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "7e2e8e0c-431c-4289-b30a-2df493dc98b7": {"node_ids": ["d2dddc55-c19b-424e-b40e-744d0ff98bbc", "19b9762f-84d2-45a9-b9fd-bbfc144df112"], "metadata": {"window": "\u00a0 \u00a0 \u00a0\u00a0\nTotal assets $62,558,746 \u00a0$56,560,616\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND ST OCKHOLDERS\u2019 EQUIT Y \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $45,836,037 \u00a0$40,192,890\nAccrued expenses and other \u00a02,353,817 \u00a0\u00a02,214,592\nShort-term debt \u00a0641,344 \u00a0\u00a01,070,473\nTotal current liabilities \u00a048,831,198 \u00a0\u00a043,477,955\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt \u00a04,146,113 \u00a0\u00a04,632,360\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes \u00a0310,676 \u00a0\u00a0320,274\nDeferred income taxes \u00a01,657,944 \u00a0\u00a01,620,413\nAccrued litigation liability \u00a05,061,795 \u00a0\u00a05,461,758\nOther long-term liabilities \u00a01,884,733 \u00a0\u00a0976,583\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity \u00a0666,287 \u00a0\u00a071,273\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and stockholders' equity $62,558,746 \u00a0$56,560,616\n\u00a0\nCENC ORA, INC.\n CONDENSED C ONSOLID ATED ST ATEMENT S OF CASH FL OWS\n(in thousands)\n25", "original_text": "\u00a0 \u00a0 \u00a0\u00a0\nTotal assets $62,558,746 \u00a0$56,560,616\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND ST OCKHOLDERS\u2019 EQUIT Y \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $45,836,037 \u00a0$40,192,890\nAccrued expenses and other \u00a02,353,817 \u00a0\u00a02,214,592\nShort-term debt \u00a0641,344 \u00a0\u00a01,070,473\nTotal current liabilities \u00a048,831,198 \u00a0\u00a043,477,955\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt \u00a04,146,113 \u00a0\u00a04,632,360\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes \u00a0310,676 \u00a0\u00a0320,274\nDeferred income taxes \u00a01,657,944 \u00a0\u00a01,620,413\nAccrued litigation liability \u00a05,061,795 \u00a0\u00a05,461,758\nOther long-term liabilities \u00a01,884,733 \u00a0\u00a0976,583\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity \u00a0666,287 \u00a0\u00a071,273\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and stockholders' equity $62,558,746 \u00a0$56,560,616\n\u00a0\nCENC ORA, INC.\n", "page_label": "25", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "b7f3c838-ea4a-4758-8a6e-83ef3ac74947": {"node_ids": ["512c2c9b-6956-43bf-abf7-13f78971b843"], "metadata": {"window": "(unaudited)\n\u00a0\n\u00a0Fiscal Y ear Ended\nSeptember 30,\n\u00a0 \u00a02023 \u00a0\u00a0\u00a02022 \u00a0\nOperating Activities: \u00a0 \u00a0\u00a0\nNet income $1,732,576 \u00a0\u00a0$1,666,540 \u00a0\nAdjustments to reconcile net income to net cash provided by operating activities \u00a01,304,216 \u00a0\u00a0\u00a01,176,210 \u00a0\nChanges in operating assets and liabilities, excluding the effects of acquisitions and divestitures: \u00a0 \u00a0\u00a0\nAccounts receivable \u00a0(2,711,786 )\u00a0\u00a0(1,659,525 )\nInventories \u00a0(2,183,368 )\u00a0\u00a0(665,370 )\nAccounts payable \u00a06,103,451 \u00a0\u00a0\u00a03,320,725 \u00a0\nOther, net \u00a0(333,755 )\u00a0\u00a0(1,135,492 )\nNet cash provided by operating activities \u00a03,911,334 \u00a0\u00a0\u00a02,703,088 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures \u00a0(458,359 )\u00a0\u00a0(496,318 )\nCost of acquired companies, net of cash acquired 1 \u00a0(1,409,835 )\u00a0\u00a0(133,814 )\nCost of equity investments 2 \u00a0(743,275 )\u00a0\u00a0(18,491 )\nProceeds from the divestiture of businesses \u00a0\u2014 \u00a0\u00a0\u00a0272,586 \u00a0\nOther, net \u00a09,004 \u00a0\u00a0\u00a07,600 \u00a0\nNet cash used in investing activities \u00a0(2,602,465 )\u00a0\u00a0(368,437 )\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet debt repayments \u00a0(623,258 )\u00a0\u00a0(923,103 )\nPurchases of common stock 3 \u00a0(1,180,728 )\u00a0\u00a0(483,704 )\nExercises of stock options \u00a061,152 \u00a0\u00a0\u00a093,912 \u00a0\nCash dividends on common stock \u00a0(398,752 )\u00a0\u00a0(391,687 )\n26", "original_text": "(unaudited)\n\u00a0\n\u00a0Fiscal Y ear Ended\nSeptember 30,\n\u00a0 \u00a02023 \u00a0\u00a0\u00a02022 \u00a0\nOperating Activities: \u00a0 \u00a0\u00a0\nNet income $1,732,576 \u00a0\u00a0$1,666,540 \u00a0\nAdjustments to reconcile net income to net cash provided by operating activities \u00a01,304,216 \u00a0\u00a0\u00a01,176,210 \u00a0\nChanges in operating assets and liabilities, excluding the effects of acquisitions and divestitures: \u00a0 \u00a0\u00a0\nAccounts receivable \u00a0(2,711,786 )\u00a0\u00a0(1,659,525 )\nInventories \u00a0(2,183,368 )\u00a0\u00a0(665,370 )\nAccounts payable \u00a06,103,451 \u00a0\u00a0\u00a03,320,725 \u00a0\nOther, net \u00a0(333,755 )\u00a0\u00a0(1,135,492 )\nNet cash provided by operating activities \u00a03,911,334 \u00a0\u00a0\u00a02,703,088 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures \u00a0(458,359 )\u00a0\u00a0(496,318 )\nCost of acquired companies, net of cash acquired 1 \u00a0(1,409,835 )\u00a0\u00a0(133,814 )\nCost of equity investments 2 \u00a0(743,275 )\u00a0\u00a0(18,491 )\nProceeds from the divestiture of businesses \u00a0\u2014 \u00a0\u00a0\u00a0272,586 \u00a0\nOther, net \u00a09,004 \u00a0\u00a0\u00a07,600 \u00a0\nNet cash used in investing activities \u00a0(2,602,465 )\u00a0\u00a0(368,437 )\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet debt repayments \u00a0(623,258 )\u00a0\u00a0(923,103 )\nPurchases of common stock 3 \u00a0(1,180,728 )\u00a0\u00a0(483,704 )\nExercises of stock options \u00a061,152 \u00a0\u00a0\u00a093,912 \u00a0\nCash dividends on common stock \u00a0(398,752 )\u00a0\u00a0(391,687 )\n26", "page_label": "26", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "33c63d93-9b01-43c3-9fc2-750e06a8cd22": {"node_ids": ["081a6624-c870-4e51-a2d3-ff7a8089a4c0", "6b8b5f4c-a6ce-44fc-a5b1-55d4d9d84a25", "72d4c6ed-6de5-4018-9f69-928914e7ce5c", "5d299aec-446f-412f-8010-4f3fbc3ae56a"], "metadata": {"window": "Employee tax withholdings related to restricted share vesting \u00a0(71,279 )\u00a0\u00a0(38,076 )\nOther, net \u00a0(9,413 )\u00a0\u00a0(10,122 )\nNet cash used in financing activities \u00a0(2,222,278 )\u00a0\u00a0(1,752,780 )\n\u00a0 \u00a0 \u00a0\u00a0\nEffect of exchange rate changes on cash, cash equivalents, and restricted cash \u00a072,759 \u00a0\u00a0\u00a0(57,850 )\n\u00a0 \u00a0 \u00a0\u00a0\n(Decrease) increase in cash, cash equivalents, and restricted cash, including cash classified within\nassets held for sale \u00a0(840,650 )\u00a0\u00a0524,021 \u00a0\nLess: Increase in cash classified within assets held for sale \u00a0\u2014 \u00a0\u00a0\u00a0(610 )\n(Decrease) increase in cash, cash equivalents, and restricted cash \u00a0(840,650 )\u00a0\u00a0523,411 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of year 4 \u00a03,593,539 \u00a0\u00a0\u00a03,070,128 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of year 4 $2,752,889 \u00a0\u00a0$3,593,539 \u00a0\n________________________________________\n1Includes $1,406.5 million for the acquisition of PharmaLex.\n\u00a0\n 2Includes a $718.4 million investment in OneOncology.\n\u00a0\n 3Includes $28.4 million of purchases in September 2022 that cash settled in October 2022.\n\u00a0\n 4The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated S tatements of Cash Flows:\n\u00a0 \u00a0September 30,\n(amounts in thousands) \u00a0\u00a02023 \u00a0\u00a02022 \u00a0\u00a02021\n27", "original_text": "Employee tax withholdings related to restricted share vesting \u00a0(71,279 )\u00a0\u00a0(38,076 )\nOther, net \u00a0(9,413 )\u00a0\u00a0(10,122 )\nNet cash used in financing activities \u00a0(2,222,278 )\u00a0\u00a0(1,752,780 )\n\u00a0 \u00a0 \u00a0\u00a0\nEffect of exchange rate changes on cash, cash equivalents, and restricted cash \u00a072,759 \u00a0\u00a0\u00a0(57,850 )\n\u00a0 \u00a0 \u00a0\u00a0\n(Decrease) increase in cash, cash equivalents, and restricted cash, including cash classified within\nassets held for sale \u00a0(840,650 )\u00a0\u00a0524,021 \u00a0\nLess: Increase in cash classified within assets held for sale \u00a0\u2014 \u00a0\u00a0\u00a0(610 )\n(Decrease) increase in cash, cash equivalents, and restricted cash \u00a0(840,650 )\u00a0\u00a0523,411 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of year 4 \u00a03,593,539 \u00a0\u00a0\u00a03,070,128 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of year 4 $2,752,889 \u00a0\u00a0$3,593,539 \u00a0\n________________________________________\n1Includes $1,406.5 million for the acquisition of PharmaLex.\n\u00a0\n", "page_label": "27", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "577e95e3-3be8-440d-a07a-76a197f7dc46": {"node_ids": ["280c0370-118c-4aeb-ad3d-933b36c88449", "a97359e8-4d14-44a8-af3b-f031a0e70269", "a56f2b0e-568b-458b-84a3-8721977473ba", "85b6e3c3-db0a-4e97-85e4-e4b52f9b54e0", "45782755-5f85-4625-9f3c-62c437d771f6", "bc8b899d-5500-4738-91b7-ca996189f9f9", "e63a11d3-2f7f-400b-9f2a-bac120294f77", "2e046d66-e957-4a15-8d6b-b44141f79aa1", "486479f3-266c-4b4c-a597-50827ef8df24", "17483c1b-2f00-45e7-b6ef-3b21d7719345", "3a537d0f-b1dc-4ebf-9caa-ea6e1da43621", "30855a9d-a778-4906-b0fd-899107dc395b", "41c9d689-02e7-48d1-9e76-ef355524b839", "7dfe1b24-be78-41e6-8095-ef5f22a38ed5", "cbc7f4e0-ecb8-4269-a428-a6c26aeb7ef3", "d23080df-e17b-4048-a273-68a4da838b02", "9cbc5f78-bc73-4f6f-8544-03c21b1d05c7", "36a00b13-e8b9-417b-9cb0-ea04653cb2df", "7a54b6b6-6ab4-403b-a336-c44b0136be4d", "be9b4b96-464f-46e0-b18c-70cc547e4f95", "8b19d01b-ba69-4c67-bad3-2af44b90b466", "71b64171-42c0-4980-b307-64d08eb87ab8"], "metadata": {"window": "Cash and cash equivalents \u00a0$2,592,051 \u00a0$3,388,189 \u00a0$2,547,142\nRestricted cash (included in Prepaid Expenses and Other) \u00a0\u00a097,722 \u00a0\u00a0144,980 \u00a0\u00a0462,986\nRestricted cash (included in Other Assets) \u00a0\u00a063,116 \u00a0\u00a060,370 \u00a0\u00a060,000\nCash, cash equiv alents, and r estrict ed cash \u00a0$2,752,889 \u00a0$3,593,539 \u00a0$3,070,128\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n", "original_text": "Cash and cash equivalents \u00a0$2,592,051 \u00a0$3,388,189 \u00a0$2,547,142\nRestricted cash (included in Prepaid Expenses and Other) \u00a0\u00a097,722 \u00a0\u00a0144,980 \u00a0\u00a0462,986\nRestricted cash (included in Other Assets) \u00a0\u00a063,116 \u00a0\u00a060,370 \u00a0\u00a060,000\nCash, cash equiv alents, and r estrict ed cash \u00a0$2,752,889 \u00a0$3,593,539 \u00a0$3,070,128\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S. ", "page_label": "28", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "b6ce48e9-6291-4029-92f1-4d8ffacab73d": {"node_ids": ["16ec3b65-a79b-4ae7-90eb-2d39624eb0cc", "7bab9e85-82de-4fd7-92c7-e0f400e1e0a6", "ee03e2be-e51c-4c49-92bc-e2bf21431daf", "458f655b-c0d0-4231-93ff-dde3f058eb1c", "71b02232-d5cc-4aee-a942-28c892c46502", "27c84ada-3a05-48fe-bb07-6840f73e746f", "125c1d80-8fa5-46f6-b252-82fb300d9581", "eb0ea4a1-1c90-448c-b46b-2695bda5b028", "5e70f10b-99c9-4a62-9b2e-83bb8c391a86", "41bb9c0d-9d28-44c5-a6c2-ee2e9d4466cd", "9ae155f6-73f4-4fca-a1bc-54db5ec793ae", "b56344fe-0076-4d30-af1c-a654dccc3690", "ef66c963-4862-4885-90af-49cd3f181809", "9e95f243-3d53-41bf-8532-5b7d6848c2d7", "c148761a-5b9a-4623-8e9d-4688ad6a2b84", "e6340bbc-27ab-4211-8bd2-6a7145d5af99", "504caf1e-ffe7-468c-aa7f-9ddb1d4af397", "e14f3436-eb07-4f72-8feb-7aafb66fdb04", "d77f5401-00df-4ca7-87c4-7e44404488b6", "f02c7f7b-37f8-460c-bcc5-84ce8c81f486", "aa602770-38b0-494d-969f-dbd7312a2671", "ec136266-5f1f-4dbe-a156-39b40eb370f7", "897d7bdd-d77d-4611-8467-c8639437d5dc", "94330c16-fdcb-48b6-aa28-c46b9cdd2e5c"], "metadata": {"window": "Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the gain (loss) on the\ncurrency remeasurement of the deferred tax asset relating to 2020 S wiss tax reform, the gain on the sale of non-core\nbusinesses, and the gain on the remeasurement of an equity investment are excluded from adjusted income before income\ntaxes because these amounts are unusual, non-operating, and/or non-recurring.  Management believes that this non-GAAP\nfinancial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes. ", "original_text": "Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income. ", "page_label": "29", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "c37dba28-e111-4586-9210-488c4a7cda52": {"node_ids": ["08e62781-d6e8-45fa-a58d-c8dfa11f81f8", "eb6b779e-96d3-41dc-85fa-0ba472d42497", "f3ded855-013d-49f4-9837-9d213fcb0ea5", "c8f42f9b-eef8-4258-8725-2d5cd66688b7", "922ebad1-3d5a-4dbc-a2b7-46e29aef8de4", "c93f9df6-c4b2-4dde-97db-52264c50645c", "cfb39a9c-0d19-4d03-8c82-60c0c093911a", "0aa8a436-e3a9-4829-893e-23d7b4f541a3", "3066a540-dcf1-4894-881c-77189419b393", "371ebb77-1a11-40f7-a1f1-399c9eb61997", "d5bedafa-8c0a-4811-9110-7c731478ae16"], "metadata": {"window": "operations outside of the United S tates reporting in currencies other than the U.S.  dollar and management believes that this\npresentation provides a framework to assess how its business performed excluding the impact of foreign currency exchange rate\nfluctuations.  For the fourth quarter of fiscal 2023, (i) revenue of $68.9 billion was negatively impacted by foreign currency translation\nof $37.6 million, resulting in revenue on a constant currency basis of $69.0 billion, and (ii) operating income of $801.0 million was\nnegatively impacted by foreign currency translation of $1.5 million, resulting in operating income on a constant currency basis of\n$802.5 million.  For the fourth quarter of fiscal 2023 in the International Healthcare Solutions segment, (i) revenue of $6,994.7 million\nwas negatively impacted by foreign currency translation of $37.6 million, resulting in revenue on a constant currency basis of\n$7,032.3 million, and (ii) operating income of $168.2 million was negatively impacted by foreign currency translation of $1.5 million,\nresulting in operating income on a constant currency basis of $169.6 million. ", "original_text": "operations outside of the United S tates reporting in currencies other than the U.S. ", "page_label": "30", "file_name": "CEN-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 260802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}}}